<SEC-DOCUMENT>0001610618-25-000047.txt : 20250508
<SEC-HEADER>0001610618-25-000047.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508164725
ACCESSION NUMBER:		0001610618-25-000047
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		25927054

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cdtx-20250331.htm
<DESCRIPTION>CIDARA THERAPEUTICS, INC. FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:772584df-f722-4edc-81e3-b26e5bb232b0,g:477eac6b-6822-4ddf-a883-4a61404b9849,d:49f81b51ab9a48059db3fc4265446fcd-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:cdtx="http://cidara.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdtx-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001610618</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-30">--12-31</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-41" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="f-309">0.05</ix:nonFraction><ix:nonNumeric contextRef="c-42" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-326">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-103" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-459">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdtx-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>cdtx:vote</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>cdtx:option</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>cdtx:employee</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdtx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdtx:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-23</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-20</xbrli:startDate><xbrli:endDate>2024-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-23</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-20</xbrli:startDate><xbrli:endDate>2024-11-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-26</xbrli:startDate><xbrli:endDate>2024-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-19</xbrli:startDate><xbrli:endDate>2024-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:FinanceLeaseRightOfUseAssetAndLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-20</xbrli:startDate><xbrli:endDate>2023-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-09</xbrli:startDate><xbrli:endDate>2024-09-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-11</xbrli:startDate><xbrli:endDate>2024-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:RezafunginAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-24</xbrli:startDate><xbrli:endDate>2024-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2024-04-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-08</xbrli:startDate><xbrli:endDate>2025-05-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i49f81b51ab9a48059db3fc4265446fcd_1"></div><div style="min-height:30.6pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">MARCH&#160;31, 2025</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36912</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">CIDARA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:23.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.405%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-1537286</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">6310 Nancy Ridge Drive,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 101</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92121</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">(858)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">752-6170</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices, including Zip Code)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:38.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">CDTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.573%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of May&#160;5, 2025, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">12,969,823</ix:nonFraction> shares of Common Stock ($0.0001 par value) outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:30.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.681%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.010%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_13">Item&#160;1. Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_16">Condensed Consolidated Balance Sheets as of March 31, 2025 (unaudited) and December 31, 2024 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2025 and 2024 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_22">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_64">&#8217;</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25"> Equity (Deficit) for the three </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25">months ended </a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25">March 31, 2025</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25"> and 202</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25">4</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25"> (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_64">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_64">29</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_82">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_82">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_85">39</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_88">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_88">40</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_91">40</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_94">40</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_127">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_127">74</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_130">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_130">74</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_133">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_133">74</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_136">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_136">74</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_139">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_139">76</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_142">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i49f81b51ab9a48059db3fc4265446fcd_142">78</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_13"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">168,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">189,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">6,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">6,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">1,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">12,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">12,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">188,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">210,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-42">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-44">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-47">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-48">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-49">191,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">214,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">4,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">3,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">19,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">13,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">20,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">26,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">4,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-60">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">48,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">49,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term finance lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-66">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">1,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-69">50,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-70">51,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-71"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-72"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-73"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-74">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2025 and December&#160;31, 2024:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-77"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-78"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series A Convertible Voting Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-79"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-80">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82">204,725</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="cdtx:PreferredStockSharesIssuedIncludingConversion" format="ixt:num-dot-decimal" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="cdtx:PreferredStockSharesIssuedIncludingConversion" format="ixt:num-dot-decimal" scale="0" id="f-84">240,000</ix:nonFraction></ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-86">204,725</ix:nonFraction></ix:nonFraction> shares outstanding at March&#160;31, 2025 and December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-89"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-90">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-91">3,818,495</ix:nonFraction> shares authorized at March&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92">4,947,759</ix:nonFraction> shares authorized at December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-93">2,156,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-94">975,208</ix:nonFraction> shares outstanding at March&#160;31, 2025; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95">2,156,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96">2,104,472</ix:nonFraction> shares outstanding at December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-99"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-100">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-102">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-104">12,209,150</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2025 and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-106">10,946,635</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-107">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-108">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-109">776,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-110">774,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-111">634,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-112">611,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">141,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">163,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">191,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">214,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:376.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-118">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-120">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">24,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">5,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">6,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">3,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reversal of indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="3" id="f-125">5,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-127">25,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-128">9,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">25,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">8,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingExpense" scale="3" id="f-131">110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherNonoperatingExpense" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-133">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-134">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-136">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-137">23,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-138">8,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-140">2,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-141"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">23,480</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-143"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">10,326</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-145"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-146">1.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-148">1.80</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-149"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-150">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-151"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-152">0.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-153"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-154">1.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-155"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-156">2.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-157"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-158">14,177,743</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-159"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-160">4,537,782</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;See accompanying notes.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">23,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">10,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-163">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-164">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-165">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-166">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-167">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-168">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-169">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-172">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on assignment of finance lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:LossOnAssignmentOfFinanceLease" scale="3" id="f-173">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="cdtx:LossOnAssignmentOfFinanceLease" format="ixt:fixed-zero" scale="3" id="f-174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-175">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-176">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-177">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-178">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reversal of indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="3" id="f-179">5,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-182">8,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-184">1,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-185">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-186">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-187">7,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-188">4,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" scale="3" id="f-189">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-190">2,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-191">2,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-192">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-194">3,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-195">329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-196">197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-197">21,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-198">6,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-200">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-201">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-203">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-204">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-205">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance costs for private placement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-208">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-209">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-210">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment for shares withheld to fund payroll taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-212">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-213">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-214">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-215">21,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-216">6,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-217">196,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-218">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-219">174,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-220">29,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="f-221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="f-222">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"/><td style="width:19.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2025</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series A Convertible Voting Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-223">204,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-225">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-227">10,946,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-228">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">774,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-230">611,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">163,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-232">1,129,264</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-233">564,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="cdtx:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-234">657,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-235">6,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-236">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-237">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-238">33,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-239">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-240">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-241">23,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-242">23,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-243">204,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-245">975,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-247">12,209,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-248">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">776,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-250">634,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-251">141,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.783%"><tr><td style="width:1.0%"/><td style="width:32.088%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Deficit</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-252">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-254">4,530,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-255">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-256">433,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">441,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">8,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-259">31,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Value of shares withheld to fund payroll taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-260">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-261">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-262">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-263">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">10,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">10,326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-266">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-268">4,561,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-269">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">433,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">451,757</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">17,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-273" continuedAt="f-273-1" escape="true">THE COMPANY AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="f-273-1" continuedAt="f-273-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company using its proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform to develop drug-Fc conjugate, or DFC, therapeutics designed to save lives and improve the standard of care for patients facing serious diseases. The Company&#8217;s proprietary Cloudbreak platform enables development of novel DFCs that inhibit specific disease targets while simultaneously engaging the immune system.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prophylaxis and treatment of seasonal and pandemic influenza, which has completed Phase 1 and Phase 2a clinical trials under a partnership with J&amp;J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, or Janssen. On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, under which the Company reacquired all rights for CD388 from Janssen to develop and commercialize CD388.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is currently conducting a 5,041 subject, randomized, double-blind, controlled Phase 2b clinical trial, or the NAVIGATE study, evaluating the efficacy and safety of CD388 for pre-exposure prophylaxis of seasonal influenza. Top-line data from the NAVIGATE study is expected in late June 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sale of Rezafungin</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s first commercially approved product in the United States, or U.S., was REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, the Company and Napp Pharmaceutical Group Limited, or Napp, an affiliate of Mundipharma Medical Company, or Mundipharma, entered into an asset purchase agreement, or the Napp Purchase Agreement, pursuant to which the Company sold to Napp all of the Company&#8217;s rezafungin assets and related contracts. The Company completed all conditions of the sale on April 24, 2024. The Company determined that the sale of rezafungin represented a strategic shift that will have a major effect on the Company&#8217;s operations and financial results. Accordingly, the sale of rezafungin is classified as discontinued operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as income from discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all prior year periods presented, including any gain or loss recognized on closing. There were <ix:nonFraction unitRef="usd" contextRef="c-37" decimals="INF" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-274"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="INF" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-275"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="INF" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-276"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="INF" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-277">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets and liabilities related to discontinued operations as of March&#160;31, 2025 and December&#160;31, 2024, as all balances were recognized in income from discontinued operations at the completion of the transaction. See Note 9 for additional information.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company effected the approved 1-for-20 reverse stock split of its shares of common stock, or the Reverse Stock Split. All references in this Quarterly Report on Form 10-Q to the number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Stock Split on a retroactive basis. As a result of the Reverse Stock Split, an immaterial amount was reclassified from common stock to additional paid-in capital.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-278" continuedAt="f-278-1" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2025, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-279">634.7</ix:nonFraction> million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-273-2" continuedAt="f-273-3"><ix:continuation id="f-278-1"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-280">174.5</ix:nonFraction> million, which the Company expects will provide sufficient liquidity to support its planned operations for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company&#8217;s ability to execute on its business plan.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComparabilityOfPriorYearFinancialData" id="f-281" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended March&#160;31, 2025 and 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-282" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-283" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company&#8217;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#8217;s collaboration, license, and purchase agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-284" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, which is the Chief Executive Officer of the Company. The Company views its operations and manages its business as a single reportable segment with a single operating segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company manages research and development, or R&amp;D, activities on a consolidated basis. The Company expects to generate future revenue from a combination of license fees and other upfront payments, funded R&amp;D agreements, milestone payments, product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing of the successful commercialization of its product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Comprehensive loss is the measure of segment profit or loss used by CODM in making decisions regarding resource allocation and assessing performance, which is also reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The CODM uses comprehensive loss in making decisions regarding resource allocation and evaluating financial performance.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-273-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-285" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table represents the results of the Company&#8217;s reportable segment for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues generated in the U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-287">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development - Cloudbreak platform</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-288">21,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-289">2,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-290">6,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-291">4,206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-292">2,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-293">1,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="f-294">658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" id="f-295">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reversal of indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="3" id="f-296">5,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other segment items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-298">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-299">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-301">2,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Segment net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-302"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-303">23,480</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-304"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-305">10,326</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The settlement of certain indirect tax liabilities resulted in the reversal of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" format="ixt:num-dot-decimal" scale="6" id="f-306">5.5</ix:nonFraction>&#160;million in legal liabilities during the three months ended March&#160;31, 2025, which consisted of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="f-307">3.7</ix:nonFraction>&#160;million in indirect tax amounts that were determined not to be due and payable and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="cdtx:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="f-308">1.8</ix:nonFraction>&#160;million in indirect tax interest and penalties that were determined not to be due and payable. The Company paid an immaterial amount in penalties for registration and compliance in one jurisdiction during the three months ended March&#160;31, 2025.</span></div></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-310" continuedAt="f-310-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-310-1" continuedAt="f-310-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-311" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="f-312" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-313" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Restricted cash consists of cash held as collateral to secure a standby letter of credit as required by certain contracts.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-310-2" continuedAt="f-310-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-315" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-314" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-316">168,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-317">189,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-318">6,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-319">6,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-320">174,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-321">196,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-322" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable is stated at the original invoice amount and consists of indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#8217;s customers is considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-323"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="f-324">not</ix:nonFraction></ix:nonFraction> record any credit losses as of March&#160;31, 2025, or December&#160;31, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-325" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:f-326">three</span> to <ix:nonNumeric contextRef="c-43" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-327">seven years</ix:nonNumeric>).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-328" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#8217;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 842, the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#8217;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-329" continuedAt="f-329-1" escape="true"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reports deferred income taxes in accordance with ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-310-3" continuedAt="f-310-4"><ix:continuation id="f-329-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="cdtx:TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" id="f-330" escape="true"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indirect Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product were subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense was included in R&amp;D expenses within discontinued operations. Prior to the sale of rezafungin, the related interest and penalties were included in selling, general and administrative, or SG&amp;A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in general and administrative, or G&amp;A, expenses in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#8217;s supply chain activities or in connection with commercial sales of REZZAYO. When any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses are reversed as part of continuing operations at that time. Indirect tax amounts on the rezafungin asset transfer that can be billed to and recovered from our customers are included in accounts receivable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-331" continuedAt="f-331-1" escape="true"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-310-4" continuedAt="f-310-5"><ix:continuation id="f-331-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 6 and Note 9 for additional information.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-332" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses consist of wages, benefits and stock-based compensation charges for R&amp;D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to R&amp;D expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-333" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">G&amp;A expenses relate to finance, human resources, legal and other administrative activities. G&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other G&amp;A expenses include facility and overhead costs not otherwise included in R&amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" id="f-334" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&amp;D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-335" continuedAt="f-335-1" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-310-5" continuedAt="f-310-6"><ix:continuation id="f-335-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#8217;s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company&#8217;s common stock during the equivalent period of the calculated expected term of the Company&#8217;s stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-336">zero</ix:nonFraction> reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-337" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Earnings (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the guidance in ASC 260, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series A Convertible Voting Preferred Stock, or Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and pre-funded warrants, see Note 4 for additional information. Basic net EPS is then calculated by dividing the net income attributable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net EPS by using the more dilutive of the (1) treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method. Dilutive common stock equivalents are comprised of warrants (excluding pre-funded warrants), Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans and ESPP, on an as converted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series A Convertible Preferred Stock or the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#8217;s losses. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 260, if a company had a discontinued operation, the Company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed in Note 4, as part of its November 2024 Private Placement (as defined below), the Company issued and sold pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-338">3,149,035</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-339">14.9119</ix:nonFraction> per pre-funded warrant (representing the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-340">14.912</ix:nonFraction> per share purchase price less the exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-341">0.0001</ix:nonFraction> per pre-funded warrant share). Since the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-342">0.0001</ix:nonFraction> exercise price per pre-funded warrant share represents little consideration and is non-substantive in relation to the purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-343">14.9119</ix:nonFraction> per pre-funded warrant, and as the pre-funded warrants are exercisable at any time after their original issuance with no further vesting conditions or contingencies associated with them, the shares underlying the pre-funded warrants are therefore included in the calculation of basic net loss per common share.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-310-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-344" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-345">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-346">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-347">14,330,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-349">487,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-350">1,052,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-351">3,151,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-352">828,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-353">17,970,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-354">1,881,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-355" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-356" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update, or ASU, 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025, and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#8217;s condensed consolidated financial statements or related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#8217;s condensed consolidated financial statements or related disclosures, or do not apply to the Company.</span></div></ix:nonNumeric></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-357" continuedAt="f-357-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-357-1" continuedAt="f-357-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-357-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-358" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-359">168,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-360">168,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-363">6,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-364">6,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-367">174,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-368">174,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-371">189,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-372">189,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-375">6,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-376">6,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-379">196,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-380">196,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-383" continuedAt="f-383-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-383-1" continuedAt="f-383-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company effected the Reverse Stock Split of its shares of common stock and decreased its authorized number of shares of common stock from <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-384">200,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-385">20,000,000</ix:nonFraction> shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All references in this Quarterly Report on Form 10-Q to the number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Stock Split on a retroactive basis.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Cantor Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald &amp; Co., or Cantor. The Company has <ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-386">not</ix:nonFraction> sold any shares of its common stock under the Cantor Sales Agreement since July 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">April 2024 Private Placement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company entered into a securities purchase agreement with certain institutional and other accredited investors, pursuant to which the Company issued and sold, in a private placement, or the April 2024 Private Placement, <ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-387">240,000</ix:nonFraction> shares of Series A Convertible Preferred Stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-388">1,000</ix:nonFraction> per share. The closing of the April 2024 Private Placement took place on April 24, 2024, and the Company received total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-389">240.0</ix:nonFraction>&#160;million. The Company received total net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-390">239.1</ix:nonFraction>&#160;million, after deducting issuance costs payable by the Company.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-383-2" continuedAt="f-383-3"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">November 2024 Private Placement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 20, 2024, the Company entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company issued and sold, in a private placement, or the November 2024 Private Placement, (i) an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-67" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-391">3,892,274</ix:nonFraction> shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-392">14.912</ix:nonFraction> per share, and (ii) in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-393">3,149,035</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-394">14.9119</ix:nonFraction> per pre-funded warrant (representing the $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-395">14.912</ix:nonFraction> per share purchase price less the exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-396">0.0001</ix:nonFraction> per pre-funded warrant share). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The closing of the November 2024 Private Placement took place on November 26, 2024, and the Company received total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-397">105.0</ix:nonFraction>&#160;million. The Company received total net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-398">98.2</ix:nonFraction>&#160;million, after deducting issuance costs payable by the Company.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Company's amended and restated certificate of incorporation, as amended, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-399">10,000,000</ix:nonFraction> shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-400">10,000,000</ix:nonFraction> shares of preferred stock authorized at March&#160;31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2024, the Company designated <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-401">240,000</ix:nonFraction> shares of preferred stock as Series A Convertible Preferred Stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-402">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 18, 2024, the Company&#8217;s stockholders approved, for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-403">16,800,000</ix:nonFraction> shares of common stock upon conversion of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-404">240,000</ix:nonFraction> shares of Series A Convertible Preferred Stock issued in the April 2024 Private Placement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 19, 2024, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-405">2,469,250</ix:nonFraction> shares of common stock upon the automatic conversion of <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-406">35,275</ix:nonFraction> shares of Series A Convertible Preferred Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, including that shares of Series A Convertible Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than <ix:nonFraction unitRef="number" contextRef="c-71" decimals="4" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="f-407">9.99</ix:nonFraction>% of the Company's outstanding shares of common stock as of the applicable conversion date. After conversion, the converted shares of Series A Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series A Convertible Preferred Stock. As of March&#160;31, 2025 and December&#160;31, 2024, shares of preferred stock designated as Series A Convertible Preferred Stock totaled <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-408">204,725</ix:nonFraction>.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series A Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="f-409">70</ix:nonFraction> shares of common stock. Holders are not permitted to convert Series A Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="c-73" decimals="4" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="f-410">9.99</ix:nonFraction>% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series A Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#8217;s common stock. If dividends are paid on shares of common stock, holders of Series A Convertible Preferred Stock are entitled to participate in such dividends on an as-if-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the Company, each holder of Series A Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of Series X Convertible Preferred Stock and common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of the Series A Convertible Preferred Stock are entitled to vote together with the holders of common stock on an as-if-converted basis on all matters submitted to a vote of stockholders; provided that holders of Series A Convertible Preferred Stock are not permitted to vote with respect to matters submitted to a vote of stockholders, to the extent that after giving effect to such action, such holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="c-73" decimals="4" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="f-411">9.99</ix:nonFraction>% of the number of shares of common stock outstanding immediately after the action.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-383-3" continuedAt="f-383-4"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, and determined that equity treatment is appropriate as it does not meet the criteria for liability accounting. Additionally, the Series A Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series A Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Series X Convertible Preferred Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-412">5,000,000</ix:nonFraction> shares of preferred stock as Series X Convertible Preferred Stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-74" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-413">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, at the request of certain holders, <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-414">52,241</ix:nonFraction> shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-415">26,120</ix:nonFraction> shares of the Company&#8217;s common stock. In March 2025, at the request of certain holders, <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-416">1,129,264</ix:nonFraction> shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-417">564,632</ix:nonFraction> shares of the Company&#8217;s common stock. After conversion, the converted shares of Series X Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series X Convertible Preferred Stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, shares of preferred stock designated as Series X Convertible Preferred Stock totaled <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-418">3,818,495</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-419">4,947,759</ix:nonFraction>, respectively.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="f-420">0.5</ix:nonFraction> shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="f-421">9.99</ix:nonFraction>% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#8217;s common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the Company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have <ix:nonFraction unitRef="vote" contextRef="c-80" decimals="INF" name="cdtx:NumberOfVotesEntitlementForEachShareHeld" format="ixt:fixed-zero" scale="0" id="f-422">no</ix:nonFraction> voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 18, 2024, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-423">20,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-424">50,000,000</ix:nonFraction> shares, which amendment was filed by the Company with the Secretary of State of the State of Delaware on July 18, 2024 and was effective as of such date.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-425">50,000,000</ix:nonFraction> shares of common stock authorized as of March&#160;31, 2025. Holders of outstanding shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-83" decimals="INF" name="cdtx:NumberOfVotesEntitlementForEachShareHeld" format="ixt-sec:numwordsen" scale="0" id="f-426">one</ix:nonFraction> vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="cdtx:CommonStockDividendsInArrearsOrDefault" format="ixt:fixed-zero" scale="0" id="f-427">no</ix:nonFraction> dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-383-4"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, (i) warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-428">866</ix:nonFraction> shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-429">230.95</ix:nonFraction> per share and (ii) pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-430">2,491,975</ix:nonFraction> shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-431">0.0001</ix:nonFraction> per share. During the three months ended&#160;March&#160;31, 2025, pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="cdtx:ClassOfWarrantOrRightExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-432">657,060</ix:nonFraction> shares of common stock were cashless exercised resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="cdtx:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-433">657,052</ix:nonFraction> shares of the Company's common stock and an immaterial cash payment by the Company in lieu of fractional shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, (i) warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-434">866</ix:nonFraction> shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-435">230.95</ix:nonFraction> per share and (ii) pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-436">3,149,035</ix:nonFraction> shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-437">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had <ix:nonFraction unitRef="usd" contextRef="c-88" decimals="INF" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt:fixed-zero" scale="0" id="f-438"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="INF" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt:fixed-zero" scale="0" id="f-439">no</ix:nonFraction></ix:nonFraction> intrinsic value as of March&#160;31, 2025, and December&#160;31, 2024, and the pre-funded warrants had a total aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-440">53.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-441">84.6</ix:nonFraction>&#160;million as of March&#160;31, 2025, and December&#160;31, 2024, respectively. The intrinsic value of a warrant and pre-funded warrant exercisable for common stock is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-442" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants, including pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-443">2,492,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-444">3,149,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-445">14,330,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-446">14,330,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-447">487,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-448">1,052,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options and RSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-449">3,151,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-450">2,481,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-451">660,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-452">1,021,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-453">88,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-454">63,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-455">21,211,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-456">22,099,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-457" continuedAt="f-457-1" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="f-457-1" continuedAt="f-457-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2024, the Company&#8217;s board of directors approved and adopted the Company&#8217;s 2024 Equity Incentive Plan, or 2024 EIP. In July 2024, the Company&#8217;s stockholders approved the adoption of the 2024 EIP. The 2024 EIP is the successor to and continuation of the Company&#8217;s 2015 Equity Incentive Plan, or 2015 EIP, previously approved and adopted in March 2015 by the Company&#8217;s board of directors and stockholders. The 2024 EIP became effective on July 18, 2024. Upon the effectiveness of the 2024 EIP, <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-458">no</ix:nonFraction> additional awards were or will be granted under the 2015 EIP, although all outstanding stock awards granted under the 2015 EIP continue to be governed by the terms of the 2015 EIP. Under the 2024 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company&#8217;s board of directors approved and adopted the 2020 Inducement Incentive Plan, which was most recently amended in February 2025, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors (or the compensation and human capital committee thereof), subject to the provisions of the 2024 EIP, 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:f-459">three</span>- or <ix:nonNumeric contextRef="c-104" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-460">four-year</ix:nonNumeric> period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to <ix:nonNumeric contextRef="c-102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-461">10</ix:nonNumeric> years from the date of grant. The exercise price for stock options granted under the 2024 EIP, 2020 IIP and 2015 EIP must be at a price no less than <ix:nonFraction unitRef="number" contextRef="c-102" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-462">100</ix:nonFraction>% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than <ix:nonFraction unitRef="number" contextRef="c-102" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" scale="-2" id="f-463">10</ix:nonFraction>% of the voting power of all classes of stock of the Company, the exercise price shall be no less than <ix:nonFraction unitRef="number" contextRef="c-105" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-464">110</ix:nonFraction>% of the value on the date of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-457-2" continuedAt="f-457-3"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to <ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-465">85</ix:nonFraction>% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to <ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-466">15</ix:nonFraction>% of the employee&#8217;s eligible compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2025 and 2024, <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:fixed-zero" scale="0" id="f-467"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:fixed-zero" scale="0" id="f-468">no</ix:nonFraction></ix:nonFraction> shares were issued pursuant to the ESPP. As of March&#160;31, 2025, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately <ix:nonNumeric contextRef="c-108" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-469">0.5</ix:nonNumeric> years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-470" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2025:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-471">177,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-472">14.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-473">206,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-474">21.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-475">33,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-476">17.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-477">11,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-478">15.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-479">337,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-112" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-480">18.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted by the Company during the three months ended March&#160;31, 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-481">13.70</ix:nonFraction> per share. The total fair value of RSUs vested during the three months ended March&#160;31, 2025 and 2024 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-482">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-483">0.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2025, estimated unrecognized compensation expense related to RSUs granted was approximately $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-484">5.9</ix:nonFraction>&#160;million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-111" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-485">2.9</ix:nonNumeric> years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-486" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-487">2,303,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-488">18.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-114" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-489">8.84</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-490">29,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-491">730,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-492">21.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-493">7,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-494">16.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-495">213,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-496">22.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-497">2,813,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-498">18.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-499">8.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-500">17,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-501">2,813,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-502">18.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-503">8.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-504">17,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-505">661,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-506">30.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-507">6.76</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-508">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the three months ended March&#160;31, 2025, and 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-509">15.76</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-510">9.80</ix:nonFraction> per share, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, total unrecognized share-based compensation expense related to unvested stock options was approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-511">23.6</ix:nonFraction> million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-115" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-512">2.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-513" escape="true"><ix:continuation id="f-457-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for RSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-514">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-515">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-516">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-517">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense recorded in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-518">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-519">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense recorded in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-521">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stock compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-522">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-523">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i49f81b51ab9a48059db3fc4265446fcd_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-524" continuedAt="f-524-1" escape="true">SIGNIFICANT AGREEMENTS AND CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="f-524-1" continuedAt="f-524-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company reacquired all rights to develop and commercialize CD388 when the Company and Janssen entered into the Janssen License Agreement, which also effectively terminated the Janssen Collaboration Agreement (as defined below), including the license granted by the Company to Janssen.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Janssen License Agreement, the Company assumed responsibility for further clinical development, manufacture, registration and commercialization of DFCs based on the Company&#8217;s Cloudbreak platform for the prevention and treatment of influenza, including CD388 and products or compounds containing CD388. Janssen granted the Company an exclusive, worldwide, fee-bearing royalty-free license for certain Janssen-controller technology to develop, manufacture, and commercialize compounds and products, including CD388. Janssen agreed to (i) transfer and disclose to the Company certain Janssen-controlled know-how related to CD388, including manufacturing know-how, data and documentation, (ii) transfer all existing quantities of CD388 clinical materials, and (iii) transfer the cell banks used by or on behalf of Janssen for the production of CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company paid Janssen an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-525">85.0</ix:nonFraction>&#160;million on April 24, 2024. The Company is also obligated to pay Janssen up to $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="cdtx:CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" format="ixt:num-dot-decimal" scale="6" id="f-526">150.0</ix:nonFraction>&#160;million in development and regulatory milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="cdtx:CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" format="ixt:num-dot-decimal" scale="6" id="f-527">455.0</ix:nonFraction>&#160;million in commercialization milestone payments, with respect to CD388. The Company has no obligation to pay any royalties to Janssen for future sales of any commercialized CD388 product. The Company&#8217;s contingent future obligation to pay Janssen with respect to CD388 will be recognized if and when the contingency is resolved and the consideration is paid or becomes payable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the Company had an existing license and collaboration agreement with Janssen, or the Janssen Collaboration Agreement, the Company considered the contract modification and consideration payable to a customer guidance in ASC 606. The Company determined this bundled arrangement would be accounted for as a termination of the existing revenue contract and the creation of a new arrangement. No amounts paid or payable to Janssen were recorded against revenue as the consideration payable to Janssen does not exceed the fair value of the distinct assets acquired in the Janssen License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company was determined to be the accounting acquirer and substantially all of the fair value of the gross assets acquired is concentrated in the acquired in-process research and development, or IPR&amp;D, of CD388. The reacquired license to develop, manufacture, and commercialize activities of CD388 is part of the acquired IPR&amp;D. The transaction was accounted for as an asset acquisition. The acquired IPR&amp;D did not have an alternative future use as of the acquisition date. Therefore the initial purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="cdtx:ResearchAndDevelopmentExpenseAcquiredInProcess" format="ixt:num-dot-decimal" scale="6" id="f-528">85.4</ix:nonFraction>&#160;million, inclusive of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="cdtx:DirectTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-529">0.4</ix:nonFraction>&#160;million in direct transaction costs, was expensed as of the acquisition date as acquired IPR&amp;D in the condensed consolidated statements of operations and comprehensive loss during the second quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the acquisition, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-530">0.5</ix:nonFraction>&#160;million in contract liabilities related to deferred revenue balances and unearned cancelled performance obligations associated with the Janssen Collaboration Agreement. The settlement of the preexisting contract liabilities was recorded as an offset to the Janssen License Agreement&#8217;s initial purchase price resulting in $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="cdtx:ResearchAndDevelopmentExpenseAcquiredInProcess" format="ixt:num-dot-decimal" scale="6" id="f-531">84.9</ix:nonFraction>&#160;million expensed as acquired IPR&amp;D in the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-524-2" continuedAt="f-524-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company&#8217;s Cloudbreak platform, for the prevention and treatment of influenza, including CD388.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen collaborated in the research, preclinical development and early clinical development of CD388, or the Development Candidate, under a mutually-agreed R&amp;D plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, the Company was responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company was the IND holder for the Research Plan clinical trials. Both parties were responsible for conducting certain specified chemistry, manufacturing and controls, or CMC, development activities under the Research Plan.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2023, Janssen delivered its Election to Proceed Notice for CD388, whereby Janssen assumed the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continued to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and was reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement. Following Janssen&#8217;s Election to Proceed Notice, Janssen was obligated at its sole expense to diligently continue development and commercialization.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Janssen Collaboration Agreement was terminated upon the effectiveness of the Janssen License Agreement on April 24, 2024, and all potential future milestone payments and royalties were forfeited by the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Janssen Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price is equal to the up-front fee of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-532">27.0</ix:nonFraction>&#160;million, plus the R&amp;D funding of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="f-533">47.8</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-534">10.0</ix:nonFraction>&#160;million. The transaction price included the total estimated costs related to R&amp;D and clinical supply services. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&amp;D efforts and costs for manufacturing clinical supplies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of the distinct performance obligations identified under the Janssen Collaboration Agreement was as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The R&amp;D services performed represented a distinct performance obligation. The Company recognized revenue based on actual amounts incurred as the underlying services were provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company&#8217;s initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognized revenue based on actual amounts incurred as the underlying services were provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In March 2022 and September 2023, the Company achieved milestones under the Janssen Collaboration Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was expected to be recognized as revenue over the remaining progress of these performance obligations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the termination date of the Janssen Collaboration Agreement there was <ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:fixed-zero" scale="6" id="f-535">no</ix:nonFraction> aggregate transaction price allocated to performance obligations that were unsatisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, the Company recorded <ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="f-536"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="f-537">no</ix:nonFraction></ix:nonFraction> accounts receivable or contract liabilities associated with the Janssen Collaboration Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="f-538" continuedAt="f-538-1" escape="true"><ix:continuation id="f-524-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.308%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.492%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-539">971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-540">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Janssen Collaboration Agreement</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-541">973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i49f81b51ab9a48059db3fc4265446fcd_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-542" continuedAt="f-542-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease Obligations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into a finance lease for lab equipment in November 2023. The finance lease had a term of <ix:nonNumeric contextRef="c-135" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durmonth" id="f-543">36</ix:nonNumeric> months, monthly lease payments of $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="0" name="cdtx:LesseeFinanceLeaseMonthlyRate" format="ixt:num-dot-decimal" scale="0" id="f-544">25,009</ix:nonFraction>, and an option to purchase the lab equipment for $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="0" name="cdtx:LesseeFinanceLeaseOptionPurchaseEquipment" scale="0" id="f-545">1</ix:nonFraction> at the end of the finance lease term. In March 2025, the Company entered into an assignment and assumption agreement whereby the Company agreed to transfer and assign to a third party all of the Company's present and future rights, interests, duties, obligations and liabilities under the finance lease, resulting in a derecognition of the finance lease right-of-use asset and finance lease liabilities as of March&#160;31, 2025, and the recognition of a $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" scale="6" id="f-546">0.2</ix:nonFraction> million loss on disposal in other expense, net in continuing operations during the three months ended March&#160;31, 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Finance lease costs were immaterial for the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Obligations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into an operating lease for laboratory and office space in San Diego, California in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015. On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional <ix:nonNumeric contextRef="c-138" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-547">36</ix:nonNumeric> months and increased the base rent to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="INF" name="cdtx:LesseeOperatingLeaseMonthlyRate" format="ixt:num-dot-decimal" scale="0" id="f-548">133,371</ix:nonFraction> per month effective January 1, 2024, subject to <ix:nonFraction unitRef="number" contextRef="c-139" decimals="2" name="cdtx:LesseeOperatingLeaseAnnualRateIncrease" scale="-2" id="f-549">4</ix:nonFraction>% increases every January. The operating lease expires on December 31, 2026 with options for <ix:nonFraction unitRef="option" contextRef="c-138" decimals="INF" name="cdtx:NumberOfOperatingLeaseOptionsForExtension" format="ixt-sec:numwordsen" scale="0" id="f-550">two</ix:nonFraction> individual <ix:nonNumeric contextRef="c-139" name="cdtx:LesseeOperatingLeaseOptionRenewalTerm" format="ixt-sec:durwordsen" id="f-551">two-year</ix:nonNumeric> extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2025, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes. The incremental borrowing rate used in measuring the Company&#8217;s operating lease liability was <ix:nonFraction unitRef="number" contextRef="c-138" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-552">12.0</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-553" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount and timing of cash flows arising from the Company&#8217;s operating lease as of March&#160;31, 2025 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-554">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-555">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-556">2,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-557">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-558">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-559" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-560">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-561">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-562">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-563">2,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-542-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the weighted average remaining operating lease term was <ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-564">1.8</ix:nonNumeric> years.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-565"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-566">0.4</ix:nonFraction></ix:nonFraction> million for each of the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-567"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-568">0.4</ix:nonFraction></ix:nonFraction> million for each of the three months ended March&#160;31, 2025 and 2024. These costs are primarily related to the Company&#8217;s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than <ix:nonNumeric contextRef="c-1" name="cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" format="ixt-sec:durday" id="f-569">30</ix:nonNumeric> days.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for R&amp;D activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reduction in Force</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 9, 2024, management of the Company, as authorized by the board of directors of the Company, approved a reduction in the Company&#8217;s workforce, or the Reduction, of <ix:nonFraction unitRef="employee" contextRef="c-140" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="f-570">20</ix:nonFraction> employees, which represented approximately <ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="cdtx:RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" scale="-2" id="f-571">30</ix:nonFraction>% of the Company&#8217;s workforce. The Reduction reflects the Company&#8217;s focus on the clinical development of CD388, its influenza product candidate. The Reduction was completed on November 1, 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result of the Reduction, the Company incurred charges of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-572">1.2</ix:nonFraction>&#160;million for severance payments and employee benefits in 2024. The Company does not expect to incur additional charges related to the Reduction. As of March&#160;31, 2025, all amounts have been paid.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Standby Letter of Credit</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 11, 2024, the Company established a standby letter of credit with its banking institution, Wells Fargo, for $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="f-573">6.0</ix:nonFraction>&#160;million for the benefit of its indirect tax service provider, as it relates to indirect tax compliance services in various tax jurisdictions outside of the U.S. in connection with the rezafungin supply chain activities and commercial sales of REZZAYO. The letter of credit expires on November 30, 2025 and is automatically extended without amendment for an additional <ix:nonNumeric contextRef="c-142" name="us-gaap:GuarantorObligationTerm1" format="ixt-sec:durwordsen" id="f-574">one-year</ix:nonNumeric> period from the current expiration date, unless notified by the Company to terminate prior to <ix:nonNumeric contextRef="c-142" name="cdtx:GuarantorObligationsTerminationNoticeTerm" format="ixt-sec:durday" id="f-575">90</ix:nonNumeric> days from the expiration date. The cash held as collateral for this standby letter of credit is recorded as restricted cash and is held in an interest-bearing account.</span></div></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-576" continuedAt="f-576-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-576-1"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company estimates an annual effective income tax rate based on projected results for the year and applied the rate to net loss before taxes to calculate income tax expense or (benefit). When applicable, the income tax provision also includes adjustments for discrete tax items. Any refinements made due to subsequent information that affects the estimated annual effective income tax rate are reflected as adjustments in the current period. For the three months ended March&#160;31, 2025, and 2024 the Company recognized <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-577"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-578">no</ix:nonFraction></ix:nonFraction> income tax expense or (benefit) from continuing operations.</span></div></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-579" continuedAt="f-579-1" escape="true">DISCONTINUED OPERATIONS</ix:nonNumeric></span></div><ix:continuation id="f-579-1" continuedAt="f-579-2"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, the Company and Napp entered into the Napp Purchase Agreement, pursuant to which the Company sold to Napp, effective as of April 24, 2024, the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">all of the Company&#8217;s rezafungin assets, including all of the Company&#8217;s right to receive future milestones and royalties under a license agreement between Melinta Therapeutics, LLC, or Melinta, and the Company, or the Melinta License Agreement, and a collaboration and license agreement between Mundipharma and the Company, or the Mundipharma Collaboration Agreement,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">all rezafungin intellectual property rights, including patents and know-how, all product data, regulatory approvals and documentation,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">rezafungin and comparator inventory,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">specified prepaid assets and specified contracts, in exchange for Napp&#8217;s assumption of certain liabilities of the rezafungin business, including the ongoing costs of the ReSPECT Phase 3 clinical trial and the ReSTORE Phase 3 clinical trial in China and the Company&#8217;s obligations from and after closing under the Melinta License Agreement,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Commercial Supply Agreement between the Company and Melinta, and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Commercial Supply Agreement between the Company and Mundipharma, or the Mundipharma Commercial Supply Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-579-2" continuedAt="f-579-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">No Company employees were transferred to Napp.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company, Napp and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Mundipharma Commercial Supply Agreement from the Company to Napp, or the Novation Agreement. In the Novation Agreement, Mundipharma agreed to forgive the Company&#8217;s obligation to refund a $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" format="ixt:num-dot-decimal" scale="6" id="f-580">11.1</ix:nonFraction>&#160;million development milestone advance due as of December 31, 2024, net of royalties, to Mundipharma under the Mundipharma Collaboration Agreement, provided that (a) the Company performed its obligation to provide carryover services under a Transition Services Agreement with Napp, or the TSA, for a period of <ix:nonNumeric contextRef="c-143" name="cdtx:CollaborativeArrangementCarryOverServicesAgreementTerm" format="ixt-sec:durday" id="f-581">45</ix:nonNumeric> days following the closing, (b) the Company delivered all of the purchased assets, including product know-how and product-data, in accordance with the Napp Purchase Agreement and a know-how transfer plan delivered in connection with the Napp Purchase Agreement and (c) the Company performed its obligation to provide other services in accordance with the TSA for <ix:nonNumeric contextRef="c-143" name="cdtx:CollaborativeArrangementOtherServicesAgreementTerm" format="ixt-sec:durday" id="f-582">75</ix:nonNumeric> days following the closing. On July 18, 2024, the Company received a notice of satisfaction from Mundipharma that it had completed the required performance obligations under the TSA and, accordingly, the $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" format="ixt:num-dot-decimal" scale="6" id="f-583">11.1</ix:nonFraction>&#160;million development milestone advance previously made to the Company, and reimbursable to Mundipharma, was forgiven by Mundipharma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The action to divest rezafungin was taken because of the Company&#8217;s strategy to streamline its portfolio and focus on the Cloudbreak platform and other financial considerations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has determined that the sale of rezafungin represents a strategic shift that had a major effect on its result of operations. Rezafungin met the criteria to be reported as discontinued operations at the time of the sale. The Company has separately reported the financial results of rezafungin as discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all prior year periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-37" decimals="INF" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-584"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="INF" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-585"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="INF" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-586"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="INF" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-587">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets and liabilities related to discontinued operations as of March&#160;31, 2025 and December&#160;31, 2024, as all balances were recognized in income from discontinued operations at the completion of the transaction.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There were no discontinued operations during the three months ended March&#160;31, 2025. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-588" continuedAt="f-588-1" escape="true">The results of operations from discontinued operations during the three months ended March&#160;31, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:</ix:nonNumeric></span></div><ix:continuation id="f-588-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Major line items constituting pretax income (loss) of discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-589">7,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="f-590">1,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="cdtx:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-591">5,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-592">2,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">9,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-594">2,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. The total net cash used in operating activities from discontinued operations was $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="f-595">6.9</ix:nonFraction> million for the three months ended March&#160;31, 2024. There were <ix:nonFraction unitRef="usd" contextRef="c-144" decimals="INF" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="0" id="f-596"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="INF" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="0" id="f-597"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="INF" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="0" id="f-598"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="INF" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="0" id="f-599">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> investing or financing activities from discontinued operations for the three months ended&#160;March&#160;31, 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&amp;D expense in the period incurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 2.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-579-3" continuedAt="f-579-4"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta Therapeutics, LLC, or Melinta, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#8217;s product to the customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">(i) Napp Purchase Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the execution of the Napp Purchase Agreement, the Company modified its existing collaboration and license arrangements and Commercial Supply Agreements with Mundipharma and Melinta. As a result of the modified revenue contracts and the termination of these revenue arrangements, the Company concluded the Napp Purchase Agreement and the other aforementioned arrangements represented a bundled arrangement with a single commercial objective that required assessment under the guidance for revenue recognition. As a result, the Company identified the distinct performance obligations within the arrangements (including whether the distinct performance obligations were within the scope of ASC 606), determined the transaction price and the standalone selling prices of the distinct performance obligations, and allocated the transaction price using the relative standalone selling price method to the distinct performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, as of the execution date of the Napp Purchase Agreement (and all other bundled arrangements), the Company determined the transaction price is equal to $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="cdtx:CollaborativeArrangementTransactionValue" format="ixt:num-dot-decimal" scale="6" id="f-600">21.2</ix:nonFraction>&#160;million for the sale of all rezafungin assets, including the Company&#8217;s right to receive future milestones and royalties from Mundipharma and Melinta, all rezafungin intellectual property rights, including patents and know-how, rezafungin and comparator inventory, specified prepaid assets, the Commercial Supply Agreements with Melinta and Mundipharma, and certain transition services. The transaction price includes the forgiveness of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" format="ixt:num-dot-decimal" scale="6" id="f-601">25.3</ix:nonFraction>&#160;million in contract liabilities (inclusive of the $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" format="ixt:num-dot-decimal" scale="6" id="f-602">11.1</ix:nonFraction>&#160;million development milestone advance) and $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" format="ixt:num-dot-decimal" scale="6" id="f-603">0.6</ix:nonFraction>&#160;million for the transition services agreement. The Company paid $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-604">2.1</ix:nonFraction>&#160;million to Napp and forgave $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="cdtx:AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" format="ixt:num-dot-decimal" scale="6" id="f-605">2.6</ix:nonFraction>&#160;million in accounts receivable, both of which are included as a reduction to the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="cdtx:CollaborativeArrangementTransactionValue" format="ixt:num-dot-decimal" scale="6" id="f-606">21.2</ix:nonFraction>&#160;million transaction price was allocated to the distinct performance obligations on the basis of their respective relative standalone selling prices.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-579-4" continuedAt="f-579-5"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">All Rezafungin assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company transferred all rezafungin assets, including all rezafungin intellectual property rights, including patents and know-how, rezafungin and comparator inventory in April 2024 at a point in time. Therefore, the Company recognized the revenue related to this bundled performance obligations in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-607">20.8</ix:nonFraction>&#160;million as revenue in the results from operations from discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Specified Prepaid Assets and Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company transferred specified prepaid and contracts in April 2024 at a point in time. The nature of the assets transferred were determined to be outside the scope of ASC 606 and therefore, the $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="cdtx:DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="f-608">0.3</ix:nonFraction>&#160;million was recorded as part of the loss on disposal of discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Transition Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company performed its services under the TSA over the initial <ix:nonNumeric contextRef="c-143" name="cdtx:CollaborativeArrangementTransitionsServicesTerm" format="ixt-sec:durwordsen" id="f-609">76-day</ix:nonNumeric> period subsequent to the effective date of the Napp Purchase Agreement. In connection with the carryover services provided after the sale of rezafungin, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-610">0.1</ix:nonFraction>&#160;million as revenue in the results of operations from discontinued operations during the second quarter of 2024. The Company's costs to provide the TSA services predominantly related to employee labor costs which were reported within R&amp;D and SG&amp;A expenses within the results of operations from discontinued operations during the second quarter of 2024. The remaining unsatisfied performance obligation as of March&#160;31, 2025 was <ix:nonFraction unitRef="usd" contextRef="c-149" decimals="INF" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:fixed-zero" scale="0" id="f-611">zero</ix:nonFraction>.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">(ii) Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Under the Mundipharma Collaboration Agreement, the Company was responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that included the Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and CMC development activities for the Mundipharma Licensed Product. Mundipharma was responsible for performing all development activities, other than Global Development Plan activities, that were necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;The Mundipharma Collaboration Agreement was terminated upon the effectiveness of the assignment to Napp on April 24, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Mundipharma Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-612">30.0</ix:nonFraction>&#160;million, plus the R&amp;D funding of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="f-613">31.2</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-614">27.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement was as follows:</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Mundipharma in September 2019.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma shared equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represented a distinct performance obligation. The Company recorded these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the R&amp;D services was best measured in an amount proportional to the R&amp;D expenses incurred and the total estimated R&amp;D expenses.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represented a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services was best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-579-5" continuedAt="f-579-6"><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In November 2020, the Company achieved a milestone under the Mundipharma Collaboration Agreement, and received payment for this milestone in January 2021. Mundipharma was entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma had not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company would have been obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. The full amount was forgiven in July 2024 as part of the rezafungin asset sale and the Company included it in the transaction price of the Napp Purchase Agreement. In December 2021, August 2022, December 2023 and January 2024, the Company achieved milestones under the Mundipharma Collaboration Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in January 2022, September 2022, February 2024 and April 2024, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">(iii) Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contained or incorporated rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company was responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that included, among other activities, (a) completion of the ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a supplemental new drug application, or sNDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that were required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company remained the holder of the rezafungin IND and new drug application, or NDA, before the Melinta License Agreement was assigned as part of the Napp Purchase Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Melinta License Agreement was terminated upon the effectiveness of the assignment to Napp on April 24, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Melinta License Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-615">30.0</ix:nonFraction>&#160;million, plus a milestone achieved of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-616">20.0</ix:nonFraction>&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&amp;D efforts and costs for manufacturing clinical supplies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of the distinct performance obligations identified under the Melinta License Agreement was as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company was required to provide R&amp;D services, at its sole expense, as described under the Melinta Development Plan, which represented a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the R&amp;D services was best measured in an amount proportional to the R&amp;D expenses incurred and the total estimated R&amp;D expenses.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="f-579-6"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represented a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services was best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In March 2023, the Company achieved a milestone under the Melinta License Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in April 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the termination date of both the Mundipharma Collaboration Agreement and the Melinta License Agreement, there was <ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:fixed-zero" scale="6" id="f-617">no</ix:nonFraction> aggregate transaction price allocated to performance obligations that was unsatisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, the Company recorded <ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="f-618"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="INF" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="f-619">no</ix:nonFraction></ix:nonFraction> accounts receivable or contract liabilities associated with the Mundipharma Collaboration Agreement and Melinta License Agreement. As of March&#160;31, 2025, the Company recorded accounts receivable associated with the Napp Purchase Agreement of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-620">1.7</ix:nonFraction>&#160;million.</span></div><ix:continuation id="f-538-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from Collaboration, License and Commercial Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestone achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-621">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-623">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-625">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-626">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-627">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-628">317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-629">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenue from Collaboration, License and Commercial Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-631">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-632">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation><div id="i49f81b51ab9a48059db3fc4265446fcd_1119"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-633" continuedAt="f-633-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-633-1"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Pre-funded Warrants Exercise</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2025, pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="cdtx:ClassOfWarrantOrRightExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-634">337,552</ix:nonFraction> shares of common stock were cashless exercised resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="cdtx:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-635">337,548</ix:nonFraction> shares of the Company's common stock and an immaterial cash payment by the Company in lieu of fractional shares.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Series A Convertible Preferred Stock Conversion</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2025, at the request of certain holders, <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-636">5,587</ix:nonFraction> shares of the Company&#8217;s Series A Convertible Preferred Stock were converted to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-637">391,090</ix:nonFraction> shares of the Company&#8217;s common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Termination of Controlled Equity Sales Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, the Company and Cantor terminated the Cantor Sales Agreement.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Entry into Open Market Sale Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or the Jefferies Sales Agreement, with Jefferies LLC, or Jefferies, under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company's common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="cdtx:SaleOfStockConsiderationReceivablePerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-638">150.0</ix:nonFraction>&#160;million through Jefferies as the Company's sales agent. The Company has <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-639">not</ix:nonFraction> sold any shares of its common stock under the Jefferies Sales Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, or our Quarterly Report, and our Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the Securities and Exchange Commission, or the SEC, on March 6, 2025, or our Annual Report.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, clinical and nonclinical data, future operations, future financial position, future revenues, projected costs and prospects and plans and objectives of management. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a biotechnology company using our proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform to develop drug-Fc conjugate, or DFC, therapeutics designed to save lives and improve the standard of care for patients facing serious diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lead clinical-stage asset is CD388, a novel long-acting antiviral which we are developing for broad spectrum influenza prophylaxis. CD388 combines a novel multivalent presentation of zanamivir, the antiviral small molecule that is the active ingredient of an FDA-approved drug, with a human antibody fragment to prolong half-life. As a broad-spectrum antiviral that is not dependent on the host immune response for activity, it has the potential to overcome key limitations of existing vaccines. Its unique properties substantially enhance its antiviral activity, making it a potential best-in-class neuraminidase inhibitor. We believe it has the potential to provide universal protection against all influenza A and B virus strains, including high pathogenicity strains like H5N1, also known as avian influenza or bird flu, with potential for single dose per flu season protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara discovered and advanced CD388 to the clinic under a license and collaboration agreement, or the Janssen Collaboration Agreement, that we entered in March 2021 with J&amp;J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, or Janssen. In 2023, as part of a prioritization of its research and development, or R&amp;D, business, Janssen disclosed its intention to discontinue internal development of multiple product candidates in its infectious disease pipeline, including CD388. Janssen subsequently conducted a competitive divestiture process of its infectious disease portfolio in which we participated and subsequently reacquired all rights to develop and commercialize CD388 in April 2024. Under the terms of a license and technology transfer agreement we entered into with Janssen in April 2024, or the Janssen License Agreement, we received an exclusive, worldwide, fee-bearing but royalty-free license under certain Janssen-controlled technology to develop, manufacture and commercialize CD388 for prophylaxis and treatment of influenza. To date, we have completed two Phase 1 studies and one Phase 2a study of CD388 under the Janssen Collaboration Agreement, and we are currently conducting a 5,041 subject, randomized, double-blind, controlled Phase 2b clinical trial, or the NAVIGATE study, evaluating the efficacy and safety of CD388 for pre-exposure prophylaxis of seasonal influenza. Top-line data from the NAVIGATE study is expected in late June 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Concurrent with the CD388 reacquisition in April 2024, we completed a private placement, which provided $240.0&#160;million in gross proceeds, or the April 2024 Private Placement, of which we used $85.0&#160;million to fund the upfront payment under the Janssen License Agreement. The remainder of the gross proceeds of $155.0&#160;million, together with gross proceeds of $105.0&#160;million from a private placement we completed in November 2024, or the November 2024 Private Placement, are being utilized to fund the ongoing development of CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, in April 2024 we simultaneously divested rezafungin, our sole non-Cloudbreak asset, to enable us to focus our resources on the development of CD388. We entered into an asset purchase agreement, or the Napp Purchase Agreement, with Napp Pharmaceutical Group Limited, or Napp, an affiliate of Mundipharma Medical Company, or Mundipharma, our licensee for the asset in all territories other than the United States, or U.S., and Japan, pursuant to which we sold to Napp all of our rezafungin assets, including our right to receive future milestones and royalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following these transactions, our sole R&amp;D focus has now shifted to developing CD388 as a highly potent antiviral designed to deliver universal prophylaxis and treatment of seasonal and pandemic influenza.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe our Cloudbreak platform has the potential to offer a fundamentally new approach to treat and prevent serious diseases such as viral infections and solid tumors cancers, by developing product candidates designed to provide potent disease targeting activity without immune system engagement in a single long-acting molecule. We believe this is a potentially transformative approach, distinct from current therapies, including antibody drug conjugates, or ADCs, monoclonal or multi-specific antibodies and vaccines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">DFCs are fundamentally different from ADCs: DFCs are biologically stable drug-Fc conjugates designed to engage extracellular targets, while ADCs are designed to enter target cells to deliver and release cytotoxic small molecule drugs. DFCs are conjugated using non-cleavable linkers and remain intact in the body until elimination with minimal degradation products. In contrast to ADCs and monoclonal antibodies, DFCs are smaller, providing the potential for better tissue penetration and targeting multiple sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed above, our most advanced Cloudbreak product candidate is CD388, a highly potent antiviral designed to deliver universal prophylaxis and treatment of seasonal and pandemic influenza. Our lead oncology DFC is CBO421, a development candidate targeting CD73, a key component of the adenosine pathway, for the treatment of solid tumors, which received investigational new drug application, or IND, clearance in July 2024. We do not plan to initiate clinical trials for any oncology product candidates at this time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cloudbreak Influenza Program (CD388)</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have completed two Phase 1 studies and one Phase 2a study of CD388:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">A Phase 1 randomized, double-blind, dose-escalation study to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy subjects (NCT05285137);</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">A Phase 1 Japanese bridging study to assess safety, tolerability and pharmacokinetics in Japanese adults (NCT05619536); and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">A Phase 2a randomized, double-blind human challenge study to evaluate the pre-exposure prophylactic activity of CD388 against influenza (NCT05523089).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We initiated the NAVIGATE study in September 2024 and expect top-line results in late June 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022, we received the first U.S. patent for CD388 (no. 11,838,212). The patent includes claims directed to the composition of matter of CD388. The patent is projected to expire in 2039 plus any available patent term extension. The latest of the issued patents and any patents that result from our currently pending applications would be expected to expire in 2044, should they be issued, excluding any additional term for patent term adjustments or applicable patent term extensions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2023, the U.S. Food and Drug Administration, or FDA, granted Fast Track designation to CD388 for the prevention of influenza A and B infection in adults who are at high risk of influenza complications due to underlying immunodeficiency and may not mount an adequate response to influenza vaccine or are at high risk of severe influenza despite influenza vaccination, including those for whom vaccines are contraindicated. Fast Track designation aims to facilitate the development and expedite the review of drugs to treat serious conditions with unmet medical needs. The purpose is to get important new drugs to patients earlier. Companies that are granted this designation are given the opportunity for more frequent interactions with the FDA, and, if relevant criteria are met, eligibility for Priority Review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">CD388 Phase 1 and Phase 2a Results</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 21, 2023, we announced safety and pharmacokinetics data from our Phase 1 studies, as well as safety and efficacy data from our Phase 2a human challenge study evaluating the pre-exposure prophylactic activity of CD388 against an H3N2 influenza A virus strain.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 Clinical Data Supports Potential for Season-long Influenza Protection:</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In total, 108 subjects were dosed in our Phase 1 and Phase 2a studies, 84 of which were dosed subcutaneously, or SQ, and 24 were dosed intramuscularly, or IM. CD388 was well-tolerated up to 900 milligrams, or mg, (maximum dose tested).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.600%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.604%"/><td style="width:0.1%"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Percent of SQ CD388 or Placebo Treatment Related Adverse Events in Phase 1 and Phase 2a studies</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">First in Human Study (Phase 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Japanese Bridging Study (Phase 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Human Challenge Study (Phase 2a)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Dose</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CD388 N=8/dose;<br/>Placebo N=12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CD388 N=7*/dose;<br/>Placebo N=6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">50mg N=2;<br/>150mg N=28;<br/>Placebo N=29</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Placebo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">50 mg</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">150 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">450 mg</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">900 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Safety Summary:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No treatment-emergent serious adverse events, or SAEs, and no discontinuation of study drug or withdrawals due to safety findings.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No consistent adverse event, or AE, patterns. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No hypersensitivity reactions.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Most treatment-emergent adverse events, or TEAEs, were Grade 1 (90%), few Grade 2, all resolved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Incidence of TEAE not dose-dependent.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Few injection site events (pain, IM, route mainly), Grade 1, all resolved spontaneously.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No clinically relevant electrocardiogram, or ECG, vital signs or physical exam abnormalities.</span></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">* 150mg N=8</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Single CD388 dose of 150 mg to 450 mg potentially provides seasonal coverage:</span></div><div style="margin-top:6pt"><img src="cdtx-20250331_g1.jpg" alt="cdtx-2025-03_g01.jpg" style="height:373px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" id="i-1"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 demonstrated protection in Phase 2a Human Challenge Model:</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Phase 2a prophylactic efficacy results are based on 56 subjects enrolled in the trial, with 28 subjects receiving a single dose of CD388 (150 mg) and 28 subjects receiving a placebo.</span></div><div style="margin-top:6pt"><img src="cdtx-20250331_g2.jpg" alt="cdtx-2025-03_g02.jpg" style="height:310px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" id="i-2"/></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All participants included in the analysis received either CD388 or a placebo and were then challenged with influenza five days later. As shown above, despite the small sample size in this analysis, a decrease in influenza infection was observed in participants receiving a single dose of CD388 when compared to placebo. No treatment emergent adverse events leading to study discontinuation or SAEs were reported in the analysis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">CD388 Phase 2b NAVIGATE Study</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We initiated the NAVIGATE study during the 2024-25 Northern Hemisphere influenza season, with dosing of the first subjects on September 20, 2024. Dosing of 5,041 subjects in the NAVIGATE study were completed in early December of 2024 across clinical sites in the U.S. and the United Kingdom. The NAVIGATE study is a randomized, double-blinded, controlled trial with single doses of CD388 or placebo administered at the beginning of the influenza season with subjects followed for the influenza season to monitor for breakthrough cases of influenza. Randomization was 1:1:1:1 to treatment with either one of three CD388 dose groups (150 mg, 300 mg, or 450 mg) and one placebo group. The primary endpoint of this study will compare the rates of laboratory-confirmed clinical influenza between different dose levels of CD388 and placebo over an influenza season. The patient population in this study is comprised of healthy adults who have not received an influenza vaccination for the 2024-25 season. The NAVIGATE study was initially designed primarily to determine dose selection for a Phase 3 study and was not powered for statistical significance. However, as a result of the severity of the 2024-25 flu season, we are discussing potential changes to the study's statistical analysis plan with the FDA to evaluate possible implementation of inferential statistical testing of the primary endpoint. We have established April 30, 2025 as the data cutoff for the primary efficacy analysis of the 5,041 subjects dosed in the NAVIGATE study. Top-line data is expected in late June 2025. Pending the results of the NAVIGATE study and our regulatory discussions, we plan to initiate a Phase 3 study in the spring of 2026 during the Southern Hemisphere influenza season. Refer to other risks described in Part II, Item 1A. &#8220;Risk Factors&#8221; of this Quarterly Report.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Compliance with Nasdaq Listing Requirements and Reverse Stock Split</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Capital Market, which has as one of its continued listing requirements a minimum bid price of at least $1.00 per share, or the Minimum Bid Price Requirement. On November 9, 2023, we received a notification letter from the Listing Qualification Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, advising us that for 30 consecutive trading days preceding November 6, 2023, the bid price of our common stock had closed below the Minimum Bid Price Requirement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At our special meeting of stockholders held on April 4, 2024, our stockholders approved a proposal to (i) amend our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding common stock at a ratio in the range of 1-for-10 to 1-for-30, inclusive; and (ii) if and only if the reverse stock split is approved and implemented, a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the reverse stock split ratio.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 12, 2024, our board of directors approved a reverse stock split of all outstanding shares of our common stock at a ratio of 1-for-20, or the Reverse Stock Split, and a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the Reverse Stock Split ratio. On April 22, 2024, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment of our Amended and Restated Certificate of Incorporation, or the Charter Amendment, to effect the Reverse Stock Split. The Charter Amendment became effective at 5:00 p.m. Eastern Time on April 23, 2024. Our common stock began trading on The Nasdaq Capital Market on a split-adjusted basis when the market opened on April 24, 2024 under a new CUSIP number (171757206).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 14, 2024, we received a letter from the Staff notifying us that we had regained compliance with Nasdaq&#8217;s requirements for continued listing. In addition, the Nasdaq Hearings Panel, or the Panel, imposed a discretionary Panel monitor until May 14, 2025, such that if we fail to maintain compliance with any continued listing requirement during such period, the Staff will issue a delist determination letter and we will promptly schedule a new hearing before the Panel to address such noncompliance.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Impact of Macroeconomic Conditions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our business is subject to various trends, events or uncertainties that are reasonably likely to cause our reported financial information not to be necessarily indicative of future operating results or of future financial condition. We may be impacted by broader macroeconomic conditions, including global pandemics, inflation, bank failures, labor shortages, supply chain disruptions, recession risks, the recent presidential election in the U.S., current or future tariffs and potential disruptions from the ongoing Russia-Ukraine conflict and related sanctions and the active conflicts in the Middle East. The stock market, and in particular the market for pharmaceutical and biotechnology company stocks, has recently experienced significant decreases in value. This volatility and valuation decline have affected the market prices of securities issued by many companies, often for reasons unrelated to their operating performance.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Equivalents Outstanding</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had 12,209,150 shares of common stock outstanding, 204,725 shares of Series A Convertible Voting Preferred Stock outstanding, which are convertible into 14,330,750 shares of common stock, 975,208 shares of Series X Convertible Preferred Stock outstanding, which are convertible into 487,604 shares of common stock, warrants to purchase up to 866 shares of our common stock outstanding, pre-funded warrants to purchase up to 2,491,975 shares of our common stock outstanding, and outstanding stock options and restricted stock units covering 3,151,477 shares of our common stock for a total of 32,671,822 shares of common stock equivalents outstanding.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Overview</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have a limited operating history and the sales and income potential of our business and market are unproven. We have experienced net losses and negative cash flows from operating activities since our inception. As of March&#160;31, 2025, we had an accumulated deficit of $634.7&#160;million. We expect to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support our cost structure.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2025, we had cash, cash equivalents and restricted cash of $174.5 million, which we expect will provide sufficient liquidity for a period of at least one year following the date that our condensed consolidated financial statements are issued as part of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to execute our current business plan depends on our ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. We may not be able to raise additional funding on terms acceptable to us, or at all, and any failure to raise funds as and when needed will compromise our ability to execute our business plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We plan to continue to fund our losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have generated all of our revenues from our strategic partnership with Janssen. In the future, we may generate revenue from a combination of license fees and other upfront payments, other funded R&amp;D agreements, milestone payments, product sales, government and other third-party funding and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of nonclinical, clinical, regulatory and commercialization milestones, the timing and amount of payments relating to such milestones and the extent to which our products are approved and successfully commercialized.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to fund our development costs or we are unable to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, our R&amp;D expenses have related primarily to nonclinical and clinical development of our Cloudbreak platform. R&amp;D expenses consist of wages, benefits and stock-based compensation for R&amp;D employees, as well as the cost of scientific consultants, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials. We accrue clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies or other activities within studies and other events.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the study or project and the invoices received from our external service providers. We adjust our accruals as actual costs become known.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of development, primarily due to the increased size and duration of later-stage clinical trials. However, it is difficult to determine with certainty the duration, costs and timing to complete our current or future nonclinical programs and clinical trials of our product candidates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">per patient trial costs;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients that participate in the trials;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of sites included in the trials;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the countries in which the trials are conducted;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of doses that patients receive;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">potential additional safety monitoring or other studies requested by regulatory authorities;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the duration of patient follow-up;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the phase of development of the product candidate; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and safety profile of the product candidates.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses by major program or category for</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> the three months ended March&#160;31, 2025 and 2024,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cloudbreak platform</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,600&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,919&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We typically deploy our employees, consultants and infrastructure resources across our programs. Thus, some of our R&amp;D expenses are not attributable to an individual program but are included in other R&amp;D expenses as shown above.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative, or G&amp;A, expenses relate to finance, human resources, legal and other administrative activities. G&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning, and support functions. Other G&amp;A expenses include facility and overhead costs not otherwise included in R&amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Other income, net</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income and expense, and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market accounts for cash, cash equivalents and restricted cash. Interest expense represents interest on finance lease liabilities.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, we entered into the Napp Purchase Agreement with Napp, pursuant to which we sold to Napp all of our rezafungin assets and related contracts. We completed all conditions of the sale on April 24, 2024. We determined that the sale of rezafungin represented a strategic shift that will have a major effect on our operations and financial results. Accordingly, the sale of rezafungin is classified as discontinued operations.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We present discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net loss from discontinued operations, net of income taxes, in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 to the condensed consolidated financial statements for additional information.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon unaudited financial statements that we have prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these unaudited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities as of the date of the financial statements, and the revenues and expenses incurred during the reporting periods. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements. While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements contained in our Annual Report, and there have not been any material changes in our significant accounting policies since December 31, 2024, the significant accounting estimates that we believe are important to aid in fully understanding and evaluating our reported financial results include the following:</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances known at that time. Our accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to R&amp;D expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended March&#160;31, 2025 and 2024 </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2025 and 2024 (in thousands):</span></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(973)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reversal of indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5,510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration revenue</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Collaboration revenue was zero for the three months ended March&#160;31, 2025 and $1.0 million for the three months ended March&#160;31, 2024. Collaboration revenue for the three months ended March&#160;31, 2024 related to R&amp;D and clinical supply services provided to Janssen under the Janssen Collaboration Agreement. The Janssen Collaboration Agreement was terminated upon the effectiveness of the Janssen License Agreement on April 24, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses were $24.6 million for the three months ended March&#160;31, 2025 and $5.9&#160;million for the three months ended March&#160;31, 2024.&#160;The increase in R&amp;D expenses is primarily due to higher expenses associated with our NAVIGATE study and higher personnel costs in continuing operations without allocation to discontinued operations and other one-time personnel costs, offset by lower nonclinical expenses associated with our Cloudbreak platform.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">G&amp;A expenses were $6.2 million for the three months ended March&#160;31, 2025 and $3.6 million for the three months ended March&#160;31, 2024. The increase in G&amp;A expenses is primarily due to higher personnel costs, offset by lower legal costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Reversal of indirect tax liabilities</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2025 we determined that accrued indirect taxes totaling $5.5 million were not due and payable upon voluntary disclosure and full compliance in certain jurisdictions and the associated liabilities and operating expenses were reversed as part of continuing operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other income, net</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income, net during the three months ended&#160;March&#160;31, 2025 related primarily to interest income generated from cash held in interest-bearing accounts and a gain on disposal of property and equipment, offset by interest expense on the finance lease liability before its assignment and a loss on assignment of the finance lease. Other income, net during the three months ended&#160;March&#160;31, 2024 related primarily to interest income generated from cash held in interest-bearing accounts, offset by interest expense on finance lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Loss from discontinued operations</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, we entered into the Napp Purchase Agreement with Napp, pursuant to which we sold to Napp all of our rezafungin assets and related contracts. We completed all conditions of the sale on April 24, 2024. We determined that the sale of rezafungin represented a strategic shift that will have a major effect on our operations and financial results. Accordingly, the sale of rezafungin is classified as discontinued operations.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss from discontinued operations was zero for the three months ended March&#160;31, 2025.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Loss from discontinued operations was $2.1 million for the three months ended&#160;March&#160;31, 2024 and primarily consisted of revenue of $7.5 million related to R&amp;D and clinical supply services and product sales provided to Mundipharma and Melinta Therapeutics, LLC, offset by (i) cost of product revenue of $1.6 million, (ii) R&amp;D expenses of $5.7 million associated with rezafungin clinical trial and development costs, (iii) and selling, general and administrative expenses of $2.4 million associated with rezafungin.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash, cash equivalents and restricted cash, as well as equity financings. We have devoted our resources to funding R&amp;D programs, including research, preclinical and clinical development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to fund future operating needs will depend on a combination of equity, debt or other financing structures, potentially entering into collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide from geopolitical and macroeconomic events, including global pandemics, the recent presidential election in the U.S., the ongoing Russia-Ukraine conflict and related sanctions, the active conflicts in the Middle East, and bank failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 8, 2018, we entered into the controlled equity offering sales agreement with Cantor Fitzgerald &amp; Co., or the Cantor Sales Agreement, under which we could offer and sell, from time to time at our sole discretion, shares of our common stock. We have not sold any shares of our common stock under the Cantor Sales Agreement since July 2023. On May 8, 2025, we and Cantor terminated the Cantor Sales Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or the Jefferies Sales Agreement, with Jefferies LLC, or Jefferies, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as our sales agent. We have not sold any shares of our common stock under the Jefferies Sales Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the April 2024 Private Placement, on April 23, 2024, we entered into a securities purchase agreement with certain institutional and other accredited investors, pursuant to which we issued and sold 240,000 shares of Series A Convertible Voting Preferred Stock at a purchase price of $1,000 per share. The closing of the April 2024 Private Placement took place on April 24, 2024, and we received total gross proceeds of $240.0&#160;million. As a condition to the effectiveness of the Janssen License Agreement, we paid Janssen an upfront payment of $85.0&#160;million on April 24, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 9, 2024, our management, as authorized by our board of directors, approved a reduction in our workforce of 20 employees, which represented approximately 30% of our workforce, or the Reduction. The Reduction was completed on November 1, 2024 and has and is expected to continue to substantially reduce our capital needs related to recurring personnel costs going forward.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the November 2024 Private Placement, on November 20, 2024, we entered into a securities purchase agreement with certain institutional and other accredited investors named therein, or the November 2024 Purchasers, pursuant to which we issued and sold (i) an aggregate of 3,892,274 shares of our common stock at a purchase price of $14.912 per share, and (ii) in lieu of shares of common stock to certain November 2024 Purchasers, pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The closing of the November 2024 Private Placement took place on November 26, 2024, and we received total gross proceeds of $105.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 11, 2024, we established a standby letter of credit with our banking institution, Wells Fargo, for $6.0&#160;million for the benefit of our indirect tax service provider, as it relates to indirect tax compliance services in various tax jurisdictions outside of the U.S. in connection with the rezafungin supply chain activities and commercial sales of REZZAYO. The letter of credit expires on November 30, 2025 and is automatically extended without amendment for an additional one-year period from the current expiration date, unless notified by us to terminate prior to 90 days from any expiration date. The cash held as collateral for this standby letter of credit is recorded as restricted cash and is held in an interest-bearing account.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we have no outstanding loan balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lease with Nancy Ridge Technology Center, L.P. expires on December&#160;31, 2026 with options for two individual two-year extensions, which have not been exercised, and remain in effect and available to us. As of March&#160;31, 2025, we were not reasonably certain that we would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. Total undiscounted operating lease payments were $3.0&#160;million as of March&#160;31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. Sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of pandemics, sanctions, current or future tariffs, or other macroeconomic events may pose operational challenges in those countries. We will continue to monitor these conditions and will attempt to adjust our business plans, as appropriate, to mitigate macroeconomic risks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with vendors for R&amp;D activities, manufacturing, and professional services that generally provide for termination either on notice or after a notice period. Our material cash requirements include costs to conduct R&amp;D activities associated with our Cloudbreak platform, as well as personnel and G&amp;A support costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the three months ended March&#160;31, 2025 and 2024 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21,950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21,688)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,760)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.0 million for the three months ended March&#160;31, 2025, compared to $6.6&#160;million for the three months ended March&#160;31, 2024. Cash used in operating activities for the three months ended March&#160;31, 2025 was primarily due to a net loss of $23.5 million adjusted for (i) $3.3&#160;million of non-cash operating activities, primarily for stock-based compensation, non-cash operating lease expense, loss on assignment of finance lease, and reversal of indirect tax liabilities, and (ii) $4.8 million of changes in operating assets and liabilities. Cash used in operating activities for the three months ended March&#160;31, 2024 was primarily attributable to a net loss of $10.3&#160;million adjusted for (i) $1.1&#160;million of non-cash operating activities, primarily for stock-based compensation and non-cash operating lease expense, and (ii) $2.6 million of changes in operating assets and liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For all periods presented, the primary use of cash was to fund R&amp;D activities for our product candidates, which activities and uses of cash we expect to continue to increase for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the three months ended March&#160;31, 2025 consisted of proceeds from sales of property and equipment. Net cash used in investing activities during the three months ended March&#160;31, 2024 consisted of purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the three months ended March&#160;31, 2025 consisted of proceeds from the exercise of stock options, offset by the payment of finance lease liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in financing activities during the three months ended March&#160;31, 2024 consisted of the payment of finance lease liabilities and the payment for shares withheld to fund payroll taxes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. The total net cash used in operating activities from discontinued operations was $6.9 million for the three months ended&#160;March&#160;31, 2024. There were no investing or financing activities from discontinued operations for the three months ended&#160;March&#160;31, 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The absence of cash outflows from discontinued operations is expected to reduce our operating cash outflows from continuing operations given that we no longer have any future obligations related to rezafungin-related assets and contracts sold to Napp in April 2024. The expected cash outflows for these obligations to complete the ongoing clinical trials, development activities, and manufacturing activities would have been offset by any near-term future milestones and royalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. We plan to continue to fund our losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide information typically disclosed under this item.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we carried out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March&#160;31, 2025.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_97"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We need substantial additional funding to advance CD388 beyond Phase 2b, and to advance CBO421 and our other Cloudbreak programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We depend heavily on the success of CD388, which has completed Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If clinical trials for CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Any of our product candidates that receive marketing approval may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We have no experience manufacturing product candidates on a clinical or commercial scale and we are dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be unable to resume our preclinical Cloudbreak programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, as well as the other information in this Quarterly Report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_103"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We need substantial additional funding to advance CD388 beyond Phase 2b, and to advance CBO421 and our other Cloudbreak programs.*</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to advance CD388 beyond Phase 2b, and to advance CBO421 and other product candidates from our other Cloudbreak programs is dependent on our ability to obtain additional funding.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There can be no assurance that additional funds will be available from any source or, if available, will be available on terms that are acceptable to us. There can also be no assurance that additional funds will be available to us without first obtaining the approval of our stockholders, which can be a difficult and lengthy process with an uncertain outcome.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if we raise additional capital, our expenses may increase in connection with our ongoing activities beyond what is currently expected. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing to complete our CD388 trials through to Phase 2b;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs, timing and outcome of any regulatory review of CD388, CBO421 or future development candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to establish and maintain collaborations, when and if necessary, on favorable terms, if at all;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing of commercialization activities, including manufacturing, marketing, sales and distribution, for any future product candidates that receive marketing approval;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the scope, progress, results and costs of drug discovery, preclinical development, manufacturing development, laboratory testing and clinical trials for our product candidates, for the Cloudbreak platform; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Identifying potential development candidates and conducting preclinical studies, manufacturing development and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for any of our current or future product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accordingly, we will need substantial additional funding in connection with our continuing operations and to achieve our goals. As of March&#160;31, 2025, we had cash, cash equivalents and restricted cash of $174.5 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive. In addition, we may not be able to access a portion of our existing cash, cash equivalents and restricted cash due to market conditions such as potential future disruptions in access to bank deposits or lending commitments due to bank failures, which could have a material adverse effect on our business and financial condition. In addition, if the financial market disruptions and economic slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could negatively affect our financial condition and our ability to pursue our business strategy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional capital on attractive terms or at all, we may be forced to delay, reduce or eliminate our development programs, including CD388 or one or more of our other Cloudbreak DFC programs, or any future license or collaboration agreements, and/or be forced to make reductions in spending, extend payment terms with suppliers, and/or liquidate or grant rights to assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity, debt or other financing structures, as well as potentially entering into collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2018, we entered into the Cantor Sales Agreement, under which we could offer and sell, from time to time at our sole discretion, shares of our common stock. We have not sold any shares of our common stock under the Cantor Sales Agreement since July 2023. On May 8, 2025, we and Cantor terminated the Cantor Sales Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, we entered into the Jefferies Sales Agreement, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as our sales agent. We have not sold any shares of our common stock under the Jefferies Sales Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the April 2024 Private Placement, we received $240.0&#160;million in gross proceeds, of which we used $85.0&#160;million to fund the upfront payment under the Janssen License Agreement. The remainder of the gross proceeds of $155.0&#160;million together with gross proceeds of $105.0&#160;million from the November 2024 Private Placement, are being utilized to fund the ongoing development of CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, like our sale of Series A Convertible Voting Preferred Stock in the April 2024 Private Placement and our sale of common stock and pre-funded warrants in the November 2024 Private Placement, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds by entering into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. We may need to enter into agreements with third parties for the development and commercialization of DFCs identified from our Cloudbreak program which may require that we relinquish valuable rights to these products.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds through government grants and contracts, we may be subject to restrictions on our operations or certain unfavorable terms. U.S. government grants and contracts, if available, typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. If we receive a U.S. government grant or contract, we would be required to comply with numerous laws and regulations relating to the formation, administration and performance of the grant or contract, which can make it more difficult for us to retain our rights under such grant or contract and result in increased costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity, debt or other financing structures, or through collaborations, strategic alliances or licensing arrangements with third parties, or through receiving government and/or charitable grants or contracts, we may be required to delay, reduce or terminate our advancement of the Cloudbreak program for non-influenza DFCs, or be forced to grant rights in the Cloudbreak program for non-influenza DFCs that we would otherwise prefer to retain for ourselves.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since our inception, and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.*</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We incurred a net loss of $23.5&#160;million and $10.3&#160;million for the three months ended March&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2025, we had an accumulated deficit of $634.7 million. To date, we have financed our operations primarily through sale of our stock in public offerings and private placements, through borrowings under loan facilities, and through payments received in connection with our prior collaborations. We have completed Phase 1 and Phase 2a studies of CD388. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">submit investigational new drug applications, or INDs, to the U.S. Food and Drug Administration, or FDA, and equivalent filings to other regulatory authorities, and seek approval of our clinical protocols by institutional review boards at clinical trial sites;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue to advance CD388 through clinical development;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">resume the preclinical development of CBO421 and other DFCs from our Cloudbreak platform or otherwise, and advance one or more of such product candidates into clinical trials;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">seek marketing approvals for CD388, CBO421 and other product candidates;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establish or contract for a sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain marketing approval;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">maintain, expand and enforce our intellectual property portfolio;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">hire additional manufacturing, clinical, regulatory, quality assurance and scientific personnel;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">add operational, financial and management systems and personnel, including personnel to support product development; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenue that is significant or large enough to achieve profitability.&#160;Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development, or R&amp;D, efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the recent global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, rising inflation, bank failures, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make access to our liquidity within the U.S. banking system and any additional debt or equity financing more difficult, more costly and more dilutive.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The active conflicts in the Middle East and the conflict between Russia and Ukraine could lead to disruption, instability and volatility in global markets and industries that could negatively impact our operations. For example, in connection with the conflict between Russia and Ukraine, the U.S. government and other governments in jurisdictions in which we operate have imposed severe sanctions and export controls against Russia and Belarus, as well as Belarusian and Russian interests, and threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia or Belarus, is currently unknown and they could adversely affect our business, supply chain, partners or customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We operate in a global economy, which includes utilizing third-party suppliers in certain countries outside the United States. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. The U.S. government has recently </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">announced substantial new tariffs affecting a wide range of products and jurisdictions and has indicated an intention to continue developing new trade policies, including with respect to the pharmaceutical industry. In response, certain foreign governments have announced or implemented retaliatory tariffs and other protectionist measures. These developments have created a dynamic and unpredictable trade landscape, which may adversely impact our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not own or operate facilities for the manufacture of our product candidates and we currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties, including manufacturers and suppliers located in China, the United Kingdom, and the European Union, for the manufacture of supplies of our product candidates for preclinical and clinical activities and materials used in those product candidates. In particular, our most advanced product candidate, CD388, is currently manufactured solely by WuXi XDC and affiliated companies in China. While we are assessing options for moving manufacturing to alternate third-party manufacturers outside China, technology transfer is a long, complex and expensive process and there can be no certainty that we will be able to establish additional or alternate manufacturing locations for any component of CD388 production. We expect to rely on third parties as well for commercial manufacture if any of our product candidates receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current or future tariffs may result in increased research and development expenses, including with respect to increased costs associated with active pharmaceutical ingredients, raw materials, laboratory equipment and research materials and components. In addition, such tariffs may increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, developments in trade and other regulations may restrict our ability to work with partners in China and other countries, thereby potentially disrupting our supply chain. In the event any of our product candidates is approved, tariffs and trade restrictions could hinder our ability to establish cost-effective commercial production and distribution capabilities, negatively impacting our growth prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The complexity of announced or future tariffs may also increase the risk that we or our partners, suppliers or future customers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to compete internationally and attract non-U.S. investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition and prospects. In addition, tariffs and other trade developments have and may continue to heighten the risks related to the other risk factors described elsewhere in this Quarterly Report.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have no history of commercializing pharmaceutical products, which may make it difficult for you to evaluate the prospect for our future viability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have not yet demonstrated an ability to conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop one new product from the time it is discovered to when it is commercially available. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had product candidates in advanced clinical trials.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. We will need to continue to transition from a company with a research focus to a company capable of supporting late-stage development activities and, if a product candidate is approved, a company with commercial activities. We may not be successful in any step of such a transition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Drug Discovery, Development and Commercialization</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of CD388, which has completed Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We received IND clearance for CD388, our DFC for prevention and treatment of influenza, from the FDA in March 2022 and have completed a Phase 1 clinical trial and a Phase 2a clinical trial of CD388 to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus as well as a separate Phase 1 Japanese bridging study. In September 2024, we initiated the CD388 Phase 2b NAVIGATE trial to be conducted during the Northern Hemisphere influenza season and on December 4, 2024 we announced that enrollment in the trial was complete. We received IND clearance for CBO421 in July 2024. Our assumptions about why CD388 is worthy of continued development, as well as our assumptions about the market for CD388 or any other potential products from our Cloudbreak program, are based on data primarily collected by other companies. The timing and costs of our preclinical and clinical development programs, the likelihood of any marketing approval for CD388, and the regulatory paths for marketing approval for additional products from our Cloudbreak program remain uncertain. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lead oncology DFC is CBO421, a development candidate targeting CD73, a key component of the adenosine pathway, for the treatment of solid tumors, which received IND clearance in July 2024. We do not plan to initiate clinical trials for any oncology product candidates at this time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The success of CD388 and any other product candidates we may develop will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to secure adequate additional funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">agreement with regulatory authorities on study designs and other requirements for study initiation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful completion of preclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful enrollment and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">demonstration of safety and efficacy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">negotiation of favorable indications and other key elements of the product labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">launching commercial sales of the product candidates if and when approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">effectively competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a continued acceptable safety profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enforcing and defending intellectual property rights and claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we do not accomplish one or more of any of the other goals in a timely manner, or at all, we could experience significant delays or an inability to successfully complete the development of and commercialize our product candidates, which would harm our business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in enrolling patients in our clinical trials our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may not be able to complete the ongoing CD388 Phase 2b NAVIGATE trial or enroll a sufficient number of eligible subjects into one or more Phase 3 trials to support regulatory approval of CD388, as required by the FDA or similar regulatory authorities outside the U.S., or if we do not believe that the number of patients required by such regulatory authorities can be enrolled in a reasonable timeframe.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our CD388 clinical development program is a global program and, as such, our ability to timely enroll the clinical trials may be affected by many different factors specific to those global localities, such as, delays in our receipt of approval to commence trials in a particular country from applicable regulatory authorities and ethics committees, timely completion of clinical trial site initiation within each country, delays in local importation and receipt of necessary clinical trial supplies, and our ongoing compliance with local regulations, which may change during the course of the clinical trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we are heavily reliant on third-party contractors, including contractors that import clinical trial materials, and contract research organizations, or CROs, that conduct and monitor our clinical trials, and interact with regional or local regulators and ethics committees on our behalf. If we experience significant difficulties with any of our key contractors such that we determine it is in the best interests of the clinical trials to replace a key contractor, this could result in a significant delay in enrollment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or new clinical trials for product candidates that would treat the same indication as CD388, or be used in the same patients and, therefore, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment may also be affected by other factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">eligibility criteria, including regional or local practices that place additional limitations on patient eligibility;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">availability, safety and efficacy of approved medications or other investigational medications being studied clinically for the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">perceived risks and benefits of CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reluctance of physicians to encourage patient participation in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">delays or failures in maintaining an adequate supply of quality drug product for use in clinical trials; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changing treatment patterns that may reduce the burden of disease which CD388 addresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our inability to enroll and retain a sufficient number of patients into Phase 3 clinical trials in a reasonable timeframe may require us to abandon the entire CD388 clinical development program. Any enrollment delays would result in increased development costs, which could cause the value of our company to decline and could limit our ability to obtain necessary additional financing.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A delay in starting or completing our clinical trials would materially impact our timelines and our ability to complete development of our product candidates in a timely manner or at all. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A failure of one or more clinical trials could occur at any stage of testing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a particular clinical trial do not necessarily predict final results of that trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. For example, the historically observed high rate of correlation for clinical efficacy for antivirals based on preclinical data may not apply for our current or future product candidates, and any of the potential benefits that we anticipate for human clinical use may not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not know whether clinical trials of CD388 will be completed on schedule. We may experience numerous unforeseen events that could delay or prevent our ability to commence or complete our clinical trials, which could then delay or prevent our ability to receive marketing approval or commercialize CD388, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial on our expected timeline, or at all, or conduct a clinical trial at a prospective trial site or in a given country;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may disagree with our interpretation of preclinical data, which may impact our ability to commence our trials on our expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may require that trials or studies be conducted, or sized or otherwise designed in ways, that were unforeseen in order to begin planned studies or to obtain marketing authorization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, modify planned clinical trial designs or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enrollment in these clinical trials may be slower than we anticipate, clinical sites may drop out of our clinical trials or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators, institutional review boards or the data safety monitoring board assembled by us to oversee our clinical trials may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks due to serious and unexpected side effects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the FDA or comparable foreign regulatory authorities could require that we perform more studies than, or evaluate clinical endpoints other than, those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the supply of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be delayed or insufficient, or the quality of such materials may be inadequate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may be required to delay or terminate studies due to financial constraints.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials, or other tests of our product candidates beyond those that we currently contemplate, if we are unable to complete clinical trials of our product candidates or other tests successfully or in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to significant restrictions on reimbursement from public and/or private payors; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Product development costs will also increase if we experience delays in testing or in receiving marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, could allow our competitors to bring products to market before we do, could increase competition from generics of the same class, and could impair our ability to successfully commercialize our product candidates, any of which may harm our business and results of operations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because it is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval, the risk of each of our programs is high. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For our DFCs, the bispecific mechanism of action, including the use of the immune system, may lead to side effects that are not anticipated based on the preclinical work we have conducted to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the biotechnology industry, many agents that initially show promise in early stage testing may later be found to cause side effects that prevent further development of the agents. In addition, infections can occur in patients with co-morbidities and weakened immune systems, and there may be adverse events and deaths in our clinical trials that are attributable to factors other than investigational use of our product candidates.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any of our product candidates that receive marketing approval may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any of our product candidates that receive marketing approval may nonetheless fail to gain sufficient market acceptance by hospitals and hospital pharmacies, physicians, patients, third-party payors and others in the medical community for us to achieve commercial success. If our product candidates do not achieve an adequate level of acceptance, we may not generate sufficient product revenue to become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and potential advantages compared to alternative therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size of the markets in the countries in which approvals are obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terms, limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of the target patient population to try new therapies or dosing regimens;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of physicians to prescribe these therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the success of competing products and the marketing efforts of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sufficient third-party payor coverage and adequate reimbursement; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the prevalence and severity of any side effects.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved.*</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure. To achieve commercial success for any approved product, we must license the rights to third parties with such capabilities, develop a sales and marketing organization or outsource these functions to third parties.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot reposition our sales and marketing personnel.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability of sales personnel to obtain access to physicians or to achieve adequate numbers of prescriptions for any future products; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenues to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties and any of them may fail to market and sell our products effectively, including by failing to devote the necessary resources and attention. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Regulatory incentives to develop drugs for treatment of infectious diseases have increased interest and activity in this area and will lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the indications on which we are focusing our product development efforts. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that CD388 will compete against approved and investigational agents for the treatment or prevention of viral influenza infections, including influenza vaccines, monoclonal antibodies targeting hemagglutinin, and small molecule neuraminidase inhibitors such as Tamiflu, Relenza and Peramivir, and endonuclease inhibitors such as Xofluza. We may develop other product candidates through our Cloudbreak platform for the treatment or prevention of other serious diseases, such as solid tumors and viral infections.&#160;We are aware of a large number of approved and investigational therapies in these areas also.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater name recognition, financial resources and expertise in R&amp;D, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These same competitors may invent technology that competes with our CD388 or our Cloudbreak platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we publicly disclose interim, preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analysis of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:15pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the U.S., new and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product-licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial marketing approval is granted. As a result, we might obtain marketing approval for a drug in a particular country but then be subject to price regulations that delay its commercial launch, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to commercialize and generate revenue from one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside the U.S. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our overall financial condition. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and we face an even greater risk for our products that receive marketing approval. If we cannot successfully defend ourselves against claims that our product candidates and products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">decreased demand for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injury to our reputation and significant negative media attention;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant costs and distraction of management to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the initiation of investigations by regulatory bodies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability to commercialize any products we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we have product liability insurance for our clinical trials, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue or expand our clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees in our workplace, including those resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, chemical, hazardous or radioactive materials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_109"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may seek to selectively establish collaborations and, if we are unable to establish them on commercially reasonable terms or at all, we may have to alter our research, clinical development and commercialization plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may seek to collaborate with pharmaceutical and biotechnology companies to advance the Cloudbreak program for DFCs. We may also seek funding from government grants or contracts to advance the Cloudbreak program for DFCs. We cannot be certain that we will be successful in completing any such collaboration or obtaining any such government grants or contracts, or completing any of them on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate pharmaceutical or biotech collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, on the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Those factors may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the design or results of preclinical studies, chemistry, manufacturing and controls, or CMC, development activities or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the likelihood of approval by the FDA or similar regulatory authorities outside the U.S.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential market for the product candidate in the territories that are the subject of the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and complexities of manufacturing and delivering such product candidate to patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential of competing products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">industry and market conditions generally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also face significant competition for government grants and contracts for the Cloudbreak program, and there can be no assurances that such funding would be available to us if and when needed, or at all. For instance, government funding may be available only at certain phases of R&amp;D, such as only after Phase 1 clinical trials have been completed. In order to advance the Cloudbreak program for DFCs, we will need to obtain significant funding to complete manufacturing development and Phase 1 clinical trials. Government grants and contracts may not be available to fund our activities at this earlier phase of the R&amp;D process.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third parties, such as CROs, contract manufacturers of clinical supplies, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and to conduct some aspects of our research and preclinical testing. Many of these third parties may terminate their engagements with us at any time. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our reliance on these third parties for R&amp;D activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory authorities require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, available at www.clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing product candidates on a clinical or commercial scale and we are dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.*</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical studies and clinical trials and for commercial supply of any of these product candidates should we obtain marketing approval.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have established agreements with third-party manufacturers for production of our products for clinical and commercial use, and our reliance on these- manufacturers entails additional risks, including:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with current U.S. Good Manufacturing Practice requirements, or cGMPs, or similar regulatory requirements outside the U.S. Our failure, or the failure of our third-party manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our product candidates or approved products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product that we develop may compete with other product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us. Furthermore, some materials for our product candidates may continue to be sourced from a single-source supplier, and we may be unable to identify an alternative supplier in the event any such single-source supplier is unable to perform. For example, our most advanced product candidate, CD388 is manufactured solely by WuXi XDC and affiliated companies in China.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers or suppliers, including a failure that may not relate specifically to our product candidate or approved product, could delay clinical development or marketing approval or adversely impact our ability to generate commercial sales. If any one of our current contract manufacturers cannot perform as agreed, we may be required to seek to replace that manufacturer, and we may be unable to do so on a timely basis, favorable terms or at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our primary manufacturers and suppliers for DFC product candidates are currently located in China, and we are therefore exposed to developments in international trade policies, including restrictions and tariffs, which may restrict our ability to work with certain of our manufacturers and suppliers and increase the costs in, or otherwise disrupt, our supply chain. As a consequence, we may experience increased costs and expenses, which would increase our development costs and may have adverse effects on the development of our product candidates, our business operations and prospects. See the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the House of Representatives of the prior Congress (the 118th Congress) passed the BIOSECURE Act which proposed targeting U.S. government contracts, grants and loans for entities that use biotechnology equipment or services from certain named Chinese biotechnology companies and potentially other biotechnology companies designated in the future. The language of the proposed BIOSECURE Act would, among other things, prohibit U.S. federal agencies from entering into or renewing any contract with any entity that uses biotechnology equipment or services produced or provided by a &#8220;biotechnology company of concern&#8221; to perform that contract. The version of the bill passed by the prior House of Representatives included a &#8220;grandfathering&#8221; provision which provided that the BIOSECURE Act&#8217;s prohibitions would not apply to pre-existing contracts and agreements entered into prior to the legislation&#8217;s effective date until January 1, 2032. The BIOSECURE Act did not become law in the 118th Congress. It is unclear whether the current Congress (the 119th Congress) will introduce the BIOSECURE Act or similar legislation in this current congressional session and, if so, how the scope, prohibitions, or designated biotechnology companies of concern may differ from the version of the BIOSECURE Act passed by the House in the prior 118th Congress. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies to contract with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties to release, label, store and distribute drug supplies for our clinical trials. Any performance failure on the part of these third parties, including a failure that may not relate specifically to our product candidate or approved product, could delay or otherwise adversely impact clinical development or marketing approval of our product candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, our manufacturers and suppliers may experience difficulties related to their overall businesses and financial stability, which could result in delays or interruptions of supply of our product candidates or approved products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have alternate manufacturing plans in place at this time. If we need to change to other manufacturers, the FDA and comparable foreign regulators may have to approve these manufacturers&#8217; facilities and processes prior to our use, which would require new testing and compliance inspections. In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for production. This would result in delays and costs, and in the case of approved products, the potential loss of revenue.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_112"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, release, safety, efficacy, regulatory filings, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">the U.S. and by comparable authorities in other countries. For example, in order to commence clinical trials of our product candidates in the U.S., we must file an IND and obtain FDA agreement to proceed. The FDA may place our development program on clinical hold and require further preclinical testing prior to allowing our clinical trials to proceed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must obtain marketing approval in each jurisdiction in which we market our products. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. As a company we may not be able to prepare our contract manufacturers and clinical sites for inspection associated with NDA review, or appearing before an FDA advisory committee. We may receive a Complete Response Letter rather than approval. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process, testing and release and inspection of manufacturing facilities and personnel by the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the U.S. and elsewhere, is expensive, may take many years and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot assure you that we will ever obtain any marketing approvals in any jurisdiction. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical or other studies, changes in the manufacturing process or facilities or clinical trials. Moreover, approval by the FDA or an equivalent foreign authority does not ensure approval by regulatory authorities in any other countries or jurisdictions, but a failure to obtain marketing approval in one jurisdiction may adversely impact the likelihood of approval in other jurisdictions. In addition, varying interpretations of the data obtained from preclinical testing, manufacturing and product testing and clinical trials could delay, limit or prevent marketing approval of a product candidate. Additionally, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of promotional materials and safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements for product facilities, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and related recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not comply with these restrictions, we may be subject to enforcement actions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes and facilities or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on such products, manufacturers or manufacturing processes or facilities;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">requirements to conduct post-approval clinical trials, other studies or other post-approval commitments;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">warning or untitled letters;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of the products from the market;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">recall of products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product seizure; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Healthcare professionals and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute our medicines for which we obtain marketing approval.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restrictions under applicable federal and state healthcare laws and regulations include the following, among others:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal healthcare anti-kickback statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false claims laws, which impose criminal and civil penalties, including civil whistleblower or qui tam actions under the federal civil False Claims Act, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal anti-kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, also imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates and their covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which require, among other things, certain manufacturers of drugs, devices, biologics and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and information regarding ownership and investment interests, held by physicians and their immediate family members; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business activities, including sales or marketing arrangements and claims involving healthcare items or services including, in some states, those reimbursed by non-governmental third-party payors, including private insurers, some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities, marketing expenditures, or drug pricing, state and local laws that require the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.&#160;Interpretations of standards of compliance under these laws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems, or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties with whom we work, collect, store, use, transmit, receive, generate, transfer, disclose, make accessible, protect, secure, dispose of, process, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data (collectively, sensitive data). As a result, we and the third parties with whom we work face a variety of evolving threats that could cause security incidents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties with whom we work. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work may be vulnerable to a heightened risk of these attacks, including retaliatory cyberattacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We and the third parties with whom we work are subject to a variety of evolving threats, including but not limited to, social-engineering attacks (including through deep fakes, which are increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by artificial intelligence, or AI, and other similar threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">It may be difficult and/or costly to detect, investigate, mitigate, contain, and remediate a security incident. Our efforts to do so may not be successful. Actions taken by us or the third parties with whom we work to detect, investigate, mitigate, contain, and remediate a security incident could result in outages, data losses, and disruptions of our business. Threat actors may also gain access to other networks and systems after a compromise of our networks and systems.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Remote work has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, our reliance on third parties could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third parties to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, CROs, contract manufacturers of clinical and commercial supplies, clinical data management organizations, medical institutions, clinical investigators, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. We also rely on third parties to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If the third parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or that of the third parties with whom we work have not been compromised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We have not and may not in the future, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we have (and may in the future) experienced delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain of the previously identified or similar threats have in the past and may in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. For example, in November 2020, Covington &amp; Burling LLP, a law firm that has represented us, was the target of a cyberattack in which a sophisticated actor exploited a software vulnerability to access the firm&#8217;s network, including confidential client materials. Our files were not impacted by this data breach. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to manufacture or deliver our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations have required us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or take other action, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we may experience material adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant material consequences may negatively impact our ability to grow and operate our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, our sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employee&#8217;s, personnel&#8217;s, or vendor&#8217;s use of generative artificial intelligence, or AI, technologies.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations (or such failure by the third parties with whom we work) could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.*</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, we process sensitive data, and as a result, our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, and their respective implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Numerous U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, or CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines for intentional violations and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. The CCPA and certain other comprehensive U.S. state privacy laws exempt some data processed in the context of clinical trials, but these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties with whom we work. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations, and industry standards govern data privacy and security. For example, the EU&#8217;s General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, and Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018) impose strict requirements for processing personal data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or EEA, and the United Kingdom, or UK, have significantly restricted the transfer of personal data to the U.S. and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may or have already adopted similarly stringent data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement/Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Additionally, the U.S. Department of Justice issued a rule entitled the Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons, which places additional restriction on certain data transactions involving countries of concern (e.g., China, Russia, Iran) and covered individuals (i.e., individuals and entities located in or controlled by individuals or entities located in those jurisdictions) that may impact certain business activities such as vendor engagements, sale or sharing of data, employment of certain individuals, and investor agreements. Violations of the rule could lead to significant civil and criminal fines and penalties. The rule applies regardless of whether data is anonymized, key-coded, pseudonymized, de-identified or encrypted, which presents particular challenges for companies like ours and may impact our ability to transfer data in connection with certain transactions or agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and we are or may become in the future subject to such obligations. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal information in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Any use of this technology could result in additional compliance costs, regulatory investigations and actions, and consumer lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We use AI and machine learning, or ML, to assist us in making certain decisions, which is regulated by certain privacy laws. Due to inaccuracies or flaws in the inputs, outputs, or logic of the AI/ML, the model could be biased and could lead us to make decisions that could bias certain individuals (or classes of individuals), and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We publish privacy policies, marketing materials, and other statements, such as statements related to compliance with certain certifications or self-regulatory principles, concerning data privacy and security. Regulators in the U.S. are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans or restrictions on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions (including in relation to clinical trials); limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.&#160;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160;We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&#160;Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160;The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&#160;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are also subject to export control and import laws and regulations. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors or collaborators, or those of our affiliates, will comply with all applicable anti-corruption, export and import control, and sanctions laws and regulations. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results and financial condition.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently, we are not conducting any clinical trials in China nor licensing any products in China but we may do so in the near future in respect of our development of CD388. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For example, in order to conduct a clinical trial in China, sponsors must not only obtain the approval of the National Medical Product Administration of China, but also a separate approval from or filing with the Ministry of Science and Technology under the Administrative Regulations on Human Genetic Resources of the People&#8217;s Republic of China, or HGR Regulation, for clinical trials involving HGR Materials or Information. Any failure to comply with these requirements could cause any clinical trial to be suspended by governing authorities, may result in fines and also may constitute a breach under our agreements with third parties assisting us in the conduct of the trial in China, such as our CRO. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Certain changes or amendments to policy or law may result in increased compliance costs on our business, or cause delays in the timely completion of any trial in China. Chinese authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of any clinical activities in China.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.*</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system, including cost-containment measures, that could reduce or limit coverage and reimbursement for newly approved drugs, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, in March 2010, the Affordable Care Act was signed into law, a sweeping law intended to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act and subsequent regulations revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. However, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, effective January 1, 2024. Further, the Affordable Care Act imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were also enacted under the Affordable Care Act, which may affect our business practices with healthcare practitioners. There have been amendments to and executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any additional healthcare reform measures of the second Trump administration will impact the Affordable Care Act and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments will remain in effect until 2032 unless additional Congressional action is taken.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. The IRA, among other things, (1) directs the Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs that have been on the market for at least seven years covered under Medicare, or the Medicare Drug Price Negotiation Program, and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions began to take effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon reimbursement prices of the first 10 drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected 15 additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted within and outside the U.S. in the future, particularly in light of the recent change in administrations. The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions, for example, include directives to reduce agency workforce, program cuts, rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation to consider new payment and healthcare models to limit drug spending and eliminating the Biden administration&#8217;s executive order that directed HHS to establishing an AI task force and developing a strategic plan, directing HHS and other agencies to lower prescription drug costs for Medicare through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program, and directing certain federal agencies to enforce existing law regarding hospital and plan price transparency and by standardizing prices across hospitals and health plans. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo, or Loper Bright, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA. Any of these reform measures could add difficulty to the regulatory approval processes for our product candidates or limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. The continuing efforts of third-party payors to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability and the level of taxes that we are required to pay.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_115"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to CD388, CBO421, our other Cloudbreak compounds or our other product candidates or compounds are not adequate, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to CD388 and CBO421 and our other product candidates and compounds. Any involuntary disclosure to or misappropriation by third parties of our proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our markets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain and our commercial success will depend on our ability to obtain patents and maintain adequate protection for our DFCs and other compounds and product candidates in the U.S. and other countries. We currently hold issued U.S. utility and foreign patents and multiple pending U.S. utility patent applications, pending U.S. provisional patent applications and pending international, foreign national and regional counterpart patent applications covering various aspects of our DFCs. The patent applications may fail to result in issued patents in the U.S. or in foreign countries or jurisdictions. Even if the applications do successfully issue, third parties may challenge the patents.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the existing and/or future patents, if any, may be too narrow to prevent third parties from developing or designing around these patents. If the sufficiency of the breadth or strength of protection provided by the patent and patent applications we own with respect to our DFCs or the patents we pursue related to any of our other product candidates or compounds is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize the product candidates or compounds. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced, although a patent term extension or supplementary protection certificate having varied scope may be available in certain jurisdictions to compensate for some of the lost patent term. In addition, we do not know whether:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to make the inventions covered by each of our pending patent applications or our issued patents;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to file patent applications for these inventions;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">others will independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our pending patent applications will result in issued patents;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our patents, once issued, will be valid or enforceable or will issue with claims sufficient to protect our products, or will be challenged by third parties;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any patents issued to us will provide us with any competitive advantages;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we will develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the patents of others will have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office, or USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the first to file provisions, only became effective in March 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable in one or more jurisdictions, inventions for which patents are difficult to enforce and any other elements of our drug discovery program that involve proprietary know-how, information and technology that is not covered by patents. Although we require all of our employees, consultants, advisers and third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or used in an unauthorized manner or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There also may be challenges or other disputes concerning the inventorship, ownership or right to use our intellectual property. For example, our consultants and advisors may have obligations to assign certain inventions and/or know-how that they develop to third-party entities in certain instances, and these third parties may challenge our ownership or other rights to our intellectual property, which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An inability to obtain, enforce and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. We may encounter significant problems in protecting, enforcing and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties or are otherwise unable to protect, enforce or defend our intellectual property, we will not be able to establish or, if established, maintain a competitive advantage in our markets, which could materially adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various foreign or jurisdictional governmental patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm to pay these fees due to foreign patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such noncompliance events are outside of our direct control for (1)&#160;non-U.S. patents and patent applications owned by us and, (2)&#160;if applicable in the future, patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents with claims to materials, methods of manufacture or methods of treatment related to the use or manufacture of our DFCs and/or our other product candidates or compounds. If any third-party patents were held by a court of competent jurisdiction to cover the DFC manufacturing process, any molecules formed during these processes or the final products or any use thereof, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patent or patents or until such patents expire. These same issues and risks arise in connection with any other product candidates we develop as well. We cannot predict whether we would be able to obtain a license on commercially reasonable terms, or at all. Any inability to obtain such a license under the applicable patents on commercially reasonable terms, or at all, would have a material adverse effect on our ability to commercialize the affected product until such patents expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, third parties may obtain patents in the future and claim that our product candidates and/or the use of our technologies infringes upon these patents. Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products, which may be impossible and/or require substantial time and monetary expenditure. In addition, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of one or more of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would not be able to further develop and commercialize such product candidates, which could harm our business significantly.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be required to file lawsuits or take other actions to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Competitors may infringe our current or future patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our asserted patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Pursuit of these claims would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Interference proceedings or derivative proceedings provoked by third parties or brought by the USPTO may be necessary to determine the entitlement to patent protection with respect to our patents or patent applications. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or patent office proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws or legal process may not protect those rights as fully as in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates and technologies could be found invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technologies, the defendant could counterclaim that the patent covering our product candidate or our technology, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates or our technologies. The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art or that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection directed to our product candidates or technologies. Such a loss of patent rights could have a material adverse impact on our business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and are therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has implemented wide-ranging patent reform legislation, including patent office administrative proceedings that offer broad opportunities to third parties to challenge issued patents. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and foreign governmental bodies and tribunals, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> the U.S. Supreme Court held in 2013 that certain claims to DNA molecules are not patentable and lower courts have since been applying this case in the context of other types of biological subject matter. We cannot predict how future decisions by the courts, the U.S. Congress, the USPTO or foreign governmental bodies or tribunals may impact the value of our patent rights.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws and legal processes of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any of our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of any of our current or future patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors, and academic or research institutions. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_118"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to U.S. Government Contracts and Grants</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be unable to resume our preclinical Cloudbreak programs.*</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have suspended research and development activities for our preclinical Cloudbreak programs. In order to resume work on our preclinical Cloudbreak programs for DFCs, we will need to seek funding from partnerships, the government or other sources of funding. There can be no assurances that we will be able to obtain funding from partnerships, or enter into new contracts with the U.S. government or obtain other sources of funding to support such programs. The process of completing a partnership or obtaining government contracts is lengthy and uncertain and we will have to compete with other companies and institutions in each instance. Further, with respect to government contracting, changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the discovery and development of oncology products. If we cannot obtain or maintain government or other funding for our preclinical Cloudbreak programs for DFCs we may be unable to resume those programs.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our use of government funding adds uncertainty to our research and commercialization efforts and may impose requirements that increase our costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contracts funded by the U.S. government and its agencies include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terminate agreements, in whole or in part, for any reason or no reason;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">audit contract-related costs and fees, including allocated indirect costs;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend or debar the contractor from doing future business with the government;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">control and potentially prohibit the export of products; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">pursue criminal or civil remedies under the Federal Civil Monetary Penalties Act and the federal civil False Claims Act and similar remedy provisions specific to government agreements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, government contracts contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">specialized accounting systems unique to government contracts;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory socioeconomic compliance requirements, including labor standards, anti-human-trafficking, non-discrimination, and affirmative action programs and environmental compliance requirements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we fail to maintain compliance with these requirements, we may be subject to potential liability and to termination of our contracts.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the&#160;FDA, the SEC,&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund R&amp;D activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018 and ending on January 25, 2019, the U.S. government has shut down several times and certain regulatory authorities, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If repeated or prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to audit by the U.S. government and a negative audit could adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. government agencies routinely audit and investigate government contractors and recipients of Federal grants. These agencies review a contractor&#8217;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Government agencies also review the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">termination of contracts;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">forfeiture of profits;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension of payments;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or prohibition from conducting business with the U.S. government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our government grant contracts. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Federal Acquisition Regulations, or FAR, and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the federal Anti-Kickback Statute and Foreign Corrupt Practices Act;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">export and import control laws and regulations; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any changes in applicable laws and regulations could restrict our ability to obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_121"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our senior management team and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management team, as well as the other principal members of our R&amp;D teams. All of our executive officers are employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory, quality assurance and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisers, including scientific, regulatory, quality assurance and clinical advisers, to assist us in formulating our R&amp;D and commercialization strategy. Our consultants and advisers may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our operations, and may encounter difficulties in managing our growth, which could disrupt our business.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect to expand the scope of our operations, particularly in the areas of drug development, manufacturing, clinical, regulatory affairs, quality assurance and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_124"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the commencement, timing, enrollment or results of the current and planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter, &#8220;complete response&#8221; letter, or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse results, suspensions, terminations or delays in pre-clinical or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial or development program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in laws or regulations applicable to our products, including but not limited to requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the structure of healthcare payment systems or limitations on the ability of hospitals and outpatient treatment centers to receive adequate reimbursement for the purchase and use of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse developments concerning our contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices or acceptable quality;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to establish collaborations, if needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to commercialize our product candidates successfully, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">announcements of significant acquisitions, strategic partnerships, joint ventures, government grants or contracts or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size and growth of our influenza or other target markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to successfully enter new markets or develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our cash position and our ability to raise additional capital and the manner and terms on which we raise it, and the expectation of future fundraising activities by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">publication of research reports or other media coverage about us or our industry or our therapeutic approaches in particular or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sales of our common stock by us or our stockholders in the future or the expectation of such sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">disputes or other developments relating to proprietary rights, including patent rights, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">general political and economic conditions including the military conflict in Ukraine and Russia, the active conflicts in the Middle East and bank failures; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">other events or factors, many of which are beyond our control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Capital Market, pharmaceutical companies have experienced extreme price and volume fluctuations that may or may not have been related or proportionate to the operating performance of these companies or their product potential. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders&#160;and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders have the ability to significantly influence us through this ownership position. These stockholders may be able to significantly influence all matters requiring stockholder approval, including elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Capital Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to continue to result in substantial legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. These costs could decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations could make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. We had 12,209,150 shares of common stock outstanding as of March&#160;31, 2025.&#160;We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate and may make it more difficult for you to sell shares of our common stock. In addition, shares of common stock that are either issuable upon the exercise of outstanding options, warrants or pre-funded warrants or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933 as amended, or Securities Act.&#160;If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, through the conversion of our Series A Convertible Voting Preferred Stock and Series X Convertible Preferred Stock, or through exercise of warrants and pre-funded warrants, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Significant additional capital will be needed to continue our operations as currently planned, including conducting clinical trials, commercialization efforts, expanded R&amp;D activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, new investors could gain rights, preferences and privileges senior to our existing stockholders and our existing stockholders may be materially diluted by such subsequent sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, there were (i) 975,208 shares of Series X Convertible Preferred Stock outstanding, which are convertible into an aggregate of 487,604 shares of common stock, subject to the limitations on conversion set forth in the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock and (ii) 204,725 shares of Series A Convertible Voting Preferred Stock outstanding, which are convertible into an aggregate of 14,330,750 shares of common stock, subject to the limitations on conversion set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock. Additionally, as of March&#160;31, 2025, there were (i) warrants to purchase up to an aggregate of 866 shares of common stock outstanding, each at an exercise price of $230.95 per share and (ii) pre-funded warrants to purchase up to an aggregate of 2,491,975 shares of common stock outstanding, each at an exercise price of $0.0001 per pre-funded warrant share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to our 2024 Equity Incentive Plan, our management is authorized to grant equity awards to our employees, directors and consultants. Further, we may grant awards under our 2020 Inducement Incentive Plan, as amended, to certain eligible employees. Additionally, we may grant or provide for the grant of rights to purchase shares of our common stock pursuant to our 2015 Employee Stock Purchase Plan. Any future grants of equity awards, warrants, pre-funded warrants or other securities exercisable or convertible into our common stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price of our common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of working capital and may not use it effectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our working capital. Because of the number and variability of factors that determine our use of our working capital, its ultimate use may vary substantially from its currently intended use. Our management might not apply our working capital in ways that ultimately increase the value of your investment. We expect to use our working capital to fund R&amp;D activities and general operating expenses. The failure by our management to apply this working capital effectively could harm our business. Pending its use, we may invest our working capital in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our working capital in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, as amended, and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer or by a majority of the total number of authorized directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation, as amended, and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While the Delaware courts have determined that exclusive choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely, but the deductibility of such federal net operating loss carryforwards in a taxable year is limited to 80% of taxable income in such year. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of capital raising and other transactions that have occurred since our inception in 2012, we have identified several ownership changes that will impact our ability to utilize our net operating loss and credit carryforwards. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December&#160;31, 2024, we had U.S. federal net operating loss carryforwards of approximately $202.8&#160;million, portions of which will begin to expire in 2035, and which could be limited by reason of one or more ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited. For example, California imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2023 and before 2027. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions, including jurisdictions outside of the U.S., could materially affect our tax obligations and effective tax rate. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may adversely impact our business, financial condition, results of operations, and cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The amount of taxes we pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the U.S., to our international business activities, tax rates, new or revised tax laws, or interpretations of tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to our intercompany arrangements or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Tax Act eliminated the option to deduct R&amp;D expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the U.S. and over 15 years for research activities conducted outside the U.S. Although there have been legislative proposals to repeal or defer the capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the further development of our product candidates could be delayed.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, public health crisis, pandemic diseases and other events beyond our control, the occurrence of which could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Businesses located in California have, in the past, been subject to electrical blackouts as a result of a shortage of available electrical power and any future blackouts could disrupt our operations. We are also vulnerable to a major earthquake, wildfire, inclement weather and other natural and man-made disasters and public health crisis and pandemic diseases, and we have not undertaken a systematic analysis of the potential consequences to our business as a result of any such natural disaster, public health crisis or pandemic diseases and do not have an applicable recovery plan in place. In addition, if any of our third-party contract manufacturers are affected by natural disasters, such as earthquakes, power shortages or outages, floods, wildfire, public health crises, such as pandemics and epidemics, terrorism or other events outside of our control, our business and operating results could suffer. For example, as a result of global pandemics, we experienced significant disruptions in the conduct of our clinical trials and our general business operations as the result of various federal, state and local stay-at-home, shelter-in-place and quarantine measures. We carry only limited business interruption insurance that would compensate us for actual losses from interruption of our business that may occur and any losses or damages incurred by us in excess of insured amounts could cause our business to materially suffer.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i49f81b51ab9a48059db3fc4265446fcd_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;5. <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-640"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-641"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-642"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-643">OTHER INFORMATION</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Entry into Open Market Sale Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, we entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Jefferies Sales Agreement, with Jefferies LLC, or the Agent, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $150.0 million through the Agent as our sales agent, or ATM Offering.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Agent may sell the common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act, including without limitation sales made by means of ordinary brokers&#8217; transactions on the Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by us. The Agent will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us (including any price, time or size limits or other customary parameters or conditions we may impose). We will pay the Agent a commission of up to 3.0% of the gross sales proceeds of any common stock sold through the Agent under the Jefferies Sales Agreement, and we have also provided the Agent with customary indemnification rights.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are not obligated to make any sales of our common stock under the Jefferies Sales Agreement. The offering of shares of common stock pursuant to the Jefferies Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Jefferies Sales Agreement or (ii) termination of the Jefferies Sales Agreement in accordance with its terms.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The foregoing description of the Jefferies Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Jefferies Sales Agreement, a copy of which is filed as Exhibit 10.5 to this Quarterly Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The shares of common stock being offered pursuant to the Jefferies Sales Agreement will be offered and sold pursuant to a shelf registration statement on Form S-3 and prospectus relating to the ATM Offering that we will file with the SEC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This Quarterly Report shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Termination of Controlled Equity Offering</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, we and Cantor Fitzgerald &amp; Co., or Cantor, agreed to terminate the Controlled Equity Offering</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Sales Agreement, or Cantor Sales Agreement, that we entered into with Cantor on November 8, 2018, effective May 8, 2025. Under the Cantor Sales Agreement, we were permitted to offer and sell, from time to time at our sole discretion, shares of our common stock, through Cantor by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act. We sold an aggregate of $41.1&#160;million of shares of our common stock under the Cantor Sales Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000054/exhibit212024-04x29.htm">Asset Purchase Agreement, by and between the Registrant and Napp Pharmaceutical Group Limited (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A, filed on April 29, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000054/exhibit222024-04x29.htm">Assignment and Novation Agreement, by and between the Registrant and Napp Pharmaceutical Group Limited (incorporated by reference to Exhibit 2.2 to the Registrant&#8217;s Current Report on Form 8-K/A, filed on April 29, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000054/exhibit232024-04x29.htm">First Amendment to Melinta License Agreement, dated April 23, 2024, by and between Melinta Therapeutics, LLC and the Registrant (incorporated by reference to Exhibit 2.3 to the Registrant&#8217;s Current Report on Form 8-K/A, filed on April 29, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000041/exhibit322023-12.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Annual Report on Form 10-K, filed on April 22, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000091/exhibit312024-07x18.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on July 18, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex312018-05x21.htm">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May 21, 2018).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000051/exhibit312024-04x24.htm">Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed with the SEC on March 13, 2015).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312516729294/d161044dex102.htm">Form of Warrant to Purchase Common Stock issued to Pacific Western Bank (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on October 3, 2016).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex412018-05x21.htm">Form of Common Stock Purchase Warrant for First Private Placement (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May 21, 2018).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061824000146/ex412024-11x26.htm">Form of Pre-Funded Warrant to Purchase Common Stock for Private Placement (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 26, 2024).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061825000017/exhibit10302024-12.htm">Employment offer letter between the Registrant and Frank Karbe, dated February 7, 2025 (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 6, 2025).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061825000002/exhibit1012025-01x07.htm">Separation Agreement by and between the Registrant and Taylor Sandison, dated January 7, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on January 7, 2025).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312525028641/d928043dex101.htm">Separation Agreement by and between the Registrant and Preetam Shah, dated February 14, 2025 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on February 18, 2025).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1042025-03.htm">Employment offer letter between the Registrant and Nicole Davarpanah, M.D., J.D., dated April 25, 2025.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1052025-03.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.15pt;vertical-align:baseline" href="exhibit1052025-03.htm">SM</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1052025-03.htm">, dated May 8, 2025, by and between Cidara Therapeutics, Inc. and Jefferies LLC.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3112025-03.htm">Certification of Principal Executive Officer required by Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3122025-03.htm">Certification of Principal Financial Officer required by Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3212025-03.htm">Certification of Principal Executive Officer required by Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3222025-03.htm">Certification of Principal Financial Officer required by Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Registrant&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certifications attached as Exhibits 32.1 and 32.2 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i49f81b51ab9a48059db3fc4265446fcd_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cidara Therapeutics, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: May 8, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: May 8, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Frank Karbe</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Frank Karbe</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">78</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>exhibit1042025-03.htm
<DESCRIPTION>EXECUTIVE OFFICERS EMPLOYMENT AGREEMENT, AS AMENDED
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if7fc1d52c492443c88d12c0c338064bc_1"></div><div style="min-height:115.92pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Exhibit 10.4</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;BY EMAIL&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah, M.D., J.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14403 Marine Drive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Silver Spring, MD 20905</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Re&#58; Employment Agreement </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Nicole&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) sets forth the terms of your employment as the Chief Medical Officer of Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Agreement will become effective as of May 1, 2025, upon your acceptance by executing this Agreement.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of its effective date, this Agreement replaces and supersedes in its entirety the offer letter and severance agreement between you and the Company dated July 3, 2023 and July 6, 2023, respectively (collectively the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Prior Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) except that the terms of your Employee Confidential Information and Invention Assignment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">executed on July 6, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restrictive Covenant Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall continue to apply. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As the Company&#8217;s Chief Medical Officer you will report to the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This is a full-time employment position.  It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time) unless you first obtain the approval of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which approval shall not be withheld unreasonably.  Notwithstanding the foregoing, you will be allowed to continue to engage in the business activities set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof while rendering services to the Company, provided that such activities do not interfere with the fulfillment of your duties to the Company </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and you may also engage in religious, charitable and other community activities so long as such engagements and activities do not interfere or conflict with your obligations to the Company, as determined by the Board in its discretion. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Salary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will pay you a base salary payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be paid at the rate of $500,000 per year (on an annualized basis), subject to periodic review and adjustment at the Board&#8217;s discretion.  This is a full-time, exempt position, meaning that you are not eligible for overtime compensation. The annual base salary in effect at any given time shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Stock Options.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As further consideration for your promotion, you will be granted a stock option to purchase 20,000 shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This stock option will vest over a three-year period in 36 equal monthly installments following the Vesting Commencement Date.  You will also be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 2</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">granted a Restricted Stock Unit Award (&#8220;RSUs&#8221;) for 10,000 shares of the Company&#8217;s common stock.  Your RSUs vest in three equal annual installments, with 1&#47;3 vesting on each anniversary of the June 10 Quarterly Vesting Date (June 10, 2026, June 10, 2027, and June 10, 2028). Your stock options and RSUs will be subject to the terms and conditions set forth in the Plan and the respective Stock Award Agreements, including the requirement that in order for your stock options and RSUs to vest, you must be in &#8220;Continuous Service&#8221; (as defined in the Plan) with Cidara on such vesting dates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will be eligible to participate in the Company&#8217;s amended and restated bonus plan.  Your bonus target percentage will be 40% of the Base Salary amount actually paid to you in the applicable year, based on achievement of individual and corporate performance objectives to be determined and approved by the Board or the Compensation Committee thereof. Bonuses are paid on an annual basis, after the close of the fiscal year and after determination by the Board (or the Compensation Committee thereof) of (i) the level of achievement of the applicable individual and corporate performance targets and (ii) the bonus earned by you (if any).  No bonus is guaranteed and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing of the Company on the scheduled bonus payment date in order to be eligible for any bonus payment.  The Company&#8217;s bonus program will be the only incentive compensation, commissions, or other bonus program that will apply to you.  However, nothing in this paragraph will prevent you from participating in incentive compensation, commission plan, retention plan, or other bonus programs created after the commencement of your employment which is specifically designed to include you and&#47;or to which you are specifically invited to participate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Benefits&#47;Vacation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> You will continue to be eligible to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees including medical, dental, vision, disability, life and 401(k), all subject to the terms and conditions of such plans and programs.  Details of such benefits programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will continue to be made available to you.  You will be entitled to accrue Paid Time Off (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with subject to the terms and conditions of the Company&#8217;s PTO policy (which includes a maximum accrual cap), as may be amended from time to time.   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">At-Will Employment&#59; Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your employment is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time, with or without Cause (as defined below) or advance notice. In the event of the ending of your employment for any reason and at any time, the Company shall pay you&#58; (i) any unpaid base salary through your last day of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) any accrued but unused PTO, and (iii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to the Date of Termination and not yet reimbursed (together the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case at such time that is not within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into, do not revoke and comply with the terms of a separation agreement in a form provided by the Company which shall include a general release of claims against the Company and related persons and entities and must be returned to the Company and become effective no later than sixty days </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 3</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following your Date of Termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) the Company will provide you with the following termination benefits&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a lump sum cash payment equal to your Base Salary for a nine month period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with the full cost of the monthly premium for such benefits paid by the Company until the earlier of (i) the date immediately following the expiration of the period of time following the Date of Termination equal to the Severance Period&#59; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you elect health care continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Health Care Benefit Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Health Care Benefit Payment shall be paid in monthly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer and shall be equal to the amount, and paid for the same duration of time, that the Company would have otherwise paid for your COBRA benefits as described above (which amount shall be calculated based on the premium for the first month of coverage).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case, within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into and do not revoke the Release, the Company will provide you with all of the termination benefits set forth in Section 7 above, on the same schedule as set forth in Section 7 above, except that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Severance Period shall be twelve months&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">you will also receive a lump sum cash amount equivalent to&#160;your target annual bonus for the year in which the Date of Termination occurs (calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable), multiplied by the quotient of twelve divided by twelve, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">in addition, the vesting of all equity compensation awards granted to you by the Company (or its successor), to the extent outstanding as of immediately prior to your termination, shall become fully vested and immediately exercisable by you.  Any stock options and other equity compensation awards that you hold as of your Date of Termination shall remain </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 4</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">outstanding following your Date of Termination if and to the extent necessary to give effect to this Section 8(c).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, in no event shall you be entitled to benefits under both Section 7 and this Section 8.  If you are eligible for benefits under both Section 7 and this Section 8, you shall receive the benefits set forth in this Section 8 and such benefits will be reduced by any benefits previously provided to you under Section 7.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means&#58; (i) your commission of any felony or commission of a crime involving dishonesty&#59; (ii) conduct by you in connection with your service to the Company that is fraudulent, unlawful or grossly negligent&#59; (iii) your willful failure or refusal to comply with lawful directives of the CEO or the Board&#59; (iv) willful breach by you of a written Company policy or your representations, warranties, covenants and&#47;or obligations under this Agreement  or any other agreement between you and the Company (including the Restrictive Covenant Agreement), which, if curable, is not cured by you within 30 days following your receipt of written notice from the Company detailing the nature of such breach&#59; and&#47;or (v) material misconduct by you which adversely impacts, discredits or damages the Company or any of its affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred upon the consummation of (i) the dissolution or liquidation of the Company&#59; (ii) the sale or disposition by the Company of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity&#59; (iii) a merger, reorganization or consolidation in which the Company consolidates with or merges into another corporation or entity, or any other corporation or entities consolidates with or merges into the Company, other than (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, (B) a merger or consolidation which would result in a majority of the board of directors of the combined entity being comprised of members of the board of directors of the pre-transaction Company and the chief executive officer of the combined entity being the chief executive officer of the pre-transaction Company, in each case immediately following the consummation of such merger or consolidation, or (C) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person becomes the beneficial owner, directly or indirectly, of a majority of the total voting power of all shares of then outstanding Common Stock&#59; (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transaction by a person or group of persons&#59; (v) an acquisition of more than 50% of the then outstanding voting securities of the Company by another entity or person in a single transaction&#59;  or (vi) any other acquisition of the business of the Company, as determined by the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that any public offering, private placement of the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 5</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">securities or other capital raising event, or a merger effected solely to change the Company&#8217;s domicile shall not constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that you have complied with the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (hereinafter defined) following the occurrence of any of the following events, without your prior written consent&#58; (i) a material reduction of at least 20% in your then-current Base Salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (ii) relocation of your principal place of employment to a place that increases your  one-way commute by more than 75 miles as compared to your then-current principal place of employment immediately prior to such relocation&#59; (iii) a material diminution in your primary duties, responsibilities or authorities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless your new duties are materially reduced from the prior duties&#59; or (iv) a material diminution in the authority, duties or responsibilities of the supervisor to whom you are required to report, including, if applicable, a requirement that you report to a corporate officer or employee instead of reporting directly to the chief executive officer and&#47;or president of a corporation unless you are required to report directly to the board of directors of a corporation (or similar governing body with respect to an entity other than a corporation).  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that (A) you have reasonably determined in good faith that a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; condition has occurred&#59; (B) you have notified the Company in writing of the first occurrence of the Good Reason condition within 90 days of the first occurrence of such condition&#59; (C) you have cooperated in good faith with the Company&#8217;s efforts, for a period of 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to remedy the condition&#59; (D) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (E) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Confidential Information and Restricted Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition of continued employment, you shall continue to abide by the Restrictive Covenant Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the terms of which are incorporated by reference herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Taxes&#59; Section 409A.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the of the Internal Revenue Code of 1986, as amended and the regulations and other guidance thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 6</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deferred compensation subject to the 20% additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service (as defined below), or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#8220;separation from service&#8221;. The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code.  If your Date of Termination occurs at a time when the Release could become effective in one of two different calendar years (for example, your Date of Termination occurs in December), to the extent necessary to avoid adverse taxation under Section 409A of the Code, the effective date of the Release (for purposes of timing of receiving your severance benefits) shall in all events be considered as occurring no sooner than the later of such two different calendar years.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The severance benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its exemption from or compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from, or if not exempt from, comply with, Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Interpretation, Amendment and Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 7</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Dispute Resolution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To ensure the rapid and economical resolution of any disputes that may arise in connection with your employment, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to any statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment, or the termination of your employment, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by a single arbitrator and under the JAMS Employment Arbitration Rules &#38; Procedures (which are accessible on the JAMS&#8217; website at http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;, and which will be provided to you on request).  The arbitration will be held in the JAMS&#8217; office closest to your assigned office location, or such other location as then-agreed by the parties.  You and the Company shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, the parties waive the right to resolve any such dispute through a trial by jury or judge or by administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall&#58; (1) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding&#59; and (2) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this section apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The Company shall bear JAMS&#8217; arbitration fees and administrative costs in excess of the court filing fees that you would be required to pay if the dispute was litigated in civil court.  Nothing herein shall prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee Initials for Section 13&#58;__&#47;s&#47; ND__________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenant Agreement) without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and a duly authorized officer of the Company. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 8</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Other Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By signing this Agreement, you represent to the Company that you have no contractual commitments or other legal obligations that would or may prohibit you from performing your duties for the Company.  As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:115.92pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">April 25, 2025</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page 9</font></div><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please acknowledge, by signing below, that you have accepted this Agreement.  </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; _&#47;s&#47; JStein______________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Jeffrey Stein, Ph.D.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       President and Chief Executive Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have read and accept this employment offer&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_&#47;s&#47; Nicole Davarpanah____________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nicole Davarpanah, M.D., J.D.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;  _4&#47;30&#47;2025_______________________</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Encl&#58; Exhibit A -  Signed </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee Confidential Information and Invention Assignment</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if7fc1d52c492443c88d12c0c338064bc_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Oncology staff physician volunteer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>exhibit1052025-03.htm
<DESCRIPTION>OPEN MARKET SALE AGREEMENT
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia3764b00eb5f488da7206be9b3ec1d20_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:144%">Exhibit 10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:144%"> </font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">OPEN MARKET SALE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">SM</font><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">May 8, 2025</font></div><div style="padding-right:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">JEFFERIES LLC <br>520 Madison Avenue</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10022</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ladies and Gentlemen&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and&#47;or principal (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), on the terms set forth in this agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Certain Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the following respective meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agency Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period commencing on the date of this Agreement and expiring on the earliest to occur of (x) the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y) the date this Agreement is terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Floor Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the minimum price set by the Company in the Issuance Notice below which the Agent shall not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent and which in no event </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8220;Open Market Sale Agreement&#8221; is a service mark of Jefferies LLC</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be less than $1.00 without the prior written consent of the Agent, which may be withheld in the Agent&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a written notice delivered to the Agent by the Company in accordance with this Agreement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that is executed by its Chief Executive Officer, President or Chief Financial Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuance Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Sales Price less the Selling Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Maximum Program Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Common Shares with an aggregate Sales Price of the lesser of (a) the number or dollar amount of Common Shares registered under the effective Registration Statement (as defined below) pursuant to which the offering is being made, (b) the number of authorized but unissued Common Shares (less Common Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#8217;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable), or (d) the number or dollar amount of Common Shares for which the Company has filed a Prospectus (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or other entity of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Principal Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Nasdaq Capital Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selling Commission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the first business day following each Trading Day during the period set forth in the Issuance Notice on which Shares are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s Common Shares issued or issuable pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trading Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day on which the Principal Market is open for trading.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  REPRESENTATIONS AND WARRANTIES OF THE COMPANY </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company represents and warrants to, and agrees with, the Agent that as of (1) the date of this Agreement, (2) each Issuance Notice Date, (3) each Settlement Date, (4) each Triggering Event Date (as defined below) and (5) as of each Time of Sale (as defined below) (each of the times referenced above is referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), except as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company has prepared and will file with the Commission a shelf registration statement on Form&#160;S-3&#160;that contains a base prospectus.  Such registration statement registers the issuance and sale by the Company of the Shares under the Securities Act.  The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act as from time to time amended or supplemented, is herein referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and the base prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form S-3 under the Securities Act, in each case, as from time to time amended or supplemented, is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use.  The Registration Statement at the time it originally became effective is herein called the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Original Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;  As used in this Agreement, the terms &#8220;amendment&#8221; or &#8220;supplement&#8221; when applied to the Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date&#59; and all references in this Agreement to amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prospectus, as the case may be, as of any specified date. The Company&#8217;s obligations under this Agreement to furnish, provide or deliver or make available (and all other similar references) copies of any report or statement shall be deemed satisfied if the same is filed or furnished with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EDGAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At the time the Original Registration Statement was or will be originally declared effective and at the time the Company&#8217;s most recent annual report on Form&#160;10-K was filed with the Commission, if later, the Company met the then-applicable requirements for use of Form&#160;S-3 under the Securities Act.  During the Agency Period, each time the Company files an annual report on Form 10-K the Company will meet the then-applicable requirements for use of Form S-3 under the Securities Act. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compliance with Registration Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Original Registration Statement and any Rule&#160;462(b) Registration Statement have been or will be declared effective by the Commission under the Securities Act.  The Company has complied to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental information.  No stop order suspending the effectiveness of the Registration Statement or any Rule&#160;462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Prospectus when filed complied or will comply in all material respects with the Securities Act and, if filed with the Commission through EDGAR (except as may be permitted by Regulation&#160;S-T under the Securities Act), was identical to the copy thereof delivered to the Agent for use in connection with the issuance and sale of the Shares.  Each of the Registration Statement, any Rule&#160;462(b) Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.  As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Time of Sale Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The Prospectus, as amended or supplemented, as of its date and at each Representation Date, did not and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule&#160;462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  below.  There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Ineligible Issuer Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act.  Any Free Writing Prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act.  Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at each Representation Date through the completion of the issuance and sale of the Shares did not, does not and will not include any information that conflicted, conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein.  Except for the Free Writing Prospectuses, if any, and electronic road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent&#8217;s prior consent (which consent shall not be unreasonably withheld, conditioned or delayed), prepare, use or refer to, any Free Writing Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Incorporated Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable, and, when read together with the other information in the Prospectus, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Exchange Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Prospectus, at the time the Registration Statement and any amendments thereto become effective and at each Time of Sale (as defined below), as the case may be, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Statistical and Market-Related Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All statistical, demographic and market-related data included in the Registration Statement or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material respects. To the extent required, the Company has obtained the written consent to the use of such data from such sources.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disclosure Controls and Procedures&#59; Deficiencies in or Changes to Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#8217;s principal executive officer and its principal financial officer by others within the Company and its consolidated subsidiaries&#59; (ii) have been evaluated by management of the Company for effectiveness as of the end of the </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company&#8217;s most recent fiscal quarter&#59; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the Company&#8217;s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">This Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement has been duly authorized, executed and delivered by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Authorization of the Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares that have not been duly waived or satisfied. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">No Applicable Registration or Other Similar Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus&#58; (i) there has been no material adverse change, or any development that would reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, taken as a whole (any such change being referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) the Company and its subsidiaries, taken as a whole, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company, or has entered into any material transactions not in the ordinary course of business&#59; and (iii)&#160;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company and its subsidiaries, taken as a whole, and there have been no dividend or distribution of any kind declared, paid or made by the Company or its subsidiaries or any repurchase or redemption by the Company or its subsidiaries of any class of capital stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Independent Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Ernst &#38; Young LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PCAOB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The financial statements filed with the Commission as a part of the Registration Statement and the Prospectus present fairly, in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#8217; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus. All disclosures contained in the Registration Statement or the Prospectus and any Free Writing Prospectus, that constitute non-GAAP financial measures (as defined by the rules and regulations under the Securities Act and the Exchange Act) comply with Regulation G under the Exchange Act and Item 10 of Regulation S-K under the Securities Act, as applicable. To the Company&#8217;s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement and the Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Company&#8217;s Accounting System</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company makes and keeps accurate books and records and maintains a system of internal accounting controls designed, and which the Company believes is sufficient to provide reasonable assurance that&#58; (i) transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets&#59; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization&#59; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Incorporation and Good Standing of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of California and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on the condition (financial or otherwise), earnings, business, properties, operations, assets, liabilities or prospects of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Subsidiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each of the Company&#8217;s &#8220;subsidiaries&#8221; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the Prospectus. Each of the Company&#8217;s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#8217;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other entity other the subsidiaries listed in Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Capitalization and Other Capital Stock Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement and the Prospectus as of the dates stated therein (other than for subsequent issuances, if any, pursuant to employee benefit plans, upon the exercise of outstanding options, warrants or pre-funded warrants, upon the vesting and settlement of restricted stock units, or upon the conversion of shares of the Company&#8217;s preferred stock, in each case as described in the Registration Statement and the Prospectus). The Common Shares (including the Shares) conform in all material respects to the description thereof contained in the Prospectus. All of the issued and outstanding Common Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding Common Shares were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those described in the Registration Statement and the Prospectus and other than equity awards subsequently issued pursuant to employee benefit plans described in the Registration Statement and the Prospectus Supplement. The descriptions of the Company&#8217;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement and the Prospectus accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Stock Exchange Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Common Shares are registered pursuant to Section 12(b) of the Exchange Act and are listed on the Principal Market, and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such registration or listing. To the Company&#8217;s knowledge, it is in compliance with all applicable listing requirements of the Principal Market.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt;text-decoration:underline">Non-Contravention of Existing Instruments&#59; No Further Authorizations or Approvals Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any of its subsidiaries are in violation of its charter, by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Existing Instrument</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The Company&#8217;s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement and the Prospectus and the issuance and sale of the Shares (including the use of proceeds from the sale of the Shares as described in the Registration Statement and the </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prospectus under the caption &#8220;Use of Proceeds&#8221;) (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter, by-laws, partnership agreement or operating agreement or similar organizational documents of the Company or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries, except for such conflicts, breaches, Defaults, Debt Repayment Triggering Event, lien, charge or encumbrance specified in clauses (ii) and (iii) above that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#8217;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky Laws or the Financial Industry Regulatory Authority, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FINRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). As used herein, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Debt Repayment Triggering Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">No Material Actions or Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or materially and adversely affect the consummation of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder&#59; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject, including ordinary routine litigation incidental to the business, if determined adversely to the Company or such subsidiary, would not reasonably be expected to have a Material Adverse Effect. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company or its subsidiaries, exists or, to the knowledge of the Company, is threatened or imminent, which could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and each of its subsidiaries owns, possesses or has valid and enforceable licenses or other rights to use, or can acquire on reasonable terms, all Intellectual Property (as defined below) necessary for the conduct of the Company&#8217;s and its subsidiaries&#8217; business as now conducted or as described in the Registration Statement and the Prospectus to be conducted, except as such failure to own, possess, or acquire such rights would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. Furthermore, except as disclosed in the Registration Statement or the Prospectus (including the documents incorporated therein), (A)&#160;to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property&#59; (B) there is no pending or, to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company&#8217;s or any of its subsidiaries&#8217; rights in or to any such Intellectual Property&#59; (C) the Intellectual Property owned by the Company and its subsidiaries, and to the knowledge of the Company, the Intellectual Property licensed to the Company and its subsidiaries, has not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property&#59; (D) there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, and neither the Company or any of its subsidiaries has received any written notice of such claim&#59; and (E) to the Company&#8217;s knowledge, no employee of the Company or any of its subsidiaries is in or has ever been in material violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#8217;s employment with the Company or any of its subsidiaries or actions undertaken by the employee while employed with the Company or any of its subsidiaries. Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, the Company and each subsidiary has complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiary, and all such agreements are in full force and effect.  Except as would not reasonably be expected individually or in the aggregate, to have a Material Adverse Effect, the product candidates described in the Registration Statement and the Prospectus as under development by the Company or its subsidiaries fall within the scope of the claims of one or more patents or applications owned by, or exclusively licensed to, the Company or the applicable subsidiary. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names, technology, know-how and other intellectual property.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">All Necessary Permits, etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective business as currently conducted and as described in the Registration Statement or the Prospectus (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except where the failure to so possess would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit, except where failure to be so in compliance would not be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt;text-decoration:underline">Title to Properties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries possess good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above (or elsewhere in the Registration Statement or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The real property, improvements, equipment and personal property held under lease by the Company are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Tax Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns that have come due or has properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against it except as may be being contested in good faith and by appropriate proceedings, except where the failure to so file or pay would not reasonably be expected to have a Material Adverse Effect. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subsidiaries is being contested or has not otherwise been finally determined, except as would not reasonably be expected to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Company Not an &#8220;Investment Company.&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company is not, and will not be, either after receipt of payment for the Shares or after the application of the proceeds therefrom as described under &#8220;Use of Proceeds&#8221; in the Registration Statement or the Prospectus, required to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Company and its subsidiaries are insured by financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for companies of similar size, engaged in similar businesses in similar industries including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, and acts of vandalism and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries have been denied any insurance coverage which it has sought or for which it has applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.38pt;text-decoration:underline">No Price Stabilization or Manipulation&#59; Compliance with Regulation M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any of its subsidiaries nor any of their respective directors, officers, nor, to the Company&#8217;s knowledge, any of their respective Affiliates or controlling persons, have taken, directly or indirectly, without giving effect to the activities of the Agent in connection with the offering of Shares pursuant to this Agreement, any action designed to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the Common Shares or of any &#8220;reference security&#8221; (as defined in Rule 100 of Regulation M under the Exchange Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulation M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) with respect to the Common Shares, whether to facilitate the sale or resale of the Common Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(bb)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Related Party Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There are no business relationships or related party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement or the Prospectus that have not been described as required.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(cc)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FINRA Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers and directors and, to the Company&#8217;s knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete, correct in all material respects and compliant with FINRA&#8217;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules is true, complete and correct in all material respects.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(dd)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Unlawful Contributions or Other Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any of its subsidiaries, nor, to the Company&#8217;s knowledge, any employee, director, officer, Affiliate, agent or other person acting on behalf of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any applicable Law or of the character required to be disclosed in the Registration Statement or the Prospectus.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ee)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect&#58; (i) neither the Company nor any of its subsidiaries are in violation of any applicable federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements&#59; (iii) there are no pending or, to the Company&#8217;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries&#59; and (iv) to the Company&#8217;s knowledge, there are no events or circumstances, existing as of the date hereof, that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ff)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Periodic Review of Costs of Environmental Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the ordinary course of its business, the Company conducts a periodic review of the effect of Environmental Laws on the business, operations and properties of the Company and its subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties). No facts or circumstances have come to the Company&#8217;s attention that could result in costs or liabilities that could be expected, individually or in the aggregate, to result in a Material Adverse Change. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(gg)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries and, to the knowledge of the Company, any &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)) established or maintained by the Company, its subsidiaries or their &#8220;ERISA Affiliates&#8221; (as defined below) are in compliance in all material respects with ERISA. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of which the Company or such subsidiary is a member. No &#8220;reportable event&#8221; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit plan&#8221; established or maintained by the Company, its subsidiaries or any their ERISA Affiliates. No &#8220;employee benefit plan&#8221; established or maintained by the Company, any of its subsidiaries or any of their ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any &#8220;amount of unfunded benefit liabilities&#8221; (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &#8220;employee benefit plan&#8221; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification. </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(hh)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Outstanding Loans or Other Extensions of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(jj)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries have been and are in compliance with all applicable Laws, rules and regulations, except where failure to be so in compliance would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(kk)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dividend Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as disclosed in the Prospectus, no subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#8217;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ll)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption and Anti-Bribery Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any of its subsidiaries nor any director, officer, employee, nor, to the knowledge of the Company, any agent, Affiliate or other person acting on behalf of the Company or its subsidiaries have, in the course of its actions for, or on behalf of, the Company or its subsidiaries (i) made any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity&#59; (ii) made any direct or indirect unlawful payment to any domestic government official, &#8220;foreign official&#8221; (as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or employee&#59; (iii) violated or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation&#59; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any domestic government official, such foreign official or employee&#59; and the Company, its subsidiaries and, to the knowledge of the Company, the Company&#8217;s and such subsidiaries&#8217; Affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.  No part of the proceeds of the offering will be used, directly or indirectly, in violation of the Foreign Corrupt Practices Act of 1977 or the U.K. Bribery Act 2010, each as may be amended, or similar law of any other relevant jurisdiction, or the rules or regulations thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(mm)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Money Laundering Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(nn)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and each of its subsidiaries have such permits, licenses, patents, franchises, certificates of need and other approvals, consents and other authorizations issued by the appropriate domestic or foreign regional, federal, state, or local regulatory agencies or bodies necessary to conduct the business of the Company, including, </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">without limitation, any Investigational New Drug Application (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and&#47;or New Drug Application (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as required by the U.S. Food and Drug Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), any authorizations issued by the Drug Enforcement Administration, or any other authorizations issued by domestic or foreign regional, federal, state, or local agencies or bodies engaged in the regulation of pharmaceuticals such as those being developed by the Company and its subsidiaries (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Regulatory Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), except for any of the foregoing that would not reasonably be expected to, individually or in the aggregate, have a Material Adverse Effect&#59; the Company is in compliance in all material respects with the requirements of the Regulatory Permits, and all of such Regulatory Permits are valid and in full force and effect&#59; the Company has not received any notice of proceedings relating to the revocation, termination, modification or impairment of rights of any of the Regulatory Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to result in a Material Adverse Effect&#59; the Company has not failed to submit to the FDA any IND or NDA necessary to conduct the business of the Company, any such filings that were required to be made were in material compliance with applicable Laws when filed, and no material deficiencies have been asserted by the FDA with respect to any such filings or submissions that were made. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(oo)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor any of its subsidiaries has failed to file with the applicable regulatory authorities (including, without limitation, the FDA, or any foreign, federal, state, provincial or local governmental or regulatory authority performing functions similar to those performed by the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or in the aggregate, would not have a Material Adverse Effect&#59; except as disclosed in the Registration Statement and the Prospectus, all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable Laws when filed and no deficiencies have been asserted by any applicable regulatory authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies that, individually or in the aggregate, would not have a Material Adverse Effect.  The Company has operated and currently is, in all material respects, in compliance with the FDCA (as defined below) and all applicable rules and regulations of other federal, state, local and foreign governmental bodies exercising comparable authority. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(pp)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Data and Regulatory Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The studies, tests and preclinical and clinical investigations conducted by or on behalf of the Company and its subsidiaries were and, if still pending, are, in all material respects, being conducted in accordance with established  protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable Laws and authorizations, including, without limitation, the FDCA and implementing regulations including good laboratory practice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) regulations (21 C.F.R. Part 58) if any such studies, tests or preclinical and clinical investigations are being or have been conducted pursuant to GLP, and good clinical practice and IND requirements (21 C.F.R. Parts 50, 54, 56, and 312) if any such studies, tests or preclinical and clinical investigations were or are subject to good clinical practice regulations or were or are being conducted under an IND&#59; the descriptions of the results of such studies, tests and trials contained in the Registration Statement and the Prospectus are accurate in all material respects and fairly present the data derived from such studies, tests and trials&#59; except to the extent disclosed in the Registration Statement and the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question in any material respect, the study, test, or trial results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described and the clinical state of development&#59; and neither the Company nor any of its subsidiaries have received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical investigations conducted by or on behalf of the Company or any of its subsidiaries, except for material modifications reflected in protocol amendments to clinical and preclinical trials arising from joint discussions with such Governmental Authority.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(qq)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Neither the Company nor any of its subsidiaries nor any of their respective officers directors, or employees, nor, to the Company&#8217;s knowledge, any agent, affiliate or representative of the Company or its subsidiaries, is a government, individual, or entity (in this paragraph (i), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that is, or is owned or controlled by a Person that is&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the subject of any sanctions administered or enforced by the U.S. government (including the Department of Treasury&#8217;s Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Department of State), the United Nations Security Council, the European Union, His Majesty&#8217;s Treasury, or other relevant sanctions authorities, including designation on OFAC&#8217;s Specially Designated Nationals and Blocked Persons List or OFAC&#8217;s Foreign Sanctions Evaders List (as amended, collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), nor</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">located, organized or resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (including Cuba, Iran, North Korea, Syria, Russia, the Crimea, Kherson and Zaporizhzhia regions of Ukraine, the so-called Donetsk People&#8217;s Republic and the so-called Luhansk People&#8217;s Republic) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sanctioned Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">The Company represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">to fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject of Sanctions or is a Sanctioned Country&#59; or</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">in any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as the Agent, advisor, investor or otherwise).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">The Company represents and covenants that for the past 10 years, it has not engaged in, is not now engaging in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions or is or was a Sanctioned Country.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(rr)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sarbanes-Oxley</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ss)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duties, Transfer Taxes, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No stamp or other issuance or transfer taxes or duties and no capital gains, income, withholding or other taxes are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the Company of the Shares.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(tt)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cybersecurity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IT Systems</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time-bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including all &#8220;Personal Data&#8221; (defined below) and all sensitive, confidential or regulated data (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) used in connection with their businesses. &#8220;Personal Data&#8221; means (i) a natural person&#8217;s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver&#8217;s license number, passport number, credit card number, bank information, or customer or account number&#59; (ii) any information which would qualify as &#8220;personally identifying information&#8221; under the Federal Trade Commission Act, as amended&#59; (iii) &#8220;personal data&#8221; as defined by GDPR (as defined below)&#59; (iv) any information which would qualify as &#8220;protected health information&#8221; under HIPAA&#59; (v) any &#8220;personal information&#8221; as defined by the California Consumer Privacy Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CCPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and (vi) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems, Confidential Data, and Personal Data and to the protection of such IT Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(uu)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Data Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, CCPA, and the European Union General Data Protection Regulation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GDPR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (EU 2016&#47;679) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  To ensure compliance with the Privacy Laws, the Company has in place, complies with, and takes appropriate steps to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data and Confidential Data (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Company has at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect.  The Company further certifies that neither it nor any subsidiary&#58; (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice&#59; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law&#59; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Other Underwriting Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company is not a party to any agreement with an agent or underwriter for any other &#8220;at the market&#8221; or continuous equity transaction.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ww)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each of the Company and its subsidiaries  is, and at all times has been, in compliance in all material respects with all applicable Health Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Health Care Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.) and the regulations promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Physician Payment </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sunshine Act (42 U.S.C. &#167;&#160;1320a-7h), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &#167; 1320a-7), the civil monetary penalties law (42 U.S.C. &#167; 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.), and the regulations promulgated pursuant to such statutes&#59; (iii) Medicare (Title XVIII of the Social Security Act)&#59; (iv) Medicaid (Title XIX of the Social Security Act)&#59; (v) the Controlled Substances Act (21 U.S.C. &#167;&#167; 801 et seq.) and the regulations promulgated thereunder&#59; and (vi) any and all other applicable health care laws and regulations. Neither the Company nor, to the knowledge of the Company, any subsidiary has received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the Company&#8217;s knowledge, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Neither the Company nor, to the knowledge of the Company, any subsidiary is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, its subsidiaries nor any of its respective employees, officers or directors has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(xx)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Off-Balance Sheet Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  There are no transactions, arrangements and other relationships between and&#47;or among the Company, and&#47;or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structural finance, special purpose or limited purpose entity (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Off-Balance Sheet Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that could reasonably be expected to affect materially the Company&#8217;s liquidity or the availability of or requirements for its capital resources, including those Off-Balance Sheet Transactions described in the Commission&#8217;s Statement about Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations (Release Nos.  33&#8209;8056&#59; 34&#8209;45321&#59; FR&#8209;61), required to be described in the Prospectus which have not been described as required.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(yy)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Forward-Looking Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each financial or operational projection or other &#8220;forward-looking statement&#8221; (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i)&#160;was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&#160;is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that it was false or misleading.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(zz)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Contract Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Other than with respect to the termination as of the date hereof of that certain Controlled Equity Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Sales Agreement, dated November 8, 2018, by and between the Company and Cantor Fitzgerald &#38; Co., neither the Company nor any of its subsidiaries have sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in any preliminary prospectus, the Prospectus or any Free Writing Prospectus, or referred to or described in, or filed as an exhibit to, the Registration Statement, or any document incorporated by reference therein, </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and no such termination or non-renewal has been threatened by the Company or, to the Company&#8217;s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  ISSUANCE AND SALE OF COMMON SHARES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Sale of Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Mechanics of Issuances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(i) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Issuance Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on which the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and Section 5(b) shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance Notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (A) in no event may the Company deliver an Issuance Notice to the extent that the sum of (x) the aggregate Sales Price of the requested Issuance Amount, plus (y) the aggregate Sales Price of all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount&#59; and (B) prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e-mail to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agent Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice, the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement.  For the avoidance of doubt, the parties to this Agreement may modify an Issuance Notice at any time provided they both agree in writing to any such modification.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Method of Offer and Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Shares may be offered and sold (A) in privately negotiated transactions with the consent of the Company&#59; (B) as block transactions&#59; or (C) by any other method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on the Principal Market or sales </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">made into any other existing trading market of the Common Shares.  Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the preceding sentence, and (except as specified in clauses (A) and (B) above) the method of placement of any Shares by the Agent shall be at the Agent&#8217;s discretion.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confirmation to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of Shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company in respect thereof.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlemen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">t.  Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of Shares and, subject to the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its designee&#8217;s account at The Depository Trust Company through its Deposit&#47;Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the Company prior to the Settlement Date.  The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Time of Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Suspension or Termination of Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Consistent with standard market settlement practices, the Company or the Agent may, upon notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable email), suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that (A) such suspension and termination shall not affect or impair either party&#8217;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice&#59; (B) if the Company suspends or terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to such Shares&#59; and (C) if the Company defaults in its obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that the Company has not delivered Shares to settle sales as required by subsection (v) above, and may use the Shares to settle or close out such borrowings.  The Company agrees that no such notice shall be effective against the Agent unless it is made to the persons identified in writing by the Agent pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Guarantee of Placement, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in placing Shares&#59; (B) the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares&#59; and (C)&#160;the Agent shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Non-Public Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of this Agreement, the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material non-public information.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As compensation for services rendered, the Company shall pay to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(b)(vi))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by the Agent deducting the Selling Commission from the applicable Issuance Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&#160;all expenses incident to the issuance and delivery of the Shares (including all printing and engraving costs)&#59; (ii)&#160;all fees and expenses of the registrar and transfer agent of the Shares&#59; (iii)&#160;all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Shares&#59; (iv)&#160;all fees and expenses of the Company&#8217;s counsel, independent public or certified public accountants and other advisors&#59; (v)&#160;all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus  prepared by or on behalf of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement&#59; (vi)&#160;all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and printing a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Blue Sky Survey</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or memorandum and a &#8220;Canadian wrapper&#8221;, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions&#59; (vii) the reasonable fees and disbursements of the Agent&#8217;s counsel, including&#160;the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#8217;s participation in the offering and distribution of the Shares&#59; (viii)&#160;the filing fees incident to FINRA review, if any&#59; (ix) the costs and expenses of the Company relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft chartered in connection with the road show&#59; and (x)&#160;the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#8217;s counsel pursuant to subsections (vi) and (vii) above shall not exceed (A) $100,000 in connection with execution of this Agreement, (B) $25,000 in connection with a Triggering Event Date (as defined below) related to the filing with the Commission of an annual report on Form 10-K on which the Company is required to provide a certificate pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(o)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, (C) $15,000 in connection with a Triggering Event Date related to the filing with the Commission of a quarterly report on Form 10-Q on which the Company is required to provide a certificate pursuant to Section 4(o)(C) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and (D) $25,000 for each program &#8220;refresh&#8221; (filing of a new registration statement, prospectus, or prospectus supplement relating to the Shares and&#47;or an amendment of this Agreement)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  ADDITIONAL COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Exchange Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the Agency Period, the Company shall (i) file, on a timely basis, with the Commission all reports and documents required to be filed under Section 13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act&#59; and (ii) either (A) include in its quarterly reports on Form 10-Q and its annual reports on Form 10-K, a summary detailing, for the relevant reporting period, (1) the number of Shares sold through the Agent pursuant to this Agreement and (2) the net proceeds received by the Company from such sales, or (B) prepare a prospectus supplement containing, or include in such other filing permitted by the Securities Act or Exchange Act (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Interim Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such summary information and, at least once a quarter and subject to this Section </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4, file such Interim Prospectus Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Securities Act Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission&#59; (ii) of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus, or any Free Writing Prospectus&#59; (iii) of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective&#59; and (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.  If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order as soon as reasonably practicable.  Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Amendments and Supplements to the Prospectus and Other Securities Act Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees (subject to Sections&#160;4(d) and 4(f)) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act.  Neither the Agent&#8217;s consent to, or delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&#8217;s obligations under Sections 4(d) and 4(f). Notwithstanding the foregoing, the Company shall not be required to file such amended or supplement if there is no pending Issuance Notice and the Company believes that it is in its best interest not to file such amendment or supplement&#59; provided that the Agent shall not be obligated to accept an Issuance Notice from the Company until such amendment or supplement is filed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Agent&#8217;s Review of Proposed Amendments and Supplements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to amending or supplementing the Registration Statement (including any registration statement filed under Rule&#160;462(b) under the Securities Act) or the Prospectus (excluding any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company shall not file or use any such proposed amendment or supplement without the Agent&#8217;s prior consent, and to file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Use of Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Company nor the Agent has prepared, used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#8217;s prior written consent, any &#8220;written communication&#8221; that constitutes a &#8220;free writing prospectus&#8221; as such terms are defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Free Writing Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Free Writing Prospectuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed Free Writing Prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company and the Company shall not file, use or refer to any proposed Free Writing Prospectus or any amendment or supplement thereto without the Agent&#8217;s consent, which shall not be unreasonably withheld, conditioned or delayed.  The Company shall furnish to the Agent, without charge, as many copies of any Free Writing Prospectus prepared by or on behalf of, or used by the Company, as the Agent may reasonably request.  If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule&#160;173(d)) to be delivered in connection with sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any Free Writing Prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such Free Writing Prospectus to eliminate or correct such conflict or so that the statements in such Free Writing Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such subsequent time, not misleading, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that prior to amending or supplementing any such Free Writing Prospectus, the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented Free Writing Prospectus and the Company shall not file, use or refer to any such amended or supplemented Free Writing Prospectus without the Agent&#8217;s consent, which shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Filing of Agent Free Writing Prospectuses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a Free Writing Prospectus prepared by or on behalf of the Agent that the Agent otherwise would not have been required to file thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Copies of Registration Statement and Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule&#160;173(d)) to be delivered in connection with sales of the Shares, the Company agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies of the Prospectus and each amendment or supplement thereto in the form in which it is filed with the Commission pursuant to the Securities Act or Rule&#160;424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time&#59; and, if the delivery of a prospectus is required under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such offers as soon as practicable)&#59; and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance&#59; provided, however, that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Blue Sky Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall cooperate with the Agent and counsel for the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares.  The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.  The Company will advise the Agent promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof as soon as practicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Earnings Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As soon as reasonably practicable, the Company will make generally available to its security holders and to the Agent an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act, which requirement may be satisfied by publicly filing or furnishing the required information on EDGAR.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Listing&#59; Reservation of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  (a)  The Company will maintain the listing of the Shares on the Principal Market&#59; and (b) the Company will reserve and keep available at all times, free of preemptive rights, Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Transfer Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Due Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during normal business hours and at the Company&#8217;s principal offices, as the Agent may reasonably request from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i) an affirmation to the Agent that the representations and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as may be disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto)&#59; and (ii)&#160;an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Deliverables at Triggering Event Dates&#59; Certificates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(A)&#160;&#160;&#160;&#160;the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to Section 4(a)(ii)(B)), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of documents by reference into the Registration Statement or Prospectus&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(B)&#160;&#160;&#160;&#160;the filing with the Commission of an annual report on Form 10-K (including any Form 10-K&#47;A containing amended financial information or a material amendment to a previously filed annual report on Form 10-K) of the Company&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C) the filing with the Commission of a quarterly report on Form 10-Q (including any Form 10-Q&#47;A containing amended financial information or a material amendment to a previously filed quarterly report on Form 10-Q) of the Company&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(D)&#160;&#160;&#160;&#160;the filing with the Commission of a current report on Form 8-K of the Company containing amended financial information (other than information &#8220;furnished&#8221; pursuant to Item 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) that is material to the offering of securities of the Company in the Agent&#8217;s reasonable discretion&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(any such event, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Triggering Event Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall furnish the Agent (but in the case of clause (D) above only if the Agent reasonably determines that the information contained in such current report on Form 8-K of the Company is material) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A) confirming that the representations and warranties of the Company contained in this Agreement are true and correct, (B) confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(a)(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof, and (C) containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be waived for any Triggering Event Date occurring at a time when no Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a Triggering Event Date) and the next occurring Triggering Event </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent with a certificate under this Section 4(o), then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a certificate in conformity with this Section 4(o) dated as of the date that the instructions for the sale of Shares are issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Legal Opinions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, a negative assurance letter and the written legal opinion of Cooley LLP, counsel to the Company, a negative assurance letter of Latham &#38; Watkins LLP, counsel to the Agent and the written legal opinion of Clark + Elbing LLP, intellectual property counsel to the Company, regarding the intellectual property of the Company, each dated the date of delivery, shall be furnished to the Agent, each in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of such Triggering Event Date). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Comfort Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to Section 4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall cause Ernst &#38; Young LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel&#59; provided, however, that any such comfort letter will only be required on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus.  If requested by the Agent, the Company shall also cause a comfort letter to be furnished to the Agent on the date of occurrence of any material transaction or event requiring the filing of a current report on Form 8-K containing material amended financial information of the Company, including the restatement of the Company&#8217;s financial statements&#59; provided, that, such comfort letter shall not be required to be delivered to the Agent unless and until the Company delivers an Issuance Notice that is effective on or after the date of occurrence of such material transaction or event. Subject to the preceding sentence, the Company shall be required to furnish no more than one comfort letter hereunder per annual report on Form&#160;10-K&#160;or Form&#160;10-K&#47;A&#160;and quarterly report on Form&#160;10-Q&#160;or Form&#160;10-Q&#47;A&#160;filed by the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(r)    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Secretary&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery (i) certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby (including, without limitation, the </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii) certifying and attesting to the office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii) containing any other certification that the Agent shall reasonably request. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.36pt;text-decoration:underline">Agent&#8217;s Own Account&#59; Clients&#8217; Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company consents to the Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#8217;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Investment Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Market Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its Affiliates to, comply with all applicable provisions of Rule 100 of Regulation M.  If the limitations of Rule 102 of Regulation M (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rule 102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in Section (d) of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its Affiliates to, comply with Rule 102 as though such exception were not available but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d) of Rule 102. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notice of Other Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice&#59; and will not directly or indirectly enter into any other &#8220;at the market&#8221; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement&#59; provided, however, that such restrictions will not be required in connection with the Company&#8217;s (A) issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards or vesting and settlement of restricted stock units pursuant to any employee or director share option, incentive or benefit plan, share purchase or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under the Principal Market&#8217;s rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (B) issuance or sale of Common Shares issuable upon exchange, conversion or redemption of securities (including shares of the Company&#8217;s preferred stock) or the exercise or vesting of warrants, pre-funded warrants, options or other equity awards outstanding at the date of this Agreement, (C) issuance or sale of any securities, Common Shares or securities convertible into or exchangeable for Common Shares in connection with strategic transactions including mergers, acquisitions, other </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">business combinations, joint ventures or strategic alliances, manufacturing, marketing, sponsored research, collaboration, license or distribution arrangements which are not issued primarily for capital raising purposes&#59; provided that the aggregate number of Common Shares issued or sold under this subsection (C) shall not exceed 5% of the number of Common Shares outstanding immediately prior to giving effect to such sale or issuance, and (D)&#160;modification of any outstanding options, warrants, pre-funded warrants or any rights to purchase or acquire Common Shares. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accuracy of the Company&#8217;s Representations and Warranties&#59; Performance by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall have delivered the certificate required to be delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on or before the date on which delivery of such certificate is required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall have performed, satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 4(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Injunction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Adverse Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as disclosed in the Prospectus and the Time of Sale Information, (a) in the judgment of the Agent there shall not have occurred any Material Adverse Change&#59; and (b) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#8220;nationally recognized statistical rating organization&#8221; as such term is defined for purposes of Section 3(a)(62) of the Exchange Act.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Suspension of Trading in or Delisting of Common Shares&#59; Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The trading of the Common Shares (including without limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and shall not have been delisted from the Principal Market or any of their constituent markets.  There shall not have occurred (and be continuing in the case of occurrences under clauses&#160;(i) and </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;below) any of the following&#58;  (i)&#160;trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on the Principal Market shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges by the Commission or FINRA&#59; (ii)&#160;a general banking moratorium shall have been declared by any of federal or New York, authorities&#59; or (iii)&#160;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#8217; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus or to enforce contracts for the sale of securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Documents Required to be Delivered on each Issuance Notice Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Agent&#8217;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Misstatement or Material Omission</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Agent shall not have advised the Company that the Registration Statement, the Prospectus or the Time of Sale Information, or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&#8217;s reasonable opinion is material, or omits to state a fact that in the Agent&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  INDEMNIFICATION AND CONTRIBUTION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Indemnification of the Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&#160;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule&#160;430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; (ii)&#160;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading&#59; or (iii) any act or failure to act or any alleged act or failure to act by the Agent in connection with, or relating in any manner to, the Common Shares or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">based upon any matter covered by clause (i) or (ii) above, provided that the Company shall not be liable under this clause (iii) to the extent that a court of competent jurisdiction shall have determined by a final judgment that such loss, claim, damage, liability or action resulted directly from any such acts or failures to act undertaken or omitted to be taken by the Agent through its bad faith or willful misconduct, and to reimburse the Agent and each such officer, employee and controlling person for any and all expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action&#59; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in (b) below.  The indemnity agreement set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  shall be in addition to any liabilities that the Company may otherwise have.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Indemnification of the Company, its Directors and Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&#160;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or Prospectus, or any amendment or supplement thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading&#59; or (ii)&#160;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading&#59; but only to the extent arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information set forth in the &#91;first sentence of the ninth paragraph&#93; under the caption &#8220;Plan of Distribution&#8221; in the Prospectus and the Agent&#8217;s name, and to reimburse the Company and each such director, officer and controlling person for any and all expenses (including the reasonable and documented fees and disbursements of counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this Section&#160;6(b) shall be in addition to any liabilities that the Agent or the Company may otherwise have.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Notifications and Other Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Promptly after receipt by an indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for contribution or otherwise than under the indemnity agreement contained in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> or to the extent it is not prejudiced as a proximate result of such failure.  In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party&#59; provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and&#47;or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties.  Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#8217;s election to so assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&#160;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the indemnified party (in the case of counsel for the indemnified parties referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above), (ii)&#160;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Settlements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The indemnifying party under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment.  Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&#160;such settlement is entered into more than 30&#160;calendar days after receipt by such indemnifying party of the aforesaid request&#59; and (ii)&#160;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement.  No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the indemnification provided for in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&#160;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement&#59; or (ii)&#160;if the allocation provided by clause&#160;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&#160;(i) above but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations.  The relative benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from the offering of the Shares (before deducting expenses) received by the Company bear to the total Selling Commissions received by the Agent.  The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the other hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section 6(c), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.  The provisions set forth in Section 6(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 6(e)&#59; provided, however, that no additional notice shall be required with respect to any action for which notice has been given under Section 6(c) for purposes of indemnification.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notwithstanding the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Agent shall not be required to contribute any amount in excess of the Selling Commissions received by the Agent in connection with the offering contemplated hereby.  No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.  For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each officer and employee of the Agent and each person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  TERMINATION &#38; SURVIVAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the term of this Agreement shall continue from the date of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination&#59; Survival Following Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) &#160;&#160;&#160;&#160;Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement, upon ten (10) Trading Days&#8217; notice to the other party&#59; provided that, (A) if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with respect to such Shares and (B) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall survive termination of this Agreement.  If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) In addition to the survival provision of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 7(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any termination of this Agreement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">  MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Press Releases and Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form&#160;8-K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Advisory or Fiduciary Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company acknowledges and agrees that (i) the transactions contemplated by this Agreement, including the determination of any fees, are arm&#8217;s-length commercial transactions between the Company and the Agent, and do not constitute a recommendation, investment advice, or solicitation of any action by the Agent, (ii) when acting as a principal under this Agreement, the Agent is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii) the Agent has not assumed nor will assume an advisory or </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fiduciary responsibility in favor of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv) the Agent and its respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, (v) the Agent has not provided any legal, accounting, financial, regulatory, investment or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate, and (vi) none of the activities of the Agent in connection with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation of any action by the Agent with respect to any entity or natural person. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Research Analyst Independence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company acknowledges that the Agent&#8217;s research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#8217;s research analysts may hold views and make statements or investment recommendations and&#47;or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions.  The Company understands that the Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Agent&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Jefferies LLC<br>520 Madison Avenue<br>New&#160;York, NY 10022<br>Facsimile&#58;  <br>Attention&#58;  General Counsel</font></div><div style="padding-left:54pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy (which shall not constitute notice) to&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Latham &#38; Watkins LLP<br>12670 High Bluff Drive<br>San Diego, CA 92130<br>Facsimile&#58; (858) 523-5450</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Michael E Sullivan</font></div><div style="padding-left:54pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to the Company&#58;<br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cidara Therapeutics, Inc.</font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6310 Nancy Ridge Drive, Suite 101</font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">San Diego, California 92121</font></div><div style="padding-left:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Jeffrey Stein, Ph.D., CEO</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy (which shall not constitute notice) to&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cooley LLP</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10265 Science Center Drive</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">San Diego, California 92121</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Facsimile&#58; (858)&#160;550-6420</font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Charles Bair, Esq.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and in each case their respective successors, and no other person will have any right or obligation hereunder.  The term &#8220;successors&#8221; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Partial Unenforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof.  If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Governing Law Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state.  Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Specified Courts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">General Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.  This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com).  This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be </font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">waived unless waived in writing by each party whom the condition is meant to benefit.  The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page Immediately Follows&#93;</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="ia3764b00eb5f488da7206be9b3ec1d20_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC. </font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#47;s&#47; Jeffrey Stein, Ph.D.   &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; Jeffrey Stein, Ph.D.</font></div><div style="padding-left:247.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the date first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JEFFERIES LLC </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#47;s&#47; Donald Lynaugh&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58; Donald Lynaugh   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58; Managing Director   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="ia3764b00eb5f488da7206be9b3ec1d20_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUANCE NOTICE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jefferies LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">520 Madison Avenue</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">New York, New York 10022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attn&#58; &#91;__________&#93;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Reference is made to the Open Market Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> between Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Jefferies LLC (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) dated as of May ___,  2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sales Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. Capitalized terms used herein and not defined shall have the respective meanings ascribed to such terms in the Sales Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date that the Base Registration Statement Expires&#58; &#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">2</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Delivery of Issuance Notice (determined pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3(b)(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#58; _______________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Issuance Amount (equal to the total Sales Price for such Shares)&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of days in selling period&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">First date of selling period&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Last date of selling period&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Settlement Date(s) if other than standard T+1 settlement&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Floor Price Limitation (in no event less than $1.00 without the prior written consent of the Agent, which consent may be withheld in the Agent&#8217;s sole discretion)&#58; $ ____ per share</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Comments&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______________________</font></div><div style="padding-left:252pt"><font><br></font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NTD&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This needs to be filled in and should not be left blank.</font></div><div style="height:91.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Name&#58;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;  </font></div><div><font><br></font></div><div style="height:91.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:10.00pt">A-2</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:right"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="ia3764b00eb5f488da7206be9b3ec1d20_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:10.00pt">Schedule A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:10.00pt">Notice Parties</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jeffrey Stein, Ph.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Frank Karbe</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shane Ward </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Agent</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Michael Magarro </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Donald Lynaugh</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit3112025-03.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7546f9d1df66496499a4631a5cf126c8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">I, Jeffrey Stein, Ph.D., certify that&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit3122025-03.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia4bd66c000984eda9d4038c10e809e29_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">I, Frank Karbe, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Frank Karbe</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Frank Karbe</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit3212025-03.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0d750ab7d0954d41afcae04669da8479_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">March&#160;31, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof and to which this certification is attached as an exhibit (the &#8220;Report&#8221;), I, Jeffrey Stein, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167; 1350)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cidara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit3222025-03.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib69bf708bf4d4c33af445a096cc70ac6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">March&#160;31, 2025</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof and to which this certification is attached as an exhibit (the &#8220;Report&#8221;), I, Frank Karbe, Chief Financial Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167; 1350)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; May 8, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Frank Karbe</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Frank Karbe</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cidara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cdtx-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:772584df-f722-4edc-81e3-b26e5bb232b0,g:477eac6b-6822-4ddf-a883-4a61404b9849-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://cidara.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://cidara.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>9952154 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATION" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION">
        <link:definition>9952156 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952158 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952159 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANS" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS">
        <link:definition>9952160 - Disclosure - EQUITY INCENTIVE PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTS" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS">
        <link:definition>9952161 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://cidara.com/role/INCOMETAXES">
        <link:definition>9952163 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISCONTINUEDOPERATIONS" roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONS">
        <link:definition>9952164 - Disclosure - DISCONTINUED OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://cidara.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952165 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONTables" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables">
        <link:definition>9955512 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955513 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9955514 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955515 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSTables" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables">
        <link:definition>9955516 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSTables" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables">
        <link:definition>9955517 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9955518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISCONTINUEDOPERATIONSTables" roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSTables">
        <link:definition>9955519 - Disclosure - DISCONTINUED OPERATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails">
        <link:definition>9955520 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>9955521 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Schedule of Segment Reporting Information by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>9955522 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9955525 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>9955526 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>9955527 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSAdditionalInformationDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails">
        <link:definition>9955528 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails">
        <link:definition>9955529 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails">
        <link:definition>9955530 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9955531 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails">
        <link:definition>9955532 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
        <link:definition>9955533 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails">
        <link:definition>9955534 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails">
        <link:definition>9955535 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1">
        <link:definition>9955535 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails">
        <link:definition>9955536 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://cidara.com/role/INCOMETAXESDetails">
        <link:definition>9955537 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISCONTINUEDOPERATIONSAdditionalInformationDetails" roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails">
        <link:definition>9955538 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails">
        <link:definition>9955539 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
        <link:definition>9955540 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://cidara.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955541 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cdtx_SeriesAConvertibleVotingPreferredStockMember" abstract="true" name="SeriesAConvertibleVotingPreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_SeriesXConvertiblePreferredStockMember" abstract="true" name="SeriesXConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_PreferredStockSharesIssuedIncludingConversion" abstract="false" name="PreferredStockSharesIssuedIncludingConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdtx_OperatingLeaseRightOfUseAmortization" abstract="false" name="OperatingLeaseRightOfUseAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LossOnAssignmentOfFinanceLease" abstract="false" name="LossOnAssignmentOfFinanceLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" abstract="false" name="IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" abstract="false" name="TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" abstract="false" name="PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cdtx_RezafunginMember" abstract="true" name="RezafunginMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" abstract="false" name="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_OtherSegmentItemsAbstract" abstract="true" name="OtherSegmentItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_PrefundedWarrantsMember" abstract="true" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" abstract="true" name="ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CommonStockWarrantMember" abstract="true" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" abstract="false" name="ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_NumberOfVotesEntitlementForEachShareHeld" abstract="false" name="NumberOfVotesEntitlementForEachShareHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_CommonStockDividendsInArrearsOrDefault" abstract="false" name="CommonStockDividendsInArrearsOrDefault" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ClassOfWarrantOrRightExercisesInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdtx_WarrantsAggregateIntrinsicValueOutstanding" abstract="false" name="WarrantsAggregateIntrinsicValueOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_AuthorizedSharesForFutureStockAwardsMember" abstract="true" name="AuthorizedSharesForFutureStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandFifteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" abstract="true" name="MoreThanTenPercentVotingRightsClassesOfStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" abstract="true" name="TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_UpfrontPaymentMember" abstract="true" name="UpfrontPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_PaymentsRelatedToCollaborativeAgreements" abstract="false" name="PaymentsRelatedToCollaborativeAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" abstract="false" name="ResearchAndDevelopmentExpenseAcquiredInProcess" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_DirectTransactionCosts" abstract="false" name="DirectTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" abstract="false" name="CollaborativeArrangementMaximumThirdPartyShareOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ClinicalSupplyServicesMember" abstract="true" name="ClinicalSupplyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" abstract="true" name="FinanceLeaseRightOfUseAssetAndLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_LesseeFinanceLeaseMonthlyRate" abstract="false" name="LesseeFinanceLeaseMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" abstract="false" name="LesseeFinanceLeaseOptionPurchaseEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseMonthlyRate" abstract="false" name="LesseeOperatingLeaseMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseAnnualRateIncrease" abstract="false" name="LesseeOperatingLeaseAnnualRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_NumberOfOperatingLeaseOptionsForExtension" abstract="false" name="NumberOfOperatingLeaseOptionsForExtension" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseOptionRenewalTerm" abstract="false" name="LesseeOperatingLeaseOptionRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" abstract="false" name="LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" abstract="false" name="RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cdtx_GuarantorObligationsTerminationNoticeTerm" abstract="false" name="GuarantorObligationsTerminationNoticeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_NappPharmaceuticalGroupLimitedMember" abstract="true" name="NappPharmaceuticalGroupLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_MelintaTherapeuticsIncMember" abstract="true" name="MelintaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_MundipharmaMedicalCompanyMember" abstract="true" name="MundipharmaMedicalCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_RezafunginAssetsMember" abstract="true" name="RezafunginAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" abstract="false" name="CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" abstract="false" name="CollaborativeArrangementCarryOverServicesAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementOtherServicesAgreementTerm" abstract="false" name="CollaborativeArrangementOtherServicesAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTransactionValue" abstract="false" name="CollaborativeArrangementTransactionValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTransitionsServicesTerm" abstract="false" name="CollaborativeArrangementTransitionsServicesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" abstract="true" name="LicenseOfIntellectualPropertyUponMilestonesAchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_OpenMarketSaleAgreementMember" abstract="true" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_SaleOfStockConsiderationReceivablePerTransaction" abstract="false" name="SaleOfStockConsiderationReceivablePerTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cdtx-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:772584df-f722-4edc-81e3-b26e5bb232b0,g:477eac6b-6822-4ddf-a883-4a61404b9849-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_152f789c-58c9-4073-90e8-da8bcc742e71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6bdda2b2-2e4b-4746-bca9-26807514dc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_152f789c-58c9-4073-90e8-da8bcc742e71" xlink:to="loc_us-gaap_StockholdersEquity_6bdda2b2-2e4b-4746-bca9-26807514dc0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_32f76938-aa9a-42a9-9e7b-037ee01ed628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_152f789c-58c9-4073-90e8-da8bcc742e71" xlink:to="loc_us-gaap_CommitmentsAndContingencies_32f76938-aa9a-42a9-9e7b-037ee01ed628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d78b89dd-6309-4629-b1bd-f973f21ecd87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_152f789c-58c9-4073-90e8-da8bcc742e71" xlink:to="loc_us-gaap_Liabilities_d78b89dd-6309-4629-b1bd-f973f21ecd87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5f7b77a2-2cc9-45e1-9edb-a66fe3ee0aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59928cff-da5e-44c0-b3ee-7fb1c5a66d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f7b77a2-2cc9-45e1-9edb-a66fe3ee0aac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_59928cff-da5e-44c0-b3ee-7fb1c5a66d2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b753a271-f431-4de8-9cba-b89fe2c81ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f7b77a2-2cc9-45e1-9edb-a66fe3ee0aac" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b753a271-f431-4de8-9cba-b89fe2c81ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_70427904-89a3-49d6-b74b-21b2e7060f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f7b77a2-2cc9-45e1-9edb-a66fe3ee0aac" xlink:to="loc_us-gaap_CommonStockValue_70427904-89a3-49d6-b74b-21b2e7060f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1eafd362-1bb3-49fa-9524-7fc879f3e4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5f7b77a2-2cc9-45e1-9edb-a66fe3ee0aac" xlink:to="loc_us-gaap_PreferredStockValue_1eafd362-1bb3-49fa-9524-7fc879f3e4a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f2258fb3-f44d-4b1a-8947-c6067c7f1fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d26799bc-3544-4a98-b543-528f46c027c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2258fb3-f44d-4b1a-8947-c6067c7f1fd7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d26799bc-3544-4a98-b543-528f46c027c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90f3af70-0a75-4b7e-9a29-9202d9f0309a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2258fb3-f44d-4b1a-8947-c6067c7f1fd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_90f3af70-0a75-4b7e-9a29-9202d9f0309a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_394e7daf-a485-4737-bdaa-903b2c002fff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2258fb3-f44d-4b1a-8947-c6067c7f1fd7" xlink:to="loc_us-gaap_RestrictedCashCurrent_394e7daf-a485-4737-bdaa-903b2c002fff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18e6892d-e1d8-4cad-86e2-02f13e26d93b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f2258fb3-f44d-4b1a-8947-c6067c7f1fd7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_18e6892d-e1d8-4cad-86e2-02f13e26d93b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_11d2aa67-8ab2-4ecd-87b8-bf71415e7262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8a426afb-091b-48f1-a508-1969c1b4a6de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_11d2aa67-8ab2-4ecd-87b8-bf71415e7262" xlink:to="loc_us-gaap_AssetsCurrent_8a426afb-091b-48f1-a508-1969c1b4a6de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8de6efbb-3df2-46de-82d3-c662fd9e6e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_11d2aa67-8ab2-4ecd-87b8-bf71415e7262" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8de6efbb-3df2-46de-82d3-c662fd9e6e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f0206d4b-5376-496b-9724-9b531565964c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_11d2aa67-8ab2-4ecd-87b8-bf71415e7262" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f0206d4b-5376-496b-9724-9b531565964c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4086bfde-59fb-46ea-943b-2d8308012b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_11d2aa67-8ab2-4ecd-87b8-bf71415e7262" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4086bfde-59fb-46ea-943b-2d8308012b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_73543994-df4e-4817-ac8e-182d45a8ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_11d2aa67-8ab2-4ecd-87b8-bf71415e7262" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_73543994-df4e-4817-ac8e-182d45a8ab47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5e261892-c2bc-4ea0-b3d0-ee26aae2a822" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1e5af08c-cab6-4a07-b2ff-24cbbf869e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5e261892-c2bc-4ea0-b3d0-ee26aae2a822" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1e5af08c-cab6-4a07-b2ff-24cbbf869e6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_84e81668-e610-4a61-83df-0a7086488720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5e261892-c2bc-4ea0-b3d0-ee26aae2a822" xlink:to="loc_us-gaap_LiabilitiesCurrent_84e81668-e610-4a61-83df-0a7086488720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9cb4e812-2cb2-49b5-9aeb-a691972b6c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5e261892-c2bc-4ea0-b3d0-ee26aae2a822" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9cb4e812-2cb2-49b5-9aeb-a691972b6c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_12439751-9565-4d33-a121-118e94c3c13f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_12439751-9565-4d33-a121-118e94c3c13f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d794da10-aa01-4a6d-afec-ec4f634258e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d794da10-aa01-4a6d-afec-ec4f634258e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9d25bdcc-b192-49ac-9d43-80aa4a60637a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:to="loc_us-gaap_AccountsPayableCurrent_9d25bdcc-b192-49ac-9d43-80aa4a60637a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b051a444-4820-481f-8ba5-65dcf86b7d82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b051a444-4820-481f-8ba5-65dcf86b7d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b502237f-11ae-4123-8384-185981df6436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b502237f-11ae-4123-8384-185981df6436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_5dc8351b-291f-48f4-bbd2-2e0725461c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cdff5972-e793-4e8f-ac4e-a2c33ab8fff7" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_5dc8351b-291f-48f4-bbd2-2e0725461c9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_dec189b2-71a0-4445-848f-27e9699bf7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_922d6fe9-2af1-48da-a7ae-845c7e4aaf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_dec189b2-71a0-4445-848f-27e9699bf7f1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_922d6fe9-2af1-48da-a7ae-845c7e4aaf1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_02b5b9fb-b7c7-4043-9af9-53bcdcfc523e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_dec189b2-71a0-4445-848f-27e9699bf7f1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_02b5b9fb-b7c7-4043-9af9-53bcdcfc523e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6c41a92a-4270-437f-ae36-2e7fb5102d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_fd8c5ec9-f18a-4428-833e-af6e8c7d7a89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6c41a92a-4270-437f-ae36-2e7fb5102d01" xlink:to="loc_us-gaap_Revenues_fd8c5ec9-f18a-4428-833e-af6e8c7d7a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6f67e794-416c-4d6c-b8a1-b88a9a6240ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6c41a92a-4270-437f-ae36-2e7fb5102d01" xlink:to="loc_us-gaap_OperatingExpenses_6f67e794-416c-4d6c-b8a1-b88a9a6240ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c5f594bc-48d4-4679-8b71-e16a7ee71bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_16472c2d-5593-4907-be75-75903c786e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c5f594bc-48d4-4679-8b71-e16a7ee71bc2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_16472c2d-5593-4907-be75-75903c786e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39dd331b-a8a2-49bd-a078-d3a0b06722d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c5f594bc-48d4-4679-8b71-e16a7ee71bc2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39dd331b-a8a2-49bd-a078-d3a0b06722d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_54badd4f-015d-48ca-887f-5cabc2f97d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c5f594bc-48d4-4679-8b71-e16a7ee71bc2" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_54badd4f-015d-48ca-887f-5cabc2f97d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b27f9fa7-1bc8-45ce-938b-0a93b00f77a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ffbefe9d-2fe8-4d84-a6d6-a333863f4792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b27f9fa7-1bc8-45ce-938b-0a93b00f77a4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ffbefe9d-2fe8-4d84-a6d6-a333863f4792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0e055f41-16cd-4bd2-9865-fc0d92597e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b27f9fa7-1bc8-45ce-938b-0a93b00f77a4" xlink:to="loc_us-gaap_OperatingIncomeLoss_0e055f41-16cd-4bd2-9865-fc0d92597e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_78fbf162-e51f-42fe-b5da-037dc3544084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f6f130c3-7385-42e5-a488-a43393a61aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_78fbf162-e51f-42fe-b5da-037dc3544084" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f6f130c3-7385-42e5-a488-a43393a61aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_a7362744-8bec-4edb-ae81-9199b74e0eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_78fbf162-e51f-42fe-b5da-037dc3544084" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_a7362744-8bec-4edb-ae81-9199b74e0eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebbbc38a-f6ea-4797-b303-e9d9d2ecd24d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6c878a53-7211-42d6-9ce5-b51df22de9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebbbc38a-f6ea-4797-b303-e9d9d2ecd24d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6c878a53-7211-42d6-9ce5-b51df22de9fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7cabb405-99e0-4912-9839-0db8613e6153" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ebbbc38a-f6ea-4797-b303-e9d9d2ecd24d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7cabb405-99e0-4912-9839-0db8613e6153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d334fe41-69f2-433e-84b9-98e34e68c848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f0227fee-4a3e-455a-a146-a130f88668f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d334fe41-69f2-433e-84b9-98e34e68c848" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f0227fee-4a3e-455a-a146-a130f88668f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_42bd5608-afa3-416a-b692-b8575f0db80a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d334fe41-69f2-433e-84b9-98e34e68c848" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_42bd5608-afa3-416a-b692-b8575f0db80a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_038f27ec-6fc3-4146-a907-4d1ce2328255" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_129b231c-5fd7-4eaf-b9eb-fc960c797a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_038f27ec-6fc3-4146-a907-4d1ce2328255" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_129b231c-5fd7-4eaf-b9eb-fc960c797a4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_209e5141-cd85-47eb-9da3-b42b6ba62eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_038f27ec-6fc3-4146-a907-4d1ce2328255" xlink:to="loc_us-gaap_OtherNonoperatingExpense_209e5141-cd85-47eb-9da3-b42b6ba62eb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c589c297-a694-4293-8629-0630f6a7c6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2a5a1f6b-f2ed-44ba-900d-69cfe56d8bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c589c297-a694-4293-8629-0630f6a7c6c1" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2a5a1f6b-f2ed-44ba-900d-69cfe56d8bf9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d2bde6a-8737-442c-9709-2ffca64b6d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_693a762e-8ef1-4bc6-98ba-0e72966cd6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d2bde6a-8737-442c-9709-2ffca64b6d4e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_693a762e-8ef1-4bc6-98ba-0e72966cd6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8ff457ea-84f3-4def-a59d-35773a1ed12a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d2bde6a-8737-442c-9709-2ffca64b6d4e" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8ff457ea-84f3-4def-a59d-35773a1ed12a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c412d49e-895a-4720-afcf-8c977811e1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4088d4d0-e685-4cca-80c8-b3d7d2f53f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c412d49e-895a-4720-afcf-8c977811e1e9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4088d4d0-e685-4cca-80c8-b3d7d2f53f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_fe7607f8-b91e-4396-a7e8-eb85b0da75dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c412d49e-895a-4720-afcf-8c977811e1e9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_fe7607f8-b91e-4396-a7e8-eb85b0da75dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6f24e966-71a6-4bca-913d-56d11805e592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c412d49e-895a-4720-afcf-8c977811e1e9" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6f24e966-71a6-4bca-913d-56d11805e592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_031b29ce-c07a-45cb-bda6-63bc62b35fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c412d49e-895a-4720-afcf-8c977811e1e9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_031b29ce-c07a-45cb-bda6-63bc62b35fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e91c673-ccc5-4f2c-8ad5-005a48873afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_47992167-43bf-40b7-a49e-1c69f0a71891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e91c673-ccc5-4f2c-8ad5-005a48873afb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_47992167-43bf-40b7-a49e-1c69f0a71891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfdd85d5-65c6-4ecd-8f67-947ee312c7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e91c673-ccc5-4f2c-8ad5-005a48873afb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfdd85d5-65c6-4ecd-8f67-947ee312c7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cb2e503-a9fc-4d4d-b072-b5f6d27c2fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e91c673-ccc5-4f2c-8ad5-005a48873afb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7cb2e503-a9fc-4d4d-b072-b5f6d27c2fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_38465281-a22c-42d8-b7d5-e458449ad494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_DepreciationAndAmortization_38465281-a22c-42d8-b7d5-e458449ad494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c8188b4f-ac69-460a-9d18-1647e074d5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c8188b4f-ac69-460a-9d18-1647e074d5d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_73f3e7fe-c5b3-4eda-a1ac-9c37b49527e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_73f3e7fe-c5b3-4eda-a1ac-9c37b49527e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0b86ae80-d72f-48aa-91c2-68776266c58c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0b86ae80-d72f-48aa-91c2-68776266c58c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LossOnAssignmentOfFinanceLease_1bfc9438-a500-4d00-b589-9e9a91cd45fe" xlink:href="cdtx-20250331.xsd#cdtx_LossOnAssignmentOfFinanceLease"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_cdtx_LossOnAssignmentOfFinanceLease_1bfc9438-a500-4d00-b589-9e9a91cd45fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_ae748908-356c-4a4d-898a-26d2a818f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_PaidInKindInterest_ae748908-356c-4a4d-898a-26d2a818f9fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3e63f821-9522-4fb9-9bcb-05eb78dd7d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_ShareBasedCompensation_3e63f821-9522-4fb9-9bcb-05eb78dd7d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3cac9aac-ec6a-46ba-997c-0221fa0f245c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3cac9aac-ec6a-46ba-997c-0221fa0f245c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c8542b03-a2fa-4260-be87-1a07a45d4a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c8542b03-a2fa-4260-be87-1a07a45d4a3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_0cf56b58-8a01-49c0-8d62-1a3cffeff9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_0cf56b58-8a01-49c0-8d62-1a3cffeff9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ec770509-c01f-4efd-9563-d47487a7347c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ec770509-c01f-4efd-9563-d47487a7347c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0dd7e884-f50f-4f43-a8eb-5f323c1dd1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0dd7e884-f50f-4f43-a8eb-5f323c1dd1fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f8ef562b-d510-4027-8135-7133da0f091f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f8ef562b-d510-4027-8135-7133da0f091f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_e0a0cb88-b8c8-4ddd-9ff7-122a3e421326" xlink:href="cdtx-20250331.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_e0a0cb88-b8c8-4ddd-9ff7-122a3e421326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b9f85704-fa76-4710-b8cf-a749a2f90f42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_NetIncomeLoss_b9f85704-fa76-4710-b8cf-a749a2f90f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1a7bc558-622c-4792-a28a-269977c74e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1a7bc558-622c-4792-a28a-269977c74e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_416ea9a1-427b-4ab1-a7ed-6f4c617c3222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_416ea9a1-427b-4ab1-a7ed-6f4c617c3222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_e4a6deaa-8f49-4e06-83fd-781db78884b5" xlink:href="cdtx-20250331.xsd#cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_136075c8-a3e9-4759-b659-ef52df6eb163" xlink:to="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_e4a6deaa-8f49-4e06-83fd-781db78884b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3133f1f9-b9ec-421c-8d4a-41163dc4b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3133f1f9-b9ec-421c-8d4a-41163dc4b20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_5574c937-e51f-4ad1-94c2-a744cf4ee414" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_5574c937-e51f-4ad1-94c2-a744cf4ee414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_94be35ac-e28e-40e9-a80d-7e9651e74df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_94be35ac-e28e-40e9-a80d-7e9651e74df1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_9934ee4f-ef96-4748-942b-a2173dcefe32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_9934ee4f-ef96-4748-942b-a2173dcefe32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_056165cc-21a0-4e82-b5fa-fe3667a19a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_Revenues_056165cc-21a0-4e82-b5fa-fe3667a19a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_95a66a34-e395-44c9-8924-22312ba55beb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_95a66a34-e395-44c9-8924-22312ba55beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c83273f4-5543-439f-ab27-d09505c424ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c83273f4-5543-439f-ab27-d09505c424ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_6184056a-ccb8-480a-a0a0-39287bbccb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9afd47d2-2207-4be6-ac74-f52be5f12afd" xlink:to="loc_us-gaap_LaborAndRelatedExpense_6184056a-ccb8-480a-a0a0-39287bbccb7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a499f2b4-b835-48ee-bb20-00471c5e4f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cbc32d68-00ce-46e0-8ebd-6e14f1965fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a499f2b4-b835-48ee-bb20-00471c5e4f89" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cbc32d68-00ce-46e0-8ebd-6e14f1965fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_40b2beff-d252-4d3e-a3b0-da74c37cdaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a499f2b4-b835-48ee-bb20-00471c5e4f89" xlink:to="loc_us-gaap_RestrictedCashCurrent_40b2beff-d252-4d3e-a3b0-da74c37cdaf8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_94af4a8d-5f10-48ee-a64a-f4b68176fc62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2fa6672e-b41e-4c8b-85ad-e4544226c7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_94af4a8d-5f10-48ee-a64a-f4b68176fc62" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2fa6672e-b41e-4c8b-85ad-e4544226c7fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_7e10b2ae-7128-444a-a763-cec008a0bb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_94af4a8d-5f10-48ee-a64a-f4b68176fc62" xlink:to="loc_us-gaap_RestrictedCash_7e10b2ae-7128-444a-a763-cec008a0bb02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0382b61-6cfc-4c80-a617-7b25ddd95e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c654da83-5eaf-4da2-8622-1fce3a8f68d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0382b61-6cfc-4c80-a617-7b25ddd95e6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c654da83-5eaf-4da2-8622-1fce3a8f68d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_506eaa29-a18e-4320-9854-16a8b5926406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0382b61-6cfc-4c80-a617-7b25ddd95e6f" xlink:to="loc_us-gaap_OperatingLeaseLiability_506eaa29-a18e-4320-9854-16a8b5926406" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8365865-c3f5-4390-b2d3-4c69690d207e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_26013766-62fa-4cf2-bf95-fba1928006b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8365865-c3f5-4390-b2d3-4c69690d207e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_26013766-62fa-4cf2-bf95-fba1928006b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8e482e11-396a-4257-a014-d8bd25be48f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8365865-c3f5-4390-b2d3-4c69690d207e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8e482e11-396a-4257-a014-d8bd25be48f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_56f59460-8b09-4291-a12e-cf8a0868837e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ee9d72f8-b149-41c7-81ad-e729872b0c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_56f59460-8b09-4291-a12e-cf8a0868837e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ee9d72f8-b149-41c7-81ad-e729872b0c0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b0943bad-449b-493d-8dad-8c76d7a8e78f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_56f59460-8b09-4291-a12e-cf8a0868837e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b0943bad-449b-493d-8dad-8c76d7a8e78f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b80aa528-c0e2-4144-8598-27c79cf49f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4e76a4ed-c548-444a-8176-c1faa70a9e08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b80aa528-c0e2-4144-8598-27c79cf49f9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4e76a4ed-c548-444a-8176-c1faa70a9e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a86e5740-421f-4231-82fc-7bdcb048d65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b80aa528-c0e2-4144-8598-27c79cf49f9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a86e5740-421f-4231-82fc-7bdcb048d65b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_23ec662c-e76d-49c4-8a14-d7ab212eaed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_eaaddafc-a356-4ea0-8ff3-a206fc89d1b9" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_23ec662c-e76d-49c4-8a14-d7ab212eaed8" xlink:to="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_eaaddafc-a356-4ea0-8ff3-a206fc89d1b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_f39cb7c2-f3f6-4eae-8b6f-9ac4ebc17085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_23ec662c-e76d-49c4-8a14-d7ab212eaed8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_f39cb7c2-f3f6-4eae-8b6f-9ac4ebc17085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_ab64a65b-d576-4643-8575-f87434064ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_23ec662c-e76d-49c4-8a14-d7ab212eaed8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_ab64a65b-d576-4643-8575-f87434064ae7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cdtx-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:772584df-f722-4edc-81e3-b26e5bb232b0,g:477eac6b-6822-4ddf-a883-4a61404b9849-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:to="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:to="loc_us-gaap_ClassOfStockDomain_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:to="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_9d0db232-18c4-411e-aaea-d00290789579" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_9d0db232-18c4-411e-aaea-d00290789579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_4ff43a78-85dd-4634-be80-b95fabd1256f" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_4ff43a78-85dd-4634-be80-b95fabd1256f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:to="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94adc73e-0bd3-4303-953a-bf332c800267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94adc73e-0bd3-4303-953a-bf332c800267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f8d4a1b6-2043-4d8d-a602-fdb31990c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_RestrictedCashCurrent_f8d4a1b6-2043-4d8d-a602-fdb31990c1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_25579388-cb6b-4872-ae04-dd69daa0e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_25579388-cb6b-4872-ae04-dd69daa0e91c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3827c181-2fe6-4e46-a5db-4886cb9e85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3827c181-2fe6-4e46-a5db-4886cb9e85a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_52e32295-0d41-48ec-a524-5a934e76a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_AssetsCurrent_52e32295-0d41-48ec-a524-5a934e76a4e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ad2615a-2bc4-4918-827a-b4a5d255d7da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7ad2615a-2bc4-4918-827a-b4a5d255d7da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_769868d3-80b6-47eb-affe-b8d457d6f615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_769868d3-80b6-47eb-affe-b8d457d6f615" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c39598e0-058f-414c-94a2-b3d71f428216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c39598e0-058f-414c-94a2-b3d71f428216" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e3a44b4e-8bbf-4747-9547-e5550b60ad21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e3a44b4e-8bbf-4747-9547-e5550b60ad21" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6725f854-4e84-4f9a-a252-126333b4faa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_Assets_6725f854-4e84-4f9a-a252-126333b4faa6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1943b874-6ee0-45ca-980f-6a360ec8c14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_AccountsPayableCurrent_1943b874-6ee0-45ca-980f-6a360ec8c14d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0471f8d6-3eeb-4667-baf6-6793aa52a934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0471f8d6-3eeb-4667-baf6-6793aa52a934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f076a681-1317-4b02-971b-dac58ffec846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f076a681-1317-4b02-971b-dac58ffec846" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46517ea7-4931-4832-ab2b-9fb9532e520f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46517ea7-4931-4832-ab2b-9fb9532e520f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8f9d72f-9e8c-440b-b454-b28a650d4b41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8f9d72f-9e8c-440b-b454-b28a650d4b41" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46d9c0c6-1b6f-4a10-93a6-7d382f8d9275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46d9c0c6-1b6f-4a10-93a6-7d382f8d9275" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b628ae38-cb8d-44d5-82c9-682433afefa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_LiabilitiesCurrent_b628ae38-cb8d-44d5-82c9-682433afefa4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0a3172ca-3924-4a20-8f55-f6fcc8d33316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0a3172ca-3924-4a20-8f55-f6fcc8d33316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d07eb9e-0fa6-4fcd-94d9-c2d4578601af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d07eb9e-0fa6-4fcd-94d9-c2d4578601af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_55e135ec-e2ef-4c62-84c0-aaa94788d972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_Liabilities_55e135ec-e2ef-4c62-84c0-aaa94788d972" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3579dcb4-8067-474f-b0bf-d19f5c3b7fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3579dcb4-8067-474f-b0bf-d19f5c3b7fa0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cd0af794-4050-415b-858c-c22a541022f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_PreferredStockValue_cd0af794-4050-415b-858c-c22a541022f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8f7dbc0a-06b1-47bd-9be9-8d67129fd135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_CommonStockValue_8f7dbc0a-06b1-47bd-9be9-8d67129fd135" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_260d0ee5-9c93-4771-8984-e7696c6dbe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_260d0ee5-9c93-4771-8984-e7696c6dbe7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_739edf1a-e058-4cd5-93a3-69449807017e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_739edf1a-e058-4cd5-93a3-69449807017e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1cdc7cc6-9698-462e-9438-0d2e64cee6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_StockholdersEquity_1cdc7cc6-9698-462e-9438-0d2e64cee6c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e7a2b8-4e2f-40be-b453-929f35be5484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e7a2b8-4e2f-40be-b453-929f35be5484" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_163bf331-bcd3-4ee9-90c2-e2a991722da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:to="loc_us-gaap_ClassOfStockDomain_163bf331-bcd3-4ee9-90c2-e2a991722da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:to="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8a82c79c-c7d6-4da2-b79c-f4f234ecdf4d" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8a82c79c-c7d6-4da2-b79c-f4f234ecdf4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_72785647-caad-4d0d-8940-6c92954edbdb" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_72785647-caad-4d0d-8940-6c92954edbdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9764fac4-2b75-43d6-98f4-eee55f0b4610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9764fac4-2b75-43d6-98f4-eee55f0b4610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9a0ea0b7-0289-4953-8e02-7e5220615962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9a0ea0b7-0289-4953-8e02-7e5220615962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreferredStockSharesIssuedIncludingConversion_8d61091b-3149-421d-9340-35ba14c2dc92" xlink:href="cdtx-20250331.xsd#cdtx_PreferredStockSharesIssuedIncludingConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_cdtx_PreferredStockSharesIssuedIncludingConversion_8d61091b-3149-421d-9340-35ba14c2dc92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4f96f6b6-1c59-4a5b-9928-f5c49cc62697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4f96f6b6-1c59-4a5b-9928-f5c49cc62697" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3e4780e7-0735-4233-8f87-12923a577e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3e4780e7-0735-4233-8f87-12923a577e78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1bef8539-02de-40ba-aa89-7f5c42cc40fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1bef8539-02de-40ba-aa89-7f5c42cc40fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fed35237-20d9-4c5e-bb4e-0ba83a169aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fed35237-20d9-4c5e-bb4e-0ba83a169aa0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8bb8ef9f-ce06-401e-ac79-43f6df6c933f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockSharesIssued_8bb8ef9f-ce06-401e-ac79-43f6df6c933f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_781bb26b-b708-47d4-bf10-9aa382c45924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_781bb26b-b708-47d4-bf10-9aa382c45924" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0ed65459-37c1-4584-baf4-e847f3fabff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0ed65459-37c1-4584-baf4-e847f3fabff1" xlink:to="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1b0086ed-2c14-47f4-9134-105390325504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:to="loc_us-gaap_ClassOfStockDomain_1b0086ed-2c14-47f4-9134-105390325504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:to="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_089cd0f9-ca79-477a-8cbf-ed60240a4835" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_089cd0f9-ca79-477a-8cbf-ed60240a4835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_c0790c89-a2ed-44e9-a09f-db10d158837a" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_c0790c89-a2ed-44e9-a09f-db10d158837a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a596686d-0d90-42c3-8074-c89664b30b39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:to="loc_us-gaap_EquityComponentDomain_a596686d-0d90-42c3-8074-c89664b30b39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:to="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_fe72071d-9c7e-442a-a98b-5f43e0251034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_PreferredStockMember_fe72071d-9c7e-442a-a98b-5f43e0251034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_caaba9a5-462a-4912-8a16-f35869c26d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_CommonStockMember_caaba9a5-462a-4912-8a16-f35869c26d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_49b2b958-c76b-49e9-b6e5-6943ec4c3772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_49b2b958-c76b-49e9-b6e5-6943ec4c3772" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7cb1e3c7-e76b-464e-9824-725143968fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_RetainedEarningsMember_7cb1e3c7-e76b-464e-9824-725143968fed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0ed65459-37c1-4584-baf4-e847f3fabff1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ba67ce6c-9c02-4da0-9328-31cc2ed7b653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ba67ce6c-9c02-4da0-9328-31cc2ed7b653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f27f45d7-1395-4650-aac7-c9d8a76a7464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockholdersEquity_f27f45d7-1395-4650-aac7-c9d8a76a7464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5b3bc88-5ab6-4883-8122-15ecbf7b86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5b3bc88-5ab6-4883-8122-15ecbf7b86c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b435ebbd-8588-4e23-b136-d7593ef86d44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b435ebbd-8588-4e23-b136-d7593ef86d44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_cc385158-46f7-44d1-ac2a-2ffa2889c53c" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_cc385158-46f7-44d1-ac2a-2ffa2889c53c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74e8fe89-56cd-43f9-8c10-a2be7fbd425c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74e8fe89-56cd-43f9-8c10-a2be7fbd425c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5395778e-b124-433b-958e-7ddf076a9651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5395778e-b124-433b-958e-7ddf076a9651" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2cab22c4-77f8-428d-85b1-3a480c229919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2cab22c4-77f8-428d-85b1-3a480c229919" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b2715dcf-9741-4561-8e31-aceed59d2c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b2715dcf-9741-4561-8e31-aceed59d2c83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c4aa3f7c-4fcb-46e0-983b-ef47849d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c4aa3f7c-4fcb-46e0-983b-ef47849d1871" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a058d90-9f41-4896-8f9f-a74a189f292d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_NetIncomeLoss_7a058d90-9f41-4896-8f9f-a74a189f292d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cae6a818-3bf9-4f43-a14f-09ec24e35b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aac6e99a-39f0-4dc0-94a7-a0cd46f479e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcc78fae-22dc-4292-b6d0-90f3194385e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4d63bce1-4f4e-4ebf-bca6-53836927e075_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4d63bce1-4f4e-4ebf-bca6-53836927e075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ae172946-e6a1-49c5-b3d4-c8e41c5993f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ae172946-e6a1-49c5-b3d4-c8e41c5993f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e8150d1d-779b-409c-bd49-7627ae449b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ae172946-e6a1-49c5-b3d4-c8e41c5993f0" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e8150d1d-779b-409c-bd49-7627ae449b1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f3dc202e-9f31-4682-a9fe-03fefc4459f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f3dc202e-9f31-4682-a9fe-03fefc4459f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f2a0826-97bb-45d9-bf69-b98e90008f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f2a0826-97bb-45d9-bf69-b98e90008f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_9777fbb6-b8c3-42b8-8602-9020ab1e0ca1" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f2a0826-97bb-45d9-bf69-b98e90008f0f" xlink:to="loc_cdtx_RezafunginMember_9777fbb6-b8c3-42b8-8602-9020ab1e0ca1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1122229a-d2e3-45bb-b1be-745695d7ec48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1122229a-d2e3-45bb-b1be-745695d7ec48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e33ba6f6-8205-423d-8337-c4d86faf380c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e33ba6f6-8205-423d-8337-c4d86faf380c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb9c1896-329e-4753-ba94-83d26db8fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb9c1896-329e-4753-ba94-83d26db8fb21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f895162e-55ba-4b3e-be1e-52c0d8d50c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f895162e-55ba-4b3e-be1e-52c0d8d50c8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_99f49b32-b7ac-4fae-9bef-bb7828f5ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_99f49b32-b7ac-4fae-9bef-bb7828f5ddd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5c6b0e56-a0c1-4b5d-ab9a-077882eef850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5c6b0e56-a0c1-4b5d-ab9a-077882eef850" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_5d978b11-ea39-4967-a2bc-132861727784" xlink:href="cdtx-20250331.xsd#cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_5d978b11-ea39-4967-a2bc-132861727784" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0b64cd28-76bd-40ef-9174-8e879721ec7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:to="loc_us-gaap_SegmentDomain_0b64cd28-76bd-40ef-9174-8e879721ec7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5669c109-b3dd-4196-87cc-fc33ced8d370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:to="loc_us-gaap_SegmentDomain_5669c109-b3dd-4196-87cc-fc33ced8d370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ReportableSegmentMember_75ace0cc-98d3-431f-a959-89025ffad36e" xlink:href="cdtx-20250331.xsd#cdtx_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5669c109-b3dd-4196-87cc-fc33ced8d370" xlink:to="loc_cdtx_ReportableSegmentMember_75ace0cc-98d3-431f-a959-89025ffad36e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e6c2a11d-115a-43e0-a56d-d4c371371b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_Revenues_e6c2a11d-115a-43e0-a56d-d4c371371b2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e373809-4db0-44c1-8aa4-5a3afa99c046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e373809-4db0-44c1-8aa4-5a3afa99c046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_240989f4-45c0-488d-b987-a98622ebcfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_LaborAndRelatedExpense_240989f4-45c0-488d-b987-a98622ebcfaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_14007f12-542b-4f1e-a537-238a3a8ab2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_14007f12-542b-4f1e-a537-238a3a8ab2b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_b6c9f679-6bd4-4ddd-8e41-acca057a1878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_b6c9f679-6bd4-4ddd-8e41-acca057a1878" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c435a233-1841-4767-a29b-0aa6753ae58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c435a233-1841-4767-a29b-0aa6753ae58a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:href="cdtx-20250331.xsd#cdtx_OtherSegmentItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4d31a944-51fa-4ac9-a0c3-5b52a8a861b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4d31a944-51fa-4ac9-a0c3-5b52a8a861b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_83354217-e120-4dca-a865-c256d3ae0879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_83354217-e120-4dca-a865-c256d3ae0879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_246a1bbf-80c0-41fd-b4ac-da3c868a3cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_NetIncomeLoss_246a1bbf-80c0-41fd-b4ac-da3c868a3cbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_86eabd7f-91ea-46e9-8def-617a3ff79795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_86eabd7f-91ea-46e9-8def-617a3ff79795" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:to="loc_srt_RangeMember_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:to="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7768b4e-04b4-4def-a7e0-5d132a273041" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:to="loc_srt_MinimumMember_e7768b4e-04b4-4def-a7e0-5d132a273041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2498761e-4fdc-4868-8fc1-f0e59012bf89" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:to="loc_srt_MaximumMember_2498761e-4fdc-4868-8fc1-f0e59012bf89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3939d34f-3c28-458b-b8bf-1eeb2c03010e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3939d34f-3c28-458b-b8bf-1eeb2c03010e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7587a0b8-9e69-4786-b775-9bdf2adeb79b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7587a0b8-9e69-4786-b775-9bdf2adeb79b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember_1b4df015-79a2-428f-adff-6d738c2eb003" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7587a0b8-9e69-4786-b775-9bdf2adeb79b" xlink:to="loc_cdtx_PrefundedWarrantsMember_1b4df015-79a2-428f-adff-6d738c2eb003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1c0f32a-ce33-4b1a-b637-1f8ea6cfbea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1c0f32a-ce33-4b1a-b637-1f8ea6cfbea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_369cfbb1-2ef1-4c72-a13e-c008d319b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1c0f32a-ce33-4b1a-b637-1f8ea6cfbea3" xlink:to="loc_us-gaap_PrivatePlacementMember_369cfbb1-2ef1-4c72-a13e-c008d319b88f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_35c995f3-8b00-4891-b659-dd9801a0baf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_35c995f3-8b00-4891-b659-dd9801a0baf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_08d743d5-b898-4c2c-8ab4-a9c8375814fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_08d743d5-b898-4c2c-8ab4-a9c8375814fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71b8657a-0df9-4fa6-b522-7fcee1557ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71b8657a-0df9-4fa6-b522-7fcee1557ae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_55b32e0b-87e1-4944-8d08-2df4e099d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_55b32e0b-87e1-4944-8d08-2df4e099d18b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4dc63441-b200-459b-b7c5-d563e25a624d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4dc63441-b200-459b-b7c5-d563e25a624d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20863793-be5d-4a78-a016-8823806a02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20863793-be5d-4a78-a016-8823806a02c4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2eb4e7a6-458b-48f6-81e6-e88648312c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2eb4e7a6-458b-48f6-81e6-e88648312c1e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_547b7cdb-a399-425a-80fd-62b8252ba869_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_547b7cdb-a399-425a-80fd-62b8252ba869_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5f9ec1aa-b9c8-4d63-b405-da7c651e5b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:to="loc_us-gaap_WarrantMember_5f9ec1aa-b9c8-4d63-b405-da7c651e5b2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_d96b17fa-c9e9-41f5-9005-b64c8559f689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_d96b17fa-c9e9-41f5-9005-b64c8559f689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_3b75fd03-8873-45cf-9dd7-861ae43c474c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:to="loc_us-gaap_StockCompensationPlanMember_3b75fd03-8873-45cf-9dd7-861ae43c474c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:to="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_710b736d-d858-4b54-b5d8-e8e56f6924bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:to="loc_us-gaap_ClassOfStockDomain_710b736d-d858-4b54-b5d8-e8e56f6924bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:to="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_0c254909-acb8-4d1a-b833-c7940db32576" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_0c254909-acb8-4d1a-b833-c7940db32576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_72000222-6bd1-4431-a9b0-64041512f054" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_72000222-6bd1-4431-a9b0-64041512f054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e453906a-bb04-48c9-a931-6679740c71fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2eb4e7a6-458b-48f6-81e6-e88648312c1e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e453906a-bb04-48c9-a931-6679740c71fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e542a55-3020-4790-bc23-0644d090852b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e542a55-3020-4790-bc23-0644d090852b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd1c7dda-7b76-4860-9344-caeeba2e06cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd1c7dda-7b76-4860-9344-caeeba2e06cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_13c5cb6a-8f65-49e3-8e07-578deb3af495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_13c5cb6a-8f65-49e3-8e07-578deb3af495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ccccbc88-7ec3-440a-b6c9-0226e2983309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ccccbc88-7ec3-440a-b6c9-0226e2983309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9305dc00-ab49-4c3b-b4a7-9d4d671c3027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9305dc00-ab49-4c3b-b4a7-9d4d671c3027" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e542a55-3020-4790-bc23-0644d090852b" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ebd054a0-42cc-4207-919a-fe767db14cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ebd054a0-42cc-4207-919a-fe767db14cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d24dc3ac-d2cd-4c78-9ed7-3658744a79c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:to="loc_us-gaap_RestrictedCash_d24dc3ac-d2cd-4c78-9ed7-3658744a79c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f2fe2312-5d33-44c1-84f8-b340c68e8260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f2fe2312-5d33-44c1-84f8-b340c68e8260" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d5997da2-a6b2-42bb-ba4f-c4099b2e0057" xlink:href="cdtx-20250331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d5997da2-a6b2-42bb-ba4f-c4099b2e0057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b49618e9-e083-4a32-aeec-326d5494d8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:to="loc_us-gaap_PrivatePlacementMember_b49618e9-e083-4a32-aeec-326d5494d8f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_05a6eab6-69b0-43f4-9be4-3ab4d4f43888_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:to="loc_us-gaap_ClassOfStockDomain_05a6eab6-69b0-43f4-9be4-3ab4d4f43888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:to="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8e44e4d0-4826-4aac-88db-8c1197d99e19" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8e44e4d0-4826-4aac-88db-8c1197d99e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertiblePreferredStockMember_c75a9b9d-dc24-487b-a6c3-6a940ac7e815" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_cdtx_SeriesAConvertiblePreferredStockMember_c75a9b9d-dc24-487b-a6c3-6a940ac7e815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_f9a6a26a-fa11-4362-975c-cf9455a62d83" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_f9a6a26a-fa11-4362-975c-cf9455a62d83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c651565c-eab2-418e-b29d-85af4db5cdff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_us-gaap_CommonStockMember_c651565c-eab2-418e-b29d-85af4db5cdff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4c5d2922-a2bd-40f4-8674-401b388451ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4c5d2922-a2bd-40f4-8674-401b388451ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember_bf643559-1fa9-4ef3-8931-d16aed942aaf" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:to="loc_cdtx_PrefundedWarrantsMember_bf643559-1fa9-4ef3-8931-d16aed942aaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_25033174-9cf8-493b-acbf-a085f3130747" xlink:href="cdtx-20250331.xsd#cdtx_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:to="loc_cdtx_CommonStockWarrantMember_25033174-9cf8-493b-acbf-a085f3130747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5acb031-4671-49b1-82df-a03b8e766f39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:to="loc_us-gaap_EquityComponentDomain_b5acb031-4671-49b1-82df-a03b8e766f39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cec1f672-9f6e-4f0f-9363-0af0085e8037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:to="loc_us-gaap_EquityComponentDomain_cec1f672-9f6e-4f0f-9363-0af0085e8037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3697c0bd-0392-41b3-a048-b91c469ac05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cec1f672-9f6e-4f0f-9363-0af0085e8037" xlink:to="loc_us-gaap_CommonStockMember_3697c0bd-0392-41b3-a048-b91c469ac05b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0ea316dd-76a9-4c90-99fd-305dda9b6b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0ea316dd-76a9-4c90-99fd-305dda9b6b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_885fb656-1b80-423a-8d91-6eb64cbc2bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_885fb656-1b80-423a-8d91-6eb64cbc2bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ae950161-da9e-4efb-99b9-2b789284f63d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ae950161-da9e-4efb-99b9-2b789284f63d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3a207d4b-1be5-4b3e-aa20-8760c4823eed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3a207d4b-1be5-4b3e-aa20-8760c4823eed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_68248169-0d90-4d3e-8972-55d5945fe8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_68248169-0d90-4d3e-8972-55d5945fe8e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea7fb9cf-c825-4065-919b-1ecb72ceaa55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea7fb9cf-c825-4065-919b-1ecb72ceaa55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2e04a48f-9fbf-48dc-b68f-b98aaa295188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2e04a48f-9fbf-48dc-b68f-b98aaa295188" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9dafaead-1642-451b-aab7-f45efd4c2e61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9dafaead-1642-451b-aab7-f45efd4c2e61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_7626da55-eb9e-4dc0-8055-9d2d16182a58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_7626da55-eb9e-4dc0-8055-9d2d16182a58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_621e9f65-1212-4d4c-a2e3-9d2324aa7003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_621e9f65-1212-4d4c-a2e3-9d2324aa7003" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_e9596020-277a-4ff1-9e7d-edb79d7590b8" xlink:href="cdtx-20250331.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_e9596020-277a-4ff1-9e7d-edb79d7590b8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d7875461-3467-4292-9463-c81c4622f139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d7875461-3467-4292-9463-c81c4622f139" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_deb0ae85-fc67-4b9c-bc4b-71f14c2c6095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_deb0ae85-fc67-4b9c-bc4b-71f14c2c6095" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5ed888e-a291-44d7-b556-95766465bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5ed888e-a291-44d7-b556-95766465bd53" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_5e4e30b4-5ff8-4bd0-8cf9-c01e68957bc1" xlink:href="cdtx-20250331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_5e4e30b4-5ff8-4bd0-8cf9-c01e68957bc1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9d12affd-d474-43f0-bfd7-7196735ae091" xlink:href="cdtx-20250331.xsd#cdtx_CommonStockDividendsInArrearsOrDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9d12affd-d474-43f0-bfd7-7196735ae091" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7f8c834d-b4e9-448a-a718-b952b0f13362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7f8c834d-b4e9-448a-a718-b952b0f13362" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_6a0ea0c2-0be2-4469-9f95-066b0d177527" xlink:href="cdtx-20250331.xsd#cdtx_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_6a0ea0c2-0be2-4469-9f95-066b0d177527" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_bc425807-8db3-465f-949e-1babe280aa42" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_bc425807-8db3-465f-949e-1babe280aa42" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_582a05df-172a-4683-aa8c-96f2aa7b9f79" xlink:href="cdtx-20250331.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_582a05df-172a-4683-aa8c-96f2aa7b9f79" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_91859a00-7e0f-4406-8e04-1912f5681664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_91859a00-7e0f-4406-8e04-1912f5681664" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:to="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71e165c3-93a7-4ea4-92f5-18d4d189aa03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_71e165c3-93a7-4ea4-92f5-18d4d189aa03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_08d6c296-ec75-4aaf-bd98-a9398a6f023a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_us-gaap_WarrantMember_08d6c296-ec75-4aaf-bd98-a9398a6f023a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertiblePreferredStockMember_346653d8-2742-4151-a1c0-2c530a02230f" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_cdtx_SeriesAConvertiblePreferredStockMember_346653d8-2742-4151-a1c0-2c530a02230f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_b8b1aa4e-8ab0-4027-916a-15e03a37af01" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_b8b1aa4e-8ab0-4027-916a-15e03a37af01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_bfd681b6-54e0-48af-8412-b11307c551e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_us-gaap_StockCompensationPlanMember_bfd681b6-54e0-48af-8412-b11307c551e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_79ba9b96-9742-4d68-9a9e-dc0c3be130f2" xlink:href="cdtx-20250331.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_79ba9b96-9742-4d68-9a9e-dc0c3be130f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f45eec8a-6841-46f6-890f-89dbe313162c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_us-gaap_EmployeeStockMember_f45eec8a-6841-46f6-890f-89dbe313162c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401bb4ac-41a1-4502-8b53-53538d24c176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91859a00-7e0f-4406-8e04-1912f5681664" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401bb4ac-41a1-4502-8b53-53538d24c176" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f501b054-9432-460c-9cd9-b85e957fa1a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:to="loc_us-gaap_PlanNameDomain_f501b054-9432-460c-9cd9-b85e957fa1a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:to="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b7fb6806-5317-490e-b2db-f7dd5839475f" xlink:href="cdtx-20250331.xsd#cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:to="loc_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b7fb6806-5317-490e-b2db-f7dd5839475f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_511f7d8e-0262-4f03-ae8b-4545547da26d" xlink:href="cdtx-20250331.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_511f7d8e-0262-4f03-ae8b-4545547da26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d254b2d3-5faf-48cc-9d16-66b0ca433ceb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:to="loc_srt_RangeMember_d254b2d3-5faf-48cc-9d16-66b0ca433ceb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:to="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d0d8463d-0938-4dcf-8d43-c2422ef91bf8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:to="loc_srt_MinimumMember_d0d8463d-0938-4dcf-8d43-c2422ef91bf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6062d777-2662-49a4-ac90-dc2b051fcbeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:to="loc_srt_MaximumMember_6062d777-2662-49a4-ac90-dc2b051fcbeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_929e7424-2015-4ab3-82d9-e88acb592e9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_929e7424-2015-4ab3-82d9-e88acb592e9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4fa7e23a-c57f-4944-b7f2-185c8e06b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4fa7e23a-c57f-4944-b7f2-185c8e06b90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_fc3b6d32-e47f-44db-907b-7bc4b0bc7d82" xlink:href="cdtx-20250331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fa7e23a-c57f-4944-b7f2-185c8e06b90c" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_fc3b6d32-e47f-44db-907b-7bc4b0bc7d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a8b348-0959-4f42-93aa-1105083075af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95a8b348-0959-4f42-93aa-1105083075af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6910e79e-4f29-4110-af93-be6329259486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:to="loc_us-gaap_EmployeeStockMember_6910e79e-4f29-4110-af93-be6329259486" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9f65b7eb-85cb-41b5-9d82-be38dceb761a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9f65b7eb-85cb-41b5-9d82-be38dceb761a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_92f708fd-b346-4436-a706-1ec8771c7979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_92f708fd-b346-4436-a706-1ec8771c7979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54b8f10d-90ee-4a7e-b0a7-03a58db5c628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54b8f10d-90ee-4a7e-b0a7-03a58db5c628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51ee76ec-2a54-4f85-8bb8-1b3e433e59e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51ee76ec-2a54-4f85-8bb8-1b3e433e59e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3d0d5f9-bff6-473b-b132-81cc6537abf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3d0d5f9-bff6-473b-b132-81cc6537abf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd02f103-7eee-4b92-bcc7-0efd22f10157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd02f103-7eee-4b92-bcc7-0efd22f10157" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_76d7c4cf-3f38-44f3-ad06-e0193d2d8ecf" xlink:href="cdtx-20250331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_76d7c4cf-3f38-44f3-ad06-e0193d2d8ecf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b63ca5a5-b397-4aac-a4e4-a72fe12ccfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b63ca5a5-b397-4aac-a4e4-a72fe12ccfc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddaa4fca-bc58-4f81-b4a3-0fa07d986b55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddaa4fca-bc58-4f81-b4a3-0fa07d986b55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97cd72dd-05e9-4cf0-906e-dc278316bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97cd72dd-05e9-4cf0-906e-dc278316bcd0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7dddf236-51a4-4f6f-8237-1f6b213f744b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7dddf236-51a4-4f6f-8237-1f6b213f744b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5e52915d-9059-4b10-be63-9fc9644d6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5e52915d-9059-4b10-be63-9fc9644d6c85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45bfa970-ed76-4288-a7f4-25f9354592bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45bfa970-ed76-4288-a7f4-25f9354592bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5bed606-0de5-4449-8e5b-98e0fd7bd129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5bed606-0de5-4449-8e5b-98e0fd7bd129" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ca6d95cf-e7c2-4195-97b7-6be639c81d71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ca6d95cf-e7c2-4195-97b7-6be639c81d71" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:to="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5063adc1-12e2-4579-82b4-425dc9e90527_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5063adc1-12e2-4579-82b4-425dc9e90527_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d0162c-15fd-4e1b-8ebd-80885a3e3035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d0162c-15fd-4e1b-8ebd-80885a3e3035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ac99ea44-6a1a-45f1-89ce-de0777152f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d0162c-15fd-4e1b-8ebd-80885a3e3035" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ac99ea44-6a1a-45f1-89ce-de0777152f64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06d5aa4c-6b02-44f4-bd77-c02288f0330f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06d5aa4c-6b02-44f4-bd77-c02288f0330f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_109149cd-cd3c-4560-b1bd-c0c06abc6432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_109149cd-cd3c-4560-b1bd-c0c06abc6432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a66dedb0-101f-43fa-b623-9ef6d774b715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a66dedb0-101f-43fa-b623-9ef6d774b715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_808c652b-9ff3-459f-ad67-a28d55603560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_808c652b-9ff3-459f-ad67-a28d55603560" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c5b030fe-047b-4700-81c7-50abb683b611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6071d37a-c733-4c88-90bc-ca79933150ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6071d37a-c733-4c88-90bc-ca79933150ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dedf5cf8-94c3-4291-a6e3-3efa770c5e03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dedf5cf8-94c3-4291-a6e3-3efa770c5e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8cbd3788-7694-49ce-8817-a7fc9efb1bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8cbd3788-7694-49ce-8817-a7fc9efb1bc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8bbc0779-e8a3-44d0-8e2c-8949e807d490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8bbc0779-e8a3-44d0-8e2c-8949e807d490" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_17005a68-5b73-4345-92b3-391e393157fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa77bc4e-12c7-403a-981c-8638ee26ba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa77bc4e-12c7-403a-981c-8638ee26ba5e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4bea19bc-84b1-4083-b16d-333abe7e10da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4bea19bc-84b1-4083-b16d-333abe7e10da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_56f6668a-392e-40d0-924b-76af2fc1afac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_56f6668a-392e-40d0-924b-76af2fc1afac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8d0fc615-be18-4376-b5ce-13f3d29d21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8d0fc615-be18-4376-b5ce-13f3d29d21e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_139c9041-cba6-4c12-b659-7d2b9527cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_139c9041-cba6-4c12-b659-7d2b9527cc82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_bbe14e4c-a743-46c7-95e2-6c76cf77fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_bbe14e4c-a743-46c7-95e2-6c76cf77fc01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc1ac8fb-0b72-4962-8b9f-b430e0e67d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa77bc4e-12c7-403a-981c-8638ee26ba5e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc1ac8fb-0b72-4962-8b9f-b430e0e67d45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fbb9869a-0ee7-40fa-9ca0-99b468576d10_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fbb9869a-0ee7-40fa-9ca0-99b468576d10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ffdd420-add3-46ea-ba80-77b35792f1f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ffdd420-add3-46ea-ba80-77b35792f1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_1066a27a-2f4f-4074-975a-94f15c7467b8" xlink:href="cdtx-20250331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ffdd420-add3-46ea-ba80-77b35792f1f9" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_1066a27a-2f4f-4074-975a-94f15c7467b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_be13055a-1589-4844-87bf-b2c0e4783689_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:to="loc_srt_ProductsAndServicesDomain_be13055a-1589-4844-87bf-b2c0e4783689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:to="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_15c536ac-686d-495d-8623-d057f1aff20c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:to="loc_us-gaap_LicenseMember_15c536ac-686d-495d-8623-d057f1aff20c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_26cc678f-e7dd-44d3-b838-7211f6bb2880" xlink:href="cdtx-20250331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:to="loc_cdtx_MilestoneAchievementMember_26cc678f-e7dd-44d3-b838-7211f6bb2880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_fff23aa1-54e2-4608-b69b-2959dbf47d81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_fff23aa1-54e2-4608-b69b-2959dbf47d81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d1c1138f-8458-4e24-8d7b-7085a0a047dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d1c1138f-8458-4e24-8d7b-7085a0a047dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_351947f2-8459-434d-87fb-0ceb4775ee66" xlink:href="cdtx-20250331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d1c1138f-8458-4e24-8d7b-7085a0a047dc" xlink:to="loc_cdtx_UpfrontPaymentMember_351947f2-8459-434d-87fb-0ceb4775ee66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:to="loc_us-gaap_RelatedPartyDomain_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b081294-705c-4dc5-ab6c-4efcf4d4186b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:to="loc_us-gaap_RelatedPartyDomain_8b081294-705c-4dc5-ab6c-4efcf4d4186b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3d624b9b-b25d-4a77-8c17-110b6ef9af3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8b081294-705c-4dc5-ab6c-4efcf4d4186b" xlink:to="loc_us-gaap_RelatedPartyMember_3d624b9b-b25d-4a77-8c17-110b6ef9af3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02a67663-12ba-4e67-a283-fe7a979babcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02a67663-12ba-4e67-a283-fe7a979babcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed7b99f2-62f6-40b3-b9ba-a96dd80c5370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed7b99f2-62f6-40b3-b9ba-a96dd80c5370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a14e4967-5afd-446c-81e7-317a8f0b16f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed7b99f2-62f6-40b3-b9ba-a96dd80c5370" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a14e4967-5afd-446c-81e7-317a8f0b16f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_26a8f54c-7acc-4415-a903-84d6debbd6e5" xlink:href="cdtx-20250331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_26a8f54c-7acc-4415-a903-84d6debbd6e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_2a332421-b45d-4129-a3aa-ccb2eee3c422" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_2a332421-b45d-4129-a3aa-ccb2eee3c422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_d5550a53-56c0-4c71-8b4f-5b60b7723cef" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_d5550a53-56c0-4c71-8b4f-5b60b7723cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_f533b48f-ab64-4be2-b50c-218e7f6e7d13" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_f533b48f-ab64-4be2-b50c-218e7f6e7d13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DirectTransactionCosts_f3b5de3b-80cb-4c2c-ab38-b03beaeaad13" xlink:href="cdtx-20250331.xsd#cdtx_DirectTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_DirectTransactionCosts_f3b5de3b-80cb-4c2c-ab38-b03beaeaad13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_afa2c1f2-5afa-49d3-8e33-c24e757687b5" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_afa2c1f2-5afa-49d3-8e33-c24e757687b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_f43b5b2f-df20-4491-8600-f395221d1832" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_f43b5b2f-df20-4491-8600-f395221d1832" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_668c795f-9b87-483a-95e0-3a01ebcc1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_668c795f-9b87-483a-95e0-3a01ebcc1f09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_26657f3b-c56e-4151-88da-d6cf8534e117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_26657f3b-c56e-4151-88da-d6cf8534e117" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_55d1e311-cc50-4a43-9b89-33f46db04122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_55d1e311-cc50-4a43-9b89-33f46db04122" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91ad0e32-b9f3-4ede-9f0d-a91f764a2f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91ad0e32-b9f3-4ede-9f0d-a91f764a2f29" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4ff2d521-3b55-4248-a28e-bbc37bac51b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:to="loc_us-gaap_RelatedPartyDomain_4ff2d521-3b55-4248-a28e-bbc37bac51b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d9ca07ca-adca-4b95-a652-8c563c23eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:to="loc_us-gaap_RelatedPartyDomain_d9ca07ca-adca-4b95-a652-8c563c23eb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_94bfe273-e833-457d-b8ae-184dd537942e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d9ca07ca-adca-4b95-a652-8c563c23eb3b" xlink:to="loc_us-gaap_RelatedPartyMember_94bfe273-e833-457d-b8ae-184dd537942e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_546205af-81a5-4e24-ab45-d021491d3448_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_546205af-81a5-4e24-ab45-d021491d3448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_60de1c59-44f8-4ae4-b150-e740c4cbb147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_60de1c59-44f8-4ae4-b150-e740c4cbb147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_600578f7-b089-4ba2-957b-192bdf1343db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_60de1c59-44f8-4ae4-b150-e740c4cbb147" xlink:to="loc_us-gaap_TransferredOverTimeMember_600578f7-b089-4ba2-957b-192bdf1343db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df5597f3-54f7-4691-979f-dfc3af8e2775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df5597f3-54f7-4691-979f-dfc3af8e2775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de6fa94-0ea0-49f4-815d-8d7a89014a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de6fa94-0ea0-49f4-815d-8d7a89014a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8e46ab9f-9c38-4581-8646-718d0a1768df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de6fa94-0ea0-49f4-815d-8d7a89014a7f" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8e46ab9f-9c38-4581-8646-718d0a1768df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_933ece02-e2a3-4b38-b790-02f4c8efd945_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:to="loc_srt_ProductsAndServicesDomain_933ece02-e2a3-4b38-b790-02f4c8efd945_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:to="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_379ce135-b998-47db-8acc-416580bd5cde" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_379ce135-b998-47db-8acc-416580bd5cde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_4a19f78e-da0f-47d1-8256-6afd4e647d06" xlink:href="cdtx-20250331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_4a19f78e-da0f-47d1-8256-6afd4e647d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b4bb8c7-c59a-462c-b16a-649290b71843_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b4bb8c7-c59a-462c-b16a-649290b71843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f830f64f-0275-44e8-bac8-cf3accd42e8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f830f64f-0275-44e8-bac8-cf3accd42e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_fbbeb6e6-c240-4791-a2b4-d6b1148f27c6" xlink:href="cdtx-20250331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f830f64f-0275-44e8-bac8-cf3accd42e8c" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_fbbeb6e6-c240-4791-a2b4-d6b1148f27c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_98bdebed-4f23-4509-b179-48437b38a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91ad0e32-b9f3-4ede-9f0d-a91f764a2f29" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_98bdebed-4f23-4509-b179-48437b38a4f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_3b35f0d3-3934-46dc-95a3-e73aff4e92e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_3b35f0d3-3934-46dc-95a3-e73aff4e92e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_7e8358e3-9521-4bb1-811e-11a26e03f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_7e8358e3-9521-4bb1-811e-11a26e03f26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_9944df2d-b419-4fc9-98ac-e1424bd8e322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_7e8358e3-9521-4bb1-811e-11a26e03f26d" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_9944df2d-b419-4fc9-98ac-e1424bd8e322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6d61c1f9-ab07-4a2a-996e-74455ecc1572_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6d61c1f9-ab07-4a2a-996e-74455ecc1572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b26334dd-fea9-4355-9352-12efe4b44233" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b26334dd-fea9-4355-9352-12efe4b44233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_d3a78ff7-0a69-493c-92a9-25bf174b77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b26334dd-fea9-4355-9352-12efe4b44233" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_d3a78ff7-0a69-493c-92a9-25bf174b77f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e4b2ff82-d351-407a-845f-732e4309d543_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e4b2ff82-d351-407a-845f-732e4309d543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_381bab73-397e-4c08-866c-a301e7c32f00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_381bab73-397e-4c08-866c-a301e7c32f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_a871c824-32d0-442d-ba46-f077959f0141" xlink:href="cdtx-20250331.xsd#cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_381bab73-397e-4c08-866c-a301e7c32f00" xlink:to="loc_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_a871c824-32d0-442d-ba46-f077959f0141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_c5f4f842-1caf-4b42-bfb6-4ae48eb954bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_c5f4f842-1caf-4b42-bfb6-4ae48eb954bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseMonthlyRate_6003b93a-fd08-45c3-ac4f-0eadf07e1c8d" xlink:href="cdtx-20250331.xsd#cdtx_LesseeFinanceLeaseMonthlyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_cdtx_LesseeFinanceLeaseMonthlyRate_6003b93a-fd08-45c3-ac4f-0eadf07e1c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_abd3ff4a-609b-4128-aab7-ea709fff38a4" xlink:href="cdtx-20250331.xsd#cdtx_LesseeFinanceLeaseOptionPurchaseEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_abd3ff4a-609b-4128-aab7-ea709fff38a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f75070cc-5c35-4792-bb52-4c3a2da117d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f75070cc-5c35-4792-bb52-4c3a2da117d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5c5bb305-f8c2-4045-b055-7aca28aa16f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5c5bb305-f8c2-4045-b055-7aca28aa16f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate_4a4071ad-3f91-4a56-bbb8-6626af5e9543" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeOperatingLeaseMonthlyRate_4a4071ad-3f91-4a56-bbb8-6626af5e9543" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_34a4ecfa-2ebb-42c4-b367-35537a58589b" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_34a4ecfa-2ebb-42c4-b367-35537a58589b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_cdae6a42-853c-4375-9b85-d074bb7c658a" xlink:href="cdtx-20250331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_cdae6a42-853c-4375-9b85-d074bb7c658a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_67e5804b-904f-4a89-9889-2619db070241" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_67e5804b-904f-4a89-9889-2619db070241" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_bd3e3cd6-f331-4ad9-a305-6b41ac10c14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_bd3e3cd6-f331-4ad9-a305-6b41ac10c14d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_597ddb70-ea7d-4bf3-ab66-95d1d6e09c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_597ddb70-ea7d-4bf3-ab66-95d1d6e09c9c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d4c60720-aa80-4e55-8f01-0da074233534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_OperatingLeasePayments_d4c60720-aa80-4e55-8f01-0da074233534" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_c1d867be-bf76-41e4-8298-860a09005e91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_OperatingLeaseExpense_c1d867be-bf76-41e4-8298-860a09005e91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_fd781ed8-1c40-4a88-81a0-2bbf079fcb9f" xlink:href="cdtx-20250331.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_fd781ed8-1c40-4a88-81a0-2bbf079fcb9f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_5e622b9a-5a7e-43cf-86b1-363d53069bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_5e622b9a-5a7e-43cf-86b1-363d53069bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_23d8646e-9a89-4d0a-ae81-fe0971f82dd3" xlink:href="cdtx-20250331.xsd#cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:to="loc_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_23d8646e-9a89-4d0a-ae81-fe0971f82dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c660d7db-8fb9-419d-a44b-ab62ff0d4e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:to="loc_us-gaap_SeveranceCosts1_c660d7db-8fb9-419d-a44b-ab62ff0d4e1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_c4e9df0d-4c04-409d-a1df-78c9238ca551" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_c4e9df0d-4c04-409d-a1df-78c9238ca551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantorObligationTerm1_2380e739-9ceb-4569-96f8-524fb51be5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuarantorObligationTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:to="loc_us-gaap_GuarantorObligationTerm1_2380e739-9ceb-4569-96f8-524fb51be5f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_GuarantorObligationsTerminationNoticeTerm_719d9912-a93e-4c0f-836f-5f0addecc179" xlink:href="cdtx-20250331.xsd#cdtx_GuarantorObligationsTerminationNoticeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:to="loc_cdtx_GuarantorObligationsTerminationNoticeTerm_719d9912-a93e-4c0f-836f-5f0addecc179" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64c7c7eb-e788-40d1-8a95-6825d1163367_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_64c7c7eb-e788-40d1-8a95-6825d1163367_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NappPharmaceuticalGroupLimitedMember_4c2cb285-00b5-47b9-8155-9a208c0dd2a6" xlink:href="cdtx-20250331.xsd#cdtx_NappPharmaceuticalGroupLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:to="loc_cdtx_NappPharmaceuticalGroupLimitedMember_4c2cb285-00b5-47b9-8155-9a208c0dd2a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_9c0cfc61-1e40-4d80-9c97-1f084f241f83" xlink:href="cdtx-20250331.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_9c0cfc61-1e40-4d80-9c97-1f084f241f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_f5e74a2e-587f-4487-82d2-d96d26518634" xlink:href="cdtx-20250331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_f5e74a2e-587f-4487-82d2-d96d26518634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a0e61daa-d832-4ced-860b-a90aca9ccabf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a0e61daa-d832-4ced-860b-a90aca9ccabf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e30f64e2-1b79-4fcd-95fa-7944dcbe2393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e30f64e2-1b79-4fcd-95fa-7944dcbe2393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f96cafa1-b6bb-42be-90f8-aa5f3906348f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e30f64e2-1b79-4fcd-95fa-7944dcbe2393" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f96cafa1-b6bb-42be-90f8-aa5f3906348f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3094022d-f30b-403f-b166-fd0690eefde3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3094022d-f30b-403f-b166-fd0690eefde3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc98a58d-25e2-45fe-b777-669541fa79a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc98a58d-25e2-45fe-b777-669541fa79a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_03e3c527-237d-4d65-8fa5-b04e8ed1b57b" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc98a58d-25e2-45fe-b777-669541fa79a8" xlink:to="loc_cdtx_RezafunginMember_03e3c527-237d-4d65-8fa5-b04e8ed1b57b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:to="loc_us-gaap_RelatedPartyDomain_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5516362e-f60d-4e90-99ca-f635bd973320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:to="loc_us-gaap_RelatedPartyDomain_5516362e-f60d-4e90-99ca-f635bd973320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_35cee232-2682-46d9-8b44-4f2a3495cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5516362e-f60d-4e90-99ca-f635bd973320" xlink:to="loc_us-gaap_RelatedPartyMember_35cee232-2682-46d9-8b44-4f2a3495cef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8006e1f2-4f1e-4d35-836f-ef6b6d321792_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8006e1f2-4f1e-4d35-836f-ef6b6d321792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b30adeeb-cc84-4998-90e8-52d286ef2e42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b30adeeb-cc84-4998-90e8-52d286ef2e42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_1eb81591-7c72-4e62-8c8f-b034f6ee6174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b30adeeb-cc84-4998-90e8-52d286ef2e42" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_1eb81591-7c72-4e62-8c8f-b034f6ee6174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0dc39025-766d-4f93-b97c-779d5579fb46_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:to="loc_srt_ProductsAndServicesDomain_0dc39025-766d-4f93-b97c-779d5579fb46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:to="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginAssetsMember_7e54d10f-0bea-4f10-b6f0-f09db92cd51a" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:to="loc_cdtx_RezafunginAssetsMember_7e54d10f-0bea-4f10-b6f0-f09db92cd51a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_e0467d65-1747-46a8-8dbb-16479ac003f6" xlink:href="cdtx-20250331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:to="loc_cdtx_MilestoneAchievementMember_e0467d65-1747-46a8-8dbb-16479ac003f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_3d881abd-bcc8-4853-9246-92fe22575a57" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_3d881abd-bcc8-4853-9246-92fe22575a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_3f15c8bf-06c2-432e-b7c2-4dfd2e430afc" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_3f15c8bf-06c2-432e-b7c2-4dfd2e430afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_89af8032-a6c7-4724-98c4-339cb62dfe5a" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementOtherServicesAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_89af8032-a6c7-4724-98c4-339cb62dfe5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_454642f0-c4d1-42a7-869c-bf9213add5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_454642f0-c4d1-42a7-869c-bf9213add5cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_882e3d7f-83e8-4e92-83d3-f13940bf522b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_882e3d7f-83e8-4e92-83d3-f13940bf522b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1c409f8e-4c17-4e92-83a8-d23550a29f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1c409f8e-4c17-4e92-83a8-d23550a29f8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_792458b3-51a5-4e6c-811e-81b3f6e211a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_792458b3-51a5-4e6c-811e-81b3f6e211a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5675b0b3-6b13-45df-b22c-ae80bf515bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5675b0b3-6b13-45df-b22c-ae80bf515bee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionValue_9376b4c7-1320-474d-ac9f-8ded76633af9" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementTransactionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementTransactionValue_9376b4c7-1320-474d-ac9f-8ded76633af9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_99afa2d5-6d97-45ed-8332-4d29c71c3241" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_99afa2d5-6d97-45ed-8332-4d29c71c3241" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_8c6901c4-cb43-4b13-9490-630d8ae5645e" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_8c6901c4-cb43-4b13-9490-630d8ae5645e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_98123c81-49e3-41ad-84e1-42882b7569f8" xlink:href="cdtx-20250331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_98123c81-49e3-41ad-84e1-42882b7569f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_08dc90f3-9b70-4b1c-b249-db91f5b3d61c" xlink:href="cdtx-20250331.xsd#cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_08dc90f3-9b70-4b1c-b249-db91f5b3d61c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_143ef7f9-b49b-4688-b287-7ed855ab58fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_143ef7f9-b49b-4688-b287-7ed855ab58fc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_c47c68db-2e28-4bde-baff-029c38395425" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_c47c68db-2e28-4bde-baff-029c38395425" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_8bb7fc9b-f4ba-426e-aebb-699595127ca0" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_8bb7fc9b-f4ba-426e-aebb-699595127ca0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_85c6fb0f-172c-4995-b6c0-3273eb8e358d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_85c6fb0f-172c-4995-b6c0-3273eb8e358d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransitionsServicesTerm_741f6378-8ae7-4afc-a2e7-2371114d3b39" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementTransitionsServicesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementTransitionsServicesTerm_741f6378-8ae7-4afc-a2e7-2371114d3b39" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_94454391-f39b-487f-895b-2e4278e20fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_94454391-f39b-487f-895b-2e4278e20fb8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8baa0769-df15-40d1-8c53-06e00ec29c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8baa0769-df15-40d1-8c53-06e00ec29c66" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_54c95377-1e80-492d-8b0e-b83b181bcbb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_54c95377-1e80-492d-8b0e-b83b181bcbb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b1f744d6-f9b1-4783-9f1f-c203f821aae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b1f744d6-f9b1-4783-9f1f-c203f821aae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f7b6c994-0908-412d-92ef-c06833d9369a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b1f744d6-f9b1-4783-9f1f-c203f821aae1" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f7b6c994-0908-412d-92ef-c06833d9369a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e0c0f434-538a-49c0-b266-8ec99c05d311_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e0c0f434-538a-49c0-b266-8ec99c05d311_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17749e21-45e9-41e5-a8b5-6aefac4b8b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17749e21-45e9-41e5-a8b5-6aefac4b8b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_e037cae2-2e5f-4961-ac7b-af37cb2456b8" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17749e21-45e9-41e5-a8b5-6aefac4b8b03" xlink:to="loc_cdtx_RezafunginMember_e037cae2-2e5f-4961-ac7b-af37cb2456b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_71a590d0-5e33-42b8-afd7-2ee9c665ab69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_RevenuesAbstract_71a590d0-5e33-42b8-afd7-2ee9c665ab69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_beb73115-ffb6-4b9b-8add-5afda20021c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_71a590d0-5e33-42b8-afd7-2ee9c665ab69" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_beb73115-ffb6-4b9b-8add-5afda20021c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4892f444-a8bb-431d-ac76-8e90df6cc22a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4892f444-a8bb-431d-ac76-8e90df6cc22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_e922e479-6ae9-44f4-a7e4-f2bb5230963f" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_e922e479-6ae9-44f4-a7e4-f2bb5230963f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e523b1e0-38c8-4623-b146-0fef63698120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e523b1e0-38c8-4623-b146-0fef63698120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f9af0e0b-7809-4214-93d0-ef016a107b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f9af0e0b-7809-4214-93d0-ef016a107b65" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_58f7417a-d87c-4a56-9f79-568785a87c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_58f7417a-d87c-4a56-9f79-568785a87c0a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6c168de-dabb-428e-a43d-3cdb11da3250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6c168de-dabb-428e-a43d-3cdb11da3250" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_79018f88-0b84-4133-955c-87eed87707dc" xlink:href="cdtx-20250331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_79018f88-0b84-4133-955c-87eed87707dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_2f7e05ef-3774-4d08-a4a9-7bfb1505f005" xlink:href="cdtx-20250331.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_2f7e05ef-3774-4d08-a4a9-7bfb1505f005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0e5ffe92-909f-4451-abe2-8cb89921305d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:to="loc_srt_ProductsAndServicesDomain_0e5ffe92-909f-4451-abe2-8cb89921305d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:to="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_e82dabf8-1bb8-404f-9f5e-fb088095beba" xlink:href="cdtx-20250331.xsd#cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_e82dabf8-1bb8-404f-9f5e-fb088095beba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5c6a0f1b-cc86-42cd-8792-395500120bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_us-gaap_ProductMember_5c6a0f1b-cc86-42cd-8792-395500120bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_be7aed20-4ad1-4467-b4ac-c42f5f4776b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_us-gaap_RoyaltyMember_be7aed20-4ad1-4467-b4ac-c42f5f4776b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_197801cc-5d98-4f6e-8d53-81ad370a1e05" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_197801cc-5d98-4f6e-8d53-81ad370a1e05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_9e7e215e-448a-426f-9d5b-d0d7c9742089" xlink:href="cdtx-20250331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_9e7e215e-448a-426f-9d5b-d0d7c9742089" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eef4599b-c4bf-426a-9a03-97664df1e560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eef4599b-c4bf-426a-9a03-97664df1e560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f1be8e1f-dd9b-46fd-b3d1-44212140c338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_eef4599b-c4bf-426a-9a03-97664df1e560" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f1be8e1f-dd9b-46fd-b3d1-44212140c338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_284601cf-d224-466f-ac4f-c7c1204b7c2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_284601cf-d224-466f-ac4f-c7c1204b7c2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6bcb5908-ea95-4768-bc9b-01cb949bc850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6bcb5908-ea95-4768-bc9b-01cb949bc850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_1efd3aed-2005-443d-961e-e6e9bbf26d32" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6bcb5908-ea95-4768-bc9b-01cb949bc850" xlink:to="loc_cdtx_RezafunginMember_1efd3aed-2005-443d-961e-e6e9bbf26d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:to="loc_us-gaap_RelatedPartyDomain_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b31e1907-81a9-4346-9749-876ba2dd636d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:to="loc_us-gaap_RelatedPartyDomain_b31e1907-81a9-4346-9749-876ba2dd636d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_967f3bf2-61c2-4788-b767-8b6a044ca84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b31e1907-81a9-4346-9749-876ba2dd636d" xlink:to="loc_us-gaap_RelatedPartyMember_967f3bf2-61c2-4788-b767-8b6a044ca84e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_8966f9ca-21a9-4095-93c8-8ece8cae6bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_8966f9ca-21a9-4095-93c8-8ece8cae6bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_18f08c58-b279-427e-b10a-b564d0ef1182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:to="loc_us-gaap_TransferredOverTimeMember_18f08c58-b279-427e-b10a-b564d0ef1182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bead399-b25b-4133-980f-2fd0a54f1dcf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1bead399-b25b-4133-980f-2fd0a54f1dcf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b50b3d-8138-4a48-a08b-2e6501b18a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b50b3d-8138-4a48-a08b-2e6501b18a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3a3fa96b-9c2d-4be4-aa8e-a1f5b24447e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b50b3d-8138-4a48-a08b-2e6501b18a28" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3a3fa96b-9c2d-4be4-aa8e-a1f5b24447e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fa889a60-8b14-45a7-9de1-783ccd6976f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6c168de-dabb-428e-a43d-3cdb11da3250" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fa889a60-8b14-45a7-9de1-783ccd6976f7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_fc383daf-8aad-4bc5-a7f6-9251e9141141_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_fc383daf-8aad-4bc5-a7f6-9251e9141141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_135640be-2eb3-4178-ae12-fc73477b6a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_135640be-2eb3-4178-ae12-fc73477b6a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember_92b5738d-b0a8-44d5-9127-8612a8e57ccb" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_135640be-2eb3-4178-ae12-fc73477b6a88" xlink:to="loc_cdtx_PrefundedWarrantsMember_92b5738d-b0a8-44d5-9127-8612a8e57ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f40c711b-4d99-4fd3-958a-1d78b1ee0239_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f40c711b-4d99-4fd3-958a-1d78b1ee0239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c613f2f7-fa21-4b8e-a3a7-4ae77ed5525c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c613f2f7-fa21-4b8e-a3a7-4ae77ed5525c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d134f7e7-9517-4d1e-bf9e-2178d07542f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c613f2f7-fa21-4b8e-a3a7-4ae77ed5525c" xlink:to="loc_us-gaap_SubsequentEventMember_d134f7e7-9517-4d1e-bf9e-2178d07542f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a1ea1e90-424f-4d93-aa32-3ea6435efda9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:to="loc_us-gaap_ClassOfStockDomain_a1ea1e90-424f-4d93-aa32-3ea6435efda9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:to="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8befc78e-d04d-4e1c-9345-90fa303c7019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:to="loc_us-gaap_CommonStockMember_8befc78e-d04d-4e1c-9345-90fa303c7019" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7740b5f2-6b96-40fb-8768-e22ea16cf99c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7740b5f2-6b96-40fb-8768-e22ea16cf99c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e3575c0-8c8d-4f32-a069-f8e15c814dfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e3575c0-8c8d-4f32-a069-f8e15c814dfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2fbd5dda-89ae-4689-9d8d-e146ea6fe326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2fbd5dda-89ae-4689-9d8d-e146ea6fe326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OpenMarketSaleAgreementMember_ea3e5026-a5dd-4d99-8903-810d04253ade" xlink:href="cdtx-20250331.xsd#cdtx_OpenMarketSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2fbd5dda-89ae-4689-9d8d-e146ea6fe326" xlink:to="loc_cdtx_OpenMarketSaleAgreementMember_ea3e5026-a5dd-4d99-8903-810d04253ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_57b66f8e-0727-4935-8e61-7cf5a322d50b" xlink:href="cdtx-20250331.xsd#cdtx_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_57b66f8e-0727-4935-8e61-7cf5a322d50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_b06731f6-c31c-47e7-bdc9-de691367ed29" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_b06731f6-c31c-47e7-bdc9-de691367ed29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d118b50a-978f-4dfb-8386-cfcd409b37b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d118b50a-978f-4dfb-8386-cfcd409b37b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationReceivablePerTransaction_bb27b1d9-0f94-4390-a16f-93e87d53e305" xlink:href="cdtx-20250331.xsd#cdtx_SaleOfStockConsiderationReceivablePerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_cdtx_SaleOfStockConsiderationReceivablePerTransaction_bb27b1d9-0f94-4390-a16f-93e87d53e305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9e22160-b5c4-4f44-aa8d-52bb1ff45c23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9e22160-b5c4-4f44-aa8d-52bb1ff45c23" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cdtx-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:772584df-f722-4edc-81e3-b26e5bb232b0,g:477eac6b-6822-4ddf-a883-4a61404b9849-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cdtx_CommonStockWarrantMember_5d5ef133-b225-41a8-a18d-6764b1f39fb7_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrant</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_label_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_documentation_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember" xlink:href="cdtx-20250331.xsd#cdtx_CommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockWarrantMember" xlink:to="lab_cdtx_CommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c942f922-ac5a-4a13-9af1-7bbb802189ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1fdc8397-581c-4065-8bca-013ad1393923_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee payroll deduction under the stock plan (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09a66254-9eea-4fff-ba72-cbd242168a2e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fd1623d8-fa32-4cd5-91c3-07b9579ae172_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f696558-4e15-410c-8a18-f2c66312cdb6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5f6521b3-c646-4de4-adc6-f233f8b60bf3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_b5d06c1f-a9c2-4104-84ca-ce5473187887_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, other services agreement term (in days)</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Other Services Agreement Term</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Other Services Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementOtherServicesAgreementTerm" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementOtherServicesAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementOtherServicesAgreementTerm" xlink:to="lab_cdtx_CollaborativeArrangementOtherServicesAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_abbc174d-bfa0-4d18-99c8-f3bfc7617302_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_2cf843cf-bb2a-4132-b457-f02ea07d7dec_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e4563c52-d4ba-480d-9585-48620fd266e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_b1fe0289-5871-4919-af10-65e389d68d02_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4306d928-a53c-4e35-97df-0e0d57ff86a0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit losses</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_eb0c8857-7f50-4860-95ae-7394d056f443_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_017150f5-9fe5-4f68-9224-88a56532e8fe_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_07f481a4-4dba-4723-bfeb-1296b3f83e70_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_a62bf5a2-f389-4123-ab6c-04bdacaa28e7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8811ae2e-cfa2-47f1-b1fb-492977e49bce_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fe3c63be-de3f-4ee5-b68a-9ca8c498356c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d056b30e-f5b9-49b5-af7f-1977402abd15_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3b5831c3-8d9a-4981-9106-23e19340aa75_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3f5eceda-7527-4821-9d2c-93442301eb70_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_48af7e87-1a2b-4e04-9c35-dfff809c23cb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_7fd86b72-2329-49b2-b7d9-95a3d832ddf9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in Force</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_60d9a18a-ddf5-4209-bfd6-6438f11d7686_terseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:href="cdtx-20250331.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:to="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_793fbc4c-fc4c-428e-bd14-368d3f488bfd_terseLabel_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 10% of Voting Power</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_label_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More Than Ten Percent Voting Rights Classes Of Stock [Member]</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_documentation_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">More than ten percent voting rights classes of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:href="cdtx-20250331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:to="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b0cb3398-cd08-42c2-9159-c5a5eefc53a1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_67c1f37a-486d-4b65-87b7-8df1392d73e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f4d8e99a-d73d-4dcb-bb8f-ab31cf1b5057_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_12e05898-c646-43cf-86dc-60807ee73447_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_265fc596-2017-4f39-957a-30c4efbd937a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4f8243bb-62bd-49a4-acbc-b7e8d4e15b69_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0aa064b1-bdf1-4aed-ac0f-821575740e46_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_bf07b849-2a9e-4472-bd1b-3161e6f73371_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_67fdb709-7006-4837-b351-cca9cbc4f24e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5199556b-88ab-43f1-8122-2b0d07ad6287_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SeriesAConvertiblePreferredStockMember_f981c20b-bf3e-4be4-815d-aa91471c9c78_terseLabel_en-US" xlink:label="lab_cdtx_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_cdtx_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_cdtx_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_cdtx_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertiblePreferredStockMember" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SeriesAConvertiblePreferredStockMember" xlink:to="lab_cdtx_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4723efb1-7537-4205-b7f2-fe45aaef8700_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_c84c1d80-0062-47fb-835e-38375d6c3af1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_a2767cb4-0684-4209-bc37-81689ad9aac5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for each preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0a3c48aa-9f9a-47da-8a63-627ec748ffce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0bdaeb48-ce61-4134-8cc8-ed928691f793_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a329b9e9-f240-48e2-b196-f9e56b0d8a79_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_a688612f-03b4-4848-b41d-44bfd292ae2f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_5d63aa43-c574-4d6a-9203-5c396723a8ff_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reversal of indirect tax liabilities</link:label>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_d3936322-5276-4c56-a71d-c74b1ba4a105_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reversal of indirect tax liabilities</link:label>
    <link:label id="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_label_en-US" xlink:label="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="lab_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3e107986-b8e5-4134-852d-75e252eb79fc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_797eaf3a-c5d3-4689-836b-95ca9bf80ee2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, net</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c14ddb04-31b3-451d-8f41-c08e03de55c2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5896eeed-87cf-48e1-a6eb-50f39f3ab3c2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9cccb513-4040-4253-9904-8011de02af6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_1e5e34bf-ede0-4428-b791-3f3a655b832a_terseLabel_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, option, purchase equipment</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_label_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Option, Purchase Equipment</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_documentation_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Option, Purchase Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:href="cdtx-20250331.xsd#cdtx_LesseeFinanceLeaseOptionPurchaseEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:to="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7990303d-1655-4041-a870-116a07ad50e8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_974bcd0c-cdcc-429b-9243-69adcac74b51_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_fd9eac18-a5bf-4c8b-81b4-b7b14ec06903_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_817e888d-080b-417d-915c-c621f898f3e5_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_c6d30629-08ce-4f74-8720-fc2a9bcf435e_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash provided by (used in) investing activities, discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d7028dc3-2c26-4ecf-accc-5a96d9ac2e30_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_ac4d595c-a11c-41ff-bf45-102ded491b81_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash provided by (used in) financing activities, discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4229a4da-ad8f-4658-8864-410d49a9b931_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_25844ff4-e968-4e1b-9c51-6eb35f90ee79_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_a4b0e83f-5cf8-4c36-8725-689b899a6515_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_d720629a-68f4-48fc-9358-e8e2d3dfc3bd_terseLabel_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_label_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use, Amortization</link:label>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_documentation_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization" xlink:href="cdtx-20250331.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_OperatingLeaseRightOfUseAmortization" xlink:to="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_635b9721-2616-410b-aca4-be74035c9db8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_f513e5b0-9439-483d-8319-424a201463c9_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment obligation, commercialization</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" xlink:to="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ab3c7996-ce2d-4b86-8743-bebde87d894b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a405e952-1420-44db-acd3-379f2da0a24b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_a75d5fd4-d18d-45f1-b478-860bdb6ace0c_terseLabel_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical and Clinical Trial Accruals</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:href="cdtx-20250331.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:to="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeFinanceLeaseMonthlyRate_975d0973-c39c-4a54-b82f-9bcadec30675_terseLabel_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, monthly rate</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseMonthlyRate_label_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Monthly Rate</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseMonthlyRate_documentation_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Monthly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:href="cdtx-20250331.xsd#cdtx_LesseeFinanceLeaseMonthlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:to="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d6370e1d-7c8d-4962-9b95-09d73cb306ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a1e30e93-5c69-4205-b12c-bdccfaa2d4c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c29d518-7024-4515-8d0c-78d44957194c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_eee7029f-41f6-4981-9fc3-27b7502dafed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f74830a7-3397-4554-a461-79682487b825_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7293a816-813a-42ff-8051-a4381c9ff6bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f8bafd9-b744-497e-9af5-342bbf079f32_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_009f67b3-5081-4244-b3fa-0e4c872a553c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PrefundedWarrantsMember_49607761-2d76-48a1-8b8e-7623993df2dd_terseLabel_en-US" xlink:label="lab_cdtx_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:label id="lab_cdtx_PrefundedWarrantsMember_label_en-US" xlink:label="lab_cdtx_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
    <link:label id="lab_cdtx_PrefundedWarrantsMember_documentation_en-US" xlink:label="lab_cdtx_PrefundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PrefundedWarrantsMember" xlink:to="lab_cdtx_PrefundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_526fa477-3930-4704-8f60-4c3e7401e86f_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage increase in base rent annual (as a percent)</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:to="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_22a311cd-62a8-447c-975d-d53ef5978fcd_terseLabel_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized for future stock awards</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_label_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorized Shares For Future Stock Awards [Member]</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_documentation_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorized Shares For Future Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:href="cdtx-20250331.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:to="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1ce907fe-c0f8-45aa-844a-adc9dd5a6db1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7068f279-e845-472e-8dcb-aba445adfe99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment for shares withheld to fund payroll taxes</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_2fd69dea-771d-4f8c-ad14-c0e75bcb24bb_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities, forgiveness amount</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Forgiveness Amount</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Forgiveness Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_47a6a5db-813b-439d-aefe-1ee45c2d0f2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ba48d538-dcaf-4d1f-a17d-bcc1e1337c5c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e921f7e4-7953-4312-967b-31df210fc6da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_bb5c34f0-2827-4193-acd7-eabc50d441da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2a33b66d-83f4-4c6c-88a4-9c6eb02bdba7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b87306a8-275f-40e0-87ec-b6cdc3be2afa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_70bec100-94ad-4c1f-8331-2579c65df755_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7e15f50f-23c3-4b05-bdff-ee8f55df8aed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0a1ded25-67eb-46b9-8a1e-0a38b0221e00_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0a998386-d78e-43a3-af6f-5e6df1a0e380_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6f1874e2-1f04-4853-bb48-1b357bb8d1da_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_36cc2ff1-ddcf-4ae5-baa4-e187fdb831f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_83f80a8b-73ff-41d6-bf69-f3db03ba12b9_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, carry over services agreement term (in days)</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Carry Over Services Agreement Term</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Carry Over Services Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" xlink:to="lab_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_fe8522d2-68aa-41f4-8bb2-574b4e512d2c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_dc8fca1b-63ea-4a5e-b09e-f2afa19364c3_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants, including pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d125ec16-93ac-461c-b86f-5feb35356d29_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_93778dcc-fe88-4c60-ae17-ad4d454f8cfa_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_033e3548-af05-4939-95ca-3c4592227b53_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, maximum cost share, forgiveness amount</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost, Forgiveness Amount</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost, Forgiveness Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" xlink:to="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_d861cfe8-b682-4ee7-852a-4a7eae524e19_terseLabel_en-US" xlink:label="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indirect tax amounts, income tax penalties and interest accrued, decrease resulting from settlement with taxing authorities</link:label>
    <link:label id="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Decreases Resulting From Settlements With Taxing Authorities</link:label>
    <link:label id="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_documentation_en-US" xlink:label="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Decreases Resulting From Settlements With Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="cdtx-20250331.xsd#cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_df89c90e-5e36-4e4d-8420-301c45ae3dad_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_7a23e946-f863-4e97-96fd-16387bea523e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_433ffe17-073d-46b0-8fea-ba170a1ae6c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f63d095c-a427-403c-a945-b050c7a34090_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fcba3443-7e92-4172-81da-712047d2fe70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6dc401e8-e16c-4b0c-a5e3-7066ec1a76a8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5ff86e36-2bfa-4196-b78a-41356f43ae38_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_44c99e6a-ef44-4a8d-b2a8-47c9795f8596_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Personnel costs</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_0538f10b-f32f-4b74-9bb9-4748657e13a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_bcea53df-37b5-4a10-a473-1246b2138f9f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3cfb4801-7470-4e0f-84a5-613885f86b6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_8f093c46-81ae-4f3c-93a6-e8a1b6a2c91f_terseLabel_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License of Intellectual Property - upon milestone achieved</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_label_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property Upon Milestones Achieved [Member]</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_documentation_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property Upon Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:href="cdtx-20250331.xsd#cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:to="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2d324f84-58c2-43a7-b613-2a42039624aa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_84db522a-2302-4932-a5ec-bda8dd544758_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_77eb3b52-78e0-490f-8009-d7b64f21799e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development - Cloudbreak platform</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7139a0-6662-4d43-bae4-e068f1f497d0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f1225cbf-0335-4fda-b902-e57ed9e34e05_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_f6c183f1-d037-4378-b333-15787488380c_verboseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_c0d94378-145d-4512-afbd-534c6d41bc1a_terseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_label_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:to="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e710f2e9-6783-4e71-8a71-d7034ede083b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_727cdeb5-cbd2-49c5-a5cc-b859d67789ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2a4880db-b384-4880-857c-36f44a5fe5e6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_79c64c1f-257e-4989-b457-2e3fb16e2c56_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_137970ac-5186-4592-8cf9-0a408a6d8b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_309d9894-53c8-48e5-a629-89506b78e4c7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease Obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8bbfcf82-8468-4feb-9ef3-b1f79f48045b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets related to discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_18215f23-2391-4467-b120-7272b0ef42b2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb961b81-30c0-4ff7-8d02-a39ab584e360_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ee16784f-2d37-41c4-a6ea-3b4d07be6ed7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6160ca5f-85e7-44b2-925a-6e35922658b1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7197da4-7cd4-40de-85c3-573bd76a4b97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a506c282-3ccb-4e0e-8d09-fa8a0ecacd08_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_99470ca7-9364-4406-b702-31982da3f97d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea7808f9-17fa-43c6-8bcf-2b5e3bad62d1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute diluted net earnings (loss) per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_9854654f-69db-428d-94a4-86c4046eabae_terseLabel_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_documentation_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:href="cdtx-20250331.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:to="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_589fd80d-3695-42f3-8114-074e72810513_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other research and development costs</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_15729344-b116-4bc7-9cfb-27982a586042_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_96f68d9c-465b-477a-ad2e-f3067f7acb8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4c6a6ac9-16b6-4214-ba5e-53dd463b6c77_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RezafunginMember_e63151b4-fb08-4066-a5dd-27350ce82ba5_terseLabel_en-US" xlink:label="lab_cdtx_RezafunginMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rezafungin</link:label>
    <link:label id="lab_cdtx_RezafunginMember_label_en-US" xlink:label="lab_cdtx_RezafunginMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rezafungin [Member]</link:label>
    <link:label id="lab_cdtx_RezafunginMember_documentation_en-US" xlink:label="lab_cdtx_RezafunginMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rezafungin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RezafunginMember" xlink:to="lab_cdtx_RezafunginMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_91fab91e-1086-4c60-a982-6938c7e1f14e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3dc6063c-ac4d-433a-8a40-138a5fd7ac06_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SIGNIFICANT AGREEMENTS AND CONTRACTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_bde5a4c0-850f-4120-a27a-9934f2c6dfaf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_abc7e8d8-9b4d-4c3f-8138-36e4bc599762_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_93c8291f-a5cf-4dee-9996-bd7c70a35567_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c7e4f33e-e911-4462-9cb9-e6b7f5df4314_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, maximum cost share</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:to="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_45212032-b2e6-4615-830a-ef71fef4b990_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_8d4171ac-1da9-49f6-a352-32f7f023800c_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_389aa2ee-0226-4f2e-a953-59b8784afcee_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_09eb15f4-23d3-417c-821b-58dab7e4da07_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_b3b02b08-4503-4747-a96b-2ea32a848c6d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2d1283e3-5fe3-4725-8c78-b9ddec747533_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_86ba66cb-0478-42da-85d1-ad99b4ea7347_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b5e7dd52-ef1e-4ca4-b177-5950d9b0a1e4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_56c30bb3-04da-425f-bb4f-8598f6965fa0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_99387903-f3e3-44ca-9ddf-b7dc35d9e756_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fc834743-6467-4a6c-b852-5a7bbb7a0b99_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_63c0c147-b4b7-4739-809b-73b9231cfddc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca69b0d6-f718-49d6-86d6-acef1f9fcffa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_98ba4c1f-53f8-4f5b-bba7-87c5254f5f14_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_5e37ad30-7f77-43ba-882d-3aae4b22051e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6f433757-8e1b-4f10-a504-e98a30ca3720_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_eceb360c-306e-47b3-b722-e756771cf09a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3e228edd-0cc2-491a-99d3-15da82cf6695_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b6a2456c-f012-4611-a9a1-691b557350a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4a247513-985b-4c9c-a842-82a02745012a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a31fb3ef-c03e-4d4f-b854-416481f14c6a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_8c250eee-99c4-4044-9ad7-1462b6e8ba4f_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1a012fd9-cab0-4535-b2b6-8e4195755c17_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_48a8d893-a861-447b-8913-a42d38b8fb5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_15538f8e-2178-4a81-b7b6-38a21114a191_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fbde19c0-a8f7-41ae-a791-58b5e1b24ae7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_500eb6b1-e19c-458d-b62f-17c47314c8a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9a8f6848-bba3-402a-95b9-dc359e976283_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f022ab9e-fc0e-4157-b534-f84c01d6cd9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_694c7036-7918-477b-87ac-94af445012a6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_c307201b-870a-4f1a-add9-55021fad0357_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_20412b62-370b-4736-b8a6-c4d3a47010c0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteesAbstract_40a8ea14-1abc-4e06-9e0e-510ce3488854_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Letter of Credit</link:label>
    <link:label id="lab_us-gaap_GuaranteesAbstract_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract" xlink:to="lab_us-gaap_GuaranteesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e18b5de8-d168-48bf-be64-4e33743099a9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ff56aa2d-be3c-47f2-9320-e2954643820f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8dd0d94e-21cd-4a45-a0a7-b2023d472df4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_b9f756f4-1b2e-4828-9211-4fbdfc24a20d_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over Time:</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_04c0e929-ccd5-481d-bbbf-e40ce464a4f1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_099e7a55-4273-44fb-ab9e-5e183ff2abd6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2d599dc0-c03b-4ace-8415-c45010310437_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_1e514836-c59f-49c3-a2ef-8774f653ce0b_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_label_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_documentation_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:href="cdtx-20250331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:to="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_25077942-054e-4eb2-80a5-800e3acb382d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c2949560-5a2c-46c9-b9e9-32d2ca0f2db6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued and Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_c43ef379-d22c-4104-b493-07d449ae1635_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_743c8807-62fd-4a3c-a149-2a5ceea09006_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b6a7deb4-3bf6-4613-a0ed-7f320fc6be30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a805fbe3-353a-4920-a439-9ebf6cd8cbdf_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_88eb45d4-199d-4ea6-9e58-14465c4a2787_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5b771b7c-3026-4550-bb75-6484349f2417_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_829221bd-5f4e-4017-ae1b-54832363afbf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations, net of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_fcf480b9-9949-4764-8aee-f1d01bd81aa3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations, net of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a0f8c5a9-6b64-43ef-a5c2-c6239b64c239_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from discontinued operations, net of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_7d3a4474-b33b-48c5-93af-0f2399c7e11c_terseLabel_en-US" xlink:label="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of discontinued operations</link:label>
    <link:label id="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) On Disposal</link:label>
    <link:label id="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_documentation_en-US" xlink:label="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) On Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b7e8ce47-3b49-473d-9e44-5cd1188961b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_66774995-bc6e-400d-967b-591bb6ddc696_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_acb2519f-67cb-41eb-a590-e7b68aa841d0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_4fc22c53-b4b7-486c-bca8-41ff560e5219_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_511b30c9-0194-46a7-b291-4dc8410facca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_cffffd13-f8a1-421d-8ae5-e55428e5f192_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, gross</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_4133e6c1-80b7-4ba0-957d-94f0685acaef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_44efa507-d179-43d7-951a-b0e7bd83c5bb_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends in arrears or default</link:label>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_label_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Dividends In Arrears Or Default</link:label>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_documentation_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock dividends in arrears or default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:href="cdtx-20250331.xsd#cdtx_CommonStockDividendsInArrearsOrDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:to="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_1191c512-7717-46e0-9b19-4674da51e4a3_terseLabel_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments related to collaborative agreement</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_label_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_documentation_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:href="cdtx-20250331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:to="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e78d408d-1b1d-4c18-9204-66d0cb615db7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_ab9b3c42-367c-4ef2-b607-fea09d1553b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f91bfad8-d2e4-4628-9aec-5001da4d8e0d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1bd31902-c1f2-4746-a764-84d7b630e5ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_95c184b4-b96a-49e6-8921-32f998e95277_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsNatureDomain_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain" xlink:to="lab_us-gaap_GuaranteeObligationsNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ce3c56f7-7378-44b7-850d-6c2a6e1f16cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3d149025-e33b-41ef-9cf5-e4fd63462ef3_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_77965818-1288-402f-8348-485849285862_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_37034926-9b88-40a1-970f-6215be4e3c8c_terseLabel_en-US" xlink:label="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, forgiveness amount</link:label>
    <link:label id="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_label_en-US" xlink:label="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, Forgiveness Amount</link:label>
    <link:label id="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_documentation_en-US" xlink:label="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current, Forgiveness Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" xlink:href="cdtx-20250331.xsd#cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" xlink:to="lab_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3f0c6221-dedc-4080-963b-2a143f1469a5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize unrecognized compensation cost (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_b33727eb-bbc9-47db-88e4-65ae2478dfdf_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes for each share held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_label_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Votes Entitlement For Each Share Held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_documentation_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of votes entitlement for each share held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:href="cdtx-20250331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:to="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_3fe74ce8-9cbf-403c-bb95-cffb9b951266_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indirect tax amounts, decrease resulting from settlement with taxing authorities</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_OpenMarketSaleAgreementMember_60ad39ce-1df7-4509-94cb-fd705084eb2a_terseLabel_en-US" xlink:label="lab_cdtx_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:label id="lab_cdtx_OpenMarketSaleAgreementMember_label_en-US" xlink:label="lab_cdtx_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
    <link:label id="lab_cdtx_OpenMarketSaleAgreementMember_documentation_en-US" xlink:label="lab_cdtx_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OpenMarketSaleAgreementMember" xlink:href="cdtx-20250331.xsd#cdtx_OpenMarketSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_OpenMarketSaleAgreementMember" xlink:to="lab_cdtx_OpenMarketSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_449a5e1c-4c2a-4452-a276-7b2019f7dcec_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_15ee4c20-9788-4c0b-a37c-b6d0ee025d73_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComparabilityOfPriorYearFinancialData_4aeef655-eeeb-4be5-a570-caa94d6269b6_terseLabel_en-US" xlink:label="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unaudited Interim Financial Data</link:label>
    <link:label id="lab_us-gaap_ComparabilityOfPriorYearFinancialData_label_en-US" xlink:label="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comparability of Prior Year Financial Data, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComparabilityOfPriorYearFinancialData"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:to="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_738dc0ba-3b11-4e69-b2aa-06d755544c86_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0b79215b-203b-4af6-96e2-79ec4e3cb631_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5fde13c7-2c1f-4b12-ad6d-b42c16e16ea3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5aec489b-f9c8-47a4-8b3b-777b3f468b6c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aaf33a11-bc98-489b-99ec-83d1feeafb67_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, other current assets, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_cc753297-f3ce-485c-b6c1-e677c8e40476_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby letter of credit</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_bd546d39-7466-412d-86a6-055daf5ef5f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be0cd3b2-ea05-412c-8104-624c65582d31_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_4d4ee444-c489-46f7-95f7-232a885ba750_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_97c62783-37a1-4b67-81fd-952ffe7df1cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_a020892c-7cca-48d5-9bbb-44f32d31be33_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_f8475540-ae59-4bae-b423-92f0aea96bf3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2dfba3eb-f77b-425c-ab61-1e937da9727d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Value of shares withheld to fund payroll taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e38a8a09-dcd6-4f5c-8241-d46c84436a83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_29ad70d7-7683-47f8-b6f4-32b058a9bd8b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash and money market accounts</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_d9056569-d520-4d44-853f-cdc5744f0496_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities related to discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fc3208cc-03de-4306-9782-751d96a641d3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c4ac62e7-5576-47a8-ae1a-48ba32a52a51_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_0bdc4a40-3097-421c-9865-c4a1f928205f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0dc441a5-96c7-435b-845f-b7f288479554_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b36c9cef-7180-4ff0-82fc-8f2ea4dd23d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6347848a-77c7-4c9d-a471-580b296631c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13daed30-a1ca-441e-81d7-83dafd60b97d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_b5a41e33-57aa-4e96-bf6c-1a1d3c37f2c4_terseLabel_en-US" xlink:label="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in force (as a percent)</link:label>
    <link:label id="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_label_en-US" xlink:label="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Total Workforce Percent Impacted</link:label>
    <link:label id="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_documentation_en-US" xlink:label="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Total Workforce Percent Impacted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" xlink:href="cdtx-20250331.xsd#cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" xlink:to="lab_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6f9c282a-bd1f-4d5f-8c36-6dcec3f006f8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_c12a25ca-d61e-49da-91ea-3b935a12a26b_terseLabel_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Melinta</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_label_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics Inc [Member]</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember" xlink:href="cdtx-20250331.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MelintaTherapeuticsIncMember" xlink:to="lab_cdtx_MelintaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9ac7b4ab-3b8f-4b3d-b3dc-3f341ad89d75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_3d30adbe-7dbd-43b6-bf13-0c3cbff3c7cf_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_1c6135f1-9495-40c6-b52b-2d74ec352374_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment obligation, development and regulatory</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" xlink:to="lab_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9e722cc-c131-4455-b193-f1809ff9fa15_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_164aced4-34e7-44c8-a523-16128b7039a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3923eda6-5c21-4896-92d4-3107b679137c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_58834f78-5c35-49d7-b0f3-780034b8ff72_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_883a29f9-b255-4e2d-a848-fffd4d79ee8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f3be0055-208e-4469-bbf9-851e616a995f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c714ca04-6d81-49a2-b1d9-442fbc49f354_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_d803b791-b6a3-452d-843c-810946e72d6b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_37f05486-2228-4900-b762-d5a0ec386c75_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_e3539976-63c1-4291-96d0-82df4b0af506_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_16d5406e-8de3-4e50-8293-2c8ce6430e6d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6b70e330-aa01-40a0-924f-bf00fa9962fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_44ca8975-2a9f-4026-b262-07c81b775f3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per common share from continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e21d2a7d-2ea3-43bd-97fa-9714fc6f582c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_04cb3e33-cc38-4af2-b163-fbd83f5a211f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6369ab62-da7e-4482-aa4c-791b4dd3016d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b92ffafd-2062-42e6-8dcc-ccca38f29d13_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_d3355e65-a2ae-4766-a2df-b30565c1fa7f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental borrowing rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DirectTransactionCosts_b9079fe1-01fb-40af-82f3-5e79dc738c5f_terseLabel_en-US" xlink:label="lab_cdtx_DirectTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct transaction costs</link:label>
    <link:label id="lab_cdtx_DirectTransactionCosts_label_en-US" xlink:label="lab_cdtx_DirectTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Transaction Costs</link:label>
    <link:label id="lab_cdtx_DirectTransactionCosts_documentation_en-US" xlink:label="lab_cdtx_DirectTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DirectTransactionCosts" xlink:href="cdtx-20250331.xsd#cdtx_DirectTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DirectTransactionCosts" xlink:to="lab_cdtx_DirectTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_11e0d011-0162-482d-af2f-f795ef9dfe02_terseLabel_en-US" xlink:label="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indirect Taxes</link:label>
    <link:label id="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Other than Income Taxes, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taxes Other than Income Taxes, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:href="cdtx-20250331.xsd#cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:to="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8ef32369-405a-411b-8f4c-84ec1f8bf5c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net earnings (loss) per common share from discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_49fc01f5-237f-4ab7-9f2b-ac603c215aba_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option renewal term (in years)</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option Renewal Term</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:to="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_efa302fb-9f0d-44a0-a38b-d393a5f4b8ea_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuarantorObligationTerm1_b47d4d4c-8327-4a58-968a-aaed6449addb_terseLabel_en-US" xlink:label="lab_us-gaap_GuarantorObligationTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby letter of credit, term (in years)</link:label>
    <link:label id="lab_us-gaap_GuarantorObligationTerm1_label_en-US" xlink:label="lab_us-gaap_GuarantorObligationTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligation, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantorObligationTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuarantorObligationTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuarantorObligationTerm1" xlink:to="lab_us-gaap_GuarantorObligationTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_c9650682-4d99-4c26-9841-39b9815b1535_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base rent per month</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:to="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_2e5c4f42-1d75-4dbf-9738-f76d342d60f6_terseLabel_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Supply Services</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_label_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_documentation_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember" xlink:href="cdtx-20250331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClinicalSupplyServicesMember" xlink:to="lab_cdtx_ClinicalSupplyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_51591c0c-972b-433f-bc4e-9fcfc7636345_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_981a2127-e565-4ebd-a592-7f4696459218_terseLabel_en-US" xlink:label="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</link:label>
    <link:label id="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Four Equity Incentive Plan, Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Four Equity Incentive Plan, Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:href="cdtx-20250331.xsd#cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a80e8822-8865-4d23-96ab-c2888938beef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a7ecc5e1-ec06-4c71-8fd7-d1786acb2e96_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated unrecognized share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RezafunginAssetsMember_f653bd93-7134-48f5-b3a1-963ae9f837b3_terseLabel_en-US" xlink:label="lab_cdtx_RezafunginAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rezafungin Assets</link:label>
    <link:label id="lab_cdtx_RezafunginAssetsMember_label_en-US" xlink:label="lab_cdtx_RezafunginAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rezafungin Assets [Member]</link:label>
    <link:label id="lab_cdtx_RezafunginAssetsMember_documentation_en-US" xlink:label="lab_cdtx_RezafunginAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rezafungin Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginAssetsMember" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RezafunginAssetsMember" xlink:to="lab_cdtx_RezafunginAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction_eef4838b-d09a-4d07-ab1a-419e4777f6b5_terseLabel_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offerring price</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction_label_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Receivable Per Transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction_documentation_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Receivable Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationReceivablePerTransaction" xlink:href="cdtx-20250331.xsd#cdtx_SaleOfStockConsiderationReceivablePerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SaleOfStockConsiderationReceivablePerTransaction" xlink:to="lab_cdtx_SaleOfStockConsiderationReceivablePerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LossOnAssignmentOfFinanceLease_001047cb-9357-41f1-8290-790743a60bf1_terseLabel_en-US" xlink:label="lab_cdtx_LossOnAssignmentOfFinanceLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on assignment of finance lease</link:label>
    <link:label id="lab_cdtx_LossOnAssignmentOfFinanceLease_label_en-US" xlink:label="lab_cdtx_LossOnAssignmentOfFinanceLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Assignment Of Finance Lease</link:label>
    <link:label id="lab_cdtx_LossOnAssignmentOfFinanceLease_documentation_en-US" xlink:label="lab_cdtx_LossOnAssignmentOfFinanceLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Assignment Of Finance Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LossOnAssignmentOfFinanceLease" xlink:href="cdtx-20250331.xsd#cdtx_LossOnAssignmentOfFinanceLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LossOnAssignmentOfFinanceLease" xlink:to="lab_cdtx_LossOnAssignmentOfFinanceLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fafc6035-68c7-4f5a-8c5d-a0004b19bb39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_aebf6db9-a86e-480f-999e-64555ef1e6c0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eb77493e-9c4b-4a4a-8316-416e2f4b5257_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0c607a35-ac49-40eb-b765-666f7e2016eb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_b28973ba-b4a4-4b1d-8eef-447c10907ae3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_4a167099-81a8-4843-b4cb-e68277d337b0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4b9ae031-059f-458e-ba7a-0af743968eb1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and money market accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_40ff60eb-8d77-41a9-a94f-9c44997d6abb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_62a74df2-7790-46b4-98fa-37770c38625b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_7319e51d-6ebf-4463-91ca-cae56c90b95a_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7904184f-188c-4bcc-b156-2a19181cf616_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c89b44f9-c9ca-406a-b45f-332d3f5a26b7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod_badc5917-ce75-4957-a247-52a83d93e833_terseLabel_en-US" xlink:label="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, cashless exercises (in shares)</link:label>
    <link:label id="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod_label_en-US" xlink:label="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercises In Period</link:label>
    <link:label id="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod_documentation_en-US" xlink:label="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod" xlink:href="cdtx-20250331.xsd#cdtx_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod" xlink:to="lab_cdtx_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c70d920e-1473-46c8-b916-40bebbf35040_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_8e7da605-7542-4b77-acb5-bde5c9f47674_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_c9a19920-8120-4ded-981c-8537c883ae08_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_11309fda-9f8a-4577-b61d-bb4f99eda77c_terseLabel_en-US" xlink:label="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease Right-Of-Use Asset And Liabilities</link:label>
    <link:label id="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_label_en-US" xlink:label="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease Right-Of-Use Asset And Liabilities [Member]</link:label>
    <link:label id="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_documentation_en-US" xlink:label="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease Right-Of-Use Asset And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" xlink:href="cdtx-20250331.xsd#cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" xlink:to="lab_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_6d106d10-bf40-4811-b0e5-7ab2a775764b_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition services</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Transition Services</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Transition Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4ac33a92-8c87-4618-98f1-3122d877f915_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_45aaf4c3-e31b-45ff-9b0b-48171a805b96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1f078222-e2d7-4201-b666-94b251d7f5a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs for private placement</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NappPharmaceuticalGroupLimitedMember_2b82240b-c797-4932-8a14-2bec3e677155_terseLabel_en-US" xlink:label="lab_cdtx_NappPharmaceuticalGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Napp Pharmaceutical Group Limited</link:label>
    <link:label id="lab_cdtx_NappPharmaceuticalGroupLimitedMember_label_en-US" xlink:label="lab_cdtx_NappPharmaceuticalGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Napp Pharmaceutical Group Limited [Member]</link:label>
    <link:label id="lab_cdtx_NappPharmaceuticalGroupLimitedMember_documentation_en-US" xlink:label="lab_cdtx_NappPharmaceuticalGroupLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Napp Pharmaceutical Group Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NappPharmaceuticalGroupLimitedMember" xlink:href="cdtx-20250331.xsd#cdtx_NappPharmaceuticalGroupLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NappPharmaceuticalGroupLimitedMember" xlink:to="lab_cdtx_NappPharmaceuticalGroupLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8b78b932-10e5-46a6-8ba5-cb780ddbe297_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember_11dadd89-4eed-4e74-9420-26c103913604_terseLabel_en-US" xlink:label="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember_label_en-US" xlink:label="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Voting Preferred Stock [Member]</link:label>
    <link:label id="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember_documentation_en-US" xlink:label="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Voting Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember" xlink:to="lab_cdtx_SeriesAConvertibleVotingPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PreferredStockSharesIssuedIncludingConversion_05c0252c-7967-4eb2-8c3c-cda790d9febe_terseLabel_en-US" xlink:label="lab_cdtx_PreferredStockSharesIssuedIncludingConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_cdtx_PreferredStockSharesIssuedIncludingConversion_label_en-US" xlink:label="lab_cdtx_PreferredStockSharesIssuedIncludingConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued Including Conversion</link:label>
    <link:label id="lab_cdtx_PreferredStockSharesIssuedIncludingConversion_documentation_en-US" xlink:label="lab_cdtx_PreferredStockSharesIssuedIncludingConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued Including Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreferredStockSharesIssuedIncludingConversion" xlink:href="cdtx-20250331.xsd#cdtx_PreferredStockSharesIssuedIncludingConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PreferredStockSharesIssuedIncludingConversion" xlink:to="lab_cdtx_PreferredStockSharesIssuedIncludingConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_64ade6f3-0be1-454e-886a-3baaf3363e2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_4c479118-af84-47d3-bdc3-986dcc8de930_terseLabel_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_label_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Acquired In Process</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_documentation_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Acquired In Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" xlink:to="lab_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_abba3cdf-209e-4316-a199-3771d7a724a6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_57001056-1ce6-43e6-8add-99d60e02412b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_54387da7-f656-4b61-b000-9ef1ee2757b4_terseLabel_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:to="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e79ee9cb-7387-449d-946c-8b8a34921382_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ef96ec36-1cca-428f-a1ee-7c75685b35ae_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1965caf3-47eb-4138-81cd-2db297a5f40c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_OtherSegmentItemsAbstract_d40536cf-f396-4c0a-851c-8e0df73043b5_terseLabel_en-US" xlink:label="lab_cdtx_OtherSegmentItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items:</link:label>
    <link:label id="lab_cdtx_OtherSegmentItemsAbstract_label_en-US" xlink:label="lab_cdtx_OtherSegmentItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Items [Abstract]</link:label>
    <link:label id="lab_cdtx_OtherSegmentItemsAbstract_documentation_en-US" xlink:label="lab_cdtx_OtherSegmentItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Segment Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OtherSegmentItemsAbstract" xlink:href="cdtx-20250331.xsd#cdtx_OtherSegmentItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_OtherSegmentItemsAbstract" xlink:to="lab_cdtx_OtherSegmentItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_af797721-bdcf-4130-b66c-0fe518facda7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_ac321be0-462f-48dd-a03d-8e62ac9eec7e_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting power threshold (as a percent)</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:href="cdtx-20250331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95f3042d-7001-4025-b50b-dd5fa19fd954_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_15714a8d-291c-41bf-b0c9-828bcc0b9ecd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_89a943e3-9d1c-44f5-842a-13c01d5fed38_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_854060a6-170b-4787-9ddf-c7aa2b7c22ec_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_081aa68b-2a38-4f8a-88d5-d74c0d0edbf1_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash provided by (used in) operating activities, discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_GuarantorObligationsTerminationNoticeTerm_01c791bd-e01e-425a-861b-249b09e0f999_terseLabel_en-US" xlink:label="lab_cdtx_GuarantorObligationsTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby letter of credit, termination notice term (in days)</link:label>
    <link:label id="lab_cdtx_GuarantorObligationsTerminationNoticeTerm_label_en-US" xlink:label="lab_cdtx_GuarantorObligationsTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Termination Notice Term</link:label>
    <link:label id="lab_cdtx_GuarantorObligationsTerminationNoticeTerm_documentation_en-US" xlink:label="lab_cdtx_GuarantorObligationsTerminationNoticeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Termination Notice Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_GuarantorObligationsTerminationNoticeTerm" xlink:href="cdtx-20250331.xsd#cdtx_GuarantorObligationsTerminationNoticeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_GuarantorObligationsTerminationNoticeTerm" xlink:to="lab_cdtx_GuarantorObligationsTerminationNoticeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_86bdd62c-6f8d-4ec0-8db2-6dd9fef6cd0f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_58de7140-4001-45f3-8922-748bf92c60ba_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_f7d1a364-8294-4a83-8314-485dbabdeedf_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_5142fcf0-eb82-4135-8393-d4c25d94f650_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="lab_us-gaap_GuaranteeObligationsByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_54470fb7-9dde-4150-a1d9-ef0a4d1b1bcf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_df136931-1345-441e-b812-5539adb06a98_terseLabel_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cdtx-20250331.xsd#cdtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4fa31852-c4a2-402c-b2e6-cbdd2504ea98_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_932ba386-5229-4a20-ac54-0f43344d252a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2f0e31d4-ce80-4d29-8082-9af34fed8dac_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d60cc26f-cf09-4e98-9aa2-fa11633ea4fb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_c0961df8-929d-4e40-a3fc-27ba4a9abdcc_terseLabel_en-US" xlink:label="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_label_en-US" xlink:label="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research And Development</link:label>
    <link:label id="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_documentation_en-US" xlink:label="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="lab_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_c9c3f667-672a-443e-9ecc-e880b0724104_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4c298562-3f3e-4b55-96e9-402662267205_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3320bf9a-a25a-4e35-9a7a-3e4340020fac_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_317f9b5a-b7ba-49f6-94b0-a0b7464b19f8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_9a5cd5f2-6248-4d30-b3f8-0827a95bb724_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_52ab2213-9fde-46c6-82de-9ef8722cd4e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_0fbfa243-0860-4b8b-8c97-329ae4f05578_terseLabel_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum ownership following conversion (more than) (as a percent)</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_label_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_documentation_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:href="cdtx-20250331.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:to="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f28da705-7cc9-4e43-92df-3c8137b277f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9764e0f3-f5bd-46c1-a0aa-ad765a9ca095_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7f2dbde2-4d0b-4d03-b9bc-6d94253e3389_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_20eef26b-e0c2-4d91-b363-bf8c45193c7c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d2484034-d039-425f-bb02-b3cb084715c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_8960c2eb-9852-4b0f-a03c-04e5d0747190_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_01c6293c-183c-4323-b871-3d2e87613591_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued indirect tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_73486a22-50e0-457f-b53c-2814639058c5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_620abf71-11c8-4bd8-b411-ecbc16137745_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_461d5a3d-18e5-4db0-8fdc-7ffb29b87fd6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_89fa3200-b13d-48c1-b6f4-f6379f839288_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b296bc36-6d70-4205-87e8-367259c7b6d2_negatedLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_17ffbe23-3c43-48d7-8200-5885f4fd00dc_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c13b3eff-e483-49c7-b6bc-e5ddeb75bd86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_56271f2d-1844-418b-bd0a-82f1af8f1ee6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a70e95b3-18d8-472d-af45-b2bab470d57b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UpfrontPaymentMember_ceaf705b-69eb-4646-98ee-b1b7f45332e2_terseLabel_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_label_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_documentation_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember" xlink:href="cdtx-20250331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UpfrontPaymentMember" xlink:to="lab_cdtx_UpfrontPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_00ff74b9-e38f-46d7-89d0-8321944a0537_terseLabel_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued indirect tax liabilities</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_label_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrual for Taxes Other than Income Taxes</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_documentation_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrual for Taxes Other than Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:href="cdtx-20250331.xsd#cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:to="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_0be7b206-8e4d-41ed-9a62-cddc41793c2b_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_b5bdaff5-a6ab-41d3-b365-2026f3c89d17_terseLabel_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_label_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_documentation_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:href="cdtx-20250331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:to="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_19cc353d-8af9-4194-a0c3-64320a56ebb5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_50d65a3c-f3ff-42db-a8b5-8cf2f3d3bfbd_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bfa1af4a-f105-4138-99ea-9eba9a74b912_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_97ad514f-21bc-4700-8105-64a89cdda15d_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Point in Time:</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm_f3389c1b-6487-4a59-8c12-c7884d8f5f1e_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, transitions services term (in days)</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transitions Services Term</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transitions Services Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransitionsServicesTerm" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementTransitionsServicesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTransitionsServicesTerm" xlink:to="lab_cdtx_CollaborativeArrangementTransitionsServicesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_a05c9e9a-26ba-4b7b-86cb-f1f0556ec70e_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f5d4eaa6-a6a9-4762-a369-9336246d416f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_9af18e50-05a9-4e4b-8fe1-b3820bc00c7a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_26005ae5-0271-46e5-88b5-fa8297376618_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_702b2044-f67f-4574-ac0c-c2872318cfec_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d9c265ea-d5b3-4e77-99fa-ab216299594c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_03671df4-5866-4341-be76-2be581bc5c0c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ba39ef3c-8484-4985-9ada-154a916e3e90_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6a1c901a-7f98-4502-897f-f73090274744_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_413e3ddb-6d19-49e3-9d6a-0d7cdc5f09b5_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of costs to obtain a contract with a customer</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_f64dff0a-fee8-4150-a8ec-e3b06a7a3556_terseLabel_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease and short-term lease term included within operating lease cost (in days)</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_label_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_documentation_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:href="cdtx-20250331.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:to="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ece8a5c1-4e63-4164-9ebf-b9dbf7f05a43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0c3528e2-e26d-4a64-ad5f-5fe335a0745b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636a19f8-76ae-4754-bd64-64bc5373ecde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_476113df-ee5d-40cc-bae2-7674295e5d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b174d342-b09a-4627-ad1b-a31f48bb628c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_02f6bf8c-0f82-4112-b255-fc77efbbafb2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_44de45de-3d79-48d3-9ea0-b79102b46016_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 50,000,000 shares authorized at March&#160;31, 2025 and December&#160;31, 2024; 12,209,150 shares issued and outstanding at March&#160;31, 2025 and 10,946,635 shares issued and outstanding at December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74c80f6b-50cd-4890-9f7b-6a8ac69bb526_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_61a849f5-6e18-4961-bc16-b539e8085f42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net earnings (loss) per common share from discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionValue_5a0a2b5a-2a34-4d42-9be0-5871cd90651c_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, transaction, value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionValue_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction, Value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionValue_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionValue" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementTransactionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTransactionValue" xlink:to="lab_cdtx_CollaborativeArrangementTransactionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8d6b5f5d-d1c4-4605-a513-07d723a95e45_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b38d8d4a-4bfe-4843-b4c2-99c89e2e7240_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_4ef018ce-faf8-45a1-a157-b51b4fa07348_terseLabel_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:href="cdtx-20250331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:to="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4e8465cf-3edc-4657-9008-ef25dc17ead7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cc4c05ea-e680-41e4-b191-c375c340372c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_6ea31074-052e-489e-aced-74a7d688f52c_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_2e3680ec-3d0a-4701-ad58-6f9a1460064c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock options and RSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0a4cfc1f-1afa-4c88-9cf5-21f1689b3d2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5c6e9aa6-9dd7-44bb-8c6f-3a955f273bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a5921a04-8d44-4d66-acc0-4332cf48902d_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awards available under the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_6e1ed788-e980-4337-9eb0-1bd1ee44212f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_20dc214a-e5e3-4ea0-9faa-c61ad4362850_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0308c374-e89a-42ca-b0d8-c5eb6a3de582_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ca9efce2-5520-44e4-8b58-2ac46edc959a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8992c145-c94d-442b-a3db-1a8b5ee5cab8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for stock options to be granted (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_7539a31c-8d0e-4871-aa04-4409af8359d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b1566e5d-374f-4c13-adf7-ad31fc1b83db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_07528ca1-1216-4d5b-9d36-6ecc66cbbb14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3b6c59ef-9571-417d-9bfc-c627240d1102_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_84120c30-09f3-40b6-b76b-c4d510ef8aca_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized share-based compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_73ca5c25-c8a6-40f7-a27b-73477d27ffc0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_1db59bd0-8d56-4eba-8b93-1d91ed8dd284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_22f89c09-76a6-4654-8fee-32e6356da510_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional awards were granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4782ffa7-893e-4e38-a692-db4cb6c89545_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8e288ff7-7384-4d78-8e7a-a3a15543deba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_ee867e8b-105c-43fc-b9a1-315ddbff258f_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MilestoneAchievementMember_f29b2470-3c51-4a09-ac60-ecd375d0601c_terseLabel_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_label_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember" xlink:href="cdtx-20250331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MilestoneAchievementMember" xlink:to="lab_cdtx_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_dbeac91e-ec55-409e-aa71-f2fb973604df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1f75fd6b-1ec2-44b0-8531-41094246a26f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_c9c8db39-6b86-45c4-ba9a-832effa36d09_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_9417c19c-315d-4c9d-8efe-0fa6338cd260_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3b241d58-8a48-4182-b9e1-5382bd328a89_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">THE COMPANY AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7b272dfb-b643-4454-8a4f-b8697f3fced3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_7c80e79c-cbc4-4fa4-9a93-b4ca21bbc7ad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f5e9e0eb-99aa-4b04-8a52-379aa63ef030_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_0fd4c3ef-97e1-456f-af9d-4cca18cb4f18_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_448c4d0b-127a-44c2-b05a-ff1dac553c09_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues generated in the U.S.</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8ac9cca1-f1aa-4a76-9442-df3928961718_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY INCENTIVE PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_62c1de29-fc3b-44c9-bf4e-ec74fcc5340a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_34bf0071-cb4c-44d3-b58e-ce4cbc2ad316_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease and Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_79a10c65-ed59-4f22-97db-763481c4aff2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d7a9b8a5-223c-49ad-8fd7-5e1ca2444e1e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ReportableSegmentMember_b5fda786-b010-43bb-83bd-629e584fb165_terseLabel_en-US" xlink:label="lab_cdtx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_cdtx_ReportableSegmentMember_label_en-US" xlink:label="lab_cdtx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_cdtx_ReportableSegmentMember_documentation_en-US" xlink:label="lab_cdtx_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ReportableSegmentMember" xlink:href="cdtx-20250331.xsd#cdtx_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ReportableSegmentMember" xlink:to="lab_cdtx_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7253b804-62bc-46e3-99e7-9d1f60ca1c30_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DISCONTINUED OPERATIONS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1040a618-03c1-4261-82fa-b0a8c5c75d89_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b16db1ad-a8ee-49a4-b39f-b068e6f7a54e_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_60866fab-32b7-49f0-b13c-4f1a71de21b9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_873b8417-a0ef-4f18-8b56-dc252612a521_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_8f18a5a7-624f-4aef-bb1b-ecc6c993f2a9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7538c829-cbdc-4ff0-b93c-7092ec9a4b18_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Revenue from Janssen Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_9d31c1ab-9950-43e0-8a72-07f224822b73_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_63497663-9214-4934-b3b0-dc72e565da9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_00fd72a0-94f4-499b-8c96-5d221a301a0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">RSUs canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_b2a0013a-8ce4-47c8-9117-1f1f56cbf34f_terseLabel_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_label_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_documentation_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:href="cdtx-20250331.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:to="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e4378fbe-fa35-43b2-adf6-b964b58f7c95_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2481af5a-b563-4550-8136-bd161ec46927_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_cea8985c-d76d-4a8b-b99a-c3256ee0b04c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingExpense" xlink:to="lab_us-gaap_OtherNonoperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_04990cb7-403d-4520-b7e5-427c44050140_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_da863d3e-4d27-40ea-8ee1-66e560e92a01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0a326470-7953-4ef7-80e1-34e92d0f0b0c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_cbdc4eef-2475-4578-a3d0-b5777627d341_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance payments and employee benefits</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e97b6833-a2b0-47f6-ba2d-1372602b8eb1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f3eaf4d5-708a-4e78-8539-169f8f1c4ce4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_01c6c93f-2056-4299-8c1a-427e348e7c0e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cdc51b68-b9d4-45bb-8857-b9b37f50fe57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7be6eaf7-236b-472c-a77c-bf1f6a64f088_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8411149e-0958-47a5-945b-6b289e25a84d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_41f975ba-573e-40cc-b30b-e48879807a13_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a06ff3a2-2c81-45e2-8917-77e5dd9f6228_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6055ae62-41d5-4a70-8856-376ab0ff3976_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6ca8c91e-0f9e-4ce8-ab7e-e7ba55c798b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_0f047467-a8ef-4649-8cb5-d103f0a02580_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_4a16f521-ceee-4ec9-a3fc-2ec10957a696_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, term of contract (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_036054e3-910f-4372-bfd7-7310a1667598_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5b548ac2-f421-49d1-b0f7-e50b8f4923b1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1899a8ef-0680-4dde-90e1-c0dbf72127c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per common share from continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e0ffffbf-941a-4e16-a639-5dcf0470eea2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_42414a02-38a7-49c1-bffb-bb91d27afc88_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_d72d9020-6fd4-4082-b8f4-e785bab0a9d8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_774584d7-5c39-49ef-abbb-6cfa2d3ae394_terseLabel_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mundipharma</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_label_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_documentation_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:href="cdtx-20250331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:to="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa98f47e-d651-4d5b-b6ef-7a8ed778f611_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_a9af21e2-1766-4fad-98a7-2ea31e727f18_terseLabel_en-US" xlink:label="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_27fa6df7-8ef4-41ab-9723-151b5abd795b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_44b538b1-dbcf-4911-be11-91da6faf20cf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c43a70a9-eaa8-4b2d-996c-bb035e5e450c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e9ea1ba-9191-48e1-a38f-f0307d1fbbac_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute basic net earnings (loss) per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_347e5a6e-f74b-45f3-bdac-26e443a00d92_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_492cafd9-9bc7-4016-86b7-80d1da20af19_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_36235a37-2105-48d8-862c-578ae1646b4b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_32961552-64b8-41aa-90f4-e751d21a7b4e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3d16c2a9-e3e4-4d92-9c0e-8949ed698538_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5479aab3-8ffe-4d15-ad29-863c1eebea05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_81e67466-2a9d-478e-8ac1-8bc63d6269fe_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cdtx-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:772584df-f722-4edc-81e3-b26e5bb232b0,g:477eac6b-6822-4ddf-a883-4a61404b9849-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/Cover" xlink:type="simple" xlink:href="cdtx-20250331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://cidara.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a8bc70c7-eac1-4013-b1b9-dc3b4e7a031c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_DocumentType_a8bc70c7-eac1-4013-b1b9-dc3b4e7a031c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0f613acb-b47c-4b51-97a3-3d8b5aaf102b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_DocumentQuarterlyReport_0f613acb-b47c-4b51-97a3-3d8b5aaf102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6fe9ead8-452e-4556-ae18-660eec7f48f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_DocumentPeriodEndDate_6fe9ead8-452e-4556-ae18-660eec7f48f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8708bfe5-f450-4ed5-bedc-870eee5e95ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_DocumentTransitionReport_8708bfe5-f450-4ed5-bedc-870eee5e95ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a19af1ad-6034-4e1b-be89-d51324cda891" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityFileNumber_a19af1ad-6034-4e1b-be89-d51324cda891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a514ac40-5e91-427a-90b6-491d87415cce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityRegistrantName_a514ac40-5e91-427a-90b6-491d87415cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_834b8bb9-ced2-436b-a7ff-1b5365f2a41a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityIncorporationStateCountryCode_834b8bb9-ced2-436b-a7ff-1b5365f2a41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c86ba84c-d424-4956-8e1e-0439cdb7acc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityTaxIdentificationNumber_c86ba84c-d424-4956-8e1e-0439cdb7acc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cc2bd60a-b9b5-43aa-88bb-a295829aa40e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityAddressAddressLine1_cc2bd60a-b9b5-43aa-88bb-a295829aa40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f6b8cc4a-3600-483f-8f7c-58c0e12ceb37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityAddressAddressLine2_f6b8cc4a-3600-483f-8f7c-58c0e12ceb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2f9ed939-e783-4a54-9d71-96c31fa520ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityAddressCityOrTown_2f9ed939-e783-4a54-9d71-96c31fa520ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_43da81a3-7a8e-4086-b928-81efb56444de" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityAddressStateOrProvince_43da81a3-7a8e-4086-b928-81efb56444de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5368b719-7c3a-4271-9605-b8d0f5e0638d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityAddressPostalZipCode_5368b719-7c3a-4271-9605-b8d0f5e0638d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bf9f2d91-8bca-4dd1-92d1-b363fa2e0f3d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_CityAreaCode_bf9f2d91-8bca-4dd1-92d1-b363fa2e0f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bf99fcb6-c33a-4da6-9a03-759de2138d19" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_LocalPhoneNumber_bf99fcb6-c33a-4da6-9a03-759de2138d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8bc8c42c-4d14-4ee3-82f5-0e66f995fa86" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_Security12bTitle_8bc8c42c-4d14-4ee3-82f5-0e66f995fa86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3772dfc6-5a0d-48f4-9798-704965eecd74" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_TradingSymbol_3772dfc6-5a0d-48f4-9798-704965eecd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8608e1df-5c2d-4d52-b6d1-44b8a687c682" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_SecurityExchangeName_8608e1df-5c2d-4d52-b6d1-44b8a687c682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_60dd9cf7-5d3d-4aca-a97e-434ec99d98a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityCurrentReportingStatus_60dd9cf7-5d3d-4aca-a97e-434ec99d98a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2dd95c6b-eb0a-4506-9f2a-5030d1ae329d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityInteractiveDataCurrent_2dd95c6b-eb0a-4506-9f2a-5030d1ae329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_736dc1c8-bc61-498e-97fb-10e421711f8d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityFilerCategory_736dc1c8-bc61-498e-97fb-10e421711f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_825461a5-fcc6-41fc-880f-4acf6e6b6cc7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntitySmallBusiness_825461a5-fcc6-41fc-880f-4acf6e6b6cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dabedf17-280a-417b-a6d6-59a3c335070b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityEmergingGrowthCompany_dabedf17-280a-417b-a6d6-59a3c335070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_f0cd525f-a9a7-413d-ab1d-3e858c9fa0fd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityShellCompany_f0cd525f-a9a7-413d-ab1d-3e858c9fa0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_d5490f61-1c06-4111-b766-2ff57896a00e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_d5490f61-1c06-4111-b766-2ff57896a00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_96a85cfd-7fac-4ded-a142-1ad6bf9efc7b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_AmendmentFlag_96a85cfd-7fac-4ded-a142-1ad6bf9efc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_00fdf652-121c-4cbf-a7ff-ea8fc162b998" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_DocumentFiscalYearFocus_00fdf652-121c-4cbf-a7ff-ea8fc162b998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_83e3671c-4035-4367-beb3-d3a66be7aa4d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_DocumentFiscalPeriodFocus_83e3671c-4035-4367-beb3-d3a66be7aa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9ed41502-655c-47b2-b05d-748a9dd0c55e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_EntityCentralIndexKey_9ed41502-655c-47b2-b05d-748a9dd0c55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_03cb348b-747d-47a1-9b50-942a8c614272" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48f41f03-06eb-4be3-a574-3c66453cb410" xlink:to="loc_dei_CurrentFiscalYearEndDate_03cb348b-747d-47a1-9b50-942a8c614272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_858fbbef-3c4a-46e6-87cc-1afd903e97d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_858fbbef-3c4a-46e6-87cc-1afd903e97d3" xlink:to="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3ce4b6f-6bbf-443f-b9cb-097a19fb268d" xlink:to="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_9d0db232-18c4-411e-aaea-d00290789579" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_9d0db232-18c4-411e-aaea-d00290789579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_4ff43a78-85dd-4634-be80-b95fabd1256f" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cfd2f272-8e4e-44aa-a0bc-2124d49784f3" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_4ff43a78-85dd-4634-be80-b95fabd1256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_715af259-63f0-45fd-90a6-89a618890896" xlink:to="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:to="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94adc73e-0bd3-4303-953a-bf332c800267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_94adc73e-0bd3-4303-953a-bf332c800267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f8d4a1b6-2043-4d8d-a602-fdb31990c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_RestrictedCashCurrent_f8d4a1b6-2043-4d8d-a602-fdb31990c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_25579388-cb6b-4872-ae04-dd69daa0e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_25579388-cb6b-4872-ae04-dd69daa0e91c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3827c181-2fe6-4e46-a5db-4886cb9e85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3827c181-2fe6-4e46-a5db-4886cb9e85a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_52e32295-0d41-48ec-a524-5a934e76a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_84a6f0a9-6330-45bc-af68-25a1ab7e9e5f" xlink:to="loc_us-gaap_AssetsCurrent_52e32295-0d41-48ec-a524-5a934e76a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7ad2615a-2bc4-4918-827a-b4a5d255d7da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7ad2615a-2bc4-4918-827a-b4a5d255d7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_769868d3-80b6-47eb-affe-b8d457d6f615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_769868d3-80b6-47eb-affe-b8d457d6f615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c39598e0-058f-414c-94a2-b3d71f428216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c39598e0-058f-414c-94a2-b3d71f428216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e3a44b4e-8bbf-4747-9547-e5550b60ad21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e3a44b4e-8bbf-4747-9547-e5550b60ad21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6725f854-4e84-4f9a-a252-126333b4faa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ebbf682a-6b60-4960-883f-9c45916dcef4" xlink:to="loc_us-gaap_Assets_6725f854-4e84-4f9a-a252-126333b4faa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1e69c0ca-3f99-487f-90a6-82fa82dd2f84" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1943b874-6ee0-45ca-980f-6a360ec8c14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_AccountsPayableCurrent_1943b874-6ee0-45ca-980f-6a360ec8c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0471f8d6-3eeb-4667-baf6-6793aa52a934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0471f8d6-3eeb-4667-baf6-6793aa52a934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f076a681-1317-4b02-971b-dac58ffec846" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f076a681-1317-4b02-971b-dac58ffec846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46517ea7-4931-4832-ab2b-9fb9532e520f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_46517ea7-4931-4832-ab2b-9fb9532e520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8f9d72f-9e8c-440b-b454-b28a650d4b41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a8f9d72f-9e8c-440b-b454-b28a650d4b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46d9c0c6-1b6f-4a10-93a6-7d382f8d9275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46d9c0c6-1b6f-4a10-93a6-7d382f8d9275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b628ae38-cb8d-44d5-82c9-682433afefa4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79e69251-261d-4476-8f94-04529a3d1dc1" xlink:to="loc_us-gaap_LiabilitiesCurrent_b628ae38-cb8d-44d5-82c9-682433afefa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0a3172ca-3924-4a20-8f55-f6fcc8d33316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0a3172ca-3924-4a20-8f55-f6fcc8d33316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d07eb9e-0fa6-4fcd-94d9-c2d4578601af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d07eb9e-0fa6-4fcd-94d9-c2d4578601af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_55e135ec-e2ef-4c62-84c0-aaa94788d972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_Liabilities_55e135ec-e2ef-4c62-84c0-aaa94788d972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3579dcb4-8067-474f-b0bf-d19f5c3b7fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3579dcb4-8067-474f-b0bf-d19f5c3b7fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cd0af794-4050-415b-858c-c22a541022f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_PreferredStockValue_cd0af794-4050-415b-858c-c22a541022f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8f7dbc0a-06b1-47bd-9be9-8d67129fd135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_CommonStockValue_8f7dbc0a-06b1-47bd-9be9-8d67129fd135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_260d0ee5-9c93-4771-8984-e7696c6dbe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_260d0ee5-9c93-4771-8984-e7696c6dbe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_739edf1a-e058-4cd5-93a3-69449807017e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_739edf1a-e058-4cd5-93a3-69449807017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1cdc7cc6-9698-462e-9438-0d2e64cee6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2d0c094a-6c40-4a04-af7e-c0c49b8ba86c" xlink:to="loc_us-gaap_StockholdersEquity_1cdc7cc6-9698-462e-9438-0d2e64cee6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e7a2b8-4e2f-40be-b453-929f35be5484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5c165d1f-76ee-47a3-a945-59dd4b9a276a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d5e7a2b8-4e2f-40be-b453-929f35be5484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9e71eb1a-31ae-491e-8a17-4669f0196b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9e71eb1a-31ae-491e-8a17-4669f0196b99" xlink:to="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:to="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163bf331-bcd3-4ee9-90c2-e2a991722da8" xlink:to="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8a82c79c-c7d6-4da2-b79c-f4f234ecdf4d" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8a82c79c-c7d6-4da2-b79c-f4f234ecdf4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_72785647-caad-4d0d-8940-6c92954edbdb" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a124627a-700f-4dc5-8b1e-1e725b81fcf9" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_72785647-caad-4d0d-8940-6c92954edbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_30ed629e-71fd-4c33-aad5-73a1d1143bbd" xlink:to="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9764fac4-2b75-43d6-98f4-eee55f0b4610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9764fac4-2b75-43d6-98f4-eee55f0b4610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9a0ea0b7-0289-4953-8e02-7e5220615962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9a0ea0b7-0289-4953-8e02-7e5220615962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreferredStockSharesIssuedIncludingConversion_8d61091b-3149-421d-9340-35ba14c2dc92" xlink:href="cdtx-20250331.xsd#cdtx_PreferredStockSharesIssuedIncludingConversion"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_cdtx_PreferredStockSharesIssuedIncludingConversion_8d61091b-3149-421d-9340-35ba14c2dc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4f96f6b6-1c59-4a5b-9928-f5c49cc62697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4f96f6b6-1c59-4a5b-9928-f5c49cc62697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3e4780e7-0735-4233-8f87-12923a577e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3e4780e7-0735-4233-8f87-12923a577e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1bef8539-02de-40ba-aa89-7f5c42cc40fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1bef8539-02de-40ba-aa89-7f5c42cc40fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fed35237-20d9-4c5e-bb4e-0ba83a169aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fed35237-20d9-4c5e-bb4e-0ba83a169aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8bb8ef9f-ce06-401e-ac79-43f6df6c933f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockSharesIssued_8bb8ef9f-ce06-401e-ac79-43f6df6c933f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_781bb26b-b708-47d4-bf10-9aa382c45924" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_33c16a65-2814-4640-9fad-7f4882cd1665" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_781bb26b-b708-47d4-bf10-9aa382c45924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9d5a81fa-ae02-4cc6-97a2-5e6d5f4d3517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_RevenuesAbstract_9d5a81fa-ae02-4cc6-97a2-5e6d5f4d3517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1681eaaf-6813-4512-b39c-7f2f647631ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9d5a81fa-ae02-4cc6-97a2-5e6d5f4d3517" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1681eaaf-6813-4512-b39c-7f2f647631ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8890c612-3ad2-4470-9381-db5e725194a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9d5a81fa-ae02-4cc6-97a2-5e6d5f4d3517" xlink:to="loc_us-gaap_Revenues_8890c612-3ad2-4470-9381-db5e725194a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c7b18339-7ae0-4974-9019-e61312137500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c7b18339-7ae0-4974-9019-e61312137500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a8fe6f87-b78c-4e9a-841e-ba30c53871d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c7b18339-7ae0-4974-9019-e61312137500" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a8fe6f87-b78c-4e9a-841e-ba30c53871d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d963ce0d-e8d2-45ab-83b0-bfc515d2c761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c7b18339-7ae0-4974-9019-e61312137500" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d963ce0d-e8d2-45ab-83b0-bfc515d2c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_94db5a9e-5875-4ede-9b11-9e7b579ef32c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c7b18339-7ae0-4974-9019-e61312137500" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_94db5a9e-5875-4ede-9b11-9e7b579ef32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_58d4eaf1-d638-4dd3-bee8-7e542f53b7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c7b18339-7ae0-4974-9019-e61312137500" xlink:to="loc_us-gaap_OperatingExpenses_58d4eaf1-d638-4dd3-bee8-7e542f53b7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9eaf01e2-8212-407b-a8e2-19c3c0a5a435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_OperatingIncomeLoss_9eaf01e2-8212-407b-a8e2-19c3c0a5a435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_47b02153-7ccd-4abc-9c76-8af67bf229ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_47b02153-7ccd-4abc-9c76-8af67bf229ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingExpense_3a5072b2-3d17-4762-8378-92a005d8845b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_47b02153-7ccd-4abc-9c76-8af67bf229ac" xlink:to="loc_us-gaap_OtherNonoperatingExpense_3a5072b2-3d17-4762-8378-92a005d8845b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_55251bfb-9c53-4452-9706-dbad5ed1ddfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_47b02153-7ccd-4abc-9c76-8af67bf229ac" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_55251bfb-9c53-4452-9706-dbad5ed1ddfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_55be1846-9858-4303-a81b-fac55874399f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_47b02153-7ccd-4abc-9c76-8af67bf229ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_55be1846-9858-4303-a81b-fac55874399f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7faecb30-5c21-4d48-96b8-f2b97e78535d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7faecb30-5c21-4d48-96b8-f2b97e78535d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e4906f7f-4c3b-4c5e-b378-91729a6ff7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_e4906f7f-4c3b-4c5e-b378-91729a6ff7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e861ff4-3bc2-4422-9224-345955263e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_NetIncomeLoss_4e861ff4-3bc2-4422-9224-345955263e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_951f2e06-a290-4bbb-9522-44a7fa56f1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_951f2e06-a290-4bbb-9522-44a7fa56f1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_49f8bf0f-980d-4c74-a3a0-72832ead1b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_49f8bf0f-980d-4c74-a3a0-72832ead1b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e6d51c25-6e6a-4d04-8f2a-21d0b2d76962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e6d51c25-6e6a-4d04-8f2a-21d0b2d76962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_13e8e005-39eb-44d7-8128-98772e6deb13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_13e8e005-39eb-44d7-8128-98772e6deb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_87831810-1225-43e3-8284-0c5212261f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_87831810-1225-43e3-8284-0c5212261f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_72e6589b-e65b-42c2-874e-044bf4d646d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_EarningsPerShareBasic_72e6589b-e65b-42c2-874e-044bf4d646d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4af0e4a4-0688-457d-a03d-a438e164336f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4af0e4a4-0688-457d-a03d-a438e164336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19e9520b-8250-4427-ab55-4aa076f8e0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19e9520b-8250-4427-ab55-4aa076f8e0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e866285-bf6e-4ebd-9dd4-48798455e52a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0d4147ae-424d-42b0-910a-eb912a87a161" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e866285-bf6e-4ebd-9dd4-48798455e52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_567661b1-b1e8-409b-bad3-f8dd16ec0f44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_567661b1-b1e8-409b-bad3-f8dd16ec0f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c4b1058f-930b-4ab6-8f25-b6d14546ac2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_567661b1-b1e8-409b-bad3-f8dd16ec0f44" xlink:to="loc_us-gaap_NetIncomeLoss_c4b1058f-930b-4ab6-8f25-b6d14546ac2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_567661b1-b1e8-409b-bad3-f8dd16ec0f44" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_890cf9a0-1fe3-452e-995c-c45cf1bf2bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_ShareBasedCompensation_890cf9a0-1fe3-452e-995c-c45cf1bf2bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_a8232009-53ef-4a65-969e-d183eb350fd0" xlink:href="cdtx-20250331.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_a8232009-53ef-4a65-969e-d183eb350fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e11df5f5-9218-49ee-8813-a62775ed6d18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_DepreciationAndAmortization_e11df5f5-9218-49ee-8813-a62775ed6d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c87b7a99-9c89-45d4-b0cf-3f008e4cec84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c87b7a99-9c89-45d4-b0cf-3f008e4cec84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_ca084537-77d1-4415-b0e3-d46d1e889978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_ca084537-77d1-4415-b0e3-d46d1e889978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LossOnAssignmentOfFinanceLease_dd3b00f2-5649-461a-97e7-9d84580df307" xlink:href="cdtx-20250331.xsd#cdtx_LossOnAssignmentOfFinanceLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_cdtx_LossOnAssignmentOfFinanceLease_dd3b00f2-5649-461a-97e7-9d84580df307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ed39b002-ee22-4cd0-bc12-3de6fd63a353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ed39b002-ee22-4cd0-bc12-3de6fd63a353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_cd29ae54-7644-4973-88b7-8abe114d4889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_PaidInKindInterest_cd29ae54-7644-4973-88b7-8abe114d4889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_efdf0049-3df7-4e70-9cef-5b3fa0481b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_efdf0049-3df7-4e70-9cef-5b3fa0481b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dad36753-0a99-406a-b368-e1415ca8f769" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8be82b61-6897-43a4-afe9-962ffdfe0f55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8be82b61-6897-43a4-afe9-962ffdfe0f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_91373adb-798d-4c5e-bb6f-2572c6e45c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_91373adb-798d-4c5e-bb6f-2572c6e45c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9c119ee5-8dae-486f-a4ee-42b327d3ed80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9c119ee5-8dae-486f-a4ee-42b327d3ed80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ddad1025-69cd-40e8-af62-dd66feb2c824" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ddad1025-69cd-40e8-af62-dd66feb2c824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_4614bb96-5e57-4115-b84d-6548e864dc73" xlink:href="cdtx-20250331.xsd#cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_4614bb96-5e57-4115-b84d-6548e864dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1ae42dee-dbc3-4a8d-be7d-01bf8d397e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1ae42dee-dbc3-4a8d-be7d-01bf8d397e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f275eb97-2975-4238-8185-12c1c2abc888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f275eb97-2975-4238-8185-12c1c2abc888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_55400244-9726-416e-82f6-2e6b53472192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80efc91e-5178-4b6d-bc1d-0224c1e5d17f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_55400244-9726-416e-82f6-2e6b53472192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6db1f68-af0b-453d-9979-9ff3852c424e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_567661b1-b1e8-409b-bad3-f8dd16ec0f44" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b6db1f68-af0b-453d-9979-9ff3852c424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97110faf-65a8-4b1b-9609-1dbef2fcbd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97110faf-65a8-4b1b-9609-1dbef2fcbd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20696fe2-6e2c-4eb8-ba82-05e8b4e9132d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97110faf-65a8-4b1b-9609-1dbef2fcbd2d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20696fe2-6e2c-4eb8-ba82-05e8b4e9132d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d209bf15-935a-4cda-bb32-7dfc257d9486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97110faf-65a8-4b1b-9609-1dbef2fcbd2d" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d209bf15-935a-4cda-bb32-7dfc257d9486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcd6ea61-82d7-41ad-855e-857e3b1ef503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97110faf-65a8-4b1b-9609-1dbef2fcbd2d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bcd6ea61-82d7-41ad-855e-857e3b1ef503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_03309e54-9d68-45f3-a3a3-fdccf0a23d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_03309e54-9d68-45f3-a3a3-fdccf0a23d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_df69a784-a055-43bc-b50b-49149de37bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_df69a784-a055-43bc-b50b-49149de37bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_174969a2-b317-4e4a-ad4f-ae4855919034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_174969a2-b317-4e4a-ad4f-ae4855919034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_86ec5a20-0dda-41b8-b17c-3bb0e2c09b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_86ec5a20-0dda-41b8-b17c-3bb0e2c09b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1aa3ada-8596-4ef6-9136-9a911f37d57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5e11e498-5b7f-4f78-b37a-6cba2a92761f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b1aa3ada-8596-4ef6-9136-9a911f37d57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_574e9919-1cc3-44ba-94e2-2d9d603eea94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_574e9919-1cc3-44ba-94e2-2d9d603eea94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed3b5fed-38f1-4742-b79c-cee653d21187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed3b5fed-38f1-4742-b79c-cee653d21187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67153a9b-0b2f-4e7d-bedb-b417000d84e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_67153a9b-0b2f-4e7d-bedb-b417000d84e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9a2a01f1-becf-482a-bf2c-f68a8b14355d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22fb5c88-69dd-4bdc-8b03-ef42d3d82446" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9a2a01f1-becf-482a-bf2c-f68a8b14355d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_29cb8596-b607-4038-82e7-6ba1b84df1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9a2a01f1-becf-482a-bf2c-f68a8b14355d" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_29cb8596-b607-4038-82e7-6ba1b84df1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_5027dc10-de11-4daa-a9ab-1398c2063e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_29cb8596-b607-4038-82e7-6ba1b84df1fa" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_5027dc10-de11-4daa-a9ab-1398c2063e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="simple" xlink:href="cdtx-20250331.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a601f626-d946-4349-9014-9743ad52c088" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a601f626-d946-4349-9014-9743ad52c088" xlink:to="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1b0086ed-2c14-47f4-9134-105390325504" xlink:to="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_089cd0f9-ca79-477a-8cbf-ed60240a4835" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_089cd0f9-ca79-477a-8cbf-ed60240a4835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_c0790c89-a2ed-44e9-a09f-db10d158837a" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7392167-d1fd-4090-a27f-aba42458d45b" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_c0790c89-a2ed-44e9-a09f-db10d158837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a596686d-0d90-42c3-8074-c89664b30b39" xlink:to="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_fe72071d-9c7e-442a-a98b-5f43e0251034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_PreferredStockMember_fe72071d-9c7e-442a-a98b-5f43e0251034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_caaba9a5-462a-4912-8a16-f35869c26d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_CommonStockMember_caaba9a5-462a-4912-8a16-f35869c26d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_49b2b958-c76b-49e9-b6e5-6943ec4c3772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_49b2b958-c76b-49e9-b6e5-6943ec4c3772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7cb1e3c7-e76b-464e-9824-725143968fed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6923eb30-4636-44a5-8183-99d848a9f837" xlink:to="loc_us-gaap_RetainedEarningsMember_7cb1e3c7-e76b-464e-9824-725143968fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0ed65459-37c1-4584-baf4-e847f3fabff1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d3ddb081-ffe2-46a6-8412-8f360dd78fb7" xlink:to="loc_us-gaap_StatementLineItems_0ed65459-37c1-4584-baf4-e847f3fabff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0ed65459-37c1-4584-baf4-e847f3fabff1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ba67ce6c-9c02-4da0-9328-31cc2ed7b653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ba67ce6c-9c02-4da0-9328-31cc2ed7b653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f27f45d7-1395-4650-aac7-c9d8a76a7464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockholdersEquity_f27f45d7-1395-4650-aac7-c9d8a76a7464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a5b3bc88-5ab6-4883-8122-15ecbf7b86c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a5b3bc88-5ab6-4883-8122-15ecbf7b86c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b435ebbd-8588-4e23-b136-d7593ef86d44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b435ebbd-8588-4e23-b136-d7593ef86d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_cc385158-46f7-44d1-ac2a-2ffa2889c53c" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_cc385158-46f7-44d1-ac2a-2ffa2889c53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74e8fe89-56cd-43f9-8c10-a2be7fbd425c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_74e8fe89-56cd-43f9-8c10-a2be7fbd425c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5395778e-b124-433b-958e-7ddf076a9651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5395778e-b124-433b-958e-7ddf076a9651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2cab22c4-77f8-428d-85b1-3a480c229919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_2cab22c4-77f8-428d-85b1-3a480c229919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b2715dcf-9741-4561-8e31-aceed59d2c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_b2715dcf-9741-4561-8e31-aceed59d2c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c4aa3f7c-4fcb-46e0-983b-ef47849d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_c4aa3f7c-4fcb-46e0-983b-ef47849d1871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a058d90-9f41-4896-8f9f-a74a189f292d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_NetIncomeLoss_7a058d90-9f41-4896-8f9f-a74a189f292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cae6a818-3bf9-4f43-a14f-09ec24e35b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cae6a818-3bf9-4f43-a14f-09ec24e35b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aac6e99a-39f0-4dc0-94a7-a0cd46f479e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_StockholdersEquity_aac6e99a-39f0-4dc0-94a7-a0cd46f479e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcc78fae-22dc-4292-b6d0-90f3194385e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_95080f18-3851-4894-8d01-cfc0245227dc" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bcc78fae-22dc-4292-b6d0-90f3194385e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a37795c2-43ba-4835-9f23-c2c90b8497be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6b459804-84f1-43f5-90fb-0464ce3c76b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a37795c2-43ba-4835-9f23-c2c90b8497be" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6b459804-84f1-43f5-90fb-0464ce3c76b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_28177688-8858-4d00-849b-8cca9c2a788d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e3b5dcb8-a570-422a-9f58-456bf3364da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28177688-8858-4d00-849b-8cca9c2a788d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e3b5dcb8-a570-422a-9f58-456bf3364da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cdtx-20250331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_95e304bd-2d5c-4ec9-befd-878d1d217f41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f37c19f6-f944-4c4c-a02e-a695e85492bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_95e304bd-2d5c-4ec9-befd-878d1d217f41" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f37c19f6-f944-4c4c-a02e-a695e85492bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cdtx-20250331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a3d3bf21-25b0-4ae3-a38e-cfab1c68b295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22c4aeb2-7615-4662-9a41-f78df79cbe3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a3d3bf21-25b0-4ae3-a38e-cfab1c68b295" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_22c4aeb2-7615-4662-9a41-f78df79cbe3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f87caa0d-16a3-4f88-9017-aeb6aad95974" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f3c1e261-14a2-4a17-80b2-ccf4c5f5adc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f87caa0d-16a3-4f88-9017-aeb6aad95974" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f3c1e261-14a2-4a17-80b2-ccf4c5f5adc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_452857b9-7873-4c32-a89e-d7a7e62124f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_537e0a73-07af-47c9-9c52-2ace4bb467c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_452857b9-7873-4c32-a89e-d7a7e62124f3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_537e0a73-07af-47c9-9c52-2ace4bb467c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c834d7ec-9c62-4211-8ce8-1198d6bbe806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_de504374-3aac-4974-af4e-761dd0b59c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c834d7ec-9c62-4211-8ce8-1198d6bbe806" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_de504374-3aac-4974-af4e-761dd0b59c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXES" xlink:type="simple" xlink:href="cdtx-20250331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_deeb84af-42ec-4414-a2e3-fd64b1ae3a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4fb0de3b-f6e2-4bf9-9372-0eb921d51e70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_deeb84af-42ec-4414-a2e3-fd64b1ae3a29" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4fb0de3b-f6e2-4bf9-9372-0eb921d51e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONS" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a5434683-1e64-4c97-adee-7f08681e1dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2f507dec-ba09-41a7-a0a3-ceb6096d061b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a5434683-1e64-4c97-adee-7f08681e1dde" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2f507dec-ba09-41a7-a0a3-ceb6096d061b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_73d579ed-84f3-4f77-96a2-2be67af0ecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5c8174c6-79cd-48df-a374-20bccd9f746b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_73d579ed-84f3-4f77-96a2-2be67af0ecd9" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5c8174c6-79cd-48df-a374-20bccd9f746b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fda78c0-24df-4ac0-aa17-6cb7280a2ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fda78c0-24df-4ac0-aa17-6cb7280a2ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComparabilityOfPriorYearFinancialData_1c8e3a21-0448-447f-b7f7-2e196ab2631c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComparabilityOfPriorYearFinancialData"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_ComparabilityOfPriorYearFinancialData_1c8e3a21-0448-447f-b7f7-2e196ab2631c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_cc4630d5-093f-4181-8156-f0a78b52af4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_cc4630d5-093f-4181-8156-f0a78b52af4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0c200b77-8c9f-4e98-a5f7-ead3d7b0d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_UseOfEstimates_0c200b77-8c9f-4e98-a5f7-ead3d7b0d71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_98627d01-0b58-452a-8da0-34f02f974d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_98627d01-0b58-452a-8da0-34f02f974d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_7fffcbfa-1a85-41f9-9268-530f197e937c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_7fffcbfa-1a85-41f9-9268-530f197e937c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1eecfabc-3bb4-4ed8-a5cc-f2100278b691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_1eecfabc-3bb4-4ed8-a5cc-f2100278b691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9929e429-32d7-48fb-a284-bc5c419f339b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9929e429-32d7-48fb-a284-bc5c419f339b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_57b2f1b9-3d47-4561-9d54-18722268aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_57b2f1b9-3d47-4561-9d54-18722268aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9f829b57-5de3-4bc2-972f-a3fea6a03b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9f829b57-5de3-4bc2-972f-a3fea6a03b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_4c58e0a2-c919-4d57-a406-17ab2c335864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_4c58e0a2-c919-4d57-a406-17ab2c335864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_eb7b5a3e-2c77-4186-9b2d-72f80d122666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_eb7b5a3e-2c77-4186-9b2d-72f80d122666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_2df6cfad-708b-47ca-868b-b588ed349031" xlink:href="cdtx-20250331.xsd#cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_2df6cfad-708b-47ca-868b-b588ed349031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ecfb3a72-dc32-42c6-83f3-fa88c2633977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_ecfb3a72-dc32-42c6-83f3-fa88c2633977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c2e68ede-d0e8-421f-9ae6-37276e3f5086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c2e68ede-d0e8-421f-9ae6-37276e3f5086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0438b8e5-61b2-4f14-9c63-e427552d5c53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_0438b8e5-61b2-4f14-9c63-e427552d5c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_3bfeea49-e051-4ab9-b1de-48585cf7b0ba" xlink:href="cdtx-20250331.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_3bfeea49-e051-4ab9-b1de-48585cf7b0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_36cd8e53-3e6d-4f1c-b943-52790a43d57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_36cd8e53-3e6d-4f1c-b943-52790a43d57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_fb3fde13-67ac-414a-b7b9-fd24a19ab10b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_fb3fde13-67ac-414a-b7b9-fd24a19ab10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7d3581e9-fad9-4edd-964d-410958d40f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7d3581e9-fad9-4edd-964d-410958d40f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_94bb9c3a-93a8-4e70-998f-34d4575db290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_783b3a8d-98f7-4e64-83f0-40c0c3e52c7e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_94bb9c3a-93a8-4e70-998f-34d4575db290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATIONTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe629870-d110-47c8-80d8-e4ab848ee471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c4cfc0bc-c0b6-458a-a594-3a5521e05554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fe629870-d110-47c8-80d8-e4ab848ee471" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c4cfc0bc-c0b6-458a-a594-3a5521e05554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_256d73a6-4795-4cdd-9686-8d157a88bc71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_77a65944-5c7b-46d0-9e31-36fe100b4cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_256d73a6-4795-4cdd-9686-8d157a88bc71" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_77a65944-5c7b-46d0-9e31-36fe100b4cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_04601e5a-7b0d-49df-82ce-3fbb5de5ed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_256d73a6-4795-4cdd-9686-8d157a88bc71" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_04601e5a-7b0d-49df-82ce-3fbb5de5ed1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c433f2f1-d235-4a84-8f1f-c159c9360ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_256d73a6-4795-4cdd-9686-8d157a88bc71" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c433f2f1-d235-4a84-8f1f-c159c9360ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ce50848c-d662-435b-b66a-842872519769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3087e0ec-0af8-4d10-96c4-6d5e636dace2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ce50848c-d662-435b-b66a-842872519769" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3087e0ec-0af8-4d10-96c4-6d5e636dace2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0c9c53b4-d9a5-4639-99d8-d248f5b56343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_b795e82c-1624-4bf5-811a-74cddff4ea67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9c53b4-d9a5-4639-99d8-d248f5b56343" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_b795e82c-1624-4bf5-811a-74cddff4ea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f195635-338e-4021-81d4-5cdb79391eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_eed52713-3df5-4b5b-900b-84fd57e82380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f195635-338e-4021-81d4-5cdb79391eb9" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_eed52713-3df5-4b5b-900b-84fd57e82380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_644633a3-df57-4c45-8291-d60354d3c879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f195635-338e-4021-81d4-5cdb79391eb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_644633a3-df57-4c45-8291-d60354d3c879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_daab9041-a918-48e9-b267-10bf152f37d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f195635-338e-4021-81d4-5cdb79391eb9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_daab9041-a918-48e9-b267-10bf152f37d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ec5932a7-3a28-4802-8cb9-d97f5a40fde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_9a650010-3661-4f28-92fa-ad034c533853" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ec5932a7-3a28-4802-8cb9-d97f5a40fde3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_9a650010-3661-4f28-92fa-ad034c533853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec1eedf6-4d54-459d-8ab1-4cce91d9f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_967f63c1-4e58-4939-8739-db3bc2bab8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec1eedf6-4d54-459d-8ab1-4cce91d9f5c8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_967f63c1-4e58-4939-8739-db3bc2bab8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_2dd416ea-3cdf-4a07-9c4c-e6d37b8f809c" xlink:href="cdtx-20250331.xsd#cdtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec1eedf6-4d54-459d-8ab1-4cce91d9f5c8" xlink:to="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_2dd416ea-3cdf-4a07-9c4c-e6d37b8f809c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSTables" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_01f83d46-9704-481f-a8a2-b736167a3595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1faaabe9-49d2-4226-a564-6eb6fa134739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_01f83d46-9704-481f-a8a2-b736167a3595" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1faaabe9-49d2-4226-a564-6eb6fa134739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7f9c6f4e-384e-4e55-994a-e421918869e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_01f83d46-9704-481f-a8a2-b736167a3595" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7f9c6f4e-384e-4e55-994a-e421918869e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4070d491-2cf8-4464-824d-4c763fc33ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c2a15c9e-7471-48f4-aa7e-fa6f9402c1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4070d491-2cf8-4464-824d-4c763fc33ab5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c2a15c9e-7471-48f4-aa7e-fa6f9402c1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc5774ad-dfc2-4383-9748-a51dbe5d572f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4070d491-2cf8-4464-824d-4c763fc33ab5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc5774ad-dfc2-4383-9748-a51dbe5d572f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82864b53-f115-4877-8df0-2611fb0a50c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4070d491-2cf8-4464-824d-4c763fc33ab5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82864b53-f115-4877-8df0-2611fb0a50c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4070d491-2cf8-4464-824d-4c763fc33ab5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ae172946-e6a1-49c5-b3d4-c8e41c5993f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_4d63bce1-4f4e-4ebf-bca6-53836927e075" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ae172946-e6a1-49c5-b3d4-c8e41c5993f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e8150d1d-779b-409c-bd49-7627ae449b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ae172946-e6a1-49c5-b3d4-c8e41c5993f0" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e8150d1d-779b-409c-bd49-7627ae449b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f2a0826-97bb-45d9-bf69-b98e90008f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f3dc202e-9f31-4682-a9fe-03fefc4459f3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f2a0826-97bb-45d9-bf69-b98e90008f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_9777fbb6-b8c3-42b8-8602-9020ab1e0ca1" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5f2a0826-97bb-45d9-bf69-b98e90008f0f" xlink:to="loc_cdtx_RezafunginMember_9777fbb6-b8c3-42b8-8602-9020ab1e0ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3dd78316-ade8-4e16-bb0c-c9bb6a6993d8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1122229a-d2e3-45bb-b1be-745695d7ec48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1122229a-d2e3-45bb-b1be-745695d7ec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e33ba6f6-8205-423d-8337-c4d86faf380c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_e33ba6f6-8205-423d-8337-c4d86faf380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb9c1896-329e-4753-ba94-83d26db8fb21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fb9c1896-329e-4753-ba94-83d26db8fb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f895162e-55ba-4b3e-be1e-52c0d8d50c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f895162e-55ba-4b3e-be1e-52c0d8d50c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_99f49b32-b7ac-4fae-9bef-bb7828f5ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_99f49b32-b7ac-4fae-9bef-bb7828f5ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5c6b0e56-a0c1-4b5d-ab9a-077882eef850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_5c6b0e56-a0c1-4b5d-ab9a-077882eef850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_5d978b11-ea39-4967-a2bc-132861727784" xlink:href="cdtx-20250331.xsd#cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4e9a7b38-8204-44fa-bd5e-8cae839dd627" xlink:to="loc_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities_5d978b11-ea39-4967-a2bc-132861727784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_163e9b2e-1b32-48be-88c1-a9d710a83915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_163e9b2e-1b32-48be-88c1-a9d710a83915" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5669c109-b3dd-4196-87cc-fc33ced8d370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0b64cd28-76bd-40ef-9174-8e879721ec7b" xlink:to="loc_us-gaap_SegmentDomain_5669c109-b3dd-4196-87cc-fc33ced8d370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ReportableSegmentMember_75ace0cc-98d3-431f-a959-89025ffad36e" xlink:href="cdtx-20250331.xsd#cdtx_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5669c109-b3dd-4196-87cc-fc33ced8d370" xlink:to="loc_cdtx_ReportableSegmentMember_75ace0cc-98d3-431f-a959-89025ffad36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8d6f7d84-816e-4baf-9359-11f080d4a69e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e6c2a11d-115a-43e0-a56d-d4c371371b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_Revenues_e6c2a11d-115a-43e0-a56d-d4c371371b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9e373809-4db0-44c1-8aa4-5a3afa99c046" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9e373809-4db0-44c1-8aa4-5a3afa99c046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_240989f4-45c0-488d-b987-a98622ebcfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_LaborAndRelatedExpense_240989f4-45c0-488d-b987-a98622ebcfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_14007f12-542b-4f1e-a537-238a3a8ab2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_14007f12-542b-4f1e-a537-238a3a8ab2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_b6c9f679-6bd4-4ddd-8e41-acca057a1878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_b6c9f679-6bd4-4ddd-8e41-acca057a1878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c435a233-1841-4767-a29b-0aa6753ae58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_eddfa365-6ba7-4008-94c1-8c92e0027607" xlink:to="loc_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_c435a233-1841-4767-a29b-0aa6753ae58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:href="cdtx-20250331.xsd#cdtx_OtherSegmentItemsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4d31a944-51fa-4ac9-a0c3-5b52a8a861b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4d31a944-51fa-4ac9-a0c3-5b52a8a861b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_83354217-e120-4dca-a865-c256d3ae0879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_OtherSegmentItemsAbstract_c8edeb69-04ad-4511-b2e3-27e306d58678" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_83354217-e120-4dca-a865-c256d3ae0879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_246a1bbf-80c0-41fd-b4ac-da3c868a3cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_NetIncomeLoss_246a1bbf-80c0-41fd-b4ac-da3c868a3cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_86eabd7f-91ea-46e9-8def-617a3ff79795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_95da4a81-5858-4939-95f6-9fd046541727" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_86eabd7f-91ea-46e9-8def-617a3ff79795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a8e3b404-05a6-41ad-9e2b-d6182e5ba7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77840a5c-56c5-44be-aac5-69db99f0cd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8e3b404-05a6-41ad-9e2b-d6182e5ba7a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_77840a5c-56c5-44be-aac5-69db99f0cd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_8e05991a-ce7b-4e8e-97e0-cbfd5504f72a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8e3b404-05a6-41ad-9e2b-d6182e5ba7a3" xlink:to="loc_us-gaap_RestrictedCashCurrent_8e05991a-ce7b-4e8e-97e0-cbfd5504f72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ad104b2-79f8-4ea7-b672-3cebda1e4f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8e3b404-05a6-41ad-9e2b-d6182e5ba7a3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ad104b2-79f8-4ea7-b672-3cebda1e4f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b4c4137e-25c1-4031-b76d-21a205aaa55e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b4c4137e-25c1-4031-b76d-21a205aaa55e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a5001e2a-ae4f-40ba-a9f0-a48e95df1fcf" xlink:to="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7768b4e-04b4-4def-a7e0-5d132a273041" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:to="loc_srt_MinimumMember_e7768b4e-04b4-4def-a7e0-5d132a273041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2498761e-4fdc-4868-8fc1-f0e59012bf89" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b1e83875-1225-43e0-ad1f-4ec628dc739b" xlink:to="loc_srt_MaximumMember_2498761e-4fdc-4868-8fc1-f0e59012bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7587a0b8-9e69-4786-b775-9bdf2adeb79b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3939d34f-3c28-458b-b8bf-1eeb2c03010e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7587a0b8-9e69-4786-b775-9bdf2adeb79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember_1b4df015-79a2-428f-adff-6d738c2eb003" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7587a0b8-9e69-4786-b775-9bdf2adeb79b" xlink:to="loc_cdtx_PrefundedWarrantsMember_1b4df015-79a2-428f-adff-6d738c2eb003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1c0f32a-ce33-4b1a-b637-1f8ea6cfbea3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_170c6484-b5f3-4ad9-9a9f-ae0c4a02aa18" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1c0f32a-ce33-4b1a-b637-1f8ea6cfbea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_369cfbb1-2ef1-4c72-a13e-c008d319b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1c0f32a-ce33-4b1a-b637-1f8ea6cfbea3" xlink:to="loc_us-gaap_PrivatePlacementMember_369cfbb1-2ef1-4c72-a13e-c008d319b88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b8f821dd-306f-481d-9aba-75d9d0739dbf" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_35c995f3-8b00-4891-b659-dd9801a0baf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_35c995f3-8b00-4891-b659-dd9801a0baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_08d743d5-b898-4c2c-8ab4-a9c8375814fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_08d743d5-b898-4c2c-8ab4-a9c8375814fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71b8657a-0df9-4fa6-b522-7fcee1557ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_71b8657a-0df9-4fa6-b522-7fcee1557ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_55b32e0b-87e1-4944-8d08-2df4e099d18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_55b32e0b-87e1-4944-8d08-2df4e099d18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4dc63441-b200-459b-b7c5-d563e25a624d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4dc63441-b200-459b-b7c5-d563e25a624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20863793-be5d-4a78-a016-8823806a02c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_1de86ac6-6eb6-4442-8c63-3e4619d4a168" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20863793-be5d-4a78-a016-8823806a02c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00f8035d-63ba-4d3d-bc45-c364f1279ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00f8035d-63ba-4d3d-bc45-c364f1279ef5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_547b7cdb-a399-425a-80fd-62b8252ba869" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5f9ec1aa-b9c8-4d63-b405-da7c651e5b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:to="loc_us-gaap_WarrantMember_5f9ec1aa-b9c8-4d63-b405-da7c651e5b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_d96b17fa-c9e9-41f5-9005-b64c8559f689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_d96b17fa-c9e9-41f5-9005-b64c8559f689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_3b75fd03-8873-45cf-9dd7-861ae43c474c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7efe40ed-2f69-4d93-adf8-65db233cfdde" xlink:to="loc_us-gaap_StockCompensationPlanMember_3b75fd03-8873-45cf-9dd7-861ae43c474c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:to="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_710b736d-d858-4b54-b5d8-e8e56f6924bb" xlink:to="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_0c254909-acb8-4d1a-b833-c7940db32576" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_0c254909-acb8-4d1a-b833-c7940db32576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_72000222-6bd1-4431-a9b0-64041512f054" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f3ba9d9f-d630-47f3-9053-16647829d90a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_72000222-6bd1-4431-a9b0-64041512f054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2eb4e7a6-458b-48f6-81e6-e88648312c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76d9d2fd-439a-4d63-92cc-3482b8ee4b67" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2eb4e7a6-458b-48f6-81e6-e88648312c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e453906a-bb04-48c9-a931-6679740c71fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2eb4e7a6-458b-48f6-81e6-e88648312c1e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e453906a-bb04-48c9-a931-6679740c71fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e22ae1f5-b7e7-40e5-b373-1bba666ca1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e22ae1f5-b7e7-40e5-b373-1bba666ca1fb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd1c7dda-7b76-4860-9344-caeeba2e06cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_13c5cb6a-8f65-49e3-8e07-578deb3af495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_13c5cb6a-8f65-49e3-8e07-578deb3af495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ccccbc88-7ec3-440a-b6c9-0226e2983309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ccccbc88-7ec3-440a-b6c9-0226e2983309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9305dc00-ab49-4c3b-b4a7-9d4d671c3027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_91d698a9-5574-4e19-a6a9-96fa745cda46" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9305dc00-ab49-4c3b-b4a7-9d4d671c3027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e542a55-3020-4790-bc23-0644d090852b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58187684-47e1-453a-8e99-68b461e4ad29" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e542a55-3020-4790-bc23-0644d090852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e542a55-3020-4790-bc23-0644d090852b" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ebd054a0-42cc-4207-919a-fe767db14cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ebd054a0-42cc-4207-919a-fe767db14cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d24dc3ac-d2cd-4c78-9ed7-3658744a79c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:to="loc_us-gaap_RestrictedCash_d24dc3ac-d2cd-4c78-9ed7-3658744a79c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f2fe2312-5d33-44c1-84f8-b340c68e8260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_80605946-7b89-4bd7-ad1e-771a695ff5ed" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f2fe2312-5d33-44c1-84f8-b340c68e8260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e107e96e-656c-4b99-b904-2a62c86529b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e107e96e-656c-4b99-b904-2a62c86529b8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0825b5b-aa7e-4b8c-9f82-2a42ff1f2dc5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d5997da2-a6b2-42bb-ba4f-c4099b2e0057" xlink:href="cdtx-20250331.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_d5997da2-a6b2-42bb-ba4f-c4099b2e0057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_b49618e9-e083-4a32-aeec-326d5494d8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e75277cd-a3f7-497d-86b8-8d63fe12763a" xlink:to="loc_us-gaap_PrivatePlacementMember_b49618e9-e083-4a32-aeec-326d5494d8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_05a6eab6-69b0-43f4-9be4-3ab4d4f43888" xlink:to="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8e44e4d0-4826-4aac-88db-8c1197d99e19" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertibleVotingPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_cdtx_SeriesAConvertibleVotingPreferredStockMember_8e44e4d0-4826-4aac-88db-8c1197d99e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertiblePreferredStockMember_c75a9b9d-dc24-487b-a6c3-6a940ac7e815" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_cdtx_SeriesAConvertiblePreferredStockMember_c75a9b9d-dc24-487b-a6c3-6a940ac7e815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_f9a6a26a-fa11-4362-975c-cf9455a62d83" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_f9a6a26a-fa11-4362-975c-cf9455a62d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c651565c-eab2-418e-b29d-85af4db5cdff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_79716970-382b-4b72-b348-bb5a7f1fc389" xlink:to="loc_us-gaap_CommonStockMember_c651565c-eab2-418e-b29d-85af4db5cdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_4c5d2922-a2bd-40f4-8674-401b388451ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember_bf643559-1fa9-4ef3-8931-d16aed942aaf" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:to="loc_cdtx_PrefundedWarrantsMember_bf643559-1fa9-4ef3-8931-d16aed942aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_25033174-9cf8-493b-acbf-a085f3130747" xlink:href="cdtx-20250331.xsd#cdtx_CommonStockWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1764be1d-d050-4ae8-ae2e-a93a87731590" xlink:to="loc_cdtx_CommonStockWarrantMember_25033174-9cf8-493b-acbf-a085f3130747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cec1f672-9f6e-4f0f-9363-0af0085e8037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b5acb031-4671-49b1-82df-a03b8e766f39" xlink:to="loc_us-gaap_EquityComponentDomain_cec1f672-9f6e-4f0f-9363-0af0085e8037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3697c0bd-0392-41b3-a048-b91c469ac05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cec1f672-9f6e-4f0f-9363-0af0085e8037" xlink:to="loc_us-gaap_CommonStockMember_3697c0bd-0392-41b3-a048-b91c469ac05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd190bad-b865-4647-bae3-a7832639723e" xlink:to="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0ea316dd-76a9-4c90-99fd-305dda9b6b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0ea316dd-76a9-4c90-99fd-305dda9b6b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_885fb656-1b80-423a-8d91-6eb64cbc2bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_885fb656-1b80-423a-8d91-6eb64cbc2bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_ae950161-da9e-4efb-99b9-2b789284f63d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_ae950161-da9e-4efb-99b9-2b789284f63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3a207d4b-1be5-4b3e-aa20-8760c4823eed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3a207d4b-1be5-4b3e-aa20-8760c4823eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_68248169-0d90-4d3e-8972-55d5945fe8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_68248169-0d90-4d3e-8972-55d5945fe8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea7fb9cf-c825-4065-919b-1ecb72ceaa55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ea7fb9cf-c825-4065-919b-1ecb72ceaa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2e04a48f-9fbf-48dc-b68f-b98aaa295188" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2e04a48f-9fbf-48dc-b68f-b98aaa295188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9dafaead-1642-451b-aab7-f45efd4c2e61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9dafaead-1642-451b-aab7-f45efd4c2e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_7626da55-eb9e-4dc0-8055-9d2d16182a58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_7626da55-eb9e-4dc0-8055-9d2d16182a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_621e9f65-1212-4d4c-a2e3-9d2324aa7003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_621e9f65-1212-4d4c-a2e3-9d2324aa7003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_e9596020-277a-4ff1-9e7d-edb79d7590b8" xlink:href="cdtx-20250331.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_e9596020-277a-4ff1-9e7d-edb79d7590b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d7875461-3467-4292-9463-c81c4622f139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d7875461-3467-4292-9463-c81c4622f139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_deb0ae85-fc67-4b9c-bc4b-71f14c2c6095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_deb0ae85-fc67-4b9c-bc4b-71f14c2c6095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5ed888e-a291-44d7-b556-95766465bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5ed888e-a291-44d7-b556-95766465bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_5e4e30b4-5ff8-4bd0-8cf9-c01e68957bc1" xlink:href="cdtx-20250331.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_5e4e30b4-5ff8-4bd0-8cf9-c01e68957bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9d12affd-d474-43f0-bfd7-7196735ae091" xlink:href="cdtx-20250331.xsd#cdtx_CommonStockDividendsInArrearsOrDefault"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9d12affd-d474-43f0-bfd7-7196735ae091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7f8c834d-b4e9-448a-a718-b952b0f13362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7f8c834d-b4e9-448a-a718-b952b0f13362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_6a0ea0c2-0be2-4469-9f95-066b0d177527" xlink:href="cdtx-20250331.xsd#cdtx_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_6a0ea0c2-0be2-4469-9f95-066b0d177527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_bc425807-8db3-465f-949e-1babe280aa42" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_bc425807-8db3-465f-949e-1babe280aa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_582a05df-172a-4683-aa8c-96f2aa7b9f79" xlink:href="cdtx-20250331.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a3b8e5d8-b06f-4864-b74d-da69f34484a4" xlink:to="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_582a05df-172a-4683-aa8c-96f2aa7b9f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9681c140-f665-43ec-9ffd-cb258b129119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9681c140-f665-43ec-9ffd-cb258b129119" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:to="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_71e165c3-93a7-4ea4-92f5-18d4d189aa03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_08d6c296-ec75-4aaf-bd98-a9398a6f023a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_us-gaap_WarrantMember_08d6c296-ec75-4aaf-bd98-a9398a6f023a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesAConvertiblePreferredStockMember_346653d8-2742-4151-a1c0-2c530a02230f" xlink:href="cdtx-20250331.xsd#cdtx_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_cdtx_SeriesAConvertiblePreferredStockMember_346653d8-2742-4151-a1c0-2c530a02230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_b8b1aa4e-8ab0-4027-916a-15e03a37af01" xlink:href="cdtx-20250331.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_b8b1aa4e-8ab0-4027-916a-15e03a37af01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_bfd681b6-54e0-48af-8412-b11307c551e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_us-gaap_StockCompensationPlanMember_bfd681b6-54e0-48af-8412-b11307c551e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_79ba9b96-9742-4d68-9a9e-dc0c3be130f2" xlink:href="cdtx-20250331.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_79ba9b96-9742-4d68-9a9e-dc0c3be130f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_f45eec8a-6841-46f6-890f-89dbe313162c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90a15482-76fc-409e-aaba-2b61d5ef7459" xlink:to="loc_us-gaap_EmployeeStockMember_f45eec8a-6841-46f6-890f-89dbe313162c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_91859a00-7e0f-4406-8e04-1912f5681664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a68326cd-e5ff-40f5-ad50-5296e6fe11dd" xlink:to="loc_us-gaap_ClassOfStockLineItems_91859a00-7e0f-4406-8e04-1912f5681664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401bb4ac-41a1-4502-8b53-53538d24c176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91859a00-7e0f-4406-8e04-1912f5681664" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_401bb4ac-41a1-4502-8b53-53538d24c176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a7d9b73-ebcb-4ecc-8957-eb8578fb5eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6a7d9b73-ebcb-4ecc-8957-eb8578fb5eea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f501b054-9432-460c-9cd9-b85e957fa1a4" xlink:to="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b7fb6806-5317-490e-b2db-f7dd5839475f" xlink:href="cdtx-20250331.xsd#cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:to="loc_cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b7fb6806-5317-490e-b2db-f7dd5839475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_511f7d8e-0262-4f03-ae8b-4545547da26d" xlink:href="cdtx-20250331.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0fb26792-b2a0-4c1c-8706-d434056b8588" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_511f7d8e-0262-4f03-ae8b-4545547da26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d254b2d3-5faf-48cc-9d16-66b0ca433ceb" xlink:to="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d0d8463d-0938-4dcf-8d43-c2422ef91bf8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:to="loc_srt_MinimumMember_d0d8463d-0938-4dcf-8d43-c2422ef91bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6062d777-2662-49a4-ac90-dc2b051fcbeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85c83291-e511-42d4-ab1d-5078f76e5b2e" xlink:to="loc_srt_MaximumMember_6062d777-2662-49a4-ac90-dc2b051fcbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_4fa7e23a-c57f-4944-b7f2-185c8e06b90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_929e7424-2015-4ab3-82d9-e88acb592e9a" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_4fa7e23a-c57f-4944-b7f2-185c8e06b90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_fc3b6d32-e47f-44db-907b-7bc4b0bc7d82" xlink:href="cdtx-20250331.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_4fa7e23a-c57f-4944-b7f2-185c8e06b90c" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_fc3b6d32-e47f-44db-907b-7bc4b0bc7d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_95a8b348-0959-4f42-93aa-1105083075af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_6910e79e-4f29-4110-af93-be6329259486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:to="loc_us-gaap_EmployeeStockMember_6910e79e-4f29-4110-af93-be6329259486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9f65b7eb-85cb-41b5-9d82-be38dceb761a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9f65b7eb-85cb-41b5-9d82-be38dceb761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_92f708fd-b346-4436-a706-1ec8771c7979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e6c59b1-fb49-40e4-83b4-18006a286fe9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_92f708fd-b346-4436-a706-1ec8771c7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5a1c46c8-ce73-4727-a529-cb19a42b8609" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54b8f10d-90ee-4a7e-b0a7-03a58db5c628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54b8f10d-90ee-4a7e-b0a7-03a58db5c628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51ee76ec-2a54-4f85-8bb8-1b3e433e59e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_51ee76ec-2a54-4f85-8bb8-1b3e433e59e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3d0d5f9-bff6-473b-b132-81cc6537abf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c3d0d5f9-bff6-473b-b132-81cc6537abf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd02f103-7eee-4b92-bcc7-0efd22f10157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dd02f103-7eee-4b92-bcc7-0efd22f10157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_76d7c4cf-3f38-44f3-ad06-e0193d2d8ecf" xlink:href="cdtx-20250331.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_76d7c4cf-3f38-44f3-ad06-e0193d2d8ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b63ca5a5-b397-4aac-a4e4-a72fe12ccfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_b63ca5a5-b397-4aac-a4e4-a72fe12ccfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddaa4fca-bc58-4f81-b4a3-0fa07d986b55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ddaa4fca-bc58-4f81-b4a3-0fa07d986b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97cd72dd-05e9-4cf0-906e-dc278316bcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97cd72dd-05e9-4cf0-906e-dc278316bcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7dddf236-51a4-4f6f-8237-1f6b213f744b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7dddf236-51a4-4f6f-8237-1f6b213f744b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5e52915d-9059-4b10-be63-9fc9644d6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5e52915d-9059-4b10-be63-9fc9644d6c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45bfa970-ed76-4288-a7f4-25f9354592bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_45bfa970-ed76-4288-a7f4-25f9354592bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5bed606-0de5-4449-8e5b-98e0fd7bd129" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d5bed606-0de5-4449-8e5b-98e0fd7bd129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ca6d95cf-e7c2-4195-97b7-6be639c81d71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c928fd2f-3f9c-40ef-8eaf-ff0661ecbd95" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ca6d95cf-e7c2-4195-97b7-6be639c81d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fd3f0c7-cb06-4208-bcf1-3692bdf58da9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fd3f0c7-cb06-4208-bcf1-3692bdf58da9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:to="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d0162c-15fd-4e1b-8ebd-80885a3e3035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5063adc1-12e2-4579-82b4-425dc9e90527" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d0162c-15fd-4e1b-8ebd-80885a3e3035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ac99ea44-6a1a-45f1-89ce-de0777152f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87d0162c-15fd-4e1b-8ebd-80885a3e3035" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ac99ea44-6a1a-45f1-89ce-de0777152f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e39ada4-023d-4e4a-a440-547f941d9297" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06d5aa4c-6b02-44f4-bd77-c02288f0330f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06d5aa4c-6b02-44f4-bd77-c02288f0330f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_109149cd-cd3c-4560-b1bd-c0c06abc6432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_109149cd-cd3c-4560-b1bd-c0c06abc6432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a66dedb0-101f-43fa-b623-9ef6d774b715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a66dedb0-101f-43fa-b623-9ef6d774b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_808c652b-9ff3-459f-ad67-a28d55603560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_808c652b-9ff3-459f-ad67-a28d55603560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c5b030fe-047b-4700-81c7-50abb683b611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4d2b665f-d696-49c0-af76-ae0548745aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c5b030fe-047b-4700-81c7-50abb683b611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5b992f06-8fb5-4b56-8058-1c797bb82df2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6071d37a-c733-4c88-90bc-ca79933150ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6071d37a-c733-4c88-90bc-ca79933150ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dedf5cf8-94c3-4291-a6e3-3efa770c5e03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dedf5cf8-94c3-4291-a6e3-3efa770c5e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8cbd3788-7694-49ce-8817-a7fc9efb1bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8cbd3788-7694-49ce-8817-a7fc9efb1bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8bbc0779-e8a3-44d0-8e2c-8949e807d490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8bbc0779-e8a3-44d0-8e2c-8949e807d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_17005a68-5b73-4345-92b3-391e393157fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8f8cb40e-759c-4aea-be19-851c12d25118" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_17005a68-5b73-4345-92b3-391e393157fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0389872f-a315-4d6b-b8b1-2c3f8939b9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0389872f-a315-4d6b-b8b1-2c3f8939b9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f0db1b6d-1f40-49ee-807a-079ae2f6d7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f0db1b6d-1f40-49ee-807a-079ae2f6d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f494ff6d-2864-4a58-aef5-e6140518be48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f494ff6d-2864-4a58-aef5-e6140518be48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57fe720c-d393-4d31-93e8-0e87fc71a4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_57fe720c-d393-4d31-93e8-0e87fc71a4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21258736-6c5a-4d2f-834a-9d148a2996d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_088ff382-6843-447a-baa5-193b2cc7d8e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_21258736-6c5a-4d2f-834a-9d148a2996d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_62032a0d-49b3-4fc4-b5a4-5439e5a682a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_62032a0d-49b3-4fc4-b5a4-5439e5a682a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62876100-382c-46bd-b174-31ceb4893691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62876100-382c-46bd-b174-31ceb4893691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_491fa27d-b82d-4a33-b42f-6ebac659d31f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_491fa27d-b82d-4a33-b42f-6ebac659d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7dbb706a-257b-45f2-b1ae-a2a38cb40808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7dbb706a-257b-45f2-b1ae-a2a38cb40808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54b99414-537f-4b16-b871-c57d75512837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54b99414-537f-4b16-b871-c57d75512837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1e466522-b28e-4491-90a1-c2009320651e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1e466522-b28e-4491-90a1-c2009320651e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_af32a5cd-2741-4ad8-a5b7-80434b1a80a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_594872c6-1edd-4008-b8d9-b03133a2cdf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_af32a5cd-2741-4ad8-a5b7-80434b1a80a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1238310d-b958-4e27-befd-321ae3cb3870" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1238310d-b958-4e27-befd-321ae3cb3870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f010a66e-cf0f-45fd-bb9c-43d879df44fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f010a66e-cf0f-45fd-bb9c-43d879df44fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68815604-bb09-40e9-b510-55100dc0dd23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68815604-bb09-40e9-b510-55100dc0dd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2191d6ca-e464-4b75-be2a-b2b3b7450bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68815604-bb09-40e9-b510-55100dc0dd23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2191d6ca-e464-4b75-be2a-b2b3b7450bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d72bc9ac-9487-440a-8377-58aa3d097b48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68815604-bb09-40e9-b510-55100dc0dd23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d72bc9ac-9487-440a-8377-58aa3d097b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e04d85c-5770-4ce3-8fb6-f6c487865907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_68815604-bb09-40e9-b510-55100dc0dd23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0e04d85c-5770-4ce3-8fb6-f6c487865907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_77308605-f685-4160-bf66-ce800165c912" xlink:href="cdtx-20250331.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ad79f9fa-4ad1-499c-92ae-a2c50b62511f" xlink:to="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_77308605-f685-4160-bf66-ce800165c912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7abce6e9-10cc-4793-a941-d6732c1ac616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_77308605-f685-4160-bf66-ce800165c912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7abce6e9-10cc-4793-a941-d6732c1ac616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2f12f8ef-f8d4-483d-89b1-8a20e052cdec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_77308605-f685-4160-bf66-ce800165c912" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2f12f8ef-f8d4-483d-89b1-8a20e052cdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0167437f-2cae-4f70-b09c-222c95e89c80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_77308605-f685-4160-bf66-ce800165c912" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0167437f-2cae-4f70-b09c-222c95e89c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a059aa6-d85f-4f56-88b9-d4b65be287c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a059aa6-d85f-4f56-88b9-d4b65be287c5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bea19bc-84b1-4083-b16d-333abe7e10da" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_56f6668a-392e-40d0-924b-76af2fc1afac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_56f6668a-392e-40d0-924b-76af2fc1afac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8d0fc615-be18-4376-b5ce-13f3d29d21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fa960138-1a78-4f38-b8f4-544f24bef949" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8d0fc615-be18-4376-b5ce-13f3d29d21e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_cc564b14-0b2d-45a9-b9a4-0dfe2dfc1751" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_139c9041-cba6-4c12-b659-7d2b9527cc82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_139c9041-cba6-4c12-b659-7d2b9527cc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_bbe14e4c-a743-46c7-95e2-6c76cf77fc01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_be196a47-5761-4308-92f8-e9a3957a0130" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_bbe14e4c-a743-46c7-95e2-6c76cf77fc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa77bc4e-12c7-403a-981c-8638ee26ba5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae3e759a-619d-444f-b109-93c0ce531aa8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa77bc4e-12c7-403a-981c-8638ee26ba5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc1ac8fb-0b72-4962-8b9f-b430e0e67d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_fa77bc4e-12c7-403a-981c-8638ee26ba5e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_dc1ac8fb-0b72-4962-8b9f-b430e0e67d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_281cddf4-bd2c-4e2f-a8ec-2c67f9b07588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_281cddf4-bd2c-4e2f-a8ec-2c67f9b07588" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ffdd420-add3-46ea-ba80-77b35792f1f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fbb9869a-0ee7-40fa-9ca0-99b468576d10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ffdd420-add3-46ea-ba80-77b35792f1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_1066a27a-2f4f-4074-975a-94f15c7467b8" xlink:href="cdtx-20250331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ffdd420-add3-46ea-ba80-77b35792f1f9" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_1066a27a-2f4f-4074-975a-94f15c7467b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_be13055a-1589-4844-87bf-b2c0e4783689" xlink:to="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_15c536ac-686d-495d-8623-d057f1aff20c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:to="loc_us-gaap_LicenseMember_15c536ac-686d-495d-8623-d057f1aff20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_26cc678f-e7dd-44d3-b838-7211f6bb2880" xlink:href="cdtx-20250331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_00775175-8950-4351-86b7-37b96c955ce6" xlink:to="loc_cdtx_MilestoneAchievementMember_26cc678f-e7dd-44d3-b838-7211f6bb2880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d1c1138f-8458-4e24-8d7b-7085a0a047dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_fff23aa1-54e2-4608-b69b-2959dbf47d81" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d1c1138f-8458-4e24-8d7b-7085a0a047dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_351947f2-8459-434d-87fb-0ceb4775ee66" xlink:href="cdtx-20250331.xsd#cdtx_UpfrontPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d1c1138f-8458-4e24-8d7b-7085a0a047dc" xlink:to="loc_cdtx_UpfrontPaymentMember_351947f2-8459-434d-87fb-0ceb4775ee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b081294-705c-4dc5-ab6c-4efcf4d4186b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_329c7a6a-4b6b-4f44-b0b3-9d6d2c2761ee" xlink:to="loc_us-gaap_RelatedPartyDomain_8b081294-705c-4dc5-ab6c-4efcf4d4186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3d624b9b-b25d-4a77-8c17-110b6ef9af3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8b081294-705c-4dc5-ab6c-4efcf4d4186b" xlink:to="loc_us-gaap_RelatedPartyMember_3d624b9b-b25d-4a77-8c17-110b6ef9af3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed7b99f2-62f6-40b3-b9ba-a96dd80c5370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_02a67663-12ba-4e67-a283-fe7a979babcf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed7b99f2-62f6-40b3-b9ba-a96dd80c5370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a14e4967-5afd-446c-81e7-317a8f0b16f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ed7b99f2-62f6-40b3-b9ba-a96dd80c5370" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a14e4967-5afd-446c-81e7-317a8f0b16f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6a2f6e0c-44a4-4ec3-b751-697242769774" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_26a8f54c-7acc-4415-a903-84d6debbd6e5" xlink:href="cdtx-20250331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_26a8f54c-7acc-4415-a903-84d6debbd6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_2a332421-b45d-4129-a3aa-ccb2eee3c422" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory_2a332421-b45d-4129-a3aa-ccb2eee3c422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_d5550a53-56c0-4c71-8b4f-5b60b7723cef" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization_d5550a53-56c0-4c71-8b4f-5b60b7723cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_f533b48f-ab64-4be2-b50c-218e7f6e7d13" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess_f533b48f-ab64-4be2-b50c-218e7f6e7d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DirectTransactionCosts_f3b5de3b-80cb-4c2c-ab38-b03beaeaad13" xlink:href="cdtx-20250331.xsd#cdtx_DirectTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_DirectTransactionCosts_f3b5de3b-80cb-4c2c-ab38-b03beaeaad13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_afa2c1f2-5afa-49d3-8e33-c24e757687b5" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_afa2c1f2-5afa-49d3-8e33-c24e757687b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_f43b5b2f-df20-4491-8600-f395221d1832" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_f43b5b2f-df20-4491-8600-f395221d1832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_668c795f-9b87-483a-95e0-3a01ebcc1f09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_668c795f-9b87-483a-95e0-3a01ebcc1f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_26657f3b-c56e-4151-88da-d6cf8534e117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_26657f3b-c56e-4151-88da-d6cf8534e117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_55d1e311-cc50-4a43-9b89-33f46db04122" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82ed38e3-0089-46fb-8baa-1b5d18eefcc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_55d1e311-cc50-4a43-9b89-33f46db04122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f034d082-b0ca-473e-ab6f-e2f389adab35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f034d082-b0ca-473e-ab6f-e2f389adab35" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d9ca07ca-adca-4b95-a652-8c563c23eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4ff2d521-3b55-4248-a28e-bbc37bac51b2" xlink:to="loc_us-gaap_RelatedPartyDomain_d9ca07ca-adca-4b95-a652-8c563c23eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_94bfe273-e833-457d-b8ae-184dd537942e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d9ca07ca-adca-4b95-a652-8c563c23eb3b" xlink:to="loc_us-gaap_RelatedPartyMember_94bfe273-e833-457d-b8ae-184dd537942e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_60de1c59-44f8-4ae4-b150-e740c4cbb147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_546205af-81a5-4e24-ab45-d021491d3448" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_60de1c59-44f8-4ae4-b150-e740c4cbb147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_600578f7-b089-4ba2-957b-192bdf1343db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_60de1c59-44f8-4ae4-b150-e740c4cbb147" xlink:to="loc_us-gaap_TransferredOverTimeMember_600578f7-b089-4ba2-957b-192bdf1343db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de6fa94-0ea0-49f4-815d-8d7a89014a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df5597f3-54f7-4691-979f-dfc3af8e2775" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de6fa94-0ea0-49f4-815d-8d7a89014a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8e46ab9f-9c38-4581-8646-718d0a1768df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1de6fa94-0ea0-49f4-815d-8d7a89014a7f" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8e46ab9f-9c38-4581-8646-718d0a1768df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_933ece02-e2a3-4b38-b790-02f4c8efd945" xlink:to="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_379ce135-b998-47db-8acc-416580bd5cde" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_379ce135-b998-47db-8acc-416580bd5cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_4a19f78e-da0f-47d1-8256-6afd4e647d06" xlink:href="cdtx-20250331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4bc1acf1-74ae-49f5-ac46-1091e5efa030" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_4a19f78e-da0f-47d1-8256-6afd4e647d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f830f64f-0275-44e8-bac8-cf3accd42e8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5b4bb8c7-c59a-462c-b16a-649290b71843" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f830f64f-0275-44e8-bac8-cf3accd42e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_fbbeb6e6-c240-4791-a2b4-d6b1148f27c6" xlink:href="cdtx-20250331.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f830f64f-0275-44e8-bac8-cf3accd42e8c" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_fbbeb6e6-c240-4791-a2b4-d6b1148f27c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91ad0e32-b9f3-4ede-9f0d-a91f764a2f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_02818541-319e-434d-a72e-2e8469745208" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91ad0e32-b9f3-4ede-9f0d-a91f764a2f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_98bdebed-4f23-4509-b179-48437b38a4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_91ad0e32-b9f3-4ede-9f0d-a91f764a2f29" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_98bdebed-4f23-4509-b179-48437b38a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9debc6bd-8d48-4727-9a13-9179a5fe00dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9debc6bd-8d48-4727-9a13-9179a5fe00dd" xlink:to="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsByNatureAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsNatureDomain_7e8358e3-9521-4bb1-811e-11a26e03f26d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsByNatureAxis_3b35f0d3-3934-46dc-95a3-e73aff4e92e0" xlink:to="loc_us-gaap_GuaranteeObligationsNatureDomain_7e8358e3-9521-4bb1-811e-11a26e03f26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_9944df2d-b419-4fc9-98ac-e1424bd8e322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsNatureDomain_7e8358e3-9521-4bb1-811e-11a26e03f26d" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_9944df2d-b419-4fc9-98ac-e1424bd8e322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b26334dd-fea9-4355-9352-12efe4b44233" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6d61c1f9-ab07-4a2a-996e-74455ecc1572" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b26334dd-fea9-4355-9352-12efe4b44233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_d3a78ff7-0a69-493c-92a9-25bf174b77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b26334dd-fea9-4355-9352-12efe4b44233" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_d3a78ff7-0a69-493c-92a9-25bf174b77f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_381bab73-397e-4c08-866c-a301e7c32f00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e4b2ff82-d351-407a-845f-732e4309d543" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_381bab73-397e-4c08-866c-a301e7c32f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_a871c824-32d0-442d-ba46-f077959f0141" xlink:href="cdtx-20250331.xsd#cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_381bab73-397e-4c08-866c-a301e7c32f00" xlink:to="loc_cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember_a871c824-32d0-442d-ba46-f077959f0141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_62ee72ed-5720-4082-9c17-acaa70f1e04c" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_c5f4f842-1caf-4b42-bfb6-4ae48eb954bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_c5f4f842-1caf-4b42-bfb6-4ae48eb954bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseMonthlyRate_6003b93a-fd08-45c3-ac4f-0eadf07e1c8d" xlink:href="cdtx-20250331.xsd#cdtx_LesseeFinanceLeaseMonthlyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_cdtx_LesseeFinanceLeaseMonthlyRate_6003b93a-fd08-45c3-ac4f-0eadf07e1c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_abd3ff4a-609b-4128-aab7-ea709fff38a4" xlink:href="cdtx-20250331.xsd#cdtx_LesseeFinanceLeaseOptionPurchaseEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_abd3ff4a-609b-4128-aab7-ea709fff38a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f75070cc-5c35-4792-bb52-4c3a2da117d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_0c352c84-3409-402c-9bff-19f7082b753f" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_f75070cc-5c35-4792-bb52-4c3a2da117d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5c5bb305-f8c2-4045-b055-7aca28aa16f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5c5bb305-f8c2-4045-b055-7aca28aa16f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate_4a4071ad-3f91-4a56-bbb8-6626af5e9543" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeOperatingLeaseMonthlyRate_4a4071ad-3f91-4a56-bbb8-6626af5e9543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_34a4ecfa-2ebb-42c4-b367-35537a58589b" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_34a4ecfa-2ebb-42c4-b367-35537a58589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_cdae6a42-853c-4375-9b85-d074bb7c658a" xlink:href="cdtx-20250331.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_cdae6a42-853c-4375-9b85-d074bb7c658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_67e5804b-904f-4a89-9889-2619db070241" xlink:href="cdtx-20250331.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_67e5804b-904f-4a89-9889-2619db070241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_bd3e3cd6-f331-4ad9-a305-6b41ac10c14d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_bd3e3cd6-f331-4ad9-a305-6b41ac10c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_597ddb70-ea7d-4bf3-ab66-95d1d6e09c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_597ddb70-ea7d-4bf3-ab66-95d1d6e09c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d4c60720-aa80-4e55-8f01-0da074233534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_OperatingLeasePayments_d4c60720-aa80-4e55-8f01-0da074233534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_c1d867be-bf76-41e4-8298-860a09005e91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_us-gaap_OperatingLeaseExpense_c1d867be-bf76-41e4-8298-860a09005e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_fd781ed8-1c40-4a88-81a0-2bbf079fcb9f" xlink:href="cdtx-20250331.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_91ea8861-f5af-4774-bce6-8e23f48185e6" xlink:to="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_fd781ed8-1c40-4a88-81a0-2bbf079fcb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_5e622b9a-5a7e-43cf-86b1-363d53069bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_5e622b9a-5a7e-43cf-86b1-363d53069bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_23d8646e-9a89-4d0a-ae81-fe0971f82dd3" xlink:href="cdtx-20250331.xsd#cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:to="loc_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted_23d8646e-9a89-4d0a-ae81-fe0971f82dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c660d7db-8fb9-419d-a44b-ab62ff0d4e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_bdfbc49a-eace-4570-94d5-49c9cf054701" xlink:to="loc_us-gaap_SeveranceCosts1_c660d7db-8fb9-419d-a44b-ab62ff0d4e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_1e6007d3-5d53-4252-9497-0297fb1b4156" xlink:to="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_c4e9df0d-4c04-409d-a1df-78c9238ca551" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_c4e9df0d-4c04-409d-a1df-78c9238ca551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantorObligationTerm1_2380e739-9ceb-4569-96f8-524fb51be5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuarantorObligationTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:to="loc_us-gaap_GuarantorObligationTerm1_2380e739-9ceb-4569-96f8-524fb51be5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_GuarantorObligationsTerminationNoticeTerm_719d9912-a93e-4c0f-836f-5f0addecc179" xlink:href="cdtx-20250331.xsd#cdtx_GuarantorObligationsTerminationNoticeTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_c1cff579-740a-4826-ba16-39188f23c045" xlink:to="loc_cdtx_GuarantorObligationsTerminationNoticeTerm_719d9912-a93e-4c0f-836f-5f0addecc179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3862314a-8f59-4220-9dab-ecce0686447d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ee81e35c-5729-40da-94cb-d55c2b59a39a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3862314a-8f59-4220-9dab-ecce0686447d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ee81e35c-5729-40da-94cb-d55c2b59a39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_55219db8-b0c7-44aa-a6a3-219ed36fb760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3862314a-8f59-4220-9dab-ecce0686447d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_55219db8-b0c7-44aa-a6a3-219ed36fb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64f137d0-b1a1-4ff8-ac8b-74778efab979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3862314a-8f59-4220-9dab-ecce0686447d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_64f137d0-b1a1-4ff8-ac8b-74778efab979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cdb483cf-f936-4a57-9cab-0e7ddc41f467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3862314a-8f59-4220-9dab-ecce0686447d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cdb483cf-f936-4a57-9cab-0e7ddc41f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_13396ae9-1eaa-42c5-81f4-e769e05116fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3862314a-8f59-4220-9dab-ecce0686447d" xlink:to="loc_us-gaap_OperatingLeaseLiability_13396ae9-1eaa-42c5-81f4-e769e05116fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b8aa62f-bf47-41c8-a24b-2e8a1bd3e12c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5964fe4-5dc0-48ac-87e1-10c5fcf8e318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b8aa62f-bf47-41c8-a24b-2e8a1bd3e12c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d5964fe4-5dc0-48ac-87e1-10c5fcf8e318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_19fdb191-376d-4773-b957-ba1c08ab2e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b8aa62f-bf47-41c8-a24b-2e8a1bd3e12c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_19fdb191-376d-4773-b957-ba1c08ab2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5e6bf16c-6ded-4ff0-9517-5dcdc357f210" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b8aa62f-bf47-41c8-a24b-2e8a1bd3e12c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5e6bf16c-6ded-4ff0-9517-5dcdc357f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2d1c5bcb-2dfe-452e-a409-efc09ed93cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b8aa62f-bf47-41c8-a24b-2e8a1bd3e12c" xlink:to="loc_us-gaap_OperatingLeaseLiability_2d1c5bcb-2dfe-452e-a409-efc09ed93cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2bd1d91e-c406-4bb8-bc93-0970a01cf399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9fefbb92-871f-4960-a39e-984c06d6c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2bd1d91e-c406-4bb8-bc93-0970a01cf399" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9fefbb92-871f-4960-a39e-984c06d6c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ff780fa6-dec0-442a-b24f-22a02b602c73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ff780fa6-dec0-442a-b24f-22a02b602c73" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_64c7c7eb-e788-40d1-8a95-6825d1163367" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NappPharmaceuticalGroupLimitedMember_4c2cb285-00b5-47b9-8155-9a208c0dd2a6" xlink:href="cdtx-20250331.xsd#cdtx_NappPharmaceuticalGroupLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:to="loc_cdtx_NappPharmaceuticalGroupLimitedMember_4c2cb285-00b5-47b9-8155-9a208c0dd2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_9c0cfc61-1e40-4d80-9c97-1f084f241f83" xlink:href="cdtx-20250331.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_9c0cfc61-1e40-4d80-9c97-1f084f241f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_f5e74a2e-587f-4487-82d2-d96d26518634" xlink:href="cdtx-20250331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_529a1b97-0671-4872-bc85-a4ea360d561f" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_f5e74a2e-587f-4487-82d2-d96d26518634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e30f64e2-1b79-4fcd-95fa-7944dcbe2393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a0e61daa-d832-4ced-860b-a90aca9ccabf" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e30f64e2-1b79-4fcd-95fa-7944dcbe2393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f96cafa1-b6bb-42be-90f8-aa5f3906348f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e30f64e2-1b79-4fcd-95fa-7944dcbe2393" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f96cafa1-b6bb-42be-90f8-aa5f3906348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc98a58d-25e2-45fe-b777-669541fa79a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3094022d-f30b-403f-b166-fd0690eefde3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc98a58d-25e2-45fe-b777-669541fa79a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_03e3c527-237d-4d65-8fa5-b04e8ed1b57b" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fc98a58d-25e2-45fe-b777-669541fa79a8" xlink:to="loc_cdtx_RezafunginMember_03e3c527-237d-4d65-8fa5-b04e8ed1b57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5516362e-f60d-4e90-99ca-f635bd973320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a353817d-648e-4cd2-a1d3-4d4df6e2b2aa" xlink:to="loc_us-gaap_RelatedPartyDomain_5516362e-f60d-4e90-99ca-f635bd973320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_35cee232-2682-46d9-8b44-4f2a3495cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5516362e-f60d-4e90-99ca-f635bd973320" xlink:to="loc_us-gaap_RelatedPartyMember_35cee232-2682-46d9-8b44-4f2a3495cef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b30adeeb-cc84-4998-90e8-52d286ef2e42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8006e1f2-4f1e-4d35-836f-ef6b6d321792" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b30adeeb-cc84-4998-90e8-52d286ef2e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_1eb81591-7c72-4e62-8c8f-b034f6ee6174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b30adeeb-cc84-4998-90e8-52d286ef2e42" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_1eb81591-7c72-4e62-8c8f-b034f6ee6174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0dc39025-766d-4f93-b97c-779d5579fb46" xlink:to="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginAssetsMember_7e54d10f-0bea-4f10-b6f0-f09db92cd51a" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:to="loc_cdtx_RezafunginAssetsMember_7e54d10f-0bea-4f10-b6f0-f09db92cd51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_e0467d65-1747-46a8-8dbb-16479ac003f6" xlink:href="cdtx-20250331.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_988259c4-7a5b-4e79-82f5-91430c03e257" xlink:to="loc_cdtx_MilestoneAchievementMember_e0467d65-1747-46a8-8dbb-16479ac003f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_8e12889f-857b-40fa-bc64-aa3fbcdb7b51" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_3d881abd-bcc8-4853-9246-92fe22575a57" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount_3d881abd-bcc8-4853-9246-92fe22575a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_3f15c8bf-06c2-432e-b7c2-4dfd2e430afc" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm_3f15c8bf-06c2-432e-b7c2-4dfd2e430afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_89af8032-a6c7-4724-98c4-339cb62dfe5a" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementOtherServicesAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementOtherServicesAgreementTerm_89af8032-a6c7-4724-98c4-339cb62dfe5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_454642f0-c4d1-42a7-869c-bf9213add5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_454642f0-c4d1-42a7-869c-bf9213add5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_882e3d7f-83e8-4e92-83d3-f13940bf522b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_882e3d7f-83e8-4e92-83d3-f13940bf522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1c409f8e-4c17-4e92-83a8-d23550a29f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1c409f8e-4c17-4e92-83a8-d23550a29f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_792458b3-51a5-4e6c-811e-81b3f6e211a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_792458b3-51a5-4e6c-811e-81b3f6e211a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5675b0b3-6b13-45df-b22c-ae80bf515bee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5675b0b3-6b13-45df-b22c-ae80bf515bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionValue_9376b4c7-1320-474d-ac9f-8ded76633af9" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementTransactionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementTransactionValue_9376b4c7-1320-474d-ac9f-8ded76633af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_99afa2d5-6d97-45ed-8332-4d29c71c3241" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount_99afa2d5-6d97-45ed-8332-4d29c71c3241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_8c6901c4-cb43-4b13-9490-630d8ae5645e" xlink:href="cdtx-20250331.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices_8c6901c4-cb43-4b13-9490-630d8ae5645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_98123c81-49e3-41ad-84e1-42882b7569f8" xlink:href="cdtx-20250331.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_98123c81-49e3-41ad-84e1-42882b7569f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_08dc90f3-9b70-4b1c-b249-db91f5b3d61c" xlink:href="cdtx-20250331.xsd#cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount_08dc90f3-9b70-4b1c-b249-db91f5b3d61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_143ef7f9-b49b-4688-b287-7ed855ab58fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_143ef7f9-b49b-4688-b287-7ed855ab58fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_c47c68db-2e28-4bde-baff-029c38395425" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal_c47c68db-2e28-4bde-baff-029c38395425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_8bb7fc9b-f4ba-426e-aebb-699595127ca0" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_8bb7fc9b-f4ba-426e-aebb-699595127ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_85c6fb0f-172c-4995-b6c0-3273eb8e358d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_85c6fb0f-172c-4995-b6c0-3273eb8e358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransitionsServicesTerm_741f6378-8ae7-4afc-a2e7-2371114d3b39" xlink:href="cdtx-20250331.xsd#cdtx_CollaborativeArrangementTransitionsServicesTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_cdtx_CollaborativeArrangementTransitionsServicesTerm_741f6378-8ae7-4afc-a2e7-2371114d3b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_94454391-f39b-487f-895b-2e4278e20fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_94454391-f39b-487f-895b-2e4278e20fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8baa0769-df15-40d1-8c53-06e00ec29c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d2e0b307-dcb1-43ab-ab2a-2a6b8450a02b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8baa0769-df15-40d1-8c53-06e00ec29c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d5cef4ba-a2e1-4224-898e-18de161377b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d5cef4ba-a2e1-4224-898e-18de161377b0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b1f744d6-f9b1-4783-9f1f-c203f821aae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_54c95377-1e80-492d-8b0e-b83b181bcbb2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b1f744d6-f9b1-4783-9f1f-c203f821aae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f7b6c994-0908-412d-92ef-c06833d9369a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b1f744d6-f9b1-4783-9f1f-c203f821aae1" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f7b6c994-0908-412d-92ef-c06833d9369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17749e21-45e9-41e5-a8b5-6aefac4b8b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e0c0f434-538a-49c0-b266-8ec99c05d311" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17749e21-45e9-41e5-a8b5-6aefac4b8b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_e037cae2-2e5f-4961-ac7b-af37cb2456b8" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_17749e21-45e9-41e5-a8b5-6aefac4b8b03" xlink:to="loc_cdtx_RezafunginMember_e037cae2-2e5f-4961-ac7b-af37cb2456b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e296436c-712e-40c7-9183-69f4bee80dab" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_71a590d0-5e33-42b8-afd7-2ee9c665ab69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_RevenuesAbstract_71a590d0-5e33-42b8-afd7-2ee9c665ab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_beb73115-ffb6-4b9b-8add-5afda20021c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_71a590d0-5e33-42b8-afd7-2ee9c665ab69" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_beb73115-ffb6-4b9b-8add-5afda20021c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4892f444-a8bb-431d-ac76-8e90df6cc22a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4892f444-a8bb-431d-ac76-8e90df6cc22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_e922e479-6ae9-44f4-a7e4-f2bb5230963f" xlink:href="cdtx-20250331.xsd#cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_e922e479-6ae9-44f4-a7e4-f2bb5230963f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e523b1e0-38c8-4623-b146-0fef63698120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e523b1e0-38c8-4623-b146-0fef63698120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f9af0e0b-7809-4214-93d0-ef016a107b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_35fb9857-cb73-4d0c-b7fe-e2c18a5c6c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_f9af0e0b-7809-4214-93d0-ef016a107b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_58f7417a-d87c-4a56-9f79-568785a87c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_de38c992-a3d0-49d9-bf24-06cbf0f88cc9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_58f7417a-d87c-4a56-9f79-568785a87c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1d48a079-7cf7-4f4f-9d94-f98d0a7a6dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1d48a079-7cf7-4f4f-9d94-f98d0a7a6dab" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1ee819ff-83e1-4b58-9f9a-30c9a4c97c8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_79018f88-0b84-4133-955c-87eed87707dc" xlink:href="cdtx-20250331.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_79018f88-0b84-4133-955c-87eed87707dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_2f7e05ef-3774-4d08-a4a9-7bfb1505f005" xlink:href="cdtx-20250331.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_80447561-fd80-4520-88b0-03d15349c870" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_2f7e05ef-3774-4d08-a4a9-7bfb1505f005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0e5ffe92-909f-4451-abe2-8cb89921305d" xlink:to="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_e82dabf8-1bb8-404f-9f5e-fb088095beba" xlink:href="cdtx-20250331.xsd#cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_e82dabf8-1bb8-404f-9f5e-fb088095beba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5c6a0f1b-cc86-42cd-8792-395500120bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_us-gaap_ProductMember_5c6a0f1b-cc86-42cd-8792-395500120bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_be7aed20-4ad1-4467-b4ac-c42f5f4776b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_us-gaap_RoyaltyMember_be7aed20-4ad1-4467-b4ac-c42f5f4776b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_197801cc-5d98-4f6e-8d53-81ad370a1e05" xlink:href="cdtx-20250331.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_197801cc-5d98-4f6e-8d53-81ad370a1e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_9e7e215e-448a-426f-9d5b-d0d7c9742089" xlink:href="cdtx-20250331.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_648866ad-ac61-4232-a84e-2624376d29ae" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_9e7e215e-448a-426f-9d5b-d0d7c9742089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_eef4599b-c4bf-426a-9a03-97664df1e560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8e0c2d9d-68d2-4c69-8181-2aae255e3bb0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_eef4599b-c4bf-426a-9a03-97664df1e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f1be8e1f-dd9b-46fd-b3d1-44212140c338" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_eef4599b-c4bf-426a-9a03-97664df1e560" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_f1be8e1f-dd9b-46fd-b3d1-44212140c338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6bcb5908-ea95-4768-bc9b-01cb949bc850" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_284601cf-d224-466f-ac4f-c7c1204b7c2a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6bcb5908-ea95-4768-bc9b-01cb949bc850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RezafunginMember_1efd3aed-2005-443d-961e-e6e9bbf26d32" xlink:href="cdtx-20250331.xsd#cdtx_RezafunginMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6bcb5908-ea95-4768-bc9b-01cb949bc850" xlink:to="loc_cdtx_RezafunginMember_1efd3aed-2005-443d-961e-e6e9bbf26d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b31e1907-81a9-4346-9749-876ba2dd636d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64ed3528-8f42-4771-b67a-eb1e5dbb8b1a" xlink:to="loc_us-gaap_RelatedPartyDomain_b31e1907-81a9-4346-9749-876ba2dd636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_967f3bf2-61c2-4788-b767-8b6a044ca84e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b31e1907-81a9-4346-9749-876ba2dd636d" xlink:to="loc_us-gaap_RelatedPartyMember_967f3bf2-61c2-4788-b767-8b6a044ca84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_9d5eef9f-bc33-4a0b-9b3b-7476ad1a436b" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_8966f9ca-21a9-4095-93c8-8ece8cae6bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_8966f9ca-21a9-4095-93c8-8ece8cae6bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_18f08c58-b279-427e-b10a-b564d0ef1182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_e0978ca2-b77b-4abd-8d43-67101d32f0e3" xlink:to="loc_us-gaap_TransferredOverTimeMember_18f08c58-b279-427e-b10a-b564d0ef1182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b50b3d-8138-4a48-a08b-2e6501b18a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1bead399-b25b-4133-980f-2fd0a54f1dcf" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b50b3d-8138-4a48-a08b-2e6501b18a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3a3fa96b-9c2d-4be4-aa8e-a1f5b24447e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_13b50b3d-8138-4a48-a08b-2e6501b18a28" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3a3fa96b-9c2d-4be4-aa8e-a1f5b24447e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6c168de-dabb-428e-a43d-3cdb11da3250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0de8c7b7-e691-474c-b40c-40dd03c71415" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6c168de-dabb-428e-a43d-3cdb11da3250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fa889a60-8b14-45a7-9de1-783ccd6976f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d6c168de-dabb-428e-a43d-3cdb11da3250" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_fa889a60-8b14-45a7-9de1-783ccd6976f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cdtx-20250331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_a7edca7b-1850-4649-a3ce-1ef43dcac837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_a7edca7b-1850-4649-a3ce-1ef43dcac837" xlink:to="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_135640be-2eb3-4178-ae12-fc73477b6a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fc383daf-8aad-4bc5-a7f6-9251e9141141" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_135640be-2eb3-4178-ae12-fc73477b6a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PrefundedWarrantsMember_92b5738d-b0a8-44d5-9127-8612a8e57ccb" xlink:href="cdtx-20250331.xsd#cdtx_PrefundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_135640be-2eb3-4178-ae12-fc73477b6a88" xlink:to="loc_cdtx_PrefundedWarrantsMember_92b5738d-b0a8-44d5-9127-8612a8e57ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c613f2f7-fa21-4b8e-a3a7-4ae77ed5525c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f40c711b-4d99-4fd3-958a-1d78b1ee0239" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c613f2f7-fa21-4b8e-a3a7-4ae77ed5525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d134f7e7-9517-4d1e-bf9e-2178d07542f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c613f2f7-fa21-4b8e-a3a7-4ae77ed5525c" xlink:to="loc_us-gaap_SubsequentEventMember_d134f7e7-9517-4d1e-bf9e-2178d07542f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a1ea1e90-424f-4d93-aa32-3ea6435efda9" xlink:to="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8befc78e-d04d-4e1c-9345-90fa303c7019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:to="loc_us-gaap_CommonStockMember_8befc78e-d04d-4e1c-9345-90fa303c7019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7740b5f2-6b96-40fb-8768-e22ea16cf99c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_729a5e9f-694c-4e98-9bfc-5f9282e81409" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7740b5f2-6b96-40fb-8768-e22ea16cf99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2fbd5dda-89ae-4689-9d8d-e146ea6fe326" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8e3575c0-8c8d-4f32-a069-f8e15c814dfa" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2fbd5dda-89ae-4689-9d8d-e146ea6fe326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OpenMarketSaleAgreementMember_ea3e5026-a5dd-4d99-8903-810d04253ade" xlink:href="cdtx-20250331.xsd#cdtx_OpenMarketSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2fbd5dda-89ae-4689-9d8d-e146ea6fe326" xlink:to="loc_cdtx_OpenMarketSaleAgreementMember_ea3e5026-a5dd-4d99-8903-810d04253ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_22155adc-35d4-4bda-a631-b9f7b4f1eb31" xlink:to="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_57b66f8e-0727-4935-8e61-7cf5a322d50b" xlink:href="cdtx-20250331.xsd#cdtx_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_cdtx_ClassOfWarrantOrRightExercisesInPeriod_57b66f8e-0727-4935-8e61-7cf5a322d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_b06731f6-c31c-47e7-bdc9-de691367ed29" xlink:href="cdtx-20250331.xsd#cdtx_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised_b06731f6-c31c-47e7-bdc9-de691367ed29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d118b50a-978f-4dfb-8386-cfcd409b37b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d118b50a-978f-4dfb-8386-cfcd409b37b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationReceivablePerTransaction_bb27b1d9-0f94-4390-a16f-93e87d53e305" xlink:href="cdtx-20250331.xsd#cdtx_SaleOfStockConsiderationReceivablePerTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_cdtx_SaleOfStockConsiderationReceivablePerTransaction_bb27b1d9-0f94-4390-a16f-93e87d53e305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9e22160-b5c4-4f44-aa8d-52bb1ff45c23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_60fcb250-ff6a-4bde-8f78-50762057c05b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a9e22160-b5c4-4f44-aa8d-52bb1ff45c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cdtx-20250331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20250331_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" =T#:0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSA)6:%HHHJ"PHHHH **** "BBB@ HJF=8L%OOL)O;<7N,_9O-7S/^^<YJY0
M4457OM1M-,A\V\NH;2+.-\\@1<_4F@"Q15"QU[3-4<I9:C:7CCJL$ZN?T-7Z
M "BBFR2+#&SNRHBC)9C@ >IH =165#XKT2XF$46L:?)*> B72%ORS6K0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 <7XZ^#?@WXF:]X?U?Q1H-KKEYH+R2:>+Q=\<+N%#-L/RD_*N"0
M<8XKLU4(H50%4#  Z"EHHV5N@;N["BBB@ HHHH **_+'_@KY\:/'GPQ^)7@:
MU\)>+]8\.6MSI4DDT.FW;PK(XF8;B%/)QQ7W7^QWK^I>*/V8/AKJVL7UQJ>I
MWFBV\UQ=W3EY)7*\LS'J:=)>UI2JKH[?G_D.HO9SC!]5?\O\SM/B)\)/"'Q6
MM;*#Q5H-IK LKA+JUDF3]Y!(C!E9''*\CL>:ZY5"J .@&!2T4ME86^X4444
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M?]6_T-/IDO\ JW^AK.I\$O0:W/PZ_8E_Y242_P#87U/_ -#>OW(K\-_V)?\
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MQ&5@ -Q5'5<X R<<]3S6'_P[G_9P_P"B5Z7_ .!%S_\ ': /$/\ A])\&/\
MH7/&/_@);_\ Q^OI#]EW]KSP+^UIH.KZCX.-];3Z3,L5YI^I0B.>(."8W^4L
MI5MKXPV?E.0*\L^-'[ 7[/OAOX/>.M7TWX9Z;:ZC8:%?75M<)<7!,<J6[LC#
M,F,A@#SZ5\Z?\$.?^/'XN?\ 733?Y7% 'ZFT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?)7_  2A^!.O?$[XU:U\;O$L#G3[269[>>:,XN[V8EG9"?[F<Y_VJ^@_ /\
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M_*XK]#?VA/\ D@?Q)_[%K4O_ $EDK\\O^"'/_'C\7/\ KIIO\KB@#]3:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^%7[4_A5O@7_P4:76O$:LNAW/B2UUY;F1/D:W>99'QZ[>0?I7[F:;?6^IZ
M?;7EI*LUM/&LL4D9RK*1D$'TQ7Q;_P %1O#/P7UKX2V]Q\2M8.A^);?=_8-S
M9)YMX[]T\L<M$3][/ Z]:_/+]G7_ (*=?%3]GKPXGAI5L?&7AZV7R[.VU@.'
MMEST612&QCH#D"HPTX^P^K/>#T?1IVT]59%XB,G56(7VEJNJ?=>3U/WHHK\E
MU_X+>:UM&?AM89QSB\>C_A]YK/\ T36Q_P# QZL@_6BBOR7_ .'WFM?]$UL?
M_ QZ_2OX#_$J3XQ?!WPCXUFLET^77-/BO6M48LL9<9V@]ZM0DXN?1:???_(G
MF2:CU9WM%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >?_ +0G_) _B3_V+6I?^DLE?GE_P0Y_X\?BY_UTTW^5
MQ7Z&_M"?\D#^)/\ V+6I?^DLE?GE_P $.?\ CQ^+G_733?Y7% 'ZFT444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5XU\+_^3C/C;_W!/_2-Z]EKQKX7_P#)QGQM_P"X)_Z1O751^"IZ?^W1
M.'$?Q:/^)_\ I$CV6BBBN4[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P
M+_;Y\4:[\=_VVM>\/P2R74EOJ4>@:9;-D+&0PCP![MR3WK[[^%/_  1Z^$.@
M^%;%?&DFJ>)]?95DN+B*\>VA5B 2BHO50<\GDU\>?MW>!;S]F?\ ;LL/B#)8
M32^']0U6W\0V\O:5UD5YD!]0P/'O7[,?#GX@Z%\4O!>E>*/#>H0ZGI&HPK-#
M/"V1R.5/H0>"#R*6$BHX*$E\5VI>3_X+OZE8IMXMZ^[9-?UY*Q\U_P##J_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45_/S\
M,?AG\6?VS/C_ .--%T3QM)'KD376HW%UJVHS1(Z).L>!Y8//SKP !@5[O_PZ
M7_:-_P"BAZ)_X.;W_P"-4 ?L?17XX?\ #I?]HW_HH>B?^#F]_P#C5'_#I?\
M:-_Z*'HG_@YO?_C5 '['T5^.'_#I?]HW_HH>B?\ @YO?_C5'_#I?]HW_ **'
MHG_@YO?_ (U0!^Q]%?CA_P .E_VC?^BAZ)_X.;W_ .-4?\.E_P!HW_HH>B?^
M#F]_^-4 ?L?17XX?\.E_VC?^BAZ)_P"#F]_^-4?\.E_VC?\ HH>B?^#F]_\
MC5 '['T5^.'_  Z7_:-_Z*'HG_@YO?\ XU1_PZ7_ &C?^BAZ)_X.;W_XU0!^
MQ]%?CA_PZ7_:-_Z*'HG_ (.;W_XU1_PZ7_:-_P"BAZ)_X.;W_P"-4 ?L?17X
MX?\ #I?]HW_HH>B?^#F]_P#C5'_#I?\ :-_Z*'HG_@YO?_C5 '['T5^.'_#I
M?]HW_HH>B?\ @YO?_C5'_#I?]HW_ **'HG_@YO?_ (U0!^Q]%?CA_P .E_VC
M?^BAZ)_X.;W_ .-4?\.E_P!HW_HH>B?^#F]_^-4 ?L?17XX?\.E_VC?^BAZ)
M_P"#F]_^-4?\.E_VC?\ HH>B?^#F]_\ C5 '['T5^.'_  Z7_:-_Z*'HG_@Y
MO?\ XU1_PZ7_ &C?^BAZ)_X.;W_XU0!^Q]%?CA_PZ7_:-_Z*'HG_ (.;W_XU
M1_PZ7_:-_P"BAZ)_X.;W_P"-4 ?L?17XX?\ #I?]HW_HH>B?^#F]_P#C5'_#
MI?\ :-_Z*'HG_@YO?_C5 '['T5^.'_#I?]HW_HH>B?\ @YO?_C5'_#I?]HW_
M **'HG_@YO?_ (U0!^Q]%?CA_P .E_VC?^BAZ)_X.;W_ .-4?\.E_P!HW_HH
M>B?^#F]_^-4 ?L?17XX?\.E_VC?^BAZ)_P"#F]_^-4?\.E_VC?\ HH>B?^#F
M]_\ C5 '['T5^.'_  Z7_:-_Z*'HG_@YO?\ XU1_PZ7_ &C?^BAZ)_X.;W_X
MU0!^Q]%?CA_PZ7_:-_Z*'HG_ (.;W_XU1_PZ7_:-_P"BAZ)_X.;W_P"-4 ?L
M?17XX?\ #I?]HW_HH>B?^#F]_P#C5'_#I?\ :-_Z*'HG_@YO?_C5 '['T5^.
M'_#I?]HW_HH>B?\ @YO?_C5'_#I?]HW_ **'HG_@YO?_ (U0!^Q]%?CA_P .
ME_VC?^BAZ)_X.;W_ .-4?\.E_P!HW_HH>B?^#F]_^-4 ?L?17XX?\.E_VC?^
MBAZ)_P"#F]_^-4?\.E_VC?\ HH>B?^#F]_\ C5 '['T5^.'_  Z7_:-_Z*'H
MG_@YO?\ XU1_PZ7_ &C?^BAZ)_X.;W_XU0!^Q]%?CA_PZ7_:-_Z*'HG_ (.;
MW_XU1_PZ7_:-_P"BAZ)_X.;W_P"-4 ?L?17XX?\ #I?]HW_HH>B?^#F]_P#C
M5'_#I?\ :-_Z*'HG_@YO?_C5 '['T5^.'_#I?]HW_HH>B?\ @YO?_C5'_#I?
M]HW_ **'HG_@YO?_ (U0!^Q]%?CA_P .E_VC?^BAZ)_X.;W_ .-4?\.E_P!H
MW_HH>B?^#F]_^-4 ?L?17XX?\.E_VC?^BAZ)_P"#F]_^-4?\.E_VC?\ HH>B
M?^#F]_\ C5 '['T5^(G[%*^/O@M_P42TCX<ZOXJN[J:WO+O2=5CM[R26VNE6
MW>3;\_5=Z(W0'*U^W= !1110 4444 %%%% !1110 4444 %>-?"__DXSXV_]
MP3_TC>O9:\:^%_\ R<9\;?\ N"?^D;UU4?@J>G_MT3AQ'\6C_B?_ *1(]EHH
MHKE.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^./_!)/_D\[XA_
M]@B__P#2V&OV.K\<?^"2?_)YWQ#_ .P1?_\ I;#7['4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'XV> _^4SU]_P!C+J'_ *1RU^R=?C9X#_Y3/7W_ &,NH?\
MI'+7[)T %%%% !1110 4444 %%%% !1110 5XU\+_P#DXSXV_P#<$_\ 2-Z]
MEKQKX7_\G&?&W_N"?^D;UU4?@J>G_MT3AQ'\6C_B?_I$CV6BBBN4[@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
MCC_P23_Y/.^(?_8(O_\ TMAK]CJ_''_@DG_R>=\0_P#L$7__ *6PU^QU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^-G@/_E,]??\ 8RZA_P"D<M?LG7XV> _^
M4SU]_P!C+J'_ *1RU^R= !1110 4444 %%%% !1110 4444 %>-?"_\ Y.,^
M-O\ W!/_ $C>O9:\:^%__)QGQM_[@G_I&]=5'X*GI_[=$X<1_%H_XG_Z1(]E
MHHHKE.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]BUJ7_I+)7YY?\$.?^/'XN?]=--_E<5^AO[0G_) _B3_ -BUJ7_I+)7YY?\
M!#G_ (\?BY_UTTW^5Q0!^IM%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'XX_\$D_^3SOB'_V"+_\ ]+8:_8ZOQQ_X
M))_\GG?$/_L$7_\ Z6PU^QU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW)K<OUVIR]E^;_K[A:***@84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'G_ .T)_P D#^)/_8M:E_Z2R5^>7_!#G_CQ^+G_
M %TTW^5Q7Z&_M"?\D#^)/_8M:E_Z2R5^>7_!#G_CQ^+G_733?Y7% 'ZFT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?CC_P $D_\ D\[XA_\ 8(O_ /TMAK]CJ_''_@DG_P GG?$/_L$7_P#Z6PU^
MQU !1110 4444 %%%% !1110 444V218T9W8*BC)9C@ >M %/6];T_PWH]YJ
MNJWL&G:991-/<W=U((XH8U&69F/  '>O@KXV?\%B/AY\/?%&M:!X4T&Z\;/9
MQLD&L6MRBV,MQM. #]YHPV,LO49Q7RG_ ,%.OVWKWXP>.+_X;>#=<AG^'>ER
M(MQ/I[MMU*Y4 OO;HR(^0N,J=H;)XKX&H _2*S_X+<?$$7D!N_A[X::U\Q?.
M$,MP'*9^;:2Y .,XS7U=^S[_ ,%7/A5\:_%-QH6L6\WP\G\M7M;C7;J/R+EL
MX*!Q@*WW< _>R<=*_"^B@#^J=6#*&4@@C(([TM?EQ_P2G_;AO=<FC^#_ ,0-
M=@=H853PW>7TA\^;!Q]D+G@X ^3)ST49P*_4>@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4445D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >?_ +0G_) _B3_V+6I?^DLE?GE_P0Y_X\?BY_UTTW^5Q7Z&_M"?\D#^
M)/\ V+6I?^DLE?GE_P $.?\ CQ^+G_733?Y7% 'ZFT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?CC_P23_Y/.^(?
M_8(O_P#TMAK]CJ_''_@DG_R>=\0_^P1?_P#I;#7['4 %%%% !7!?%WX[^ ?@
M-H]KJGCWQ/9^&[.ZF\B!KG<SRO@G"H@+$ #D@8'&>HKO:\/_ &H/V/O '[6>
MDZ/:^,X[Z"YTF5WL]0TR<13QJX DC^964JVU"<C.4&"* .:_X>0?LW_]%1T_
M_P  [K_XU1_P\@_9O_Z*CI__ (!W7_QJO'/^',7P1_Z#?C#_ ,#H/_C%'_#F
M+X(_]!OQA_X'0?\ QB@#V/\ X>0?LW_]%1T__P  [K_XU1_P\@_9O_Z*CI__
M (!W7_QJO'/^',7P1_Z#?C#_ ,#H/_C%'_#F+X(_]!OQA_X'0?\ QB@#V/\
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M);ZY+_ _RD+$_P"Z?]OQ_-7_ $/VKHHHI ?GA_P6F_Y(/X2_[#!_] %>6?\
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M*W2C[IVCS)<_5BD?X5%^Q[K$_P -_C!XQ^&VHN5$DDC0!CUFA)!Q_O1G=_P
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M>(EC,)&K%VDU]SVV]3YR_P"&_?A[_P! ;Q-_X"V__P ?H_X;]^'O_0&\3?\
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M:T9["J0E)P3U6ZZJ^UQ:*X[XA?%[PA\*_L(\4:PNEM>EA;KY$LS/MQDXC5B
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M 4444 %%%% 'XX_\$D_^3SOB'_V"+_\ ]+8:_8ZOQQ_X))_\GG?$/_L$7_\
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M?PD$#G-?I72 !0 !@#H*6@ HHHH **** "BBB@ HHHH **** "OS'_X+>?\
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M.890RM+8_: &'.'8L/T-?1=>GC/]XGZL\W!Z8>'H%%%%<9UA1110!^-G@/\
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M:C/X)2=_DO=7S?W_ "/;?%/[)?PT\1:%+86_AZ'1[C85AO;%F66)L<,></\
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MTL6?[*6Y :3,<0'TB5OS%<A\.?CD?#G[*?C#P\\YCU6UG%E9J3AA%<[MV/\
M=VS'\17TA^R#X#'@CX*Z5++'LOM8)U*;(YPX C'_ 'P%/XFNV=+ZG[>:Z^['
MYZO\+?,\RGB/[1>&IOI[\O6/NK_R:YW_ ,6_^25^,?\ L#WG_HEZ\$_X)^?\
MD\\2?]A0?^BDKWOXM_\ )*_&/_8'O/\ T2]>"?\ !/S_ ))YXD_["@_]%)7)
MA_\ =<1_V[^9Z&*_W_"_]O\ Y(X+Q$W]L?M\6<=\,QP7\ B#'CY+<,G_ (\
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M<,.OL+\7JV5EB=55,7+>H[K_  K2*^X****\P]H**** "BBB@ HHHH ****
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MS2 956T]P">W.ZNZUG]DG]MS1_#\.D:'\:;&ZTNVA6"*SCN/LFV-5P%7$)Z
M =:=-JC3J1W<FG]W](4^:I.':-_Q_K\C],FN(EF6(R*)6&50L-Q'J!4E?A-8
M_L8_M?1_$BSSIWB2.^6\4KKC:MNMXSNSYF_S,[>^,?A7[B>%;/4=/\+Z1:ZO
M=+>ZM#:11W=RHP)9@@#N/JV3^-.,4Z:G?Y";:GR-&K1114E!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?_M"?\D#^)/\
MV+6I?^DLE?GE_P $.?\ CQ^+G_733?Y7%?H;^T)_R0/XD_\ 8M:E_P"DLE?G
ME_P0Y_X\?BY_UTTW^5Q0!^IM%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"6'=W%VW;;TM_D@KX2_;Q\*VD/Q*T&_L7#ZKJUIY<UH@)<E&VQO_ ,"!V_\
M *^[:^=;W]G'Q%XJ_:.3Q]XCU#3)] LYEDLK&&21I@L:_N592@48;YCACSGU
MJ\!4C2Q"J3=DDWZZ;?UV,\TI3Q&%=&G&[DTO36]_E;\3UGX/^!4^&_PU\/\
MAX*!+:6R_:".\S?-(?\ OMF_#%=C117'4FZDW.6[U/1I4XT:<:<-DK!7S?\
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M[A%74V)G$8ZM;W/208QC<2*F,HOW9Z2Z=F7*+24H:JVOD[_E8_9:BODSX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\<?^"2?_)YWQ#_ .P1?_\
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M=".Q'0CL16_+>'/%W1AS^]R25F=!1114%A1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?CC_P23_Y/.^(?_8(O_\ TMAK]CJ_''_@DG_R>=\0_P#L
M$7__ *6PU^QU !1110 445FZ]XDTCPM9B\UK5;+2+1G$8N+^X2",L<D+N8@9
MX/'M0!I45QO_  N;X?\ _0]>&O\ P;V__P 71_PN;X?_ /0]>&O_  ;V_P#\
M70!V5%<;_P +F^'_ /T/7AK_ ,&]O_\ %T?\+F^'_P#T/7AK_P &]O\ _%T
M=E17&_\ "YOA_P#]#UX:_P#!O;__ !=8WC3]H3X;^&/"6L:M<^/_  ]!!9VD
MDS20ZE#*ZX4\JB,68Y[ $T ?"G_!2S]N;Q-H/C#3OA'\'=====>1%U6\T-G:
M]CN-XV6D;*/O'C<%);/RG'(K-_9@_P""0-O?64_B'XZ7LU[>:A;I+#HFG7;I
M+;2N=SM<2C[SCIA21\Q).0*\F_X)6_#.Q^/G[3'BGQ[XYMKSQ#J&C#^VK;4;
MC(B?47G!\R0@8:0;O, R.0#CBOVAH ^7-4_X)H?L]ZKX)L/#+>!H;6*S=774
M[65H]0EQNXDN!\S@[N0?0>@KXJ_:E_X)D^+/@!JUU\4/@/J]]_9NCI'=II<$
M\AU6R90?,DA<#]XH #8SN^8C! K]>*CN+>.[MY8)D$D4JE'4]"I&"/RH ^'?
M^"9?[;5S^T)X+F\'^.-8M9O'^C )"TA*W&IVJJ/WS9X9UY#;>3MW$<U]S5^(
MOQ&T/0OV+?\ @IEI+>'YKOP5X(AU.SN);B0,T26<ZHUTB$J2T0W.F!D@#&<B
MOV'3XU?#V159?'?AHJPR#_:]O_\ %T =G17&_P#"YOA__P!#UX:_\&]O_P#%
MT?\ "YOA_P#]#UX:_P#!O;__ != '945QO\ PN;X?_\ 0]>&O_!O;_\ Q='_
M  N;X?\ _0]>&O\ P;V__P 70!V5%<;_ ,+F^'__ $/7AK_P;V__ ,774:;J
MEGK5A#?:?=P7]E,NZ*YMI%DCD'JK*2"/I0!:HHHH ***CGGCM89)II%BAC4N
M\CG"JH&22>PI;:L#E_BI\3M!^#O@'6/%_B6\6RTC3(#-([=6/\**.[$X %?B
MWKVB^,?V_M7^+/QK\2RSZ;X-\)Z7<2:?;@DHC(N8;:/MT^9SZL:]1_:F^+?B
M;_@H?^TEI?P:^&\SGP-I-R1<WB9\J5E.);F0CJBCY4'<Y/>ON+XP_!_P]\"/
MV#O'7@OPQ:K;Z;IWAJZ3?@;YI"A+R.>[,Q)KGDOW$\7/L^1?G+_+_AT==.WU
MBGA5U:Y_O^'_ #_X8^0_^"(?_'U\3/\ <M_YFOU9K\IO^"(?_'U\3/\ <M_Y
MFOU+US4X]%T74-0F8+%:6\D[L>@55+$_I7I8J2A&,GTBCR\-%RE.*ZR9^+?Q
MJAE^/W_!5*'0S()[:WURWL4W_,JQ0*)",>F=WYU^T@T/3E  T^U _P"N*_X5
M_.SX ^)GQ"N/VFM3\1_#NW.K^.=7OKJ.Q<0>?(IE8CS$[!@O1CP*^KM7_P""
M=O[7'Q0A7Q#XE\>VIU69?,:UOM<G$ZG^Z0B; ?H:Y*7-'"4H6VNV_-VO;OL=
M5;EEBJCOV27DKZOM_P  _7G^Q-._Y\+7_ORO^%6HXDAC5(T6-%X"J, ?A7X>
M>"/VK/VB/V#?B/:^%_B&NHZCHD3#S=&UA_.26$MS);S<\GUR?0@5^RWPE^*F
MA?&CX=Z+XR\-W!N-)U2 31[OOQG^)&'9E/!%;<J=/VD'=&7,XS]G-69^0/\
MP4 \5ZG^T[^W1I7PTLKAFTW2[N'1;>-6R%D<AIY![X_]!K]@/A3\+] ^#G@/
M1_"?ANQBL=,TV!85$: &1@/F=CW9CDD^]?C-^SFR>,/^"I4-Y-T_X2.^GPR]
M2J2 ?Y]J_<>L\.N7 TGUG[S^?_!O]YIB-<9472%DOQ_1(^6?^"AW[-VC?';]
MG_Q#>?V=$WBK0;62_P!,O%0"7<@W-%N_NL!C%?-/_!%WXTW.I:#XL^&-_.TB
MZ81J>GHW2.-VVR*/^!$'\Z_2?Q5:I?>&-7MI #'+:2HV1D8*$5^,?_!)'4!I
M'[8&J:>OW+K3[N(8''RG</Y4833$5:724;_-7?Z(,5KAX5.L9)??9?YG[8T4
M44 ><_&W]H3P)^SOH-GK/CW63HNG7DWV>&46\LVY\9QB-6/2N0\;?MM?"#P#
M\+]%\>ZIXI0:%K<9DTM8X7-Q> 9&4B(W8R,9( %?,O\ P6F_Y(/X2_[#!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \__
M &A/^2!_$G_L6M2_])9*_/+_ ((<_P#'C\7/^NFF_P KBOT-_:$_Y('\2?\
ML6M2_P#262OSR_X(<_\ 'C\7/^NFF_RN* /U-HHHH *_''_@DC_R>9\0_P#L
M$7W_ *60U^QU?CC_ ,$D?^3S/B'_ -@B^_\ 2R&@#]CJ_&K]@O\ Y2C>-_\
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MWMK#<1>-=3,<R+(I/C27H1D?QU-_PPW^W#_T.FI_^%K+_P#%T ?LG17XV?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQG8%%%% 'XV> _\ E,]??]C+J'_I'+7[)U^-G@/_ )3/7W_8RZA_Z1RU^R=
M!1110 4444 %%%% !1110 4444 %>-?"_P#Y.,^-O_<$_P#2-Z]EKQKX7_\
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MQ1:7'A#5MWENUS\]L'Z8+X#)S_>4 =VKZ*CD2:-9(V5XV 964Y!!Z$&OCO\
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ME:)9+MM=/MH[:/CJ%4#)]SC/XUZ,?W.#;ZU'^$?^">1+_:,Q2Z4E_P"32_\
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M%W@:S0$RF";@=?FD0#^1KW'PS^UM\--=\-PZE=^(8=(N/+#7%A=(_FQ/CE0
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M4GR^&/\ #S(?]IEKZZ\0:+;^)-"U'2;LN+6_MY+64QG#;'4JV#V.":^>/^&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7X__ /!;3_DLGPT_[ LO_I0: /UM\+_\BUI/_7I#_P"@"M.LSPO_ ,BUI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCXD^#](\3Z#<&ZT?5;=;JUF92I>-AD'!Z4^5VOT%=7L;U%%%(84444 %%%%
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MU)27<S2(C=5)5D)QU&* /M+]F']@'X8_LUZ+,L&GIXIU^]ACCOM4UF&.;<5
MW"*,KB-"PW8Y/N:^A+SPGHFHZ7;Z;=Z-I]UIUOCR;.:U1X8L @;4(P, D<#O
M6K7CO[3W[4GA#]E/P/!XC\6+=W O)FM;*SL4#R3SB-W53S\JG9@OR 2* /!O
MVPO^"9?@+XX:7=:_X0M(_!GC*$RW4DFFVX:+4CY?$3Q;E56+*H#+C&6R#FOR
MK_9QUJ3X,_M?>"M0^(\MUH!\.ZPG]JMJBOYML(E(VL,%N  !^&.*]^OOC]^U
M3_P4,\22:7X%BO-!\.6T\8D30G>SM+1\2E&GNL[]Q7((W;20ORCBOF67X+^-
MOB#^T=_PK:?6[;Q-XTN]173I]4_M!KR%I0 &+3G)8)C:3V*XH ^T_C]_P5P\
M<^/O$]UX>^!FBR6>D7%F8([R[L#/JCRLN6EB1&*Q[,X&0_W<^U>(^*/V8_VQ
M?''Q&LOB!K?@[Q)J/C"U>":WU:9K99HVA(,1 #  J0,<=J_6S]E/]CKP1^RO
MX)L=.TJQM]3\2[3)?>(KB!3<SRLN'V,1F./' 0'H.<G)KWJ@#\=OA9_P5>^,
M/PAU33='^+_A-M:TN./[,]Q-:O8Z@[+(H>8LP*2E5W#:%4$D<BOU+^#?QV\#
M?'[PRVO>!?$%MKEC&RQW"Q966VD*AMDB'E3@_3@X)Q5#X[_LX^ /VD/#4>C>
M.M"BU2.W+O:72L8[BTD9"N^-U((ZYVG*D@9!Q7XMZGK/Q _X)@_M->+-+\/N
M+X363V]G/JD3K!>6LF#%<>6K ,R,'4$Y&0_&#B@#]JOB]^T5\./@+#9/X]\6
M6/AQKX.;6*X+-)-M'.U5!./<\9K\7_\ @H[^U?X+_:L^(7@_6O!D.J16>DZ=
M):7']J6ZPL7,I<;0KMD8^E=I^S+^PI\2_P!N:]/Q)^)WBG5+#PW/='9>7Y:6
M[U!#(S2BV#G;%&&9L':5R2 O%?H+H?\ P2]_9TTG1K&RN? W]JW%O"L4E]=Z
MA<"6X8#!=PDBKN)Y.T <]* '?!S_ (*.? 3QUX<T2#_A-(_#^I2M'8)INM0M
M#-YGRH"2NY I)X8M]<5]51R+(BNC!T89#*<@CU%?F7^TA_P1OT'4-'U'5_@]
MJ5Q8:\]V)8M"U:X!LO))PT<<FW>A7.07+9 ([@UY[^Q7^VK\2_@/\;+#X(_&
MBX<:*LBZ3%)K3"*729%W>6?-QF2-\A?F)ZI@@"@#]>*_-3_@M[_R2WX:?]AF
MY_\ 1 KH_P!KK_@K'X=^$VH7/ACX7VUMXM\56-ZUM?7=XC'3X0H&Y49&!E;<
M2N00 4/7BOB/XO>,/VG?^"@"_;I/!.I:KX<TJZ'D:;HVF%+:TG,2AL,V7)8<
MG+$?-QB@#]>?V*?^32/A%_V+5E_Z*%>UU^)_PR_;P_:%_8SM=/\  GCGPB;S
M1=)6TB2QURQ:"XM+-0 (HI$POS+T9PW./I7Z8?LN_ML?#K]J71+4Z)J,.E>*
M6B>2Y\,WDZF[@"E0S#@;T^9<,!WZ<&@#Z KG+KX;>$;VYEN+CPMHL]Q*YDDE
METZ%G=B<EB2N22>]='10!R__  JWP7_T*&@_^"R#_P")KYG_ ."D7@+PQHO[
M&/Q$N]/\-Z18W:16FRXM["*.1,W<(.&"Y''IZU]@5\N?\%-O^3)/B/\ ]<[3
M_P!*X: /'O\ @D+X)\.^(?V4[JYU30-+U*Y'B.\037EE'*^T108&YE)QR?SK
M[<_X5;X+_P"A0T'_ ,%D'_Q-?'O_  1N_P"32+O_ +&6\_\ 14%?=5 ',#X7
M>#%((\(Z$".A_LV'_P")KIZ** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_P#M"?\
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M[(OQ"U*[\)S?%#Q*+&;R]6GL5DNK:213''+&N3Y<<182,0>B$UR?_!#N-?\
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M[P)8:'X?TO3_ #VU73Q.5%P9$"0L7)7+*9&QU^2OM/\ L+3?^@=:_P#?A?\
M"I[:RM[)6%O!% &Y(C0+G\J )Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH _''_@DG_P GG?$/_L$7_P#Z6PU^
MQU?CC_P23_Y/.^(?_8(O_P#TMAK]CJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#\;/ ?\ RF>OO^QEU#_TCEK]DZ_&SP'_ ,IGK[_L9=0_](Y:_9.@ HHHH **
M** "BBB@ HHHH **** "O&OA?_R<9\;?^X)_Z1O7LM>-?"__ ).,^-O_ '!/
M_2-ZZJ/P5/3_ -NB<.(_BT?\3_\ 2)'LM%%%<IW!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?G3_P53_;6U7X1Z?!\+_!-]]BU_5K;S=4U"!OWMK;MP(U_
MNLX[^E?&G[)__!-GQ_\ M0V$?BK5K_\ X1/PE<L635+R,S7%WURT<>1N&?XF
M(_&LC]I2V/QA_P""B.MZ+JC'[/?>*XM(;+=(1*L6,]OEK]Z/#^B6?AK0]/TG
M3[>.UL;*!+>&&)0JHB@   ?2IPD8_5_K4U>4]O+K^":MYW9>)E)5_J\=%'?S
M?])_*R/@71_^"+?PJM=/ACU'Q1XAOKM1B2>,QQ*Y]0N#C\Z\Z^+7_!%&W73[
MN\^'?CB5KQ%S#IFM0#8Y]/.4\?\ ?-?J?11)<W6PHOEZ7/YZ_@M\8?B7_P $
M_P#X]26>IVMW8?99Q#K7A^X<B&ZA/<=LX^97'M7[]>#/%NG>//">D>(M(G6Y
MTS5+6.[MY5Z,CJ"/YU^9W_!;+X<Z7'I?@+QO#!'%J\D\FF3RJ &EC"[USZX.
M:^D/^"5WBJ\\4?L=^&1>R-(VGW%Q81%CG$:/A1^ -;4)RKX>7/\ %!V^7]6?
MEJ95H*E6C*'PS7X_TFO/0^NZ***S+"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /BC]KS_ ()Z_"/Q]I_Q$^*5_;ZQ
M;>)TTB[U)OL=_M@DN(H'=79&5NI49 ('IBOA;_@FA^QO\/OVKK7Q])XY.K!]
M%>S6T_LR[$ Q*)M^[*-G[BX_&OV _:$_Y('\2?\ L6M2_P#262OSR_X(<_\
M'C\7/^NFF_RN* '_ +87_!.?X!?L\?L^^*?&5M?>(+/6;>'R=*%YJ ECFNV_
MU<941<Y ;N!QUKHO^"*?@&PM_A;XR\67.A+%K%QJWV2UU:: AY+81(2D;G@J
M'WYV]\@]*^FO^"AO@W3_ !G^R#\1(K[33J<VGV)U"RC4,6CN4.$D4+U(#-[<
MFOF7_@BGX^L;CX6^,O"=SKJRZQ;ZM]KM=)FG)>.V,2 O&AX"E]^=O?)/6@#[
MW^,GA&^\??"3QIX9TR6*'4=9T:\T^WDG8B-9)8712Q )VY89P.E?E;_P23^,
M6G_!/XO^-OA3XO\ )T.^UR1/(NKZ1H2;NW+*+<*RC!=9'8%B/N =6%?L'7YA
M?\%&_P!@_P 2WWCS_A=7PCTXMJ=L&U76[>.?=.US$Z-'/;Q%3N; 9F&<?(,#
ML0#]/:BNK6&]MY(+B*.>"12KQ2J&5E/4$'@BORK_ &9_^"ODWA728_#/QRTC
M4KK4;,2;O$-E"OVB3E2B2VV%&[EOF! P%^7J:^E-3_X*O_L^:;X7TC6EUO5+
MQ]0:13IEK8;KRUV-C,R%@%#=5PQR#0!6^.W_  2[^!_Q*U/Q1XMF:]\&ZI?Q
M27$EU97*16%M-M.9VA90,9^9AN //2OS!_9U^,VG_L?_ +7RWOASQ-_PDG@:
M+4&TF\U-%:WBU"P=@OG,N&(5#ME"CJ8P,\U[E^TU_P %&/B%^UAJ1^'/P<T#
M4M,T'4FETV>*&);B[U>*8F%5<;2(496&5SD$\M7R]X#_ &4_$?B[]I:;X)7=
M_9:5XIBENK5I@3-;BXA@>79N&."4V[NV<X.* /Z+-"UW3_$VCV>K:3>PZCIM
MY$LUO=6[AXY4(R&4CJ*^2O\ @H9^PZO[57A:PU?PQ;V=O\1-+*P07MY<-%'+
M9Y9FA;"MDACE>F"S<\U^?'A?XR?M/_\ !/'Q)>^ Y[-]2TFSA::/3;RU>]TT
M+(0?/AE3:P'R$8W #YOES7O-K_P7"1='A2X^%3R:F( ))H]8"PF;;RP3RLA=
MW.,YQQGO0!Y?^SO_ ,%"OBI^Q_K"^ /C!X>U;5M"M'BLXK>^7R;S3(82(6$&
M1MEC54P%R 2O#<U]<C_@L5\##X?;4OLGB87*W0M_[-^PQ?:"I0MYP_>[=@(V
M_>SDCC'-?!OCSXS_ +0O_!1#Q+H'@X>&;&&&^1%C6RTKR+<J&\SSWN9 [J@!
MR=K $#H2>>!UK]E^3X)?M<?#[X7>,I[777O+W1SJL%ON6'%RZ&2 -D%@ Q7>
M,9ZX% 'U#^U!_P %7M:^,FBW7@3X+^'=5TP:M&L4FK2+NU%U*MYL4,,>[;D8
M^<,3C=P.H\%\=?\ !//XJ_"G]GS3/C-?/'!>PS?;;_1V.+K3K?*F*=R>"V[.
MY>HRO4Y _9[X3_LL_"?X'WEQ=^"/ VEZ%>3LK-=(K33 J&4;7D9F3AV'RD9S
MS7I6IZ79ZU836.H6D%_93+MEMKJ)9(Y!Z,K @CZT ?$/[!__  46\,?&;PGI
M'A#QWKJZ=\1;.T/VF]U%8[:UO]KL%,;[L&38$+ A<DG'I7W17YT?M4?\$B?#
MOQ#U#5O%/PMU-?"VOW4DET^BW(S82R%1A(B,&#+!B3\P&[@ "OA']H'PS^T-
M^R)>0>%?%OC_ %"/_A)[19C'IVN37 >.*8;06;#(0X'W<9'!XXH _<KXQ?&_
MP9\"/!]_XC\9:Y:Z59VL#3K \B_:+G! "0QYW.Q9E7CC+#) YK\%OVBOVH-:
M_:'_ &@X_BU<:#]FTW1[BTAM+6,-MC@BE:2*.64#&]SYAS]< [:^G_ /_!)K
MXQ_%#Q#IUU\5O'4$.@Q1)*D\>H2ZG<NC.A:)-^!'E-QW9(! X-?<.M?\$]_A
M?'^S%J?PCT?29%MY&.H0ZE+,%NY=016$4\D@&#C<4QMVA6.!GF@#VGX(_&#0
M?CI\,]#\8^'KZUO+74+='FCMI=_V:?:/,A;@$,C9'(&< ]"*[NOPU^'WQ0^.
MO_!+OXDCPQXETEKSP?)*+Z[TJ/!L;_S45?.AN=F1(!%MYZ%""M??'PS_ ."M
M'P*\=3Z=9ZI?ZEX0OKBV\VX?5K8?9;>0)N:/SE)W<Y .T9]LT ?:5?"W_!6C
M]H#0O 7[/-_\/Q/:WOB3Q8T<'V#S\36ULCB5K@J >-R(H!QG>2,[37)_%K_@
MLY\.M(\-2_\ "O- U;Q#KTF^./\ M:(6EO =C;)#@L7&[;E!M)&>17S-^SQ^
MS'\6?V^OC!IWQ+^+*7%WX-M[E+74+R[(LYKB%%=TAMT"?,@8JK'@[7X)/0 Y
M3X7_ /!//]H36O@WIGQ$\&ZG%;6]W#_:-IH<&H3VM^[!]HQ&RJ@8[0PRV",<
MUYG^U9JG[0JZMH/ACX[7VL27H0WVFV6K3PR;5=C&9%,9(&2A')_AK^AO2M+M
M=$TNSTZQA%O96<*6\$*DD)&BA549YX  K\X/^"V7@V[U'X9^ O$=II(F@T[4
M)X;[4DC7,*2*@B1FZX+;L#IG- 'VM^RQX=G\)_LW_#32+NVAM+RT\/V<5Q#;
MLC()1"N_YD)5LG)W G/7)KU.OFW_ ()\_%WPO\4_V7O!5MX<O#/<^&],M=&U
M*VD38]O<11*I!'3!QN4CJ".G2OI*@ K@_CM\/M'^*7P@\6^&=>B>73+[3IED
M\H@2+A"0R$@X8$=<5WE>*?MC?&FU^!/[/7B_Q&;[3[75OL4D&F0:@25NKAAA
M8PH(+$@GI^- 'Y_?\$1/$NJ-XO\ B3X?-]*=%6Q@OQ8Y'EBX,@0R?[VU0/H*
M_6ROYZ_V*?VL=6_8V\9:AXG;PJWB#0M=M?L<\;LUN7V,64Q2E2N0W48/'I7Z
ME?"'_@JU\#?B3;0QZUJT_@;4UM%N+B+68_\ 1UDR T4<R_?()_NKD F@#[*H
MKFO!/Q)\*_$G2;34_"_B#3]<LKJ'[1#)9SJY:/.-VWJ!GCD5TM !1110 444
M4 %%%% !1110!^-.O_\ *:*+_L9[;_TBCK]EJ_&G7_\ E-%%_P!C/;?^D4=?
MLM0 4444 %%%% !1110 4444 %%%% !1110 4444 <MJ'Q5\%:3?3V=]XPT&
MSO(',<MO<:G!')&PZJREL@^QJO\ \+F^'_\ T//AO_P;V_\ \77P/\<O^"05
M_P#&'XP^,?&\7Q,MM+CU_4YM0%DVCM(8?,8MM+"8;L9ZX%<-_P ..=2_Z*W:
M_P#@C;_X_0!^F/\ PN;X?_\ 0\^&_P#P;V__ ,71_P +F^'_ /T//AO_ ,&]
MO_\ %U^2/QX_X)&W_P $?@_XK\=R_$NVU:/0;)KPV2Z0T1FP0-H?S3CKUP:\
MW_8N_P"">=W^V%X%USQ);^-X?#"Z7J7]G&VDTYKDR?NDDW[A(N/OXQ[4 ?MM
M_P +F^'_ /T//AO_ ,&]O_\ %T?\+F^'_P#T//AO_P &]O\ _%U^9W_#CG4O
M^BMVO_@C;_X_1_PXYU+_ **W:_\ @C;_ ./T ?JQI>JV6MV$-]IUY;W]E,-T
M5S:RK)&XSC*LI((R.U6JX3X&?"6P^!7PE\,^ ],NIKVRT2U^SI<W&-\A+,[,
M<<#+,V!V&*[N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\
M@J7_ ..T ?<5%?#O_#XCX ?]35_X*E_^.T?\/B/@!_U-7_@J7_X[0!]Q45\.
M_P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\ @J7_ ..T ?<5%?#O_#XCX ?]
M35_X*E_^.T?\/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_
MP^(^ '_4U?\ @J7_ ..T ?<5%?#O_#XCX ?]35_X*E_^.T?\/B/@!_U-7_@J
M7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\ @J7_ ..T ?<5
M%?#O_#XCX ?]35_X*E_^.T?\/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35
M_P""I?\ X[1_P^(^ '_4U?\ @J7_ ..T ?<5%?#O_#XCX ?]35_X*E_^.T?\
M/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\
M@J7_ ..T ?<5%?#O_#XCX ?]35_X*E_^.T?\/B/@!_U-7_@J7_X[0!]Q45\.
M_P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\ @J7_ ..T ?<5%?#O_#XCX ?]
M35_X*E_^.T?\/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_
MP^(^ '_4U?\ @J7_ ..T ?<5%?#O_#XCX ?]35_X*E_^.T?\/B/@!_U-7_@J
M7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\ @J7_ ..T ?<5
M%?#O_#XCX ?]35_X*E_^.T?\/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35
M_P""I?\ X[1_P^(^ '_4U?\ @J7_ ..T ?<5%?#O_#XCX ?]35_X*E_^.T?\
M/B/@!_U-7_@J7_X[0!]Q45\._P##XCX ?]35_P""I?\ X[1_P^(^ '_4U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P .M_V;?^A!?_P;7G_QVOJ^B@#Y0_X=;_LV_P#0@O\ ^#:\_P#CM'_#K?\
M9M_Z$%__  ;7G_QVOJ^B@#Y0_P"'6_[-O_0@O_X-KS_X[1_PZW_9M_Z$%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLZ?]%6T;_OB;_P"-UZU8?%_P+JEC;WEMXQT&6VN(UFBD_M&$;D8 @X+9Z$4
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M %%%% 'G_P"T)_R0/XD_]BUJ7_I+)7YY?\$.?^/'XN?]=--_E<5^AO[0G_)
M_B3_ -BUJ7_I+)7YY?\ !#G_ (\?BY_UTTW^5Q0!^F?C;_D3-?\ ^P?<?^BV
MK\A/^".GB+3O"/B'XRZUJ]_#I>EV'AV*XN;V=ML<$:R,2['L!UK]>_&W_(F:
M_P#]@^X_]%M7X(_LH^.+?X?_  %_:5OKJUEO(]0\-6NBJD3 %'NIGB5SG^%2
M<D=30![I_P $@O#]KXZ_:D\9>*M:CGU?5=,TR:\L]4N)9'99Y95B=RV?F9HY
M''S9ZDU-_P $D?\ D\SXA_\ 8(OO_2R&O?O^"+/@O5="^!GBW7[R&--,UW5E
M:QD60,SB%6CDRHY7#>O6O ?^"2/_ ">9\0_^P1??^ED- '['5^-7[!?_ "E&
M\;_]?GB'_P!'O7[*U^-7[!?_ "E&\;_]?GB'_P!'O0!^RM?C?\*?^4S6K_\
M8R:M_P"DTU?LA7XW_"G_ )3-:O\ ]C)JW_I--0!^R%?C9XV_Y3/6?_8S6/\
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MW[#G[;OC70[G1M?UK4-:TFY $UC?^+TFADP0PW(TI!P0#SW% 'UQ_P $;O\
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M$Q?AAHWP]_9'\):AIJ%[WQ+&=6OKB1$#F1B5";@ 2BA3M!SC<WK7S3_P5O\
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M!E.,@@C\*WZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJGT]#%U/K%6FZ<7:+NVTTOA:ZVOOT/1:***XCTPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX(@>%&))^*6M$_\ 8,B_^+K],J* /S,_X<?^$_\ HJ6L_P#@KA_^+H_X<?\
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M\FG7MQKGA:%HV?\ M#6+)1;@CHI\IW;)[?+BOHWP9^TM\*_B!H,&M:%X_P!
MN].G9DCDEOD@8E6*D%)"K#D=QS0!Z712 Y&1R*6@ HHHH **** "BBB@ HHH
MH **** "BBB@ KYZ_P""@G_)F7Q7_P"P1_[52OH6OGK_ (*"?\F9?%?_ +!'
M_M5* /G7_@BA_P F]^-/^QF;_P!)H*_0^OSP_P""*'_)O?C3_L9F_P#2:"OT
M/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q
M_$'@W0/%AMSKFAZ;K)M]WD_VA:1S^5NQNV[P<9VKG'7 ]*SX/A9X+M3F'PAH
M,1]8],@7^2UU%%6IR2LF9NG"3YG%7]#.L?#FDZ80;/2[*T/K!;HG\A6C114M
MM[EI*.B"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOS^X^E:***S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5EN)6:+,8Y&0>?2@#]YZ*^,?^'N'[.O_ $&];_\ !--1_P /</V=?^@WK?\
MX)IJ /LZBO&?V=?VMOAW^U(NN-X"O;Z\&BF$7?VRR>WV^;OV8W=?]6W3I7LU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7[8?[+.F)XB\*C4+>WL[M+IM-\.:H+L228QYDEJI*R* H!W*1@#->Z?LA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***QO$OC3P_X+@AG\0:[INA0S,4BDU*\CMUD8#)"ER,G'84 ;-%<-_PO;X:_
M]%#\*_\ @[MO_BZ/^%[?#7_HH?A7_P '=M_\70!^46O_ /*:*+_L9[;_ -(H
MZ_9:OQ3USQ=H,G_!8"/Q NMZ:V@_\));R_VJMW&;78+- 6\W.W&>,YZU^N?_
M  O;X:_]%#\*_P#@[MO_ (N@#N:*X;_A>WPU_P"BA^%?_!W;?_%UK>&_B1X2
M\8WDEIH'BG1=<NHT\QX--U"&X=4R!N*HQ(&2!GWH Z.BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#P#]OK_DS?XL?]@5__0UKYG_X(E?\D'\>?]C+_P"V
ML-?3'[?7_)F_Q8_[ K_^AK7S/_P1*_Y(/X\_[&7_ -M8: /T7HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$W@_0O&FCWNDZ]I%
MEK&F7J>7<VE[ LL<R\'# CD<#\J\&^(7_!.W]G_XCV]E#=_#W3]'%J[.KZ /
M[/9]P (<Q8W#C@'I7TC10!^<GQ-_X(L^ -<N-4O/!7BS5/#3O;XL=-NE%S;I
M,$P"\C'S"I89/<9.*\$U7_@E7^T5\';K3O$?P_\ &%CK&OPS&-#HNH26-Q;*
MR,"X>78,8^7 .?FK]EJ* /QAA\=?MZ_LY:U>Z1/:^*?$L]Y%%.9+BS.O0Q@%
MP!'* ZH3SN4'/"Y'2NA^'O\ P6<\>>%KG3M(^(?@>RU62SF>'5;VU+6MXV';
M($)PBNO"X./N]J_7VN*\>?!7P'\4-'?2_%7A+2=<L))A<-#=6JD&09PQ(&<\
MG\Z /D/X>_\ !8SX+>*KN[B\066N>#(H45HIKVV^TK.2<%0(-Q!'7D8IG[57
M_!3+P#IG[.5UJWPOUV/7]?\ $#3:1:"&<VMUIK%&#73Q-B1=H!*'&"VWMFO0
MO'W_  2[_9\\?:C;7?\ PBDWATPQ>5Y.@7)M8I.2=S+@Y;G&?0"OS _X*&?L
M8Z9^R/XTT4>'-0U+5/#NNK//$UY;X6R(?Y(/-!Q(VW)R<$@9Q0!]/_\ !*O]
MC&R\2Z;<_&;X@V,.M"^9HM(TW5[+S?G61)/MVZ0<ME0$9<]7]J_5$<<#@5Y%
M^R+I6BZ'^S/\.+#P[K3>(=%@T>%;74VA,)G7GG8>5P<C'M7KU !7P'_P5(_8
MUT3XE?#'5_BEX>TP6_C;P_;">[>W*1K>6<8S(9<XRT<8)4CYCM"U]^5!>Q)/
M9SQRQK+&R,&210RL,="#U% 'P9_P2-_:/U#XJ?"._P# NNW%A]M\'I!;Z<L;
MA;F:S((W,G<(=J[QUW#-??5?BA_P2I^)/A3X;_M5>,?^$GUNRT!-4TRYLK*:
M^<11/*+A)"A<_*OR1L>2 <8ZXK]@M'^+G@7Q#J4&G:5XT\/:GJ$Y*Q6EGJL$
MLLA )(5%<D\ G@=J .MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWT?\..9/^BNK_P""+_[?7ZKT4 ?E1_PXYD_Z*ZO_ ((O_M]'_#CF3_HKJ_\
M@B_^WU^J]% 'Y4?\..9/^BNK_P""+_[?7TG^Q+_P3MT[]D'Q=KGB>7Q;-XIU
MC4+/^SXBMH+6*&$NKOE=SEF+(F#D8 /!S7V)10 4444 %%%% !1110 4444
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MJJ!@  = !4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?#O_  5P^#?BGXK?L[V%_P"&K1+Z/PM?MK.HP^8%D%LL+J\B
M@\-L#%CS]T,>>E?<507UC;:G9SV=Y;Q7=I<(T4UO.@>.1",%64\$$<$&@#X5
M_P""3W[3VD_$SX,V?PSO;F.'Q;X3MRL=G'"4$NGAE5)0V2&96;#=.67CFOO&
MOQV_:J_8%^*?[-_C^_\ B;\#Y[UM"GO);@:?X;,L=QI,*XE59%W$RQ90D]AA
M01R*ZGX=_P#!:S4]!\/K8?$'X<MJGB"!]C76EW?V170*H!>.16(<G<3@@<C
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MF:9')93ZE9I.]LWD71)C+ [3E5/']T5^K_[0G_) _B3_ -BUJ7_I+)7YB_\
M!)?_ )(S^TA_V"8O_2>[H _/31_%D6E^"?$6@MH=A>S:K-:RIJTT9-S9>27)
M6)NPDW@-Z[%KNOV=?CE9? _5]8O+WX;^&OB,M_ D*V_B2U,Z6VUB=\8[$YP?
MI53P/XPT/2?@!\3_  ]>7"QZYJ][H\NGPF$L9$A>X,Q#XPN Z=2,Y]J^T_\
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M[Q&.#[FO(?B%_P $8_A+XB^PGPMK^N>$?)W_ &@,POA/G;M^^1MVX;IUW>U
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MUE66*5#T964D$>XH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?CA_P]H_:-_Z)YHG_@FO?_CM'_#VC]HW_HGFB?\ @FO?_CM '['T5^,.I?\
M!8CX\Z*Z)J'@_P ,6+N,JMSIUU&6'J-TPS5Y?^"M7[1CJ&7X?:&RD9!&CWF#
M_P"1: /V0HK\</\ A[1^T;_T3S1/_!->_P#QVO7_ -E#_@HO\<OC+\<O#WA'
MQ'\-;231-0<QW5QIMC<6TEHG&9V:1V4HG4C&3V.: /TPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME'_#ZCXM?]"GX6_[]S__ !ROTP_X8A^ G_1)O"__ ( +1_PQ#\!/^B3>%_\
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M5^-O[:G_ "E<\&_]A+P]_P"AQ4 ?LE1110 5^/\ _P %M/\ DL?PT_[ LO\
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M/2M0BN6B4G +!&. 2.]=90 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?D'_ ,%OO^2G?#+_ + ]U_Z.6OUC
M\%\^#M"/_3A!_P"BUK\G/^"WW_)3OAE_V![K_P!'+7ZQ>"_^1-T'_KPM_P#T
M6M &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX?6_$7_H2M!_[[D_QK0S/V.HK\</^'UOQ%_Z$O0?^^Y/\:_4S]GOXD7GQ?\
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M5P[-&QW#YP0"0,XXXKX0^%*D_P#!9K5P 2?^$CU8_P#DK-7@/[0?_!0OXO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@".:-I89$5S&S*0''53CK7Y2_%C_@D_P#&O7O'NJZIHGQ=M]>M;Z3[3)?Z
MY=7%M=22MS(62-74?,3C!Z=A7ZO44 ?CE_PZ+_:#_P"BB:#_ .#6]_\ C517
M/_!('X^WD#P7'C_P[/"XPT<FI7C*P]"#%S7[)44 ?C18?\$=_CMI4;1V7CGP
MS9QL=Q2WU"[0$^N!#UJU_P .B_V@_P#HHF@_^#6]_P#C5?L;10!^.7_#HO\
M:#_Z*)H/_@UO?_C5?J;\ ?AA/\&/@WX3\$W6K2:Y<Z-9BWEU"4$&9RQ9CR2<
M98@9[ 5Z!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3PA_P6N^'5UX=M)/$_@OQ#8:XP;[1;Z7Y-Q;J=QV['=T8_+@\J.2:]C\%?\
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M\C\0?\$A?C5\,;JQU3X;^/;+4]5;S(YIK.>7298$('23>2P;D$#'3O7[%T4
M?B['\*?V\/V;]<)T6[\3>(9=1ML22V-W_;4"*&^Z1,&"/GG@ D'K4R_MT_MB
M?L\Z]&WQ%T"ZU1=0MF%K8^(M&$*?*RYD0P!"2.F"2/FZ5^SE-:-7QN4-]1F@
M#\GO _\ P6L\1:/)?0_$/X9V]Q,=C6BZ-.]H5'S;O,$V_.?EP1CH:]:^'O\
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ME2<#.1GBJVE_'[]O3X::#_8QT3Q1<V>D"1'O=0\-B\<JK,69KAXV,@'.&)/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHY)O[&U-A\ZH?^6<O"N=OS;1R #Z5]2@YY'(H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P""=/Q0O?BM^R;X.U'4IFN+^Q1],FFD)+2&$[0Q/J1BNJG)8BBZEK2B[/\
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MM6.E-'I$+6HWB:Y>3,K(1U R!_P$UKWOP#_;V\=::?"NM7OB,:',HAD^V:U
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M5?F.17RO0 4444 %>H?LO> M'^*/[0WP^\)>((9+C1=9U>"SNXH9#&[1LV"
MPY!]Q7E]?1'_  3Y\)ZMXL_; ^&BZ39M>-I^J1ZC=;6"^7;Q$&20Y/( /0<T
M ?M7\"_V)?@_^SMJ3ZGX.\*11:N7+QZGJ$ANKJ'*[2L<CY**1G('7)K\Y/A5
M_P IFM7_ .QDU;_TFFK]D*_&_P"%/_*9K5_^QDU;_P!)IJ /V0K\;/&W_*9Z
MS_[&:Q_](XJ_9.OQL\;?\IGK/_L9K'_TCBH _9.OQM_;4_Y2N>#?^PEX>_\
M0XJ_9*OQM_;4_P"4KG@W_L)>'O\ T.*@#]DJ*** "OQ__P""VG_)9/AI_P!@
M67_TH-?L!7X__P#!;3_DLGPT_P"P++_Z4&@#];?"_P#R+6D_]>D/_H K3K,\
M+_\ (M:3_P!>D/\ Z *TZ "OS4_X+>_\DM^&G_89N?\ T0*_2NOS4_X+>_\
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MU"VE\)^,M:\*VJ1;9K>YA6_,CY)WABR;>.,8/2N5_P"''>A_]%:U#_P21_\
MQZ@#] O#WQ\^&?BW6;;2-$^('AG5]5NF*P65EJT$LTI )(5%8DG )X]*[VOR
M?\;?\$4-:T73K>[\!?$Z.]UM)QE=6LVLD6/:V662)I&W9QQCH3S7)?\ #HW]
MH3_HHF@_^#6]_P#C5 '[&T5^,.M?\$T/VHOA5%:^*/#/BNWUW6]/N8Y;:VT7
M5YEN58-PZ^<J)A>IR?P-6_\ A"?^"BG_ #^>+_\ P;V?_P <H _9.BOQCU+P
MS_P4/TG3[J]N+WQD+>VB::3R]3M9&VJ"3A5<EC@= "3VI;/_ (*$?ME6=G!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@#];?"__ "+6D_\ 7I#_ .@"M.LSPO\ \BUI/_7I#_Z *TZ "OS4_P""WO\
MR2WX:?\ 89N?_1 K]*Z_-3_@M[_R2WX:?]AFY_\ 1 H ^P/V*?\ DTCX1?\
M8M67_HH5[77BG[%/_)I'PB_[%JR_]%"O:Z "BBL^3Q%I4,CQR:G9QR(2K*UP
M@((Z@C- &A7RY_P4V_Y,D^(__7.T_P#2N&OI#_A)M'_Z"UC_ .!*?XU\Q?\
M!2S7--O?V*?B-%;ZC:32F*TQ''.A8_Z7#T&>: .%_P""-W_)I%W_ -C+>?\
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M]8O!?_(FZ#_UX6__ *+6@#:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-)O8WN4L[2QLK2Y,ES,P+;=Q&U %5VRW'RXZD5\;_:)?^>C_ /?1K^C#P/\
M'/X&_MG:-KGA;2-4TOQS8PI&]_I%_:NA9-V5?RY54LH91\P! .,]13_^&'/@
M#_T2/PK_ ."]* /Q0_8A_:G7]E/XPMXJU*#5-5T2:REM;K2]/N GGL1^[9@Q
MVD*<D9Z9XKHOV^/VP-#_ &O?''A37=$T#4-!AT>P>TDBU"2-VD+2[\KL[8]:
M_8W_ (8<^ /_ $2/PK_X+TH_X8<^ /\ T2/PK_X+TH ^0]*_X+7> =/TNSM3
M\.O$C&"%(B1=6_.U0/7VJU_P^Z\ ?]$Y\2?^!-O_ (U]4ZG^P=^S_JFFW=FW
MPI\-VRW$3PF:ULUCECW*1N1ARK#.01T.*\F_X=#_ +/'_0,U_P#\'#_X4 <?
MX'_X+/?";Q#K@M-?\.Z_X4L/+9O[0F1;I0PQA-D66YYYQCBOFS_@I]^V/\+O
MVF_ G@G3/ &LW6IWFEZE-<W*7%A-;A8VB"@@NHSSV%?8?_#H?]GC_H&:_P#^
M#A_\*/\ AT/^SQ_T#-?_ /!P_P#A0!PO[,__  4K^ OPT_9]^'OA77?$NH6V
MLZ/HEK97D*:1<2*DJ1@, RH00#W!KTS_ (>Q_LW_ /0UZE_X)+K_ .(K-_X=
M#_L\?] S7_\ P</_ (4?\.A_V>/^@9K_ /X.'_PH Z#1/^"EG[/OQ*U2'PKI
MGCB\TW4=8W65O=W&G3VR12.I"MYCJ%4Y/!)ZXKY$\2_\$7?B#JWB+5;Z/XJ:
M5>1W-U+,MQJ$-PUS*&<D-*1D%SG+$=R:^I-+_P""3'[/VD:E:7]OINO"XM9D
MGCW:NY&Y6##(QZBOLN@#\?O^')OQ$_Z*7X>_\![C_"D;_@B7\0F&#\2O#I'H
M;>X_PK]@J* /Q]7_ ((E?$)!A?B3X=4>UO<?X4O_  Y-^(G_ $4OP]_X#W'^
M%?L#10!^/Z_\$3/B'D9^)?AX#OBWN/\ "OU1^$/PYM_A#\+_  MX*M+V;4;;
M0=/AT^.[N%"R2K&H4,P' )Q77T4 %%%% !1110 4444 %%%% !1110!^-.O_
M /*:*+_L9[;_ -(HZ_9:OQIU_P#Y311?]C/;?^D4=?LM0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %8GC3P7HGQ$\+:EX<\1Z;!JVBZC"T%S:7"!E=
M3_(@@$'J" >U;=% 'YC_ +:'_!,7X0?#KX$^)?''@Q=5\.W_ (<L9;PV_P!K
M>ZCO#E JOYI)4#GE<=:\$_X)S?L$>"_VJO"FJ^+?%NL:I##HNMK92:39[4BN
MXA%'(0TGWUSO(RI' XK]-/V^O^3-_BQ_V!7_ /0UKYG_ .")7_)!_'G_ &,O
M_MK#0!]H_ _]GSP)^SIX5?P]X#T--(L))FGF9G:6:9SW>1B6; X&3P.!7HU%
M% !1110!B>+O!'A[X@:+-H_B;1+#7]*F96DL]1MTGB8J05)5@1D$ BOE+XH?
M\$H_@1\0H]8N-.TB\\(ZQJ$OG+>Z3<N(K=MX9A';L?*"D C:%P,\5]D44 ?C
M]X\_X)&_%WX4Z^OB'X/^,HM6N+:\'V!5NCI^H01E&!E,I*ID?=(4Y(;ZUS6B
M_MS_ +5O[)<UAI7Q'T.]UC281<6EO'XIL74W,BOEG6[ #R[=W!W$;2.V*_::
MJ>IZ/8:U;M!J%E;WL+*RF.XB5UP1@C!'<4 ?GU\-/^"T'PU\076GV?C'PUJ_
MA4M;!KO48@+JW28*"51$S(5+9 )''&:^R_A3^T1\./C=9PS^"_&&EZY*]JEX
M]G!<+]I@C;&#+$3N0@D A@,'BO)OB'_P39_9]^(=E:V[^!;;PZ;=V<3>'C]C
M=\C&'*CY@.H!KXL^*7_!&/Q?X6ADOOAEX\AUCR[61Y+74E:SN9I!RL493*'=
M@#+%1GVH _7*BOQ37]I']LS]CR\N+;QI9ZQJNDP_9KBYDUVW.H6L4(;:(TND
M+)'NSM/S9SMXS7N'PP_X+9Z)J%Y<0^/O -UI$3/$MO<:'<BY5021(THDV$ #
M:1MR3SQTH _3RBO(?A/^UM\(?C8H_P"$1\=Z5?W#7/V2.SN)?LMS+)@$!(I0
MKOD$<J".OI7KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"/FZ]:\W_P"'U_PG_P"A+\7_ /?NV_\ CU 'Z'T5^>'_  ^O^$__ $)?B_\
M[]VW_P >H_X?7_"?_H2_%_\ W[MO_CU 'Z'T5^>'_#Z_X3_]"7XO_P"_=M_\
M>H_X?7_"?_H2_%__ '[MO_CU 'Z'T5X]^S#^U%X1_:N\!3^)_"27EJEK<M:7
MECJ$82:WD'(!()4Y4JP*D]<=<U[#0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEDK\9OV3O^3&/VLO^O31_P#T?)7[,_M"?\D#^)/_ &+6I?\ I+)7XS?LG?\
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M5;WJ7Z'3;@0R>8B.HR2K9&)&XQZ5ZG10!\,_\.<O@%_SV\6_^#6/_P",T?\
M#G+X!?\ /;Q;_P"#6/\ ^,U]S44 ?#/_  YR^ 7_ #V\6_\ @UC_ /C-'_#G
M+X!?\]O%O_@UC_\ C-?<U% 'PS_PYR^ 7_/;Q;_X-8__ (S79_!__@F+\%/@
MK\0=*\9:/:ZUJ.KZ7)YUHNK7RS0Q2CE9 JHOS*>1SU[5]9T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '.^*?ASX6\;6M[;Z_X=TS5X[R!K:?[7:H[21,I4J6(SC!(
MX-?-7Q!_X)9_L^>/9+)XO#%UX5^S!P5\/W9@$V['^L#A\XQQC'4U];T4 ?D[
MX_\ ^"+'B#0XGU+X<_$>*YU5+O=;6NIV[6?DPDMSY\;.2ZC:.$&>>E>7Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0?\ P G_ ,:_7RB@#\@_^'(/C3_HIN@_^ $_^-'_  Y!\:?]%-T'_P  )_\
M&OU\HH _(/\ X<@^-/\ HIN@_P#@!/\ XU]0_L&_\$[KS]D7QMK_ (JUGQ=!
MXAU&^L?[.@@L;=HH4C+J[L^[)+9C7&.,9K[;HH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#DO&?PC\$?$:ZAN?%7A#0_$=S!&8HIM4T^*X>-"<E59
MU) R2<"OE'XB_P#!(GX%>,-/AAT*VU;P7=+/YLEUIMXTYD7!'EE9BZ@9(/ !
MXK[;HH _(7XA_P#!%_QMX;N-2U;X>^.;/4VM)5FTJQO5:VNVPRXW3#"*Z\MD
M ?='2N7_ +/_ &\_V8]3OX;=_%.OI=VJ7,]TO_$^MHD0OP'<.(V')(&#@KGM
M7[14E 'Y%?#O_@M'XUT2XTVW\?\ @*QU+3X[;RY[K3#);W=Q*J@>9AR8QEN2
M !UXQ7TW\,_^"N7P.\;6^F1:Y<:EX.U6\N/L[6U];M+#!E]JN\Z#:%Q@D]AG
M/2OJ?Q]\%O 7Q2M;2V\7^#]&\1P6CM);QZC9)*(F(P2N1P2!7RY\3O\ @DE\
M#?'4&JS:+::AX.U:^G\]+K3[AGAM\N&9$MV.P*1E0!TSQTH ^H? /QL\ ?%2
M"\F\(>,=%\216;*EP^FWL<HB9@2H;!XR ?RKM0<C(Y%?D;\0O^"+/C#1[J^G
M\ ?$"QO]/2V\R*WU19+>ZGF"D^7E 4 )P 21UYKCEE_;Q_9BOM,N)4\4ZY#/
M;/:6]GN_MVVB1-G6-"XC(&T*3@XSCO0!^TE%?D'\/O\ @LYX[\+7&GZ/\1/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!X[^U!^T]X4_99^'4_B7Q'+Y]W)F+
M3M+B8>=>38X4>BCJ6["OQD^+7[?'QZ_:2\0W-AI>JZEIFGW65B\/>&4?E,Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMO#GQ3LK+P-J'E2%-;CE*Z<^WE48,2T9*@\DD$C'&17@7_!(BXCO/VP_']Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML;?4HFN)"5W;1'NW;L Y&,C!KTM9%DSM8-]#F@!U%%% !1110 4444 %%%%
M!1110 4444 %%%1732I;2M BR3A"8T8X#-C@$_6@"6BOR.\=?M1?M[:?XTUR
MVM_!.I6-O#>S)';:=X66\MXE#D!8Y_+;S5 QA\G(YK#_ .&K?V^_^A3U[_PB
ME_\ C- '[&T5^,'B3]M+]N;P?H=WK.N:+JND:39KON+Z]\(1Q0Q+D#+,T6 ,
MD#GUK/\  _[>?[:7Q,TR;4?"5K>>)+"&4P27.E^%(KB-)  2A98B <$''N*
M/VOHK\<O^&K?V^_^A3U[_P (I?\ XS1_PU;^WW_T*>O?^$4O_P 9H _8VBN"
M^ WB[Q+X\^#OA/7_ !AHK>'O$]_9++J&F/$T;02Y((*MRN< X/K7>T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/O(>S#\<5[O6]12C+W]S*G*+7N!11169H%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!&42*58!E88((R"*^0O^"B?P,^'VI_LV_$7
MQI=>#='E\5Z;HP2SU?[(HN( )1C:P]-[?G7U]7SU_P %!/\ DS+XK_\ 8(_]
MJI0!\@_\$>?@OX#\;?"O7?%>O>$M*U?Q)I/B0K8ZI>6XDFMP+>%E"D],,2?J
M37Z?6]K#9PK#;Q1P1+TCC4*H[]!7YZ_\$4/^3>_&G_8S-_Z305^A] !1110
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MI)%(H974C!!!X(([4 ?EO\//^"W5K/J$R>.?AS+9V(@_=2Z!=B>1I<CAEEV
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\>NT5XW>_P#!(OX_:';W<>C^.=%FLK82&UMX=3NH6D49*@+Y>U6;TSC)Z]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCX&O_ W@S2_#-[>ZQ+!<3V$95I(Q"6"G)/&>: /4O^'VWPR_Z$'Q9_WU:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH *S/$WAG2O&?A_4-#US3X-4TC4(6M[JSN4W1RQL,$$?YQU%:=%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[]F6VNX+EE&2(9%8C\C5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OS;_X+=?\ )(?AS_V'9O\ TG-?I)7YM_\
M!;K_ ))#\.?^P[-_Z3F@#ZR_8<_Y-!^$?_8NVO\ Z!7N5>&_L.?\F@_"/_L7
M;7_T"O<J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIKA3"8(4!W(I&<HW'M7U+_PZ%_9Y_P"@?X@_\&[_ /Q-'_#H7]GG_H'^(/\
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M ).D^)'_ & Y_P#TLAH _8BBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ_%&4G)5?9O2V_S-ZBBBL30**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \_P#VA/\ D@?Q)_[%K4O_ $EDK^9>OZ7O
MVC]5LK#X$_$.&ZO+>VEF\-ZD(DFE5"Y^S2#"@GGJ.GK7\T- !7Z6?\$0?^2G
M?$W_ + ]K_Z.:OS3K]+/^"(/_)3OB;_V![7_ -'-0!^OE%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP0?>NF\,_P#!93XH^']>M9_'7PYTN706#J\-C%/93NVT[=LDK.O!QD;3QZ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>O']:_X)R_L[:]J%]?7/PULENKR5YI7@NKB)0[DDE460*HR> !@>E %?0O\
M@I-^SKK6BV-_)\1K/2Y+F%96LKZWF6> D9V.%1@&'0X)'O7K_AWX]?#CQ7H=
MEK&E^.= N=/O(Q-!*VH11EE/0E6(8?0@&OCAO^"+/P;9B1XG\8+Z#[3;\?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _!'XEV8/_!3:ZAU'#1OX\A+>8V1L-RI'Z8K][$ "*!TQ
MQ7XE_P#!5?X6ZM\(?VHK7X@Z7'+;V.NB*_MKQ5^5+N+&X9]<J&QZ5]Z?L;_\
M%%/ _P"T=9Z%X7U!Y=%^(LL1CDTQHG:*=D7+21R 8P0"<$@]:,)[^"A37Q0;
MNODE^GZCQ?NXJ55_#)+7[W^OWZ'Y]?\ !5S1U\&?MG+J]NI5KNQL]0)QC+JS
M G_QP5^SOPI\1+XN^&/A/6U;>-0TJUN2WNT2D_J37YE_\%L?AI=_VCX$\=06
MY>S,<NF74RC[C@AXP3[@O^5>P_\ !.G]NCX>ZY\#=%\%^+O$MCX9\3^'(/LK
M?VO.EO%<P@_NWCD8A3@$*5SGY<]#2P=GA9TNL9/[M?TL_0,7IB(5>CBE\]/U
M31Y?_P %M/AW8QV/@#QO%&J:BTLNES.HP7C"[USZD'-?77_!.[XEW7Q2_9+\
M%:C?3FYOK.%M-FE9B6<PG:"3ZXQ7YX_\%7?VN/"OQQUOP_X*\%:@FL:5H,LE
MQ=ZE!S#+.PV[8V_B '<<9/%?>/\ P2_\&W?@S]CWPFEY$T,NHR3:BJL"#LD;
M*G!]A58/_=ZW9R37X_\ !%BK>UH_S)-/^O\ P$^L****0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?./[:'[:'AO]D;P
M/]HN%CU;QCJ,;?V1HF['FMT\V7'*Q*>IZG&!R:^C))%AC9W8(B@LS,<  =2:
M_$#6[75?V]/^"C$GA7Q!XCM]8\,6FL75O:F"4K!_9-L[.T<#1YPSQH<..K-N
M- %/P7\"?VA?^"FWB2+QKXBU2.+0;<M9)K6HH(;6 !68K;P(!O\ F"JQ4=2"
MQXKWO3?^"(J?\(+>K?\ Q'8^,MY^R26UKC3@N5P)%(\PG&_H1U7WS^GOA;PM
MI'@GP[I^@Z#IUOI.CZ?"MO:V=J@2.*-1@* *U: /P6^/W[ /Q7_8_P!0T[Q3
M:VMIXZT*W@>YGU2RT\W%M9LN59;B&0$!<,"&88.?5:]L_P""(3 ?$[XF D G
M1[7 SR?WS5^O%U:PWUK+;7,23V\R%)(I%#*ZD8((/4$5^(?[27@'4O\ @G?^
MVMH7B7P;J$<^F:G<?VW9:7;%K54M7G99+&3;QY>0R#&?DQGF@#]P:*AM)C<6
ML,K#:9$5B!VR,U-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5SOC3X=>%?B-9V]KXJ\.:5XDMK=S+##
MJMG'<K&Y&"RAP<''&17144 ?._Q%_P""?OP#^)US93ZK\/-.LGM$9$_L4MIZ
ML&()WB J&/'!.<<UX=X[_P""-7P<\3:X+S0]8\0>$;+RE0Z?9S+<1EP3E]TP
M9LD$<9QQ7WS10!^2_BS_ ((AZRWB"[/AGXE6*Z'E?LRZM9NUR!M&=YCPI.[.
M,#IBN,L?V _VR_AS!/H/A+Q/>6_AZRFE6T72_%)M89$WD[UBWC9N^]@C.3S7
M[-T4 ?BS!^T!^WK\._"(CN='\51:1HUI^\O=1\-).R0QKR\DSQ%FP!DLQ)/7
M-=)I?_!:;XEV<UD=6^'6@2V<;QBZDB^T1R.F0'*DOM#$9QQC)K]@64.I5@&5
MA@@C(-<_XI^'OACQOH-WHFOZ!IVKZ1=J%GLKNV1XI &# ,I'/(!_"@#X)\,_
M\%K?AOJFO6=IJ_@G7M#TV5]LVH&:.<0+@_-Y:#<W..!ZU[;X'_X*=?L\^.M>
M32K?QH=)E:-I!<:U:/96_P O8R2 *">PSS6]XZ_X)Z_L_P#CS1!ID_PXTG1D
M$JS?:=#B%E<9 (V^8F#M.>1T.!Z5XC\0?^"-?P=\1V]FGAC5=<\'RQ,QGD$W
MVWSU(&!B0_+@@\CKF@#Z\\!_'WX;_%"\NK3PCXYT'Q'=6L8EGATV_CF:-"<!
MB >!GBNZAN(K@$Q2I*!UV,#BORA\<?\ !$_7K'4+9O 7Q+M6M&B(N&UR&2"7
M?G@+Y(8%<8ZXYKB8?V$?VQO@)K%_I?PW\1W=SIEV(YI[[0->%I#.X! !25T;
M*Y(SCO0!^S%%?C!IOQ__ &[?@K+?^%+C1O$NO7%K<LTEW?Z&^K')5>$N0K!D
M],,0"36IX?\ ^"T/Q-\+Z7%I/B7P%HVKZ[9L\-W=RRR6CNX<\-"JX0KPI'^S
M0!^M7Q"\=Z1\,? ^N>+->F>#1M&M)+V[DC0NXC12S;5'WC@< =:_ W]L#]N3
MQI^U1XMOA]LO-!\# ^59^'(9R(FC5@RO. <22$@-DY /2O7OVU/^"E\'[4'P
M5TCP7HF@7WAR>>:.?75N?+DAE9 &"PN&W!1(#U R,9KX,H **** /IO]CG]N
MKQG^RSXLL8Y;V\U_P(V(;SP]-.6CCC+EB]N"<1N"S'C ;/-?O%\+_BAX:^,G
M@72O%_A+4H]5T+4H_,AN$X(/1D8'E74Y5E/(((K^8*OUJ_X(I_%Z;4O#OC3X
M;W4E]<'3F75K/S'!MK>%V"/&@SD,TC%CV.: /T^HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y_X]Y?\ </\ *OQ\_P"".7_)
MTGQ(_P"P'/\ ^ED-?L'<_P#'O+_N'^5?CY_P1R_Y.D^)'_8#G_\ 2R&@#]B*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** $8!@01D'@@UY1K7[)WP:U[3KZRNOACX5
M$=Y$\4LD.DP1RX<$$JZJ&5N>&!!!YKUBB@#Y!OO^"4G[.5U8W$,/A*\M)I(V
M1+B/5[IFB8@@. TA!(//((XKP_Q)_P $1_!K:%>C0/B'KL>L^7_HK:E#"UN'
M_P!L(@;'T-?I=10!^.>N?\$4?B-I>CWEYI7CS0=5U*")I+>R6"6 SR 95!(Q
MPI)[G@5G:O\ LC_MUZ%H]Y?'Q1XAN8[2!IC;V?B]Y9G"J3MC0299CC 4<D\5
M^SM% 'XQ:E^UM^W/\,]+CUWQ-HFN6_A_36B:ZEU/PQ''$R!U7;))Y0(#$A2<
M@_-US6Y;_P#!:GXF0W$3WOPV\/"S5U\[RS=*VS(S@E\ XZ9K]?I8DFC*2(LB
M-U5AD'\*Q/$O@+PWXRT*\T77-"T_5=)O$\NXL[JV1XY5R#A@1R,@?E0!^>L7
M_!;OP,TJ*_PV\01H2 S?;8#@=SC'->V:'_P56_9UU[6+'3H_%5]9R7<RPK/?
M:9-#!&6.-TDC#"J,\L>!7H/B']@_X!>(]#O=,D^%OAVQ2ZB,1N=/LDM[B//\
M4<BC*L/45XCXS_X(\_ [7- FM- ;6_#.ILRF/45O6NM@!!8>6YVG(R/;.: /
MHW2_VNO@IK6I6FGV'Q4\)W=]=RK!!;Q:K"7DD8A551NY)) _&O58[ZVF<)'<
M1.YZ*K@DU^8'BS_@B+I\.@W+^%?B;=OKRE3;+JUDJ6Q^8;MS1DL/ESC /.*\
MOUC_ ()7_M&_""73_$W@7QA8ZWXAM;@"%=%U&6TN( 48&0/,$7'\. <_-]:
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MYXW\/:]J3(T@L]-U.&>4J.K;$8G ]: .SHHHH **** "BBB@ HHHH *_-O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH X+XU_ _PA^T!X%N_"GC/3%U
M'3)OF1E.V6"0=)(V_A8>M?*G[,G_  3)L?V9_P!H1/'-CXG;7M%AM)TM;6Z@
M\NXMY7( R02& 3<,\'/:ON2>XBM87FFD2&)!N:21@JJ/4D]*\N\4?M5?"#P7
M>-:ZS\1?#]C<*<%&O%8C_OG-*#5*?/%V;_56').I#DEJE_G<W_C-\(/#OQV^
M'.K^#/%%M]HTK48]I9<!X7'W9$/9@:_'[XP?\$@/BYX.UJ<^#);#QGHK2$6[
MK,+>Y"8_Y:(WR@_1C7ZC_P##;WP&_P"BI^'?_ D_X4?\-O? ;_HJ?AW_ ,"3
M_A4<BYN=;E\[Y>5ZH_._]FO_ ((\^+-4\2:?JWQ;N[72/#\+"271[&;S;J<@
M_<9@-J*?4$GVK]==)TFTT+2[33K"W2ULK6)888(QA411@ #T KQK_AM[X#?]
M%3\._P#@2?\ "O7/#/B;2O&6@6.MZ)?0ZGI-]$)K:[MSE)4/1E/I72Y2E&R6
MASJ,5+F>YJ4445D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9WB)&D\/ZHBJ79K64!0,D_(>*_'O_ ((WZMIGA?\ :.\9
M:#K8&GZ_?:6T%C9W4#+-YL4A>5!D?(RHK9!QT(K]E:_$W]J/0?%_["/[=L'Q
M2AO/[4T_7=4FUV)K<>6TUO+*3<6CEE8*2&=-PR2"&XH _;*BO/\ X'?'+PG^
MT)\/[#Q?X/U!;S3[E0)(6P)K63'S12K_  L/U[5Z!0 5^3W_  6RU7P]-XD^
M'&C0Z6__  F9@DN#J00 -9EV1(=V>HE#-C'?K7Z@^//'N@?#'PEJ7B;Q/J<&
MD:)I\1EN+JX;"J!V'J3T ')K\-OC)XP\3?\ !2S]K9[3P?+!IML8&M]!M-=N
ME@6*WB7)^95)WR-N?;R07QGB@#]FOV8?#>M^#_V=_ASHGB2WFM-?T_0K6WOH
M+B3S)(YEC 96;)R0?>O3Z_&A?^":7[7*J /'5J . !XJN_\ XBE_X=I_M=?]
M#W;?^%7=_P#Q% '[+45\]_L._ GQE^S[\%!H'CSQ&WB3Q)=W\M_/(;B2X6W#
M*B"%9'.6 $>[.!RYX[GZ$H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>U?N3^R#_P $\_!/@S]G&'0?B1X=A\1ZQXD\C5-5M-3@$;V,NU2MNC(=Z[,
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M <__ *60U^P=S_Q[R_[A_E7X^?\ !'+_ ).D^)'_ & Y_P#TLAH _8BBBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'XW?\ !5C]KWQ3KOQ4OOA1X>U*XTKPUHX5+X6<C1O>SLN6
M5R#DJN<;>AKQGX6_\$P_CK\5O"]CXAL]#LM(TV]3S(/[6NQ!*ZGHWEXR 1TS
M5[X^>%?['_X*4WEEXLC'V"\\86]S)YQ^1K66=64D^FTU^\ELL<=O$L0 B5 $
M"],8XQ6>%IKZI&N]93_X#_6R[6+Q,G]9=&/PQ7]?E?SN?B!_PYY^/'_4O?\
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M2-'L)XXK#7[&ZM=01H@QDCCA:90I/*G?&AR/3'>OW8H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\,_B!I?Q6\ Z%XNT7S?[*UBU2[MO.7:^QAD9'8U^='_#D#0O^BH:A_X+$_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?XP_[\VW_P >H'_!:SX1Y&?"'C ?]L;;_P"/5]"?\.]OV=?^B4Z+_P!]3?\
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M5WB!NK2TMHKB**3NJR&12P]RH^E 'Z!45X#X,_;S^ OCS4],TS2OB3I1U/4
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M@#]C:*^>/V'?&'QG\;?!XWWQLT4:1XA%W(EJTMN+:YN( 3\TT( $9!RHX&5
M/?)^AZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OS;_ ."W7_)(?AS_ -AV;_TG
M-?I)7YM_\%NO^20_#G_L.S?^DYH ^LOV'/\ DT'X1_\ 8NVO_H%>Y5X;^PY_
MR:#\(_\ L7;7_P! KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /F_XW?\$_?@_^T)X\N?&'C'3-3NM;N(HX7DM=2DA3:BA5^4<#
M@5P/_#H_]G7_ * FM_\ @YFKV_\ :6_:D\$_LL^"UU[Q==2-+</Y5EIMH UQ
M=/C.%4D8 [L>!7D_[$/[>*_MA:]XNL6\,1^&ET=8Y;=?M9G>>-B06;Y1M(XX
M&>O6E2BI-PIK8=23BE.IULE^2_R,C_AT?^SK_P! 36__  <S4?\ #H_]G7_H
M":W_ .#F:O;/VJOVEM!_99^%-YXNUA/MER6%OI^G*^U[J<@D+GL!@DGL*_(#
MQM_P5>^/?BK66NK#6;'P[9JY,5GI]J,!<\!F;);Z\5"FI3Y%TW\BG!J*D^I^
MB?\ PZ/_ &=?^@)K?_@YFKZK^'7@'2/A;X'T7PGH$4L.C:1;+:6L<TAD=8U&
M "QY)K\U/V2?^"O&H>(O%5AX7^,-G900WTHAA\16">4D3D@*)H\D;<]6!_"O
MU,CD66-70AD89##H0>]=4HRC#?W7^:_57,%*,I6ZH=1116)H%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?\ [0G_
M "0/XD_]BUJ7_I+)7\R]?TT?M"?\D#^)/_8M:E_Z2R5_,O0!^H'_  0[_P"1
MG^+7_7GIW_H=Q7ZT5^2__!#O_D9_BU_UYZ=_Z'<5^M% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\%NO^20_#G_L.S?^DYH ^LOV'/\ DT'X1_\ 8NVO_H%>Y5X;^PY_R:#\(_\
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MCK7\TE 'Z@?\$._^1G^+7_7GIW_H=Q7ZT5^2'_!$2^MK'Q-\66N;B&W#6FG
M>;(%S\]QTR:_6#_A(-+_ .@E:?\ ?]?\: +]%1V]S%=1"2"5)HST>-@P/XBI
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "D90RD$9!X(-+10!YIXT_9H^%7Q!T&;1M=^'^@76G3,KO'%8I;
ML2I!!#Q!6'(['FO$/B%_P2O_ &??'&F6]I8^&+CPA+#-YINM"O'660;2-C>;
MY@V\YX .0.:^NJ* /S#\>?\ !$?0]0UP2^#OB/=Z-I'E*#;:M8B\F\S)W-YB
M-&-I&.-O'/->3:M_P2I_:,^'NH:I8^!/&MI<>'T?SH9;75Y]/>Y;8N28%R V
M1MY8YVCFOV5HH _%&7Q-_P % /ASX4^T7 \96NAZ+:@LTUI;3^7#&H^\=K.V
M%')Y)KJO#W_!8+XS>$];LKGQY\/M+N-!.Y)(;>TN+":5MIV[99&=00<$C:>,
M]*_82L/Q9X%\-^/+.&T\2Z!I?B&UAD\V*'5+..Y1'P1N4." <$C(]: /SX^'
M_P#P6P\#:QJ\T/B_P+JWAK3UA+1W5A=)?LTF0 A3;'@$%CNR>G3FO?O G_!3
M+]GKQQHSZ@_CB/PVRS-#]CUZ%H)S@ [PJ[@5.< YZ@UU7Q%_81^!/Q2GL9M:
M^'.DQ/9JZ1?V2K:>"&()W" H'Z#&[..<=:^=_&O_  1C^$GB#5M3OM$\0^(O
M#D=QEK;3H)(IK>V;;@ &1"[+D9.6SR>: /MO2OBCX.US3[.]L?%.CW-K>1)-
M!(E]'^\1P"I W9Y!%=17X]:]_P $3_'VE:/=WFC_ !"T75-4@C,EM9?9)+?S
MI!R%\PL0F?4BL.Y^!?[=?[/NJ:=XBT[5/$GB*Z9G@2#3]5;650%""9('+*!C
MHQ'!]Z /VAHK\95_;Z_:]_9[UZ,_$CPW-J2ZA;-]EL/$6B_9EX9<RH8 C$CI
M@DCYNE>D>"_^"VSV>DO#XW^&3RZVLS G1;SR(1'@;04E#,&SG/..E 'ZI45\
M.>#?^"P'P+U[1]/FUIM:\.:I<';/8R637"VYW$#,J\$8PV0.,^U?0>@_M@_!
M+Q1K5EI&D_%'PQ?ZG>RK!;6L.HQEY9&.%51GDDT >P456M=2M+YF6WNH;AE&
M2(I Q'Y&K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5^;?_!;K_DD/PY_[#LW_I.:_22OS;_X+=?\DA^'/_8=F_\ 2<T ?67[#G_)
MH/PC_P"Q=M?_ $"O<J\-_8<_Y-!^$?\ V+MK_P"@5[E0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'YK_\%1/V$?$/Q8U9/BE\/[%M
M5UB&W6#5=(@&9IT0866,?Q,!P5')KX UC]KCX]:?\.Y?A+J7B35[728U^QR6
M$\!2\"=/)+D>9M[;<].*_HGK/F\.Z5<3&:73+.28G)D>W0L3ZYQ64*?*G#>#
MUM_7]?(TG/F:G;WEU/R6_P""8G[!_BEOB)8?%/Q]H<NC:)I:F72;+4$*37-P
M>!)Y9Y"*.<D<DC'2OKO_ (*6?M ?$+]G/X0Z/XB\ WEK8RW%^;.\GN+99BJL
MORE0PP#D'FOKT *  , =!7.^.OAWX9^)FD1Z5XKT.RU_3HYTN4M;Z(2()%.5
M;![BM:SE5C&$79*WYZ_>C.BE3DYRU;_RT^[<_ WX'_L[_%?]NOXK/J=U)?WU
MM=7 ?5O%&H[C%"F?F"L>&8#@(M?OE\._ FE_#'P/HGA7181!I>DVL=I G^RH
MQD^YZ_C6MI^F:?X?L1!96MOIUG$O^K@C6-% 'H, <5-8WUMJ=K'=6=Q%=VT@
MW)- X=&'J&'!K7F4::I05E_7](SY7*?M)N[)Z***R- HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B']O;]A7Q]^UQXV\/Z
MAH7CNQT+0-+L/(&EWYG*_:#(Y>90@*Y*E%SU^2OEO_ARG\3/^BE>'?\ OW<_
M_$U^P5% 'XQ>./\ @CW\1?!'@KQ!XBNOB)X?N;;2-/N-0EAC2YW2)%&TA497
M&2%(Y]:_/2OZ:/VA/^2!_$G_ +%K4O\ TEDK^9>@#Z*_8[_8U\2?M?:AXGM?
M#OB/3_#SZ%%;RS-J"RGS1*7 "[ >GEGKZBOIS_ARG\3/^BE>'?\ OW<__$UM
M?\$._P#D9_BU_P!>>G?^AW%?K10!\P?L&?LM^,?V4? >O>&O%/BZV\3VUU>K
M<V$=F9?*M%VGS !(!C<Q!./2OI^BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!DD,<V/,C5\=-P!KS3Q%^S#\(_%VMW>L:W\-O"^JZK>/YEQ>7>
MEPR2RM@#+,5R3@"O3J* /C#QI_P26^ /B>RU;^SM(U+P[J=Z7>*\L]0E=;5V
M;.4A9MFT= I&,5X7XS_X(BZ6FANWA#XDWO\ ;8=3'_;5J@M]N?FR8QN!QTQW
MK]0Z* /QJN/^":/[4?P)UM+GX8^+$OY;ZW,=W?:#K!TYD 8$1OYK(6!P#QD<
M57TGXQ_MZ_!<WOA0:1XHUMK.Y??>7FB'5]S'&=ER4?>GIAB.37[.T4 ?CIX7
M_P""SGQ/\,6=GI?BKP-H^KZA9R&&_O&,EK-(0YW?NU^5& ^7&,9%>]^'?^"U
M7PNU37+*TU+P?XCT6PFE"3:A*8I5MU/5RB$LP'HH)K[J\4?#+PEXVT6^TC7?
M#>EZIIM\NRYM[BU1EE&<_-QZC->(^-O^"<_[/OC;0GTQOAYI^AAI%D^V:(/L
MMP,=@XSP>XH ?\._^"B7[/\ \3+Z[M--^(-EI\EM&)6;6T?3T8$XPK3!0Q]@
M<U[3X(^*/@_XEV]U/X3\4:1XEAM65)Y-*O8[A8F() 8H3@D ]?2OA?Q__P $
M6OAEKU]:R^%?%FM^%+:.,K-;S1K?^:^<A@S,I7CC'/2O&_%7_!&/XB:'KTT?
M@3XDZ9)HCHA\W4FGM+AGQ\P9(E=< ]#N[T ?KGUZ4M?BS9?!3]OGX:^'VTK2
M+SQ3;Z'I$<BPQ6.MP.@C4D_NU\S<0>2!C/.,=JFTW_@I9^U/\+X])O\ QKX2
M>?P]:-'!<-J^@361NL+C:UP5X=L9R!R0>* /V@HK\O?AY_P6YTFZN[P>.?AS
M=:=;!%-L^@W:W+L^>0XE\L 8Q@@FO<OAW_P5J^ GC2SO)M7U34O!<L$@1(-8
MLF=IP1G<I@\P8'3D@T ?:%%>8^&OVG?A+XMT&QUC3OB-X9-C>1B6+[3JD-O)
MM/\ >CD974^S &O2K>XBNH(YH9%FAD4.DD;!E92,@@CJ"* )**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\V_^"W7_ "2'X<_]AV;_ -)S7Z25^;?_  6Z_P"20_#G_L.S
M?^DYH ^LOV'/^30?A'_V+MK_ .@5[E7AO[#G_)H/PC_[%VU_] KW*@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?_M"?\D#^)/\
MV+6I?^DLE?S+U_31^T)_R0/XD_\ 8M:E_P"DLE?S+T ?J!_P0[_Y&?XM?]>>
MG?\ H=Q7ZT5^2_\ P0[_ .1G^+7_ %YZ=_Z'<5^M% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%?GM_P %<O&GC_P?H'PZ?P'J&MV$TUS>"Y.C"0E@%BV[]@/J
M<9]Z_-;_ (7=^T5_T,?CC_OF?_XFLX3Y[^3L:3AR*+[J_P"+7Z']&5<_:^ /
M#5EXH/B.VT*PM]=,+6YU"&!4F:-F#%2P'() //I7\]O_  N[]HK_ *&/QQ_W
MS/\ _$T?\+N_:*_Z&/QQ_P!\S_\ Q-:=;F?D?T8LH92",@\$&OG/XM_\$^O@
M=\9M6EU76O!\5CJL\ADGO=(D-K),V /FQP>GI7XM?\+N_:*_Z&/QQ_WS/_\
M$T?\+N_:*_Z&/QQ_WS/_ /$U/*F[LI2:T1^Y7P2_8[^$O[/LR7?@[PE:VNJJ
MAC.JW.9KHJ3G&]NGX 5[17\YO_"[OVBO^AC\<?\ ?,__ ,37[I_LB:GJ^L?L
MS_#B]UZ:ZN-9GT:![J2]!$S2%>2^><_6NGEE.FZC>S2^^_\ D8W49**6_P#P
M#U^BBBL#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \__ &A/^2!_$G_L6M2_])9*_F7K^FC]H3_D@?Q)_P"Q:U+_
M -)9*_F7H _4#_@AW_R,_P 6O^O/3O\ T.XK]:*_)?\ X(=_\C/\6O\ KST[
M_P!#N*_6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M96P0",@CJ* +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQU*X:UMI(?$YN"T@7<01'(2.!WH _9C_ (9Q^$__ $3+P?\ ^"*U_P#B*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\$MP?\ ABSP3Q_RTO/_ $IDKYU_X+>1O+X7^%P1&<_:KW[JD_PQ5^>?@/\
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M:***R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \Z_:*^'LOQ8^!?CKP?!>IITVL:3/:+=21F18BRGYBH.3TZ"OS5_X(Q?
M%^'PSXO\:_#+5;BQT_\ M';J%G'=$QW4]T@"/$H)P0$4L1C/%?<_[8G[9FB_
ML=Z/X:U#6?#M_P"(4UR>:"-+&:.,Q&-58EMW7._MZ5^+/QS^/'A;Q!^T-!\6
M/A5H^K>$M4:_&M3V^K2QW*)?B7S/,CQ_"S?,5;C)(''% ']%U?C5_P %,?\
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MM_P3>_9]\<SZU=W'@&WT_4]4\UGO-/N9H##(X/[R.-7\M2"<@;=N1TKZ:HH
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M)4KC=GOG% 'ZQT5\#?#W_@LI\'?$TE\OB;2M<\&K"$,#2P_;!<9SN'[H';C
MZ]=WM7OW@_\ ;N^ OC3P]:ZQ:_$W0=/AN-P%MJUVMG<IM8K\T4A#+G&1D<@@
MT >]T5F:'XFTCQ-I5EJ>DZG::EI][$LUM=6LRR1S(PRK*0>00:TZ "BBB@ H
MHHH **** "BBB@ HHHH *_-O_@MU_P DA^'/_8=F_P#2<U^DE?FW_P %NO\
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MO_@)'_A6Q10!C_\ "':!_P! /3?_  $C_P *U+>WBM84A@B2&)!A8XU"JH]
M!TJ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-#'<1M'+&LL;=5< @_@
M:X/X@? 'X;_%9K)O&'@?0O$36(<6S:A8I(8MV-VW(XSM'Y5W]% 'RIX\_P""
M8?[/7C[5XM0E\&'0GCA$/V?0;EK*!L$G<43@M\V,^@'I7@6L_P#!$?P3=ZE?
M3Z=\1M:L+225WM[1[&*7R4))5"Y8%L# SC)Q7Z444 ?C-K7_  26^/WPVL8]
M?\)^,-)UG6--GBFLK/2;V:WN P<8=&E5$4K][ENW&:BU4?M^? >YT[Q1JESX
MMUJ%)S"MF;M=8B=F1O\ 66\;.2N,G)& 0.<XK]GJ* /QOT?_ (*T?'OX2:I>
MZ=\3/!%GJ-]/''-;6NI64FDS0)E@6VA<NK'N1QL..]>J^ ?^"W'A^;2YSXV^
M'>I6NI"8^4N@7$<T)BVC!8RLA#;MW0$8Q7Z4:GX7T;6KA9]0TFQOYE78)+JV
M21@N2<98'C)/YUY/XR_8K^!_Q UR^UG7?AIH=[JMZ )[H0F-FP@0'"D $ #G
M':@#SWP1_P %//V?/&C:);_\)D='U+4_*3['J5G-$+:5\#9)+M\M<$X+;MO&
M<XKWGP[\:OA[XNU:'2M#\<^'-9U.?=Y5G8:K!--)@%CM17). ">!T%?&GC7_
M ((R_!_5O#\]OX9UOQ#X?U=F4QWUU.MY&BAAN!BVIG(R,[N.O->*^-/^"*_B
MKPY:V=[\/OB7;W^LK-A_[2MWT\1QE6RR21M(2V<#&!P3S0!^M-%?BY%^RO\
MMN_L[ZU>Z;X'U+6-4MKZ**:XOM!U9)+=V4N%4_:"K!ER<X7^(<FH[']LO]M+
MX%2:GX:U_0]1UF^M9O.GN-<T.2]>$&-3M6:(A"F,-P3@L>>U '[3T5^2FB_\
M%OM<M]-L8=4^%UE>7J1(MS=0:LT2RN  [JGE':"<D+DXSC-?1?@G_@K]\"O%
MGB"UTV^_M[PQ#,K%M1U6S3[-$0I;#&)W;DC PO4CI0!]P5'<7$5K!)/-(L,,
M:EWDD("JH&223T %>+> OVU_@;\3-6FTSP]\2M%NKV&$W#QW#O:C8&"DAIE0
M$Y8< YYZ5X#_ ,%-OVOC\+?@7IVF^ M;AGU7Q;<362ZMIS1W,,5O$J_:$$BL
M0LA\V,#@\%NG% '%?M;_ /!7+0O LDGA[X/+:^*-6V317.N7",+6SE#%%\M2
M/WQRI;/W""N":_-#X]?M4?$O]I34([CQWXCFU&VA=9+?385$5I;N$"%HXAPK
M$=3WR:\FHH ^D/@S_P %"OC?\"_#*>'O#WBE;K1X4CBMK75K=;M;2- 0$AW?
M<7!Z#T%?JK^Q?_P4:\(?M0S6WA;5(&\,^/DM5=K2X91;W[C/F?9FSSC .QL-
M@G&0":_!JKFBZU?^'=6M-4TN[FL-1M)5FM[JW<I)$ZG(92.A!H _J<HKPG]B
MK]H.U_:2_9]\.^)A.LFM6\?]GZO%O+M%=Q@ [F*C+.I23@8'F8[5[M0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16;KOB72?"]D]
MWJ^IVFF6J#<TMW,L:@?4FN3\._'WX;^+=0%CHWCG0=2O"2H@M[^-F)'48S0O
M>=EN)NVK.^HIJLLBAE(96&0P.0:=0,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** //_VA"1\!/B3CC_BFM2_]
M)9*_F7K^FC]H3_D@?Q)_[%K4O_262OYEZ /Z<_@B<_!?P"3R?^$?T_\ ])HZ
M[6N)^"'_ "1?P!_V+^G_ /I-'7;4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6\\-ZU"SVS.."0IP5^J$9KU3QY_P6 ^-_C'0)--TZ#0?"LTG!O\ 2K5S.!W
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M!C9T?:03D8[YKSK_ (?@>+/^B6Z-_P"#2;_XB@#]-OVA/^2!_$G_ +%K4O\
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MY4I?_)GW?17PA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U']N9?_S\_"7^0?\
M$+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\ \KW_ -S4?\/1/^J9_P#E>_\
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M>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F?=]%?"'_  ]$_P"J9_\
ME>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_Q"WB_P#Z O\ RI2_^3/N
M^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W,O\ ^?GX2_R#_B%O%_\
MT!?^5*7_ ,F?=]%?"'_#T3_JF?\ Y7O_ +FH_P"'HG_5,_\ RO?_ '-1_;F7
M_P#/S\)?Y!_Q"WB__H"_\J4O_DS[OHKX0_X>B?\ 5,__ "O?_<U'_#T3_JF?
M_E>_^YJ/[<R__GY^$O\ (/\ B%O%_P#T!?\ E2E_\F?=]%?"'_#T3_JF?_E>
M_P#N:C_AZ)_U3/\ \KW_ -S4?VYE_P#S\_"7^0?\0MXO_P"@+_RI2_\ DS[O
MHKX0_P"'HG_5,_\ RO?_ '-1_P /1/\ JF?_ )7O_N:C^W,O_P"?GX2_R#_B
M%O%__0%_Y4I?_)GW?17PA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U']N9?_S\
M_"7^0?\ $+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\ \KW_ -S4?\/1/^J9
M_P#E>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F?=]%?"'_  ]$_P"J
M9_\ E>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_Q"WB_P#Z O\ RI2_
M^3/N^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W,O\ ^?GX2_R#_B%O
M%_\ T!?^5*7_ ,F?=]%?"'_#T3_JF?\ Y7O_ +FH_P"'HG_5,_\ RO?_ '-1
M_;F7_P#/S\)?Y!_Q"WB__H"_\J4O_DS[OHKX0_X>B?\ 5,__ "O?_<U'_#T3
M_JF?_E>_^YJ/[<R__GY^$O\ (/\ B%O%_P#T!?\ E2E_\F?=]%?"'_#T3_JF
M?_E>_P#N:C_AZ)_U3/\ \KW_ -S4?VYE_P#S\_"7^0?\0MXO_P"@+_RI2_\
MDS[OHKX0_P"'HG_5,_\ RO?_ '-1_P /1/\ JF?_ )7O_N:C^W,O_P"?GX2_
MR#_B%O%__0%_Y4I?_)GW?17PA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U']N9
M?_S\_"7^0?\ $+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\ \KW_ -S4?\/1
M/^J9_P#E>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F?=]%?"'_  ]$
M_P"J9_\ E>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_Q"WB_P#Z O\
MRI2_^3/N^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W,O\ ^?GX2_R#
M_B%O%_\ T!?^5*7_ ,F?=]%?"'_#T3_JF?\ Y7O_ +FH_P"'HG_5,_\ RO?_
M '-1_;F7_P#/S\)?Y!_Q"WB__H"_\J4O_DS[OHKX0_X>B?\ 5,__ "O?_<U'
M_#T3_JF?_E>_^YJ/[<R__GY^$O\ (/\ B%O%_P#T!?\ E2E_\F?=]%?"'_#T
M3_JF?_E>_P#N:C_AZ)_U3/\ \KW_ -S4?VYE_P#S\_"7^0?\0MXO_P"@+_RI
M2_\ DS[OHKX0_P"'HG_5,_\ RO?_ '-1_P /1/\ JF?_ )7O_N:C^W,O_P"?
MGX2_R#_B%O%__0%_Y4I?_)GW?17PA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U
M']N9?_S\_"7^0?\ $+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\ \KW_ -S4
M?\/1/^J9_P#E>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F?=]%?"'_
M  ]$_P"J9_\ E>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_Q"WB_P#Z
M O\ RI2_^3/N^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W,O\ ^?GX
M2_R#_B%O%_\ T!?^5*7_ ,F?=]%?"'_#T3_JF?\ Y7O_ +FH_P"'HG_5,_\
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M_P#Z O\ RI2_^3/N^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W,O\
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M/_RO?_<U']N9?_S\_"7^0?\ $+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\
M\KW_ -S4?\/1/^J9_P#E>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F
M?=]%?"'_  ]$_P"J9_\ E>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_
MQ"WB_P#Z O\ RI2_^3/N^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W
M,O\ ^?GX2_R#_B%O%_\ T!?^5*7_ ,F?=]%?"'_#T3_JF?\ Y7O_ +FH_P"'
MHG_5,_\ RO?_ '-1_;F7_P#/S\)?Y!_Q"WB__H"_\J4O_DS[OHKX0_X>B?\
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MB?\ 5,__ "O?_<U'_#T3_JF?_E>_^YJ/[<R__GY^$O\ (/\ B%O%_P#T!?\
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M^5*7_P F?=]%?"'_  ]$_P"J9_\ E>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\
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M\_"7^0?\0MXO_P"@+_RI2_\ DS[OHKX0_P"'HG_5,_\ RO?_ '-1_P /1/\
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M?_E>_P#N:C^W,O\ ^?GX2_R#_B%O%_\ T!?^5*7_ ,F?=]%?"'_#T3_JF?\
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M_DS[OHKX0_X>B?\ 5,__ "O?_<U'_#T3_JF?_E>_^YJ/[<R__GY^$O\ (/\
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M\J4O_DS[OHKX0_X>B?\ 5,__ "O?_<U'_#T3_JF?_E>_^YJ/[<R__GY^$O\
M(/\ B%O%_P#T!?\ E2E_\F?=]%?"'_#T3_JF?_E>_P#N:C_AZ)_U3/\ \KW_
M -S4?VYE_P#S\_"7^0?\0MXO_P"@+_RI2_\ DS[OHKX0_P"'HG_5,_\ RO?_
M '-1_P /1/\ JF?_ )7O_N:C^W,O_P"?GX2_R#_B%O%__0%_Y4I?_)GW?17P
MA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U']N9?_S\_"7^0?\ $+>+_P#H"_\
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M$O\ (/\ B%O%_P#T!?\ E2E_\F?=]%?"'_#T3_JF?_E>_P#N:C_AZ)_U3/\
M\KW_ -S4?VYE_P#S\_"7^0?\0MXO_P"@+_RI2_\ DS[OHKX0_P"'HG_5,_\
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MY4I?_)GW?17PA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U']N9?_S\_"7^0?\
M$+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\ \KW_ -S4?\/1/^J9_P#E>_\
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M>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F?=]%?"'_  ]$_P"J9_\
ME>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_Q"WB_P#Z O\ RI2_^3/N
M^BOA#_AZ)_U3/_RO?_<U'_#T3_JF?_E>_P#N:C^W,O\ ^?GX2_R#_B%O%_\
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M?_E>_P#N:C_AZ)_U3/\ \KW_ -S4?VYE_P#S\_"7^0?\0MXO_P"@+_RI2_\
MDS[OHKX0_P"'HG_5,_\ RO?_ '-1_P /1/\ JF?_ )7O_N:C^W,O_P"?GX2_
MR#_B%O%__0%_Y4I?_)GW?17PA_P]$_ZIG_Y7O_N:C_AZ)_U3/_RO?_<U']N9
M?_S\_"7^0?\ $+>+_P#H"_\ *E+_ .3/N^BOA#_AZ)_U3/\ \KW_ -S4?\/1
M/^J9_P#E>_\ N:C^W,O_ .?GX2_R#_B%O%__ $!?^5*7_P F?=]%?"'_  ]$
M_P"J9_\ E>_^YJ/^'HG_ %3/_P KW_W-1_;F7_\ /S\)?Y!_Q"WB_P#Z O\
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M2_R#_B%O%_\ T!?^5*7_ ,F?=]%?"'_#T3_JF?\ Y7O_ +FH_P"'HG_5,_\
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M /*]_P#<U'_#T3_JF?\ Y7O_ +FH_MS+_P#GY^$O\@_XA;Q?_P! 7_E2E_\
M)GW?17PA_P /1/\ JF?_ )7O_N:C_AZ)_P!4S_\ *]_]S4?VYE__ #\_"7^0
M?\0MXO\ ^@+_ ,J4O_DS[OHKX0_X>B?]4S_\KW_W-1_P]$_ZIG_Y7O\ [FH_
MMS+_ /GY^$O\@_XA;Q?_ - 7_E2E_P#)GW?17PA_P]$_ZIG_ .5[_P"YJ/\
MAZ)_U3/_ ,KW_P!S4?VYE_\ S\_"7^0?\0MXO_Z O_*E+_Y,^[Z*^$/^'HG_
M %3/_P KW_W-1_P]$_ZIG_Y7O_N:C^W,O_Y^?A+_ "#_ (A;Q?\ ] 7_ )4I
M?_)GW?17PA_P]$_ZIG_Y7O\ [FH_X>B?]4S_ /*]_P#<U']N9?\ \_/PE_D'
M_$+>+_\ H"_\J4O_ ),^[Z*^$/\ AZ)_U3/_ ,KW_P!S4?\ #T3_ *IG_P"5
M[_[FH_MS+_\ GY^$O\@_XA;Q?_T!?^5*7_R9]WT5\(?\/1/^J9_^5[_[FH_X
M>B?]4S_\KW_W-1_;F7_\_/PE_D'_ !"WB_\ Z O_ "I2_P#DS[OHKX0_X>B?
M]4S_ /*]_P#<U'_#T3_JF?\ Y7O_ +FH_MS+_P#GY^$O\@_XA;Q?_P! 7_E2
ME_\ )GW?17PA_P /1/\ JF?_ )7O_N:C_AZ)_P!4S_\ *]_]S4?VYE__ #\_
M"7^0?\0MXO\ ^@+_ ,J4O_DS[OHKX0_X>B?]4S_\KW_W-1_P]$_ZIG_Y7O\
M[FH_MS+_ /GY^$O\@_XA;Q?_ - 7_E2E_P#)GW?17PA_P]$_ZIG_ .5[_P"Y
MJ/\ AZ)_U3/_ ,KW_P!S4?VYE_\ S\_"7^0?\0MXO_Z O_*E+_Y,^[Z*^$/^
M'HG_ %3/_P KW_W-1_P]$_ZIG_Y7O_N:C^W,O_Y^?A+_ "#_ (A;Q?\ ] 7_
M )4I?_)GW?17PA_P]$_ZIG_Y7O\ [FH_X>B?]4S_ /*]_P#<U']N9?\ \_/P
ME_D'_$+>+_\ H"_\J4O_ ),^[Z*X/X&_%'_A='PMT3QE_9G]C_VEY_\ H7VC
MS_+\N>2+[^U<Y\O/W1C..V:[RO9IU(U8*I!W35U\S\UQ>%K8'$5,)B(\LZ<G
M&2T=G%V:NKIV:Z.P4445H<@4444 %%%% !1110 4444 %%%% !1110 4444
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M]3M([B.2-@0,J,J?<'((]JZ:NNMS>TES[W..CR^SCR[6/R$_X+)?L^:-X/\
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MC_T3GPE_X([7_P"-T?\ "@_AC_T3GPE_X([7_P"-UWE%'U>C_(ON0?VMF/\
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MAC_T3GPE_P"".U_^-T?\*#^&/_1.?"7_ (([7_XW7>44?5Z/\B^Y!_:V8_\
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MX8_]$Y\)?^".U_\ C==Y11]7H_R+[D']K9C_ -!$_P#P*7^9P?\ PH/X8_\
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M -!$_P#P*7^9P?\ PH/X8_\ 1.?"7_@CM?\ XW1_PH/X8_\ 1.?"7_@CM?\
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M@_AC_P!$Y\)?^".U_P#C==Y11]7H_P B^Y!_:V8_]!$__ I?YG!_\*#^&/\
MT3GPE_X([7_XW1_PH/X8_P#1.?"7_@CM?_C==Y11]7H_R+[D']K9C_T$3_\
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M44?5Z/\ (ON0?VMF/_01/_P*7^9P?_"@_AC_ -$Y\)?^".U_^-T?\*#^&/\
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MU_\ C==Y11]7H_R+[D']K9C_ -!$_P#P*7^9P?\ PH/X8_\ 1.?"7_@CM?\
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M)?\ @CM?_C='_"@_AC_T3GPE_P"".U_^-UWE%'U>C_(ON0?VMF/_ $$3_P#
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M_P!!$_\ P*7^9P?_  H/X8_]$Y\)?^".U_\ C='_  H/X8_]$Y\)?^".U_\
MC==Y11]7H_R+[D']K9C_ -!$_P#P*7^9P?\ PH/X8_\ 1.?"7_@CM?\ XW1_
MPH/X8_\ 1.?"7_@CM?\ XW7>44?5Z/\ (ON0?VMF/_01/_P*7^9P?_"@_AC_
M -$Y\)?^".U_^-T?\*#^&/\ T3GPE_X([7_XW7>44?5Z/\B^Y!_:V8_]!$__
M  *7^9P?_"@_AC_T3GPE_P"".U_^-T?\*#^&/_1.?"7_ (([7_XW7>44?5Z/
M\B^Y!_:V8_\ 01/_ ,"E_F<'_P *#^&/_1.?"7_@CM?_ (W1_P *#^&/_1.?
M"7_@CM?_ (W7>44?5Z/\B^Y!_:V8_P#01/\ \"E_F<'_ ,*#^&/_ $3GPE_X
M([7_ .-T?\*#^&/_ $3GPE_X([7_ .-UWE%'U>C_ "+[D']K9C_T$3_\"E_F
M<'_PH/X8_P#1.?"7_@CM?_C='_"@_AC_ -$Y\)?^".U_^-UWE%'U>C_(ON0?
MVMF/_01/_P "E_F<'_PH/X8_]$Y\)?\ @CM?_C='_"@_AC_T3GPE_P"".U_^
M-UWE%'U>C_(ON0?VMF/_ $$3_P# I?YG!_\ "@_AC_T3GPE_X([7_P"-T?\
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MP?\ PH/X8_\ 1.?"7_@CM?\ XW1_PH/X8_\ 1.?"7_@CM?\ XW7>44?5Z/\
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M -$Y\)?^".U_^-UWE%'U>C_(ON0?VMF/_01/_P "E_F<'_PH/X8_]$Y\)?\
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MR+[D']K9C_T$3_\  I?YG!_\*#^&/_1.?"7_ (([7_XW1_PH/X8_]$Y\)?\
M@CM?_C==Y11]7H_R+[D']K9C_P!!$_\ P*7^9P?_  H/X8_]$Y\)?^".U_\
MC='_  H/X8_]$Y\)?^".U_\ C==Y11]7H_R+[D']K9C_ -!$_P#P*7^9P?\
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M^B<^$O\ P1VO_P ;H_X4'\,?^B<^$O\ P1VO_P ;KO**/J]'^1?<@_M;,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;?\ 8_\ @A:7$4\/PH\(Q31,'21-(A!5@<@@[>H->OT %%%% !1110 4444
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M*F1%(![AN/K3<^9.C%6F]G]U_P"N]NA*C9JJW>*W7]?U^!Z]\:_^"B7QO_:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7&_$KX.^"OC#I(TWQGX9TWQ%9CE$OH Y0^JGJ#
M]*[*O+/CU^TQ\/\ ]FWPY_:WC;6X[%G'^CV$6)+JY//"1YR>AY.![U$W&WO;
M%PYK^YN;'P;^"?A'X!^$3X:\%Z;_ &9I'VB2Y\DR%SO<Y/)[>GI7=U^1'Q8_
MX+5^*-0FFM_AWX,L=(@64^7?:U(;EY$[9B7:%/\ P(UX[/\ \%</VA)I6<:I
MH<88YVQZ6 !]/FJE)RU9/*H['[LUXM^T7^R-\/OVI#H0\=VU[<)H[2-;K971
M@)W@9#$=1\HK\G-'_P""OWQ]TVX1KF7P]J,.[+QS::5)'<!E<8KZO^!?_!9?
MP=XMU"'3?B/X<F\'R2,J+J=G*;JU![M(,!D'T#5:I\S3ZK4GG<3[H^%?P9\%
M_!/PZFA^"O#UEH&GC!=;6,!Y6P!N=NK,<=37:UE^&?%&D>,]#L]9T+4;?5M*
MO(Q+!=VL@>.12.H(_EVK4IS<G)\^XH\MO=V"BBBH*"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^1/VPO\ @G=HO[7GC_2?
M%.I>,K_PY-I^FKIRVUK91S*ZB223>2S Y_>$8]J\'_X<?^%/^BI:S_X*XO\
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M[#H_\_9_^!+_ "#_ (BIF/\ T 8;_P %2_\ DS\U/^%*_M>?]!'Q;_X64?\
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M /)5'_"E?VO/^@CXM_\ "RC_ /DJOTKHH_L.C_S]G_X$O\@_XBIF/_0!AO\
MP5+_ .3/S4_X4K^UY_T$?%O_ (64?_R51_PI7]KS_H(^+?\ PLH__DJOTKHH
M_L.C_P _9_\ @2_R#_B*F8_] &&_\%2_^3/S4_X4K^UY_P!!'Q;_ .%E'_\
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M "51_P *5_:\_P"@CXM_\+*/_P"2J_2NBC^PZ/\ S]G_ .!+_(/^(J9C_P!
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M_P E4?\ "E?VO/\ H(^+?_"RC_\ DJOTKHH_L.C_ ,_9_P#@2_R#_B*F8_\
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M_P! &&_\%2_^3/S4_P"%*_M>?]!'Q;_X64?_ ,E4?\*5_:\_Z"/BW_PLH_\
MY*K]*Z*/[#H_\_9_^!+_ "#_ (BIF/\ T 8;_P %2_\ DS\U/^%*_M>?]!'Q
M;_X64?\ \E4?\*5_:\_Z"/BW_P +*/\ ^2J_2NBC^PZ/_/V?_@2_R#_B*F8_
M] &&_P#!4O\ Y,_-3_A2O[7G_01\6_\ A91__)5'_"E?VO/^@CXM_P#"RC_^
M2J_2NBC^PZ/_ #]G_P"!+_(/^(J9C_T 8;_P5+_Y,_-3_A2O[7G_ $$?%O\
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MXBIF/_0!AO\ P5+_ .3/S4_X4K^UY_T$?%O_ (64?_R51_PI7]KS_H(^+?\
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M ,+*/_Y*K]*Z*/[#H_\ /V?_ ($O\@_XBIF/_0!AO_!4O_DS\U/^%*_M>?\
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M_P!!'Q;_ .%E'_\ )5'_  I7]KS_ *"/BW_PLH__ )*K]*Z*/[#H_P#/V?\
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M%*_M>?\ 01\6_P#A91__ "51_P *5_:\_P"@CXM_\+*/_P"2J_2NBC^PZ/\
MS]G_ .!+_(/^(J9C_P! &&_\%2_^3/S4_P"%*_M>?]!'Q;_X64?_ ,E4?\*5
M_:\_Z"/BW_PLH_\ Y*K]*Z*/[#H_\_9_^!+_ "#_ (BIF/\ T 8;_P %2_\
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M5'_"E?VO/^@CXM_\+*/_ .2J_2NBC^PZ/_/V?_@2_P @_P"(J9C_ - &&_\
M!4O_ ),_-3_A2O[7G_01\6_^%E'_ /)5'_"E?VO/^@CXM_\ "RC_ /DJOTKH
MH_L.C_S]G_X$O\@_XBIF/_0!AO\ P5+_ .3/S4_X4K^UY_T$?%O_ (64?_R5
M1_PI7]KS_H(^+?\ PLH__DJOTKHH_L.C_P _9_\ @2_R#_B*F8_] &&_\%2_
M^3/S4_X4K^UY_P!!'Q;_ .%E'_\ )5'_  I7]KS_ *"/BW_PLH__ )*K]*Z*
M/[#H_P#/V?\ X$O\@_XBIF/_ $ 8;_P5+_Y,_-3_ (4K^UY_T$?%O_A91_\
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M64?_ ,E4?\*5_:\_Z"/BW_PLH_\ Y*K]*Z*/[#H_\_9_^!+_ "#_ (BIF/\
MT 8;_P %2_\ DS\U/^%*_M>?]!'Q;_X64?\ \E4?\*5_:\_Z"/BW_P +*/\
M^2J_2NBC^PZ/_/V?_@2_R#_B*F8_] &&_P#!4O\ Y,_-3_A2O[7G_01\6_\
MA91__)5'_"E?VO/^@CXM_P#"RC_^2J_2NBC^PZ/_ #]G_P"!+_(/^(J9C_T
M8;_P5+_Y,_-3_A2O[7G_ $$?%O\ X64?_P E4?\ "E?VO/\ H(^+?_"RC_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7YJ?\ !2S_ )+KH7_8MP?^E5U7Z5U^:G_!2S_D
MNNA?]BW!_P"E5U7S?$'^XOU1^U>$/_)40_P3_)'Z5T445](?BH4444 %%%%
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MS8XZ,L9+!\KNE>_3I_F>IT445Q'I!1110 4444 %%%% !1110 4444 %%%%
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MJ(H[DUYUX3_9I\!>!?&=CXF\/Z9/I=_:)(BQQW4DD3;U*DL'+'.">A%>'_\
M!0+QI=6UIX:\+02-';7/F7URJG DVD+&#Z@'<?KBH]E2Q%>%/#W2??IO?\#3
MV^(P>%J5L99N.UNNUOQ=O0[C5?V[OAOIU\]O!!KFIQ*<"YM;-!&WN/,D1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MITL'&I)>_-Z>G]6^\\*EBJM?,9TH/]W!:_XOS[_<=+1117EGNA1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<J***@D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKG?$?Q&\)^#[N.UU[Q/HVB74B>8D.I:A%;NRY(W!78$C((S[5D_\
M"\_AO_T4'PK_ .#JV_\ BZ *_P"T)_R0/XD_]BUJ7_I+)7\X?PB_Y*QX*_[#
M=E_Z/2OZ"OCQ\:/A]J'P.^(=K;>._#-Q<S>'=1CBABUBW9W8VT@"J ^22> !
M7\^7PIGBM?BCX.FGD2&&/6;-WDD8*J*)T)))Z #O0!_3_17#_P#"\_AO_P!%
M!\*_^#JV_P#BZ/\ A>?PW_Z*#X5_\'5M_P#%T =Q16-X;\9^'_&4,TWA_7=-
MUR&%@DLFFW<=PL;$9 8H3@X]:V: "BBB@ HHHH **** "BBB@ HHHH ****
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MQQ]JOK1/*'U\MW8?E7OMCJ%KJ5C#>VES%=6<R"6*XA<-&Z$9#!AP1CO7Q_\
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MVI_%3XH-X0TEWFTG3;H65O:PG_CYNL[68^IW':/3'N:]Y^'/[#_@G1=!M_\
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M_7H?>5><:#^T1\/?$WBQ/#.F^(DN=;>5X5MOLLZAG7)8!V0+V/?M7H]?FO\
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MMUU-)3<U%/HK?C?]3\./^'/7[0']SPQ_X-C_ /&Z/^'/7[0']SPQ_P"#8_\
MQNOV\TW6K#6DE?3[VWO4B<QNUO*KA6'4$@]:NUH9GX;?\.>OV@/[GAC_ ,&Q
M_P#C='_#GK]H#^YX8_\ !L?_ (W7[CLPC5F8[549)/:N(\"_'+X?_$S4-0L?
M"WB_2=<O;"8P75M:7*M)%("05*]<Y!H6KL@Z7/QO_P"'/7[0']SPQ_X-C_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]K_Z*6O,RC_?8^C_ $/9S[_<9>J/T1T*PM]+T33[.TA2WM;>WCBBAC&%10H
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M_P#R;WX/_P"N,W_I1+7FO_!0+_DG'AO_ +"W_M&2O2OV3_\ DWOP?_UQF_\
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MKQ7]L3_DW_Q%_OV__HY*\JC_ !J?^*/YH^@Q'\"K_AE^3/*?^">/_(,\<?\
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MY_\ 1K5:365Z_P WZLRNGG3M_*8?[>G_ "1FP_[#$/\ Z*EJ+]@?_DD&J?\
M89E_]%15+^WI_P D9L/^PQ#_ .BI:B_8'_Y)!JG_ &&9?_14511_Y%U3_%_\
MB.O_ ,CJC_A_^2/I:OS4_:@C6/\ :4\0;1C==6['ZF*.OTKK\UOVHO\ DY37
MO^OFV_\ 14=/)O\ ?%Z/\XCXD_Y%S_Q+\I'Z4UYY^T+&LGP/\;AAD?V5,WXA
M<C]17H=>??M!?\D1\;_]@FX_] ->-'XD?2R^%GRM_P $^_\ DH'B?_L&+_Z-
M6ONJOA7_ ()]_P#)0/$__8,7_P!&K7W57L9M_O/R1\[P_P#[E\V%>1_M8:I)
MI?P!\5O$2&FBCM\CT>5%;]":]<KRW]I[0I/$7P)\6VT,;22QVHN55>O[MU<_
MHIKR*=E4BWM=?=?4]^LFZ4U'>SMZVT/@OX'_ !UU#X&WVJWFFZ59ZE/?QI$S
M79<>6JDG VD=21^0KUS_ (>">*O^A8T?_ON7_P"*H_X)_P#B2&Q\<^(]%ED5
M)-0LDFB4_P ;1,<@>^V0GZ U]U5]+F%:C3KVJ4N9V6M['Q>48?$UL-S4<1RJ
M[TY4_P!3\WOC!^UAKGQB\'MX>U'1-.L;<SQW'G6S.7!7.!\Q([U[Y_P3_@O(
MOAWXA>6*1+.34@T#,I"N?+4.5]>B@U]2T5YU3'4W0E0IT^5/SOV\O(]JCEE6
M.*CBJU;G<5;:W?S\SPS]M+_DW_6O^OBU_P#1RUYU_P $]?\ D6_&7_7W;_\
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M%?$D&C?&.>PG<)_:NG26\63C,BLL@'UVH]?H/49PG]85^W^97#K7U-I?S/\
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M;+;2S#%RAM?\;O\ X)^;OQ(_Y.XO?^QEA_\ 1J5^E%?FO\2/^3N+W_L98?\
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MVSLBR*0=AGD*G![$$$>QKYZ_X*#?\CQX5_[!TG_HTU]S5\,_\%!O^1X\*_\
M8.D_]&FEA*GMLP52UKMO\&/,*/U;*)T;WY5%?^31/J3]GO\ Y(CX)_[!</\
MZ#7H5>>_L]_\D1\$_P#8+A_]!KT*N'%_[Q4_Q/\ ,]; _P"ZTO\ #'\D?FO-
M&L?[815%"J/&(  ''_'U7Z45^;%U_P GBM_V.(_]*J_2>O0QW\##_P"']$>)
ME'^]8O\ Q?K(_.W]N/\ Y+I-_P!@ZW_DU??7@W_D4-#_ .O&#_T6M? O[<?_
M "72;_L'6_\ )J^^/!,BS>#- D0[D;3[=@?4&-:O$_[A1]?\QX+_ )&F)^7Z
M&U7YH_M%01W7[3GB"&50\4FHVZ.IZ$&.($5^EU?FK^T)_P G2:Y_V$[;_P!
MBI9-_O?_ &Z_SB/B/_D7K_&O_29'Z36]O%:V\<$,:Q0QJ$2-!A54#  '8 5)
M14=Q,+>WEE(R(U+$#V&:\*4K7;/IHK9(\Q^,/[1GA'X,;;;5)I;[6)$WQZ98
M@-+M/1G)("#ZG)[ U\\:M_P4*U220_V7X.L[>//!N[QY21_P%5Q7COP[TAOC
MW^T):P>()Y)$U:^EN+LAB&:-%9S&#V&U0H]!7Z1>&?!NA>#+!++0M(L]*MD
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M[#]B'_D@]G_U_7/_ *$*(_\ (MEZ_P"14O\ D<K_  'OM?F_^V<JK^T#K)
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M1\UE'^\8K_'^K/"OVU(U;X :P2,E;FU(]CYJC^1->>?\$]?^1<\9?]?=O_Z
M]>B_MI?\F_ZU_P!?%K_Z.6O.O^">O_(M^,O^ONW_ /0'JL/_ ,BVO_B7_MH\
M9_R.<-_@?_MY]<5^=?[<**OQVN"!@MI]L3[G!']!7Z*5^=O[<?\ R72;_L'6
M_P#)JQRO_>E\S;/?]QEZK\S[Z\&_\BAH?_7C!_Z+6OE3_@H=_P >?@?_ *Z7
MG\H:^J_!O_(H:'_UXP?^BUKY4_X*'?\ 'GX'_P"NEY_*&IH?\C"/^)_DS7'?
M\BR?^%?H>G?L5_\ ) =(_P"OFY_]&M7NM>%?L5_\D!TC_KYN?_1K5[K66/\
M]ZJ>IOE?^Y4O0*JZH,Z;=@C(\E__ $$U:K%\;:@ND^#=>O6("V]A/*2>GRQL
M?Z5YL]8L]>G\:N?G5^R>2O[1OA<*<#S;D<>GV>6OTOK\XOV*]+?4?CYI4P&5
ML[6YN'^GEE!^KBOT=KZ+.?XT%_=_5GR'#MW0J3[R_1!1117@'U@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?FI_P33_ .2ZZ[_V+<__ *56M?I77YJ?\$T_^2ZZ[_V+<_\ Z56M?I77S?#_
M /N*]6?M7B]_R5$_\$/R"BBBOI#\5"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*2^_D1WMK_P4(UJ/0Q#/X0L9M7"X^V+>.L);U,6TG\-]<?)\(OB=^T%H^O\
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M$]LQVC. )ER:\Z_X)[1NOAGQ@Y5@C7< 5B.#A'SBOK:BG3Q7L\-/#V^)WO\
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MJM:_2NOF^'_]Q7JS]J\7O^2HG_@A^04445](?BH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'XR?\%I5NO^&@/"ADW_ &/^PE\O/W=WG2;L>_W:_4?]
ME;[-_P ,W?#3[((Q#_PC]E_JQ@;O)7=^N:^*O^"T7PANM>^'_A+Q_90O*NBW
M$EE>[%SMCEP48^@#*1_P(5W7_!)W]I6P^)GP3A\ :C>0Q^)_"V88[=FP]Q:$
MY1U'?;G:?I1@]</5I=5*_P M7^4D_O[#Q;_>TJO1QM\]%_[;^7<^[Z***!!1
M12,P522< <DF@#\UO^"VUO:-\,?A[,^W[:NJS*G/.WRN?Z5Z]_P25-S_ ,,<
MZ-YY8K_:5YY6XY^7?QBO@W_@K!^TE8_&;XS6?A'P]=Q7^A>%5:!KBW;<DUVW
M^LP1UV_=X[@U^HG["_PTN/A/^RSX#T.\B\B_:Q6[N8\8*R2_.0??FG@_]WJS
MZ2:M_7G:X8I_OJ5/K%._]>5[?(]ZHHHI %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >?_ +0G_) _B3_V+6I?^DLE
M?SA_"+_DK'@K_L-V7_H]*_H\_:$_Y('\2?\ L6M2_P#262OYP_A%_P E8\%?
M]ANR_P#1Z4 ?T^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?FI_P4L_Y+KH7_8MP?\ I5=5^E=?FI_P4L_Y+KH7_8MP?^E5U7S?$'^XOU1^
MU>$/_)40_P $_P D?I71117TA^*A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!\U?%S]B/P_XZU:YUCP]J3>&M0N&,DUOY/FVTCGDD+D%"3R<$CV%
M>3Q_L+_$O3F:/3_%.BQ0$_PWES%GZA8C_.ONVBO1I8_$4H\BE=>>IX];*<)7
MFZCC:3ZIV/BWPK_P3]U">\6;Q7XKA6+=EX=*C:1Y!_UTD VGWVM7UAX#^'^A
M?#3P[#HGAZQ6QL8SN.#N>5SU=V/+,<#D^@ P !7145E6QE;$+EJ2T[&V%R[#
M81\U*.O?=A1117&>D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\S*-6G*3A&2;6ZOJO46BBBH-0HHHH **** "BBF33);PO+(VV-%+,Q[ #)-
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MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_@FG_R777?^Q;G_ /2JUK]*Z_-3_@FG_P EUUW_ +%N?_TJM:_2NOF^'_\
M<5ZL_:O%[_DJ)_X(?D%%%%?2'XJ%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'G_[0G_) _B3_P!BUJ7_ *2R
M5_.'\(O^2L>"O^PW9?\ H]*_H\_:$_Y('\2?^Q:U+_TEDK^</X1?\E8\%?\
M8;LO_1Z4 ?T^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?9-"U;_B9["YT^[C,,^!U(!X;'?:3CO6LL+7A'FE!V]#GAC\+4G[.%1-^O\
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M6NBIA:\*;G*#2.6ACL+4K*G"HF[]SXV_8I_Y+[I?_7I=?^BC7Z.5^<?[%/\
MR7W2_P#KTNO_ $4:_1RO6SG^/'_#^K/GN&_]TG_B?Y1"BL;Q9XRT3P+H\FJ:
M_J=OI5A'P9KA\9/]U1U8^P!->&:E^WA\-[&Z:*"VU[48P<">VLXPA]P))%;\
MQ7D4Z%6M_#BV?0UL50PUO;34?4^C**\J^&W[37@'XHWD=AI>JM9ZI)]RPU*/
MR97]E.2K'V5B?:O5:FI3G2?+-69I2K4J\>:E)->1\[?MU_\ )$H_^PI!_P"@
MR5E_L _\DIUS_L-/_P"B(:U/VZ_^2)1_]A2#_P!!DK+_ & ?^24ZY_V&G_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNOBUIEBQ_=6FE1E![O(Y)_0?E7CX:+Q6+BJVM]_DCZ'&U(X' 3>'TLM/F_\
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M;3_T4M?)/_!0+_DHWAS_ +!?_M5Z^MO@;_R1GP/_ -@6T_\ 12U%3_D6TO\
M$_SD*A_R.J_^%?E$\/\ VW/C9>>$M+M/!FBW+6U[J<)FOIXFPZ6^2H0$=-Y!
MS[#'>LG]G/\ 8]T'4?"5CXE\<6TFHW.H1">VTSS6CBAB8 HS[2&9B,'&< '!
M!->'_M=:M)J7[0'B3S>5M3!;HO\ LK$AQ^9/YUW]K^WYXGL[6&WB\+Z,L42!
M$4-+@ # 'WJ[J5"M'!0^K+WIZM[.W3^O\SS:^*PTLRJ/&OW8:)6NKK?\?ZT/
M<OB#^QE\/_$VAW,>AZ;_ ,(YJX0FWNK>61DW=@Z,Q!4]\8/O7SY^R/\ $;5?
MAE\77\#ZI(R:=J5R]E-;.V5@NUR%9?<E=A]<CT%:W_#P3Q5_T+&C_P#?<O\
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M')NUOVVV]3GHX2GBLSKJKK%6=NC?GZ'RW\</V,O"<7@G4=5\%VD^DZKI\#7
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M;!((]&C;IV/TK]/T<2(KJ<JPR#7YS_ML1JGQ\U J,%K.V8^YV8_I7Z$^'?\
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M*UE?5[?)?B=K^W7_ ,D2C_["D'_H,E9?[ /_ "2G7/\ L-/_ .B(:U/VZ_\
MDB4?_84@_P#09*R_V ?^24ZY_P!AI_\ T1#7%1_Y%U7_ !?_ ")Z.(_Y'5'_
M  O_ -N*?[?'CB^T7PAH7AVSE>"'5II)+HH<;XX]N$/L68$C_9%4_P!F+]E[
MP3X@^&>F>)_$EA_;NH:F'E1))G6*! [(%"J1N/RY);/H,8Y](_:L^"=W\8O
M]N=(VMKNDR-/:PL0HG5@ \>3T)PI!/&5QWS7R=\*?VB?&O[.UQ-X;U+2WN],
MAE+2:/J0:"6!B?F\ML93)YP01W Y)K?!J57!NE0E:=[OI=?U;[CGS!PH9C&O
MBXWI<MEI=)_U?[_(^F?'G[$?@'Q/;[M#2X\*WP.1+;.T\1_WHW;_ -!9:]_M
M+<6EK# &9Q&BH&8Y)P,9->2_"?\ :E\$_%B>&PM[J31];DX73M1 1I&](W!V
MO[#(8_W:]@KRL1+$1M2KWT[GO86.$E>MA4M=[?Y?TPHHHKC/1"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _-3_ ()I_P#)===_[%N?_P!*K6OTKK\U/^":?_)=
M==_[%N?_ -*K6OTKKYOA_P#W%>K/VKQ>_P"2HG_@A^04445](?BH4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'R!_P40_:!^)?PA\.^%/#?PJTIK_Q1
MXMFN+:.>WA::XMU14R8T QGY_O'[N,U\U? C_@DGX@^(&I'QA\?O$EX]]>/Y
M\VCVMQYMS*3G/G3\[3D]%S7ZG26=O-<17$D$;SPY$<K("R9ZX/49]JFI4XQA
M>35Y/J^B[(J<G-**T2_%]_T/,_A3^S7\,_@I8?9?!W@W2](+*JR7"P*TTNT<
M%W/)/O7I8 4  8%+15RDY.[9"2CH@HHHJ1F9KGAG2?$UE-9ZOIEIJ5K,ACDB
MNH5D5E/4'(KXU^/'_!)OX0_%*&>\\*02?#[6F'R-IJ[K,D X!A)P,GJ0:^W:
M*B4%(I2:/R#^'>C_ +2__!.GXCZ-HEW$WBOX9:EJ,-F[Q,\]A^\<+O7C= PR
M.H .,5^O4;;XU;U&:9<6T-W$8IXDFC)!*2*&'!R.#[U)6W.W!1EJUU\M-/E^
MIGRQ4G**LGT\Q:***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,GQ7KEOX9\,ZKJUW>6]A;V=M).]U=.$BCVJ3N9B< 9]:_F=^
M+7Q7\4?&KQYJOBWQ?JLFKZU?2EGE;A$7HL<:]$11@!1T %?T"?MS8_X9 ^+F
M?^A>N?\ T&OYRZ "BBB@ KZT_P""9_Q\UWX._M*:!H>FP07FE^,KRWT:_AF)
M!57DPLB'LRDYQWQBODNNO^#Z>*9/BIX47P2;@>+CJ4 THVI42_:-XV;2W&<^
MO% ']/-%0V?F?8X/.SYWEKOSUW8Y_6IJ "BBB@ HHHH **** "BBB@ HHHH
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MSA_:6=M*_:7\0W$R%52]MY\'C*B.,Y_2OTMKXV_;>^".J:EJD/CO1+.2]A$
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M (?U9\_PWIA9_P")_E$^?OVX_P#DA<W_ &$;?^;5S/\ P3\_Y)YXD_["@_\
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MM[@*. KMM<-@<9P#QR33/&G[4WQ&^.4G_"->$M'ETJ*Z&U[72=\]U(IX(:7
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MA/14=2CK90!E88((C7@TL3_N%'U_S-<%_P C3$_(^*/^"@7_ "4;PY_V"_\
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M_#IY?U8PJ3_LO,*E>JOW=3KV?G\[_>?HU17QM<?\%$!Y+>1X$Q-C@R:KE1^
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M&42GC\2\75^Q%17K;5_F_F35^:OPC_Y.PTS_ +#\_P#Z')7Z55^;7PCM9O\
MAK/3T\J3>FO7#,NTY #2$D^V*Y\I^.I_A.W//AH_XT?H'\1M?E\*^ ?$6L6X
MS<6.GSW$7^^J$K^N*_/K]EOX=V'QC^+\B>)2U_:6\$NI7,4CG-R^]0 Q'."S
MY/KC'>OT7\0Z+!XDT'4=)NAFVOK>2VD_W74J?YU^;5NOC']DOXM+=2V9\V O
M&K2J1;ZA;$\[6]" #QRI STQ3RMK]["+M-K3\?\ @$9Y%IT*LU>G&7O?AO\
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ME5+!=3@)P.@VOR:R_P!@.)X_A/K3,C*KZS(5)& P\F$<>M=='_D75?\ %_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^:G_!-/_DNNN_\
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MD8'Z)BOUW^"/_!-;X)?!NPMS+X:A\7ZPJ;9M1U]1<>8?41']VOX"O=[7X,>
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MP[@C(-;RC%PC5IN\9?U_PQC&4HS=*?Q(?1116)J%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!F>)]&A\1>'-3TRXM8+V&[M
MI(6M[I \3[E(PRD$$9]:_F;^+WPI\2_!/XA:QX.\76']G:YITNV6)6#HRGE'
M1AU1E(8'N"*_IWKY&_;@_P""?7A_]K.WMM;TN[M_#'CVUV1C5FB+1W4(('ES
MJO+$#[K=1@#IQ0!^"%%>C?&3]GOQ_P# 7Q--HGC/PW>Z5.KR+#<-$Q@NE0X,
MD4F,.G(Y'K7G*J68 #)/  H *^N?^"9?[/NM_&3]I#0M?L;F*QTGP9>6^L7T
MTREC)LDRL2#H68C!.> <X-<Y^S3^P!\5?VD+JQO;+19M!\)3.AEU_4T,431%
MV5FA!P92"C A>AQGK7[>?LT_LZ>'?V7_ (7VG@KPY))>0132SS:A=11K<73N
MY;=(44!BH(4>R@4 >K4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ3@]&W^8\'1Y<)1IU8ZQC'?H[(15"J%48 X %+117(>@%%%% !1110 5X_\
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M6"BBBI*"BBB@ HHHH *KWVGVNJ6KVUY;0W=LXP\,\8=&^H/!JQ10!R5O\(_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /ZA(XTA0)&BH@Z*HP!3J_&G_AXI^V/_ -",W_A(7/\ C1_P\4_;'_Z$9O\
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M?] +PE_X!W7_ ,DT?\/+/B=_T O"7_@'=?\ R37Z5T4?V;CO^@M_^ _\$/\
M73A?_HGH?^#7_P#*S\U/^'EGQ._Z 7A+_P  [K_Y)H_X>6?$[_H!>$O_  #N
MO_DFOTKHH_LW'?\ 06__  '_ ((?ZZ<+_P#1/0_\&O\ ^5GYJ?\ #RSXG?\
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MNBC^S<=_T%O_ ,!_X(?ZZ<+_ /1/0_\ !K_^5GYJ?\/+/B=_T O"7_@'=?\
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M_AY9\3O^@%X2_P# .Z_^2:/^'EGQ._Z 7A+_ , [K_Y)K]*Z*/[-QW_06_\
MP'_@A_KIPO\ ]$]#_P &O_Y6?FI_P\L^)W_0"\)?^ =U_P#)-'_#RSXG?] +
MPE_X!W7_ ,DU^E=%']FX[_H+?_@/_!#_ %TX7_Z)Z'_@U_\ RL_-3_AY9\3O
M^@%X2_\  .Z_^2:/^'EGQ._Z 7A+_P  [K_Y)K]*Z*/[-QW_ $%O_P !_P""
M'^NG"_\ T3T/_!K_ /E9^:G_  \L^)W_ $ O"7_@'=?_ "31_P /+/B=_P!
M+PE_X!W7_P DU^E=%']FX[_H+?\ X#_P0_UTX7_Z)Z'_ (-?_P K/S4_X>6?
M$[_H!>$O_ .Z_P#DFC_AY9\3O^@%X2_\ [K_ .2:_2NBC^S<=_T%O_P'_@A_
MKIPO_P!$]#_P:_\ Y6?FI_P\L^)W_0"\)?\ @'=?_)-'_#RSXG?] +PE_P"
M=U_\DU^E=%']FX[_ *"W_P" _P#!#_73A?\ Z)Z'_@U__*S\U/\ AY9\3O\
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M=_T O"7_ (!W7_R31_P\L^)W_0"\)?\ @'=?_)-?I711_9N._P"@M_\ @/\
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M_ ?^"'^NG"__ $3T/_!K_P#E9^:G_#RSXG?] +PE_P" =U_\DT?\/+/B=_T
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M+_P#NO\ Y)H_X>6?$[_H!>$O_ .Z_P#DFOTKHH_LW'?]!;_\!_X(?ZZ<+_\
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M?] +PE_X!W7_ ,DT?\/+/B=_T O"7_@'=?\ R37Z5T4?V;CO^@M_^ _\$/\
M73A?_HGH?^#7_P#*S\U/^'EGQ._Z 7A+_P  [K_Y)H_X>6?$[_H!>$O_  #N
MO_DFOTKHH_LW'?\ 06__  '_ ((?ZZ<+_P#1/0_\&O\ ^5GYJ?\ #RSXG?\
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MNBC^S<=_T%O_ ,!_X(?ZZ<+_ /1/0_\ !K_^5GYJ?\/+/B=_T O"7_@'=?\
MR31_P\L^)W_0"\)?^ =U_P#)-?I711_9N._Z"W_X#_P0_P!=.%_^B>A_X-?_
M ,K/S4_X>6?$[_H!>$O_  #NO_DFC_AY9\3O^@%X2_\  .Z_^2:_2NBC^S<=
M_P!!;_\  ?\ @A_KIPO_ -$]#_P:_P#Y6?FI_P /+/B=_P! +PE_X!W7_P D
MT?\ #RSXG?\ 0"\)?^ =U_\ )-?I711_9N._Z"W_ . _\$/]=.%_^B>A_P"#
M7_\ *S\U/^'EGQ._Z 7A+_P#NO\ Y)H_X>6?$[_H!>$O_ .Z_P#DFOTKHH_L
MW'?]!;_\!_X(?ZZ<+_\ 1/0_\&O_ .5GYJ?\/+/B=_T O"7_ (!W7_R31_P\
ML^)W_0"\)?\ @'=?_)-?I711_9N._P"@M_\ @/\ P0_UTX7_ .B>A_X-?_RL
M_-3_ (>6?$[_ * 7A+_P#NO_ ))H_P"'EGQ._P"@%X2_\ [K_P"2:_2NBC^S
M<=_T%O\ \!_X(?ZZ<+_]$]#_ ,&O_P"5GYJ?\/+/B=_T O"7_@'=?_)-'_#R
MSXG?] +PE_X!W7_R37Z5T4?V;CO^@M_^ _\ !#_73A?_ *)Z'_@U_P#RL_-3
M_AY9\3O^@%X2_P# .Z_^2:/^'EGQ._Z 7A+_ , [K_Y)K]*Z*/[-QW_06_\
MP'_@A_KIPO\ ]$]#_P &O_Y6?FI_P\L^)W_0"\)?^ =U_P#)-'_#RSXG?] +
MPE_X!W7_ ,DU^E=%']FX[_H+?_@/_!#_ %TX7_Z)Z'_@U_\ RL_-3_AY9\3O
M^@%X2_\  .Z_^2:/^'EGQ._Z 7A+_P  [K_Y)K]*Z*/[-QW_ $%O_P !_P""
M'^NG"_\ T3T/_!K_ /E9^:G_  \L^)W_ $ O"7_@'=?_ "31_P /+/B=_P!
M+PE_X!W7_P DU^E=%']FX[_H+?\ X#_P0_UTX7_Z)Z'_ (-?_P K/S4_X>6?
M$[_H!>$O_ .Z_P#DFC_AY9\3O^@%X2_\ [K_ .2:_2NBC^S<=_T%O_P'_@A_
MKIPO_P!$]#_P:_\ Y6?FI_P\L^)W_0"\)?\ @'=?_)-'_#RSXG?] +PE_P"
M=U_\DU^E=%']FX[_ *"W_P" _P#!#_73A?\ Z)Z'_@U__*S\U/\ AY9\3O\
MH!>$O_ .Z_\ DFC_ (>6?$[_ * 7A+_P#NO_ ))K]*Z*/[-QW_06_P#P'_@A
M_KIPO_T3T/\ P:__ )6?FI_P\L^)W_0"\)?^ =U_\DT?\/+/B=_T O"7_@'=
M?_)-?I711_9N._Z"W_X#_P $/]=.%_\ HGH?^#7_ /*S\U/^'EGQ._Z 7A+_
M , [K_Y)H_X>6?$[_H!>$O\ P#NO_DFOTKHH_LW'?]!;_P# ?^"'^NG"_P#T
M3T/_  :__E9^:G_#RSXG?] +PE_X!W7_ ,DT?\/+/B=_T O"7_@'=?\ R37Z
M5T4?V;CO^@M_^ _\$/\ 73A?_HGH?^#7_P#*S\U/^'EGQ._Z 7A+_P  [K_Y
M)H_X>6?$[_H!>$O_  #NO_DFOTKHH_LW'?\ 06__  '_ ((?ZZ<+_P#1/0_\
M&O\ ^5GYJ?\ #RSXG?\ 0"\)?^ =U_\ )-'_  \L^)W_ $ O"7_@'=?_ "37
MZ5T4?V;CO^@M_P#@/_!#_73A?_HGH?\ @U__ "L_-3_AY9\3O^@%X2_\ [K_
M .2:/^'EGQ._Z 7A+_P#NO\ Y)K]*Z*/[-QW_06__ ?^"'^NG"__ $3T/_!K
M_P#E9^:G_#RSXG?] +PE_P" =U_\DT?\/+/B=_T O"7_ (!W7_R37Z5T4?V;
MCO\ H+?_ (#_ ,$/]=.%_P#HGH?^#7_\K/S4_P"'EGQ._P"@%X2_\ [K_P"2
M:/\ AY9\3O\ H!>$O_ .Z_\ DFOTKHH_LW'?]!;_ / ?^"'^NG"__1/0_P#!
MK_\ E9^:G_#RSXG?] +PE_X!W7_R31_P\L^)W_0"\)?^ =U_\DU^E=%']FX[
M_H+?_@/_  0_UTX7_P"B>A_X-?\ \K/S4_X>6?$[_H!>$O\ P#NO_DFC_AY9
M\3O^@%X2_P# .Z_^2:_2NBC^S<=_T%O_ ,!_X(?ZZ<+_ /1/0_\ !K_^5GYJ
M?\/+/B=_T O"7_@'=?\ R31_P\L^)W_0"\)?^ =U_P#)-?I711_9N._Z"W_X
M#_P0_P!=.%_^B>A_X-?_ ,K/S4_X>6?$[_H!>$O_  #NO_DFC_AY9\3O^@%X
M2_\  .Z_^2:_2NBC^S<=_P!!;_\  ?\ @A_KIPO_ -$]#_P:_P#Y6?FI_P /
M+/B=_P! +PE_X!W7_P DT?\ #RSXG?\ 0"\)?^ =U_\ )-?I711_9N._Z"W_
M . _\$/]=.%_^B>A_P"#7_\ *S\U/^'EGQ._Z 7A+_P#NO\ Y)H_X>6?$[_H
M!>$O_ .Z_P#DFOTKHH_LW'?]!;_\!_X(?ZZ<+_\ 1/0_\&O_ .5GYJ?\/+/B
M=_T O"7_ (!W7_R31_P\L^)W_0"\)?\ @'=?_)-?I711_9N._P"@M_\ @/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+%U_Z/MZ /VUHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#\U/^"T/P<O=?\"^$_B%80M+%HLLEE?[1DK')@QM] P8'ZBNG_P""7?[9
M7A?QC\)=)^&?B+5;;2?%NA VUI'=2!!?6^<H4)X+*#M*]>,U]T>./!.B_$;P
MGJGAKQ#8QZEHVI0M;W-M*,AU/\B.H/J*_'[]H;_@D+\1/!?B"XU#X5RQ^+=
MD<O#:R7"P7MLO7:VX@/CH"IR?2LJ,GAW.G)7A)W]'_P]_O?D:5(JLH33M*.G
MJOZ_)'Z7?M3_ +4?A+]G'X6ZQK>H:S:#6VM772].217FN;@C" )G.T,02>@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&^-_C!X.^&
M^N>'])\3Z_::)>Z]))%IXO'V),Z %EWGY0<,.I'6NP5ED4,I#*PR&!R"*^;O
MVX/V.K/]KSP%86*ZO)HOB'17DGTRYQNA+N &21>N#M7D'CWK\[/#?[2G[2W_
M  3Q\2KX6\?:=/XD\+1R!8X]29YH)(\];:ZZC/HV>G2IC./PST?3L_\ @ER@
M[*4-5;7NG_E8_::BOBGX/_\ !6;X)_$:&&'Q!>7?@34S&7E358]]LI_NK,F<
MGZJ*^I?#/QC\"^,M/M[W1/%^BZC;7 !C:&^CRV?8G/Z5HXM&2DF=?)&LT;(Z
MAT8896&00>QJEIN@:9H[$V&FVEB6X)MH%CS^0%3Q:A:SQB2.YAD1NC+("#^-
M4M0\6:)I)(OM9T^S(.#]HNDC_F:DHU:*^??BA^WK\#?A,EZFK^/+"\U"U7<V
MFZ6?M,[^RA?E)_X$*^'OC;_P6/UWQ/-+H/P<\(O;33L88=4U-#/<2 C ,<"?
M=;/3);Z5GSW^%7]"^5I7EH?IK\0OBSX1^%-G:W/BK7K/1TNYX[:W2=_WDTCL
M%540?,W)'0<5UJL&4$<@\BORB_9G_8)^+'Q^\?:7\5OC[X@U.W@AGCO[73KJ
M7-Y.ZL&4E,;84X!P!DCL*_5U0%4 =!Q70X<L%S/WM=.RTM\]S%34G[JT[]_^
M +1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'G_P"T)_R0/XD_]BUJ7_I+)7Y%?\$9?^3JM7_[%BZ_]'V]?KK^T)_R
M0/XD_P#8M:E_Z2R5^17_  1E_P"3JM7_ .Q8NO\ T?;T ?MK1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%XT\#>'_B)H%QHGB;1[
M/7-*N!B2UOH5D3IC(!Z$=B.16[12:4E9C3:=T?G-\=O^"-7@GQ9+-J'PUUZ?
MP;=L01I]Z#=68'?:2=X)_P!XBOC+QO\ \$M/VA/A_,US8:#!K\:2E89M$O \
MI Z-LX9:_>:BIC'EV97-?='\]8_9X_:NTB..W3PI\1[:(':D<;7(7Z##8JWI
M_P"PO^TW\3+_ ,O4?!?B3>SC,_B"5HUSC&2TA].]?T$T5II>[,WMH?CO\(O^
M"+OCC6YHKCXA^*+#PU:K+B2RTS_2IWC]5D^XI^H-?H=^S]^Q'\)OV<889O#7
MAR*ZUM N[6]3Q/=%AGYE)XC/)^X!7O5%:>T:5HZ$>S3^+4****R- HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S_]
MH3_D@?Q)_P"Q:U+_ -)9*_(K_@C+_P G5:O_ -BQ=?\ H^WK]=?VA/\ D@?Q
M)_[%K4O_ $EDK\BO^",O_)U6K_\ 8L77_H^WH _;6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \_P#VA/\ D@?Q)_[%K4O_ $EDK\BO^",O_)U6K_\ 8L77_H^WK]=?VA/^
M2!_$G_L6M2_])9*_(K_@C+_R=5J__8L77_H^WH _;6BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC[-MO6Z^[6_Z$-RYDDM#T*BBBLBPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#S_\ :$_Y('\2?^Q:U+_TEDK\BO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \_P#VA/\ D@?Q)_[%K4O_ $EDK\\O^"'/_'C\7/\ KIIO\KBO
MT-_:$_Y('\2?^Q:U+_TEDK\\O^"'/_'C\7/^NFF_RN* /U-HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFWY6:T_$]GHHHI#"BBB@ HHHH \__:$_Y('\2?\ L6M2_P#262OSR_X(<_\
M'C\7/^NFF_RN*_0W]H3_ )('\2?^Q:U+_P!)9*_/+_@AS_QX_%S_ *Z:;_*X
MH _4VBBB@ HHHH **** "BBB@ HHHH **** "BBDR.!WH 6BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HI 0W(.12T %%%% !1110 4444 %%%% !111
M0 4444 %%)D=.]+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%)D9QGF@!:*** "BBB@ HHHH **** "B
MBB@ HHHH ***2@!:*2EH **** "BBB@ HHHH **** "BBB@ HHHH **3(SCO
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1129'([T +1110 4444 %%%% !1110 4444 %%%% !112$@
M=>* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **16#=#GZ4M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444@(/3F@!:*** "BBB@ HHHH **** "BBB@ HHHH ***3(H 6BBB@ H
MHHH **** "BBB@ HHHH **** "BBDSCD\"@!:*0$-R#D4M !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A
M(7DG HZ]* %HHHH **** "BBB@ HHHH **** "BBB@ HHI-PSC(SZ4 +1110
M 4444 %%%% !1110 4444 %%%% !112%@O).* %HI*6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **1F"]
M3CZTM !1110 4444 %%%% !1110 4444 %%%% !112!@W0YH 6BBB@ HHHH
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M(_&MMK$[:X]FUK_95LDP B$N[=N=<?ZQ<=>] '[C45\(?\/EO@3_ - [Q?\
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M%L/_ ,?H ^[Z*^$/^'RWP)_Z!WB__P %L/\ \?H_X?+? G_H'>+_ /P6P_\
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M_P#P6P__ !^@#[OHKX0_X?+? G_H'>+_ /P6P_\ Q^C_ (?+? G_ *!WB_\
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M_P#'Z/\ A\M\"?\ H'>+_P#P6P__ !^@#[OHKX0_X?+? G_H'>+_ /P6P_\
MQ^C_ (?+? G_ *!WB_\ \%L/_P ?H ^[Z*^$/^'RWP)_Z!WB_P#\%L/_ ,?H
M_P"'RWP)_P"@=XO_ /!;#_\ 'Z /N^BOA#_A\M\"?^@=XO\ _!;#_P#'Z/\
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M_P#Q^@#[OHKX0_X?+? G_H'>+_\ P6P__'Z/^'RWP)_Z!WB__P %L/\ \?H
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M>+__  6P_P#Q^C_A\M\"?^@=XO\ _!;#_P#'Z /N^BOA#_A\M\"?^@=XO_\
M!;#_ /'Z/^'RWP)_Z!WB_P#\%L/_ ,?H ^[Z*^$/^'RWP)_Z!WB__P %L/\
M\?H_X?+? G_H'>+_ /P6P_\ Q^@#[OHKX0_X?+? G_H'>+__  6P_P#Q^C_A
M\M\"?^@=XO\ _!;#_P#'Z /N^BOA#_A\M\"?^@=XO_\ !;#_ /'Z/^'RWP)_
MZ!WB_P#\%L/_ ,?H ^[Z*^$/^'RWP)_Z!WB__P %L/\ \?H_X?+? G_H'>+_
M /P6P_\ Q^@#[OHKX0_X?+? G_H'>+__  6P_P#Q^C_A\M\"?^@=XO\ _!;#
M_P#'Z /N^BOA#_A\M\"?^@=XO_\ !;#_ /'Z/^'RWP)_Z!WB_P#\%L/_ ,?H
M ^[Z*^$/^'RWP)_Z!WB__P %L/\ \?H_X?+? G_H'>+_ /P6P_\ Q^@#[OHK
MX0_X?+? G_H'>+__  6P_P#Q^C_A\M\"?^@=XO\ _!;#_P#'Z /N^BOA#_A\
MM\"?^@=XO_\ !;#_ /'Z/^'RWP)_Z!WB_P#\%L/_ ,?H ^[Z*^$/^'RWP)_Z
M!WB__P %L/\ \?H_X?+? G_H'>+_ /P6P_\ Q^@#[OHKX0_X?+? G_H'>+__
M  6P_P#Q^C_A\M\"?^@=XO\ _!;#_P#'Z /KOXUZI>:'\&_'FI:=<R66H6>@
M7]Q;W,)P\4B6\C(ZGU! (^E? '_!%?QUXB\5:3\5;/6=;OM4M+>ZL[J&&[F,
MBQRS";S7&>A?8F?]T5N_%+_@KC\$_&7PQ\7^'["P\5K?:MH]Y80&;3XE022P
MNB[B)C@989.*^3?^";'[9W@/]DN'QXGC6VUB=M<:S-K_ &5;)-CRA-NW;G7'
M^L7'7O0!^Y%%?"'_  ^6^!/_ $#O%_\ X+8?_C]'_#Y;X$_] [Q?_P""V'_X
M_0!]WT5\(?\ #Y;X$_\ 0.\7_P#@MA_^/T?\/EO@3_T#O%__ (+8?_C] 'W?
M17PA_P /EO@3_P! [Q?_ ."V'_X_1_P^6^!/_0.\7_\ @MA_^/T ?=]%?"'_
M  ^6^!/_ $#O%_\ X+8?_C]'_#Y;X$_] [Q?_P""V'_X_0!]WT5\(?\ #Y;X
M$_\ 0.\7_P#@MA_^/T?\/EO@3_T#O%__ (+8?_C] 'W?17PA_P /EO@3_P!
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M@=XO_P#!;#_\?H_X?+? G_H'>+__  6P_P#Q^@#[OHKX0_X?+? G_H'>+_\
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M_0.\7_\ @MA_^/T?\/EO@3_T#O%__@MA_P#C] 'W?17PA_P^6^!/_0.\7_\
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M_P /EO@3_P! [Q?_ ."V'_X_0!]WT5\(?\/EO@3_ - [Q?\ ^"V'_P"/T?\
M#Y;X$_\ 0.\7_P#@MA_^/T ?=]%?"'_#Y;X$_P#0.\7_ /@MA_\ C]'_  ^6
M^!/_ $#O%_\ X+8?_C] 'W?17PA_P^6^!/\ T#O%_P#X+8?_ (_1_P /EO@3
M_P! [Q?_ ."V'_X_0!]WT5\(?\/EO@3_ - [Q?\ ^"V'_P"/T?\ #Y;X$_\
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M_P ?H ^[Z*^$/^'RWP)_Z!WB_P#\%L/_ ,?H_P"'RWP)_P"@=XO_ /!;#_\
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M_P#\%L/_ ,?H_P"'RWP)_P"@=XO_ /!;#_\ 'Z /N^BOA#_A\M\"?^@=XO\
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M1BI,PR,J<<"NO_X?+? G_H'>+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\
M\%L/_P ?H_X?+? G_H'>+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/
M_P ?H_X?+? G_H'>+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?
MH_X?+? G_H'>+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?H_X?
M+? G_H'>+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?H_X?+? G
M_H'>+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?H_X?+? G_H'>
M+_\ P6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?H_X?+? G_H'>+_\
MP6P__'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?H_X?+? G_H'>+_\ P6P_
M_'Z /N^BOA#_ (?+? G_ *!WB_\ \%L/_P ?H_X?+? G_H'>+_\ P6P__'Z
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M\P_\.T/V;?\ HFEM_P"#"[_^.T?\.T/V;?\ HFEM_P"#"[_^.U]/44 ?,/\
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M /':^GJ* /F'_AVA^S;_ -$TMO\ P87?_P =H_X=H?LV_P#1-+;_ ,&%W_\
M':^GJ* /P]_X*K?L\_#[]GOQWX$L/A_X>C\/6FHZ;<3W4<<\LHD=90JG]XS$
M8'I7Z(^%_P#@FW^SEJ'AG2;J?X;V\D\]I#+(QU"[Y9D!)XE]37QI_P %OO\
MDIWPR_[ ]U_Z.6OUB\%_\B;H/_7A;_\ HM: /GO_ (=H?LV_]$TMO_!A=_\
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M=H_X=H?LV_\ 1-+;_P &%W_\=KZ>HH ^8?\ AVA^S;_T32V_\&%W_P#':/\
MAVA^S;_T32V_\&%W_P#':^GJ* /F'_AVA^S;_P!$TMO_  87?_QVC_AVA^S;
M_P!$TMO_  87?_QVOIZB@#YA_P"':'[-O_1-+;_P87?_ ,=H_P"':'[-O_1-
M+;_P87?_ ,=KZ>HH ^8?^':'[-O_ $32V_\ !A=__':/^':'[-O_ $32V_\
M!A=__':^GJ* /F'_ (=H?LV_]$TMO_!A=_\ QVC_ (=H?LV_]$TMO_!A=_\
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MZ>HH ^8?^':'[-O_ $32V_\ !A=__':/^':'[-O_ $32V_\ !A=__':^GJ*
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MYA_X=H?LV_\ 1-+;_P &%W_\=H_X=H?LV_\ 1-+;_P &%W_\=KZ>HH ^8?\
MAVA^S;_T32V_\&%W_P#':/\ AVA^S;_T32V_\&%W_P#':^GJ* /F'_AVA^S;
M_P!$TMO_  87?_QVC_AVA^S;_P!$TMO_  87?_QVOIZB@#YA_P"':'[-O_1-
M+;_P87?_ ,=H_P"':'[-O_1-+;_P87?_ ,=KZ>HH ^8?^':'[-O_ $32V_\
M!A=__':/^':'[-O_ $32V_\ !A=__':^GJ* /F'_ (=H?LV_]$TMO_!A=_\
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M\P_\.T/V;?\ HFEM_P"#"[_^.T?\.T/V;?\ HFEM_P"#"[_^.U]/44 ?,/\
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MEM_X,+O_ ..U]/44 ?,/_#M#]FW_ *)I;?\ @PN__CM'_#M#]FW_ *)I;?\
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M /':^GJ* /F'_AVA^S;_ -$TMO\ P87?_P =H_X=H?LV_P#1-+;_ ,&%W_\
M':^GJ* /F'_AVA^S;_T32V_\&%W_ /':]>^#OP$\ _ '0[K2? /AJU\/65U-
MY\XA+/)*^  6D<EB !P"<#)QU->@44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $%]?6VF6<MU>7$5K:PJ7
MDFF<(B*.I)/ %?-'Q@_X*._ SX/QS13^+8?$>IHFY+'01]J+^WF+^[!^K5\T
M?\%M-2O-/\)_#-+6\N+9)KF]6589619!MBX8 \_C7Y<?#N#P5)JROXVN]7@T
MZ-E8Q:1;I))*,\KN=AMSZX-8TY.LVD[6=C:I%4HQ;UNK_BU^A]__ !@_X+3>
M*]8:XM/AQX2M?#]ON!AU'6"+BXQW!B'R#\S7SO\ ;/VI?VV+Z.)6\5>*M/N9
M6EB7+P:9&PZ[6.V)<>F:];^$_P"TU^Q[\'S;3Z?\&M?UK4[>3SH]1UV2&ZF5
MO;Y@H'MBOHRQ_P""SWPJTRW6WL_ 6NVENOW8H%@11] &Q6WLZ2^+5_U_70PY
MI]-#Q_X0?\$6O%NO)#>?$;Q?:>'(9(]S6.E)]JND?^ZS'"?B":^W/A1_P39^
M WPI\N:+PA%XBOU"DW6O-]J(<8^95;Y5Y'85X5_P^M^&G_0E^(_SA_\ BJ/^
M'UOPT_Z$OQ'^</\ \55\S7PZ$\O?4_0^QT^UTNW2WL[:&U@0!5CA0(H X P*
ML5^='_#ZWX:?]"7XC_.'_P"*K[H^$7Q(L_C!\,_#GC33[::SLM;LTO88+C'F
M(K#(#8XS1RR<7/HOU_X8?,DU$Z^BBBH*"BBB@ HHHH **** "BBB@".XMXKJ
M"2&>-9H9%*/'( 592,$$'J*^(?C5_P $C_A#\4-8FU70;B_\!WMQ*99TTT++
M;L3V6)B G//%?<5%2XIOFZEJ3BK+8^ ?AK_P1L^%'A'5X[WQ)KFL>,HXW#I:
M3A;6(D'.&"$EAZC/-?=V@^']-\+:/::3H]C!INF6D8B@M;9 D<:CH !TK0HK
M7GDUR]#)12=^IROQ3\!P_%'X=^(?"5Q>2:?#K%F]H]U"@9X@PQN /!-?,O[)
M?_!-_0OV3_B1/XOTSQIJ6OSRV;V9M;JSCB3#$?-E23GBOL2BHA^[FZD=VK?+
M7_-E2_>04);)W^>G^2"BBB@#Y?\ VR/V%='_ &Q+[PU<ZIXKOO#AT2.:-$L[
M5)A+YA4DG<1C&W]:]Q^$/PZ@^$GPS\.>#K:]EU*#1K1;1+N9 CRA?XB!P#]*
MZ^BB/N1<([-W^>O^;"7OR4I;I67I_2"BBB@ HHHH **** //_P!H4X^ ?Q*)
M_P"A:U+_ -)9*_/S_@A_I5[;^'_BIJ$MG<1V%Q<6$4%TT9$4KHLY=5;H2NY<
M@=-P]:_4":%+B%XI462)U*LCC*L#P01W%0:?I=EI%O\ 9["T@LH,EO*MXEC7
M)ZG &,T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /EW_@ICI5]K'[%OQ"M]/L[
MB^G5+68Q6T9D8(ES$[O@=E52Q/8 FO/?^".I_P",0G_[&*]_] AK[AFA2XB>
M*5%DC=2K(XR&!X(([BH-.TNRT>W\BPM(+*#);RK>)8UR>IP!C- %JBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@#\BO^"UVGW6K?%WX56-E;RWE[<:7<0PV\"%Y)7:X4*JJ.222
M *_5[P?"]OX3T2*5&CD2Q@5D88*D1J""/6K5WHNGW]U!=7-C;7-S;G,,TT*L
M\9SG*L1D<\\5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /QX_:RTN]UG_ (*X
M^$X-/L[B^FCU'09GCMXR[+&BQ.[D#^%5!8GL 37[#U2_L73_ .TO[1^P6W]H
M8V_:_)7S<8QC?C/3CK5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _'O\ 97TR
M\OO^"NGC6[MK2>XM;/6=>>YGCC+) K+,JER.%!8A1GJ2!7["52M-%T^PNY[J
MVL+:WN9SF6:&%5>3G/S,!D\^M7: "BBB@ HHHH **** "BBB@ HHHH ****
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M\\RTW'T!F5031'W](ZA+W%>6A[O12*P90RD$$9!'>EH **** "BBB@ HHHH
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M (9_&J-6\%^,]+UR5N1;13;)_<^4^'_2JBG)70F^7<])HHHI#"BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK"Q##?=W##"(!Z9Y)[ &OY__ !]XX\6?%'XQ6OC7QAY[:CKU]%>1O,"%,1D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOA,S:@DEXMOJUQ:L=MQ.#S$6''E1]6/3(/85^FOQ&6Z;P#XC%D)6O#I\XA$
M)<OY9QMQWS7\\W@?X>_M"_#/Q&^O^%?"7C_0-:960W]CI-W',0WWAN"9YK#W
M:E=0J+W8V;\][+\-?E\]KN%)RA\3T7EW?XZ?,_=C]E7]FS0?V7?A/I_A/2$6
M:]($VI:AM >[N"/F8GT'0#L*_+O_ (*R_P#)Z7AS_L&V'_HYZ\Q_X69^VK_T
M$/B[_P" U]_\17B'Q>USXHZUXXMKKXES>(Y?%BQ1B!O$"2K=^6&.S:) &QG.
M*Z)2E4KPJRZ._P"%K(RII4Z-2DOM*WXIW9_2=X1_Y%71?^O*'_T6M:U?CO\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q8_X*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<^]=/3J1]G-P[$TY>T@IVW"BBBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M:]E&<9"(6Q^.,5_.=XO^.DGQ.^/D_P 1?'^FMXMMY[[[3/I)N3;I+"I^2 .
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MQ$C;>!]YL >M4TXOE:UV^>UB.9-<R>FYWU%%%(H**** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHP/.90TG_CS&OP^_9%\(W/[2'[:^ARWT)OX+G5Y=:O\ ?_SR5RY)_$J*_H,
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MI!;-LN)=%O4C8*#AC X'!Z\UCC+X>E-)WE&.K[M+5_>:X9JO.+VC)Z>2;T_
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M#V*@UK'][*DEIS<U[?W>?;S]V]N^FQ/PQK-Z\B37_DC_ %:]-=SWOX&?M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\2?\
M%>O^31Y_^PQ:_P GKYQ_X(?_ /(T?%/_ *]+'_T.:OH[_@KU_P FCS_]ABU_
MD]?./_!#_P#Y&CXI_P#7I8_^AS4\!\>)]/TB5C/X-'U_]N/UIHHHI$GYB?\
M!;G_ )%#X<?]?EQ_Z *]6_X(\_\ )ITG_8<NO_08Z\I_X+<_\BA\./\ K\N/
M_0!7JW_!'G_DTZ3_ +#EU_Z#'2P'P8KU7_MH\9\6'_KI(\U_X+=?\D[^&O\
MV$KK_P!%I7#?\$8_@/I&O7WBCXG:K:1W=YIDJZ=IJS1AEA=E#/*N?XL';[5W
M/_!;K_DG?PU_["5U_P"BTKNO^"-MO''^S'J4JKAY-:F+G/7  'Z56 T5>2W5
M_P 7%?DV+&ZQP\7L_P!'-_FC[UK\1?\ @L-X%L?"_P"TQ9:Q8P16YUS2HY[A
M8UP7F5BK.WN1M_*OVZK\:_\ @M5_R6[P=_V!V_\ 1E<-=VJ4FOYFO_)9?Y'5
M1^"KZ?\ MR/JK_@DC\#]'\#_ +.]MXW-E&_B'Q/-)*UY(@\Q($8HD:GLN58\
M=<U]TLH92",@\$&OG7_@GG_R9O\ #/\ Z\&_]&O7T77L8S2M*'1:?):'F8;^
M$I=]?O/YZ/V[O#%C\-?VR/&MMH4$=C;QZBM[%#"NU(W?#D =ADU^_G@BYDO/
M!N@SRG,DEA ['W,:DU^#/_!2S_D]#QO_ -=8?_0!7[P_#_\ Y$/P[_V#K?\
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M<-%T/A>_K_6OF[WVTY9.;Q$E6W6R\OZ^Y6[G-?&RWO+KX.^.(=/+"^DT2\6
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M$UMRTZNE^OY&<95*6MOZ^9^LO[)O[('AS]D?P_JVF>'M9U355U25)[G[>Z[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M >N>*O'7C;Q2WCOXI>*V!U/6O+*11)D,8H@>2"P&3A1A$ 50O/M7P;^%.C_
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M5G-)*+V25UNU!C41E"O^D+R7!^4\=*^F:*N,N5Q:^S>WSO\ _),6ZFG]O?\
M#_)&9XHTN76_#6K:="R)->6DUNC2$A0SH5!..V37B'["_P"SWX@_9B_9_L/
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ML6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cdtx-20250331_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20250331_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ;E#S # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **PK3QYX:O]<DT2V\0Z5<:S'G?IT-[$UPN.N8PVX8^E;M.S6Y,91E>SO8**
M**104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZO5JI3TTZZ['T11117.>F%%%% !1110 4444 %%%% !1110 4444 %%%<?\
M%?XG:=\(/!=UXGU:QU"_T^V=$E338T>10[;0V'=1C)&>>]-:M)=2)SC3BYR=
MDE=^B.PHKYJ\,?M]_#KQ5XDTO1H=,\16DVH7,=K'/=VUNL2,[!07(G)"Y/)
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M?C7:5E.$J<N62LSNI585X*K3=XO9A1114&H454U?4HM%TF]U"=7:&T@>=UC
M+%54L0,D<X'K7S%_P\:^&W_0$\5?^ EM_P#)%;4Z-2LVJ:O8X,5CL-@>5XF:
MCS7M?K:U_P T?5%%?*__  \:^&W_ $!/%7_@);?_ "11_P /&OAM_P! 3Q5_
MX"6W_P D5O\ 4\1_(S@_M[+/^?Z/JBBN!^"_QHT3XZ>%[C7M!M=0M+."[:S9
M-1C1)"ZJK$@([C&''?UXKOJY9PE3ERS5F>O1K4\1356E*\7LPHHHJ#<****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5\@?\%(O^2>^$O^PH_P#Z):OK
M^OD#_@I%_P D]\)?]A1__1+5TX;^/#U7YGB9W_R+:_\ A9\:?#/X*^,_C VH
M+X1T;^UVT\1FY_TJ&'R]^[;_ *QUSG8W3/2MWQ5^S[\5?A)9G7-3\.:AI-O;
MG<U_8W$<HA_VF:%VV#W.!7T1_P $T?\ CZ^(/^Y8_P YZ^Q_'NI:7I'@K7+O
M6I88M*CLY3<M.0$*%2"#GUSC'?->YCL?4PM5PBDTDORN? 9+PWA<RP4<3.I*
M,G?9JRL[7VO^)\0_LE_M?>(8_%VF^#?&NHRZSINI2K;6FHW;;KBWF8X16<\N
MK' ^;)!(YQQ7J'_!1;_DC^B?]AA/_14E? GA*&XNO&6C1:<K?:I+^%;=1G.\
MR (/SQ7WW_P46_Y(_HG_ &&$_P#14E+&T84Z]&I%6;>OR:_S+R?'5\3E.-HU
MI<RA%V;\U+2_E;\3AO\ @FC_ ,?7Q!_W+'^<]?<M?#7_  31_P"/KX@_[EC_
M #GKZQ^,7Q-L_A!\.]6\4WD7V@6: 0VX;;YTK$*B9[9)&3V&:X<S_P!Z:7]W
M\D?3<+RC#*(SD[)<S?DDW<[2BOS'M?C5\>?VBO%4NG^&=5U))L&466ARBQAM
MX^F6E!4@<]7<DDX'I3?&.O?M%?L_W%C?>(O$'B"SCN6*P2WFI+J-N[#DJ0SR
M(#@=",XS1_9TE:,YI2?0R?%-*2E5I4)RIK>26G]>K1^G5%>'_LH_M!2_'GP3
M=R:G!%;^(=)D6&]6 $1RJP)251VW;6!'8J>Q J[^TM^T-9_ 'PG!<);IJ&OZ
M@S1V%G(V$X'S2/@YV+D=.22!QU'!4H5*=7V+7O'TE+,<-6PGUY2M3M>[Z6W^
M=]/78]CHK\M8?C%\>OCAJ]R=#U;Q'=O%\[V_AW?;Q0*<X!\K&!P<;B2<=34N
MG_M$?&_X&^(DM-=U+5WE7$DFF^)T><2I[-)\X!]48=*]'^S9_"YKF['S'^MF
M'_B>QG[/;FMI^?ZW\C]1:*X/X)_%O3OC7\/K'Q-I\1MFD+0W5HS;FMYUQN3/
M<<@@]PPX'2O%?VM?VN+CX1W@\*>%$AE\2O$)+F\F4.EDK?= 4\,Y'// &,@Y
MKSO85/:^QM[Q]/4S'"TL)]=E/]W:]^]]M._E]Y]345^:/AW3_P!IWXLZ;_PD
M>D:EXJGL)CN2:/5QI\<@]8XS)&&7W5<5I?#O]L'XE?!OQ?\ V%\0A>:SI]O(
M(;RSU*,+>VX_OI(0"QQSAR0PZ$9S7?\ V=.[C&:<ETN?.QXHHJTZU"<*<MI-
M:?UZ7/T<K\;KW_DKD_\ V'&_]**_871]7L_$&DV6IZ?.MU8WD*7$$R='C90R
ML/J"*_'+7KU--^)FHW<BLT=OJ\DK*O4A9B2![\5OE/NXA\W1?JCS>,Y*6#HR
MB[IR_0_9FBOSH\1?%;]H+]H*:[UCPA9:]I7AF-V^S1:&6MUVC(QYP*M*WJ 2
M,] *Y7X9_M>?$OX4^)UM_$&IZAX@T^&;R[[2];=I)UP<,%D?YT<<\$XSU%80
MRZI)6YES=KZ_,]*IQ3A:4US4Y^S>T[:/T[K\?(_4&BLWPWX@L?%GA_3M:TR8
M7&GW\"7,$H_B1@"/H>>G:OBW]IG]N#5]+\1W_A;X?2Q6D=DY@NM:9%E=Y!PR
MQ!LJ%!XW$$D@XQC)X*="I5J>RBM?R/H<9F6&P.'^LUI>Z]K:WOM;^K'W)17Y
M=6\W[26K:2/$4%W\0);!U$RRQ7-R%=2,AEB#<KCG(7&*]"^ /[=?B+2/$%IH
MOQ%N%U;1IY!#_:C1*EQ9D\!GV@!T!ZY&X<G)QM/H/+:EGR24FNB/G:?%.'<X
MK$4I4XRVDUH_Z\KGZ!T4U761592&5AD,#D$>M.KR#[4**** "BBB@ HHHH *
M*** "BBB@"AKVO6'A?1;W5M4N4L].LHFGGGD.%1%&2:_-[XY?ML>,/B)JES9
M>%[ZX\+>&U8I$MF_EW4XS]^24?,N?[JD#GG/6OH#_@HAXUN=#^&.C:!;2&,:
MU>DS[21NBB ;;]"S(?PKP_\ 8'^%-AXZ^)&HZ_JMNEW:>'8HY889!E3<R,?+
M8COM".?KM/:O9P%&G[.6)JJZCM\O^#HC\^S_ !V*K8REE.#ERN>[ZZ]/1)7=
MM]O7S73_ -G7XN^-K4ZPOA+6KU91YGVB^/ER2 X^8"5@S9SU YJ/1_B9\5O@
M#KRV0U+6_#]S!\QTK4@Y@93W\F3*D''W@/H:_6ZO(OVDO@#:_'SP?!IRS6^G
M:Q:3K+:ZC+$7,:]'3@@D,.V>H![5<<SYI*-2"Y?R,JW"?L:3JX.O+VRUWM=]
MNEK^;96_9G_:,L?C]X7GDD@33O$>G[5O[)#E#G.V6//.PX/!Y4C!SP3X_P#\
M%)O^1+\&_P#80F_]%BND_9P_9#UKX#_$%_$$OBFUU*TFLY+2:UAMGC+ABK Y
M+$<,HKF_^"DW_(E^#?\ L(3?^BQ6#5'ZW!T'HVOEJ>C5EC7D599A&U11:Z:K
MH]-/^&/CGX<_!GQE\6EOSX3T1]8%CL%QLGBC\O?NV_?9<YVMT]*W-:^ 7Q8^
M&Z-J5QX6UK3D@^9KRQ_>"(#G<7A)VCW)Q7TE_P $T_\ 5?$#_>L?_:]?;U>C
MC,=4P]9TXI-:?BDSYK)>&\-F.!ABISE&;OM:VC:[7Z=S\RO@K^VQXV^'6IV]
MMXBOKCQ;X=9@)HKY_,NHE[M'*?F)']UR0<8&W.:_2'PQXFTWQEX?L-;T>Z2]
MTR^A6>"=.C*?;L1T(/(((-?G]^WS\'=-\"^,M+\3Z-:I96>NB074$0"H+E,$
MN .FX-D^X)[UZI_P3C\:W&J>"?$WAF>1GCTJZCN;?<<[4F#;E'H T9/U<UAB
M(4L5AOK5-6:W^^W]/L>EE.*Q>6YF\HQ<^>+^%OTNODUI;H]%YR?MJ?M1:Q\.
MM0A\%>$;G[!JLL GOM20 R0(V=L<>>C$#);J 1C!.:^6?#7P#^+GQKT\^)K+
M1]0UVVF)VZAJ-]&C3D'!*F:0,XR",CC(/-?<OQ/_ &+?!/Q9\;:AXHUC5O$,
M&H7NSS([.Y@6)=J! %#0L1PH[UV.J?$WX=_ #2=&\*ZSXABTA;'3XDMHKE&>
M62%!L#'8F"3L.< 9.>*PP^)AAZ,52C>H]]/ZV_X)UX_*:^88RI4S"KR8>/PV
M:79:WT5]W?7IV/SM\)_&#XH?LV^,#IL]WJ%HUE(%NM U21I+=UX) 0DA<CHZ
M8/H<5^H'@/QE9_$#P7HWB2Q!2TU*U2Y5&.2FX<J?=3D'Z5^8O[2WQ&MOC]\:
MVOO"UC<W4#Q0Z=9(L1,UV5+88)C.26P!UP!]*_1SX)^![KP'\'/#'AK43B]M
M+!8[D*<[)&RSJ".N"Q&?:M<?[V%A5E&U1_\ !_X'I<YN&YSIX_$86C4<Z$=G
MOK=6L]MK[:.USX(_:"_:>\9?%KQY=Z#X;O[ZPT!+HV5EI^FNR27AW; SE#N<
ML>B]!D<9YK(UK]DOXO> _#K>+)--:$VR&XF6QOE:[MU')<A3SCK\I)%<Y#;W
MG[/?[0EI)KUA*QT'5TN'BQS-"'R'0G@Y7D'UK[M\??MC_"^S^'U_>Z?X@AUB
M\NK62.VTV&)_-=V4@*ZLHV#)Y+8]LUO4G+"T*;PD>:Z[7O\ \.>5AJ%#-<5B
M99O7<)0>BO;E5WM?MY?J>/?L4_M1>(?$'BV'P%XMU";64NXW;3M0NFWSI(BE
MS&[GEP5#$%B2",9((Q]._'_XL)\%_A?JGB40+=7D>V"S@?[KS.<+N_V1RQ]A
M7P3^PWX#U+Q5\=-,UB"!_P"S-"62ZN[C'RJ6C9(TS_>9FZ>BL>U?87[:_@74
MO'7P)U"/2H'NKO3;F/4#!&"6=$#!\ =2%8G'M7+F5.E'$02TO:_W[^6G^9[G
M#V*QE3**TW>4H\W)?6]HW2\]?\CX7TJW^*_[5WBRYMXKV^\03K^^F$]SY5G:
M*3@?*2$0>BJ,G!X/-2>*/!WQ8_93UJRGDO+W0/M#;K>[TV[WVMP5P2K ':W7
M[KKSZ$5Z#^PU\=/"_P )M6\1Z7XHNO[,M]7$#PZ@Z,T:/'O&Q\ D B3(/3Y3
MG%=!^W-^T%X0^)&AZ+X9\+W\>M26MX;RXO84/E1X1E"*Q W$[B21D<=:]*I.
MI2Q$:%.'N:=/O]+?UNCY.CA\+7RV>8U\0_K"O]K6]]%;=WW\ODSZ=_9=^-DG
MQR^&<6K7L4<&LV4QLK]8N%:155A(H[!@P..QR.U>OU\Q_L ^ ]2\)?"&\U/4
MH7MCKEY]JMHI!@F!4"J^/]H[B/48/>OIRO QL84\1*-/;_@:_B?J.2UJU?+Z
M-3$?$U_PS^:LPHHHKB/:*FK:I:Z'I=YJ-],+>RM(7GGF()"1JI9FP.> #TKX
M]^-W_!0#2;?2[G2_AQ'-?:A*I3^VKJ$QPP@_Q1QM\S-Z;@ /0]*^K_'F@W'B
MGP/XAT:U>..YU#3[BTB>8D(K/&R@L0"<9/. :^7?A)_P3UT?PWJ5MJ?C?5U\
M0RPD.NEVD9CM2P_OLWS2+[87ISD<5V854&Y/$/16LN^]_P!.Q\[F\LSER4LN
M27-?FD_L[6M^/1OL?!?VR?4M8^UW4SW%S//YDLTC%F=BV2Q)ZDFOVP@_U,?^
MZ/Y5^,/B:-(?'FK1QJJ(NI3*JJ,  2G  K]GH/\ 4Q_[H_E7JYG)2H49)6O?
M\HGR7!\)4\5BX2=VN57[ZR/CW_@I-?;/!O@VSSS)J$TN/]V,#_V>OE+P#^S5
M\2/B?X=CUWPSX<_M+2I)&B6X^W6T664X8;9)%;CZ5]$?\%*M08ZIX%L<_*L-
MU,1[EHQ_0UC?!G]LKP_\#O@OH'ARUT&Z\0:W&T\UVOG"V@C+S.5&\JQ)V[>B
MXYZU6"E4IX/GI*\G)_FU^ARYU3P>)SR=/'5'"$8+5=[)V6CO\78\S_X8G^,_
M_0F_^52R_P#CU?I1\+=%O/#GPS\*:3J,/V>_L=*M;:XAW*VR1(E5ERI(."#R
M"17S?X'_ ."B_A36]0CMO$OAV^\-1R,%%U#.+R)/=\*C ?[JM7U'-XBLY/"\
MNN65S#>6/V1KN&XA<-'(@0L&##@@CO7%CJV)]G:O"RWT_P"'/I.'L#E=.K*K
MEU9S;5FFUIKVY4SX?_;(_:NUQ?%=[X'\':E+I5CIY\K4+^S<I-/-_%&KCE57
MH<8).1T'/SLWP?\ B2GA4>/#H&K#2"/M']JY._;U\W&=^WOOQC'.:QO"UG)\
M1/BAI-K>,S2:YK$4<[=3F:8!C_X\:_8UM,M&TTZ=]GC%B8?(^SA0$\O;MVX]
M,<8KNJ2_LVA!0BG)[_A?_@=CYO"8:7%.+KUJ]1JG'X4NE[VT?9+79MO='PQ^
MQM^U=KD_BNR\"^,M2EU6SOSY6G:A>.7GAF_AB=SRZMT&<D$@=#Q]XU^,OB"&
M7P!\2]1BLF:&;1=6D$#C(*F*8[#_ ..BOV0TN^35--M+R/\ U=Q"DR_1E!'\
MZYLQIPY85Z:MS?\ #K^O(]WA;&5YJM@L1*[I/1_>K?)K\2U117YF?M3?%OQS
MX>^/WC#3M*\9^(=,T^"XC$5K9ZK/%%&##&2%17 '))X'>O-PU!XFI[-.VE_R
M_P SZ3-LRAE.&6)G%R3DHV7FF_T/TSHK\Y]>_:9^,7Q@TVUTKX?:=KD.G:?9
MP07=SI5O)<7<THC 9Y)E!*98$@ @GJ2>WG&A_M&?%[X6^+#]N\2:Y+>6L@6Y
MTKQ#-+.I[E'CE)*Y'<8//!KNCEM23:<DGV/GZO%F%IVDJ<G!_:MI?LK[V^1^
MK]%? WC[]L[X@?%RYCT7X4Z#J5C_ *.LEU)9VIN[PL0-^W:K!$!.-V,G@Y7I
M7B=[\9OC5\-?$D8U;Q/XLTS5(\2BSUJ>9E*GH3#-E2I_W<5-/+JL_B:B^W4T
MQ/%6$HN]*$IQZR2T^]]?ZN?K+17F'[.7QA'QN^%UAXAEACMM221K2_ABSL6=
M,9*Y[,K*P';=C)QFO!_VM_VPM6\!>(I_!?@EXK;4K=1]OU5T$C1,PR(HU8$9
M ()8@]<#D9KC^K5'6]@E[W]:^A[M7-<+1P2Q\I?NW:W=WZ6[_P#!OL?8]<-\
M3?C9X+^#]O!)XJUN+3I+@$P6RHTLTH'<(@)Q[G ]Z^+-+^%?[3WB3PJOBN+Q
M7KD0FC^TQ::^O317$J$;@5B!V#(Z*2#[5Y9\.9;7XY?&[3M/^*VM:Q++J&W3
MTO(72.5)AA8HWW(0%)RIP,Y;)[FN^GEZE)IS3Y=TMSYS$<25:<(J.'<93MRN
M>D?G_7S/TY^'/Q"TCXI>$++Q+H;3-IEXTBQ-<1^6YV.R'*YXY4UTU<Q\-OAY
MI/PK\&V/AG0_/_LRS,AB^TR;W^=V=LG SRQKIZ\NIR<[]G\/2Y]EA_;>RC[>
MW/;6VU_(****S.@**** "BBB@ HHHH _/#_@HY_R5KP]_P!@5?\ T?+7C/P_
M_9O^(OQ2\/\ ]M^%_#O]IZ9YK0>?]NMH?G7&X;9)%;N.U>S?\%'/^2M>'O\
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MU)FCT^Z92598F(8'!!P:\_&8=X-VD[Z7_/\ R/H\GS.&<476IQ<;2Y=?1/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5]?Z/_P3HUK5])LK]?&EA&MU DX0V3DJ&4-C[WO7R!7[3>"_^1-T'_KPM_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRO QU[5M4A&.)C!4W)W7O-OR=_E_P#SH5JU3*9UY8F-.$E*U.,8K>ZMWN_\
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M'7H?1J[\+*+QM?E>KM^#=W][_$\/.:4Z67Y=.LO<C\7E=1:3^2?W,_8, *
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MK=6UM9:'R[^R7^TQJOPK\4V'@K6HH6\,7EV+9U\A(I;.=VV^86 !89P&#9(
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M:5;7,JPKC?+)$K.[>K$DDDU\0_\ !0JSAM_CA:2QQJDD^D0M(P_B(>103[X
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M445XA]R%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?#?\ P4J_X^/
MG^[=_P XJR?^";/_ ".7C/\ Z\(/_1AK6_X*5?\ 'QX$_P!V[_G%63_P39_Y
M'+QG_P!>$'_HPU]'A/\ D72_[>_-GY=C?^2JA_V[_P"D(POV\/@C_P (5XVC
M\::7;[-&UUR+E4'RPW>,M] X&[ZAJ\-^#WPUU'XR?$;2/#5HSC[2X-Q<'YO(
MMT WO^"C 'KM'>OUL\;>!]#^(WAVYT+Q'IZ:GI5P5,EN[,F2IR"&4AE((Z@@
MUSGPV^ O@/X0WUY>>$] 32KN[C$,TQN9IV* YV@RNVT9Y.,9P,]!7/A<P]A1
M]G)7:V_2_I^1WYEPM]<S#ZS3DE3DTY+6]^MM.OF]VSS']LC0;'PO^RG?Z/ID
M"VVGV+6-O!"O1469 !^0ZU\1_LJ_\G#>!O\ K_\ _9&K[K_;H_Y-OU__ *^;
M3_T>E?"G[*O_ "<-X&_Z_P#_ -D:NO*FY4JC>_-^B/+XGBH9OA(Q5DHP_P#2
MY'Z5?M :]/X9^"?C74K9_+N(=+F$;>C,NT'_ ,>K\D_"NL0^'?$VDZK<V2ZE
M;V-W%<R6<C;5G5'#%"<' .,=#UK]=?C=X9F\9?"+Q?HML-US=Z;,D2XSEPI*
MC\P*_)3P+JECX?\ '&@W^KV<=[IMI?PRW=I<1"1)8ED!=&1@005!&"*RR>W-
M42WT_4TXTY^?#-_#[WW^[?\ 0^N?^'EMW_T3Z'_P;G_XS7AW[1W[12_M"7>B
M7<GAI-"NM-22(R)>&?S48J0#\BXP0?7[U?HUI_P;^%FK:?;7UEX%\(W5G<QK
M-#/#H]JR2(PRK A.00:\@^/GBSX+_ &_TFRU/X6:#JMUJ$;S"*ST>S!B12 "
MVY1U)./]TUC2K8:-6/LZ3YNFK[/]+G=CL#FE3"3^MXV/LFE?W5:UU;5+O:UC
MS[_@FMK4S?\ "=:2S,;=?LMTB]E8^8K'\0%_[YKZ(^/WP]^&'BC2;76OB:8H
MM/TL.L,\U[+;JI?!*@(P+L=HP,$\<5S7[+?Q1\"?$Z3Q%+X*\!V_@[[$(%NI
M8+.W@\_?O*KF(<XVMU]:^5?V_?&&H:S\:VT.69QINCVD(@@Z+OD4.[X[DY S
M_LU-6,\3CDDN25OFK+_+\S:C6HY7D-VU6C=I?RN\O/HG^1Z9X1_:D^!/P'&J
M6?@'PYKUREZZ//,F?+E*9"X,\N\ !F_A'6N4^-'[==C\4OAWKGA2V\'3V2ZE
M"L8O)K]6,9#JV=@CY^[_ 'JZ3]B7]F_P5XU\!R>,?$VGQ:_>R7LEO!:W#$P6
MZH!]Y <,Q))^;(QMP.IKTK]K+P7\./ ?P)U]X/#GAS1-3N46#3VM].ABF:4N
MI(C*INSM!)([9S5U_JU.MR24IRNM6_2QS899KB,O=>%2G1I--\JBMM;^2OJ?
M%W[*;%?VA_ V#C_3\?\ CC5^H?Q._P"2;>*_^P5=?^BFK\N_V5?^3AO W_7_
M /\ LC5^HGQ._P"2;>*_^P5=?^BFHSKX8^C-."?]VJ_XE^1^/G@^Q@U3Q=HE
MG<IYMM<7T$,J9(W*TB@C(]B:_9_2]+L]%TZVL-/MHK*RMHUBAMX$")&@& J@
M< "OQG^'_P#R/GAO_L)6W_HU:_:*NG-_@IKS?Z'#P3%6Q$K:^[_[<?GU_P %
M(+&"'XC>%KI(U6>?3&61P.6"RG;GZ;C7=?\ !-=C_P (KXW7)P+VW('_  !Z
MXS_@I)_R/7@__L&R_P#HVNR_X)K_ /(K^-_^ORV_] >LZ?\ R*Y?/_TLJ6G%
MVG]?NC[,HHHKYX_3SY9_X*#?#W_A)/A39>)((]UWH-T#(RKD^1+A6Y] PC/Y
MU\S?L.>.O^$-^/.G6DLFRTUR&339,GC></&?KO15_P"!5^D?CCPM;>./!^M:
M!=J&M]2M)+9L]MRD _@<'\*_';_B9?#WQH#S;:MHM_D=BDT4G_Q2U]!E<E4A
M4P\MOT>C^[?YGYAQ53E@L;A\SIKLGZQ=U]ZT]$?8'_!1_P >;[CPOX.@DX17
MU.Y56[G*1 C\)#^58_\ P3G^'O\ :7B_7_&-Q%F'3(!96K,./.EY<@^H1<?]
MM*^?OCY\3C\7OBGK/B5 Z6MP4CMHWX*1(H51^A/XU^CO[)GP\_X5Q\"_#MG+
M%Y=_?Q_VG=\8.^7# 'W5-B_\!K1IX/ <KTE+]?\ @:&.%E'.N(77CK3IZK_M
MW1??+WCV&OR8_:P_Y.)\<_\ 7Z/_ $6E?K/7Y,?M8?\ )Q/CG_K]'_HM*X,K
M_P!Y_P"W7^<3W.,O^19'_KY'_P!)F?;O[!7_ ";S8?\ 7_=?^AU]%5\I_L2_
M$?PGX:^ ]C8ZOXHT72KU;ZY8VU[J$,,@!?@[68'!KWO_ (7-\/\ _H>O#7_@
MWM__ (NHQT9/$2:7]6/6R6O2CEM!.:ORKJCL:*QO#WC3P]XN,XT+7=,UHV^W
MSO[/O(Y_+SG&[8QQG!QGT-;-><TXZ,^AC*,U>+NC!\>_\B+XB_[!MS_Z*:OQ
M=K]HO'O_ "(OB+_L&W/_ **:OQ=7[PKWLGUG4_[=_P#;C\RXX^##?]O_ /MA
M]0V7_!/#XCWUG!<QZUX7$<T:R*&N[G(!&1G_ $?WJ?\ X=R_$G_H-^%?_ NY
M_P#D>OT'\._\B_I?_7K%_P"@"M&L)YC7C-I-?<>Q3X3RR4(R:>J[G,_#'PS=
M>"_ASX8T"^DAEO-+TVWLYI+<DQL\<:JQ4D D9'&0/I7Y,_&K_DL'C7_L,7?_
M *-:OV,K\<_C5_R6#QK_ -AB[_\ 1K566R=3%2F]VG^:.+BZG&CEM&E#:,DE
M\HL_3W]F?PWIGAOX%^#$TRRALQ>:7;WMP8EP9II(U9W8]223WZ  #@ 4G[3G
MB"?PS\ _&M];2&*?[ T"2+U4R,(\C_ONM/X!?\D/\ ?]@*R_]$I53]HWPQ/X
MP^!WC+2[6/S;F33WDBC R6:,B0 >YV5YV*=Z\^;;F=_2^OX'UN#BUEM.-)6?
M(K6[\O\ F?EO\'?#,'C/XJ^$M#ND\RTOM4MX9TSC=&9!O'_?.:_8V*-(8TCC
M18XT 5548  Z #TK\;/A3XJB\#_$OPOK\^?L^G:E!<S;>OEJX+_^.YK]CM/U
M"VU:PMKZRGCNK.YC6:&>%@R2(PRK CJ"#7M9MS6AVU_0^'X)<.6NOM>[]VI\
M6?\ !2/PG9K9^$?$J1JE\TLMA*X RZ;=ZY^A#?\ ?5<I_P $X?$$]K\2/$VB
MAS]FO-+%TR?[<4JJ#^4K5O\ _!1WQY8W<WACPC;S)->VKR7]TBD$Q;E"Q@^A
M(W''ICUK'_X)O^%[BX\=>*/$)0BTM-/6QWXX,DLBO@?01'/U%+"_\B^?-MK;
M^O4RQUI<3TO8_%[M[>FO_DNYW/\ P4F_Y$OP;_V$)O\ T6*\Q_X)W>']-U;X
MJZU>WMG%=76G:;YMI)*NXPNTBJ67T;!(SUY->G?\%)O^1+\&_P#80F_]%BN!
M_P"";O\ R4;Q7_V"E_\ 1RTL(VL%4:\_R-,R2EQ+037\OZGZ S1)<0O%(H>-
MU*LK#((/!!K\5O%5I%I_BC6+6%=D,-Y-&B^BJY 'Y"OVLK\6?''_ ".FO_\
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MOKD7(NN,M&AVJ(2>?E"_,!@L3@5]>?%SX>6/Q2^'FM>'+Z%)1=6[>0[ $Q3
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M+!JDE75Y:]^^GX'TV9T\^EBY/ 32I:6OR]E?=-[W-G]G;]L+_A?GCBZ\._\
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M3BI1V84444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&&-8H8U")'&H554#   Z "I***M>I6_B2N7@\OPN BXX:FHW^_[WJ>;?&?X
M^$_CII<-OX@MI(KVW!%MJ5FP2XASU )!#*?[K CZ'FOG'_AVE9_;M_\ PL"?
M['NSY/\ 9(\S;Z;_ #L9]]OX5]KT55+$U:"M3E9'/C,HP./FJF)I)R[ZI_.U
MK_,\Y^#/P#\)_ W29;7P]:R/=W&/M6I7;![B?'0%@  H[*H [\GFO1J**RG4
ME4ES3=V>C0H4L-35*C%1BNB"OE#XO_L(_P#"UOB1K?BO_A./[+_M*1)/L?\
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MGBZ]&/+"6AYV)R/+L74]K6HIR[ZJ_K9J_P SSOX/_ ;PA\$-,EMO#=BWVF<
M7.HW;"2YGQT#-@ #_94 =\9YKT2BBN><Y5)<TW=GJT:%+#TU2HQ48KH@HHHJ
M#<^=/C=^Q-X4^+FNSZ]9:A<>&-;N3NN);>(303M_?:,E?F]PPSW&>:X_P/\
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M?$9%EN)J.K5HKF?JOOLTF>>?!_X#^$?@?I<MIX;LG%Q<8^TZA=N)+F?'0,V
M !_=4 =\9YKKO%/A?2_&GA^]T36K.._TR\C,<UO(.&'UZ@@\@CD$5JT5S3G*
MI+FF[L]>C0I8>FJ5**45T6Q\:>(O^";.C7FJ/+HGC6\TNQ8Y%M=V"W3KST#B
M2/CZC/UKM=&_85\'>'_A[KNAVE]-/KVK6XMVUZ^@65K<!E8^5$"H4';S\V[G
M[V.*^EJ*Z98RO*/(YZ'DT\BRVE4=6%%)OU_!7LOD?-?[/G[&W_"B?'K>)?\
MA+_[<W6<EI]E_LS[/]\J=V[SGZ;>F.]?2E%%95JU2NU*H[M'?@\#A\OI^QPT
M>6-[[MZ_-L****P.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4=1JVWX*Q]GEN CEN&CAH2NE?5^;N8OC:WENO!NO001O--)87")'&I9F8QL
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M$5WB*%1TI/>VW_ ^^WD?E-X#_9?^*7Q>USSY]&U#3X;B3?<ZQKZO$.>K_/\
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M%%%<A[)A>-O!6C_$3PQ?:!KUFM[IEXFR2-N"#V93V8'D$="*_/+XP?L+>-_
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MZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMY2C(71AD':P!'XBK]G-14[:/KT.>.(HU*CHPFG);JZNO5;FI1114'0%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117B?[5WQLUSX%^
M ].UO0;33[NZN+];5TU*.1T"E';(".ASE1WJHQ<Y**W>AA7K0P]*5:IM%-OT
M1[917S[^RG^U"/CSI^H:?K4-GIWBJQ/FM;6898I[<D 2(&9CE2<,,GJI[X'T
M%6E:C.A/DFM3'!XRCCZ*KT'>+"BO,/VD?BAJOP>^$NI^*-&M[.YU"UE@C2.^
M1WB(>54.0K*>A/>D_9M^*&J_&+X3Z=XGUFWL[:_N9IXWCL4=(@$D*C 9F/0>
MM$:4I4W56R=@EC*4<5'!OXW'F^5VOS1ZA1116)VA1110 45\U?'_ /;3TGX3
M:]+X9T'2SXE\1Q$).ID*06SGHA(!+OR/E&,9ZYXKRRX_;*^.>AV_]J:S\+H;
M;1%^9YY-'OK==O\ UU9RH^N*[*>$JU8J:5D]KZ7/ Q.>8+"U71E)N4=^5-V]
M;'W117D/[/O[2GA_X_:7<_8H7TG7+-0UWI4\@=E4G =&P-Z9XS@$'J!D9]2U
M?5K/0=+N]2U&YCL[&UB::>XE.%C11DL3]*YZE.=&3C45F>KAL51QE)5J$N:+
MZERBOC'Q#^W=XD\6>(;C2?A5X#EU\0Y(N+J":XDD4'&_R(<%%]RW?D#I46F_
MMS^-_ ^KVUK\4OAS-I%M<'Y9K6VGM) O=ECG+"3'H&7ZUUK UVEI9OI=7/%E
MQ#E\9-<[<5O)1;C]]O\ @'VG167X8\3:9XR\/V&MZ-=QW^EWT0F@N(^C*?;J
M"#D$'D$$'D5J5PM.+:>Y]#"<:D5.#NGLPHHHI%A1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=^-7A?X)^'UU3Q)=NAE)6VL[==\]RP&2$7(''<D@#(YY%?,K?\%++#^T=@\
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M=-&\#WFH6H.%FO=02U<^^U8Y/YUXC^W!\2+SQI\;-1TDRM_9>@ 65O#GY=^
MTKX]2QQ]%%?2_P"SO^Q[X$MOAEHNJ^*-$CU[7=5M4O)GNW?9"LBAEC1 0!A2
M,DC.<\XP!-+#T:6'6(Q&O-LO7;_,>(S/'X_,)X#+6H*G\4FKZK1]^NBTUWN3
M?#/]OWP/XTU"#3]>L;KPA=3-M6>XD6>T!/0-* "OU*!1W(KZ=5UD564AE89#
M Y!'K7YL_MJ?L\Z+\&]9T;5_#$+VFB:MYD;6;2-(()DP?E+$G:P.<$G!![8
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M\-]%D\"/"?#4,(AMXH@08MOWD<'D/DY.>23GG.3VU>9BY^TKRE:Q]IE-%8?
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MC$XW@<8)&1CG(Y^9O _AS]HCP.LOA_PUI/C+2+::0AH8[65+<,>K*[#8I/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% 'A?[;'_ ";AXG_WK;_T>E<__P $_?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNGY,,KISCGV+FXNS3U^:/F__ (*3?\B7X-_["$W_ *+%2?\ !-O_ )$/Q?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=)J'VK^U/M.[9)&FS;Y*8SYF<Y[=.: /J>BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH/\ X+(/_B:/^%5^"O\ H3]!_P#!9!_\374T4 <M_P *K\%?]"?H/_@L@_\
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M_!7_ $)^@_\ @L@_^)H_X57X*_Z$_0?_  60?_$UU-% '+?\*K\%?]"?H/\
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M^"O^A/T'_P %D'_Q-=310!RW_"J_!7_0GZ#_ ."R#_XFC_A5?@K_ *$_0?\
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M^"R#_P")H_X57X*_Z$_0?_!9!_\ $UU-% '+?\*K\%?]"?H/_@L@_P#B:/\
MA5?@K_H3]!_\%D'_ ,374T4 <M_PJOP5_P!"?H/_ (+(/_B:/^%5^"O^A/T'
M_P %D'_Q-=310!RW_"J_!7_0GZ#_ ."R#_XFC_A5?@K_ *$_0?\ P60?_$UU
M-% '+?\ "J_!7_0GZ#_X+(/_ (FC_A5?@K_H3]!_\%D'_P 374T4 <M_PJOP
M5_T)^@_^"R#_ .)H_P"%5^"O^A/T'_P60?\ Q-=310!RW_"J_!7_ $)^@_\
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M^)H_X57X*_Z$_0?_  60?_$UU-% '+?\*K\%?]"?H/\ X+(/_B:/^%5^"O\
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M-=310!RW_"J_!7_0GZ#_ ."R#_XFC_A5?@K_ *$_0?\ P60?_$UU-% '+?\
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MRW_"J_!7_0GZ#_X+(/\ XFC_ (57X*_Z$_0?_!9!_P#$UU-% '+?\*K\%?\
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M!_\ $UU-% '+?\*K\%?]"?H/_@L@_P#B:/\ A5?@K_H3]!_\%D'_ ,374T4
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M/T'_ ,%D'_Q-=310!RW_  JOP5_T)^@_^"R#_P")H_X57X*_Z$_0?_!9!_\
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M0QM-96<<+E202I*J#C(!Q["MJB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "OBK]IK_@H!>_#GQY/X'^'>B6FOZW:2""[O+Q9)8EG[PQ1
M1LK.PZ$[L Y&#BOM.1ML;$=0,U\!?\$T?#MEXG\8?$SQQJ4*W>OI=I%%<2KN
M:+SFE>5E)Z%B "?0>YJ8ISJ<M]$KO[[+^O\ ABF^6'-;5M)?B_R0[P/_ ,%#
M/'OA/Q586'QC\!_V%I%\X1+Z#3[FREA!.#(4F9O,49&=N"!D\]#ZO^TA^WMX
M7^".J?V!HNGGQ=XD\I)9(XIQ%:VZNH9-\@#%F(*MM4=#RPKUW]H[P'I7Q$^"
M?C#2=6MXYXUTV>Y@=E!:&:.-GCD7T(8#\,CH:^5_^"9?PXT/7_#'B#Q]JUE'
MJOB6+4AIUM>7BB1K:..&)LQY^ZQWXW#G"@9ZU4?WCE';E5_5/1+[R9?NTI;\
MVGHUK?[CCF^/'[7'QUPOA/PO<^'=/F7Y9K#3%M8G4]Q<79//NC"OOKX7Z?K>
MD_#?PM9>)9I+CQ#;Z9;Q:C+++YK/<"-1(2^3N);//>NHHJKI1<4MR;-M2;"B
MBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFT[['<-OWYV_O%C,8S@]6'2JLU+E>^Q-U;FZ'H-%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD3NV[M_@ON7]=26W4FI6LDK+\W]X4445)04444 %%%% !1110 4444 %%%%
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M'U)%1SU^ZZ2'KS]ZO%_V!?#UMX1_:V^)NAV<DTMIIMK>6D+W#!I&2.\C52Q
M&3@<G KU-?BI^TA\?H?[#T#X>-\(M.N/W5[X@UMI/M$"'J84=(VW8SC"'G^)
M>HX[]B/X*^)OA/\ M._$*'4-%UV/0H+6ZL[/6]3L)8HKT+=1[761E"L65=W!
M.>36U*ZK:Z+EE^7]6[F56SHZ:OFC^?\ 7H:__!5;_DFO@G_L+R?^B37U[\-?
M^2=>%?\ L%6O_HE:\8_;F^ ^L_';X0PVGAR)+G7](O5O[>U=PAN%V,CQJQP
MQ# C)P=N.]8'['OQ6^*NK367@/Q[\.-0\.V.B:1Y<6O7-E/ EPT1CCCCRR["
MQ0DY5N=I(%11VJ0ZMI_)1*J[TY]$FOFV?55?G9^WTPT/]K+X4:Y>?NM-2&R+
M3'H/*OG9_P @ZG\:_1.O"/VNOV9X/VD? <%I:W$5AXFTMVGTR[F!\LE@ \4A
M )"-@<CH5!YY!GF<)PJI7Y7<T24HSIMVYE8]V#!@"#D'H:\^^*GQ^\!_!.;2
MX?&>O?V/+JF_[(@LY[@R["H;B*-\??7KC.>*^2_"/QY_:8^"NBVWA/Q%\']1
M\:/I\8@MM3M+>:=FC487?+ )$?  YX; YR>:C\(_ 3XM?M2_&;2/'WQCTM/"
M_AK22CVNBX\MW56WK$L1)906Y=I,,>@'3;JHJ4TD_=ZOR_S,K\L&Y+WNB\_\
MCZE_:E82?LV_$=EY#:#=$?\ ?LUY%_P3,_Y-OE_[#EU_Z!%7M/[26DWVN_ +
MQ_IVFV=QJ&H7.C7,4%K:Q-++*Y0@*J*"6)] *\L_X)Y^$==\%? &73O$.BZC
MH.H'6+F46NIVLEM+L*18;8X!P<'G'8U%+XZO^%?^E#J7Y*7^)_\ I)WW[77_
M ";/\1?^P1+_ $KS;_@FS_R;+:_]A6[_ )K7JO[4>CW_ (@_9[\>Z;I=C<ZE
MJ%SI<D<%I9PM++*QQA5102Q]@*\__P""?OA/6_!G[/-MIOB#1M0T+41J=U(;
M34K5[>4*2N&V. <'UQ2I?'4_PK_TH*GPT_\ $_R/+_CK\=OB;\4_VCF^"7PO
MU1/"T5O^[O\ 6%&)B1&))6WX)14!  3#%N^#QUUO_P $^;'6K53XS^+'CSQ-
M>D?O)%U 1QOTR-L@E../[U<'\?\ X)_$_P"$?[21^-7PQT9O%,%V?,O--B4R
MRHQC$<B-$"'=' R"F2#U P,]3;_'[]H_XNP_V-X6^#[_  ^N9OW<VO>(S*J6
MRG@R(DL<>2/99/\ =-33UIJRO+KZ_E8N=U4=W:/3^NYXU^S[\/M.^%?_  44
MNO"FD3W5SIVFQ7,<,M]())F!L@YW,  3ECV%?07_  4J_P"3:)O^PO:?^SUX
MY\ ?@#XR^%O[<GG:C9Z_KFDPV\[S^++RPF%O=3RVFZ1O.(*\R,P'S$]N37U=
M^UA\'[WXY?!#7/#&EM&NKDQW=D)FVJTL;!@A/;<-RY/ W<TJR;P]/JTE^$KL
M=.RKU.B;=OG%6)/V2?\ DVGX<_\ 8'A_E7RK\:O^4F/@'Z6/_H,E=C^QOX_^
M,/@^]\.?"CQ?\,=2T_0K!9XAXBFLYTCB15>1%:0*8F^;Y0P89!'4\FK^VM\#
M?'Z_&'PI\8/AWI#:_>Z2D N+&"/S)5DAD+H_E@AI$8-M(7D8]\CHJR7UBG6^
MSS7^6IA3BW0G2^URV^>A]*?M+:;<:O\ L^_$2TM8S+<2:%=[$'4XB8X'OQ7P
M/^QK^QY\/OVC/AOJ6M:]K'B"SUFQU%[26WTRY@2,1[$9&VO"YR=S<YQ\M?=/
M[/'Q*\5_&#P+J%_XX\#W/@F_CO'LQIM]!-&9XO+0^9ME53M)=EZ$?*>:^7+S
MX'_%[]CKXG:OXD^$>D#QIX'U8[KC10-\L:AB5C:,$.63<0LB;N/O#L<E%4ZL
MN?JE9]GO^*9JY.=-<FZ;T[]/PL=G/_P2\^$UK#)-+XC\8)%&I=V:]M,  9)_
MX]J]$_9!^'/PJ^'FE^)8OA;XON/%MM=30-?27%W#<>0RJX0 QQIC(+=<]*\7
M\:_M ?M%_&KP]>>$O#7P3U7P;+J436USJ6I),FV-AAMDDT<2(2"1D[B >.<&
MO?\ ]DC]G<?LY_#'^Q[NYBO=>U";[9J5Q!GR_,VA5C0GDJH&,D#)).!G%:0O
M:3>BLK>>OY$2M[MM7?[M/S/FCXU?\I,? /TL?_09*_06OAOXO?#OQ7J7_!0K
MP3XCL_#.L77AZW%EYVK06$KVD>T2;MTH78,9&<GC-?<E9T_X"7]Z7YCG_&;_
M +L?U/SZ^)O_ "E"\)?2U_\ 25Z^I_VLM!\)^(_@'XILO&>K1Z%HYA5UU*1"
MY@G5@8F"+RYWX&T<D$BOGGXB?#OQ7??\%&?#'B6W\,ZQ<>'(1;>9K$5A*UHF
M+=P=TP78,$@<GK7K?[>5QX+_ .&?-4M/&>HW6GQW$\?]F_8(Q)/)>+ED"H2
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M/RK2#4G*#6J5U]Z3_,SFG%*:>E[/Y['W51114E!1110 4444 %%%% !1110
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M7*K@9Y/:@"Q15>\O%LUC+1R2;W"?NUW8SW/M2WET+.V>9HY)0HSMB7<Q^@H
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MPRKM8?A0!/15>UO%NS*!'+'Y;E#YB;<^X]11'>++>2VXCE5HP"79,(<^A[T
M6**@:["WB6_ER$LN[S OR#V)]:+BZ%O)"ACD?S&VY09"^Y]J )Z*@O+L6</F
M&.249 VQ+N/-.N;@6MO),4=PB[MJ+EC]!0!+14<4PF@64*RAEW;6&&'MCUIE
MG=B^MUE6.2($D;95VMQ[4 3T57M;Q;MIE$<L?E/L/F)MW>X]12QW8DNI8/+D
M!C .]EPISZ&@">BH&N@MTD'ER$LI;>%^4>Q-%Q=BVDA4QR/YC;08UR%]S[4
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MI2K,%7=M498\=,>M $E%1V\PN($E"L@89VN,,/J*99W0O(?,$<D0R1MD7!H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ->D/_H K3I %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWD8($A:-?E$H)!)'W@2<#!SMATE.52+O)?I_EN9UF^2,&K)_K_GL?:M?F/\
M\%4/^2O>$_\ L!_^UY*_3BOS'_X*H?\ )7O"?_8#_P#:\E<E7XZ?K_[:SII_
M#/T_5'T-_P $S/\ DV^7_L.77_H$5?65?)O_  3,_P"3;Y?^PY=?^@15UG[:
M7[0_B/\ 9R\":%K7AJRTN^NK[4OL<B:K%)(@3RG?*B.1#G*CJ3]*[<1)1DF^
MT?R1QX>+E%I=Y?FSZ&HK\MO^'I7Q6_Z%_P '?^ 5W_\ )-?6_P"Q/^TEXF_:
M0\->)=1\36.DV,VF7<5O"NDPRQJRLA8EO,D?)R.Q%0HN2;70MR2:3ZGP!^W=
M_P G5>.?^NEM_P"DT5?IM^R5_P FT_#G_L#P_P J_,G]N[_DZKQS_P!=+;_T
MFBK/\(_L7?&3QUX9TWQ!H?@[[=I&HPK<6MQ_:EE'YD9Z':\P8?0@&L\/)_5U
M&W;\F;8A+V][_P!:'UQ_P4X^*GA>Z^'>D^"[;4;74/$;:G'>R6]O(LCVL21N
M"SXSM+%P #@D9/05Y?\ \$L='O+CXO>*M40-]AM=%\B5L<>9)-&4&?7$;_E7
M*^"?^";?Q?\ $=\B:W:Z;X3L]P\R:\O8[A]N>2J0%\GV)4>XK]%_V?\ X!^'
MOV>? R>'M"WW,TK^=?:C. );N;&-Q ^ZH'"J.@]223K1BJ7--O5W_%6_+\3"
MLW4Y8):*WX._YGYB?M[^,KCQ=^TYXHCDD+6VD"+3+=<Y"JB!F'_?QW/XU]]_
ML$_#.Q\ ?LZZ!?16ZKJGB!#J=Y<;?F?<2(ESZ+'MP/4L>]?G9^VMH<^@_M0>
M/8IT9?M%XMW&6_B22-'!'MR1^%?IM^QKXEM?%'[,_@*>U=7^RV L95'5)(28
MV!_[YS]"*C"_[K?J[7^=V_QL7B/XZ3VUM^%OP/::^;OV@?V'/"7[07CB/Q3?
MZOJ&B7_V5+:9=/2/;/L+;7;<#\V"%^BBOI&O*_BS^T]\./@?K5II'C'7FTS4
M+JW^U10QV<\Y,>XJ&)C1@.5/7TJ)<MU?Y%*]G8F_9[^!5A^SSX&E\+Z9JU[J
M]F]Y)>+)?!0R%U4%1M &,KG\37YC_P#!0#_DZ[QE_N67_I)#7ZH_"GXQ>%/C
M9X>GUSPAJ$FI:9#<M:/-);2P?O JL0!(JD\.O(XK\KO^"@'_ "==XR_W++_T
MDAJ:G-[:'-V?Z6_ NCR\D^7^O>5S[E_95^/?PV\,?L\>!=+U?QYX=TS4K73P
MD]I=:G#'+$V]CAE+9!Y[UXK_ ,%"/VH/ GC[X?6?@CPGJMOXDOFOX[RYO+/+
MP6Z1JP $F,,S%OX20 #GJ*\;^&O_  3U^(OQ4\":-XLTG6O"]OIVJP?:((KR
MZN5F5<D88+;L >.Q-<#\7?V?O'7[+GB729_$NGZ;>P3.7M+N-5O+&Y9<;D99
M%'."/E91P<BM:]IS_>::_C>YC1]R"Y-=/T/IC_@EQ\*]6C\0>(OB#=6TEOI#
M61TJSED! N':1'D*^H7RU!/JV.QK]%:^=_V*_P!HVR^/7PYDMFTVRT/7-!\N
MVNM.TZ,1VWED'RY(D_A0[6&WL5/8BOHBMZU[J/1+3\_U,J>S?5O_ ( R::.V
MADFE=8XHU+N[' 4 9))]*_)W]I7]M?QM\8_&-WH?@W4[[1/":SFUL[;2W:.X
MU#YMH>1E^<[^T8.,$ @GFOT;_:6U*?2?V??B)=VKF.>/0KO:XZC,3#(_.ORO
M_8@TFUUK]J;P%!=Q+-$ES-<!6&1OCMY9$/X,JG\*Y:<?;5^26R5_S_*VATSE
M[*BZBWU_!?\ !-FX_89^.UCHK>)3X=D^T)']I,,>HQ&] '.=H?);'.T'=VQG
MBNY_8[_;2\7^$OB!I'@_QGJ]UKWAG4[A+%9-2D:6XL)6.U&61OF*;B 58D <
MC&#G]2*\,NOV(_@K>>(9=<E\%_\ $TENC>M.NJWJ_OB^\L%$P4?-S@#'M6T)
M<LU?X>QE./-!V^(].^)/C_2_A;X%UKQ7K+LFG:7;M/($^\YZ*B_[3,0H]R*_
M)GQS\?/B_P#M:^/DT+2[G4#'J$K)9>&=(G,5NJ<G]X<J'P.3)(<#D_*.!]J_
M\%-M3N+']G.V@A<K'>:Y;0S ?Q*(Y9 /^^D4_A7A'_!*O2+6Y^)'C34I(@UW
M::7%%"Y'W5DERV/KL6L:,56JR4MH_HK_ / -:LG2IQ<=W_G;_@GDOB[]D3XW
M_ W19/&!L9K."S3S[B]T/4@T]H!U9MC!L#J67( Y)%?1?["_[:VN>+O$UI\.
M_']ZVJ7-VI72M9F_US2*I/DS'^/(!VN?FR,'.1C[UOK.'4K&XM+F-9;>>-HI
M8W&596!!!]B#7X8>#9'\*_&S16TZ;:^G^((1!*I_N7  /Z5K1E>LJ,MG_P -
M^&EC*K%*BZJW7]?IJ?J7_P % O\ DU7Q;_UTL_\ TICK\U/V>OC!XQ^%&N:S
M#X#L#>^)O$%F-+M6CA,\L3&17W1QX.Y\*0,@@9S@XQ7Z5_\ !0+_ )-5\6_]
M=+/_ -*8Z^.?^"8-O%-^T)JCR1([Q>'[AXV902C>= N1Z'!(^A-1AX\U2:]?
M_236N^6E!^?ZH\_^+'[,OQXTO1;WQSXYT?4;V"%1-=7USJ<5W/$I/WF59&<
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ME@M+6P@ABC48"HL:@#\A7Y]?\%6K&WB\8?#^[2"-;J:QNHY)@H#NJ21E03W
M+MC_ 'C2K?NZBA':]OP>HJ/[RFYO>U_Q6A[%_P $P?\ DWW4_P#L/7'_ **A
MKZ^KY!_X)@_\F^ZG_P!AZX_]%0U]?5TU_B7I'\D<]'X7ZR_-A1117.;A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !11533]7L=5$ALKVWO!&0'^SRJ^W/3.#Q0!;KX<_:8UB_
MM?V^/@U9P7MS#:316/F6\<K+&^;N<'*@X/3O7W'7SK\7/V9=8^(G[2W@+XEV
MFL6-KIWAU+=9K*97,TOESR2':0,<AP.?2B.E:E)[*6OW,):T:D5NXZ?>CZ*H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!&^Z:_/[_@G#_R<%^T=_V%_P#V[NZ_0%ONFOS^_P""</\ R<%^T=_V%_\
MV[NZ!GZ!4444""O OVSO^2::3_V%X_\ T3+7OM9?B#POI/BRSCM=9TZVU.VC
MD$JQ748=0X! 8 ]\$_G3 7PQ_P BWI/_ %Z0_P#H K3ID,*6\*11((XXU"JJ
MC   P *?2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***^>?VGOVR_#'[.B+I:V__"0^+IH_,CTJ&78D*G.UYGP=H/90
M-Q]AS0!]#45^2'B3_@HW\:M:OGFL-7TWP_ 3\MM8:;%(H&>F9A(Q_/\ *NS^
M%O\ P4[\<:#J$4/CC2['Q1I;-^\N+2(6MV@]5V_NVQ_=*C/]X4 ?IY17*_#/
MXF^'?B[X0L_$OAB_6_TRZ!P<;7C8<,CKU5@>H/UZ$&NJH ***^6?VUOVI/%_
M[.=]X/M_"NFZ-J#:R+CS1JT,LA!0QA0FR5,9WG.<]J3=FEW*46[OL?4U%?$*
M_'C]L)E!'P>\/D'D?Z-+_P#)M:_PJ_;TU(?$&U\"_&#P8_@37+IUBBO%62.#
M>QP@>.3+*C'@2!F&?09-7%<SY5N9N2BN9['V/17C?[67QDUKX#_!N]\6:!:V
M%YJ,-W;P+%J4;O"5=\$D(Z'..G-=7\#?'-_\3/A#X3\5:I#;P:AJUA'=3QVB
MLL2LPY"AF8@?4FIC[RDUT=OO5RG[K2?77]#N:*** "BBB@ HHHH **** "BB
MOFGX@?M+>)_"O[7WA'X56EAI,GA[5[>*:>YFAE-VI83$[&$@0#]VO5#U-"]Z
M48+>3L@>D92Z)7/I:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _);_@HI\,;WP5^T!?:^8&_LGQ+$EW;SX^7S514E3/J"H;Z.*]Q_9N
M_P""B'@WPO\ "C2/#OCJ+4K75]$M5M([BTM_/CNXD&V/&""KA0 =W!QG/.!]
MH?$;X8^&/BUX;ET'Q9I$&L:9(P<1RY5HW'1T=2&1AD\J0>2.]?-\?_!,7X1)
MJ@NS>^)Y(-^[["U_%Y.,_=R(0^/^!Y]ZFES4XNET_JWW;%5.6<E4Z_U^9\9_
MM@?M/7O[2FM:=<V.D7&E>#M)>2&P^T*#)+*X4NTC#*AL!?D!.!W.:^I?^"5?
M_),/&G_883_T0M<1_P %)/ /A[X9_#OX9:#X8TFWT;2;>ZO=EO;KU)2++,3R
MS'NS$D^M=O\ \$J_^28>-/\ L,)_Z(6M,/R\M51Z?YQ(K7O2<NO_ -L>8_\
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MPR:G)')+O<*",HB#'RCMZ\UZ'714DINZ[+\$C"G%P5GW?XMGGO\ PSO\*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUZ=/RU+Y>:M[)=+)^O7[CY6N/^"HGPJM[B6(Z#XP<QL5W+96N#@XR,W-1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,J#Y2<N1P">G-=Y7QU^Q%\.=6\<:_K_Q[\;QF37_ !'(Z:3%(#BVM<[2Z@]
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M/ DK!>@+*"<>W-7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?V3X 8&(>(1<7&S:1YOV?:N<]\;]N/?..];4?P)_;!:-2OQAT *0,#[3+_\
M(5:GPO\ V!M2F\?6OC?XQ>,Y/'>LVSK)%9*\DD)=3E-\LF&9 >1&%4>N1D4W
M#GDKNR3OY_(RA+V<-%=V+_[<37K?L3V)U//]I'^RS<[LY\W"[\Y_VLU[#^R3
M_P FT_#G_L#P_P J\Z_X*/?\FOZI_P!A&S_]&5Z+^R3_ ,FT_#G_ + \/\JT
MA+F5:7>2_P#227'D]E'M%_F>5?M&?M2^,M+^+5A\(OA+H]KJGC2Y17NKR\ :
M.UW)O"JI(7(3#LSY ! P2>.9\567[8GPR\/77BJY\9>&/%MKI\;7-SH]O91;
MS&HRV,6T18 9) <-QQFMGXK_ !T^&'PI^/%U_P (C\/KSQ]\8K@>5<_V/OW*
M2@!C9_G^8(JY"1G ')%7M;^,'[2.O:'>O;_ S3=+T^2WD$G]HZ_ \@0J<_+O
M0YQGJM<_,U2YX[ZZ]/\ *QT63JJ+VTTZ_P##GJ?[,'Q^MOVBOAA!XD6T73M2
M@F:SU"S1BRQS* <J3SM965AGIDCG&:\]_:F_:TU+X6>)])^'W@#1H_$GQ#U;
M9LAE4O%;!SA 54@L[<D D!1\QXXKS[_@E7_R3#QI_P!AA/\ T0M<Y\%E_P"$
MG_X*6^/KW4HS+<:>M[]F\SG9L$<"$?\ ;,D?C734BI5XTUHFN9_))M?B<\).
M-&4WJT[+YMK]#J[_ $K]M+PYI3^(G\1^&M;\I?/?PY!;P--@#)08@3<1Z+*2
M>Q->P?LE_M/6_P"TAX1OI;NQ32/$^D2+#J5C&28_F!VRQYY"G:PVG)!4C)X)
M]WK@?A_\"/ WPM\1:YKOA?0_[*U36V+W\RW<\HF)<O\ <=V5?F8GY0.N.E3%
MZM/:WS3_ ,BI+1-;_H>3?M0?M2ZQ\-O%6B_#KX>:-'XC^(VM!6BAF&Z*U1B0
MI8 C+'#'DA5 W-QP>)O?#_[9WAK37U\^+/"OB)H5,S^'8;:+>XQG8"+>/)Z\
M"7MP37C&I^)/B*/V_P#QYJ7@'PW8^*O%-GYL,%EJDRQQQVZQQ1EU+2QC.W&!
MNZ.>#7N__"T?VQ/^B.^%/_!C#_\ )U90UI1GUEK_ )?\$N>E1PZ+3_/_ (!Z
MA^RO^TI:_M&>#;NYFL?['\2Z3*+;5=-R2J.0=KIGG8VUN#R"K YP"?E;]K#Q
MW:?#+]O7PAXHO;>>[M]-TJ"8V]LNZ29L7*JBCU9BH_&O1OV-?@S\5O OQR\>
M>+/'/A2#PUI_B."6=H[6]MYHA<-<"0*B1RNP #28SV[US7QNM8;S_@I9\-8K
MB))H_LEJ^R10PW+]H93@]P0"/<5M;FK4&M&VOD[/_AR/AIUUNDG;S5U_PQUU
M^O[8GQ LF\1Z3>^&? 5K(OFV_AN9(Y+K9U57:2"0!R,9RZ<]0O0=!^R;^U=K
MGQ,\4:S\.?B+ID>C?$#1PY/E)Y:W*H0) 5R0LBY!^4[6!R,8KZGKX ^(4:^'
M_P#@J!X4GL$,4E_% UQLP-Y>VDC8G_@*C\JF%O:QIVTEIZ/IK^83O[.4[ZQU
M]>Z_R/J;]I3]H32?V<OAZVOWUN=1U"XD^S:=IROL-Q-@GD_PHH&2<'L.I%?/
M_AT_MC_%;1[?Q18^(/#'@>QO$$]MH]U:QB0QD94X:WF9<C'#.#SR!7+_ /!0
M1CK_ .T=\&O#MZADTF1XBT9^Z_FW:I(/^^44?C7Z *H50J@  8 ':IIKFINJ
M^K:7E;_,N;Y9J"[)OYGR3\#?VL/%]I\6/^%2?&?1K?1O%LF%L-3M %AO"02H
M8 E?G .UTP"?E*@U];U\"?\ !2J-?#_Q(^$'B6Q(CUB.>50R<.1%- \?Y,[8
M^IK[YC8O&K$8)&<5<7STE-[W:^XB2Y*G*MFDU^OXCJ***D84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S+^VU^S+XH_:2TOPI;>&;_ $BQDTF:XDG.K32Q
MAA(J ;?+C?/W3G..U7_V*_V<_$G[./@WQ!I/B6^TJ^N=0OUNHFTJ661 HC"X
M8R1H<Y'8&OHNBB'[M24?M;_A_D$O?Y;]/^#_ )A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117S9\2OV_?A?\-?'$OA:4:MX@OH66.:XT.&":WBD)P8R[S)EE[X! SC.
M00!:R45NQ]'+HCZ3HIJ,)$5AT89IU!*=]4%%%% PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;<+=]/M958?WH+ERP'T!4_C34HRJ8:K:W,T_S!QE&&(I7O9-?BC],54*H &
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M_1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %?.7_!02]DM?V6O$\,2L[W4]G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** "BBB@ HHHH 1ONFOS^_X)P_\ )P7[1W_87_\
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MB\/_ +>'A#5/"FE_VWKUCI=M<V^G#K<A#<,\8]R@<#'.>F37Z,JH50J@!0,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /SC_X*$?%[XL^"?B]::?I&MZUX:\*_9(GL
M)=)F>W2YD/\ K"TB8+,&XV$\  XYY^POV5?$'C'Q3\!_"^I^.XYD\131.9'N
M8O*EEC$C")W7 PS(%/09Z]Z\ _;!_;:\<_L^_%J+POX=TKP_>Z>VFPWADU.W
MGDEWNT@(RDR#'R#MZ\U]%_LU_$[5/C'\%?#GB_6K>SM=2U))6FBL$=(5VS.@
MVAF8CA1U)YHH_P *5M=?U85OXD4]-/T7]>IZ=17Y^_M%?\% OB'\(_C3XH\(
M:/HWAFYTW2YXXX9;ZUN'F8-$CG<5G4$Y8] *V?BU_P %-+#PS8Z?8>#-(M?$
M6MM:0RWM_<,Z6,,S(K-'&H.^3!)!^8 8QEJF,E**FNI4HN,W!]/T/NFBOS<\
M _\ !4_Q,FO0)XT\*:1/H[N%EET,2PSQ*3RP621P^/[N5SZU]L?%3XM?\(W\
M ];^(?A9[/5%ATK^T]/>X5F@F4@%2P4JV"#TR#52]R#J/9$Q]Z:@MV>1?MK?
MM@WO[.JZ3H/ANPM;WQ/J4+71FOE9H;6 ,5#;0069F#8YP-ISGI7RQ\/?VLOV
MF?B%XATZXTV\U34M$>_BAN7TWPU!-!&I==ZF00,5^4]VR!S7A'QX^/&O_M#>
M,(/$GB.STVROH;1+)8]+BDCB**S,"0[N<Y<]_3BO7OV>?VX?''PNT7PO\/\
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MS#Y;2%!G<>B\9XQ7MOBKP+X:\=VT%MXE\/:5XAMX'\R*'5;**Z2-B,%E$BD
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M]R*^2/\ @FU\.;ZZL_%WQ9UQ&.H^)+J2"UD<<M&)"\T@]FDP/^V9HI:U^?\
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M/NS9;\:Z6NJK)2F[;;?=H<U)-05^NOWZA1116)J%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7SC^W)^SUJ/Q[^%MN- 59?$FASM=VENS!?M*%<2
M1 G@,0%(SQE0.,YKZ.HJ)Q4U9EQERNY^=?P'_P""@;?!WPS:> _BEX5UB.]T
M*-;**ZM(E%R(U&%CFAE9,%1@;@>0!\N>2[X]_P#!05?B[X5N? GPN\,ZT]_K
MR&QENKR)?M!1^&C@AB9RS,"1N)& 3QW'WIXH\ ^&/&ZQKXC\-Z3KZQ_<75+&
M*Y"_3>IQ3/"_P[\*>!S(?#GAC1O#YD&'_LO3XK;=]=BC-7+][_$Z[^9$?W?\
M/IMY'B'[#?[.]]\ _A?</KT:Q>)]=E6ZO85(;[.B@B*$D<$@%B<=W(YQFO<O
M'GC33OAWX,UGQ-JTGE:?I=J]U*<\D*,A1[DX ]R*WJS?$'AO2/%NE3:7KFEV
M6LZ;,5,EGJ%ND\+X((W(X(." 1D=13JRE4O;1_D*G&,+7U1^>?["O@_4?CU^
MT%XI^,GB:/SDL+AY8-PRGVR4$*J^T473TRGI7Z/5D>&?"&A>"=-.G^'=$T[0
M; N93:Z9:1VT1<X!;8@ R<#G'85KTVTHQA%625A:N4IRW;"JVI:E:Z/IUU?W
MT\=K9VL3333RG"QHH)9B>P !-6:IZOH]AX@TRYT[5+&VU+3[E#'/:7D*RQ2J
M>JLC AA[$5$KV=MRU:^NQ\2? _3;K]L+]I+4_BWK4#_\()X5F^Q^';.=3MEE
M4Y1\'N,^:W^TR#HM?;]_9Q:E8W%I,-T-Q&T3CU5@0?T-5/#OAG1_"&E1Z9H6
MDV.BZ;$6:.STZV2WA0DY)"( !DDD\5ITY*/(J2V2^^^[?J).7.ZCW_*VR^1^
M=W[,/Q>TK]C'QEX[^&/Q.:ZT.Q-]]MT_4_LLLT<HQL#;45F*NBH0P!&0P.#6
MKX4U\_M@?MN:-XP\/6MR? O@J!,:A/$8Q*Z%V3@]"\CY"GG:F2!TK[>\5> ?
M#'CJ**+Q)X<TGQ#'"<QIJMC%<A#Z@.IQ^%7M!\.Z5X7TV/3M%TRSTC3X\[+2
MPMT@B7/7"* !^55&3O&<]7';[K)OT7R%-)J48:*6_P!]VEZFA1114C"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHOCC_L%1?^CJ]5_X*8?%'PS#\*8?!*ZI#/XGN=0@NO[/@8.\,2!LO)C[@.0
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M88@2P&[!#X]-Q]:]7_8C_8U^''Q&^$=EXV\7V<GB.^U">98[-KJ2&&U6.1D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Z\'D5Y^W[//PJ9BS?#/
MP>6)R2= M,G_ ,AUZ#37!*L!P<<5+T3=A^1Y_P#\,[_"G_HF7@[_ ,$%I_\
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MHQ/EEL[<Y ZX/Y4 =E1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6OR]_:H_92O/@K\*;/Q?XK\3S^+/'>LZS'#=W9D=HHT,,C,H9_FD)*K\[8X
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M=Q'YMWIVM6T:21AP3PTJ,1CL5_"OUGHHI_NY\\?4*G[R')+T/'OVHOV>[/\
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M6OI_]DG]@U/@CXAB\8>+]2M=8\3PHRV=K8AC;698$,^]@"[X) ^4 9/7@C[
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M/P'_ &J-+\!K'X4\60>!_#MP&ELM#U^\$UU#$V2H&+9_+.#R!Y9R<E5-;O\
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ME@B2-%VHBA54=@.@K&\=?\B1XA_[!UQ_Z*:L<7+GA4EWN:8:+BX1?2Q\3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !7S3^RG_R5[]H+_L9(?\ T4U?2U?-/[*?_)7OV@O^QDA_]%-0!]+4444
M%%%% !1110 445\S^-/VPO$7@_7M7L1\"OB!J5EI\LB'5+;3I#;2HO616\O&
MW SG/2@#Z8HKY(\/_MY:SXJTZVU'1_@-\0=4TVXYBO;*Q>:%QG!*NL9!&<]#
MVKZOTZZ:^T^UN7@DMGFB60PRC#QD@':P]1G'X4 6**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\#FO2**<O?\ BU%'W?AT/CK_ (=:_"G_ *&#QC_X&VG_ ,C5U_@+_@GG\'/
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MK44+W4TNNH/WFF^FAE>*/"NC^-M!N]%U[3;?5M*NTV36EU&'1Q]#T(/((Y!
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M_F))*/*MK6^1\F_\%'OB!XF\#_!_28- N[G3+/5]1^QZE?VA*R)#Y;,(PPY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>I5Y:O1?B4[*UM6?/^J?\%5H9+J1-#^&5U>VZGB:ZU41N1[HD+@?]]&JUO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_6W_P 8KZR\#^$[7P'X-T/PW92S3V>D64-C#+<$&1TC0(I;  R0.< 5P/\
MPUE\'/\ HH_A_P#\"Q7IVCZQ9>(-)L]4TVYCO=/O(5N+>YA.4EC8 JRGN""#
M57ERM=#.RO?J7****DH**BFNH;?'FRI%NZ;V S^=1_VG9_\ /W!_W\7_ !H
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M "BBB@#/\0>(-.\*:'?:QJ]W'8:98PM<7-S+G;%&HRS''8"O*?\ ALKX*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=V<[V\R#2[A@KHQ5AD)@\@TW3?\ @H3\$=6U"UL;;Q'>/<7,JPQJ=+N "S'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7S%^W/\ \@SX5?\ 8Z67\GKZ=KYB_;G_ .09\*O^QTLOY/0!].T444 %%%%
M!1110 4444 ?,'B/_E(+X0_[%2[_ /0J^GZ^8/$?_*07PA_V*EW_ .A5]/T
M%%%% !1110 4444 %?-/[*?_ "5[]H+_ +&2'_T4U?2U?-/[*?\ R5[]H+_L
M9(?_ $4U 'TM1110 4444 %%%% !7/\ Q!_Y$'Q+_P!@RY_]%-705S_Q!_Y$
M'Q+_ -@RY_\ 134 >4_L/?\ )KO@;_KVD_\ 1KU[M7A/[#W_ ":[X&_Z]I/_
M $:]>[4 %%%% !1110 4444 ?-__  4 _P"3=[K_ +"VG_\ H]:^@=!_Y >G
M?]>T?_H(KY^_X* ?\F[W7_86T_\ ]'K7T#H/_(#T[_KVC_\ 010!?HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;.TX&32
MTUFVJ2!D@9J9.T6P/G[]EG]I^^^/^K>--*U?0;?P]J?AV>.%K>*=I"X+2*Q.
MX#&&CQ^->_-:PM*)6AC:4='*C/YU^5&H_&3XBZ/\<G^)?@[X5:MX7UBX+QZM
M9QVMS/9ZFI(R7C\M2K' )*GJ >#DGU?_ (;]^-?_ $1EO_ &]_PJD[QB^MM?
M7O\ ,<HN-22Z7T_R^1^@M%?GU_PW[\:_^B,M_P" -[_A7W%\./$5]XN^'_AO
M7-3LO[-U'4M.@N[FSVLOD2/&K,F&Y&"2.>>*KE?*Y$<RORG1T445)05\/?\
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M.G27:7AMKB/=(LD:A,R#'(=CZ_+7U+2<7%)OJ"DFVET"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** $;[IK\_O^"</_)P7[1W_87_ /;N[K] 6^Z:_/[_
M ()P_P#)P7[1W_87_P#;N[H&?H%1110(*\"_;._Y)II/_87C_P#1,M>^UY#^
MTUX#UWXA>!]/T_P_8_;[R+44G>/SHX\((Y%)R[ =6'&<\TUN(]+\,?\ (MZ3
M_P!>D/\ Z *TZHZ%;26>AZ?;S+LFBMXXW7(.&"@$9'O5ZD,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[]J+_ )-Q^)7_
M & +S_T4U7?V=?\ D@OP]_[ 5G_Z)6J7[47_ ";C\2O^P!>?^BFJ[^SK_P D
M%^'O_8"L_P#T2M 'HE%%% !1110 4444 %?,7[<__(,^%7_8Z67\GKZ=KYB_
M;G_Y!GPJ_P"QTLOY/0!].T444 %%%% !1110 4444 ?,'B/_ )2"^$/^Q4N_
M_0J^GZ^8/$?_ "D%\(?]BI=_^A5]/T %%%% !1110 4444 %?-/[*?\ R5[]
MH+_L9(?_ $4U?2U?-/[*?_)7OV@O^QDA_P#134 ?2U%%% !1110 4444 %<_
M\0?^1!\2_P#8,N?_ $4U=!7/_$'_ )$'Q+_V#+G_ -%-0!Y3^P]_R:[X&_Z]
MI/\ T:]>[5X3^P]_R:[X&_Z]I/\ T:]>[4 %%%% !1110 4444 ?-_\ P4 _
MY-WNO^PMI_\ Z/6OH'0?^0'IW_7M'_Z"*^?O^"@'_)N]U_V%M/\ _1ZU] Z#
M_P @/3O^O:/_ -!% %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\
MGB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[
M4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBH
MH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^
M_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_
M )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C
M^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB
M?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U
M-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ*
M .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_O
MT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_
M^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:
M/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">
M)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M3
M4_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@
M#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]
M&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\
MGB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[
M4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_
M[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U
M/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH
MYW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1
MKHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_Y
MXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_
MM34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG
M_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3
M_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .
M=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:
MZ*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">
M)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M3
M4_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_O
MT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_
M^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G
M?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&N
MBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB
M?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U
M-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^
M_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_
M )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW
M^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KH
MJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG
M_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3
M_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1
MH_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_Y
MXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_
MM34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*
MB@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_
M[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U
M/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]
M&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\
MGB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[
M4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBH
MH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^
M_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_
M )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C
M^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB
M?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_^>)_[]&NBHH YW^U
M-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ*
M .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">)_[]&C^U-3_YXG_O
MT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M34_\ GB?^_1H_M34_
M^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@#G?[4U/_ )XG_OT:
M/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]&NBHH YW^U-3_P">
M)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\ GB?^_1KHJ* .=_M3
M4_\ GB?^_1H_M34_^>)_[]&NBHH YW^U-3_YXG_OT:/[4U/_ )XG_OT:Z*B@
M#G?[4U/_ )XG_OT:/[4U/_GB?^_1KHJ* .=_M34_^>)_[]&C^U-3_P">)_[]
M&NBHH YW^U-3_P">)_[]&C^U-3_YXG_OT:Z*B@#G?[4U/_GB?^_1H_M34_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X__ $3+36XF>U>&/^1;TG_KTA_] %:=9GAC_D6])_Z](?\ T 5ITAA1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 5\Q?MS_\ (,^%7_8Z67\GKZ=KYB_;G_Y!GPJ_['2R_D] 'T[1110
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M3;V*X&/^ ,:^8/%7_!,#X1:YO?2KC7_#LF<JMK>K-&/8B5&8_P#?5>/^)/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7;>9].UBSM\^7'=1A22F>=CHZ.!SC>5R=N:]YH 1ONFOS^_X)P_\G!?M'?\
M87_]N[NOT!;[IK\_O^"</_)P7[1W_87_ /;N[H&?H%1110(*\\^-WQ3E^$?A
M>SU:'3DU)I[Q;4Q/*8P 4=MV0#_<_6O0Z\"_;._Y)II/_87C_P#1,M- >YZ7
M>'4=+L[LIL,\*2E0<XW*#C]:M5F>&/\ D6])_P"O2'_T 5IT@"BBB@ HHHH
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M>O0R^K=!T'K7V%110!\P>(_^4@OA#_L5+O\ ]"KZ?KY@\1_\I!?"'_8J7?\
MZ%7T_0 4444 %%%% !1110!XC\>_V/\ X>?M$74&H>(;6[T_6X4$2ZMI,JQ3
ML@Z(^Y65P.V5R.Q%>+_L*_ _PM\/?BC\6DM;1K_4/#NIQ:98:G?$//'"T;%P
M, *"Q') !QQ7VM7S3^RG_P E>_:"_P"QDA_]%-0![IXE^'/A/QFI'B#PQH^N
M!NO]HV$5Q_Z&IKR'Q1^P;\#_ !4)&D\$0Z;.W2;2[F:VV_1%?9^:U] 44 ?$
M7BC_ ()3> -0WMH'BS7]&D;D+=B&[C7Z +&V/JQKRW4_^"7OQ(\)W9N_!?Q"
MTR:51\LLAN-.F/L#'YG_ *%7Z7T4 ?F-_P (#^VQ\*'W6&J:YK=M$?E=-3@U
M13[".=F?'_ :%_;N_:/^&(V>-/ \<T2#YY=9T*XLG(]0R%$_':17Z<TA&1@C
M(H _/WPO_P %9].DV)XC^'MU;<_--I>H+-GW".B8_P"^J\T_:3_X*/>(OB#(
MVD?#DW'ACPW+;F.YFO+>(WEP6!#J>75%P<?*<GU'2OT8\4?!'X>^-MYUWP1X
M?U61CDS7.FQ-)GU#[=P/T-?EW^V-^Q[XA^$_Q U/5O"_AN[O/ EXWGVTNGPO
M,ED,9:*3&2H!SAFP"#[4 =K^P=^V-KGA/Q/H/PS\1-'?>%KR3[+83>6J2V,C
M$D#< -Z%CSNR1G@XXK]1:_$'X.?LW_%WQ]:GQ9X'\.7QCTUA<6^H%UMO,=3G
M]PTA D8$=%SZ>U?2OP[_ ."CWQ ^%NK?\(W\8?"EQJ$MN0DMP+?[#J,0]7B8
M!']L!,^IH _2FBO,/A#^TK\.OCA;H?"GB2VN;[;N?2[D^1>1^N8FY(']Y<K[
MUZ?0 4444 %%%% 'S?\ \% /^3=[K_L+:?\ ^CUKZ!T'_D!Z=_U[1_\ H(KY
M^_X* ?\ )N]U_P!A;3__ $>M?0.@_P#(#T[_ *]H_P#T$4 7Z*** "BBB@ H
MHHH *^8?C]_R=K\ O^NM]_Z*-?3U?,/Q^_Y.U^ 7_76^_P#11H ^GJ*** "B
MBB@ HHHH **** /FOX2_\GJ?&K_L&:7_ .@FOI2OFOX2_P#)ZGQJ_P"P9I?_
M *":^E* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBN>A^(GA2X\2/X>B\3Z-)KZ'#:4E_$;H$=08MV[]*.M@\SH:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^B/M_P!_;C_XU5K0AZGV;\'O@WX9^!O@V#PUX7M&@M$;S)IYFW37,I !DD;
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MXV5I..ME?H]C)_8[_8NTK]G_ $N'Q!KR1:GX^NHL2S</%IZL.8H?]K'#/WY
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M^M $]%5Y+>5[R*9;ADB0$-" ,.3W)HNK>2X:$I.T 1PS;0/G'H: /G/X2_\
M)ZGQJ_[!FE_^@FOI2OF3X8P27/[97QMCBF:WD;3-*Q(H!(^4U]+RQM);NBR%
M'*X$@'(..M $E%1V\;0PHCN9648+GO3+."2WAV23-.V2=[#F@">BH+>WDADF
M9YVE5VRJL/N#TI%MY5OGF-PQB9 H@P-H/KF@"Q15>6WDDNH95N&2- 0T0 P^
M>F?I1>6\MQY7EW#6^QPS;0#O']TT 6**AO(7N+=HXYF@<XPZC)'-.DC9H&02
M%6*[1(.H..M $E%1V\;0PHCR&5E&"YZFF6=O);P[)9VN&R3O88./2@">BJ]O
M;RPS3N]PTRR-E48 ",8Z"A;>07S3&X8Q% HAP-H/K0!8HJO-;RR74$JW#1QQ
MYW1 ##Y]?I2W4$D_E>7.T.UPS;1G</2@">BH;R%[BW>..5H';&)%'(YITD;-
M"R!RK%<!QU!QUH DHJ*UB>&W1))#,ZC!<C!-,LK>6VC99;AKEBQ8,X P">G'
MI0!8HJO;V\D,\[O</*DC K&P&$XZ"C[/+]N,_P!H8Q;-OD8&W.?O9H L45!-
M;R27,,BSM&B9W1@</GIGZ475O)<+&(YFA*N&.T?> _AH GHJ&\A>XMWCCF:!
MVZ2*,D<TYHV,)0.0^W'F8YSCK0!)14-G"]O;1QR3-<.HP9&&"WO3;.WDMHW6
M2=K@LY8,X P">!^% %BBJ\%O+%<3R/<-*DA!6-@,1X':E^SR?;?.\]O*V;?)
MQQG/WJ )Z*@FMY)+B"19FC2/=NC X?(XS]*2\MY+A4$<[6Y5PQ*@'<!U% %B
MBH;R%[BUDCCF:WD88$BC)7WIPC;R=A=BVW'F<9SCK0!)14%G ]M:QQR3-<.H
MP9&&"WO26=O);+();AK@LY8%P!M!_AX]* +%%5X;>2.YGD:=I$D(VQD<)@=O
MK2_9Y/MOG><WE>7L\G'&<YW?6@">BJ\]O)+<02).T21DEHP 0^1W^E%[;R7,
M:K%<-;,'#%D )('4<^M %BBH;N%[BUDCCF:"1EP)%&2I]:>L;+"$+DMMQOXS
M]: 'T5!9026UK'%+.US(HP96 !:DM+>2W$HDG:?=(7!8 ;0>B_A0!8HJO#;R
M1W4\K3M(DFW;&1PF!SCZT-;R&^6<7#"(1[3!@;2<YW9H L457N+>2::W=+AH
M4C8ET4 B08Z&B]MY+J$)%<-;,&#%D )(!Y'XT 6**BNH7N+:2..5H'9<"11D
MJ?6G1HR0JC.7<* 7(&2<=: 'T5!9026MJD4L[7,B]96&"W-):6\EOYWF3M/O
MD+KN&-@/11["@"Q15>*WDCO)Y6N&>.0+MA(&$P.<?6K% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45\C_ +;W[8]W\"5MO"?A#R6\7WL'VB:\
MF02)80DD*0IX:1B"0&!  R0<BOC7P+XK_:>^+DUUKWA;7?'&LPP2'S)K6^E2
MT#CDH$W"(GD?(!W'%3&7/>VR*DN6U]V?L%17Y%_%K]L?XLZQX3TGPIKE_K?A
M+QEH=Y*+Z]L)9=,GNHV1=BSQH4PZG)Z $$' .<_6/_!-7QUXD\=_#KQ;<^)?
M$.J^(;F#54CBFU6]ENGC7R5.U3(Q(&><"M(QYN9K9?CM_F9R?+RI[O\ #?\
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M""VV_!_Y'1_$YYOU_%?YGSU\-_V8_B;\7/#IUWPEX6DUC2A,UN;A+NWC'F*
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MP#@C ( \]_X*CZOH<?PA\/:;<R0MK\NK+/9Q9'FK$L;B5\=0N2@/;)%>*_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^NY>N2O2OM?3M2M-8L8+VPNH;VSG0217%O()(Y%/0JPX(]Q0!9HHHH ****
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M&X=BQ_VCA1[L*>'3^M1DME:_WW_#7[R:S7U:2?7;[OUT/T>_X*!?\FJ^+?\
MKI9_^E,=?%O_  32\/:9KW[0UQ+J-C#>OI^C37EH9T#>3,)85$B@_P 0#M@]
MLU]I?\% O^35?%O_ %TL_P#TICKX]_X)>?\ )P.L_P#8NW'_ *46]/"_Q9_/
M_P!)*Q/\&'K_ .W(_13XZ6-OJ7P6\=VUU$L\#Z'>[D<9!Q Y'Y$ _A7Y,?L4
MS-#^U)\/F7J;UU/T,,@/\Z_6_P",W_)(?''_ & [W_T0]?D9^Q?_ ,G1?#W_
M *_V_P#13TL-_OB_[=_-A7_W7_P+\D?K/\?O^2%_$3_L7M0_])Y*_*[]@O\
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M7JW_  3E_P"37='_ .O^\_\ 1IKS#_@JU_R)/@'_ +"%S_Z+6NC&_9_[<_\
M;3'"]?\ M[]2K_P2HT33V\.^.=7:SA;5%NX+5;PH#*L10L4#=0I(!('7 ]!7
MJ'_!22S@N/V9;R66)7EM]3M'B9ARC%BI(_X"Q'XUYY_P2G_Y$/QY_P!A*W_]
M%&O2?^"CW_)K^J?]A&S_ /1E+&;+_MS]!87J_P#%^I\U_P#!*UV'Q8\8+N.T
MZ("5SP2)X\']3^=<_P#\%.-<N=0_:#L]/D<_9M/T:!8DSP"[R,Q_'C\A6_\
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MR#_D;87_ *^1_P#2D?$*_!/]M-ANB\2ZR(CRG_%3Q#Y>W_+3TI?^%(_MK?\
M0S:U_P"%1%_\<K]++/\ X](/]Q?Y5-7K1V1X<OB9^9O_  I']M;_ *&;6O\
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M_HIJ /I:BBB@ HHHH **** "N?\ B#_R(/B7_L&7/_HIJZ"N?^(/_(@^)?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^$/VG_ /E(+\%?^N-C_P"ED]?=]9EYX9T?4=4M
M]2N])L;K4;?'DWDULCS18)(VN1D8))X/>B.E2$_Y7?\ ,):TYP_F5C3HHHH
M**** "N=^(/C_0_A?X/U+Q-XCO5L=)L(_,ED(RQ.<*BC^)F)  '4FNBKXJ_X
M*374^K+\*/![3R0:7KFMM]J,9QG:8HU/X"=S42YFXPCO)I?>7&VKELDW]RN<
M3JO_  4 ^+GQ,U.Z3X3_  RDNM)B?9Y[:?<:C<#T+&(A(R1_"0V/4U7C_;E_
M: ^&CQWOQ!^%Q_L/>!)-<:3=:>W/99F)0'ZJ:^_?"OA72?!/AZPT/0[&'3=*
ML8A#!;0+M55'\R>I)Y)))K1NK6"^M9;:YACN+>9#')#*H9'4C!4@\$$=JM^[
M\&OJ0O>^+3T.$^"/QN\-?'SP3#XC\-SMY>[RKJSGP)[24#)1P"?7((X(.17H
M%?#/[*>DV_PO_;:^+_@/0U:#PX;3[7':@_)$5>%D4>RBX=1[5]S53M*,*D=%
M)7)UC*5-[Q=@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@!&^Z:_/[_@G
M#_R<%^T=_P!A?_V[NZ_0%ONFOS^_X)P_\G!?M'?]A?\ ]N[N@9^@5%%% @HH
MKA/C#\5(OA'X<M-6ETY]36>[6U\I)1&5RCMNR0?[G3WH [NBJVFW@U'3K6["
M;!/$DH7.<;@#C]:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7P)_P4R^.TJVVE_"30)6EO\ 4&2ZU18#EMF[]S!QW9AN(ZX5
M>S5]I?%#XAZ9\*? &M^*]8?98Z9;-,RC&Z1NBHN2,LS$*/<U^>'[$/P[U+]I
M+]H77OB_XNC^TV>FW?VM1(N4EO&_U,:_[,2@'OC:@/6@#Z TOX%P_ /]@WQK
MHLL2KKMYX>O+W59=HW&=X3^[SZ(,+UQD,1UKW3]G7_D@OP]_[ 5G_P"B5JE^
MU%_R;C\2O^P!>?\ HIJN_LZ_\D%^'O\ V K/_P!$K0!Z)7E7[3?_ "2+4?\
MKYM?_1R5ZK7E7[3?_)(M1_Z^;7_T<E>/G/\ R+<1_@E^3/>R#_D;87_KY'_T
MI'I]G_QZ0?[B_P JFJ&S_P"/2#_<7^535ZT=D>'+XF%%%%42%?,7[<__ "#/
MA5_V.EE_)Z^G:^8OVY_^09\*O^QTLOY/0!].T444 >/?%#_DMWPQ_P!^Z_\
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M?]=;[_T4:^7_ (Q?L2_$+]F&^N?B!\*?$UU=:3IRF>1EF$%]:QCD[QPDR>H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445Y=\6_VE_AY\#=4L=.\9:W)I=W
M>PFX@1+*>?<@;:3F-& Y'>E=+<=FSU&BN5^&?Q.\.?%[PI#XD\*WS:CH\TCQ
M).T#PDLAPPVN W!]JZJJ::W)33V"BBBD,**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN?\
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M;6)=*BEC0J8PV6$DCG.3V(KVOQ]X\T7X9^$=3\3>(;P6.D:?%YLTI!8]<!5
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MW!_&N[^!_P#P4*C\2>-(/!GQ-\,GP3KLTHMTNQOC@$QZ1RQ2#?#G@ DL,GG
MYIQBY.RW%)J*N]C[,HI"<<G@5\D>+/\ @H!%)XOU+0OAM\-M<^)ZZ8Q6\OM-
M9TB7!P60)#*Q3((W,%!QQD<U-U>Q5G:Y]<45XU^SG^U%X:_:+TZ_73K:YT77
MM-(%_HU\1YL63C<I'WTR",X!!'(&1GV6K<7'<E-/8**\'U+]J+[3^T=:_"3P
MOX9_X2.YBC$NKZM]O\F+3E'+Y41/O*J5XROS.%]2/>*E:Q4ULQO23B]T%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOFC_ ()^_P#)"[G_ +#M_P#^CC0!]%Z/I%GH&E6FFZ? +:QM(EA@A4DA$48
MR>>!ZU<HHH **** "BBB@ HILDBQ1L[G:JC)/H!7CLG[8OP6AD:-_B+HRNI*
MLID;@C_@- 'LE%>2Z+^UA\(?$6K6>EZ;X^TF\U"\E6"WMXW;=)(QPJCY>I)K
MUJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOQ#L-)^%VK>-]+,.N:=::3-JUOY$P5+I$B,@ < X# 8S@XSTK\COVJOVF/\
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MZ$2>5N$N[;Z9VC\J^W/BQX9TKP;^S=XYT;1+"'2]*M/#FHK!:6Z[8XP8)&(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOV59%*L RL,$$9!%*V=IQUK\X?BTW[:%UHVK0:C;:G_PC[M(&70QIYN'AR<
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MU_Y(+\/?^P%9_P#HE:I?M1?\FX_$K_L 7G_HIJN_LZ_\D%^'O_8"L_\ T2M
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MC_&PO^/_ -LD?1Y3_N^-_P"O7_M\#V*BBBO;/G HHHH *^:?V4_^2O?M!?\
M8R0_^BFKZ6KYI_93_P"2O?M!?]C)#_Z*:@#Z6IDW^J?_ '33Z9-_JG_W32>P
MUN>4_LT_\B'J/_88N_\ T(5ZS7DW[-/_ "(>H_\ 88N__0A7K->/DW_(NH?X
M4>]G_P#R-<1_B84445[)X 5S_P 0?^1!\2_]@RY_]%-705S_ ,0?^1!\2_\
M8,N?_134 >4_L/?\FN^!O^O:3_T:]>[5X3^P]_R:[X&_Z]I/_1KU[M0!P?QV
M_P"20^*?^O,_^A"MWP#_ ,B/H'_7C#_Z *POCM_R2'Q3_P!>9_\ 0A6[X!_Y
M$?0/^O&'_P! %>+'_D:R_P"O<?\ TJ1]!+_D30_Z^R_](B;]%%%>T?/A1110
M!\W_ /!0#_DW>Z_["VG_ /H]:^@=!_Y >G?]>T?_ *"*^?O^"@'_ ";O=?\
M86T__P!'K7T#H/\ R ]._P"O:/\ ]!% %^O'OV@/^0O\._\ L.I_Z":]AKQ[
M]H#_ )"_P[_[#J?^@FO$SK_<9^L?_2D?1</_ /(RI^DO_2)'L-%%%>V?.A11
M10 5\P_'[_D[7X!?]=;[_P!%&OIZOF'X_?\ )VOP"_ZZWW_HHT ?3U%%% !2
M,H=2K ,I&"",@TM% 'SW\7OV%?A-\73/=2Z'_P (WK$N6.I:$1;L6/=X\&-N
M>I*Y/K7R-XB_8<^.?[.NJS>(/A3XFFUN!#D_V3,;6[9!SB2W8E)1_LAGS_=K
M]/:* /S=^'7_  4P\9^ M2_L'XN^$);N>W8)-=6L!LKZ/U,D#@(Q^GEU];^$
M_P!LSX.>,/"]SKEOXWT^QAM8O-N+34F-O=1#N/*;YG/;Y-P)Z$UWOQ$^$?@W
MXM::+#Q?X;T_7H%!"-=1#S8L]?+D&'0^ZD5^9/[=G[(/A_\ 9ZBT77_",NHO
MH^J7$D$MI=L)5M' #*%DP#@@G ;)^7J: /8?A/\ MD?#"W_:L^(?B2]U:YT[
M0?$5M96=C?W5JRQ[X@0Q?&2BDG@D?7%??UM<Q7EO%<6\J3P2J'CDC8,KJ1D$
M$=017\\E?LO^P+XDD\1?LQ>%A/?QWMQ9"6T94E5VA57.Q&P3M(7'!YQB@#Z)
MHHHH **** "BBB@ KYH_X)^_\D+N?^P[?_\ HXU]+U\T?\$_?^2%W/\ V';_
M /\ 1QH ^EZ*** "BBB@ HHHH 1E$BE6 96&"",@BOE7]L[X)_#SPW^S5XZU
M?2/ 7AC2]5A@A>*^LM'MX9XV-S$"5=4# D$C@]S7U77@_P"W1_R:C\0/^O>W
M_P#2J&@#H/AK\"_AM9^&?#.JV_P^\*P:I':6]PE['HMLLRRA%(<.$W!L\YSG
M->L5S_P]_P"1#\._]@^W_P#1:UT% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;\K?UY#PZM&2EO+_ #O^2L6O^"<,Z3?LPZ8J,&:+4;Q''H?,SC\B#^->7_\
M!5K0;FX\*> -912;2TO+JUE8#HTJ1LOZ0M7S#X3\)?M*_!];K2O#>@?$#1;:
M27S)H-,T^YD@9^FX%%9"< #(Z@#VK]4/B)\+=+^-/PGG\)^)DE\F^M8]TV,3
M03  K(N>C*W//N#U-5B%[6*J1Z6_!!0?LI\LNO-^/_#GR1_P2H\46+>'/'/A
MTRJNI)=PWZQ$\O$R;"0/9E&?]X5]8_M#>+K+P/\  _QOJ]_*D<4>DW$2!SC?
M+)&4C0>Y9E'XU^:OBS]COXZ?L_\ BTZIX1M=2U5+=B+76O"LC&9D/9HD/F*2
M/O+@KU&6%4M<^'_[3_[0-Q;:;XAT7QEJ4,;ADBUJ![&U1L8WXE$<><$\]>M3
M6_VB'+'=JS^ZWY#I?N)WELG?]?S.=_8GT.ZU[]I_P)':H6^S7;7<K 9"QQQL
MQ)_(#ZD5]H_\%2O^2(^'/^P]'_Z(FKL_V./V/X?V=--NM8UJY@U/QGJ40BFD
MMP3#9Q9R8HR0"Q) +-@9P !@9.+_ ,%(/!7B'QS\'] LO#>@ZGX@O(];25[?
M2[.2YD5/)E&XJBD@9(&?<48FWLXP6MFOS7Z(>&_B2F^J?Y/_ #/)_P#@D]_Q
M\?$S_=T[^=S7T9^WE_R:CXY_W+3_ -*X:\4_X)E?#GQ9X"G^(9\3>&-9\."Z
M6P\C^UM/EM?.VFXW;/,4;L;ESCID>M>]_MJ>'M5\5?LS^,M+T73+S6-3N%MO
M)LK"!YYI,743':B DX )X'0&GC=8JW:/Z$X32M=_S+]#X6_X)D_\G&7/_8#N
M?_1D-?I/\9O^20^./^P'>_\ HAZ^ _\ @G?\)?''@GX]7&H>(O!GB#0; Z-<
M1"ZU32Y[:(N7B(7<Z 9.#QGL:_0+XLV=QJ7PM\8VEI!)=74^CWD44$*%WD=H
M7"JJCDDD@ "C&:X=)?RO\Y#PNE>[_F7Y(_(;]B__ ).B^'O_ %_M_P"BGK[V
M_P""AWQR\0?"'X8Z3I_AF\DTS4_$%S) ^H0$K+#"B@OY;#[K,64;AR!G&#@C
MX^_9)^"7Q%\-_M'>!=3U?P#XGTO3;>]+S7E[HUS##$OE.,L[( !DCJ>]?>'[
M9G[.-S^T5\-[>STF>*W\1Z1.;JP^T-MCFRN'B8_P[@!@^JC/&:=>[P\4OYOP
M]T5&RK-OM^.I\,?L<_LCVO[3TFOZ_P")]?OK32;&X6"1;-E-W<S,N\DR.&"@
M CDAB2>V*]$_;(_9"^&?P"^"ZZUH#7YUV74(+6%]1O@[2*0Q?:@"@G !.!Q[
M5Y)\//"O[3?[/.M:A9^$O#'BO2I;HJMRMKH_VZUE*YPVXQR1$C)^8'OUKLOB
M?^S'\>?B+\/]4^(7Q%GU;6_$5N88M,\.6L7VJZ*O*H=O)@!2)0I)VH,DC+ 8
MYFK:45[/1:?I^?Y#IW4GSZO7^OE^9T/_  2I_P"2B^./^P5%_P"CJ]>_X*E?
M\D1\.?\ 8>C_ /1$U<-_P33^&/C'P'X\\8W'B7PGKGAVWGTR*.*75M-FM5D8
M2Y*J9% )QV%?4G[5GP-D_:!^#]_X:M+B*UU:*9+[3Y9\^7YZ @*Q'0,K,N>V
M[/.,4\3>5.%NEOPE<6&?+4G?K?\ &-CY=_X)07$?V?XD0;AYNZQ?;WVXG&:^
MQOC]_P D+^(G_8O:A_Z3R5^5.D_!O]HGX%^(+EM \,>,=(OY$\J6X\/V\MS'
M*F<@%X-R,,\\GBOT/\*0^,?$7[$M]!XFM=7NO&EYX:U&*>UOK>07TDS+,J(8
MR-Q8C: ,9.12Q3]K0E-=K?@_\AX9>SQ$8OJ[_BC\Z?V'_P#DZ?P#_P!?,W_I
M/+7VG_P5$T2YU#X&:'?PJ6AT_7(VGP/NJ\4J GVW$#\17R_^QW\%?B'X8_:2
M\$ZGK'@/Q-I.FV]Q*TUY?:/<0PQ@P2 %G9 !R0.3WK]1?B%X"T?XH>"]6\+Z
M];_:=*U*$PS*IPR]U=3V96 8'U K3$)RH04=T[_<TR:,N6LV]K6^^Z/@#_@E
M3XFL;'Q=X[T*:98[_4+2UN;=&."ZPM(' ]2/-4_3-?>OQ8^(=G\)_ASXA\6W
MR+-#I-H]P(&E$7GN!\D0;!P68JN<'KT-?F'\1?V'?C'\$_%9U7P;;WVOV5K+
MYECK'AZ4K>1CMF)3YBOCKL##WK$UCP#^T[\<&MM%UW1O'.JVZ/O2'7(9K6U5
MNFXF;9'D9/).>34SFZT5R:.UOZ^0XQ5*;<]4W<^Q_P!G;]ON;X__ !2L/!\7
MP^.CK<0S3R7XUC[1Y*QH6R4\A,Y.%^\/O5]>5\P?L7_L@_\ #.^G7FN>()X+
M[QEJ40AD^SG=%90Y#>4C$?,Q(!9NGR@#@9/T_5S459+YF<')W;VZ%35_^03>
M_P#7!_\ T$U^'WP(_P"2_?#_ /[&2P_]*4K]PM41I-,NU52S-"X"J,DG:>*_
M';X+_ ?XEZ7\;O ]_>_#OQ79V-OX@LIIKFXT2Y2.*-;A"SLQ3 4 $DG@ 5&&
MTQ<6_P"[^;-:W^ZR7K^1^G_[5'_)N'Q(_P"P%=?^BS7YH?\ !/S_ ).J\)_]
M<KS_ -)I*_3K]I/2;[7?@%X_T[3;.XU#4+K1KF*"UM8FEEE<H0%5%!+$^@%?
MGM^P[\&_'_A+]I3PQJFN>!O$FC:;#'="2\U#2+B"%,V\@&YW0 9) &3U-&'T
MQ$F_Y?TD3B-<.DN[_P#;3]3YO]4_^Z:_"[X3_P#);_!__8PV?_I2E?NC+S&X
M')P:_&CX8_ 7XF:?\8?"M[=?#KQ9;6<.NVLTMQ-H=TL:(+A269BF  .<GC%&
M&TQ<6_+\RZG^[37];,_9>;_5/_NFOPY^!_\ R<)X#_[&:Q_]*DK]QI>8W Y.
M#7XY?!WX$_$O2_CIX*O[SX>>*[2QM_$-G/-=3Z)<I%'&MRA9V8I@* "23P!1
MA],7%OR_,57_ '6HOZV9^R%?AC\>(VA^._CY'&UE\0WP(/;_ $AZ_<ZOS0_;
M,_8I\<W'Q0USQKX+T>3Q'HNL2F\GM;'!N;:9A^\'EYW.&;+ H">2"!@$Y*3I
MUH5+:*_YK_(UCK3E#KI^O^9^D^G.LFGVKHP96B4AE.01@<U^'/QZB:U^/'C]
M)1M9/$%]N'I_I#U]Q_L"3?&BU\>:CI?Q!MO&%MX:M-',=E'X@M;B.!)!+&%5
M&E4 D+N &>@..*XG]M[]B_Q???$;4_'G@?2)O$&FZLPGO;"R&^YMY\ .RQ]7
M5B-WRY().1C!K2?[NM"LMM?STO\ <8T/X,J756^=ET^\_1/0[V#4M%T^[MI%
MFMKBWCEBD4Y#*R@@@^A!K\C?^"@/B+3/$O[36O3:5?0ZA#;V]O:RR6[[E65(
MP'3(X)4\''0@CJ*F^'OPI_:?\26<'A+2H/'6@Z'M\DP:G<W6G64,9ZC$A4;?
M55!SZ&L_XW?L8^._A?XJL=&T/P]X@\9QG3H;BZU/2=)GGMOM#%M\:,B'A<#J
M<GJ<9P)JQYIQETOI]S_"WXA1]RFX=;?Y'Z/_ +(<'VK]E?P%#G'F:24SZ99Q
M7Y"6GAVST[XG0Z%XHDFL=/@U<66IR0D+)#&)MDI4L" 0-Q&01QTK]C?V4=%U
M'P[^SKX$TW5K"ZTS4;;3PD]G>0M#-$V]CAD8 J?8BOG#]LK]@[4_B+XFNO'/
MP[2WDU:\^?4M%FD6+[1)C'FQ.Q"ACQN5B 2,YR<&ZSY,4ZEKJ[O]^GZDT?>P
MRIWL[+\CH(O^"77PFGC22/Q'XPDC<!E9;ZT((/0@_9J\C^(G[-?[*/PI\57'
MASQ3\3/&&F:U;JCRVJH)]@=0RY:.Q9<D$'&<\UYWX?U;]K?X8Z2OAC2M-\=0
M:?;CRHX8]&>]2)>@6.4Q/M4=MK8':KOPM_82^+'QD\8+K/CV&\\/:9<S>??Z
MEK,V^^N.?F"QDE]Y]9-H'OC%'*Y2]U^[YCORQ][<_1#X9:9X<T?]G_2+/PA?
M76I^&(M&;^S[R]4K--"48J[ HA!.?[J_2OR&_9J_Y."^'7_8>L__ $:M?M,_
MA^UT'P*VB:5;>59V>G&TM;>,9VHL>U% [\ "OR1_9]^!/Q*T7XY> K_4/A[X
MJL+&VUJTEGNKG1+F.*)!*I+,S( H ZDU=)IXWFZ7COZLBJG]3Y>MG^2/V,K\
M.?VC?^3A/B-_V,5]_P"E#U^XU?CE\?/@3\2M8^.GCZ_L/AYXJOK&YUZ\F@NK
M;1+F2*6-IW*NK!"&4@@@C@USQ_WB#\G^<3J7\*7JOR9^O&AW$5KX7T^>>188
M8[.-WDD8*JJ$!))/0 5^3_[:G[3UQ^T)X[CT30))&\&Z3,8["*,'-],?E,Y7
MOGH@Z@'L6(K[U_:VT?Q'JG[*.M:7X<L-3O=9N+6S@^Q:;!)+<.ADC$B;$!8C
M;NW#'3.:_,#1?@A\8_#NK6FJ:;\.O&=I?VDJS07">'[K=&ZG*L,Q]0>0>U74
MM4KRYMD_Z?\ D94[PH1<=VOZ^\_1[]AS]EE/@9X,_P"$@UZV7_A-M:B5IPPR
M;& X98!Z-T+^X _AR?IVXF6W@DE?[D:EC] ,U^2?_"7?M=?\\/B?_P""F[_^
M-U]E_L(ZA\4-8\)^+/\ A:D7B(7GVR)+1?$EK+"YB,9W;!(HRN>N*UGS5%)Q
MTLM#*-J;2>MWJ?GS\2OBAXO_ &J/C):6NH:I((]4U1+'2]/DD86MDLD@CC 0
M< X(W-C)YK[H\*_\$P?ACI5C!_;>JZ]KE\%'G.MQ';PLW<JBIN4>Q<_6OE[X
M^?L._$?X6>.KO5/!6CZAXB\/&Z-UIUUHJM+=6OS;E1HT^<,AQAE!!P#D'@=?
MH-G^V%\>+-?"^IW6NZ#H4H$-U>:O91Z5B/H=[B-)I 1P0N[.>>YK*E;V2C!>
M]Y_K^/J;5?XKE)^[TM_7X'RI\6-%TGPW\5/%FDZ$ZOHMCJUS;63++YH,*2LJ
M?/GYN .>]?N?X;_Y%W2_^O6+_P! %?C7\2?V4?B'X-\?:SHFC^"_%7B'3+&X
M\F#5;;0[AXKI0!^\4HA7!.>A/UK]EM C>'0M.CD1DD6VC5E88((49!%:T_\
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MM?\ ;N\8Q^#_ -F/Q:2^V?5%CTR%<XW&5P&'_?L.?PK*O'DPT:+=VH\OS?\
MP78UHRYL0ZO1RO\ )?\ #7/&/^"4]F\?@'QU='=Y<FIP1C)XRL1)Q[_./TK[
MGKYI_P"">O@63P9^S7I%Q<1^5<:Y<S:HP/78Q"1G\4C4_P# J^EJ[:WQV[)+
M[DCDH_#?S?YL****P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-3FO],?5O"DLI+&VTR=&MLDY)"2(Q7Z*P ["LSPK_P $P_A?HM]'<ZMJFO\
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M5\Q?MS_\@SX5?]CI9?R>OIVOF+]N?_D&?"K_ +'2R_D] 'T[1110!X]\4/\
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M_P"/_P!LD?1Y3_N^-_Z]?^WP/8J***]L^<"BBB@ KYI_93_Y*]^T%_V,D/\
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MY$?0/^O&'_T 5XL?^1K+_KW'_P!*D?02_P"1-#_K[+_TB)OT445[1\^%%%%
M'S?_ ,% /^3=[K_L+:?_ .CUKZ!T'_D!Z=_U[1_^@BOG[_@H!_R;O=?]A;3_
M /T>M?0.@_\ (#T[_KVC_P#010!?KQ[]H#_D+_#O_L.I_P"@FO8:\>_: _Y"
M_P ._P#L.I_Z":\3.O\ <9^L?_2D?1</_P#(RI^DO_2)'L-%%%>V?.A1110
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M[EE_Z20U^PU<=X@^#7P_\6:M-JFN>!O#>LZG-M\V]U#2+>>:3: J[G="QP
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M&=I8C>5]DC"1 ^[#M7VWKF@:9XHTJ?3-9TVTU;3;@ 36=] LT,@!! 9&!!Y
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M1?M%? [2?@Y9^#9=,O[R];6]?M])F%V4PD<@;++M4?,,=\BCZUQ%_P! T/\
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M1(]AHHHKVSYT**** "OF'X_?\G:_ +_KK??^BC7T]7S#\?O^3M?@%_UUOO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?AQ-(TDGP_\ "TDC'<S-HML23ZD[*ZG2=#T[0;;[-IFGVNG6^<^3:0K$GY*
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M!\W_ /!0#_DW>Z_["VG_ /H]:^@=!_Y >G?]>T?_ *"*^?O^"@'_ ";O=?\
M86T__P!'K7T#H/\ R ]._P"O:/\ ]!% %^O'OV@/^0O\._\ L.I_Z":]AKQ[
M]H#_ )"_P[_[#J?^@FO$SK_<9^L?_2D?1</_ /(RI^DO_2)'L-%%%>V?.A11
M10 5\P_'[_D[7X!?]=;[_P!%&OIZOF'X_?\ )VOP"_ZZWW_HHT ?3U%%% 'C
MS?\ )T:?]@$_^ABO8:\>;_DZ-/\ L G_ -#%>PUXF5[XC_KY+]#Z+.?^87_K
MU#]0HHHKVSYT**** /FOX2_\GJ?&K_L&:7_Z":^E*^:_A+_R>I\:O^P9I?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RE_P""FO\
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M/]SK[U[C^SC^P3JWQ,\)>$OB'!XNL[&VGN!="QDLW9P(IRI7<&QSL].]5?\
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M .DUO7G7_!5__C^^&_\ USOOYP5Z+_P2U_Y(3XB_[&*7_P!)K>EA?X=7Y_\
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M^T1XHCT?SKS0/AU;7(Q9VZ+)<3@'F:5=ZJ[XR53<%''.?FKW;X+_ +;GP!^
M_@Z'P_X8\)^,8DX>ZO);*S,]W)CF21OM/)]!T X %?81_9W^%3$D_#+P<3_V
M +3_ .-TG_#._P *?^B9>#O_  06G_QNE#W(\JZ[^?\ 7]="IVG+F[;>1U'@
MGQ9:>//!^B>)-/CFAL=7LH;Z".Y4+*L<B!U# $@-@C."1[UM56TW3;31M/MK
M#3[6&QL;6-88+6VC$<44:C"HJ@ *H   ' JS52MS/EV(C>RYMPHHHJ2@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ HHHH _*7_@IK_P G'P?]@*U_]&35]O?L)_\
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M^8JW[RI&:V2M^"1\9?\ !2K]GO5/%EIIOQ(T"TDOI=+MC9ZK;PJ6D%N&+),
M.H4LX;T!!Z D>0_LG?M[)\#?!B>#O%.B76L:):R/)976GNOGP!V+-&4<A67<
M20=P(R1SQC]2:\?\9?LA?!WQ]J#WVL> ]-:[D8M)+8M+9%V/)9O(=-Q/J>:B
MGS4[Q6S_ *_/^K%3M4LWNOZ_(^$OVG/^"@6L?%:'3=-^'YUOP1IUK*9YKZ&_
M:WO+EMI 0^2V%09)QN;)QTQS]7_L"Z#\08?A??>(OB#KFN:I=:W.DNGV^N7L
MUQ)#;*IPX$C'9O+$^X53WKT+P3^R3\(/A[?)>Z)X$TV.\C8-'/>&2\>-AR&4
MSL^TCU&#7KM:1Y81:6[,Y7FU?9'Y1?\ !0']GG5OAY\5-3\;65G)/X4\13_:
M3=1KE;:Z;_61R>FYLLI/7<1U!KN?A!_P4VG\&^ =,T'Q1X2FUR_TV!;:+4;6
M]$1G11A3(K*<,  "P)SUP*_1O4--M-7L9[*_M8;VSG4I+;W$8DCD4]592,$>
MQKQ36OV'_@=X@U![RZ\ 6<4SG)6RNKFTC_".*55'X"LJ:E3C[-?#_5ON-)VG
M+G>Y^8OQ0\?>+OVOOC8E[::.TFJZCLLM.TFS)D$$*YVJ6(&<99F<@#DG@<#]
M=O@C\.5^$GPG\,>$1(LTFEV:Q32QC"O,<M(P]B[-CVJ7X=_!GP/\)K=X?"/A
MC3M#WKLDFMXLS2+Z/*V78?4FNSK9<L(>SAZ_U]YF[SGSR/QZ_;W\$ZCX2_:7
M\3W5W!(EGK)CO[.=E.V5#&JM@]]KJP/I@5]2_LN_M\6WC2^\!_#:]\*W$6KR
M0Q::VII>*T3&.+'F;2N[D)TSU/6OKKQW\-?"OQ.TM=.\5Z!8:]9J2R)>PAS&
MQ&"R-U0X[J0:\]\'?L<?!_X?^*K#Q)H'@\:?K5A(9;:Y74KQQ&Q!&=C3%3P3
MP144/W:5.6L=/N7_  "JW[QN<?B_K]3Y9_X*O_\ ']\-_P#KG??S@KT7_@EK
M_P D)\1?]C%+_P"DUO7T+\6/V?? /QPDTU_&V@_VTVG"06I^V7%OY8?;N_U4
MBYSM7KGI6C\+?@_X1^"N@W&C>#-(_L;3;BX-W+#]IFGW2E54MNE=B.$48!QQ
M3H_NX3B^O^:8ZW[QP:Z?Y-'P1_P4A_9VU73?&DGQ/T:REN]%U&.--5:%=WV2
M=%"+(P'1'4*-W0,#G[PJG^SC_P %%C\*OA[I_A'Q7X<N=;@TN/R;*_L9U63R
MA]R-T88.T<!@>@ QQD_IG-#'<0O%*BRQ.I5T<95@>"".XKQ;Q+^Q9\$_%FH/
M>7_@"PCG<Y;^SYI[)"?79!(B_I6=/FIIP7PO^O\ AON'.U1J3W1^:_[37[2F
MN_M7>--'CM=%DL-/L\V^F:/;N;B:220@,Q(4;G;"@ #C '/)/Z)_L3_ 6[^
M_P '8K36(_*\1ZO-_:&H19!\@E0J0Y'=5'/^TS5WWPY_9[^'/PEF\_PGX0TW
M2;O!47@0S7(!Z@32%G /INKT.MH\M.#C#KO^?YF<N:<E*70_(7_@HA_R=-XC
M_P"O6S_])TK]'_V2?^3:?AS_ -@>'^51_$3]DGX4?%?Q5<^)/%7A7^U-:N%1
M);G^T;N'<J*%4;8Y548 '05Z1X1\)Z5X%\,Z;X?T.U^PZ1IT*V]K;^8\GEQC
MH-SDL?J236=']W1=-[WO^?\ F54]^HIKHK?E_D?GG_P5:_Y'?P#_ -@ZY_\
M1JU[C_P3,_Y-OE_[#EU_Z!%7M/Q6_9S^'GQNOK"\\:^'O[:N+"-HK9_MMQ!L
M5B"1B*10>0.N:W/AE\*?"WP=\-G0/"&E_P!D:29VN3;_ &B6?]XP 9MTK,W(
M4<9QQ3H_NX2B^M__ $JXJW[R49+I_E8ZVBBB@84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV?&3XC^+O%NOZA9:)IU[]EM([(J9-I9_*C0N&"HB*"?EY+9ZDFO4?V78-?\
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M0Z3IL9'F3$&:XD8[I)I& &79B2>PX    '=T44 (WW37Y_?\$X?^3@OVCO\
ML+_^W=W7Z M]TU^?W_!.'_DX+]H[_L+_ /MW=T#/T"HHHH$%%%>%?M@ZA=:;
M\.=*DM+F:UD.K1J7AD*$CRI>,CM3 ]UHK-\-LTGAW2F8EF:UB)8G))V"M*D
M4444 %%%% !7S-X?_P"4AGB;_L08O_2R.OIFOF;P_P#\I#/$W_8@Q?\ I9'0
M!],T45YG\=/C-%\(/#]O-%;+>ZM?,R6MO(2$&T#<[8YP,C@<DD=.M<F*Q5'!
M498BO*T8[G=@L%7S'$0PN&CS3EHD9?P3_P"1^^*?_86C_P#0&KV"OA+X>_M)
M:UX,\5:MJ=S96E[;:S=+<7\*J48$9&8SGC@]#FOH/4OVNOA]8PH\$^H:BS*"
M8[:T*E3CH?,*C(Z<$U\;DO$&6_5'&=51<7+26F\FU;OH^FQ^@<1<*YO]>4Z=
M!S4HQ5XZJ\81B[]M5I?<]JHKY=UC]MR!0RZ5X5D<_P ,EY=A<?554Y_[ZKS3
MQ3^W-XDB+@W^@Z HZ *#(/\ OXQR?PKLJ<697%\M*4JC[1BW^=C@I<#YS*//
M7C&E'O.27Y7/N74-1M=)L9[R^N8;.S@0R2W%Q($CC4=69CP![FOR._;_ /C!
MI7QQ^,VGIX/U.3Q#HFDZ>MLCVT;F/[09',ICX^8$",;AP=O&:]VT2S^(7[6>
MG[S-<>(-!A?>+C4(_(T]GSU0%0DC C^ -M]LUZ%X?_8?UA8U2_U[3=-CZ[+&
M!YL?@=@K+^WL?7_W3 3?G)J'Y_YFO^K.68;_ '[,Z:\H)S_+_(_,C3/AMXJO
MG22WT:ZC(.Y6F A_'YR*_6'PS^U]H&A^ _#MKJ%OJFK^((=,MH[Z140(UR(E
M$N79LGY]W(!S7 ?LV_!'0/BD?&\FN2WI/A[Q)=Z)$EK*L:3)"0-[Y4D$YZ C
M%?1VC?LZ?#O1 IB\-6]RXZM>.\^?P<D?I1?B7$[*G27SD_U0<O"&$W=:L_E&
M/Z,^,OC%\4+CXK>+Y-6>*2ULTC6*VM'DW^4H'/8#).3T]!VKCM/M3?7UO;A6
M<RR*@5/O')QQ[U]N_&+]G'PUXPTDWMA''X=OK&!MK6-NHB=%!.UHQ@?0@CKW
MKC/V:?@%HTVDZ-XXU&YDO[J0M+;690+%"RNRACR2YRN1T ]#7YYBN&<RKYI[
M*M)2<[R<O*ZN[;Z72M]VA^K8+C')\-DWMJ$7!4[04+-N]FXJ^VMF[W]==_;_
M (>_"WP[\,=.^RZ)9".1QB:\F.^>;_>;T]A@>U=;117[G1HT\/35*C%1BMDC
M^;<1B*V*JRK5YN4GNV[L****V.<\N_:B_P"3<?B5_P!@"\_]%-5W]G7_ )(+
M\/?^P%9_^B5JE^U%_P FX_$K_L 7G_HIJN_LZ_\ )!?A[_V K/\ ]$K0!Z)7
ME7[3?_)(M1_Z^;7_ -')7JM>5?M-_P#)(M1_Z^;7_P!')7CYS_R+<1_@E^3/
M>R#_ )&V%_Z^1_\ 2D>GV?\ QZ0?[B_RJ:H;/_CT@_W%_E4U>M'9'AR^)A11
M15$A7S%^W/\ \@SX5?\ 8Z67\GKZ=KYB_;G_ .09\*O^QTLOY/0!].T444 >
M/?%#_DMWPQ_W[K_T%:]AKQ[XH?\ );OAC_OW7_H*U[#7B8#_ 'G%_P"-?^D0
M/H\T_P!SP/\ U[?_ *<F%%%%>V?.!1110 4444 ?*7[8G@'3=+M],\0Z=I<5
MM<7$[17EQ I7><94L!QG@_-C)KY>K]._$7AO3?%NCW.E:M:1WMA<+MDAD_0@
M]00>A'(KYH\&?L_^$KGXV>)-$N8;JZTO2H(;B"WDFX9F/(<@ D>V?KFOQ[B3
MAJM7S"-;#<J55I6VL[-MZ+JE?O<_?.$N+Z&&RN>'QBDY44Y7WO&Z26KW3=K;
M6.3^''[4FM_#GPY8:+>Z%%J5E;J1#(TKPR%"<XR0P(&>.*]6T/\ ;-\(WV%U
M+3=3TR3NRHDT8_$$'_QVO<YM%T^YL8[*:QMIK.-0B6\D2M&J@8 "D8QBN*US
M]G_X?>(-WVCPO90,W.ZR#6Q!]?W9 KZ:EE>>X&G&GAL7&<4K)3C;\5=GQU;.
M>&\RJ2JXS RIRDVVX3OOUL[(?H?Q[^'_ (@Q]F\4V,3'^&\8VQ^G[P+7;V=_
M;:E )K2XANH6Z20N'4_B*\$US]B_PI>[VTS5=3TV0]%D*3QC\" W_CU<1=_L
M>^+_  _.;CP[XHM9)%Z/NEM)#]-N[^=:_P!HY]AO]XP:FN\)?H[LQ_LKAK%_
M[KCY4WVJ0O\ BK(^NJ*^/EM/VA? ?W'U/48$_P!N+4-P^AW/_(U);?M:^._"
M\RV_B7PU;R,IP5F@EM)3ZYSD?^.TUQ5AJ6F,HU*3_O1=OP_R$^"<967-@*]*
MNO[LU?[GI^)]>TR;_5/_ +IKYYT/]M3PW=X75=#U'3G/>W9+A!]22A_2J'Q-
M_;!L;6S@@\%1)?7$RYEN;Z%U6'_9"<9;WSCZUV3XFRF-%UE732Z=?N>IY]/@
M[/)8B-!X9IOJ[<J]9*Z._P#V:?\ D0]1_P"PQ=_^A"O6:^-/V?OVBF\(WJ:!
MK<%N-)OKMYC?+E7@DD(R6YP4S[#'O7U7_P +!\+?]#+H_P#X'Q?_ !59\/9G
MA,1E].,)J\$DT]+,UXIR;'83,ZDJE-M3;::U37R_(Z"BN?\ ^%A>%O\ H9='
M_P# ^+_XJC_A87A;_H9='_\  ^+_ .*KZ3ZS0_G7WH^1^IXG_GW+[F=!17/_
M /"PO"W_ $,NC_\ @?%_\51_PL+PM_T,NC_^!\7_ ,51]9H?SK[T'U/$_P#/
MN7W,Z"BN?_X6%X6_Z&71_P#P/B_^*H_X6%X6_P"AET?_ ,#XO_BJ/K-#^=?>
M@^IXG_GW+[F8?QV_Y)#XI_Z\S_Z$*W? /_(CZ!_UXP_^@"OEGXZ?M.7/B1M5
M\,Z#!;C0WS;RWD@+R3X/)3G"KD>ASUKO/V?/VCK+7K.+P[XB-II-U9P!;>[,
MGEPRHH PQ8\-CWP?:OC*&?Y?6SB4(U-XJ*?1M-O?YZ/J?H.)X7S7#Y#&I.EM
M-S:ZJ+C%:KY:K==3Z)HKG_\ A87A;_H9='_\#XO_ (JC_A87A;_H9='_ / ^
M+_XJOL_K-#^=?>C\^^IXG_GW+[F=!6?X@AU&XT/4(M(N(K35'@=;6>9=R1RE
M3M9A@Y ..U9,WQ.\'6S!9O%FAQ,>0'U*$?S:H_\ A:_@G_H<= _\&D'_ ,74
M_7,,M'4C]Z+6!Q;U5&7_ ("_\CY6^(W[./[3/Q8\+MX?\2_$KP?>:8TT=PT<
M=BT1WQL&4[E@!ZBO1?AOX!_:1T3Q9H;^*?B'X6U/PM;2*+RQL]/V32Q!2-JM
MY(P<X[CI7LG_  M?P3_T..@?^#2#_P"+H_X6OX)_Z''0/_!I!_\ %TOKF&_Y
M^Q^]#_L_&?\ /F7_ ("_\CJJ\>_: _Y"_P ._P#L.I_Z":VO&_QZ\(^%/#-Y
MJ5IKNEZU=QKB&QLKZ.221SP!A22!ZG%?(WBK]H;Q9XPUC3;V_:S\O3KL7EK:
MQP 1HP[$YW$8]37R'$6>X'#T?JSGS2E9Z:V2DGK]Q]YPKPUF6*Q'UQ0Y80YE
M[VC;<6M%;S7D?H!17%_"7XDV_P 4O!UOK,4/V6?)BN+?=N\N0=<'T/4?6NTK
M[2A7IXFE&M2=XR5TS\]Q.&JX.M/#UXVG%V:\T%%%%;G,%?,/Q^_Y.U^ 7_76
M^_\ 11KZ>KYA^/W_ "=K\ O^NM]_Z*- 'T]1110!X\W_ "=&G_8!/_H8KV&O
M'F_Y.C3_ + )_P#0Q7L->)E>^(_Z^2_0^BSG_F%_Z]0_4****]L^="BBB@#Y
MK^$O_)ZGQJ_[!FE_^@FOI2OFOX2_\GJ?&K_L&:7_ .@FOI2@#SCQUX(\=:]K
MS76@>.O^$?T\QJHL_L*388=6W'UKS#X>Z?\ %'Q\NM&/XD-9?V9?O8G=I\;^
M85 ^;MCKTKZ6KQW]G/\ U?CC_L/S_P A7R>,P-.6.HKGFE/FNE.:6BNK)2T^
M1]QE^958Y;7E[.FW3Y%%NG3;U=G=N.OSN>G>&-/U#2]!LK75=0_M74(H]LUY
MY83S6]=HZ5J445]3"*IQ4%LOG^)\74FZDW.6[UT5E]RT044459F%?-'_  3]
M_P"2%W/_ &';_P#]'&OI>OFC_@G[_P D+N?^P[?_ /HXT ?2]>)^,-7^,OA^
M'5]3A'A<Z39K).@82F7RER1D=-V!7ME<O\4/^2<>)_\ L'3_ /H!KR\QHNK0
ME*-247%-^Z[=.I[64XB-'$QA*E&:DTO>5[:]#S+PGKWQJ\4:3I>KQ#PL-.O8
MTG 991)Y;<],XSBO<TW;%W?>QSCUKCO@S_R2?PG_ -@Z'_T$5V=9Y71E3P\*
MDJDIN2B_>=^G0TSG$1JXJ=*%*,%"4DN56OKU[[&=KGAO2?%%F;36=+LM6M#U
M@OK=)HS_ ,!8$5XQXR_8;^"?C8N]QX&L]+N&Z3:-(]EM]PD;!/S4U[Q17L'@
MGPGXP_X)0>$KYI'\,>-=7T<GE8M2MX[Q![97RCCZY/UK\\OB9\/]1^%OC[7/
M"FJ\WNE73VSR*I59 #PZY_A88(]C7[\U\H?\%!?@OX-\1?!7Q-XZO-%B/BS2
M+>$6NIQ,T<FTSQH5?!PXVL<;@<=L4 ?F#\'_ !9XF\!_$/2?$OA&R>_US27-
MS%"MN\ZE=I5]ZISM*L0<$=>HK[5\)_\ !6#4;6;[/XO^'L+NIQ)-I-XT+*1U
M'E2*W_H8KZO_ &:?V=_ GP:\)V&H^&M&$&K:G9127>HW$C33R;E#%0S?=7/\
M*@#@9S7HWBKX;^$_'4;)XC\,Z1KRD8_XF-C%.?P+*<4 ?._@_P#X*6?!CQ+L
M74;S5O#$K<$:GI[.N?\ >@,G'N<?A7N/@_XZ_#OX@,B>'?&VA:M._2W@OX_.
M_&,G</Q%>3^,/^">?P1\6+(8O#4_A^X?_EXT>]DC(^B.7C'_ 'S7A_C#_@DU
MIDN^3PKX_N[7'W;?6+%9L_62-DQ_WP: /T"HK\PQ^Q]^U+\&PS>"_%DFH6T?
M*V^B:\\2L/>&?8A..W/MFC_AJK]K'X,X/B_PO=:I91##3:UH+"+ _P"F]N$!
M/N6/OF@#]/**_/;P?_P5FMF9(O%7P_EB'\=SH]^'/X12*/\ T.O;_!__  46
M^"7BORTN-=O?#D\G BUBPD7!]WCWH/J6H 9^UM_R5S]GK_L9Y?\ T6M?3M?E
ME^U)^W99^.OBAX3O/!VCQW&G>"]3>\L[^^=MNH.0%)\L8*1\<<[CU..E?8_[
M)?[7^D_M-:7?6TFG_P!A>*=-57NM/\WS(Y(R<"6)B 2,\$$94D<G() /H:BB
MB@ HHHH **** /+/CE\+?&GQ,BT9?!_Q,O/ARUFTQN6L[ 77VL/LV YD3;MV
MMZYW]L5\M6'@'XUWW[0NI_"__AH36D^Q:*FL?VK_ &4IW[G5/+\KSN/O9W;^
MW2OOBOF/0?\ E(5XF_[$J'_T>E 'JGP1^''BWX;Z+J%IXN^(5W\0[NXN/-AO
M+NR%L8$V@>6%$CY&03G(ZUZ1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO\*[_P 8?\$ZO!5[X-TC2?!^LW_@W5[ 21RZXB_:)K^.0 2+< -'N! X *@
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MWI )XS\H*@CC:QKZC_9]_P"";/A#X>_9]6\?2P^-->0AQ9[2-.@;TV'F;ZN
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MO*OVF_\ DD6H_P#7S:_^CDKQ\Y_Y%N(_P2_)GO9!_P C;"_]?(_^E(]/L_\
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M_P  5_\ BZ/^&(;+_H;;C_P!7_XNOIVBC_57)O\ GQ^,O\P_UVX@_P"@E_\
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M . P_P#D3YH@_8CTI5/G>*+R0YX\NU1?YL:E_P"&)=$_Z&74/^_"5])45?\
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M*\3%?[_A?^W_ ,D?18'_ )%F,_[A_P#I3/8J***]L^="BBB@ KYH_P""?O\
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M>%_L0_\ 'C\8_P#LHFJ?^@0U]+4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:.R/#E\3"BBBJ)"BBB@ HHHH \>^*'_);OAC_OW7_H*U[#7CWQ0_Y+=\,?\
M?NO_ $%:]AKQ,!_O.+_QK_TB!]'FG^YX'_KV_P#TY,****]L^<"BBB@ HHHH
M *\=\#_\G%>/?^O&VKV*O'? _P#R<5X]_P"O&VKQ,Q_C87_'_P"V2/H\I_W?
M&_\ 7K_V^![%1117MGS@4444 %%%% !3)O\ 5/\ [II],F_U3_[II/8:W/*?
MV:?^1#U'_L,7?_H0KUFO)OV:?^1#U'_L,7?_ *$*]9KQ\F_Y%U#_  H][/\
M_D:XC_$PHHHKV3P HHHH **** .#^.W_ "2'Q3_UYG_T(5N^ ?\ D1] _P"O
M&'_T 5A?';_DD/BG_KS/_H0K=\ _\B/H'_7C#_Z *\6/_(UE_P!>X_\ I4CZ
M"7_(FA_U]E_Z1$WZ***]H^?"BBB@ HHHH *\>_: _P"0O\._^PZG_H)KV&O'
MOV@/^0O\._\ L.I_Z":\3.O]QGZQ_P#2D?1</_\ (RI^DO\ TB1[#1117MGS
MH52U;1K#7K)[/4K*WU"T?[T-S$LB'\"*NT5,HJ2<9*Z9492A)2B[-'@_C?\
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MF*\@CG@E2>&0;DDC8,K#U!'45+7ZW>^J/PMIIV84444Q'S7\)?\ D]3XU?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P 3"BBBO9/ "BBB@ HHHH X/X[?\DA\4_\ 7F?_ $(5N^ ?^1'T#_KQA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC$5O!&L4<:]%51@#\A6'X#^'/AGX7Z!'HOA71;30]-0[O)M4P7;&-SL<L[8
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M&ZUC4L&:Z.QA&$)(7[^W*Q[R,<L!P:4G4=ET^Y$M*FF_^'9]1T445)04444
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M%%% 'CWQ0_Y+=\,?]^Z_]!6O8:\>^*'_ "6[X8_[]U_Z"M>PUXF _P!YQ?\
MC7_I$#Z/-/\ <\#_ ->W_P"G)A1117MGS@4444 %%%% !7CO@?\ Y.*\>_\
M7C;5[%7CO@?_ ).*\>_]>-M7B9C_ !L+_C_]LD?1Y3_N^-_Z]?\ M\#V*BBB
MO;/G HHHH **** "F3?ZI_\ =-/IDW^J?_=-)[#6YY3^S3_R(>H_]AB[_P#0
MA7K->3?LT_\ (AZC_P!AB[_]"%>LUX^3?\BZA_A1[V?_ /(UQ'^)A1117LG@
M!1110 4444 <'\=O^20^*?\ KS/_ *$*W? /_(CZ!_UXP_\ H K"^.W_ "2'
MQ3_UYG_T(5N^ ?\ D1] _P"O&'_T 5XL?^1K+_KW'_TJ1]!+_D30_P"OLO\
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MY5XP^ 7C3X,ZJWB'P-J%U?V<1W?Z/_Q\QKUVR1CB1?H/JHKZ1^#/_))_"?\
MV#H?_0179U\[_8&"QV"H-1Y)J,;2CHT[>6^O<^I_UHS'+<PQ"<_:4Y2DI0G[
MT6KVZ[:=OQ1\\?"G]K73=>:+3?%Z1Z-J/W!?+D6\A_VN\9^N1[CI7T)#-'<1
M)+$ZR1N-RNAR&!Z$'O7E'Q6_9Q\-_$E9;R!%T77&Y^VVZ?+(?^FB=&^HP?<]
M*\$LM>^)7[+^II9W\)O_  \[X2.1B]I+S_RS?K&W7CCU*FN19EF&1OV>:1]I
M2Z5(K5?XE^OYG?+*,JXC3JY++V5?K2D]'_@E^G_I*/M6O!_VZ/\ DU'X@?\
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M %%%5M02:2S=;<D2G&"#CN.] %FBN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
M\]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__
M #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHK
MG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>
MC['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H
M Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\ [^__ %Z .BHKG?L>K_\ /1_^
M_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\ \]'_ ._O_P!>C['J_P#ST?\
M[^__ %Z .BHKG?L>K_\ /1_^_O\ ]>C['J__ #T?_O[_ /7H Z*BN=^QZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%U3P#=PW)@33]58F25 JGS!E%XR2.G\)KT*BB@ HHHH **** "BBB@ HHHH
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M7-C:KEY;)>B6@4445ZIX@4444 %>/^*?^3E_!_\ V![C_P!":O8*\?\ %/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)<MYGG.=[G+<^5TKW;0TU"/1[-=5DAEU(1@7#V^?+9^Y7(''X5>HKEP.74\
MN6G.35K6<FTO0Z\QS6KF;YJU."E>[<8I-^KZA1117JGBA1110 4444 %%%%
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M.(ZBBBO:/G@HHHH **** "O'_%/_ "<OX/\ ^P/<?^A-7L%>/^*?^3E_!_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP^60*&V_@:GHH C9',)02$/MQYF!G/KBFV<,D%K''-,;B51AI2H&X^N*FHH
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M8/3WI4AE6ZDD:;=$P 6+;]T]SFIZ* *\D,S7D<JSE854AH=H^8^N:+JWFF>
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M;1WUTMTL_,_6N*^*LYP;@L'1E1AHW.4;IN44^7WHM*VJ?6Z>UCYQ_P"&'?\
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MA9,J!L4]%XZX]:L44R2O%#,EW/(UP7A<+LAV@;,#GGOFK%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3(9DN(DEB=9(W 970Y
M# ]"#W%.9=RD'H1BOB#5?V>?CQ^S;=3WGP9\72>+/"YD,I\,ZP49XP3DJJOA
M#[M&8V/3!J>:SM+8JUUIN?8/CWP3IOQ'\&ZOX9U?SCIFJ0-;W'D/L?8>N#@X
M-4OA7\,M%^#W@?3_  GX?%P-)L3(81=2>9)\\C2-EL#/S,:^-;7_ (*4>)_
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MF2RN9))+:)F9CDDE 236A0 4444 %%%% !1110 4444 %%%% !1110 4444
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M+>:1CZ!5<DUV= !16;X@\2:1X2TJ;5-<U2RT;382HDO-0N$@A3) &YW( R2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!6U#3;35K5[6^M8;VV?AX;B,2(WU4C!KBI_P!G
M_P"%]U,99OAOX1EE)R7DT*U9C^)CKOJ* ,?P]X-\/^$83%H6AZ;HL3=4T^TC
M@4_@@%;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 (WW37Y_?\ !.'_ )."_:._["__ +=W=?H"WW37Y_?\$X?^3@OV
MCO\ L+_^W=W0,_0*BBB@05X%^V=_R332?^PO'_Z)EKWVN(^+7PMM?BUX>M=)
MN[Z:PC@NENA)"@8DA&7'/;Y_TIH#I/#'_(MZ3_UZ0_\ H K3JOIUFNG:?:VB
ML76")8@QZD* ,_I5BD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !16!\0/$[>"? ?B3Q$D NGTG3;F_$#-M$ABB9]N>V=N
M*_+;X)_\%BO'^N_$KPU9_$'PGX8L_!6JWZZ?/J6E6]U;R6Q8H#)ODGD1A'YB
M,RX!P>HXHI_O*OLH[Z?C>WY!/W*?M7MK^&Y^M%%("& (.0:6@ HK\U/VQO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:I =4NI !F224[@3]$V+]%%?G%^W+X9G\,?M0>-%F0K'?31W\+=G22-22/\
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M+CQ+B6UL$AB,LGFS1/""BCJP\S('J!7[6?&;_DD/CC_L!WO_ *(>OR,_8O\
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MO$T_/\+_ -?,\#\ ^)_CY^UQX5TWX:Z+J4CZ!I$/E7^I32M#'(A)V"[FY:3
MPH1020N2#C(Y3X_?L8^.?V>/#MIKVMW.E:KI,\XMFN-+ED;R9""5#AT4@'!P
M1D9&#C(S]5?\$I_^1#\>?]A*W_\ 11KTG_@H]_R:_JG_ &$;/_T91B/W=FMW
MRW\[V_S"A[]T]E>WRO\ Y'F7_!,'XP:KXBT?Q'X#U6[DO(-(CCO=-,S[FBA9
MBLD0S_"&V$#MN-=A_P %!/VG-5^#?AW3?"GA6[:P\1ZY&TLM]'_K+2U!VY0]
MG=L@-U 5L8."/!_^"5O_ "5OQ?\ ]@/_ -N(ZY7_ (*823/^TD%E+&--&M1$
M#T"[I"<?CFC%>][._P!K?Y7_ ,E<6'T=3^[M\[?YLJ?LY_L/^*/VE-!N/&&I
M^)$\/:1<3R+#>7%NUY<WD@.'?:73Y=V1N+9)!X[UD_'W]F?QK^QQK^B>(M,\
M2-=V<TQ2RUS3@UK-%,HW;'3<=I(SC#," <^E=!\'_ W[5FI?#C1;KX?W&K1^
M$)8W:P6UUJS@CV[VW81Y0P^?=U K0\<?L[?M<?$O28]+\4V&IZ[I\<PN$M[S
M7K!T60 @,!Y_7#,/QIU+QE^[TL$+23Y];_TC[8_8V_:!G_:"^$L>I:IY:^(]
M,F^PZEY:[5D< %)0!TWJ>0.-P;'&*^//^"A_[2FL>(OB!??#;1;^6R\.:1MC
MU!;=ROVVX*AF5R.J)D#;TW!B<X&/=/\ @GO\!OB)\#W\;Q^-M#_L6VU$6C6J
M_;8+CS'3S0YQ$[XP&7KCMC/-?GS^T#)+-\>/B"UP6,I\07V[=P?]>]362G6A
M%;-7^>GZMET;QIR?5.WR=W_P/O/;?@Y_P3M\;_%?P%:>*9]9TWPY;ZA%Y]A:
MW:/)++&1E7?:,(K#!'4X.<5Y3\?M#^(GP]U'2?A]\0)7G/AU)#I<K.94:VE*
M\Q2'EHLQ_*" 5^88&,#]H/",45OX5T6*W55@2RA6-4^Z%$:@ >V*_/O_ (*O
M*/\ A)/ATV!N-I>@GO\ ?B_QHK^Y548[7M^#U]14/?I.3WM?\5^!ZY_P3!_Y
M-]U/_L/7'_HJ&OKZOD'_ ()@_P#)ONI_]AZX_P#14-?7U=-?XEZ1_)'/1^%^
MLOS84445SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@!&^Z:_/[_@G#_R<%^T=_V%_P#V[NZ_0%ONFOS^_P""</\ R<%^T=_V%_\
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M 5=9%#*0RGD$'(-<E\8=.N]8^$GC:PT]&DO[K1+V&W5#AC(T#A0/?)%?E/\
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MCCY(\1!B!U8Y).% BG%S51R=E%K\MOGW\BIR48TYQ5^:_P"FOR5]/,H?!O\
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M&6:-(D<3*9(8CM)=E^[C*'DU\1?LV_\ *83XN_\ 7OJ/\[>OTT\3?\BWJO\
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M%>4_\%!OVW/A5^UMX3\-'PKX7\0Z/XRT:^WIJFJ6UO&#:,C;XM\<SM_K/+8
MC PW(SSJ[4I)?$KV?^:_X/\ P"(WJ)OX7T_R?_ _X)^WE%<-\"]>U+Q5\%/
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_)L/P\_[!H_]#:LO]N/P0/''[,WB^)8_,N=-B75(>,E3"P9R/^V?F#\:]?\
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M[7F*G@GJ#11_=XCVKVT_!O\ S"I[]'V:WU_%(]IK\Q_^"J'_ "5[PG_V _\
MVO)7Z<5YC\5/V:?AO\;-8M-4\:>'/[9O[2#[-#+]NN8-L>XMMQ%(H/)/)&>:
MRG%RE%KH_P!&OU+C)14D^J_5,\P_X)R_\FNZ/_U_WG_HTUYA_P %6O\ D2?
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M&OB739-+T*Z$UKHEN@/D)'&R^8$8_?.77<^.3P,;<#]-K']AWX':?JJZC%X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/'+&PRK*PX(((((K2_NM6,_M)W+5%%%04%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "-]TU^?W_!.'_DX+]H[_L+_P#MW=U^@+?=
M-?G]_P $X?\ DX+]H[_L+_\ MW=T#/T"HHHH$%>!?MG?\DTTG_L+Q_\ HF6O
M?:\*_;!T^ZU+X<Z5':6TUU(-6C8I#&7('E2\X':FMQ,]B\,?\BWI/_7I#_Z
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M_&[P/\<+'5[[P+X@M_$ECI5\VG75U:(_DB=45RJ.R@2#:ZG<A*G/!KY*T?\
MX(T_ ?2]52[N=1\9ZO;JV38WFIP+"P]"8K='Q]'!KZ[^$_P<\%_ WPG'X:\"
M^'K3PYHR.93!:ABTLA !DD=B7D<A5&YR3@ 9XJE;5OY?\'Y$:Z)'YN?M1_\
M*7[X2?71_P#T9+7ZK5X)XZ_8O\"_$+]H[PW\:M3OM<C\5:"L M[2VN8ELI#"
M6*&1#$7)RYZ. <#WS[W4T_=H*F]^:3^3:L$E>NZBV<8K[KW_ #/+?VH/@_#\
M>/@%XV\$2(C7&IZ>_P!C9^B728D@;\)$3/MFOQCTK]K"_P!+_8'U?X"GSU\3
MR>)%LXK?:PD73G8SR(/]K[0A0KZ2XK][J^29/^"8OP=D^/7_  M8R>(!JW]L
M?VX='^UP_P!FFYW^9G9Y/F;?,^;;YF,\=.*B,$ZCC/X)6O\ *2?XJZ?EH;.;
M4$X_%%MKYIK\-&O,]?\ V5?@[%\!/V??!/@E8U2[T^P1KYE_CNY,R3M[_O';
M'L!7YM?M41Z'\3O^"IVE>$OC-J<EC\-[1+>"UCNKAK:V\IK3S57S-PV+)<$J
MS@@]LC (_7RO$?VCOV./A?\ M36]J?&^BR-JMG&8K76M-F-O>0H3G:&P5=<D
MD*ZL 22 "36DYN5>-=J]FW;U[>:Z&=.*A1E1ONK7^[\^IP?Q@\%?LF?L_?#N
MXUCQ/X&^&VG6B6S?9(WT.RN+R[;;\JPJ4,DK$XYYQU) R:^9O^"'[*^D_%]D
M&U#=:<0,=!MN*]\^$_\ P2A^ WPL\10:S)8:SXSN[>19;>/Q/>1S01,.A\J*
M*)'^D@8>U>N_LZ_LF^#?V8]0\9W?A.\UBZD\57JWUZNJ3Q2+$RF0A(A'&FU1
MYK?>W'IS5TWR.;;OS1MZ:I_CK?T7<BI>4(Q2V=_P?_ ^_P CX5_X*O\ _)UW
MP!_[8_\ I<E?JI7@G[0'[%_@7]I#X@>#/&'BB^URUU/PJRM:1:7<Q1PS 2K*
M%E#Q.2-R_P )4X)YZ8][K&BN2@J;WYIOY-W1=3WJSJ+;EBON3N%%%%4 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '@G[5W[+'_  T]I_AVU_X2?_A&O[(EFEW?V?\ :_-\P(,8\U-N-GOG-7/V
M5?V:/^&9?"^M:/\ \)'_ ,))_:5XMWYWV'[+Y>$";=OF/GIG.17M]%$?<NH]
M=_Z^02]ZU^FW]?,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%?GW^W1^U-\4/@Y\;(= \'^)_P"R-);28+DV_P#9]K/^\9Y
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M7'Q(_P""E7Q*\7:T]MX&LK3POI[2;+8"V6\O9.<#<7#)D_W53C.,GK6)H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM.EM;CG^]<Q CKZ9K.M+FP\:D=')?B]"J,>7$.D]5%_A_7X'RA\.?B7^V?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBI^=OR96_P""I/AW3KCX/>'=<>UC.JVNM):Q76T;Q%)#*S)GK@E%./45Y_\
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M7Z+_ +&?P]TKX?\ [.W@X:?;QQW&K6$6J7MPJC?-+,H?+'OM#!1Z!17Y[?\
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M*^ KOPG^T=J6K/$PL/$-O#>V\V/E9E18I%SZAD!QZ,OK7UE^R/#\#/B[\(M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS;2^MR%N+23&-Z,01R."I!!]. 1\*>*/^"5GC2WOV'ASQCH.HV6?E?5%GM)
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M[/\ X-&@>&H9&$C^==WUR0T]U+C&YR !@#@*  ![Y)]%HK3F:5D9\J;NS/\
M$6A6GBC0-2T>_C\ZQU"VDM9XS_%&ZE6'Y$U^9=U_P2T^*"W4PMO$7A%[?>?+
M:6[NE<KG@L!;$ X[ FOU$HK/E7-S=33F?+RGGWP#^%<?P6^$?AOP@'BFN-/M
M_P#2IH,[);AB7E89 )&YCC(!P!78>(O#VF^+-#OM&UBSBU#2[Z%H+BUF7*2(
MPP0?\\5HT5=1^T;<NI$%[-)1Z'Y[?$[_ ()8S3:E/=> /%EO#9R,633=>1QY
M(]!/&&+#TRF?4GK7)^'_ /@E;X\N+Y%USQ?X=T^SS\TNGBXNI!]$>.(?^/5^
MFM%3%<I3U/*OV?/V<?"W[.?A>72] 66[O;ME>^U2ZQYURP!P..%09.%'3)R2
M<D^2?MM?LG^+OVDM6\)W7AG4=%L8])@N(YQJT\T98R-&5V^7$^1\ASG':OK"
MBG/]XU*73_*P1]Q-1Z_\.>$?L<_ C7_V>OA;>>&_$=YIM[?3:G+>K)I<LDD6
MQDC4 ET0YRA[>G->[T454I.3N_ZMH1&*BK+^KZGQA\??^";F@_$37[WQ#X*U
MA/"FHW;M-/IL\!DLY)#R60J0T63R0 P] *\-M?\ @EE\3&NE6X\3>$XK;/,D
M4]R[@>NTP 9_X%7Z@T5G&*CHMC24G+5GS9^S+^Q#X8_9YU$Z]<:A)XF\5F,Q
MI?RPB&*V5AAA%'EL$@X+%B<=-N3GZ3HHK24G+<S45'8****DH**** "BBB@
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M^) N>H#D.,=1*#11^W2_[>7_ +<OU8ZOV*G;W7^:?Z'V=7B_[87P]\0?%/\
M9_\ $7AOPOI_]IZU=O;&&U\Z.'<$G1F^:1E4852>3VKVBBIE%25F7&3@^9'@
M7[$?PO\ $_PA^!EOX>\6Z9_9.L+J%Q.;?SXIOD8KM.Z-F7G![U[[116DI.3N
M_P"K&48J*L@KX:_;9_9M^(WQ=^.GA3Q#X2\._P!K:/8Z?;P7%S]NMH=CK<RN
MPVR2*QPK*> >M?<M%2M)QGUB[E/6$H=)*P4444 >-?M70?$;5_A1>Z#\,]%?
M4];U@_9)[I;R"V^QVY'[Q@977+,/E&W.,D\8%:W[./P3L/@'\*]*\,6PCDO@
MOVC4;I!_Q\73 ;V^@P%'^RHKT^BB/N\UNOZ=/3KZA+WN6_3]>OKT.2^*_P .
M-.^+GP[UWPCJK-'9ZI;F$S*H+1."&20 ]2K!6_"OCSPGX*_:V^"/A:7X>^%M
M,\/^(= A,D=AKTMS%YMI&Q)^023(1@DG#1O@G R *^\**GEU?GOYE<VB7;8\
M%_9%_9ME_9Y\&ZC_ &Q?1ZKXMUR<76J7<1+(",[8U9@"P!9B6(&2Q]JRO^"@
M7C9/!_[,_B"W$@2ZUJ6'3(5SR=SAW_\ (:/^=?1]?!?[3!F_:J_:K\*_"/27
M:7P_X:)NM<N(N51CM,V3ZJFR,>CR$45$ZTHTEULO1+?Y6T"FU23J/IKZM[?.
MY[A^P=\/Y/ /[-?AM;B/R[S6#)JTJD8.)2/+_P#(:Q_G7T)4-G:0V%K#:V\:
MPV\*+''&@PJ*!@ #T %35M4ESS;6WZ=#&G%QBD]_UZA11169H%%%% !1110
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M'P4_Y]?%7_@MB_\ CU 69]FT5\9?\/8/@I_SZ^*O_!;%_P#'J/\ A[!\%/\
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M'P4_Y]?%7_@MB_\ CU 69]FT5\9?\/8/@I_SZ^*O_!;%_P#'J/\ A[!\%/\
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M'P4_Y]?%7_@MB_\ CU 69]FT5\9?\/8/@I_SZ^*O_!;%_P#'J/\ A[!\%/\
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M'P4_Y]?%7_@MB_\ CU 69]FT5\9?\/8/@I_SZ^*O_!;%_P#'J/\ A[!\%/\
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M8[88FM(VG!SCT=OZ^XB5XS47U5S:HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_+,R$D_6NQ_;%^%6O?&K]G_Q%X1\,QP2ZS?- 85N91$AV2JQRQZ< UO?LU^
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MNXHH X?_ (47\-O^B>^%?_!+;?\ Q%'_  HOX;?]$]\*_P#@EMO_ (BNXHH
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M *)[X5_\$MM_\11_PHOX;?\ 1/?"O_@EMO\ XBNXHH X?_A1?PV_Z)[X5_\
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MNXHH X?_ (47\-O^B>^%?_!+;?\ Q%'_  HOX;?]$]\*_P#@EMO_ (BNXHH
M_.#PW\/?"TO_  5#\0Z _AK1WT*/2=Z:6UA$;96\B(Y$6W:#DDYQWK[G_P"%
M%_#;_HGOA7_P2VW_ ,17@^A_LY>,K']O;6?BO+!9CPA=:=]FCE%R#-O\F-,&
M/KU4U]84#9P__"B_AM_T3WPK_P""6V_^(H_X47\-O^B>^%?_  2VW_Q%=Q10
M(X?_ (47\-O^B>^%?_!+;?\ Q%'_  HOX;?]$]\*_P#@EMO_ (BNXHH X?\
MX47\-O\ HGOA7_P2VW_Q%'_"B_AM_P!$]\*_^"6V_P#B*[BB@#A_^%%_#?\
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M\17$_L8_"?Q!\$?V>/#G@_Q/%!#K5C+=M,EM,)4 DN9)%PPZ_*PKVZ@#A_\
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M);V>.V56E9(U+$*&(!.!QDCZU\K?\/2OA3_T+_C'_P  K3_Y)KZJ\0:!IWQ
M\'7VCZDC3:7J]FUO.L;E2T<B88!AR.#UKYJ\4?L'?L_^"_#NH:[K5C?6&E6$
M+3W%Q+JLP5% ^O)[ =22 *RE>#;ELO\ @W+CRSC'EW?_  +&5_P]*^%/_0O^
M,?\ P"M/_DFOH+X&?'#0OV@/!+>*/#UIJ-GIZW4EF8]3CCCEWH%).$=QCYAW
M]>*_&76-+LOB#\3)--^'WA^ZMK+4+L6^E:6TK3SE3A5W,2?F/WCV&3V&:_8?
M]F/X(I\ /A'IGA9KK[;?[VO+^=3\AN) -X3_ &0 %'KC/>MX).FYR^7K_P ,
M93;4U!?/T_X<W/BM\;_!/P3TN*_\8Z]!I*3Y$$!5I)YR.NR- 68#(R<8&1DB
MOGJX_P""H7PFAN6B32/%EP@.!-'8VX0^_P UP#C\*\3_ &K?V6?CG\9OCKXA
MU^R\+-J&A^8MMIDS:I9HHMD4!<(\P9<G<Q! .6-?1&C_ +!?P,\+^$K33_$&
MDK=ZEY"I<:I>ZK-#*\I'+*%D5%YS@!<<<YYK"%Y0YY?=U-9VC+D7WGH?P;_:
MP^&WQTO/[/\ #6MLFLA#(=*U"$P7!4=2H/ROCOL9L=Z]@K\,O$T$OP0^.>HQ
M>'=2>9O#>M/]AOHW&YUBE^1B1P<J!G'!R>U?N+I]T+^PMKD#:)HED /;(!_K
M6RY9THU8]3-WA4=.7]=RQ7R#^VA\1O@/H'C+1M%^*_@;5_$VJBQ%W:W>EJ$*
M0M(Z[&D%Q$Y^9&.TY'.>I-?7U?EW_P %2O\ DNGAW_L7HO\ THN*YJCM*"\_
MT9T05XS?9?JC[U_9L\6^#?&GP?T74? .B3>'O"V98+73[B%(GCV2,K$A'<$E
M@3G<2<Y/->;_ !9_;\^'WP;^(&J^$-:T?Q-=:EIK(LTMA:V[PMN17&TM.I/#
M#J!SFI/^">/_ ":QX;_Z^;S_ -*'KX!_;N_Y.J\<_P#72V_])HJZ,1>-?E75
M?Y?YF-%*5*4NW^;/TE^(W[87PT^%OAW1]2US59A=ZM90W]MHUK$)KWRI$#J7
M0-M3@_Q, <'!.*XCP/\ \%'/A#XTUR#3)I-9\--,P2.ZUNTC2 L3@ O%))M'
MNV .Y%>(?L\_\$\-.^)?@/3/&/Q$\1ZI)/K%K%<V=GI<R!HX"@\LR22(^X[-
MN%  4 #)Z#YV_; _9ZL_V<_BA#HFE7UQJ&C7UDE]:27A4S("S(R.5 !(*$Y
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M6ZC4%L1JC2S J ,9PHYSUK]4[S4K32]-EOKRXALK&"(RRSW#B..) ,EF8\
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MD<$$'.:\]\0:_P"#_CQX-\4^#?#7CG1+Z^O].FMI9-*OH;V2U5U*>8T<<F<
ML.I'/&:\@_X)N^++OQ-^SA%9WDQG_L?4[BPA+')6+"2JOX>:0/;%> >+_@'\
M9_V4_C=JOC?X6:/+XET.]DE:..T@-UF&1MQMYX%(D.TXPR?W0<@Y%%6,8U/9
MR^%K\UI?[QTI2</:1^)/\GK^1P?QA_9^UK]B'QOX4\82W.C_ !"TR:=A&-5L
M"J^<@!VO$7;!QRK!C@J>!@9_3_X;^-K7XD> ?#_BFRB:"VU>RBO$AD.6CWJ"
M4)[D'(S[5^<?CSPS^TA^VEKVA:?XE\$MX4TO3G;#W&GS:=:P[\!Y6$[&21L
M#"Y]@,DU^CWPZ\%6OPX\!Z!X7LI&FM=(LHK-)7&&DV* 6([$G)_&KC?V34^^
MGIU_3^KD2M[1./;7UZ?U_P  Z*BBBLRPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3RJ_-U"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1DJQ5@0<'L1B@#TZBOR"^#'[2/[>O[0GA>?Q%X 73]?T:&Y:TDN?L^CVV)5
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M/GA$>*/ <>GZ[H1G>V^U>1H]O^\3&Y=DS(W&1SC% 'Z[T5^8']L_\%+_ /H
MZ?\ ]_- _P#CM>J?LQZE^V_<?&;1$^,>DV=K\/BD_P!OEB?2"P;RF\K_ (]Y
M#)]_;]T?7B@#[KHHHH **** "BBODS_@I=^T!XU_9O\ @'I'B?P'J,.F:S<>
M(K?3Y)IK6.X4PO;W+LNV0$ [HDYZ\>] 'UG17YV?\$R?VZ?''[1/CKQ9X/\
MB5JEOJ&JQV,6I:2\-E%:_NU;;.I"* W^LA8=\;NU?HG0 45\[_MZ?M$W?[,W
M[.>L^*='GC@\374\.FZ.TL:R*+B1MQ8JP(.V))6Y!&5 [U\X?\$Q/VR/BI^T
MM\1/&6D?$#6K?4[/3=,CN;>.'3X;8I(9=I),:@GCL: /T7HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^7W_  4I_P"3F)_^P1:?^SUIB_XZ_P 3_)F>%_@?]NK\T?>O[$O_ ":S\/\
M_KSE_P#2B6OE;_@J]_R,7PY_Z]+W_P!#AKZI_8E_Y-9^'_\ UYR_^E$M?*W_
M  5>_P"1B^'/_7I>_P#H<-/%_P ?_MY_DPPG^[_]NK\T>M_\$P?^3?=3_P"P
M]<?^BH:^-_\ @H!_R==XR_W++_TDAK[(_P""8/\ R;[J?_8>N/\ T5#7QO\
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MER2Z\WX_\.?-?_!*?5K63P/XZTP2K]MBU&&Y:+OY;Q;5/YHU?6/QSUJT\/\
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M "=/X!_Z^9O_ $GEK]9/C-\*M+^-7PWUGPAJ[-%;W\6([A!EH)5(:.0#N58
MX[C([UIB$Y4(6[W^YIDT9*-9W[6^^Z/A_P#X)1:I;1:[\1=.>11>3VUE/''G
MED1IE<CZ&1/SK[Y\=>,=/^'O@W6O$VJ^9_9VDVDEY.(0#(RHI)502 6.,#)
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MN^$__);_  ?_ -C#9_\ I2E&&_WR/_;OYEU/]UG_ %T9^Z,W^J?_ '37X<_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW-B.VSH \UB ORZM.6_($?G7ZIT ?EM_P5VL9/AC\9O@E\6M#B$&MVL[Q27
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M^5/K\OH_^"+^N,BM_P -"Z@,C/\ R+TG_P G4[_AR[KG_1PNH?\ A/2?_)U
M'Z?T5PGP,^&4OP:^$?A;P3-K#:_+HEDEFVI20F%KC;_&4+OMSZ;C]:[N@ HH
MHH *_)__ (+0,5^)WPA8<$03$?\ ?]*_6"OR>_X+1?\ )3/A%_UPF_\ 1R4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEAM[2UB6.*&-1A415 "@#@ 4 ?F__P %A/ 6K:!=_"WXT:'#(TGAJ^^R7DR
MGRB9$FMG./NJ'21<^LB#J1G[O^"_QK\*?'CX>Z9XP\*:I;WVG7<*O-&DJM)9
MR%06AF'5'4Y!!],C((-=)XO\'Z+X^\,ZCX>\1:9;ZQHFHPF"ZLKI-\<J'L1^
MH(Y! (Y%?"7B;_@C+\,KS6;FX\.>-?%?AC3;HD3:;'+%<(%)^XKLH;;C/WRY
M]Z /'_VW/%FG?ML?MI?"WX0>"KQ-=T?0IV35+^PD#P*TCH]T0ZG#"*&$<@_>
M++U!K]8T18T5$4*JC 51@ >E>&?LP_L9?#?]D_3KQ/!UE<W6KWRA+S7-5D6:
M\F0'(C#*JJB9YVJHR0,YP,>ZT %%%% !7Y,_L!_\I//CE_U\>(/_ $YK7ZS5
M\\?"']A_P+\%?CMXK^+&B:MXBNO$7B1[Q[NUU"Y@>T0W,XGD\M4A5QAA@9<\
M=<GF@#Y5_P""NG@V^\!^+?A+\=M 7R=3T/4$T^XN%&2&1_M%J3CHH99Q]7 ^
MK?V.-7'[8W[?'CSXXRV\Q\,^%K".QT2.X.?)DD0QQC!ZC:+J3V9QTXK[P^/G
MP,\-_M'?"_5? ?BIKN+2-0:)VGT]T2XA>.19%:-G1@#E0.5.02.]87[,?[+O
MA#]D_P "WGA;P?/J=[:7E\U_/=ZQ+%+<.Y14VEHXXQM 08&WC)]: /A?_@MW
M_J?@_P#]=]0_E;U^DOPV_P"2=^%O^P5:_P#HE:\G_:F_8Q\%?M=+X;7QAJFO
MZ:-!>9[;^P[B"+>9-F[?YL,F?]6,8QU/6O;M#TF'0=%L-,MV=X+*WCMHVD(+
M%44*"2 !G ]* +M%%% !1110!^2G_!:1EC^+7PB9B%5;2Y)8G  \Z&OTK_X:
M$^%G_12_!_\ X/K7_P".5YE^U/\ L)^ OVNM8T'4O&.K^(]-GT:"6WMUT.YM
MXE99&5B7\V"0DY48P17AO_#E3X(?]#3\0/\ P8V/_P AT ?7_P#PT)\+/^BE
M^#__  ?6O_QRNA\*?$#POX\6Y;PUXDTCQ$MJ5$[:3?170B+9VA_+8[<X.,]<
M&OA__ARI\$/^AI^('_@QL?\ Y#KZ%_94_8S\%?L@6GB2W\&ZIKVIIKSV\ER=
M<N()2AA$@79Y4,>,^:V<YZ#I0![U1110 4444 ?EE_P6T_X__@[_ -=;[^<%
M?<WQ/^%MO\:OV4=0\&3JN[5/#<<4#L,^7,(%:)_J'"G\*R?VI/V+_!/[6TWA
MJ3Q?JFOZ:V@-*UK_ &)<01!_,*;M_FPR9^X,8QWKW'1],BT72;'3H&=X+2!+
M>-I""Q5%"@G '.!Z4 ?@KX;^-_B3QQ^S)H/[,%K#='Q%=>,X[;R'/6V9LBW'
MH5N1N_&OV4\?>"+#X:_LGZ]X4TM MAHWA6:QAPH&X);E=Q'J2"3[DUY_X2_X
M)U?"SP;^T1)\9+&XUZ3Q"U]/J2Z;/<0'3TGE#;G5!")!AF+C]YPWJ.*^BO&/
MA>U\;>$]8\/WTDT5EJEK)9S26[!9%1U*DJ2" <'C(/TH _.O_@B)_P DS^)7
M_85M?_13U^EE>'?LL_LA^#OV1=#US2O!^I:YJ5OJ]Q'<SMKD\,KJR*5 0Q11
M@#!/4&O<: "BBB@ KQ/]MG_DT;XO?]BU>_\ HHU[97+?%+X=Z;\6_ASXC\%Z
MQ/=6VEZ]8RZ?<S6+JDZ1R*58H65E#8/&5(]J /@;_@D5\5/!7@G]F_6+'Q%X
MOT'0;UM?GD6VU/4X+:0H8H@&"NP.,@\^U?<7_#0GPL_Z*7X/_P#!]:__ !RO
MD#_ARI\$/^AI^('_ (,;'_Y#H_X<J?!#_H:?B!_X,;'_ .0Z /L?3OCG\-]8
MO[>QL/B#X5O;VX<10VUOK5M))*YZ*JA\DGT%=Q7Q%\.?^"1WP?\ ACX\T#Q;
MI?B3QO<:CHM[%?6\5Y?6;0M)&P90X6T4E<CG!!]Z^W: "BBB@ KS?]I+_D@/
MQ#_[ 5W_ .BFKTBL3QMX2L_'O@_6?#FH23PV.JVDEG/);,%E5'4J2I8$ X/<
M'Z4 ?GM_P1(_Y)+\1/\ L,0?^BC7G?[0OB0?L-?\%(5^(AAF7PMXMT^2YN%C
M&$9GC,<@"CKMD6-_JU??7[+?[)'@_P#9'\.ZSHW@_4M;U*UU6Y2ZG?7)X975
ME4J IBBC &#W!JG^U1^QCX#_ &N[/0H?&-SK&G3:-)(]M=Z)-#%,5< ,C&6*
M0%<@'  .0.: / ?^"3/P_O+KP+XV^,.O1%M?\<ZO+(DTG+?9U<L=I_NM(Q_[
M]BO#_P!HC_E,-\.O^OS2?_9J_3_X7?#?1_A#\/=!\&>'TE31]%M5M;;SV#2%
M1R68@ %B22< #)/%>0^,_P!AWP)XY_:2T7XVW^K>(H?%6DR6\L%G;W,"V+&'
M.S<AA+D'/.''X4 ?0]%%% !1110 5^0FI>(-+\,?\%C+_4M9U*TTG3H;[,MW
M?3K#$F;10-SL0!^)K]>Z^.OC=_P2U^%/Q[^)VM^.O$'B#QC9ZOJTBR3PZ;>V
MB0*50*-JO;.PX4=6- 'T+_PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\
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M1+JWBB:,2/)EA+!(2V7/0@8QQ0!ZK#^T)\+!"@/Q*\'_ '1_S'K7_P".4_\
MX:$^%G_12_!__@^M?_CE?('_  Y4^"'_ $-/Q _\&-C_ /(='_#E3X(?]#3\
M0/\ P8V/_P AT ?<?A7QUX;\=6\]QX;\0Z5XA@@?RY9=*O8KE8VQG:Q1B <$
M'!K<KQ']EG]D?P?^R/X=UG1O!^I:YJ5KJMTMY.^N3PRNKA @"F**, 8'<'ZU
M[=0 4444 %?D]_P6B_Y*9\(O^N$W_HY*_6&OGO\ :=_8B\#?M7ZYX<U7Q=JO
MB'3KC0D9+9=%N8(D<,P8[Q)#(3R.Q% &U^U'\(Q\<?V7?%WA!(C-?76D>=8J
MH!;[5$HEB ]"SH%^C&OQ^\,?&;7?CM^S[\*/V8K(W U5O%LD%U)DD_8\J83G
MN$,UQE>PA3K7[SV\*VMO%"I)6-0@+=< 8KYA^%__  3I^%?PD^/4_P 6=$GU
MU]=:>ZN8-/NKB!K"T>?<&\I%A5P KLJY<X!.<T =G^T3X:L?!G['/C_0=+@2
MUT[3/"%U9V\,?W4C2V95 ]L"OF+_ ((G_P#)N/C/_L:Y?_2.UK[J^(G@>Q^)
MG@/Q!X3U26X@T[6[&:PN);1E69(Y$*L4+*P#8/&01[5YY^R[^ROX3_9*\%:G
MX7\(:AK.I6&H:@VI2R:W/%+*)#''&0IBBC&W$:\$$Y)YH ]EHHHH **** /G
M7_@H=_R9?\4_^P='_P"E$5?/O_!)_P"+'@?P;^RNFG^(/&7A_0[_ /MF[D^R
MZEJD%O+M)7#;7<'!]<5]L?&7X4Z3\<?ACK_@77;B]M-(UJ%8+B;3G1)U4.KY
M1G5E!RHZJ:^-/^'*GP0_Z&GX@?\ @QL?_D.@#Z__ .&A/A9_T4OP?_X/K7_X
MY5O2?C=\.M>U*WT_3/'WA?4;^X?RX;6TUFVEEE;^ZJ*Y+'V KXU_X<J?!#_H
M:?B!_P"#&Q_^0ZZOX4?\$G?A'\'OB-X?\::-XB\:W.J:)=+=V\-]?6CP.ZYP
M'"VJL1SV84 ?:E%%% !1110 5\#?\%I/^34_#W_8WVG_ *27E??->0_M/?LQ
M^%OVL/A_9^#_ !=?ZOIVF6NI1ZHDNBS113&5(Y8P"9(Y!MQ,W&W.0.?4 YK]
MD/P]8^+OV(/ASH6IQ>?INJ>$H;*ZB_OQ20;'7\58BOR2TOXU:]^RQ\*/VAOV
M?+EIQJNIZNFGV;0@@)AVBO'QW$L,<2C'4-WK]Q?A7\.=-^$/PY\.^"]&GNKG
M2]"LH[&VFOG5YWC08!<JJJ6^B@>U>$?$C_@G5\+/BE^T#;_%[5[G7H?$$=Y:
M7TNGVEQ NGW$EOL">9&T#.0PC7< XSSTS0!Z!^R'\&U^ O[.7@?P:T @U"TL
M%GU$9!)O)<RS\]P)'8#V ':OSW_X(_\ _)R/QC_Z\S_Z5FOUIZ<5\\?LW_L-
M^!/V7O&WB7Q1X5U;Q%J&H:_'Y5U'K%S!)$@\PR?((X8R#D]R>* /HBBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM9/_#%/P$_Z)#X/_\
M!3%_A1_PQ3\!/^B0^#__  4Q?X4 :W_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/
MP0_Z+)\/_P#PJ+'_ ..UD_\ #%/P$_Z)#X/_ /!3%_A1_P ,4_ 3_HD/@_\
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M^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM9/_#%/P$_Z)#X/_\
M!3%_A1_PQ3\!/^B0^#__  4Q?X4 :W_#6/P0_P"BR?#_ /\ "HL?_CM'_#6/
MP0_Z+)\/_P#PJ+'_ ..UD_\ #%/P$_Z)#X/_ /!3%_A1_P ,4_ 3_HD/@_\
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MUC\$/^BR?#__ ,*BQ_\ CM9/_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\
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M^B0^#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^% &M_PUC\$/^BR?#__ ,*BQ_\
MCM'_  UC\$/^BR?#_P#\*BQ_^.UD_P##%/P$_P"B0^#_ /P4Q?X4?\,4_ 3_
M *)#X/\ _!3%_A0!K?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B
MQ_\ CM9/_#%/P$_Z)#X/_P#!3%_A1_PQ3\!/^B0^#_\ P4Q?X4 >J>%?%VA>
M.M%@UCPWK6G>(=(G+"+4-*NX[FWD(.#MD0E3@@@X/:M>L/P7X'\/_#GP];Z#
MX7T:ST#1;<L8;'3X1%#&6)+84<#))-;E &1XJ\8:#X%T676/$NMZ=X>TF$A9
M+_5;N.V@0DX ,DA"C)]37 _\-8_!#_HLGP__ /"HL?\ X[7<>-? OA[XD>'Y
M]"\4Z+9:_HTY5I;'4(1+$Y4Y!*G@X->8_P##%/P$_P"B0^#_ /P4Q?X4 :W_
M  UC\$/^BR?#_P#\*BQ_^.T?\-8_!#_HLGP__P#"HL?_ ([63_PQ3\!/^B0^
M#_\ P4Q?X4?\,4_ 3_HD/@__ ,%,7^% &M_PUC\$/^BR?#__ ,*BQ_\ CM'_
M  UC\$/^BR?#_P#\*BQ_^.UD_P##%/P$_P"B0^#_ /P4Q?X4?\,4_ 3_ *)#
MX/\ _!3%_A0!K?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
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M]$A\'_\ @IB_PH_X8I^ G_1(?!__ (*8O\* -;_AK'X(?]%D^'__ (5%C_\
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M_HD/@_\ \%,7^% &M_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J*Z_X]I?]P_RJ6HKK_CVE_P!P
M_P J /R>_P""2/\ R=9\:?\ KTN/_2Y:_6:OR'_X)6^)=(\,_M3?&6;6-5LM
M*ADMKA$DOKA(59OMRG +$9-?J1<_&+P#9P//<>./#<$*#+22:M;JJCU)+\4
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M'5%^)/A!F8@!5UVU))/0#]Y0!W]%(K!U#*0RD9!'0TM !1110 4444 %%%%
M!1110!X9^W)_R:#\7/\ L7KK_P!!KY__ ."-/_)K.I_]C#<?^BXJ^@/VY/\
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MD?N8HB[X^[E@>00/UGC7;&J^@Q0 ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBHKBYALX6FGE2")?O22,%4<XY)]Z ):*S?^$DTC_H*67_@0G^-'_"2
M:1_T%++_ ,"$_P : -*BLW_A)-(_Z"EE_P"!"?XT?\))I'_04LO_  (3_&@#
M2HK-_P"$DTC_ *"EE_X$)_C1_P ))I'_ $%++_P(3_&@#2HK-_X232/^@I9?
M^!"?XT?\))I'_04LO_ A/\: -*BLW_A)-(_Z"EE_X$)_C1_PDFD?]!2R_P#
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M?XT?\))I'_04LO\ P(3_ !H TJ*S?^$DTC_H*67_ ($)_C1_PDFD?]!2R_\
M A/\: -*BLW_ (232/\ H*67_@0G^-'_  DFD?\ 04LO_ A/\: -*BLW_A)-
M(_Z"EE_X$)_C1_PDFD?]!2R_\"$_QH TJ*S?^$DTC_H*67_@0G^-'_"2:1_T
M%++_ ,"$_P : -*BLW_A)-(_Z"EE_P"!"?XT?\))I'_04LO_  (3_&@#2HK-
M_P"$DTC_ *"EE_X$)_C1_P ))I'_ $%++_P(3_&@#2HK-_X232/^@I9?^!"?
MXT?\))I'_04LO_ A/\: -*BLW_A)-(_Z"EE_X$)_C1_PDFD?]!2R_P# A/\
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M ($)_C1_PDFD?]!2R_\  A/\: -*BLW_ (232/\ H*67_@0G^-'_  DFD?\
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M/^@I9?\ @0G^-'_"2:1_T%++_P "$_QH TJ*S?\ A)-(_P"@I9?^!"?XT?\
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M7_@0G^-'_"2:1_T%++_P(3_&@#2HK-_X232/^@I9?^!"?XT?\))I'_04LO\
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MCJDWC?Q;'->W,ERZ1FUVJSL6(&8>F352'_@B;\*%F0R^./&3Q C<J26BL1W
M/D'!_ U^B5% 'SW^SW^P?\'OV:=135O"OA^2\\1JA1==UJ?[5=H",'9P$C)&
M02B*2"03CBOH2BB@ KYT^*W[$OA;XM_M(>#OC+J.NZQ9Z[X9^Q_9K"U,7V:7
M[-.\R;]R%N6<@X(X%?1=% !1110 4444 %%%% !1110 4444 %?,G[6G[!?A
M']K[7M U7Q)XAUK1IM'MY+:)-*,.UU=@Q+;T;GY>U?3=% 'YU?\ #DOX6?\
M0]>,/^^K7_XS7:?#O_@C_P# GP7J4-]JY\0^-'C(;[+K%\B6V0>#L@CC8_1F
M(..G:ON&B@"EHNBZ?X<TFTTO2K*WTW3;.)8;>SM8ECBAC48"JJC  '85\E_M
M*?\ !-'P5^T]\4+GQQXB\8>);"^EMHK5;6Q:#R8HXP<!=\;$<DGKU)K[!HH
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M]S6OKV@Z;XIT6]TC6+&WU/2[V)H+FSNHQ)%*A&"K*>"*OT4 ? 'B_P#X(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7FO[1GPEG^.7P?USP7;:E'I,VHM;E;N6(R*GES
MQRG*@C.0F.O>O2J* /SC_P"'4>M_]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P
M6/\ _'*_1RB@#\X_^'4>M_\ 10]/_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'
M*_1RB@#\X_\ AU'K?_10]/\ _!8__P <H_X=1ZW_ -%#T_\ \%C_ /QROT<H
MH _./_AU'K?_ $4/3_\ P6/_ /'*/^'4>M_]%#T__P %C_\ QROT<HH _./_
M (=1ZW_T4/3_ /P6/_\ '*/^'4>M_P#10]/_ /!8_P#\<K]'** /SC_X=1ZW
M_P!%#T__ ,%C_P#QRC_AU'K?_10]/_\ !8__ ,<K]'** /SC_P"'4>M_]%#T
M_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>M_\ 10]/_P#!
M8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\ AU'K?_10]/\ _!8__P <
MH_X=1ZW_ -%#T_\ \%C_ /QROT<HH _./_AU'K?_ $4/3_\ P6/_ /'*/^'4
M>M_]%#T__P %C_\ QROT<HH _./_ (=1ZW_T4/3_ /P6/_\ '*/^'4>M_P#1
M0]/_ /!8_P#\<K]'** /SC_X=1ZW_P!%#T__ ,%C_P#QRC_AU'K?_10]/_\
M!8__ ,<K]'** /SC_P"'4>M_]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\
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M%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>M_\ 10]/_P#!8_\
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M#\X_^'4>M_\ 10]/_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\
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M/3__  6/_P#'*_1RB@#\X_\ AU'K?_10]/\ _!8__P <H_X=1ZW_ -%#T_\
M\%C_ /QROT<HH _./_AU'K?_ $4/3_\ P6/_ /'*/^'4>M_]%#T__P %C_\
MQROT<HH _./_ (=1ZW_T4/3_ /P6/_\ '*/^'4>M_P#10]/_ /!8_P#\<K]'
M** /SC_X=1ZW_P!%#T__ ,%C_P#QRC_AU'K?_10]/_\ !8__ ,<K]'** /SC
M_P"'4>M_]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>
MM_\ 10]/_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\ AU'K?_10
M]/\ _!8__P <H_X=1ZW_ -%#T_\ \%C_ /QROT<HH _./_AU'K?_ $4/3_\
MP6/_ /'*/^'4>M_]%#T__P %C_\ QROT<HH _./_ (=1ZW_T4/3_ /P6/_\
M'*/^'4>M_P#10]/_ /!8_P#\<K]'** /SC_X=1ZW_P!%#T__ ,%C_P#QRC_A
MU'K?_10]/_\ !8__ ,<K]'** /SC_P"'4>M_]%#T_P#\%C__ !RC_AU'K?\
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M4>M_]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>M_\
M10]/_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\ AU'K?_10]/\
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MOT<HH _./_AU'K?_ $4/3_\ P6/_ /'*/^'4>M_]%#T__P %C_\ QROT<HH
M_./_ (=1ZW_T4/3_ /P6/_\ '*/^'4>M_P#10]/_ /!8_P#\<K]'** /SC_X
M=1ZW_P!%#T__ ,%C_P#QRC_AU'K?_10]/_\ !8__ ,<K]'** /SC_P"'4>M_
M]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>M_\ 10]/
M_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\ AU'K?_10]/\ _!8_
M_P <H_X=1ZW_ -%#T_\ \%C_ /QROT<HH _./_AU'K?_ $4/3_\ P6/_ /'*
M/^'4>M_]%#T__P %C_\ QROT<HH _./_ (=1ZW_T4/3_ /P6/_\ '*/^'4>M
M_P#10]/_ /!8_P#\<K]'** /SC_X=1ZW_P!%#T__ ,%C_P#QRC_AU'K?_10]
M/_\ !8__ ,<K]'** /SC_P"'4>M_]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P
M6/\ _'*_1RB@#\X_^'4>M_\ 10]/_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'
M*_1RB@#\X_\ AU'K?_10]/\ _!8__P <H_X=1ZW_ -%#T_\ \%C_ /QROT<H
MH _./_AU'K?_ $4/3_\ P6/_ /'*/^'4>M_]%#T__P %C_\ QROT<HH _./_
M (=1ZW_T4/3_ /P6/_\ '*/^'4>M_P#10]/_ /!8_P#\<K]'** /SC_X=1ZW
M_P!%#T__ ,%C_P#QRC_AU'K?_10]/_\ !8__ ,<K]'** /SC_P"'4>M_]%#T
M_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>M_\ 10]/_P#!
M8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\ AU'K?_10]/\ _!8__P <
MH_X=1ZW_ -%#T_\ \%C_ /QROT<HH _./_AU'K?_ $4/3_\ P6/_ /'*/^'4
M>M_]%#T__P %C_\ QROT<HH _./_ (=1ZW_T4/3_ /P6/_\ '*/^'4>M_P#1
M0]/_ /!8_P#\<K]'** /SC_X=1ZW_P!%#T__ ,%C_P#QRC_AU'K?_10]/_\
M!8__ ,<K]'** /SC_P"'4>M_]%#T_P#\%C__ !RC_AU'K?\ T4/3_P#P6/\
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M%C__ !RC_AU'K?\ T4/3_P#P6/\ _'*_1RB@#\X_^'4>M_\ 10]/_P#!8_\
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M#\X_^'4>M_\ 10]/_P#!8_\ \<H_X=1ZW_T4/3__  6/_P#'*_1RB@#\X_\
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MD,.C:U+'>W!4$*<_N;M?J5._ZO7Z25\K_P#!1GX7_P#"=? .76[:'S-1\,7
MOE*]?(;"3#Z %7/_ %SK.4O93C67V7^#W^75^AI&*J1E2?VE^/3Y]/F?4L,R
M7$*2Q.)(Y%#*RG(((R"*_.#XX*W[3W[>VB^"HB;G0?#\D=I<A>4$<7[ZZ)]"
M6S']0*^A/V=?VAK6;]C-/&>I3"6Z\*Z=-9WBLV2\MNN(E/NZF+\6KRG_ ()E
M^ [K6KSQO\4]84S7VHW#6-O/(O+,S>;<.#[L8Q^#5T*/+B?*"YOOTC_P?4PY
MF\/YS]W_ .2^X^Z-54)H]XJ@*H@< #H/E-?"'_!*G_4?$S_KO9?RGK[PU?\
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M_(^W(]8M?$/A%=4L9/.LKZQ^TP2?WHWCW*?R(K\KOV-8_B;XOD\6> _AW?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S_$&AVG
MB;0M1TC4(A/8W]O):SQMT:-U*L/R)K0HJ914DXO9C3<7='XF^(_$'B?X0Z7\
M0_@L0SVUYK4*SX)RQ@=PNT=Q)F)OHB^M?K;^SS\,T^$/P9\*^%@BK<V=FK79
M7^*X?YY3_P!]LP^@%;&I?"+P+K7B Z[J'@KP[?ZX9$E.I7.E027.]<;6\UD+
M9&!@YXP*ZVM(2<:?++63M=^BM_7R)FE*IS+1*]EZE35_^03>_P#7!_\ T$U\
M'_\ !*G_ %'Q,_Z[V7\IZ^^719%964,K#!5AD$>E8/A3X?>%O 8N1X:\-:/X
M=%T5,_\ 9-A%:^:5SM+^6HW8R<9]34P]V4I=U;\;CG[T%'L[GR#^V)J_Q$^"
M/QR\+?%+2[K6]3^'\?DKJ6E6MY*+6-T)5UDC!V*'0@JQ&-PY[9]&M?\ @HI\
M$9]#6^DU^_MKLIN.F2:7.;@''W=RJ8\_\#Q[U]+21I-&T<BJZ,-K*PR"#U!%
M<1)\"?AK+?&]?X>>%7O"V\W#:);&3=Z[MF<U,;QCR=+M^>HY6E+GZV2\M#XT
M_9"T?5?C/^UIXM^,]IHUSHOA!S<_9Y)UVB>211&J#'#-M#.^TD!L<\BNC_X*
MK?\ )-?!/_87D_\ 1)K[=M[>*UACA@C2&&-0J1QJ%50.@ '05C^*O OAKQW;
M06WB7P]I7B&W@?S(H=5LHKI(V(P642*0#CC(I5(J4(TX[1M^#N$&U.4Y;RO^
M*L5_AK_R3KPK_P!@JU_]$K7Y^^*/&$?[+/\ P4"UWQ5XJL[L>'=9665+J&+<
M3#/&IWH.-VV1=I YP#UX!_2&VMH;.WBM[>)(+>%!''%&H544# 4 <  =JS/$
MW@[0/&EDMGXAT/3=>M%;<MOJ=I'<1@^H5P1FM9R;K>VCY_<R(12I>REY?>CG
M?A)\;/"'QQT.[U;P=J3ZE8VL_P!FF>2VD@*R;0VW#J">&'(XKN68*I). .23
M6+X5\$>'/ MG+:>&M TOP]:32>;)!I5E';([X W%44 G  R?2MB:&.YADAFC
M66*12CQN 592,$$'J*4K?9''^\? W[.ZG]H[]M[QG\2I@;C0?#.Z'3F893.#
M!!CZH)9/J0:^_*PO"G@/PSX#MYX/#7AW2?#L%PP>:+2;&*U61@, L(U )QW-
M;M"M&$8+HO\ AV-^].4WU?W+H@HHHI ?!/\ P5=_Y%_X=_\ 7U>?^@15]I?#
M7_DG7A7_ +!5K_Z)6I?%GP_\+^/([:/Q-X;TCQ%';%F@75K"*Z$1.,E1(IVY
MP,X]!6U;6T-G;Q6]O$D%O"@CCBC4*J*!@* .  .U*G[D91[NX3]Z4'V37WNY
MY-^UU_R;/\1?^P1+_2O-O^";/_)LMK_V%;O^:U]-ZQH]AX@TRYTW5+&VU+3[
ME#'/:7D*RQ2J>JLC AA[$56\->$]$\&:8--\/Z-I^A:<',@M--M4MX@QZML0
M 9/KBG#W93EW27W.X2]Y179M_A8^#_C5_P I,? /TL?_ $&2OT%KGK[X=^%=
M2\36_B.\\,Z/=>(;?;Y.K3V$3W<>W.W;*5WC&3C!XS70T0]VFH>;?WA+WJCG
MY)?<?GS>?\I7+?\ X#_Z:#7Z#5SS?#OPHWBP>*#X8T<^)ATUHV$7VS[FS_7;
M=_W/EZ]..E=#1'W:4*?\J_4)>]4<_)+[D?GA\%_^4FGC7_KKJ/\ Z *^E?VT
M/@/=?'KX-W&G:2BOXATN8:AIT;$+YSJI5HLDX&Y6.,\9"YKUBR^'/A/3?$T_
MB2T\+Z-:^(IRQEU>'3X4NY-W#;I@N\Y[Y/-=%6?)>C"D_LI+[G<I2Y:LZBZN
M_P"%CX8_9W_;S\.^!_!EEX(^*\&I>&O$7AZ,6#7,MG)*LJ1C:@=5!=)   05
M(.,YYP.8_:1_:FN_VFM0T'X<?!*/6KJ[DO1<7&J6ZR6I8 %0!@AEC&XLS/M
MVBONOQ1\-_"/CB2-_$?A;1?$#QC"-JFGPW)4>Q=3BK7AGP7X>\%VK6WA[0M,
MT&V8Y:'3+..W0_4(H%:R?M)<U3UTZD+]VK4_QZ&;X5\-3>#?A?IFA7-[+J-S
MIVE);37DSEWGD6+#.2>2203SZU^7O[&_QNU_X W7BGQ+_P (]=:_X":6"WUQ
MK%09[-SYAAF&<<??7DA3D#(.,_K%J_\ R";W_K@__H)KX-_X)6QK-:?$Y'57
M1IK,,K#(((GX(H@Y2K5)]>5/_P F')*-"$>G-^AW?CS_ (*8_#;2_"ES/X7A
MU/6M>DB(MK6:T,$<<A'!E=C]T'^[N)QCWK*_X)V_!'Q!H?\ PD?Q1\76TUKJ
MWB,%+2.Y0I*T3/YLLS*>@=]N/9<]"*^I;'X+_#[2]675+/P)X:M-35]ZWL&C
MVZ3!O[P<)G/OFNRIQM%N75JWHNMO7^O)2O)*/1:^O;[CXP_X* ? GQ'KEYX;
M^*O@FTEO->\-[1=6]LA>4Q1R>;%,JCEMC;L@<X;/136SX%_X*4?"[6/#,-QX
MF?4/#FN)&!<6/V-YT:0#GRW0'*D]-VTU];5Q^N?!OP!XGU%K_6/ _AO5K]CE
MKJ^TBWFE)]2S(36<;Q3ATO?T;W^\J5I-2>^WKV^X^!_&^NZW_P %%/C5X?TS
MPYH]_IGPXT!S]IU&[0#:K%3*[$$J)&555(P2>YXSC]'[>SATW38[2WC$5O!$
M(HXUZ*JK@#\A2:7I5EHEC%9:=9V]A9PC;';VL2QQH/0*H 'X59Z\'D4Y17LG
M2CUO\VR=93YY>GHC\_/^"5O_ "%OBK_O6'_H5S4G_!5S_5_##_KIJ'_MM7V_
MX5^'?A7P*]V_AKPSH_AYKO;]H;2K"*V,VW.W?Y:C=C<V,],GUI?%GP]\*^//
MLO\ PDWAG1_$7V4L;?\ M:PBNO)W8W;/,4[<[5SCK@>E:2E>=.?\MOP5C2,K
M5*D_YK_BK&S8_P#'E;_]<U_D*^!/^"HW_(R?"G_?N_\ T."OT!50JA5& . !
M7/\ BGX>>%?'$EI)XD\,Z/X@DM,_9WU2PBN3#G&=A=3MS@=/05/_ "\A/L[F
M=-<E-P\K&[;_ /'O%_NC^5?FGX7^(%G^R/\ MP>/[OQK;7D&BZRUT8KJ&$N?
M*GF6>*4#^)>"IVYP<^AK]+P H  P*Q/%'@7PWXXMXH/$?A[2O$$$1W1Q:I91
M7*H3W =3BIUC452/9KY,:2]E[*7D_FC+^%OQ9\,?&;PP?$'A+4&U+2A.]L9G
MMY(3YB@%AM=0>C#G%=A61X9\(Z%X*TTZ=X>T73M!T\N93:Z9:QVT6\XRVQ !
MDX'..PK7JG;H)7ZA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ,FB6XA>*0;D=2K#U!X-<'\*?@/X%^"*ZFO@K0_[%&I,C7?^ESS^
M84W;?]:[8QN;ICK7?T4+2[74'JK,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OGC]K#]KC_ (9@G\-Q_P#"*?\ "2_VPL[9
M_M'[)Y/EE/\ ID^[._VQBOH>OSQ_X*O_ /']\-_^N=]_."LJDG%QMU?Z,VIQ
M4N:_8G_X>R_]4K_\N'_[EJ_HO_!5[2[B^1-7^&]Y8V9/S366KK<R >R-#&#_
M -]"N-_8 _9M^'/QM\!^)]1\:>'?[9O+/4EMX)/MUS!LC,2L1B*10>2>2,UZ
M?^T?_P $^/AW9_#/7=>\#6EUX<UC2+.6]2#[9+<07"QJ69&$K,P)4'!##!Z@
MUK5_<ZRVM?\ "YC3_>NT?3]#Z;^#?QV\&_'CP^VK>$M4%V(B%N;.9?+N;5B,
MA9$[=\,,J<'!.*] K\8?V,/B%?\ P\_:+\(2VD[1VVJ7B:5>1 X66*9@@!'?
M#%6'NHK]/?VA/VHO"O[-<>AOXFT_6+X:P9A!_9,,4FWRMF[?YDJ8_P!8,8ST
M/2M*BC&,9+KI\R(<TI.'5:_+^D>PU%=7"V=K-.X8I$C.P49. ,\"O"_#?[:W
MPSUWX5W'Q O+R]\.Z)'?/IR0ZK"@NIYE16*QQQ/)NX<=^.2<#FNC^ G[2'A?
M]HS3-9O_  Q::I;6^ESK;RG4X8XRY92P*!)&XP.^#[5E).TDMTON_JZ+4EHW
MLW^6_P"1\@Z'_P %1/$6H_$JVM9O!^F+X4N+Q8%BC>7[<D;.%#%RVPL <[=@
M],]Z_12OSST'XX_LK2?&2TO[+X5Z[#XKGU58H[IX(_LR7+2A1)Y/VLQC#'=D
M1Y'4#-?>OC#Q-:^"_">L^(+Z.:6RTJRFOIX[=09&2-"[!02 6PIQD@9[BGS)
M4(R?GK\D-Q;K2BON^\UZ*^:_A'^WQ\/?C-X[L?"FCZ5XBL;^[261;C4K>WC@
M18XVD8LRSL1PI[56\??\%%/@_P"!=7ETZ&[U3Q1+$Q2270;5)(58=A)))&K_
M %0L/>A^[:_42UO;H?3M%>/_  -_:K^'W[033VWAG4)X-6@3S9-)U*(0W(3.
M-X +*PR1G:QQD9QD5S7Q6_;M^$WPGU:;2KG5;KQ!JD#%)[708%G\EAU#2,RQ
MY!X(#$C'(%$O=:3ZA'WKM=#Z%HKP/X+_ +;?PR^.&O)H>DW=]H^MS9^SV&M0
M+"]Q@9(C9'="?]G=D]@<&O?*;36K%=/0**\D^,7[5'PW^!=P+/Q/KP&KLGF+
MI=C$T]SM/0LJ\)GMO*Y[5XU#_P %1/A-)<"-M&\6Q(3CSGL;;:/?BX)Q^%2F
MI;%--;GV!17 ?"3X[^!_CCIDU[X.UR+4_L^/M%JR-%<09Z;XV 8 \X;H<'!-
M7_BW\4-*^#/P^U;QCK5O>76F::(S-%8(CS-OD6,;0[*IY<=6'&:<O<^+04??
M=HG845\\?"#]N;X=?&34=9MK&#5] ATC3VU*[OM>B@@MTA5E4G<DS\Y<=15C
MX?\ [;7P]^*GQ G\(^%8-;U>]CM9[J.Z2S2."=8EW%4WR*^X]!E ,]Q0]-^U
M_EK_ ),5T_OM\_Z:/?Z*^4O"_P#P4D^&'BGQ9I?A]-'\4Z==:A>1V2S7]I;)
M%$[N$!D*W#$ $\X!Q7U;3L[<W0+Z\O4**^??CI^VWX"_9_\ &B>%]?L-=U#4
MC:I=N=)MX9(XU<L%5B\R'=A<XQT(YKU3X4_$JQ^+W@'2O%VEV&H:=IVI*TD$
M.IQHDQ0,5#$([C!VY'/0BE'WDY+8<O=:3W.NHHKD_B3\5O"7PAT$ZSXOURVT
M6Q)VHTQ+/*W]V.-06<^R@TFTM6-)O1'645\AWO\ P4^^$EK>-!%IGBJ\B#8%
MS#8P"-O<!YU;'U6O:_@[^TO\//CJLD?A37DGU&)/,ETRZ1H+I%[G8WW@.[(6
M SUJDG+5$MI;GJ-%07UVFGV5Q=2!C'#&TC!>I &3CWXKYD^''_!0[X<_$_QS
MHOA32]%\46^H:M<"V@EO+6V6%6.>6*W#$#CL#2C[TN5;CE[L>9['U%17S?\
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MSKN1?7;D! ><%RH.#@U\NZO_ ,%8-.AO'72_AM=7EKGY9;S6%MW/U189 /\
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MODIC[^<Y[=*X/]JK]H3P/\>OV1/%-WX1U;[3-;W5B;FPN$,5S;YN$QN0]O\
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M'_OH5YQ_P3X_9]\ _'"S\:OXVT'^VFTY[46I^V7%OY8<2[O]5(N<[5ZYZ5]
M?&G_ ()T_#/4/ ^JW/@NQN?#.O6EO)<6VV]FGAF=5)$<@F9R <8RI!&<\]*W
MJ_N5>7:_ZF5/]Z^6/>Q[M\$?VBO!'[0&CRWGA346>YMP#=:9>)Y5U;9Z;DR0
M1_M*2N>,YKTVOQ _9H^(5_\ #'XY>$-9L9FB4W\5K<H&P);>5PDB-ZC!S]0#
MVK]5OVNOCD_P$^#.I:Y9,O\ ;MXZV&F!P"!.X)WD=PBJS>A( [TZMH4U4773
MYZ?G="IWG-T_ZM_2#XX_M=?#KX!S&QU[4I;_ %W:'&C:4@FN0#T+Y(6/L?F8
M$CD U\U:A_P5ALX[IUL?AG/<6V?EDN-;6)R/=1 P'_?1KX]^#7PF\3?M,?%9
M-%MKMY;Z]=[S4M6NR9/)CSF29^<L22 !GEF R.H_1?P__P $V?@[I.DK;:A;
M:OK=WMPU[<7[1-NXR56/:H'H"#UZGK4J$E%2D]RG*+ERQZ&7\-?^"F'PW\77
MD%EXCL-2\&W$IQ]HN +FT4]@9$^8?4H .Y%?6NGZA:ZM8V][8W,-Y9W""6&X
MMW#QR(1D,K#@@CN*_++]LK]B.W^ >CV_BWPIJ%UJ'A>2=;>YMKXJT]F[9V'>
MH 9"1MY (..6SD=__P $P_C3J?\ ;^K?#74+F2YTQK5]1TU9&)^SNK 2HOHK
M!MV.F5)_B-73Y:J:6C7Z:_EJ14YJ=F]4_P#AOS/J7]JK]IG_ (9E\-:)JW_"
M-_\ "2?VE=M:^3]N^R^7A"V[/EOGIC&!7S3_ ,/9?^J5_P#EP_\ W+73?\%5
MO^2:^"?^PO)_Z)->(?\ !/S]GWP-\=IO'"^--(?51IBV9M=EW-!L\PS;_P#5
MLN<[%Z^E94E*HZG]W_)?YFM1J$8OO_FT>G6W_!6.%ID%Q\+Y(H<_,\>O!V ]
M@;89_,5]*? +]KSP#^T++)8:+<7&F:_&AD?1]314F91U:,J2K@>QR.I KS+X
MH_\ !.'X6ZIX/U%O"UK>^&M;A@>6VG6]EGB:0*2%D65F^4]/E((_2OSA^#/B
M"_\ "/Q>\'ZIITC17MKJUOMV'E@9 K+QV925/L36M+EJ5/9/R_$SJ<T*?M%T
M_0_=FBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHAM):)\QR =CPIQVK]PO#NL2ZYX3TS55BS->645R(\X^9XPV/;DU^,O[7/\
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M;O\ LVYC4\2Q2C;M8=P&VM]5%?HY^WE_R:CXY_W+3_TKAK\Q?V5?^3D/AO\
M]ARV_P#0Q7Z=?MY?\FH^.?\ <M/_ $KAJ\3KAXOS_6/^9&&_WI+_  _FS\P_
MV<_@_KOQX\?GP9HNJKH\%Y;F74+B0DH+>-T8Y0$>8=VS"Y'..1C-?I3\ OV%
M_"'P!\7VGBK3]=UO5=<AMY+=OM30K;,'&&(C6/</;YS^-?'/_!,G_DXRY_[
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M"_L\Z5H.E>(;?Q7IUCI4T<&LVFWRKI?G.Y=KN,<XX8].M?D=^S5_R<%\.O\
ML/6?_HU:N,8SQKBMG;[KLB4I0P:D]U?\D?=GA[_@EGX%A\-Q1:YXGUZZUYH_
MWEU8O#%;K(1_#&T;,5!]6R?;M^?UU#JGP1^,$T-O=8U;POK+1K<1':&D@F(R
M/8[>GH:_=FOPY_:-_P"3A/B-_P!C%??^E#UG";6)A;U^YK_,V]G&5&2?DOO3
M/V<\?>.8?!'PSU[Q:ZB6+3=,EU )GA]L9=5_$X'XU^,/@KP[XA_:4^-UCIMS
M?M/KGB2_+7-]-E]@.7D?&>BHK$+Z* ,5^L/[1%C-J7[)_C*"!=\G_"-N^WV6
M(,?T!K\V?V#=4MM*_:G\&-=2"))FN+=&/3>]O(%'XG ^I%73@GBY1>R7^?YV
M1C*<EA%);O\ R7Y79]F:[_P3'^&-UX1:PTJ_UJPUU(OW6K37(E#28X,D6T*5
MSU"[3[U^:7Q \*ZMX&\:ZSX=UQMVJZ7<M9SL)-X)3Y00W=< 8]L5^]U?B1^U
M9?6^H_M'?$2XM9X[F!M8F"R1,&4X.#@CW!'X5SN3]JEW3_"W^9T)+V;?9K]3
M]B/!O_))-"_[ <'_ *3K7X>^%=/U;6/&VE:?H4DD.M7=]';V4D<IC99G<*A#
M?P_,1SVK]PO!O_))-"_[ <'_ *3K7XN_!.\@T_XZ>!;FYF2WMH?$-C))+(P5
M447*$L2>@ KKY5/'N+V;7YLYXR<<"I+I_D?H7X)_X)C_  YTWPK';^)[[5M:
MUZ6/]_>VUSY$44A'/E)M/ _V]V<9P,XKX$^-'PYU/]G'XVZGH%K?S?:=&NH[
MG3]17Y)&0A9(9..C $9QW!K]P:_(O_@HKK%KJO[3VL1VKJ[65C:VTQ4Y_>"/
M<1]0' _"N:4Y1JQE'^NM_E^IM&*=.2>I^D_@/XR6VO?L\Z9\2=0 2'^PSJ=X
MJ= \<9,JC_@2,!7Y'+/XI_:L^/%K'>WOFZYXDOQ$LDI+1VL9).%'9(T!P!V7
MU-?H+\.O#]_/_P $VY;!%>2[G\+7\L:'KM8S.H'_  $C'UKX>_8?U6UT?]J;
MP%/=R"*)[F:W5FZ;Y+>6-!^+,H_&NGDC+'2B]ELOF]/G9(PYG'!*:W=_P2M^
M9]N-_P $Q/A8?#8L1J/B :KL_P"0I]J3._'7R]FW;G^'KCC=WKX!^T>*?V4?
MCS=1V5YY6M^&[\PM)$2L=U$"#AAW21".#V;U%?MY7XS_ +<6L6FN?M2>.IK(
MJT45Q#;,R'(,D<$:/^.Y6'U%<_M)1K1:\_PL;\D94I*7E_7Z_(_6:^\26OC'
MX/W.O6)S9ZIH3WL/^Y);EQ^AK\>/V5?^3D/AO_V'+;_T,5^JOPITVXTG]DGP
M[:72&.XC\))O0]5)M<X/OS7Y5?LJ_P#)R'PW_P"PY;?^ABNF$5#'N*V37_I3
M.:<G+!*3ZI_DC]4?VS/^37_B'_V#Q_Z,2OR?^ /PHUOXW?$BS\':)J"Z6VH1
MO]KNI&(1+=,.Y*@_/]U<+W('3J/U@_;,_P"37_B'_P!@\?\ HQ*_/O\ X)O_
M /)SVG?]@V\_] %<U%*6(E?^7_Y(WK2<:,6N_P#\B?1'C+_@F%X'TWX?ZI-H
MWB'7G\26MF\T$UW+";>655+8:,1@A6(QPV1GJ<<_('[&?BR\\(_M+>!IK68Q
M)>WRZ?<+G >*;Y"I]>2#]5%?LCXE_P"1=U7_ *])?_0#7XF_LU?\G!?#K_L/
M6?\ Z-6M<.V\4H]-/Q;3(Q"2PSDM]?P2L?J]\?OV9_ OQL4:WXJL;J[O]+L9
M8[9H+MX55>7Y"GGFOR3^ _A+3?'GQF\&>'=8C>;2]3U2&UN8XW*,T;, 0&'(
M/O7[@>)?^1=U7_KTE_\ 0#7XK_LKNL?[1WPW9F"K_;EKR3@??%1ATOK*ATT_
M%NY>(;6'<NNOX)6/UB^#7[+_ ("^ NJZAJ/A"PNK2YOX5MYVN+MY@4#;A@,>
M.:^1?VQOV(?B)X^^,FI^,/!=E#X@L=9\MYK=KR*WEM9%C5"#YK*&4[005)/)
M&.,G]$JR=>\6:'X5CADUO6=/T=)FV1-?W20!VZ84N1D\C@>M*2YG%OI_5AQ?
M*FEU/*/V0/@?J?P!^#=MX=UJZBN-7N+J6_NEMW+10LX4"-2<9PJ+DXZD]1S7
MMM,BE2:-)(W62-P&5E.00>A!]*?6LI.3NS*,5%605^,/[5'CVY^.G[2FNS:<
M3=PM>IHVEQKR&2-O+7;[.^YO^!U^HG[57Q0'PB^ _BK7HY?*OVMC9V///VB7
MY$(]UR6^BFOQ?\-^)=1\(^(=/US2;C[-JEA.MS;7#1K)Y<BG*MM<%20>>0:Y
MX\LJZYMH_K^MOS.B5XTGR[O]/TO^1^JG[3'[/]M_PQ<?"FGQ"2Z\(Z?!>VS*
M.6>!?WS?5D,I^IKY<_X)F?%+_A%?C!J'A&ZEV67B6U_=*QX^TP@NGYH9!]<5
MYA=?MQ?&^^M9K:X\<RS03(T<D;:=9D,I&"#^YZ$&O)? _BV\\!^,M$\1Z>VV
M]TN\BO(N< LCAL'V.,'V-=-)OV\IR>DM_GHW^7W'/47[F,([QV^6R_/[S]R_
MBA_R33Q;_P!@B[_]$O7XE?!?_DL'@;_L.6/_ */2OVP?4K3XG?"N2]TM_.L]
M>T=GMV!ZK-"=OX_-7X?^"=6'@WX@Z#J=Y&RC2M3@N)HR/F'E2JS#'K\IJ*'[
MO&KGTMR_@W<NH_:86\==_P 4K'[V5X9^V]_R:SX^_P"O6+_THCKVG2]4M-;T
MRTU&PG2ZLKN)9X)XSE9$8 JP/H017SM_P4'\96/A?]F?7[&XFC6]UJ6"QM(6
M/S.WFK(Y ]D1CGZ>M<^(3]FXO?;\36@TZD9+;?Y;GP)^P7_R==X&_P!Z[_\
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M-?L<?\FP_#S_ +!H_P#0VKV6MJW\67JS&C_"CZ(^=/\ @H%_R:KXM_ZZ6?\
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M&N[_ %.62Y"/)N*I#!N5?X2< JH _"LZ6M23BKVWOZ?\'[RZFE.*D[7>G?\
MK3\SVW]M3]ECX2> _A!>^(_!5M;Z'KNESP[[:#49)_M$;NJ%621V((W!@1CH
M<Y[8G_!*WQA?0^-O&/A<S.VFW%@FHK"3\J3)(J%@.Q*N ?7:/2L/]H[]@?1O
M@)\&=4\7Q^+;[6M0M);>)86M4@B;S)51B1N8]#D<]N]-_P""6O\ R6WQ)_V
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M1HWX8$*3N5B0RDXQT/<?\$K]6M9OA/XNTQ&3[;;ZT+B1<_-LD@C5"1Z9C?\
M6O?_ -K.^M[#]FSXC27,T<"/HT\2M(P +NNU5'N6( 'J:Z,7^[C[O1)_A?\
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M^,8SWKV3XR?\%.M#UKP3J6E>!/#FKPZK?0/;"^UD11+;!E(+JL<C[F )QD@
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MS3M#AT2ST^2[N)M/M)4D#;E5%W-*PY+>G8UA3_>-J/3]%<WG[B3EU_SL5_\
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M1**F<7.2DWL[_@U^I4)*$7%+=6_%?Y'S9_P3Q_Y-8\-_]?-Y_P"E#U\&?\%
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MHJXR4&Y):DR3FE%O0^<_VYO@+J_QV^$45OX>03Z_HUW]OMK0L%^TKL97C!/
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M_!5K_D2? /\ V$+G_P!%K7W916=2/.K>:_!W+C+E=_7\4? '_!*'_CP^(_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y#\0_V2OA1
M\5O%5QXD\5>%/[4UJX5$EN?[1NX=P10JC;'*J\  <"NM^'7P?\%_"6RDM?"'
MANPT))0!+);1YEE Z!Y&R[X_VB>M=C11'W5:.B!^]JPHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 9-$MQ"\4@W(ZE6'J#P:\/T']B+X*^&?$&GZWIO@O
M[-J=A<QWEM/_ &K>OY<J,&5MK3%3A@#@@CVKW.BA>Z^9;@]5RO8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.WC)]-SD"J_A7XA^%?'0E/AOQ-H_B$0_ZS^RK^*YV?78QQ^-&^P;;G04444
M%%8OBGQKX>\#6,=[XDU[3/#]G))Y27&J7D=M&SX)VAG8 G )Q[&G7/C'0++P
M]%K]QK>FP:%+&LT>J27<:VSQL,JXE)VE2.0<X-'2X>1L45GZ#X@TOQ3I4&J:
M+J5GJ^FW )AO+"=)X9,$@[74D'!!'!ZBL[Q1\1/"G@<H/$?B?1M ,@RG]J7\
M5MN^F]AFAZ:,%KL=#17.>%_B1X2\<.Z>'/%&BZ^\8RZZ7J$-R5'J=C'%='0
M45S>K?$KPCX?\06N@ZIXJT33=<NB@@TR[U&&*YFWMM39$S!FW'@8')X%6O$_
MC;P[X)M4N?$6O:7H-NYPLVJ7D=LC'T!=@#1TN'6QM45@^%O'OAGQS#++X;\1
M:3X@BB.)'TN^BN50^Y1CBMZ@#S7PW^T;\._%WQ(OO 6D^(?M?BRRDGBN-/\
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MZ%1I[:ES;<WZ,OWO95.7>WZH_3+0]'MO#VBV&EV48AL[&WCMH8U'"HBA5'Y
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M_DVB;_L+VG_L]&)YO9PYM7[NO?WEJ*A;GERZ;Z=M-CKOV$_^35? W_7*X_\
M2F6OFG]MKXN>*OC!\;+#X%^#+E[>T\^&UO5BD*"[N9 &(D(_Y91J02/4,3G
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MY<7RKI&?Y(RE)RPJ;ZN'YGVE^U1_R;A\2/\ L!77_HLU\_?\$K_^2/\ BO\
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MJO/Q\_;H\*^ H3YUCIS6NGSJ.0 2;BY;\$./^ 5^C>I1K#HMW&BA$6W=54=
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M *_]:_\ 1C5ZW^V9^UE?:/?#X4?#)I-1\<:FXM+NYL?G>SW\>3'C_ELV>3_
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M1^:'_!4"R.B_&CP5KEN/+N)-+ \P?WHIV8'\-XK](]'OO[3TBQO!TN((Y?\
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M1EB2>)XI$62-P59&&0P/!!'<54M*:IT]+;>O<F.M1U)ZW_)=#XO_ &9_V_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **SM)\1:5KYN1IFIV>I&UD,,XM+
MA)?*<=5;:3M/L>:T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^1%].9;'OM%?/_[0WQ8\2V/BS0OA[X'D6W\0:L%:6\(!,*,2% )!V\*S%L9
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M_J_H.SORK5GT[17&>$_'47Q ^%L'B:S5K;[98R2;%;F*10P90?9E//M7S+\
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MP'))(5>^>0/;M6OAI>E7MX1D6\+S8_W5)_I7R]^Q+I8UR^\9>,+[]_JEQ<B
M3.,D;LR28/N2OY5,5SR:Z)7?Y(I^[&_5NR_4W(_#/[2MQ;_:SXMT"U<C=]@:
M*(L/]G(MR/\ Q_\ &K'P]_:,U[2_&T7@CXH:1'HNLS%4MK^'Y8I2W"[ADKAC
MP'4XSQ@<U]$5\W_MO^&8+SX>Z7KZKLO]-OEC69>&\N0'(S_O*I_.CFY6FUH"
MCS)KJ?1[,%4DG '))KYJ\2?M%>+/B#XPNO"WPETF&]-L2)]9N@"@P<%ER0JK
MGH6R6["NK\=>/KQOV4YO$B2LM_>:+ K2]]\NR-S]<L:A_8[\+V^A_!FROTC
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MX?GT75K[2)I=1V226%R\#.OEL<$J1D9[5] 6C%K6$DY)122?I0M4WYV_!/\
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M>#P!VK9BC$,:("Q"@*"S%B<>I/)-8_BSP7HGCG3X;'7M/BU.SBF6X6&8G;O
M(!(!&>">#QS42OT&O,^3?B3^USXFUK7M/?P6LVB>&_M'V?[;<6L;O>/E=P^=
M6"@ C@<_-D]0!]FU\H_MG:;::/;?#JSL+6&RM(;N98[>WC$<:#,7 4# KZNI
MQMR:=W^@G?FU[+\V%>:_M ?$]_A9\/;F_LB#K5VXM-.3:&_?-_%M/7: 3Z9
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MK>(+WF&Q@,@3.-[]$0>Y8@?C7,? '5/%/B+X>6NN^++\W=]JCM=00B".);>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"AI?A_2]#>Z?3=-M-/>ZD,UPUK L1FD/5WV@;F]SS7R_P#MT0I<7GP_
MBD&Y'FN58=,@F &OJ^O$_P!HWX)ZY\7KSPK+HUUI]LNE2RO/]NDD0L&,9&W:
MC9^X>N.U3:\X7V37W#OI+O9_D7F_9+^%3*0/"Y4D8W#4;K(]_P#6UYIX U#4
MO@/^T(OP\DU&YO?".K(&T^*Z<OY!8$IM]/F5D., \'&:^J:\3^//P3USXA^*
M_"?B/PU=V%EJ>C2;I&OI'0.JNKI@HC="&Z^M7%VG'ML_04E>$N_3U/;*^3_
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MS8VSV%VT\IOI'0%2H&%VHW/UQ6]1WG%K^[^%C*GI%I_WOQN=S\1O^28^)O\
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MRP+12 #_ (!S]!7TYJNJ6NB:9=ZA>RB"SM(FGFE()"(H)8X')P >E>4_&/X
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MA\5/&.L_%ZU^&?@>XM='N_)$UWJUS&)&0%-Y"JP(P%QV))/48S72?!OX#O\
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MY\MG4*=R@] 0PX['-<+J'P[^//B#39-'U+QQX?@T^=3#/=6D#?:'C(P1CR5
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MS;C(_O=*]CJ8Z4XKLOU8W\3?I^2"OF#]C?\ Y&;XG?\ 80C_ /0YZ^GZ\;^
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M;E?W*2Q2*ISAQ*^<^_(/XUYQ^W+-&-%\&Q;U\TZ@[!,_,0% )QZ<C\ZL:?\
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M377BHS1SZ;:7TWVA9/G( ++!A5)!ZLO>J7[8G_(W?"O_ +"$G_HRWKL?AK\
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MVGMI%QX_T1-/=?)>\CB;[48\8Z^2/FQWW ^]3'X>6VMW^.I4M9<U]++\#?\
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M0H4  %A^739M2K1J=+W,K<M*4.MK'9?M(?&+5?A?I>BV.@6T,VNZY.UO;RW
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MOW;?/R_X)+V6FOX>?_ /./VX)/,\/>#K55W32ZJ2@'7A,8_-A7TI$I6) >"
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MI'61P)4?Y J$$X0]2.U>QT1TI)=;R'/6JY+:T?P1\P?L;_\ (S?$[_L(1_\
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MQ1XSM+#4KKQ7%KOBS[2'N[O4F>&WCA .(H(T1@HW<]!GVZ&U:\7'1:>O2_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLVEI!86L5M;0QV]O"H2.&)0J(H&  !P !4U%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPUKQ);VUZHRT$4<D[I[,(U;:?8X->.?MQ6J0^$_!MM;JMM$E\T<:QJ%6,",
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MV[DM+AD_[[$>W'OFHOVD/AUJ/Q*\(V=C!KMEH6E6]Q]IU"6^D,:.@&%!8#
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M+?[0S^6&D@F2+.<?ZQD"8]\XKM/%_C;1? >@2:WKEZ++2XV56N!&\HRQPO"
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MR W0X]:Y^[\/V/PW_;,\/VWAZWCTRRU2UW3VENH2(;TD# *. ,HK8' -=/\
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MS(X!]P-OT)KH_A/\!/!WAWP#I$%YX=TW5+^>VCFN[J_M$FD>1E!8 N#A1G
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MR$RAMNY;6=H\_P"^(]N/?.*\S_;/\8);W'A'PM=W4MGHE]/]JU-X02QA5U
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MMR!^^&[ !X X&3770>&-'\,Z3J":/I-CI22Q,TBV-LD(<A3@D*!FO!?V%O\
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M?TO4OM6KZ42+RW\B5/*PVT_,RA6YXX)KQ?\ 86_Y)?K/_87?_P!$Q50_9_\
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M*AYX6Q)%&S;%53_"S'/S=0![Y'T)7R9X@"W/[=6E)>?ZN../R0W3(M69>_\
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M+9R".YCME^T(P4[7\W&\L"!R3SWKA_V(=3N+[X2WMO-(7BL]4EBA!_A4I&Y
M]MS,?QJHVES+JM?QL1*\>5]&VOPN>P>-?B1X9^'=I'<^(]8M]+23_5K(2TDF
M.NU%!9L>PXK@_$GQG\%?$?X:^-+7P]K]O?W2:->,;=D>&4CR6R0DBJ2!Z@'%
M>4?#KP]:?'?]HWQIK'B6$:GIFAR-!;64XS%Q(R1AEZ$81VV]"3SFO2_CM\#?
M"=]\.M:U+3-)L] U72[.:Z@N],MU@8A48M&X0#<K+E>>F:PGK1YI=5]R-HZ5
M>5;I_B1?L:?\D/LO^OVX_P#0J]%\<?%CPC\./*'B/7+?39)!N2$AI)6'KY:
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M@\.ZQXLGNFDEGD/VF6)<#C8065BQ8DXR<]>*Z:W\:=]-_P S"G_#BSVSP/\
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M+$D_B:Y;QG\#_ OQ OOMNN^'+:\O#]ZXC=X)'_WFC92WXYK><KU)26TO\_\
M@F<8^Y&+W1P?Q(_:(GM?''AKPI\/WTKQ)J5_/LO&^:>.%20!AHW ! WL<DX
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M6<0^=)%\X! .493T)[]ZSG%RA&*Z<OX6*B[3E+O?\3S[XG?\FLW_ /V (/\
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M.F0?9M/LXA#!#O9]B#H,L23^)HC[L9)]6G]RL$M>7R3_ #/F[XB_\GI>"/\
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M;&*]/M;6&RMXK>WBC@@B4)'%$H544#   X %.-HMRZVM]^XG=KEZ;GS+9_\
M)]-W_P!@_P#]M5KWGXG?\DW\5?\ 8*NO_134U/AGX:C\=/XR73<>)'C\IKWS
MY>5VA,;-VS[H ^[6]JFFVVLZ;=6%Y'YUI=1-!-'N*[D8$,,@@C()Z5E*+=%4
M^MFOS_S-(NU3F]/P2_R/$/V*_P#DBJ_]A&X_DM<S\,_^3T/'O_7B_P#[;U]
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M7#,"=Q&3Z* .IKZDT[XB>#[RXM[&P\3Z'/-(5BAMK?4(69CT"JH;GV KA_\
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M2B'QM?S*WS6OXZCEK!/^5W^_1_H=?\?OV@K#X0:<+&T$=]XGNDS;VK'Y(5/
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MD\B?(?NM(S%?PQ6,M*7++9)_<;0UJJ4=VU]YYS^PM_R2_6?^PN__ *)BKF?
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MT_PK;"ZC.Y'N99;@*1T(61V (]<5FD^50;VTOY&C?ON??7YF_P#"W7=<\3>
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MDC,:8Q@>O6N[HJ+]RSY$\1:[IWAO]MX:AJM[;Z=8Q0+YEQ<R!$7-G@9)XY)
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M^WTRQCY6"VC"+GN3CJ3W)Y-9-Y\,_#5]XXM/&$^F[_$=K'Y4-[Y\HVKM9<;
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M77M5U.TEMX;72YEN"H*G=(Y0D*JC).?3\19_8]_Y(7I/_7Q<?^C376Z#\!O
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MOS_&YK:#_P @/3O^O:/_ -!%,\2>(M.\):'>:OJUTEGI]HGF33/T Z >Y)(
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M:7?)=P^$[=Y4.X+<7$TT?XH[E3^(J4GR*#Z;>G_ '=<W/WW+?P#\=>(_B1X
MBU_Q)8VEA/=3O]FCLXWC5X1@!R'9CRV[G/0"O1Z9'&D,:1QHL<: *JJ,  =
M!Z4^M)--Z&<4TM3YA_9O_P"3@_B[_P!?<O\ Z4O2>+?^3XO"O_8/_P#:,]>[
M^&_AGX;\(^(-7US2=-^R:IJSF2]G\^5_-8L6)VLQ5>23\H%%Y\,_#5]XXM/&
M$^F[_$=K'Y4-[Y\HVKM9<; VP\.W5>]3#W8TD_LJS_'_ #*G[RJV^UM^'^1L
M>(/^0#J7_7M)_P"@&OG_ /86_P"27ZS_ -A=_P#T3%7T9<6Z75O+#*NZ*12C
MKDC((P17/^!?AUX>^&FES:=X;T_^SK.:8SO'YTDN7*A2<NS'HHXSCBB/NN3?
M5)?C<)^]&*71M_A8^;/AOX@L_@7^T=XUT;Q).-+TW7)&GM;RX.V(YD+QDL>
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MP_\ H$E>R^!/^1'\/?\ 8.M__12U'XX\ Z#\1]'72O$5A_:-@LJSB'SI(OG
M(!RC*>A/?O6U8V,.F6-O9VR>7;6\:Q1)DG:J@ #)Y/ [UG#W5)/JT_PL5+5Q
M?9/\SYHT+_D^?7O^P>/_ $FAKV#X^?\ )%_&7_8,F_\ 0:UH/AGX;MO'4_C&
M/3=OB2>/RI+WSY3N7:%QLW;!PH'"]JV-?T&Q\4:+>Z3J<'VG3[R(PSP[V3>A
MZC*D$?@:F4;T8T^J5OS-(24:O.]KK\$O\CRS]DO_ )(%X?\ ]ZY_]'R5XM^R
M5\4M!\#ZMXFTG7KI=*34;L26]]<G9;EDW!HV<\*<$'DX_3/UEX4\(Z3X%\/0
M:+H=I]ATRWWF*#S'DV[F+-\SDD\DGDU\R?LD^#]%\;^&_'FFZ[IMOJEDVI1G
MRIUSM.U_F4]5/N"#6KES5927;]48QCRP2??_ #.K_:@^-7AE_AE?>']%UBSU
MK5M8V6Z0Z=.L^Q-X+,Q0D#(& .I)^M=!IO@>^\+_ +*-UH$T3#44T&X>2'N)
M'5Y"GU&['U%=1X4_9_\ A]X)U1-2TCPS;P7T9W1S32R7!C/JOF,VT^XP:]!Z
M\&LY1O"4>LC2,FIQE_*?/O['/C#1)/A5IVA_VK9IK,=S<#[ \ZK.V6+Y5"=Q
M&TYR!V/I7)>$]9MO@+^TQXKL_$3_ -GZ+XD+7%KJ$V1$"S[URW8 LZ$]B!GC
MFO=M'^!_@;P]XM7Q-IGA^&PUE2[+-;RR(@+ AL1AM@R"?X>];OB[P-H'CS3A
M8^(-*MM5ME.56=?F0^JL/F4^X(K24FYJHM[69FH^ZX=+W_&YQ7Q5^/OAOP'X
M+OM2T[6])U/5O+Q8V<5PL_FR'[I*HV=@ZDY'3KG%6?#?C3Q?J7P1_P"$HO=)
MM1XG>RDO8M-BCD2-@"3&NTL6RR 'KU--T']FWX:^&M1COK'PK;?:8SN1KF:6
MX53V(61V7/OBO2ZEKW6D]7^!:>JNM%^)X;\._BCX&^.W@V&7Q?!X>&LQM)'/
MIU^(\Q<G#1^8=V"N#N!X.:\L\/Z7H/AC]K+0[+X:70FTF6 G4HK*X,\"?*_F
M+NR<J $/4X8X]J]_\3?L[_#KQ=J,E]J?A:U>[D.YY+>22VWD]2PB902?4\UO
M>"OACX6^'4,D?AS1+;3/,&))(P6E<>C.Q+$>Q-5%I34[6MT[_P# )E\+CO<Z
MBOF;]K;2;[P[XH\#_$.U@DN;71;E$NPG\ $BNA/H#\RY]2/6OIFH;RSM]0M9
M;:Z@CN;:92DD,R!T=3U!!X(J-4U);IW*TLXRV>AQ^G_&KP)J6AIJT?BO28[1
MH_,(FNXTD3C.UD)W!O\ 9QFO#O@PTGQ:_:4\2?$.SB=/#]E&;:VG="OFMY:Q
M*!GN5#,?3(SUKU.?]ESX77%XUT_A.$2LVXK'<SI'G_<$@7'MC%>CZ-HNG^'=
M-AT_2[*#3[&$8CM[:,(B_0"J5E+G]?Q)=^7E_K0\3_; \(RZI\/;3Q+8@KJ?
MARZ6[21?O",D!OR(1O\ @)KB/A[KW_#0W[1&G>(S&?['\-Z7#*J,, 7#+G'U
M$CO_ -^A7U-JFEVNMZ9=Z??0K<6=U$T$T+9 =&!##CU!KGO 7PM\+_#&WNX?
M#.EC3([ME>?]])*7*@@<R,Q&,G@>M*'NR;>VZ];6_KS'/WHV7H_2]SC?VI_!
M-YXX^#^HP:?$T]Y8RI?1PH,LX3(8 =SM9CCVJ'X%_'#POXF^'.C17>MV.FZK
M8VL=K=6MY<)"X9%"[@&(RI !R/7'6O8Z\X\2?LZ_#GQ9J4E_J7A:V>[D.YY+
M>66WWGN2(W4$^Y&:4;QYET?YC=I6?5'*P_'Z^\6?'.P\(>#DT[6/#\<7F:GJ
M05Y-F-Q;RY%<+C[B@X.6-<A^UI_R4WX4?]?Q_P#1T->_^#?A_P"'/A]8O:>'
M=(MM*AD(,GDJ2\F.FYSEFQ[DU!XM^&7AKQUJFDZCKFF_;;S2I/,LY//EC\IM
MRMG", W*KU!Z5<;1E!]G=_U^0M6IKNK'44445('S=\?/VC&L]6;P+X.O[6WU
MN9_L]YK%U<)#!8]F42,0 XYRW\/09;IK_!73_A;\(=)9E\<>'-1\070S>ZI)
MJL!=R>2J9?(3/XD\GMCJ=9_9D^&OB#5KW4[_ ,-^??7DSW$\OV^Y7>[$EC@2
M #))X Q5/_ADWX4_]"K_ .5&[_\ CM*%XK7=[_Y>@Y6D]-D>E:#XHT;Q3;R3
MZ+JUCJ\$;;'DL+E)U5L9P2I(!QVJ[>6RWEI/;O\ <E1HSCT(Q7/^ _AKX<^&
M>GW%EX:T[^S;6XE\Z6/SY)=SX SEV8C@#I734Y)25N@HMQ=^I\D_LN^--/\
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M=)6DK*34=C.-^57W"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]^7+3*5SN&^-. >.AKO*IIK<F]PHK@?C5\5/^%/^"_[?_LO^U_\ 28[?[/\
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MX;%F_>2*<\@?\!/Y4>0>9NT50U^\N]/T+4;JPM/M]]!;R206N<>=(%)5,^Y
M'XUQOP4\9>*_&WA6:^\7^'6\.:BERT4<!B>+S(P 0VQR6')(YZXR*%JVNP/2
MS[GH-%%% !1110 4444 %%%% !17D/QW^/S_  5O-$MX_#S:])J@DVJMWY)4
MJ5  'EON)W>W2N0;]I[QU&I9_@?XB1%&2Q:< #_P%I)IJZ&TUHSZ-HKR3X/?
MM(:!\6KZ721:W&B:_$I8Z?=D'>!][8PQDCN" ?;@U2^(?QT\6^#?%U]I&E_"
MO6O$ME;[/+U.T,WER[D5CC; PX)*_>/2F]&D^HEK>W0]HHKY>@_;)\076N2Z
M+#\)]2FUB($R:?'>2-<(  3F,6VX<$=N]>D?"KXQ^)_B!XBFT[6?AOJWA&U2
MV:=;Z^,I1F#*!&-T*#)#$]?X3Q32;V$W;<]9HHK)\7:]_P (KX5UC6?(^U?V
M?9S7?D;]GF;$+;=V#C.,9P:F4E%-OH4DY.R-:BOF30_VO?%'B:S-YH_P@U?5
M;0.8S/8W,LT>X8RNY;8C/(X]ZU='_:_MK37H-,\;>#M5\$-.0(YKO<ZC)^\X
M:-&"^X!JK.]B;Z7/H:BF0S)<1)+$ZR1.H970Y# \@@]Q7COQ,_:B\,_#_66T
M.RMKKQ-KZML:ST_&V-_[C/S\WLH8COBI;L[=2EJKGLM%?-\W[6VO:*JW7B'X
M3:_HVEY^>\=I, ?\#A13_P!]"O9?AS\3O#_Q3T/^U- O//B4[)H9%V2P-UVN
MO;ZC(/8FJMI<FYU=%>/?'3]H*3X,ZKHEA#X;;7Y=41V0)=F%@RLJA0!&^XDM
M7)O^U!XZB0O)\$/$2(HRS,TX 'K_ ,>M2G=7133B[,^C:*\G^#O[1GA_XO74
MVFQ6\^C:["I=]/NB#N ^\48?>QW! /M7K%4TT3>X4444AA1110 55U+2[/6K
M&:RU"T@O[*8;9;>YB62-QG.&5@0>1WJU10!5TO2K+0["&QTZSM["RA!$=M:Q
M+'&@))(55  Y)/'K5JBB@ HHKQ3X@?M)'PWXZD\(>&O"=]XQUNW0-<Q6LOEK
M%P#C(1R< C)P ,CFE?6P[:7/:Z*\M\=?$;QII/PJT[Q#H7@R:X\0W+QB?1I$
MDN'M5.[<2J!6?! ' 'WL]J[[POJ%_JWAO2[W5+$Z9J-Q;1RW%F3GR9"H++^!
MJK;^3L3?;S-2BBBD,**** "BBB@ HHHH **** "BO+_$7QM_L#XTZ'X _L;S
M_P"TX5F_M'[5M\O(?CR]AS]S^\.M>H4+5<W3_('H^5[_ .845YY\;/&?BWP/
MX9MKWPAX</B2_DN5BEA6*2;RXR"=VR,ACR ,]!GFNVT2ZNK[1K"YOK7[#>S0
M1R3VI.?*<J"R9[X.1^%"U3?8'I9=R[1110 45G^(->L_"^AW^KZA+Y-C90M/
M,^,D*HR<#N:\=^'?[1NL_$K7K./3/AWJ2>&[BX,)UR6X.R,#.6*B/';! ?C/
M6B/O2Y5N#T7,]CW*BO,(?C9YOQTF^'/]C8\NW\_^TOM77]T),>7L]\9W5Z?0
MM4I+9AUL%%%% !67H?A?1?#*SKH^D6&DK<-OF%C;)")&]6V@9/)ZUJ44 %%%
M% !1110 4444 %%%% !1110 45Y?X5\?>-M6^+FNZ!J?A)K#PO:*YM=7\MU$
MF"-IWD[7W9)PHR._2O4*-TI=PZM=@HHHH **\L^,GQZL_A1?:7I5OH]UXB\0
M:ES;Z;:MM)7.T$G:QR3D !23@]*Z7X9^,-9\:Z#+?:YX7N?"5VD[1+974ID9
ME"J0^2B\$DCIVHC[R;0/W6DSKJ*** "BBB@ HHK"U#QSH&D^)++0+S5;>WUF
M\4/;V3M^\E!) ('U5ORHZV#S-VBJ>L75S9:1?7%G;?;;N&!Y(;;./-<*2J9[
M9.!^-</\$_&GB[QQX;N[SQAX;;PW?1W)BBB,4D/FI@'=LD)8<Y&>A[4+5M=@
M>B3[GHE%%% !1110 5E:]X3T3Q5'"FM:-I^L)"2T2W]JDX0GJ5#@X/':M6B@
M""QL;;2[2*UL[>*TM8AMCA@0(B#T"C@"IZ*\[\0?%X:=\5]%\":9I7]JW]Y$
M;B]G^T^4MC".=Q&UMQ(!.W(ZKSS1NTNK#9-]CT2BN(^*WQ>T'X/Z''J&M/))
M+.Q2VL[< RSL.N 2  ,C)/3([D ^0R?M>ZU96J:GJ'PIURST$X/]I-(^S:>A
M!:$*<_[WXTDTQV:/:/$WPG\'^--2_M'7/#]EJ=[L$?GW"9;:,X'7IR:T-'\#
M:!X?\/SZ'IVDVUKI$^_S;-$_=OO&&R#UR.M1> O'NC_$GPW;ZYH=P9[.8E2K
MKM>-QU1QV(_^N,BNBJFN6\6+FYM2EH^BV'A[38=/TRS@T^QA!$=O;1A(TR23
M@#@<DG\:NT44@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKM:-BV#]56OH;P]/)=:!IDTQ)FDM8G?/]XH"?UJ(^]!OJG;\+HJ2Y9+LU?\
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MVL=RH!SC>H;'X9Q7!_M.+&WP)\6"3IY$9'U\U,?K5C]G&1I/@?X0+G)^QX_
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M+XNN_#?QL\0:#J6AWGA:W\2![VUTJ^5U:&12SJ!N5205\P X&=H]*W?VZ/\
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MJ7X4W,UU^S+I<DY9I/[#E3+==JJZK^@%82?-2G?[/^5S:"M4A;K_ ,#_ #/
MOV9M>^*^F^#98?!?AS2-5T)M08SW%](%D60JFX ><G 7:?NGK7TU\9/C%I?P
M;\.QW]["]]?73F*SL(FVM.XZ\X.U1D9.#U'!S7FW[#O_ "274/\ L+2_^BXJ
MP_CNBZK^U1\,].O3NL%2&58V&5+F=R1^)1!714UG"GWMK\CGIZ0E/M?\S;C^
M)'Q^GL!JT?P]T8:>P\T6;2$7?EXST\X'..VW/^S7H?P7^-6F?&+1KF:"W?3-
M6LF$=[ILS;FB)S@@X&5.#S@$$$$>OHU?+'PZ_P")3^VEXRM+'Y+6YMY'G1>F
MXK%(3_WV3^=1'6?)Y-_<7)/DY^S7XG5?%S]HZ_\ A;\7M,T">SM9_#\MFMQ.
MR02/=ECY@"1X<+DE5 RO?K65XB^,GQMTW2[CQ%'\.=/L?#L2>>T=W*9+I(1R
M695E5@0.O[OCN*SOB5#'-^VAX'61%D7[)&V&&1D><0?J" ?PKZ1\2Q)/X<U6
M.1=R/:2JR^H*'(K.[C1]IU][\&;<JE65/HU'\3PS3?VI-1\?Z/8VW@'PC<:W
MXHFA\R\MYWV6M@02/GD.T-G&1RO!'.>*J:3^T1XY\(_$#2?#OQ-\+V.C0:JR
MQV]WI[':I8[0Q/F2*PW$ @$$9S2?L*JO_"L=:; W'5G!;'.!#%C^9_.J/[;B
MA4\ S 8E74)0K#J/]6?Z"MY)1J1[-J_S[?><T7S0D^U_P_X8]Q^*GQ(L/A3X
M+O/$%_$]RL16.*WC.&FD;A5SV[DGL >O2O(['XF?'C7M*BUO3? >A+I=Q&)X
M+>>8_:7C(R#S,O)'JH/M7J?QB^&5O\6_ MWX?FN392LRS6]P%W".5>A([CD@
M_6O%M/U#X]_!S38K"71+'QQHEDBQQS6Q+S"-1@*NTJYP/5&^M8K=\S].QL]E
M;Y]SUCX)?&>U^,&BWDIL9-)UC3I1!?6$C;O+8YP0<#@X;J,@@CW/I%>._L^_
M$;PA\0O[;N=$\/1>&?$(<-JMH(U$CL2V'+@#>,EN2 02>.>?8JTETT,X]3P_
MQ5^R[8W&O7GB#PAXEU;P;KMU(TTLEK,TD,C,2S97(;!)/&['/2LIO%WQL^%:
M$^(- L_B!H\0RU]I+>7<A?4J%R<#_IG_ ,"JYKGQB^(WBK7+_2/ /@1UAM9Y
M+9M<UIMD!*L5+(,J#@CLS'_9JO%^S?XE\>2"X^)OCR^U>,D,=)TD^1:@CIV
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M+P^CM''=:U,VZ4CTQ(G/T! /&:]E^)VI^'M'\!ZS=>*D\W05AQ=0\DR@D (
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MMP20*\9^*T:P_MD?#UT&UY+2+>1W^:<?RJC^U8VJWGQJ^&UAILEJEUE7LS?
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M<&LW]BR&.^UCXAZK<?/J<EY&CLP^8*S2,?S;^0KZ+\7^#='\>:#/HVO60O\
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MCUI?VDH_A\+6P_L5K7SS/Y;_ &C=Y!DQNW[<9']WI7IWA/\ Y%;1O^O*'_T
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MSSQ01GF8A2RJ/K@#\:\$_;F53\)]+8J"PU>( XY'[J6O=O"?_(K:-_UY0_\
MH J5[].?1IV^]7_ ;]V<>S5_N9Y-^S;\</$/QB.O+KFBV]@NGN@CN+1)$0EL
MYC8.S?,,9X/?H*]NHHIMIVLA+J?*'[:7_(Y?#C_KM)_Z,BKZOKY)_;@MWNO$
MG@"".5K>21ID69>J$O$ PYZCK73W'[+_ (\F@D0_&[Q!*&4CRY%GVM['_23Q
M^%1!OV?SD:3^/Y(YGQ39V^I?ML:'_P (\$:>!8Y=2:WZ*RH_F;B.^S:#[D#K
M7UK7RO\ LTWT/PU^)NM_#K6]%LK3Q$P9H]9MR[/>@#?ABY/!4[QMVC@Y&:^J
M*M65.*6JW^\S;YIR;T>B^[_,^3_ W_)\'B?_ *XR_P#HJ.OK"OD_P-_R?!XG
M_P"N,O\ Z*CKZBUW4)M)T34+VWM)-0N+:WDFCM(L[YF520@P"<DC'0]>E*_+
M1IM_R_JRY*]:HO,O5R7Q<_Y)7XQ_[ ]W_P"B6KR'_AISQ[_T0[Q'_P!]7'_R
M+7I'B[6;KQ%\!=>U.]TV;1[NZT"YEET^XSYD#&!LHV54Y'N!659/V,WY?H52
M?[R*\S@OV(_^2-S_ /85G_\ 0(ZM?MF+I3?!FX-]Y7VX74/V#=C?YFX;MO\
MP#=FO&OV=O@SXH\?> 9-3T?XE:OX2M%O9(386(E\LL%0E_EG09.0.G;K7JFD
M?L?VUYKL&I^-O&6J^-C 04ANMR*V#]UBTCL5]@16]2/.TGIM^%C*G+D5UKO^
MI:LO&VH^ ?V0;#6G9TU./28XK=I/O*SMLB;\%92/I4'['OPULM%\!1>+;J%9
M]=UEY'%U*-SQPABH4$]-Q!8GOD>E='^U1H37WP%UR"SB"K9B"811K@"-)%R
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M5O<?98-&TY'Q<R<@CG)CVE3NSN[$9YQ]!^&X4M_#NEQQ(L<:6L2JB# 4!!@
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MJ95;2YL&.S<QPF?WCA@6^7(88/45N?L=0QQ_ W361%5I+JX9RHP6/F$9/J<
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M^+VG?"#P[%?75O)J%_=R>19:?"<//)]<' '&3@]1P<UYO_PL+X__ &/^T_\
MA7^B?8MOF_8O./VK9C.,>=][';;GVSQ7*?M/-K%Y\?OAU9:3):QWJQH]DVH
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M4MSWET A/D0Q;5(+_=S@\'@@\'J_V3=!U/PY\';2RU;3KO2[Q;N=C;WL#0R
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M] ^%_#MIX1\.Z;HM@FRSL8$MXQW(48R?<]3[FIIZ1E+OM^%_39%5-7&/;?\
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M.BBPV'4?LS_9]WV8KCS,;<YXZ]:]O\;6\MWX+U^""-YII-/N$2.-2S.QC8
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MD))147T/F3P[X.\;_&SXOZ-XV\6:"WA/0=$VM9Z?<,?/=E.X @@-][!+%5&
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M[_C<\3_:[\/ZIXE^$GV/2--O-5N_[0A?[/90/-)M ?)VJ"<#(YKIM0TN]?\
M9YGTU;.X;43X8-N+01,9?-^R[=FS&=V>,8SFO1J*R<;PE#^;_*QHG:<9]O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_PG8Z1>:E<Q:M(Z3M>RQLR@.@^7;&N.&/7/:E9J?(UK>PU:4>=;6N??%%>
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M8>)M'O;XG M;>_BDE)]-H;-=!0 45C:[XT\/>%Y$36=>TS2'<91;Z\C@+#U
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MHAK&O:9I)E&Z,7UY'#O'J-S#-:&GZK9:M8I>V-Y;WMG(-R7%O*LD;#U# X-
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MXA>%O$%X+32_$NCZE='I!9W\4K_]\JQ- '04444 %%?$_B?X<Z;\5/VOM?\
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MCPE8ZDVGW/BC1;>_5MAM9=0A64-Z;2V<_A0!T=%5-3U:QT73Y;[4;RWL+&(
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M^TR]M]1LI<^7<VDJRQO@X.&4D'D$?A5N@ HHHH **** "BBB@ HHHH ****
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M-?[)OP=\'_$;0/$-SXBT9=2FM;Y8H6:>6/8NS./D89Y]:^JOAT-WPW\, ?\
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MK^C&O<?B]\9M"^%'AR[N;N]ADU;RR+33E<&660CY<KU"@\ECQCWP*\T_8U\
MW^C>&]6\6:M&T=[X@E5X1(,,802=^/\ :9B?H >]%/XW+HDU]^W^83^!1ZMK
M\"U^V[_R1^V_["L/_H$E>V^$_P#D5M&_Z\H?_0!7B7[;O_)'[;_L*P_^@25[
M;X3_ .16T;_KRA_] %%+X*G^)?\ I(3^*'H_S.<^-?C:;X>_"_7]=M2HO+>
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MP=\(_C#X7U;X9ZY%/HNJ3"UU72[>X:2-5+*,_,<X(8D9)P5/0'%>A_LM:/\
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M?]@\?^DT-6?VZK=V^'OA^<#]W'J@#''3,3X_D:+_ +NC*7E_Z4:02]I-=/\
M[4]:^'_P9\&_#VZ_M/P]HJZ=?3VXADE6XE?<I(8C#N1U [=J^8/#K^#M6^.G
MC9/C#(XOQ=-'IZZA)(ELJ!VP"5(P-FS;GY<9/7%?9NC7D6H:-8W=NPDAF@26
M-@>"I4$&O&/"?B#P-^TU/K5AXA\)VL.JZ1+Y#PW4@-UM!()5U"N%# @@'KBJ
MDG[3T3T^?Z'-3_@J_6VOG_P3#N/@/:6GC;PWXP^#^H:=:6L$VW48XM0:6":/
M*DJI&_.5W KD#[I&#S7TA7QC\9/A]9_LW^+O#&M^ ]5O+*[O[DQR:6\_F!D!
M7C'WF0YVD-GDCFOLU264$C!(Z4U\"MW?Z%O2>O8^?OVW?^2/VW_85A_] DKV
M7P)_R(_A[_L'6_\ Z*6O&OVW?^2/VW_85A_] DKV7P)_R(_A[_L'6_\ Z*6H
MI_#4_P 2_P#21S^*'H_S/D[6_!-S\1/VM/%N@Q:M/H]G=6X%]+:\2R6XCA+1
MJ>VX[1SQC/!Z'WZU\&^&/V<_A[XEU7P]8/%Y5J;F8SSO(9Y(U;9G)P.6Q\H'
M6O+_  7_ ,GN>+/^O%O_ $7#7N/Q>\.W'BWX8>)M(M 6NKJQD6%1U9P-RK^)
M 'XU#]W#1<>L?\S726(:EM=?DCY;^$=O\+O%&FW/BCXH>(;75?%.I3N[V]]=
M.HMT#$*-JD<G&<'@#: !4/BS7O!/PC^(WAKQ)\+M<A>TN)_L^JZ3;7#21F/*
M\_,2<$%N_! (Q7=_LG:3X#\:_#M=.U+PWH5[XCTR61+H7FGPR7#(7)1R67<1
MSM]MN*W/B]K'P]^%>N>'](LOAKX<U[6M5F"+9Q6EO#)$"0%<XA;JQP.G0UT:
M1J12\K6Z_P##G/K*$K^=[]/ZZ$_[:AS\%LCD?VE;_P GJM\,_P!FOP]XD\(Z
M3K?C@3>)]7O;*!T,MS+'%:P[!Y<4:HR\!<9SWS5C]M3_ )(L.,?\3*W_ )/7
M?_ _QAI/C#X9^'Y=*O([DVMC!;7$8(WPR)&%967L<@X]1S6=/:?JOR*G>\/1
M_F>!G1%_9O\ VE/#]AH,\T?ACQ*$BDL9)"ZH7<IC)/.UMI!/."1D\YZK]J[Q
M9JU_K'A3X<Z+=/92^()E%W+&<$QLX15X_A)W$COM K!^+FJ0?$G]J/P'H>C2
MK>_V)*DMW)"0RQLL@ED!(]%1<^YQUJW^U%YO@WXP?#GQQ.CMI-K,D%Q(HSLV
M2[S^)5FQ_NFE'WHTN;9R:^73Y7*E>,JCAORI_/J=]:_LD?#.WT-=/DT22XFV
M;6OGNI1.S8QOX;:#WP!CVKB/V=]:U3X=_%CQ)\)]1O9;_3K0-<:;)-]Y%&UM
MH] R.&QT!!QUKZ/MM7L;S2TU*"[AET]X_.6Z60&,IC.[=TQCO7S%\))E^)/[
M5_BSQ?IG[W1+&$P+=*#LD;8D*X/^T%=A["KC?VMGV=_T(DE[._FK?UZ%/]IC
M3=0UK]HOP'8:7J!TJ_NK1(8KU0282TL@+C'< G'OZ5ZUX3_9=\!>%=/O+<V%
MSJ<]];FUO+J\NY-\Z%E<@A2H&613P,\=>M>=_&S_ ).Q^&/_ %SA_P#1TE?3
M]13_ (7JY?F5/^)\HGQ=\-_@_P"$-=_:1\;>&+[1EGT/3X9&M;3SY5$9#Q@'
M<&#'ACU)ZU[1\=->A^ _P-DM/"T7]F9==/L0CLQ@,A9F8%B3D .1SP2/2N&^
M%\B:;^V3X^MIV"2W-M(8@>-V3"^!_P !R?P-=?\ MD>&[KQ!\&IIK5&D.F7D
M5[(JC)\L!D8_AOS] :SFW["'FE?[_P#(N*_?S\F[?=_F>=?#_P +_ 2Q\*V;
M>)=;TW6M?N8A+?7-W>2[A*PRR@*0!@DC/4]<U#\*?$NB?#O]HB'PYX+UL:KX
M)U^/(MUF,B6\VUB "><@IC/4JPSG&:]<^#_AGX;?$+X>Z-JMKX3\-W,WV>..
M[4Z9;L\<ZJ ZO\N<Y!//4$'O6/#XJ\$Z/\>M-\%>'/A]H4]_&GFSZS8P0Q/8
ML%8L,+$3D +_ !#E\5U/W:UO73R_K6Y@O>I-_P!7.<_:EUG4_&'Q \(?"_3[
MQK*UU5DFO7C/WE9RJAO4*$9L=SCT%=I-^R)\./[&%K:Z;<V5^B 1ZI'>2F=)
M!TDP6VYSSC;CTQ7G_P"T)<#P'^T?\/\ QA>[DTAD2"6;'";78/\ DLH/YU],
MWOB#3--T=]6NM0MH-+6/S3>/*HBV8R&W9P0?UK"%O9<W6[O^AM*_M++LO^"?
M+?[*=CJ&E_'+XAV>JW?]H:E;QM%<7?\ SV=9P"_XXS^-?6E?*'[+NO6GBCX^
M?$G5K!F>RO5DGA9UVDHTX(..W%?5]7&_LJ=][?JR';VD[=_T1\P_M":IJ/Q,
M^,?AOX4V=[-8Z5,JW&I-"<%\AG(/J%1<@'C+#T%=SJ/[)'PUO-#>P@T5[*X\
MLJE_'<RM,K8^^<L0?H1CV%>>?%"Z7X:_M;>&?%6IMY&BZE;B!KIA\D9\MH6R
M>V,HQ]C7TY?:Q8Z9I<NI7=Y#;Z?%'YSW4D@$83&=V[IBIC;V5_-W^_\ R+DW
M[2WDK?UZG@'[*/C+5X;_ ,4?#S7;E[RY\.S,MM/(26\I7*,N3_""%(]FQT K
MA_B5X8O_ !E^V VC:?JTVB/=6*)+>6_^L6'[.3(J'L64%<^]=#^RI#+XL^*7
MQ&\<PPM'I5[/)#;NP(W[Y?,P/<*JY_WA4DW_ "?5!_V#O_;5J>LO9N>[6O\
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M"_AS;?M%:AKOC[Q[YVK(UVUM9V!F=(HP &(^4@[5#* ,XZDYS7U%XNTE]?\
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MW04 2(<%B1]_G;FG&ZJ-/>ST_KL3HZ=UM=:_UW/=*^8?CW_R<_\ "C_?A_\
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M2.F$.3A6"@[<XX..]<YX%T&T_:$^-WC./QW>W-W!HL[I8Z)Y[11A!(R' !!
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M2?B-\/[#6/%UQ<:OIL4DT6GZ.)GB@@^<[W.P@EF;/?H!G/&/3?\ A'[GPO\
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MVUQ*V70;@K!F.<XQGJ.#GM7(?#74(OAG^U=XVTK6I%LTU\O-9S3$*DC/)YJ
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MS,*5I1ES[:_\#]#IOVIO _AOQ)\+=4\93:>)M:MK*$6EX97!2-I5(&T-M/\
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M>8K*0P 8'\*F-YTX=^9I?)Z(M^[4DUM9?EN>>:;\*?@1\2?"[6'A>73TU.:
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MGYHV?VK/&@O_ !EX7^']SK/]@Z#?!;K5[Q7V_NBQ 4GTPC'!X)*^E0W?A/\
M9KN-%:PCU+3;>39M6\COIO.5L??R203WP1CVJI^TQI]EX;^/'@7Q3KME%?>&
M9T6TNUN81+$-KMNW*00<+(&P?[IKW5?AG\-FTW^T1X3\+&P\KS_M0TVV\KR\
M9W[MN,8YS64;>R;?=W_KTV-9/]XDNR_X/XGEG['7CB\U;2?$7A:[U#^U8=!N
M%6RN]V[? Q<  ]U!3(] V/2OHRO%OV>?'7A_QQ?^*'\-^"-.\,:=8S+;KJ%@
ML:_;N7VDA8DQ@ -@DXWU[36TG>S?9&:T;2[F)XJ\6:!X4TYYO$.IV.G6CJ0?
MMLJJ)!CD!3][Z &ODGXA7GPU^)6I26_PZ\":QJ^OJP(U'0$-C!&>S$%2!SU)
M1?\ >JK#JGPITSQ9J6H>)/#OCCQ?JWVJ3?)?6T;0 AS]U1,-R]@')&.U>J:9
M^UIX)T6SCL].\%^)K"TCX2"UTJ".-?HJR@"LHVDE)_A_F:.\6XK^OD>J?!W2
M]>T7X::%9>)WFDUV&%A=-<3^?)G>Q +Y.["E1U-=D3@9/ K"\'^,K/QEX2L_
M$,$-Q865S&T@CU!5CDC56*G> 2!]TGKTKY_\=?$;7_VAO$5QX%^'4C6WAZ,[
M=6\0X(1DZ%5(_A// Y?V7)-R<I2:2U(BDHIMZ(R?BIJA_:6^,&B^#?#W^D>'
MM#E:74=3C&Z,DD;R#T( 7:OJ6/;FOK-5"*%484# %<E\,OACHGPI\-Q:1HL&
MT<-<74G,MQ)CEW/\AT':NNHTC'E6OZO^M@^*7,_Z_KJ<U\2(]?G\#:S#X7V_
MV_+ 8[1F<)M9B 6R> 0"2/<5XE\/_P!GWP#X-\*P2_$<:=+XGNM\MY)JFI !
M"6. OS@=,'=R<D\UVW[4OC'5_!/PAOKW19Y+2\FGBMC=19#PHQ.YE/8\8SVW
M>M<S\(?V=_AW>> ](\0:G:)XDO[^U6[N=0OKAW7<RY<;=VT!3D<@G@Y-3'7F
MEVLOU*E]E>K_ $.%^&TFD?#G]J>/0/!>JQWGA36K5F:"UNQ<0HPB=P-P)R59
M.,G(#8[U/^VI\._#VCZ':>)K/3EAUS4=26.ZN_-D)D7RFXVEMH^ZO0#I63H=
MQX2D_;$\.P^"XK./1[:%X";! L+2K!-O*D?>Z@;N^.IKOOVY;=Y/A?I$RC*1
M:LF[VS%)C^5*5O9PEY_AS%1TJRCTM?YV9Z5\,_@UX.\!_9M9T+15L-2N+-8Y
M)UGE?<K!6889R.2!V[5Z'65X5NXK_P +Z1<P.)(9K.%T93D$% 16K6U3XVNQ
MA3^!,^>?&WP9U;XE_&J?5/&Y5?A[I\&+.$7H178!<A@""NYBQ)X/R@9KC/C_
M /#[X4:3X$N]4\(ZAI.F>)=-:*6WCTW4PTLGSJ"-F\G(!W9 SQUIGA?1;;]H
M#X_>,;'QQ>W-Q9:++(EAH@G:*/:LA3H"#P "<8)+ DUL_M)>"_A?\-?AIJ%G
M8Z/I=AXCO$1+%$7S+GB0%G!)+*-H8;C]*YGI2C):7U7??\SIWJR3Z:/M_P ,
M>W_!GQ)=>+_A7X9U>^<R7ES9H9I#U=URI8^Y*Y_&NLOVG6QN3; -<B-C$#T+
M8./UQ7GG[-O_ "0WPA_UZ'_T8U=[KVI/H^B:A?QVS7DEK;R3K;H<-*54MM!Q
MU.,?C6^(MS3Z;F%&]H]=CXK^!,/PVU[4M?\ ^%JS*WC&6];<VMSR0Q[<#=\V
M0H;=N!W'TQWKV'PE\#YO!?Q;T[Q/\/+^SB\$7<.S4+,7KRK)]X'R_O!@#M89
M;@Y[<5>\'VOPY_:F\.S:WJ/A>T34(YFAG02[;I, ;2TD>UB".F<C@^]>7S>%
MQ^S[^T3X2T?P?K%Y-IVM21B]TN:42;49]I# 8SQEE)&1CJ:<;J<(M6>WEM^H
M2LXSDM5OY[G2_MO?\>O@3_L(R?RCKT/]JW_D@GBCZ6__ *41UYY^V]_QZ^!/
M^PC)_*.O0_VK?^2">*/I;_\ I1'7-4_AO_%_\B;0_BQ]%^;///@?^SKH?C7P
M#H6O^-)[GQ')-:*ME9//)%!90 G:BA""3W)SC)Z9Y.):^%;;X'?M9>']*\--
M);:-KEL/,LFE9U56\Q2N222 T889)->Z_L\_\D3\'?\ 7@G\S7DOQ:_Y/$^'
M/_7I'_Z,GKLE[N*C%;.5OEJ81]ZA)OM?\C5_;(\0:A:Z!X8T"WNI+#3];O\
MR+VXC)7]V-ORD^AW$D=]M=9JG[,?PW_X0^?3%T&WM?+@;;J6YOM",%_UADSD
MX(S@\>V*YO\ ;%U:T3PCH.B7UI;BWU;4!&VK72NR:=MQF0!""6PQXZ8#<&N2
M7P;8:AHL6BW/[25M<: RB-K+[1 DK1XQL,AG+8QQ@@CVKFMS0DEO??Y+\C:]
MI1?E^K.R_8P\27^M_"J>SO7::'2[Y[6UE;_GEM5@OX%C^! KF_V6O^2R?%G_
M *_&_P#1\M>\?#7POX>\'>#[+3/"[12Z3&"4GBE$OG,?O.SCAB3_ (# XKP7
M]F%UM?CC\6+25@ERUV[",GD@7$F2/IN'YUO>]?\ [=?Z&6U%_P")?FR7]JSQ
MH+_QEX7^']SK/]@Z#?!;K5[Q7V_NBQ 4GTPC'!X)*^E0W?A/]FNXT5K"/4M-
MMY-FU;R.^F\Y6Q]_))!/?!&/:JG[3&GV7AOX\>!?%.NV45]X9G1;2[6YA$L0
MVNV[<I!!PL@;!_NFO=5^&?PV;3?[1'A/PL;#RO/^U#3;;RO+QG?NVXQCG-81
MM[)M]W?^O38TD_WB2[+_ (/XGEG['7CB\U;2?$7A:[U#^U8=!N%6RN]V[? Q
M<  ]U!3(] V/2OHF6-9HWC<;D<%6'J#7C/[//CKP_P".+_Q0_AOP1IWAC3K&
M9;==0L%C7[=R^TD+$F, !L$G&^O::UE[R5^J7]?,SC[K=NY\7_$;X/\ A#1?
MVEO!7ABRT=8-"U&W22ZM//E(D8O,"=Q;<.%7H1TKZ4M_ASX=^&_@/Q'9>'--
M73;:XM9YI(UEDDW/Y1&<NQ/0"O&OC1*FG?M;?#6[N&$=N\$40=C@;C+*O4^[
MK^=?1/C#_D4=;_Z\9_\ T6U8W_V9^LC=?[PO^W3P_P#8=_Y)+J'_ &%I?_1<
M5>9^#_AT_P 3OVB/B1I$^J7&GZ*+N:74(+5MKW:";Y8MW9=QR?I^(],_8=_Y
M)+J'_86E_P#1<59'[/\ _P G,?%?_KI-_P"E%;RUQ$;_ ,K_ "1RQ_@O_%^K
M*/[2'[.W@_P3\,[CQ'X7TZ31]1TR:%S)'=2OO5G5.=['!!8$$8/%=!\*O@9H
M_P 4_">F^,OB!=7GB[5]4MU=%N;AXHK:/HJ(J,.>.2>"3TSDGLOVK?\ D@GB
MCZ6__I1'6O\ L\_\D3\'?]>"?S-13UC-OHU^*-9?9^?X6_S/#O!/A^'X+_M<
M)X9T-YH=!UBT+?97D+A08F<#).3M>,X)YP<5T'[6WC>3^UO"W@7^UO[#TS5Y
M!-JM]OV[;??MP?;AR1WP!57Q;_R?%X5_[!__ +1GJK^UAI\&A_%+X?\ BW5;
M*._\/1NMI>Q31"6/:LF\AE((.59B >NTTOB5)/:[6OJ[#E[LZG+_ "I_-K4G
M_P"$3_9J_L?[!_:.F[]FW[9]OE\_=C[^<XSWQC'MCBKO[(/C2>6Z\5>"FU3^
MV=-T:7?IEYNW!H"[+@'^[PI [;C7K=I\-?AK?Z7'J5OX4\+3:?)'YR72:;;&
M,IC.[=MQC'>N,^ WCKPUXR\6>*[?PMX(TS0-/TUA -9T](T^VC>P486)< A=
MV-Q[5<?C:?9Z?U_70B7P)KNM?Z[GMM?'OQ:\/ZCXJ_:\L])TO4WT>XN[!(WO
M8O\ 61Q&%_,V?[13<!]:^PJ^2OB!XITWP;^VAI.IZM<"TL%M(XGG;[J%X70%
MCV&6&3VJ4DYQ3_K1ENZIS:[?JCTG4/V0/AQ=:!+8V^ESVU\T6U-3^URO,'Q]
M\@ML)SU&W'TKG_V./&&I76C^(O"&K3M<3^'KD1PM(Q)6,EE*9/960X]-V/2O
M>M6\2:9H>A3ZS>WT,&F0Q><UTSC9MQD$'OGMCKD8KYR_8UM;C6M8\?\ BYXG
MCM-3O0L.X8W'>\C?EO4?C3@WSR72VOWJQ,K<B?6ZM^IC>&-%3]J/XV>)KOQ%
M//<>$_#S^1::='*41\LRKG!R-P1F)'/09Q75?&?]F7POI'@F_P#$'@ZSE\/:
M]H\1O8I;2XD^<1C<1\S'!P"01@Y'>L/]F?4(OAU\8/'_ (*UB5;2]N[H2VGG
M';Y^UG(VYZEDD5@.X!KV7X_>--.\%_"KQ#+?3QQS7EG+:6L+, TTCJ5 4=3C
M=D^@!K&3<:$91WM?Y_\ #FL?>K24MKV^7_##/V>_B)<?$[X6Z7J]\0VHQEK6
MZ8# >1#C=^*E3]2:\I_8J_X^OB+_ -A&+^<U=M^R-X9N_#7P6T\WD;0R:A/+
M?+&PP0C85#^(4-]"*XG]BK_CZ^(O_81B_G-73/\ BOT_6-SGC_#7K^DCE?%G
M@^\\>?M@^(-%M=7GT6*YM(Q=W%KQ*T MHM\:GL6X&?0GKT/=_%3]E?P#I/PO
MUV[TC2Y+'5-/LI+J*\-U*[,8U+$,&8J=P!' '7C%9VA?\GSZ]_V#Q_Z30U[C
M\7/^25^,?^P/=_\ HEJY9>[A8M;\M_S.F/O5K/NOR1Y]^SK(GQ0_9[L=.\2(
M=2MF\VPE621@98D?Y06!!X&!P>U>.>!?@_X0U?\ :?\ %_A6[T99M L;1I+>
MS\^4!&'DX.X-N/WVZGO7K_[&G_)#[+_K]N/_ $*N0\!RKIO[;'C*&X.R2[LF
M$(/&XE('[_[*D_A79)+ZPO.+_),Y_P#EPTNDE]USZ+\+^%M+\%Z';:/HUJ++
M3;;<(H [/MRQ8\L2>I/4UK51UK6K'P[I-WJ>IW,=G86L9EFGD/RHH[__ %N]
M97@?XA>'?B1I<FH^'-3CU.TCD,3LJ.C(V,X*N PX/<<UEK)LKX4='1112&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !63XH\*Z5XTT2YTC6K*/4-.N!B2&3/X$$
M<@CL0<BM:BDU?1C3:U1X':?L5?#ZUU!9WGUJYM@^\V,MXHA/L=J!\?\  L^]
M<EX-TJST/]M;5=/T^VCL[*WTM8X8(5"HBBVAP *^J:Y>#X9^&[;QU/XQCTW;
MXDGC\J2]\^4[EVA<;-VP<*!PO:JBW&:?2S_%6$]4^^GYIB?$3X:Z!\4M!_LG
M7[0W$"MYD4D;;)87QC<C=C@]\@]Q7FOA?]C?X>^&]6COI$U+6C&=R6^ISH\.
M>Q*HB[OH<CU%>YT4E[KN@>JLS@O /P9T+X;^)?$.M:3->M<:W)YD\-PZ&*/Y
MV;$85 0,L>I/&*S_ (G?L\^$OBMJ4.IZDEW8:K&H7[=ILPBE=1T#95E..QQG
MWKTVBET2[;#ZM]SR'0?V6_ ^@Z?J</E7VHWM_;26C:GJ$XEN8D=2I,9V[5;!
MZ[<_AQ7;?#?X>Z=\+O"=OX?TJ:ZN+*!W=9+QU:0EF+')55'4^E=11579-CA/
MA?\ !S1?A+)K3Z1=7]R=6F6>?[;(C;6&[ 7:BX'SGKGM5WXH?#+2_BUX8_L+
M5Y[RVM//2XWV3HLFY<X&65ACD]JZZBILFDOZT*O;4I:'I,.@Z+8:9;L[P65O
M';1M(06*HH4$D #.!Z5Y!XP_9%\#>+_$-UK!DU72+FZ<R31Z;<(D;.3DMM=&
MQD\\8'M7ME%-ZOF>XEHN5;'G_P 2O@KH?Q4TG1M.U:ZU"WATMQ)"UG(BLQVA
M?FW(V>!V KJO$WANV\5>&=1T.[>6.TOK=[:1X2!(%9<$J2",_4&M:BB7O)I]
M07NM-=#E_AO\/=.^%WA.W\/Z5-=7%E [NLEXZM(2S%CDJJCJ?2LO6O@WHNN_
M$[2O'<]U?IJ^FQ"**&.1! P&_P"\I0L3\YZ,.U=Y13NW)2ZH5K)QZ,Y+XD?"
M_P /?%;15TSQ!:--'&V^&>)MDL+8QE&^G8Y![CBN!\-_LC^!= U"WNKE]5\0
M+;G=#;:O=+) A[?(J*#]#D>U>UT4E[KNAO569P?@+X-:'\.?$WB'6]*GO7N-
M<D\V>&X=#%&=[-B,*@(&6/4GC%4M>_9_\*^*/B!<^+=66ZO[JXM?LDMC,Z&U
M9-FS.W9NW8Y!W<'D5Z312Z)=@ZM]SP'_ (8H^'_V\3FXUMK</N%B;Q/)Q_=S
MY>_'_ L^]>W:!X?T[PMH]KI6DV<5AI]LFR*"$851_4GJ2>23DUH455W:PK:W
M/(_B+^R_X,^)/B)]<O#J&EZE+CSIM,F6/SB!@%@R,,XQR,9[UZ+XB\)Z3XMT
M&71M9LH]1TZ50KPS#KCH01R"/48(K7HJ?L\O0?7FZG@3_L6^!C(X34O$,-FS
M[C8QWJ>3],&,G]<^]>P>"_ ^B?#W0XM(T"PCL+%#N*KDL['JS,>6)]2>P'05
MNT55VE85KNX5\M:;?6^G_MP:]-=3Q6T0T\ R3.$7/V:'N:^I:\J\;?LT>"/B
M#XFN]>UBUO)-0NMGF-%=,B_*@48 ]E%3&\:BGY-?>5HXM>GYIGJ%K=07T"S6
M\T=Q"WW9(F#*>W!%2UA^"_!VF^ ?#5GH6D))'I]H&$2RN78;F+')/7DFMRJ=
MKZ$J_4*X7XM?![1OC)I%EIVM7-]:P6D_VA&L)$1BVTK@[D;C!]*[JBI:3W*3
M:V/G3_AA;P'_ -!?Q'_X$V__ ,8KM?A1^S?X:^#VO7.K:-?:M<W,]N;9EOIH
MG0*65L@+&ISE1WKU:BJ3:V):3W/"/%7['/@SQ?XDU/6[S4]>BN]0N'N94@N(
M0@9CDA082<?4FLO_ (86\!_]!?Q'_P"!-O\ _&*^BZ*E)15D4W=W9B^#?"MI
MX'\+Z;H-A)-+9V$(AB>X8-(5'=B !GZ 5P7Q!_9C\!_$6_EO[S3Y=-U&4[I;
MO2Y!"TA]64@H3[[<GUKU>BG+WGS/<2]U61X'HW[%/P[TN\2>X?6-613GR+R[
M4(?KY:(?UKW#2=(LM!TV#3]-M(;&RMUV16]N@1$'H *N44[NUA6UN1S0QW,,
MD,T:RQ2*4>-U!5E(P00>HKQ+Q1^QS\.O$E\]U#;W^ALYW-'I=PJQDGT5U<+]
M%P/:O<:*FRO<J[M8^#Y/ >F_LY?$:[D\9^#;CQ9X;WA]-U)22BC.1N7B-VQP
M4?'(R."*^M?A'\7M%^,&BW>H:':7UI;6<PMF2^C1&SM#<!'88P17=U'#!';J
M1%&L8)R0B@546^7EEJ2TKW1\Z_MIZSI]]\)H(+:^MKB==4A+1Q3*S#"2 Y -
M>\^$_P#D5M&_Z\H?_0!7E-]^R#\.=2OKB[FL[XS3R-*Y%XP&YB2?U->R6-G'
MI]G;VL((B@C6),G)VJ,#]!2A[L))[MI_A8<M9*VR37XDK*LBE6 96&"I&017
MAWB']C?X?Z[J\M_ =4T7S6W/;Z9<HD.3R<*Z-@>P('H!7N=%*RO<=W:Q\<_M
M)?#;P]\,;?X<:9X>L%LX6U*1Y9&)>69LP_,['DG]!V KZF\>>"['XB>$]0\/
M:E+<065\JK)):LJR##!A@LI'51U!JOXT^&?AKXAR:;)X@TW^T'TZ0RVI\^6+
MRV.,GY&&?NCKGI744;QY9=V_R_R%LTUV_5_YG._#_P #V'PW\)6'AW3);B>R
MLPPCDNV5I#N<L<E54=6/:G>/?!.G_$;PG?\ A[53,EE>*H=[<J)%VL&!4D$
MY Z@UT%%.7O?$$?=V.=^'_@BS^'/A.Q\/6%U=W=E9AA%)>NK289BV"551@$G
M'%<_\3O@CH?Q8U+1+[5[O4+:7269X%LI(U5B64_-N1L\J.F.]>A44VVY*3W$
MM%9;!1112&%>?>$O@GH?@WXA:WXQLKO4)=3U?S//AN)(S"N]PYV@(&'*CJQK
MT&BC9\W4'JK,**** .>\;?#_ ,/_ !%TG^SO$.F0ZE; [DWY5XV]4<$,I^AY
MKQJ;]AWX?RW!D6_UZ%"<^2EU%M'MS$3^M?0U%*RO<=WL<7\.O@]X4^%=O(GA
M_2UMYY5VRWDK&2>0>A<]![# ]JO?$;P#I_Q.\)W?A[5)KJWLKED9Y+-E60;6
M##!96'4>E=-13E[VXH^[L8?@CPA9^ ?"NF^']/EGFL["/RHI+EE:0C)/S%0!
MGGL!57XC?#_3/B?X3NO#VKM/'9W#(YDM659496# J64@'C'0\$UTU%$O>W"/
MN[&'X(\(VW@/PKIV@65Q<W5I8Q^5%+>,K2E<D@$JJCC..G0"M#6-,BUK2;W3
MYV=(;N![=VC(#!74J2,@\X/I5RBB7O7YNH1]VUCC_A;\+]*^$?AE]#T>XO+F
MT:X:Y+WSH\FY@H(RJJ,?*.U4_B=\&]%^+$VB2ZO=7]LVDS-/!]BD10S$J2&W
M(V1\@Z8[UWE%-N[3?05K*P5P?@'X-Z+\.O$WB'7--NK^>[UR4RW*74B-&A+L
M_P @5%(&6/4FN\HI+1W0]U8X_P"(WPG\,_%738[3Q#8?:##DP7,;%)H2>NUA
MV]CD''2O-]/_ &,_ EM>02WEYKNL00GY;.^O5,7T^1%;'T->\44+1W0WKHRM
M9Z;::=I\-A:VT5O90QB*.WC0!%0# 4+TQCM7BVK?L>>!;_6+B_L[C6M$$YR]
MKIMVJ0\G) #(Q ]@<#MBO<J*-W=[BV5EL>/ZM^ROX$U'0=*TFWM[O28-/N/M
M0EL95\V>0@#,KNK%NGMCMBO3_$/AW3?%FCW6E:O9QW^GW*[)8)1PP_F"#R".
M01Q6C10_>T8+35'@TO[&O@K=,MKJWB/3[.4Y:QMK]!"?;#1DD?4FO4/A]\-/
M#WPOT=M-\/6 M(9&#RR,Q>29L8W.QY/TZ#L!74T4[M*PM]3S;XJ?L_\ A+XO
M7$%UK,-S;:A"GEK?6$HCE*9SM.Y64C)/49%8?A7]DWP#X4L]0BBM[R_N;RWD
MMOMM]*LDL*NI5C'A0JM@GYMI->RT5-E9KN5=NS9RGPS^&^F?"KPK%H&DSW=Q
M9QRO*)+UU:3+')Y55&/PK.\ _!O1?AUXF\0ZYIMU?SW>N2F6Y2ZD1HT)=G^0
M*BD#+'J37>455W?FZ["Z<O01E#*01D'@@UXIXB_9%\":YK$NHVC:IX=FE),D
M>CW*Q1DGKA61MOT7 ]J]LHJ;*]QW=K'GGPQ^ _A'X3R2W&C6<LVHRKL?4+Z3
MS9ROH#@!1Z[0,]\U8^*?P<T7XNQZ2FL75_;#3)FGA^PR(FYCC(;<C9'RCIBN
M[HJFV[>1-M_,*X/P?\&]%\$^.?$/BJQNK^74=;+-<Q7$B&)-S[SL 0$<^I-=
MY12V?-U'NK',_$;P#I_Q.\)W?A[5)KJWLKED9Y+-E60;6##!96'4>E7_  EX
M9M?!OAG3=#LI)I;33X%MXGN"#(548!8@ 9^@%:]%"TNEU#>U^AX[XR_95\#^
M+]<DU=%U#0;^9B\LFCW"PB1CU)5E8 G_ &0,UJ_#7]G?P=\+]2;4].M[F_U8
M@@:AJ4HEE4'KMP H)]0,]LUZ;11'W=@E[VYQ?Q6^%.D_&#P[!HVLW%[;6L-R
MMTKV+HC[@K* 2RL,8<]O2NLT^R33=/MK2(LT=O$L2E^20H &??BK%%"T32Z@
M];7Z'!VGP<T6S^*UW\0$NK\ZS<P^0\#2)]G"[%3(79NSA!_%US6]XV\$:/\
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MP60*PP2I((S]0:\+_P"&%O ?_07\1_\ @3;_ /QBOHNBE97N.[M8^=/^&%O
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M3RGU07>S[.P<!LIL.[ 8-]X9Y]*]2Z\BA:KF0;.PM>7_  Y^."?$+X@>)O#
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M=<;0]OF_;O.;/E==^WR>F.<YQCO7K?PU^)6B_%7PS'K6ARNT!<QRPS*%EAD
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M>DNM/N9+65X;> H61BI*DS XR.X%9O\ PW3X#_Z!'B/_ ,!K?_X_7/?LZ_\
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M-G!PS*,<'O70Z'JT.O:+8:G;JZ07MO'<QK( &"NH8 @$C.#ZUXC^VM_R1?\
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M]'\53^&?"GAS4/'&MVY(N(M/)6.,C@C<%8D@\'Y<#UJ;ZV';2Y[917A7A_\
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MO/VD/!NE>(O$ND:G/<Z9)H./M%Q<QKY<K$@!(@K%G;GIM'0GM7.Z!^V1\/\
M7-:ATZ3^U-*$S!$N]0MD6 DG R5=B ?4@#UQ2C[UK=1OW;WZ'NE%<C\3/B38
M?#'P['J]_8ZAJ-O+.MNL>EPK+("RL0Q!91M^7KGN*^2?V;/CMI/POM?$T>I:
M3KFHG4+Q9XSIMLDH0 -D/N=<'D>M*+NVNPWHD^__  3[#\;?$#P]\.M-BO\
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MZ=:PH]Q"AY'F?/L4XYQN)QS74_"OXY>%OC!'<#0[B:.\MQNEL;R,1S*I. V
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M_@-$;2YEU1,KQL^C/9J*Y.Q^*GA74O&USX0MM727Q%; F6R$4@Q@ D;RNTD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRG]
MIOQY_P ('\(=7FBD\N^U!?[/ML'!W2 AB/H@8_7%>K5\K?'*X/Q8_:*\'^ 8
M3YNG:8RW-\J],D"1P?I&JCZN:B4?:-4^_P"77\"HOD3GV_I?B8/P1_:@\!_"
MGX=Z=H,NEZ[+?(6FNYH+> I)*QR2"9@2 -H&0.%J/]GGXIZ,O[0^OP:,MQ9^
M'_%#-)!!>(L;1W S(!A68=3(HP?XA7V4 %  & *^;?VR]&N=+L_"GCK3@4OM
M$OE1I%ZA6(9"?8.F/^!UKSI5%.773Y/3_(A1;@X1]?FM1?VZ.?AOH?\ V%5_
M]%25[MX'T6R\/^$-'T_3K:.TLX;6,)%&, 94$GW))))[DU\Z?M?>(;?Q;\$O
M"&LV9S;W][%<)[;H'./J#Q^%;6G_ +4@^&^DVFC?$+PQK%AK=M$L8FL8$>WN
MU  61"SKU'4#.#Z= H^ZIQ>_-^B*E[WLY+:S_,Q/B-:IX5_;+\&7UAMAEU6&
M/[2J<;BWF1,2/=0/RH_:RTVWUGXN?"RPO(Q-:75R()HST9&GB##\032_"W2-
M>^-_QS7XF:KI,^C^'=.CV:;'<@AI<*0@&?O<LSEAQGCFH/VO5U)OBE\,AHX1
MM6\TFT$GW?.\Z/9GVSC-*'N>R4OYF_D[V7_ ')\RJN+^RE?ST_JY]4V]O%9V
M\4$$20P1*$2.-0JJH&  !T %?+?PSMT\)_ME>,-*L-L=C>6TDKQ1_=!98Y>G
MLQ/YFNANOVQ]+\.VYL?$?A+7M,\31+MET\0IY9D_V79P=I/?:>/7O7_9K\#^
M(=9\<^)/B?XHL)-+N=6#1V=I,I5@C,"6P>0H"JHR.1D].KA_$Y^B3U]=B)65
M/EZW6GH8GQ$T>RU[]M3PM9ZC:QWEHUDCM#,NY&*1S,N1WPR@X]J^EO%5_)I'
MA;6+V# EM;*:9/\ >5"1_*OG7Q;_ ,GQ>%?^P?\ ^T9Z^FKJUCO;6:WF4/#,
MC1NI[J1@C\JAINC9?WOS9HVE7N^T?R/C/]F;7_B)HW@_4;KPGX&M?$<-Y?,U
MSJ5QJ,4,C2!5^0AG!P,YS_M&NB^,FA?&'XQ^'K73+WX:VFGR6MR+F&[AU:V9
MT(!! S)T.?T%5O!'B+5?V1]?UO0O$NCW]_X-O;C[19:K8Q[PIQ@9R0,E0H92
M005R 0:O>.OC9KGQZ;3?#7PLM==L"URLEYK0+6HB0 C!=&X7G)R03M  -6[5
M.7EUV^5K?=8A7A?FTW^?_#G>?M > ;WQI^S_ +;R$G7])M8;]ER&82QQ_OER
M.#\I?IU(%6/ _P 9(I/V;4\8W$@>ZT[3VAF#?Q7$8V*#[LVP_P# J]:T_3_L
MNCVUC/*][Y<"P22SDLTN%"EF)ZD]3GUKX)\1:-KGA_Q5K/P6L@PL-4U^"XMV
MR>(F!V_AM,;'WCJ97E*=-?:V];V_)_@.-HQC-_9_+?\ -?B?17['O@^71?AQ
M/XAO06U+Q%<M=O(WWC&"0F?J=[?\"KF?V;_^3@_B[_U]R_\ I2]?26C:3;Z#
MI%EIMHGEVMG EO$OHJJ%'Z"OFW]F_P#Y.#^+O_7W+_Z4O6B:>(5MN67Y(C7V
M+ONVOS9T'QBUSX=^"_BQHOB+5AJNL^-;>)4L](TP"7"X<*60X .6)'.<X(%5
M/''Q=\8>*/ _B"T/PCU:WTRXT^=);G4+M(3$A1LN8V3/ YQG/%<M\0;RZ^"G
M[34_CW6](NM2\-:A!Y<=Y;1[S 3$J$9)P&!4\$C*L<>E=%XQ^/\ >_%/P;K>
MG?#_ ,-ZA<PO93?;M8U.$0VUM#Y9+[<$[W*Y ''.#@\USO6C]^G;^NK-]JJ^
M6O?^NQM?L7S/)\$X59LB._N%7V&5./S)KEOV?_\ DYCXK_\ 72;_ -**Z;]B
MO_DBJ_\ 81N/Y+7G4WBW_AG/]HOQAK'B'2K^30]=5WM[BSB#!BSJX(+$ X.Y
M2,Y'I71+2O%O^5_DCGBFZ32[K\V>M?M=?\D)UW_KI;_^CDK/MM8N-!_8^BOK
M1BEQ'X= 1P<%2R;<CW&<U6_:)\56GC;]F&[UVP2:.SOQ;31+<*%<*9EZ@$C/
MXUU?PS\.V_B[]G30M$NB5M]0T1;9V'50R8R/<9S^%9.+]E6C;6Z_])9NI+GI
M2Z:_FC"_8[T&UTKX*Z?>0HGVC4;B:>>11R2LA103[!!^9K$_;=T6VG^&NG:Q
ML":A8:C&L,ZC#A75MRY],JI^HKE/AG\4-0_9AL[OP9X]T/4?[.AN7DT_5+&(
M21.K') )(!4GYN#D;B"*9X]\6:K^UKJ&C^&_"FC:A8>%;>Y%Q?:O?1A%R 1Q
M@D< MA<DDD< "KJ?O9)T_+Y6M^1E3_=I\_G^-ST[XL:I-KG[*=]J-R<W%WHM
MK/(3W9O+)/YFKG[*>CV.F?!#P_<6MK'!/>K)-<R(OS2OYKJ"Q[X  _"K'[06
MGPZ3^SUXDL;9=EO:V$4$:^BJZ*!^0J3]F'_DA'A+_KA)_P"CI*IM.=1KR_\
M;B4FHP3\_P#VT\P^.T*0?M3?"V>-0DTK0*[KP6 G88/X$UZ7^TA\)KWXN> 4
MT_2YXXM3L[A;NW29MJ2D*RE">Q(;@^H]\UYO\>_^3G_A1_OP_P#I0:] _:1L
M?&Y\+Z?JG@>YO1>:=<>9=6-B[![F$@<;1RV"!P.<$XK%6]BK_P S_-:FUW[5
MV[+\F<#9_M'>.?AK90V7Q"^'5ZL%N%ADU6P&(B ,9Z&-B1Z.!["O1_V?1\/K
MGP[J&H_#]9(+:\G#WMO-(YDBEQT96)V\'^'@]B<5R,?[9W@YM-,6H:/K4&K;
M=DNEFT5F+XY4$L 1GCG!]JB_9%\#:QH,/BSQ#J>F2:':ZY<I)9Z?,A1DC4R-
MG:0,#]X .!G;GIBME=N3?;?YK0Q=HQ7+WV_KL>ZMX9T=M;&LG2;$ZPJ[!J!M
MD^T!<8QYF-V,<8S6G7@=Q\?_ !/#^T2G@(>'(3H[3"+SMDGV@H4R9PV=NP=?
MN]!US7OE0M8J2V9;TDXO<Y_Q_P"+(/ O@O6=?N,%+"V>4*?XGQA%_%B!^-?'
M/[/G[0_A/X6:=KESKUGK%_X@UB\-Q<7%I!$Z;1RHRTJG.YG)X[BO4/VS/$MQ
M?6?AKP%IIW7^MW:221KUV!@L8/L7.?\ @%?07A?0+?PKX;TS1[4 6]C;1VZ8
M&,A5 S^.,_C2A?WI_+]7^-D.5O=A\_T7ZL^,6^//AR\_:4T/QGH,%_I]C>HE
MEJJ7\4:9W?(7&QVR -AY[I7T1^U8"WP$\48&?EMSQ_U\1U5_:R\&_P#"6?!O
M4Y8TWW>DLNH18'.%XD_\<9C^%/\ AS?6WQ\_9XAL[Z;,UW9-IUW)U9)D&T/]
M<A'_ !J9+FI.*WB_PW_/0I>[5C-[/\U_P"]^R^P;X#^$\$'$,H./^NTE>DZI
MQI=X3_SQ?_T$U\C_  _^)WBC]ERWG\)^-?#%[>Z%%.TEIJ5D,J QR0C'"NI/
MS8RI4DYZX&OXR_:NN_B3H]UX=^'7A76+K4=0C:W:YGB7="K##%5C+#."?F+
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MBOJROE+]E!=33XS?$P:T(AJ^\F[\C_5^:9V+;?;.<>U?5M7_ ,NJ?I^K)?\
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M/H36=<)K/[+GQ;U_7#HMYJW@+7W,LLMBFYK9BQ8 CH"I9@ Q (;@Y&*M>/\
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M^B6UII?GS6\$NV07!V(S+(26VE6"YX4<,.3BOH&DM8J2V8WI)Q>Z/!/VUO\
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M<5O_ +$?_)&Y_P#L*S_^@1U@?LC_ /)1?BS_ -A!?_1UQ72_XG_;O_R)S_\
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M73I)+F" Y2(LT!" ]]JD#OTZGK71?M5:#K7A_P ;^#?B-I6GRZG;Z*RK=1Q
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MS#]AC1[)M,\5ZH;6)M06\6W6Y*Y=8]NXJ#V!/)QUP/2O3/V6?^2!>&_]R?\
M]'25Y_\ L+_\BMXL_P"PDO\ Z!75_P OJOI_[<<\/X,?7]&7OVY[:)_A=I%P
MR*9H]614?NH:*7('UVC\J]CN&:3X5R,Q+,VBDDGDD^17D/[<G_))=-_[#$7_
M **FKVG2;$:GX!L[,G N-,2+G_:B _K7,KNC67FO_23HNE5IM]OU/%_V'?\
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MH.V&Z;^Z!_$&.]?]XCM70_!7_D[CXD_]<[C_ -'1U]35FHWITW_=_!WN5?\
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M1KI\TZ%@"4D1"Z,/<$"N$_8YUBYU7X(VT=P[.+*[GM8BW]P8<#\"Y'X5QGQ
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M*SJJD^X'&?0#TIWPZ_:LMOA]X8L/"OC;P]KEMKVEQK:*L%NI,J*,)E792&P
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M%U16DL+BRB::-3C>J+*^T^QVX/L:^KK72;*QB@CMK2"W2WC\J$11JOE)_=7
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MM:1NO:7WNOR,Y;PMM9_F>!_M/?\ );OA#_U_)_Z40UU?[9W_ "1&Y_Z_K?\
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M(^B[5S);1,QRS("?RJ+5/^09=_\ 7%__ $$U)9_\><'_ %S7^51ZI_R#+O\
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MTG4Y/)F\,S2"3S.J0'+@GZ,)!^ KZ)KX0^.RZK\'OBIXSL=)B9;#QC9855!
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MAOFYWL"<]<;CR<\>JT44NB78.K?<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G3X>^%
MM:LOVMO&VL7&D7\&D7%FZPW\MLZP2']QPLA&TGY3T/8^E?1=%%"TC&/96!ZS
ME/N[A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5YW\9/ _B3XC:5:^'])U6UTC1+QBNKS-&S7!B&"$B[?-R#
MG'3KU!]$HI-)[C3:V,[P[H-GX7T*PTC3X_*LK&%8(4ZD*HP,^I]36C115-MN
M[)225D%%%%(84444 >5-\*M8\3?%R+Q9XIU&VGTO1G8:%IEFC )G'[V4G^/I
MTSRH/&,5ZK110M$HKH'5L**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#PW]I3X9^(_%EUX5\3>&((]3U'P[<F?\ LR9@!,-R-D9(!(*<C.2#QR*A
MC_:.\5+;[)_@YXL%\."D4$C1$_\ 73R^GX5[Q126BY>FXWJ[]3Y\^%OP]\6>
M*/C)=_%#Q=I<?AO,!@LM*5P\N"FP-(1Z+GK@DGH *ZZW^%.L>(/BX/&'BO4;
M6YL])9X]"TVS1@L2M_RUE+?Q^PR,@'(P!7JM%5LU;IM_7<G>]^O]?<%%%%(8
M5\Z?'SPKK6L?';X8ZA8:1?WUA9SQFYNK:V>2*$"=22[ $+QSS7T710M)1EV=
MP>L91[JP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^/K7Q)>
M^%[NW\*75G9:U+M2.XOE8I&I.&88_B )(X(R.E=%12:NK,:=G<XSX2_#.T^%
M/@^+1K>X:]N&D:XN[R08:>9L;FQV'  'H*[.BBJ;N[DI6"N)^->G76K?"7Q9
M96-M+>7<^GRI%;P(7>1B. JCDGV%=M142CS1<>Y<9<LE+L>5?LPZ+J'A_P""
MN@V.J6-SIM[&UP7MKN)HI%S.Y&58 C((/XUZK116DI<S;,XQY58****DH***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 05, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CIDARA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,969,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 168,150<span></span>
</td>
<td class="nump">$ 189,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,694<span></span>
</td>
<td class="nump">1,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,665<span></span>
</td>
<td class="nump">12,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">188,848<span></span>
</td>
<td class="nump">210,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">191,727<span></span>
</td>
<td class="nump">214,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,897<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">19,833<span></span>
</td>
<td class="nump">13,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">20,727<span></span>
</td>
<td class="nump">26,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="nump">4,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,809<span></span>
</td>
<td class="nump">49,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">50,045<span></span>
</td>
<td class="nump">51,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 50,000,000 shares authorized at March&#160;31, 2025 and December&#160;31, 2024; 12,209,150 shares issued and outstanding at March&#160;31, 2025 and 10,946,635 shares issued and outstanding at December&#160;31, 2024</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">776,419<span></span>
</td>
<td class="nump">774,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(634,738)<span></span>
</td>
<td class="num">(611,258)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">141,682<span></span>
</td>
<td class="nump">163,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">191,727<span></span>
</td>
<td class="nump">214,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">12,209,150<span></span>
</td>
<td class="nump">10,946,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">12,209,150<span></span>
</td>
<td class="nump">10,946,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PreferredStockSharesIssuedIncludingConversion', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">3,818,495<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">975,208<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PreferredStockSharesIssuedIncludingConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Issued Including Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PreferredStockSharesIssuedIncludingConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,600<span></span>
</td>
<td class="nump">5,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,179<span></span>
</td>
<td class="nump">3,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Reversal of indirect tax liabilities</a></td>
<td class="num">(5,510)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,269<span></span>
</td>
<td class="nump">9,515<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,269)<span></span>
</td>
<td class="num">(8,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">(23,480)<span></span>
</td>
<td class="num">(8,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(23,480)<span></span>
</td>
<td class="num">(10,326)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (23,480)<span></span>
</td>
<td class="num">$ (10,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net loss per common share from continuing operations (in dollars per share)</a></td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net loss per common share from continuing operations (in dollars per share)</a></td>
<td class="num">(1.66)<span></span>
</td>
<td class="num">(1.80)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic net earnings (loss) per common share from discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted net earnings (loss) per common share from discontinued operations (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.48)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (in dollars per share)</a></td>
<td class="num">(1.66)<span></span>
</td>
<td class="num">(2.28)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (1.66)<span></span>
</td>
<td class="num">$ (2.28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net earnings (loss) per common share (in shares)</a></td>
<td class="nump">14,177,743<span></span>
</td>
<td class="nump">4,537,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net earnings (loss) per common share (in shares)</a></td>
<td class="nump">14,177,743<span></span>
</td>
<td class="nump">4,537,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,480)<span></span>
</td>
<td class="num">$ (10,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of costs to obtain a contract with a customer</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LossOnAssignmentOfFinanceLease', window );">Loss on assignment of finance lease</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use asset</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Reversal of indirect tax liabilities</a></td>
<td class="num">(5,510)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="nump">186<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">7,775<span></span>
</td>
<td class="num">(4,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">2,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(2,996)<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(329)<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,950)<span></span>
</td>
<td class="num">(6,644)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">185<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs for private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liabilities</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment for shares withheld to fund payroll taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">77<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(21,688)<span></span>
</td>
<td class="num">(6,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">196,177<span></span>
</td>
<td class="nump">35,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">174,489<span></span>
</td>
<td class="nump">29,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrual for Taxes Other than Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LossOnAssignmentOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Assignment Of Finance Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LossOnAssignmentOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_OperatingLeaseRightOfUseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_OperatingLeaseRightOfUseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th">
<div>Series A Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Series X Convertible Preferred Stock</div></th>
<th class="th">
<div>Series X Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2023</a></td>
<td class="num">$ (8,210)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 433,220<span></span>
</td>
<td class="num">$ (441,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Value of shares withheld to fund payroll taxes</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2024</a></td>
<td class="num">(17,780)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">433,976<span></span>
</td>
<td class="num">(451,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,561,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2024</a></td>
<td class="nump">$ 163,308<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">774,565<span></span>
</td>
<td class="num">(611,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2024</a></td>
<td class="nump">10,946,635<span></span>
</td>
<td class="nump">10,946,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,129,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">7,181<span></span>
</td>
<td class="nump">6,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">975,208<span></span>
</td>
<td class="nump">975,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2025</a></td>
<td class="nump">$ 141,682<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 776,419<span></span>
</td>
<td class="num">$ (634,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2025</a></td>
<td class="nump">12,209,150<span></span>
</td>
<td class="nump">12,209,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">THE COMPANY AND BASIS OF PRESENTATION</a></td>
<td class="text">THE COMPANY AND BASIS OF PRESENTATION<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company using its proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform to develop drug-Fc conjugate, or DFC, therapeutics designed to save lives and improve the standard of care for patients facing serious diseases. The Company&#8217;s proprietary Cloudbreak platform enables development of novel DFCs that inhibit specific disease targets while simultaneously engaging the immune system.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prophylaxis and treatment of seasonal and pandemic influenza, which has completed Phase 1 and Phase 2a clinical trials under a partnership with J&amp;J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, or Janssen. On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, under which the Company reacquired all rights for CD388 from Janssen to develop and commercialize CD388.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is currently conducting a 5,041 subject, randomized, double-blind, controlled Phase 2b clinical trial, or the NAVIGATE study, evaluating the efficacy and safety of CD388 for pre-exposure prophylaxis of seasonal influenza. Top-line data from the NAVIGATE study is expected in late June 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sale of Rezafungin</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s first commercially approved product in the United States, or U.S., was REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, the Company and Napp Pharmaceutical Group Limited, or Napp, an affiliate of Mundipharma Medical Company, or Mundipharma, entered into an asset purchase agreement, or the Napp Purchase Agreement, pursuant to which the Company sold to Napp all of the Company&#8217;s rezafungin assets and related contracts. The Company completed all conditions of the sale on April 24, 2024. The Company determined that the sale of rezafungin represented a strategic shift that will have a major effect on the Company&#8217;s operations and financial results. Accordingly, the sale of rezafungin is classified as discontinued operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as income from discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all prior year periods presented, including any gain or loss recognized on closing. There were no assets and liabilities related to discontinued operations as of March&#160;31, 2025 and December&#160;31, 2024, as all balances were recognized in income from discontinued operations at the completion of the transaction. See Note 9 for additional information.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company effected the approved 1-for-20 reverse stock split of its shares of common stock, or the Reverse Stock Split. All references in this Quarterly Report on Form 10-Q to the number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Stock Split on a retroactive basis. As a result of the Reverse Stock Split, an immaterial amount was reclassified from common stock to additional paid-in capital.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2025, the Company had an accumulated deficit of $634.7 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $174.5 million, which the Company expects will provide sufficient liquidity to support its planned operations for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company&#8217;s ability to execute on its business plan.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended March&#160;31, 2025 and 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company&#8217;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#8217;s collaboration, license, and purchase agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, which is the Chief Executive Officer of the Company. The Company views its operations and manages its business as a single reportable segment with a single operating segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company manages research and development, or R&amp;D, activities on a consolidated basis. The Company expects to generate future revenue from a combination of license fees and other upfront payments, funded R&amp;D agreements, milestone payments, product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing of the successful commercialization of its product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Comprehensive loss is the measure of segment profit or loss used by CODM in making decisions regarding resource allocation and assessing performance, which is also reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The CODM uses comprehensive loss in making decisions regarding resource allocation and evaluating financial performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table represents the results of the Company&#8217;s reportable segment for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues generated in the U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development - Cloudbreak platform</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,535)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reversal of indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other segment items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Segment net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(23,480)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,326)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The settlement of certain indirect tax liabilities resulted in the reversal of $5.5&#160;million in legal liabilities during the three months ended March&#160;31, 2025, which consisted of $3.7&#160;million in indirect tax amounts that were determined not to be due and payable and $1.8&#160;million in indirect tax interest and penalties that were determined not to be due and payable. The Company paid an immaterial amount in penalties for registration and compliance in one jurisdiction during the three months ended March&#160;31, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Restricted cash consists of cash held as collateral to secure a standby letter of credit as required by certain contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable is stated at the original invoice amount and consists of indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#8217;s customers is considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of March&#160;31, 2025, or December&#160;31, 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:f-326">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#8217;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 842, the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#8217;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reports deferred income taxes in accordance with ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indirect Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product were subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense was included in R&amp;D expenses within discontinued operations. Prior to the sale of rezafungin, the related interest and penalties were included in selling, general and administrative, or SG&amp;A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in general and administrative, or G&amp;A, expenses in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#8217;s supply chain activities or in connection with commercial sales of REZZAYO. When any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses are reversed as part of continuing operations at that time. Indirect tax amounts on the rezafungin asset transfer that can be billed to and recovered from our customers are included in accounts receivable.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 6 and Note 9 for additional information.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses consist of wages, benefits and stock-based compensation charges for R&amp;D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to R&amp;D expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">G&amp;A expenses relate to finance, human resources, legal and other administrative activities. G&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other G&amp;A expenses include facility and overhead costs not otherwise included in R&amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&amp;D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#8217;s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company&#8217;s common stock during the equivalent period of the calculated expected term of the Company&#8217;s stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Earnings (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the guidance in ASC 260, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series A Convertible Voting Preferred Stock, or Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and pre-funded warrants, see Note 4 for additional information. Basic net EPS is then calculated by dividing the net income attributable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net EPS by using the more dilutive of the (1) treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method. Dilutive common stock equivalents are comprised of warrants (excluding pre-funded warrants), Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans and ESPP, on an as converted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series A Convertible Preferred Stock or the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#8217;s losses. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 260, if a company had a discontinued operation, the Company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed in Note 4, as part of its November 2024 Private Placement (as defined below), the Company issued and sold pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). Since the $0.0001 exercise price per pre-funded warrant share represents little consideration and is non-substantive in relation to the purchase price of $14.9119 per pre-funded warrant, and as the pre-funded warrants are exercisable at any time after their original issuance with no further vesting conditions or contingencies associated with them, the shares underlying the pre-funded warrants are therefore included in the calculation of basic net loss per common share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,330,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">487,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,052,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,151,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">828,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,970,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,881,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update, or ASU, 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025, and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#8217;s condensed consolidated financial statements or related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#8217;s condensed consolidated financial statements or related disclosures, or do not apply to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company effected the Reverse Stock Split of its shares of common stock and decreased its authorized number of shares of common stock from 200,000,000 shares to 20,000,000 shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All references in this Quarterly Report on Form 10-Q to the number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Stock Split on a retroactive basis.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Cantor Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald &amp; Co., or Cantor. The Company has not sold any shares of its common stock under the Cantor Sales Agreement since July 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">April 2024 Private Placement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company entered into a securities purchase agreement with certain institutional and other accredited investors, pursuant to which the Company issued and sold, in a private placement, or the April 2024 Private Placement, 240,000 shares of Series A Convertible Preferred Stock at a purchase price of $1,000 per share. The closing of the April 2024 Private Placement took place on April 24, 2024, and the Company received total gross proceeds of $240.0&#160;million. The Company received total net proceeds of approximately $239.1&#160;million, after deducting issuance costs payable by the Company.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">November 2024 Private Placement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 20, 2024, the Company entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company issued and sold, in a private placement, or the November 2024 Private Placement, (i) an aggregate of 3,892,274 shares of the Company&#8217;s common stock at a purchase price of $14.912 per share, and (ii) in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The closing of the November 2024 Private Placement took place on November 26, 2024, and the Company received total gross proceeds of $105.0&#160;million. The Company received total net proceeds of approximately $98.2&#160;million, after deducting issuance costs payable by the Company.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Company's amended and restated certificate of incorporation, as amended, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at March&#160;31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2024, the Company designated 240,000 shares of preferred stock as Series A Convertible Preferred Stock with a par value of $0.0001 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 18, 2024, the Company&#8217;s stockholders approved, for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to 16,800,000 shares of common stock upon conversion of 240,000 shares of Series A Convertible Preferred Stock issued in the April 2024 Private Placement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 19, 2024, the Company issued 2,469,250 shares of common stock upon the automatic conversion of 35,275 shares of Series A Convertible Preferred Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, including that shares of Series A Convertible Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than 9.99% of the Company's outstanding shares of common stock as of the applicable conversion date. After conversion, the converted shares of Series A Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series A Convertible Preferred Stock. As of March&#160;31, 2025 and December&#160;31, 2024, shares of preferred stock designated as Series A Convertible Preferred Stock totaled 204,725.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series A Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into 70 shares of common stock. Holders are not permitted to convert Series A Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series A Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#8217;s common stock. If dividends are paid on shares of common stock, holders of Series A Convertible Preferred Stock are entitled to participate in such dividends on an as-if-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the Company, each holder of Series A Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of Series X Convertible Preferred Stock and common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of the Series A Convertible Preferred Stock are entitled to vote together with the holders of common stock on an as-if-converted basis on all matters submitted to a vote of stockholders; provided that holders of Series A Convertible Preferred Stock are not permitted to vote with respect to matters submitted to a vote of stockholders, to the extent that after giving effect to such action, such holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the action.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, and determined that equity treatment is appropriate as it does not meet the criteria for liability accounting. Additionally, the Series A Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series A Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Series X Convertible Preferred Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, at the request of certain holders, 52,241 shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of 26,120 shares of the Company&#8217;s common stock. In March 2025, at the request of certain holders, 1,129,264 shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of 564,632 shares of the Company&#8217;s common stock. After conversion, the converted shares of Series X Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series X Convertible Preferred Stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 3,818,495 and 4,947,759, respectively.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 0.5 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#8217;s common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the Company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 18, 2024, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 20,000,000 shares to 50,000,000 shares, which amendment was filed by the Company with the Secretary of State of the State of Delaware on July 18, 2024 and was effective as of such date.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had 50,000,000 shares of common stock authorized as of March&#160;31, 2025. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, (i) warrants to purchase up to an aggregate of 866 shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $230.95 per share and (ii) pre-funded warrants to purchase up to an aggregate of 2,491,975 shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $0.0001 per share. During the three months ended&#160;March&#160;31, 2025, pre-funded warrants to purchase up to 657,060 shares of common stock were cashless exercised resulting in the issuance of 657,052 shares of the Company's common stock and an immaterial cash payment by the Company in lieu of fractional shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, (i) warrants to purchase up to an aggregate of 866 shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $230.95 per share and (ii) pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of the Company&#8217;s common stock were outstanding, each with an exercise price of $0.0001 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had no intrinsic value as of March&#160;31, 2025, and December&#160;31, 2024, and the pre-funded warrants had a total aggregate intrinsic value of $53.7&#160;million and $84.6&#160;million as of March&#160;31, 2025, and December&#160;31, 2024, respectively. The intrinsic value of a warrant and pre-funded warrant exercisable for common stock is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants, including pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,492,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,149,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,330,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,330,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">487,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,052,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options and RSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,151,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,481,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">660,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,021,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,211,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,099,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY INCENTIVE PLANS</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2024, the Company&#8217;s board of directors approved and adopted the Company&#8217;s 2024 Equity Incentive Plan, or 2024 EIP. In July 2024, the Company&#8217;s stockholders approved the adoption of the 2024 EIP. The 2024 EIP is the successor to and continuation of the Company&#8217;s 2015 Equity Incentive Plan, or 2015 EIP, previously approved and adopted in March 2015 by the Company&#8217;s board of directors and stockholders. The 2024 EIP became effective on July 18, 2024. Upon the effectiveness of the 2024 EIP, no additional awards were or will be granted under the 2015 EIP, although all outstanding stock awards granted under the 2015 EIP continue to be governed by the terms of the 2015 EIP. Under the 2024 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company&#8217;s board of directors approved and adopted the 2020 Inducement Incentive Plan, which was most recently amended in February 2025, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors (or the compensation and human capital committee thereof), subject to the provisions of the 2024 EIP, 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:f-459">three</span>- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2024 EIP, 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to 15% of the employee&#8217;s eligible compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2025 and 2024, no shares were issued pursuant to the ESPP. As of March&#160;31, 2025, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately 0.5 years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2025:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">206,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">337,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted by the Company during the three months ended March&#160;31, 2024 was $13.70 per share. The total fair value of RSUs vested during the three months ended March&#160;31, 2025 and 2024 was approximately $0.6 million and $0.7 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2025, estimated unrecognized compensation expense related to RSUs granted was approximately $5.9&#160;million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.9 years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life in Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,303,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">730,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(213,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,813,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,813,723&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,215&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">661,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the three months ended March&#160;31, 2025, and 2024 was $15.76 and $9.80 per share, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, total unrecognized share-based compensation expense related to unvested stock options was approximately $23.6 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.7 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for RSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense recorded in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense recorded in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stock compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS AND CONTRACTS</a></td>
<td class="text">SIGNIFICANT AGREEMENTS AND CONTRACTS<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 23, 2024, the Company reacquired all rights to develop and commercialize CD388 when the Company and Janssen entered into the Janssen License Agreement, which also effectively terminated the Janssen Collaboration Agreement (as defined below), including the license granted by the Company to Janssen.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Janssen License Agreement, the Company assumed responsibility for further clinical development, manufacture, registration and commercialization of DFCs based on the Company&#8217;s Cloudbreak platform for the prevention and treatment of influenza, including CD388 and products or compounds containing CD388. Janssen granted the Company an exclusive, worldwide, fee-bearing royalty-free license for certain Janssen-controller technology to develop, manufacture, and commercialize compounds and products, including CD388. Janssen agreed to (i) transfer and disclose to the Company certain Janssen-controlled know-how related to CD388, including manufacturing know-how, data and documentation, (ii) transfer all existing quantities of CD388 clinical materials, and (iii) transfer the cell banks used by or on behalf of Janssen for the production of CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company paid Janssen an upfront payment of $85.0&#160;million on April 24, 2024. The Company is also obligated to pay Janssen up to $150.0&#160;million in development and regulatory milestone payments and up to $455.0&#160;million in commercialization milestone payments, with respect to CD388. The Company has no obligation to pay any royalties to Janssen for future sales of any commercialized CD388 product. The Company&#8217;s contingent future obligation to pay Janssen with respect to CD388 will be recognized if and when the contingency is resolved and the consideration is paid or becomes payable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the Company had an existing license and collaboration agreement with Janssen, or the Janssen Collaboration Agreement, the Company considered the contract modification and consideration payable to a customer guidance in ASC 606. The Company determined this bundled arrangement would be accounted for as a termination of the existing revenue contract and the creation of a new arrangement. No amounts paid or payable to Janssen were recorded against revenue as the consideration payable to Janssen does not exceed the fair value of the distinct assets acquired in the Janssen License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, the Company was determined to be the accounting acquirer and substantially all of the fair value of the gross assets acquired is concentrated in the acquired in-process research and development, or IPR&amp;D, of CD388. The reacquired license to develop, manufacture, and commercialize activities of CD388 is part of the acquired IPR&amp;D. The transaction was accounted for as an asset acquisition. The acquired IPR&amp;D did not have an alternative future use as of the acquisition date. Therefore the initial purchase price of $85.4&#160;million, inclusive of $0.4&#160;million in direct transaction costs, was expensed as of the acquisition date as acquired IPR&amp;D in the condensed consolidated statements of operations and comprehensive loss during the second quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the acquisition, the Company had $0.5&#160;million in contract liabilities related to deferred revenue balances and unearned cancelled performance obligations associated with the Janssen Collaboration Agreement. The settlement of the preexisting contract liabilities was recorded as an offset to the Janssen License Agreement&#8217;s initial purchase price resulting in $84.9&#160;million expensed as acquired IPR&amp;D in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company&#8217;s Cloudbreak platform, for the prevention and treatment of influenza, including CD388.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen collaborated in the research, preclinical development and early clinical development of CD388, or the Development Candidate, under a mutually-agreed R&amp;D plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, the Company was responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company was the IND holder for the Research Plan clinical trials. Both parties were responsible for conducting certain specified chemistry, manufacturing and controls, or CMC, development activities under the Research Plan.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2023, Janssen delivered its Election to Proceed Notice for CD388, whereby Janssen assumed the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continued to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and was reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement. Following Janssen&#8217;s Election to Proceed Notice, Janssen was obligated at its sole expense to diligently continue development and commercialization.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Janssen Collaboration Agreement was terminated upon the effectiveness of the Janssen License Agreement on April 24, 2024, and all potential future milestone payments and royalties were forfeited by the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Janssen Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million, plus the R&amp;D funding of $47.8&#160;million, plus milestones achieved of $10.0&#160;million. The transaction price included the total estimated costs related to R&amp;D and clinical supply services. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&amp;D efforts and costs for manufacturing clinical supplies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of the distinct performance obligations identified under the Janssen Collaboration Agreement was as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The R&amp;D services performed represented a distinct performance obligation. The Company recognized revenue based on actual amounts incurred as the underlying services were provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company&#8217;s initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognized revenue based on actual amounts incurred as the underlying services were provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In March 2022 and September 2023, the Company achieved milestones under the Janssen Collaboration Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was expected to be recognized as revenue over the remaining progress of these performance obligations.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the termination date of the Janssen Collaboration Agreement there was no aggregate transaction price allocated to performance obligations that were unsatisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, the Company recorded no accounts receivable or contract liabilities associated with the Janssen Collaboration Agreement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.308%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Janssen Collaboration Agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease Obligations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into a finance lease for lab equipment in November 2023. The finance lease had a term of 36 months, monthly lease payments of $25,009, and an option to purchase the lab equipment for $1 at the end of the finance lease term. In March 2025, the Company entered into an assignment and assumption agreement whereby the Company agreed to transfer and assign to a third party all of the Company's present and future rights, interests, duties, obligations and liabilities under the finance lease, resulting in a derecognition of the finance lease right-of-use asset and finance lease liabilities as of March&#160;31, 2025, and the recognition of a $0.2 million loss on disposal in other expense, net in continuing operations during the three months ended March&#160;31, 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Finance lease costs were immaterial for the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Obligations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company entered into an operating lease for laboratory and office space in San Diego, California in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015. On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional 36 months and increased the base rent to $133,371 per month effective January 1, 2024, subject to 4% increases every January. The operating lease expires on December 31, 2026 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2025, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes. The incremental borrowing rate used in measuring the Company&#8217;s operating lease liability was 12.0%.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount and timing of cash flows arising from the Company&#8217;s operating lease as of March&#160;31, 2025 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, the weighted average remaining operating lease term was 1.8 years.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was $0.4 million for each of the three months ended March&#160;31, 2025 and 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $0.4 million for each of the three months ended March&#160;31, 2025 and 2024. These costs are primarily related to the Company&#8217;s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for R&amp;D activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reduction in Force</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 9, 2024, management of the Company, as authorized by the board of directors of the Company, approved a reduction in the Company&#8217;s workforce, or the Reduction, of 20 employees, which represented approximately 30% of the Company&#8217;s workforce. The Reduction reflects the Company&#8217;s focus on the clinical development of CD388, its influenza product candidate. The Reduction was completed on November 1, 2024.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result of the Reduction, the Company incurred charges of $1.2&#160;million for severance payments and employee benefits in 2024. The Company does not expect to incur additional charges related to the Reduction. As of March&#160;31, 2025, all amounts have been paid.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Standby Letter of Credit</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On December 11, 2024, the Company established a standby letter of credit with its banking institution, Wells Fargo, for $6.0&#160;million for the benefit of its indirect tax service provider, as it relates to indirect tax compliance services in various tax jurisdictions outside of the U.S. in connection with the rezafungin supply chain activities and commercial sales of REZZAYO. The letter of credit expires on November 30, 2025 and is automatically extended without amendment for an additional one-year period from the current expiration date, unless notified by the Company to terminate prior to 90 days from the expiration date. The cash held as collateral for this standby letter of credit is recorded as restricted cash and is held in an interest-bearing account.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company estimates an annual effective income tax rate based on projected results for the year and applied the rate to net loss before taxes to calculate income tax expense or (benefit). When applicable, the income tax provision also includes adjustments for discrete tax items. Any refinements made due to subsequent information that affects the estimated annual effective income tax rate are reflected as adjustments in the current period. For the three months ended March&#160;31, 2025, and 2024 the Company recognized no income tax expense or (benefit) from continuing operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISCONTINUED OPERATIONS</a></td>
<td class="text">DISCONTINUED OPERATIONS<div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, the Company and Napp entered into the Napp Purchase Agreement, pursuant to which the Company sold to Napp, effective as of April 24, 2024, the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">all of the Company&#8217;s rezafungin assets, including all of the Company&#8217;s right to receive future milestones and royalties under a license agreement between Melinta Therapeutics, LLC, or Melinta, and the Company, or the Melinta License Agreement, and a collaboration and license agreement between Mundipharma and the Company, or the Mundipharma Collaboration Agreement,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">all rezafungin intellectual property rights, including patents and know-how, all product data, regulatory approvals and documentation,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">rezafungin and comparator inventory,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">specified prepaid assets and specified contracts, in exchange for Napp&#8217;s assumption of certain liabilities of the rezafungin business, including the ongoing costs of the ReSPECT Phase 3 clinical trial and the ReSTORE Phase 3 clinical trial in China and the Company&#8217;s obligations from and after closing under the Melinta License Agreement,</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Commercial Supply Agreement between the Company and Melinta, and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Commercial Supply Agreement between the Company and Mundipharma, or the Mundipharma Commercial Supply Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">No Company employees were transferred to Napp.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company, Napp and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Mundipharma Commercial Supply Agreement from the Company to Napp, or the Novation Agreement. In the Novation Agreement, Mundipharma agreed to forgive the Company&#8217;s obligation to refund a $11.1&#160;million development milestone advance due as of December 31, 2024, net of royalties, to Mundipharma under the Mundipharma Collaboration Agreement, provided that (a) the Company performed its obligation to provide carryover services under a Transition Services Agreement with Napp, or the TSA, for a period of 45 days following the closing, (b) the Company delivered all of the purchased assets, including product know-how and product-data, in accordance with the Napp Purchase Agreement and a know-how transfer plan delivered in connection with the Napp Purchase Agreement and (c) the Company performed its obligation to provide other services in accordance with the TSA for 75 days following the closing. On July 18, 2024, the Company received a notice of satisfaction from Mundipharma that it had completed the required performance obligations under the TSA and, accordingly, the $11.1&#160;million development milestone advance previously made to the Company, and reimbursable to Mundipharma, was forgiven by Mundipharma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The action to divest rezafungin was taken because of the Company&#8217;s strategy to streamline its portfolio and focus on the Cloudbreak platform and other financial considerations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has determined that the sale of rezafungin represents a strategic shift that had a major effect on its result of operations. Rezafungin met the criteria to be reported as discontinued operations at the time of the sale. The Company has separately reported the financial results of rezafungin as discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all prior year periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There were no assets and liabilities related to discontinued operations as of March&#160;31, 2025 and December&#160;31, 2024, as all balances were recognized in income from discontinued operations at the completion of the transaction.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There were no discontinued operations during the three months ended March&#160;31, 2025. The results of operations from discontinued operations during the three months ended March&#160;31, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Major line items constituting pretax income (loss) of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. The total net cash used in operating activities from discontinued operations was $6.9 million for the three months ended March&#160;31, 2024. There were no investing or financing activities from discontinued operations for the three months ended&#160;March&#160;31, 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&amp;D expense in the period incurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 2.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta Therapeutics, LLC, or Melinta, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#8217;s product to the customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">(i) Napp Purchase Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the execution of the Napp Purchase Agreement, the Company modified its existing collaboration and license arrangements and Commercial Supply Agreements with Mundipharma and Melinta. As a result of the modified revenue contracts and the termination of these revenue arrangements, the Company concluded the Napp Purchase Agreement and the other aforementioned arrangements represented a bundled arrangement with a single commercial objective that required assessment under the guidance for revenue recognition. As a result, the Company identified the distinct performance obligations within the arrangements (including whether the distinct performance obligations were within the scope of ASC 606), determined the transaction price and the standalone selling prices of the distinct performance obligations, and allocated the transaction price using the relative standalone selling price method to the distinct performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 24, 2024, as of the execution date of the Napp Purchase Agreement (and all other bundled arrangements), the Company determined the transaction price is equal to $21.2&#160;million for the sale of all rezafungin assets, including the Company&#8217;s right to receive future milestones and royalties from Mundipharma and Melinta, all rezafungin intellectual property rights, including patents and know-how, rezafungin and comparator inventory, specified prepaid assets, the Commercial Supply Agreements with Melinta and Mundipharma, and certain transition services. The transaction price includes the forgiveness of $25.3&#160;million in contract liabilities (inclusive of the $11.1&#160;million development milestone advance) and $0.6&#160;million for the transition services agreement. The Company paid $2.1&#160;million to Napp and forgave $2.6&#160;million in accounts receivable, both of which are included as a reduction to the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The $21.2&#160;million transaction price was allocated to the distinct performance obligations on the basis of their respective relative standalone selling prices.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">All Rezafungin assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company transferred all rezafungin assets, including all rezafungin intellectual property rights, including patents and know-how, rezafungin and comparator inventory in April 2024 at a point in time. Therefore, the Company recognized the revenue related to this bundled performance obligations in the amount of $20.8&#160;million as revenue in the results from operations from discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Specified Prepaid Assets and Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company transferred specified prepaid and contracts in April 2024 at a point in time. The nature of the assets transferred were determined to be outside the scope of ASC 606 and therefore, the $0.3&#160;million was recorded as part of the loss on disposal of discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Transition Services</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company performed its services under the TSA over the initial 76-day period subsequent to the effective date of the Napp Purchase Agreement. In connection with the carryover services provided after the sale of rezafungin, the Company recognized $0.1&#160;million as revenue in the results of operations from discontinued operations during the second quarter of 2024. The Company's costs to provide the TSA services predominantly related to employee labor costs which were reported within R&amp;D and SG&amp;A expenses within the results of operations from discontinued operations during the second quarter of 2024. The remaining unsatisfied performance obligation as of March&#160;31, 2025 was zero.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">(ii) Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Under the Mundipharma Collaboration Agreement, the Company was responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that included the Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and CMC development activities for the Mundipharma Licensed Product. Mundipharma was responsible for performing all development activities, other than Global Development Plan activities, that were necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;The Mundipharma Collaboration Agreement was terminated upon the effectiveness of the assignment to Napp on April 24, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Mundipharma Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front fee of&#160;$30.0&#160;million, plus the R&amp;D funding of $31.2&#160;million, plus milestones achieved of $27.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement was as follows:</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Mundipharma in September 2019.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma shared equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represented a distinct performance obligation. The Company recorded these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the R&amp;D services was best measured in an amount proportional to the R&amp;D expenses incurred and the total estimated R&amp;D expenses.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represented a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services was best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In November 2020, the Company achieved a milestone under the Mundipharma Collaboration Agreement, and received payment for this milestone in January 2021. Mundipharma was entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma had not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company would have been obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. The full amount was forgiven in July 2024 as part of the rezafungin asset sale and the Company included it in the transaction price of the Napp Purchase Agreement. In December 2021, August 2022, December 2023 and January 2024, the Company achieved milestones under the Mundipharma Collaboration Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in January 2022, September 2022, February 2024 and April 2024, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">(iii) Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contained or incorporated rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company was responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that included, among other activities, (a) completion of the ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a supplemental new drug application, or sNDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that were required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company remained the holder of the rezafungin IND and new drug application, or NDA, before the Melinta License Agreement was assigned as part of the Napp Purchase Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Melinta License Agreement was terminated upon the effectiveness of the assignment to Napp on April 24, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to the Melinta License Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front fee of&#160;$30.0&#160;million, plus a milestone achieved of $20.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&amp;D efforts and costs for manufacturing clinical supplies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A description of the distinct performance obligations identified under the Melinta License Agreement was as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company was required to provide R&amp;D services, at its sole expense, as described under the Melinta Development Plan, which represented a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the R&amp;D services was best measured in an amount proportional to the R&amp;D expenses incurred and the total estimated R&amp;D expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represented a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services was best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In March 2023, the Company achieved a milestone under the Melinta License Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in April 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the termination date of both the Mundipharma Collaboration Agreement and the Melinta License Agreement, there was no aggregate transaction price allocated to performance obligations that was unsatisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of March&#160;31, 2025 and December&#160;31, 2024, the Company recorded no accounts receivable or contract liabilities associated with the Mundipharma Collaboration Agreement and Melinta License Agreement. As of March&#160;31, 2025, the Company recorded accounts receivable associated with the Napp Purchase Agreement of $1.7&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from Collaboration, License and Commercial Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestone achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenue from Collaboration, License and Commercial Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Pre-funded Warrants Exercise</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2025, pre-funded warrants to purchase up to 337,552 shares of common stock were cashless exercised resulting in the issuance of 337,548 shares of the Company's common stock and an immaterial cash payment by the Company in lieu of fractional shares.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Series A Convertible Preferred Stock Conversion</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In April 2025, at the request of certain holders, 5,587 shares of the Company&#8217;s Series A Convertible Preferred Stock were converted to an aggregate of 391,090 shares of the Company&#8217;s common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Termination of Controlled Equity Sales Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, the Company and Cantor terminated the Cantor Sales Agreement.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Entry into Open Market Sale Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On May 8, 2025, the Company entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or the Jefferies Sales Agreement, with Jefferies LLC, or Jefferies, under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company's common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company's sales agent. The Company has not sold any shares of its common stock under the Jefferies Sales Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,480)<span></span>
</td>
<td class="num">$ (10,326)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2025, the Company had an accumulated deficit of $634.7 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At March&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $174.5 million, which the Company expects will provide sufficient liquidity to support its planned operations for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company&#8217;s ability to execute on its business plan.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComparabilityOfPriorYearFinancialData', window );">Unaudited Interim Financial Data</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended March&#160;31, 2025 and 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company&#8217;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#8217;s collaboration, license, and purchase agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, which is the Chief Executive Officer of the Company. The Company views its operations and manages its business as a single reportable segment with a single operating segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company manages research and development, or R&amp;D, activities on a consolidated basis. The Company expects to generate future revenue from a combination of license fees and other upfront payments, funded R&amp;D agreements, milestone payments, product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing of the successful commercialization of its product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Comprehensive loss is the measure of segment profit or loss used by CODM in making decisions regarding resource allocation and assessing performance, which is also reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The CODM uses comprehensive loss in making decisions regarding resource allocation and evaluating financial performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Restricted cash consists of cash held as collateral to secure a standby letter of credit as required by certain contracts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable is stated at the original invoice amount and consists of indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#8217;s customers is considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of March&#160;31, 2025, or December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:f-326">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Finance Lease and Operating Lease</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#8217;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 842, the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#8217;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reports deferred income taxes in accordance with ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock', window );">Indirect Taxes</a></td>
<td class="text"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indirect Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product were subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense was included in R&amp;D expenses within discontinued operations. Prior to the sale of rezafungin, the related interest and penalties were included in selling, general and administrative, or SG&amp;A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in general and administrative, or G&amp;A, expenses in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#8217;s supply chain activities or in connection with commercial sales of REZZAYO. When any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses are reversed as part of continuing operations at that time. Indirect tax amounts on the rezafungin asset transfer that can be billed to and recovered from our customers are included in accounts receivable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 6 and Note 9 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses consist of wages, benefits and stock-based compensation charges for R&amp;D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to R&amp;D expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">G&amp;A expenses relate to finance, human resources, legal and other administrative activities. G&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other G&amp;A expenses include facility and overhead costs not otherwise included in R&amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&amp;D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#8217;s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company&#8217;s common stock during the equivalent period of the calculated expected term of the Company&#8217;s stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Earnings (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the guidance in ASC 260, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series A Convertible Voting Preferred Stock, or Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and pre-funded warrants, see Note 4 for additional information. Basic net EPS is then calculated by dividing the net income attributable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net EPS by using the more dilutive of the (1) treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method. Dilutive common stock equivalents are comprised of warrants (excluding pre-funded warrants), Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans and ESPP, on an as converted basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series A Convertible Preferred Stock or the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#8217;s losses. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 260, if a company had a discontinued operation, the Company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed in Note 4, as part of its November 2024 Private Placement (as defined below), the Company issued and sold pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). Since the $0.0001 exercise price per pre-funded warrant share represents little consideration and is non-substantive in relation to the purchase price of $14.9119 per pre-funded warrant, and as the pre-funded warrants are exercisable at any time after their original issuance with no further vesting conditions or contingencies associated with them, the shares underlying the pre-funded warrants are therefore included in the calculation of basic net loss per common share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update, or ASU, 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025, and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#8217;s condensed consolidated financial statements or related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#8217;s condensed consolidated financial statements or related disclosures, or do not apply to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes Other than Income Taxes, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComparabilityOfPriorYearFinancialData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483478/205-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComparabilityOfPriorYearFinancialData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information by Segment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table represents the results of the Company&#8217;s reportable segment for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues generated in the U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development - Cloudbreak platform</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21,509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,535)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reversal of indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other segment items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Segment net loss and comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(23,480)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,326)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,330,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">487,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,052,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,151,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">828,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,970,697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,881,757&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174,489&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants, including pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,492,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,149,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,330,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,330,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">487,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,052,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options and RSUs issued and outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,151,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,481,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">660,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,021,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">63,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,211,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,099,476&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the three months ended March&#160;31, 2025:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">206,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">337,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the three months ended March&#160;31, 2025:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life in Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,303,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.84</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">730,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(213,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,813,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,813,723&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,215&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">661,275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">30.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for RSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense recorded in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation expense recorded in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stock compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.308%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Janssen Collaboration Agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from Collaboration, License and Commercial Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestone achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenue from Collaboration, License and Commercial Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount and timing of cash flows arising from the Company&#8217;s operating lease as of March&#160;31, 2025 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text">The results of operations from discontinued operations during the three months ended March&#160;31, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Major line items constituting pretax income (loss) of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from discontinued operations, net of income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.308%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Janssen Collaboration Agreement:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Janssen Collaboration Agreement</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March&#160;31, 2024 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.547%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from Collaboration, License and Commercial Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestone achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product Revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenue from Collaboration, License and Commercial Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 23, 2024</div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 634,738,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611,258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,489,000<span></span>
</td>
<td class="nump">$ 29,018,000<span></span>
</td>
<td class="nump">196,177,000<span></span>
</td>
<td class="nump">$ 35,778,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(634,738,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(611,258,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,489,000<span></span>
</td>
<td class="nump">29,018,000<span></span>
</td>
<td class="nump">196,177,000<span></span>
</td>
<td class="nump">$ 35,778,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Reversal of indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,510,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Indirect tax amounts, decrease resulting from settlement with taxing authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Indirect tax amounts, income tax penalties and interest accrued, decrease resulting from settlement with taxing authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Total revenues | Rezafungin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Decreases Resulting From Settlements With Taxing Authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Schedule of Segment Reporting Information by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues generated in the U.S.</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development - Cloudbreak platform</a></td>
<td class="num">(24,600)<span></span>
</td>
<td class="num">(5,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Reversal of indirect tax liabilities</a></td>
<td class="nump">5,510<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OtherSegmentItemsAbstract', window );"><strong>Other segment items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(23,480)<span></span>
</td>
<td class="num">(10,326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(23,480)<span></span>
</td>
<td class="num">(10,326)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cdtx_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues generated in the U.S.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development - Cloudbreak platform</a></td>
<td class="num">(21,509)<span></span>
</td>
<td class="num">(2,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel costs</a></td>
<td class="num">(6,077)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="num">(2,535)<span></span>
</td>
<td class="num">(1,768)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development costs</a></td>
<td class="num">(658)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Reversal of indirect tax liabilities</a></td>
<td class="nump">5,510<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OtherSegmentItemsAbstract', window );"><strong>Other segment items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(23,480)<span></span>
</td>
<td class="num">(10,326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (23,480)<span></span>
</td>
<td class="num">$ (10,326)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_OtherSegmentItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Segment Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_OtherSegmentItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cdtx_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cdtx_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 168,150<span></span>
</td>
<td class="nump">$ 189,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows</a></td>
<td class="nump">$ 174,489<span></span>
</td>
<td class="nump">$ 196,177<span></span>
</td>
<td class="nump">$ 29,018<span></span>
</td>
<td class="nump">$ 35,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">3,892,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 14.912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember', window );">Prefunded Warrants | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">3,149,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 14.9119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)</a></td>
<td class="nump">17,970,697<span></span>
</td>
<td class="nump">1,881,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)</a></td>
<td class="nump">14,330,750<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)</a></td>
<td class="nump">487,604<span></span>
</td>
<td class="nump">1,052,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)</a></td>
<td class="nump">3,151,477<span></span>
</td>
<td class="nump">828,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">$ 168,150<span></span>
</td>
<td class="nump">$ 189,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">174,489<span></span>
</td>
<td class="nump">196,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">LEVEL 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">168,150<span></span>
</td>
<td class="nump">189,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">174,489<span></span>
</td>
<td class="nump">196,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">LEVEL 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">LEVEL 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 18, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 17, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 22, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CommonStockDividendsInArrearsOrDefault', window );">Dividends in arrears or default | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,491,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,491,975<span></span>
</td>
<td class="nump">2,491,975<span></span>
</td>
<td class="nump">3,149,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ClassOfWarrantOrRightExercisesInPeriod', window );">Warrants, cashless exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding', window );">Warrants, aggregate intrinsic value, outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,700,000<span></span>
</td>
<td class="nump">$ 53,700,000<span></span>
</td>
<td class="nump">$ 84,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember', window );">Prefunded Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember', window );">Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230.95<span></span>
</td>
<td class="nump">$ 230.95<span></span>
</td>
<td class="nump">$ 230.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding', window );">Warrants, aggregate intrinsic value, outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion', window );">Maximum ownership following conversion (more than) (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="nump">204,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued for each preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,818,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">3,818,495<span></span>
</td>
<td class="nump">3,818,495<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion', window );">Maximum ownership following conversion (more than) (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">975,208<span></span>
</td>
<td class="nump">975,208<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued for each preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,129,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfVotesEntitlementForEachShareHeld', window );">Number of votes for each share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfVotesEntitlementForEachShareHeld', window );">Number of votes for each share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember', window );">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,892,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, gross | $</a></td>
<td class="nump">$ 105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, net | $</a></td>
<td class="nump">$ 98,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,149,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.9119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock, shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CommonStockDividendsInArrearsOrDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock dividends in arrears or default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CommonStockDividendsInArrearsOrDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfVotesEntitlementForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitlement for each share held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfVotesEntitlementForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Aggregate Intrinsic Value, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_WarrantsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertibleVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">21,211,469<span></span>
</td>
<td class="nump">22,099,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common stock warrants, including pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">2,492,841<span></span>
</td>
<td class="nump">3,149,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">14,330,750<span></span>
</td>
<td class="nump">14,330,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">487,604<span></span>
</td>
<td class="nump">1,052,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options and RSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">3,151,477<span></span>
</td>
<td class="nump">2,481,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember', window );">Authorized for future stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">660,650<span></span>
</td>
<td class="nump">1,021,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Awards available under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">88,147<span></span>
</td>
<td class="nump">63,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 18, 2024</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.76<span></span>
</td>
<td class="nump">$ 9.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Additional awards were granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="nump">$ 13.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs and PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Additional awards were granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term for stock options to be granted (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold', window );">Voting power threshold (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan | More than 10% of Voting Power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 Employee Stock Purchase Plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Employee payroll deduction under the stock plan (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details) - Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">177,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">206,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares)</a></td>
<td class="num">(33,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs canceled (in shares)</a></td>
<td class="num">(11,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">337,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 14.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted (in dollars per share)</a></td>
<td class="nump">21.25<span></span>
</td>
<td class="nump">$ 13.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs vested (in dollars per share)</a></td>
<td class="nump">17.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs canceled (in dollars per share)</a></td>
<td class="nump">15.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 18.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">2,303,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">730,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(7,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares)</a></td>
<td class="num">(213,249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">2,813,723<span></span>
</td>
<td class="nump">2,303,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">2,813,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">661,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">21.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">16.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share)</a></td>
<td class="nump">22.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">18.95<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">18.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 30.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (in years)</a></td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">6 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract', window );"><strong>Total Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 17,215<span></span>
</td>
<td class="nump">$ 29,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">17,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 3,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">$ 1,741<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">1,741<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative | Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock compensation expense</a></td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 23, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,694,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | License Agreement | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="nump">$ 85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory', window );">Milestone payment obligation, development and regulatory</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization', window );">Milestone payment obligation, commercialization</a></td>
<td class="nump">455,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DirectTransactionCosts', window );">Direct transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | License Agreement | Upfront Payment | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 84,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Milestone Achievement | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Third Party Share Of Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DirectTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DirectTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PaymentsRelatedToCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Related To Collaborative Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PaymentsRelatedToCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Acquired In Process</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total Revenue from Janssen Collaboration Agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Collaborative Arrangement | Janssen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total Revenue from Janssen Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Over Time: | Collaborative Arrangement | Research and Development Services | Janssen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total Revenue from Janssen Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Over Time: | Collaborative Arrangement | Clinical Supply Services | Janssen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Total Revenue from Janssen Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 09, 2024 </div>
<div>employee</div>
</th>
<th class="th">
<div>Apr. 20, 2023 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance Lease Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, finance lease, term of contract (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeFinanceLeaseMonthlyRate', window );">Lessee, finance lease, monthly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment', window );">Lessee, finance lease, option, purchase equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseMonthlyRate', window );">Base rent per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease', window );">Percentage increase in base rent annual (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfOperatingLeaseOptionsForExtension', window );">Number of options to extend | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseOptionRenewalTerm', window );">Option renewal term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost', window );">Variable lease and short-term lease term included within operating lease cost (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Reduction in Force</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees eliminated | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted', window );">Reduction in force (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance payments and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations | Finance Lease Right-Of-Use Asset And Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance Lease Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Gain (loss) on disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Standby Letter of Credit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Standby letter of credit</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuarantorObligationTerm1', window );">Standby letter of credit, term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_GuarantorObligationsTerminationNoticeTerm', window );">Standby letter of credit, termination notice term (in days)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_GuarantorObligationsTerminationNoticeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Guarantor Obligations, Termination Notice Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_GuarantorObligationsTerminationNoticeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeFinanceLeaseMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Monthly Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeFinanceLeaseMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Option, Purchase Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeFinanceLeaseOptionPurchaseEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rate Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseAnnualRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseOptionRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseOptionRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfOperatingLeaseOptionsForExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Lease Options For Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfOperatingLeaseOptionsForExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Number of Positions Eliminated, Total Workforce Percent Impacted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuarantorObligationTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of guarantee or group of similar guarantees, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuarantorObligationTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2025</a></td>
<td class="nump">$ 1,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease payments</a></td>
<td class="nump">$ 2,673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 2,435<span></span>
</td>
<td class="nump">$ 2,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="nump">$ 1,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1">62 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Apr. 23, 2024</div></th>
<th class="th"><div>Apr. 23, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 973,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,694,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Total revenues | Rezafungin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets related to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash provided by (used in) operating activities, discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Cash provided by (used in) financing activities, discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash provided by (used in) investing activities, discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Total revenues | Rezafungin | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_NappPharmaceuticalGroupLimitedMember', window );">Napp Pharmaceutical Group Limited | Total revenues | Rezafungin | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount', window );">Collaborative agreement, maximum cost share, forgiveness amount</a></td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm', window );">Collaborative arrangement, carry over services agreement term (in days)</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementOtherServicesAgreementTerm', window );">Collaborative arrangement, other services agreement term (in days)</a></td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionValue', window );">Collaborative arrangement, transaction, value</a></td>
<td class="nump">$ 21,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount', window );">Contract liabilities, forgiveness amount</a></td>
<td class="nump">25,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices', window );">Transition services</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount', window );">Accounts receivable, forgiveness amount</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal', window );">Loss on disposal of discontinued operations</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransitionsServicesTerm', window );">Collaborative arrangement, transitions services term (in days)</a></td>
<td class="text">76 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_NappPharmaceuticalGroupLimitedMember', window );">Napp Pharmaceutical Group Limited | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Rezafungin Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,097,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Current, Forgiveness Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Carry Over Services Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Third Party Share Of Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Third Party Share Of Cost, Forgiveness Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementOtherServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Other Services Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementOtherServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Transaction, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTransitionsServicesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Transitions Services Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTransitionsServicesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) On Disposal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PaymentsRelatedToCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Related To Collaborative Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PaymentsRelatedToCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Forgiveness Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Transition Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_NappPharmaceuticalGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_NappPharmaceuticalGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_RezafunginAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_RezafunginAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,149)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Total revenues | Rezafungin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,639<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Loss from discontinued operations, net of income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,149)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Total revenues | Rezafungin | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | License of Intellectual Property - upon milestone achieved | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Product revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Royalty Revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Research and Development Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma | Clinical Supply Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Total revenues | Rezafungin | Related Party | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | License of Intellectual Property - upon milestone achieved | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Product revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Royalty Revenue | Total revenues | Rezafungin | Related Party | Point in Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Research and Development Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta | Clinical Supply Services | Total revenues | Rezafungin | Related Party | Over Time: | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=cdtx_RezafunginMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 08, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564,632<span></span>
</td>
<td class="nump">26,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_SaleOfStockConsiderationReceivablePerTransaction', window );">Offerring price</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ClassOfWarrantOrRightExercisesInPeriod', window );">Warrants, cashless exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember', window );">Prefunded Warrants | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ClassOfWarrantOrRightExercisesInPeriod', window );">Warrants, cashless exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_SaleOfStockConsiderationReceivablePerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Receivable Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_SaleOfStockConsiderationReceivablePerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .N%J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .N%J%IG[IJ%\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( .N%J%H.Y>24[P4  ,$?   8
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M,'DS>XLF+,@DM*41\D1V$DD"4_%$B> '='4JT3<:9PS]ZEZZ$!SU!P2:Z#4
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M(H5*N*!?]81A4HUVPJ_L^R>XL%-]S@A<(=BBX#44O%X**YZF^H9_QPYXU^W
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MS3=];A.QXP!QW ZD=2"'#O& 0]0Z1(9H@\S0^D05G4T%WR*AK2&:OC"Y,=[
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M%..>.%J$PC!#FP38DF<[^A7MTU06-#LY=5T\QG'<79YXK QH)]"O'+4@12=
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M=)?Q#\53R-H!V34O+K*J^8F>VK;&!,6[BA>;-ECT8)/F^]_T:_M!G 1@\TP
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M(H$\13K+PI8IX7SM6,=J 1(60L*B_L=AJ%5@'51@_=>E2YM@;.FR>F*W;-/
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MU 90P$X4N93$U]5%"()5MTO(N]JUMQ1\4)'7I98 '3CI!HP6G_\">]<ZD.Y
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M$#14^2C45(IUQMZ%(/EKBRI3.22;CPJ-%T<EC4'$P?[N7\E@=*!IV0(#>LP
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M\ET;?DO5!55A\T%E5ZI"\UM,A%:.4_CYU>MWH_ZJA<W$NRZX8Z$9RQ5UV'%
MME;[#J/^AMY2XHB_4WQ%E/3K70\/F:@;J#*:L!!)>=$SNP7VKG+O=H61 .56
M3GA$=7#USU)^Y,OAUZ/A5(AG=&N ,0"A#<.<6(J%[%]YA))Z##+OC+)0RBD9
M"^8J.5'LE-H&RR%B(U<)(*B- >W$X1IVU!J57:#X[I?GFS8>P(W$PJ+*-W5\
M:Z!\J!WC*L*N9!51)%H\C@-R?*9(H3)G03,O'OCQW%>F'CE0IEUT]S3]D&IX
M#=WI8//5XYB5>V?\GURO5C(GN.P,<<S5C?E;'XMG\EL*>'CRT+/)#Q:2+U](
MG-CU(<AMT<,TY4OO4_[**#F( 6[*NF1H_Y?7'"G#W9<RY7#M_RCA=+D@^(T[
MCJA@ V4*/B@Y,>FHI52VX<+EO]/=X#Y_4*GV:HR$![,S#NSN%LX/_6S[G>(]
M1.CN?9>(#E0(_$K?@U7N4S!":X>O_PW6/KXD[=K68[U_$K?2-A['\V TAWO7
MH' _]D@PFY-G^/3SZ:'X%9[T%)LV8X_8W?B"TN/)P>AX_^<G^# Z.SUX(CZ@
M4[?&J(K'K%X\/AGMGY[B]Z/19/_DB?@E=H'1>TN$H.:;3+(ECC@^/,;2@]'I
MR=D3<<4(L T,N_./L?3QR>G^DW3_$.?V=-'NN$25W]9JR>/1\<%^)WJDD6V#
M+K>&#N+#>!LPXCDW.#K[61R>'(M?^8;O@;NNN($YX-L$T ?53 \R'AQ!73GU
MYB'ZMKO$1]AQ.#HZ@W3X>+ _.IQ B>28B(U0J>[%@:YQW2)V=-3>!=Q 5X^.
M^VDUOU2"V*G6=@]*YN_Z[:B;Y4 .OF4B$H?]'8.XRV<NTN,=-@W-!E?B-"8-
M/%DJ6Y7> %MQ1-'G1P?CLZWG<ONE?,PGR XQ8?P@F3LC3:G+S5=:(-Z3H" '
M B7?3H##MY^:H8XN>Y$+OT"MOM3Q9>H?T?%XT_NL>X-7EI'!%OQB-D^@3(AO
M+W=/NW>_I_&5YWYY?'$<U!8:*%JI.;;NCT^/=^*[7/E+L V_ #VS(=B:/RZ5
M1/5*"_ [#4SR%R+0O1'_\C]02P,$%     @ ZX6H6D> V9"P(0  %VP  !@
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M":H3 8+E0EIT2G+I21'G>I98?Z8#X>HIXDCE&%.;J ['0():9O<R5$6V>/0
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M!.8V#%$,)Y$]N3F[(UWK"Q)AJ36<+8*H6U#W3>S)C(&5ZT$)>%%F_Y;[#S
MR1;%<^$Z(!5$,<KLFFZQ&?>9;4<>Y*<0>Y%F&+&L[\A*5D2AXO*#ILPT:"J\
MGM)LJ)"I6]$O<W#GC._UXSD@F=ASRXI56BT&].Y_3&I#EUEM*,J2%(CBD;!"
MP=VD+:XLE@,P'FKQ#FA!K UJO$FHEQ>>DJK-P?;Z7E;!1JP@VFPVHEKA9U]1
M%97F93C5V[M$N4P+Q5C;T%]U-7 9+.!!8)?Q#EC"T&5J$=:-:EN^\%.3"( ?
M X1M*TF-?""DMS#SQD=4PR97#,RNY%CB]'MLD'NHBEJF.B=^"#1&<Q0_ .Z8
M S*L2%$WL7+%.SM4#@6A#I@G-SU#.<#[.+%&-EEO[;Y=+<;"KL[$_LK_\HG$
M_I*+BWDGTTI]T2Z7;]+;LEFLI;G@668W4D)#&"><M_M^1G<#*/=,.LE8<*DP
MH87YUB]MN,(22G"78Q@H]DMP%$4RH>+8@0L[9^B-%!?5A;1W;-%IFF41!T7A
M:5Z8>W%FFYC-M-YD=G:A6NF/=624KSY^0%;*]2_?E1(O /$P/I/)W)$/W]^^
ME@9'[7TE2F1.E-08;'1KR2_0U)A.\4$;[E%X5URR=-C(&;4V1:RLR]$6&SIE
MV#WDP'QN(-'L(SRC*W\@/9]VD$0D3G8ZD8,L"@W'14H:TP;>"\6L@?A,_DA\
MKBV8KYB4\:ZCGL]1A[ *)W82J?<)2%B;(M9UYTB]Y_#X"E_:)1G3JD,KE=X
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M5!24(R<E2"JQY-Q9>D)9K\8H4<T5$*([)0"23%N221[DZH&'891B)XUES$[
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M$2YI,'D%\S-9DF 5K^I3F6#'RX51"DAJQ>M43%5N%9/4ZX:3]0.=J85,B0+
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M&\;I@H)R$QR^:NP+I[.KSY\O;C]_N+R]$6>7YV)V=7E[<?GCA\O9Q8>;X]T
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M2<)2!!$P!L-&!)#5::XU>\@EF%W78HA,QX0[R<J,(8*P'&J[=LO!Y!4"(80
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MI%:U=TA1S"W*ME]V:/CXQU9)8%0NB..Z& X+$TP\3QD>(KK+U'TS%:WC1>X
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M4WH'45D'VD^D-,>)/:!^6:?_ E!+ P04    " #KA:A:4B-C[#H#  ##!@
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M7#4=:#,P<FV[OH4TU$/:SYR:=E1L0.M+*<W#@!UT_P:,_P502P,$%     @
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MVKSJ70>@JQY=#:PJ?%_<*$M=UC]F]%N#V@70^E8I>QRX#>H?I=$_4$L#!!0
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M;^(X%/TK5G:TFI&F36Q(>"P@4=K9J=0'*NVN5JO]8(@!:Y*8L0UT_OW:29H
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MWG%;RXCRME%V%%_8X_2>*WTXVV:N+V@@#$"/SSA7SQUS0M=7ON0O4$L#!!0
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M";@+Y_/>H@<1+YXF36C=#7]K@Y"E=<NOU?WH0NMR;]T/&G08YTFTQMB77A!
MY_ ]VA/FV9Y]^!8U]XZPU/GA5\Q6B5S04[*4>=:5+P%8=217#03=E*=:3U0(
MFI67:X*E1%6 O+^D5+P,U$%9<S Z_0E02P,$%     @ ZX6H6NU]F^BH!P
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M9=W^[$301=HPGU A:)0>S@GV"4L&R-^GE(K-23)!\9_+\#]02P,$%     @
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M=FH!/U%Q05KV;\2QG'8%G\G/I[LU=%J%\JT4KW5*^2@)^3< L@"Q81Y> RJ
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M"T!I(2@M@J*9(JG<6,=NQT[B;QO*U51#L[=KSF(B].PC".;Q*A]%=D:56H6
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M J4QH.\K(?3KQHROZN<3_@902P,$%     @ ZX6H6M.:UC/C @  H <  !D
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M#TOLF:!= .XOE;+[B3N@Z\+9'U!+ P04    " #KA:A: ]GQ4:P*  "%@
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6S5G6U/X\H9AO_***VJ78EN
MXI<D0 &)Q?-"M>PBV#WG0]4/)AD2:QT[M9UPJ,Z/[]@QF0QQ)ACNK<07B)T\
MU^/8=SSCYQZ/3Q[2[&<^E;(@?\SB)#_M3(MB?MSMYJ.IG(7YIW0N$_7.?9K-
MPD(M9I-N/L]D.*Z"9G'7[?4&W5D8)9VSDVK==79VDBZ*.$KD=4;RQ6P69H^?
M99P^G':<SM.*FV@R+<H5W;.3>3B1M[+X,;_.U%)W31E',YGD49J03-Z?=LZ=
M8]'OE0'5)WZ+Y$.^\9J47^4N37^6"Y?CTTZOW"(9RU%1(D+U;RDO9!R7)+4=
M_ZFAG77.,G#S]1.=55]>?9F[,)<7:?Q[-"ZFIYW##AG+^W 1%S?I@Y#U%^J7
MO%$:Y]5?\E!_MM<AHT5>I+,Z6&W!+$I6_\,_ZAVQ$>#X.P+<.L!]'M#?$>#5
M =Y+,_AU@/_2@'X=T'\>,-@1,*@#!B\-&-8!PY=NTF$=<%@=W=7AJ(YE$!;A
MV4F6/I"L_+2BE2\J0531ZA!&2:G=VR)3[T8JKC@++F\OOGW]?OGU!PW(MVMZ
M<_[]\MO76_)W<CX>1Z6\PIA<)JL?22FV#X$LPBC./ZJ/_+@-R(>_?CSI%FI+
M2EYW5&>]6&5U=V3UR%6:%-.<T&0LQPWQS![O.OL W X8N!9 5^W#]8YTGW;D
M9]=*/)]GGXCK'Q"WY_I->\0>?A6J<,^IPOL-X8$]_)^+1(7W=F:G+\_>%,Y>
M\MV]G>'\;>'"'A[(T:Z--XZDM_Y)>!7/V\&[3$;I3)+;(BRD.DL7!^1S&(?)
M2*VJ6I,P&6_^.((H'\5IOLAD3NX>R\5YFJOU/$L7\_Q _7A&\6(<)9/JDTIT
M4;*08_)M+K/J%Y63?WU16T N5;;\WPU?__-J<_WFS2T;M^-\'H[D:4>U7KG,
MEK)S]K>_.(/>/YIDB(0%2!A%PA@2QI$P 8(9TO;7TO9M]+,;N91*?>0^2V=$
M-1UQ>)>6*EQ*$DXR6<F]28%6:EL%KF"#"E9VK99GO9/N<E-6R'1T.]W1T.OU
MGN5DR)P<"1,@F"&8_EHP?:M@SD>C=)$4N>JFCF2T#.]BV:0/*Z2M/E:P_L8!
M<P9'_M81"Y!)*1+&D#".A(G^UH_A^;XU9#)8RV1@E<GWM% M7K8ZN^3D3W(C
M_QO>+Y))E#3)Q0IK*Q<D+$#"*!+&D#".A D0S!#><"V\X?OJJPV1TD;" B2,
M(F$,">-(F #!#&D?KJ5]:#VG?HG"NRA6RI5EZQLK@8])D9+QIC#3M3";M&CE
MM]7BX5:K_+P]1J:C2!A#PC@2)FQ[U5#-T5HU1_8.6Y[+XK6"L:+;"N9HKV"0
MZ2@2QI PCH0)VUXU!./T= 6P9Y7,19A/R3Q+E]%8*40UBQ\6N7H1)1^?Y*+:
MPZK&7)V,#MHHRIZZK:2@M !*HS5M\\@,CGJ][0M-:%H.I0D4S53B1BW:>:T2
M[Z-$=>O>HD1KZM9*=/:>W: )Z?Z$#)J00VD"13.%Y6IAN:\55I0L9?ZF4YPU
M=6MAN?N%A4Q(]R=DT(0<2A,HFBDL;14XUG+ML\)'HSR@U7LH+8#2:$W;5-+0
M/VIJ :'%>2A-H&BFGG1]WK$7Z"V%M&IAU:N_#K/B42U?&!7\\RP+D\G.&KX]
M<VLA(FD!E$:A- :E<2A-H&BF6K4YX/3?5_7-@1H14%H I5$HC4%I'$H3*)JI
M<>UL.'9KH[9,#]1)N1P*5JI3Z;$:#U,*/;V+HTFES@,2SDJOK%&74,>CIEG[
MB% C TIC4!J'T@2*9HI-NQF.M:+\4KO53FDMI^%^.4'- RB-06D<2A,UK7FL
M@ZD1;0LX=E_@:SB?D^MIJ$Y ([DHHM%3"TJ^1+.H[![^27YE-Q+J*D!I 91&
MH30&I7$H3:!HIJ*U9>$<O;-N)-0(@=("*(U":0Q*XU":0-',P<':9''WF"S-
M@^T.RK'<T6Q1CL;+"Y*KT[KJ:JK>Y41]+)%Y;NE4UAF-P3R.TV Y7-BWK:T"
MH30*I3$HC4-I D4S%:C-%7>/N6(J4+?R!V2DEAY)NI09*?-&(W5F74N4%#*;
MD0^JYS .'_.FP?Z?]V3V^U5HT[G1'ME:F5#+!4IC4!J'T@2*9BI3NS/N'G=F
MMS+38OIJ4=J3#BVB1#H4 91&H30&I7$H3:!HIBBUL^/:G1V+* OU.@]'JZ+/
M,HP7C1?I-7^S>78=M[%YAIHZ4!J%TAB4QJ$T@:*9>M/.CVMW?B[4A4JF1$5B
M/>[OQ3U!?ZN"X_:]1JE!;1LHC4)I#$KC4)I T4RI:=O&M=_4\;T\?U57T^N6
MM5%5VS=B#!HU!;5)H#0*I3$HC4-I D4S-:5M$M=NDUR'CV7C:(P\;7&#F;MM
M:;C-E[+0VSV@- JE,2B-0VD"13/%IFT2M[5-\N*F<MOL<)O/:M";+Z T"J4Q
M*(U#:0)%,X6FO1;7[K7L']YE![0M%4-I04TS"H0-4J?0K Q*XU":0-%,.6FC
MP[7?G/$E5><FU>L:/UD6Z7V;D:8U??-X-G?RH88#E$:A- :E<2A-H&CF'!;:
M</!:&0Y;]8MH986M2VO["VI[$@X'.PMJ]LBV@H32*)3&H#0.I0D4S12D]A\\
MNPL &4AES]&VN?7VW\4!34BA- :E<2A-H&BFV+2EX-FK^R\<2&6GM):3N]W?
M&C8TT $T+872&)3&H32!HIFBVI@7RFX)_!]'7IF!JYMZ&P6,G1L*.SD4=G8H
M[/10V/FAL!-$_0HCPM-&A.>_K]%8'K+V?@&E!5 :A=(8E,:A-(&BF1K7#HBW
MQP'96]?QMF=*<GN'35?;]E2M!06U/Z T!J5Q*$V@:*:@M/WAV>V/*ZG6%.&O
M'7IMWX;6)T*HDP*E42B-06D<2A,HFJE;[:1X[VS^+ ]Z:PN4%D!I%$IC4!J'
MT@2*9FI<FSB>W<1YHS5MI[=6)-3A@=(HE,:\;?=IY58\[T%Q:%Z!HIEJTQZ/
M9_=X7CO%KAW;6F90"PA*H][V'%;>4<.,O-"L'$H3*)HYB[,V=WR[UP+O;JKW
MKJ)8YD6J6N?ST312P)V304/G](+2 BB-0FD,2N-0FD#13#UK;\AWWE<WU(?Z
M3%!: *51*(U!:1Q*$RB:J7%M2?EV2^K5<^]#/2HH+8#2*)3&_&TWSFWN?T+S
M"A3-E)DVJ7R[276U2,;1O#*I?FTURKX=K74)M9Z@- JE,2B-0VD"13.UN_%T
MDG=F/?E0ZPE*"Z T"J4Q*(U#:0)%,S6NK2??;CV]L1IEI[=6)-2[@M(HE,:@
M-.YONX/-M2V!RFNJ3?M2OMV7:C'M1*/:H(X3E!9 :11*8U :][=OCO(:[R06
MJ+RFVK2;Y-OORWGU)0[4]('2 BB-^ML3@@U[1\.&QY%!_1PH3:!HILJTG^/;
M_9Q?<H73J@ *=82@M !*HU :@](XE"90-%/3VC7RW]D4:#[4CH+2 BB-0FD,
M2N-0FD#1S"=):M.J;S>M7ML[L&/;2A%*"Z T"J4Q*(WWMV>;<X=-#[@1J+PK
MF74WGFT^D]FD>LY]3JK;.U9/YUZO)=5C[R^<8UH]<O[9^G/G^+QZLGQ78\Y.
MYN%$7H69ZBWD));W"MG[-%0][6SUS/O50I'.JR>HWZ5%D<ZJEU,9CF56?D"]
M?Y^FQ=-"F> AS7Y6FWWV/U!+ P04    " #KA:A:=O_2(9,#  "^#0  &0
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MA]X!H%:%8?<"+;!&PV0\)RM@F)AI"48C+&82J72BKCM#U:]Z-)N]Q^9XEG.
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M/_S&RH*.<CR?1VGQ$SV4U[H#Y&>IY'$9#!G$8;+[I)]+(FH!@+,_ )<!^.N
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" #KA:A:@:7"D2($   '(0  #P   'AL+W=O<FMB;V]K+GAM;,6:77.;.!1
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MR%X(/(I\,%,+(/D$R/(Y-[?X91\;$Y)/<*$IT"_[V)B0? )D^8"8PYX#R2=
M7X;[;:'U=+N$Q!,<Q#,Z;KQ7;,,;5J6F>FW*2RK*A2+=H=\M"*ZZ!;W-7HC(
ME&7-HZ35<1__^!^$SS\!4$L#!!0    ( .N%J%J.83CZO0$  'H=   :
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( .N%J%IG[IJ%\@   "L"   1              "  <,   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( .N%J%J97)PC$ 8  )PG   3
M      "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ZX6H
M6@[EY)3O!0  P1\  !@              ("!)0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( .N%J%JSZ&/>BP8  ! ?   8
M      " @4H.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" #KA:A:W<'=[)X#   <$   &               @($+%0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ZX6H6L(BUX9&!0  9A<  !@
M             ("!WQ@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( .N%J%HIB$RI-0<  #X@   8              " @5L>  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #KA:A:+"J3?^L'   6
M1@  &               @('&)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ ZX6H6@L#@:QI$0  '2\  !@              ("!YRT
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .N%J%I'@-F0
ML"$  !=L   8              " @88_  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " #KA:A:=&$[9&$%  !"#0  &
M@(%L80  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ZX6H
M6OXJ)U+)#P  .3T  !D              ("! V<  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " #KA:A:"T9KRN\(  !K&0  &0
M        @($#=P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( .N%J%KPT6X-:0T  )<I   9              " @2F   !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ZX6H6M2V V:]"0  ,!@
M !D              ("!R8T  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " #KA:A:!3&2=!4#  #9!@  &0              @(&]EP
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .N%J%K#ZE!;
M4Q@  )I@   9              " @0F;  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ ZX6H6KHQKM#G P  -0D  !D
M ("!D[,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #K
MA:A:&@#C=T,"  ":!0  &0              @(&QMP  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .N%J%H3K8?K1 (  (H&   9
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M970R,BYX;6Q02P$"% ,4    " #KA:A:4B-C[#H#  ##!@  &0
M    @(&X\   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M .N%J%K/<<_"V 0  !(,   9              " @2GT  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ ZX6H6BJ L7O8 P  - D  !D
M             ("!./D  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " #KA:A:7Z*5?(0#   _"   &0              @(%'_0  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .N%J%H;-IW?L00
M #<,   9              " @0(! 0!X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ ZX6H6O<,2,%<!0  9QX  !D              ("!
MZ@4! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #KA:A:
MC[=8L P%  #>%@  &0              @(%]"P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .N%J%H[]MM%*@,  /X)   9
M      " @< 0 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ ZX6H6E@%<E?7!   X!X  !D              ("!(10! 'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #KA:A:**3"0C,$  "]$P
M&0              @($O&0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( .N%J%JX6'^S=@,  -P1   9              " @9D= 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ZX6H6N+**6HE
M%0  TFT! !D              ("!1B$! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " #KA:A:$ 6Y1#X$   D%0  &0
M@(&B-@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .N%
MJ%KM?9OHJ <  *8]   9              " @1<[ 0!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ ZX6H6J>8Y$V[ P  U@X  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( .N%J%K]/85H.@@  .A(   9
M  " @0I; 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
MZX6H6H*^8]7* @  B 8  !D              ("!>V,! 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " #KA:A:TYK6,^,"  "@!P  &0
M            @(%\9@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( .N%J%HO>=*R40(  )$%   9              " @99I 0!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ZX6H6@/9\5&L"@
MA8   !D              ("!'FP! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " #KA:A:=O_2(9,#  "^#0  &0              @($!
M=P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .N%J%KF
M4UO*TP4  .PN   9              " @<MZ 0!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ ZX6H6J#M-\-0!0  &2L  !D
M     ("!U8 ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
M" #KA:A:,Q;I7E8#  #.%0  #0              @ %<A@$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( .N%J%J7BKL<P    !,"   +              "
M =V) 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .N%J%J!I<*1(@0   <A   /
M              "  <:* 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #K
MA:A:CF$X^KT!  !Z'0  &@              @ $5CP$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #KA:A:G"O3#[T!  !W'0  $P
M            @ $*D0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .0 Y
+ (8/  #XD@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>290</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - EQUITY INCENTIVE PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANS</Role>
      <ShortName>EQUITY INCENTIVE PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - DISCONTINUED OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DISCONTINUEDOPERATIONS</Role>
      <ShortName>DISCONTINUED OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSTables</Role>
      <ShortName>EQUITY INCENTIVE PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/EQUITYINCENTIVEPLANS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - DISCONTINUED OPERATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DISCONTINUEDOPERATIONSTables</Role>
      <ShortName>DISCONTINUED OPERATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/DISCONTINUEDOPERATIONS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Schedule of Segment Reporting Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Schedule of Segment Reporting Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - STOCKHOLDERS??? EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/INCOMETAXES</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails</Role>
      <ShortName>DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cdtx-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="cdtx-20250331.htm">cdtx-20250331.htm</File>
    <File>cdtx-20250331.xsd</File>
    <File>cdtx-20250331_cal.xml</File>
    <File>cdtx-20250331_def.xml</File>
    <File>cdtx-20250331_lab.xml</File>
    <File>cdtx-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cdtx-20250331_g1.jpg</File>
    <File>cdtx-20250331_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="544">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cdtx-20250331.htm": {
   "nsprefix": "cdtx",
   "nsuri": "http://cidara.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "cdtx-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cdtx-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdtx-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 248,
   "keyCustom": 42,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 24,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 171,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 560,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 544,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://cidara.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "longName": "9952154 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited)",
     "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-26",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION",
     "longName": "9952156 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952157 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952158 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952159 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANS",
     "longName": "9952160 - Disclosure - EQUITY INCENTIVE PLANS",
     "shortName": "EQUITY INCENTIVE PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS",
     "longName": "9952161 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952162 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cidara.com/role/INCOMETAXES",
     "longName": "9952163 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cidara.com/role/DISCONTINUEDOPERATIONS",
     "longName": "9952164 - Disclosure - DISCONTINUED OPERATIONS",
     "shortName": "DISCONTINUED OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cidara.com/role/SUBSEQUENTEVENTS",
     "longName": "9952165 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables",
     "longName": "9955512 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955513 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9955514 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955515 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSTables",
     "longName": "9955516 - Disclosure - EQUITY INCENTIVE PLANS (Tables)",
     "shortName": "EQUITY INCENTIVE PLANS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables",
     "longName": "9955517 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9955518 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cidara.com/role/DISCONTINUEDOPERATIONSTables",
     "longName": "9955519 - Disclosure - DISCONTINUED OPERATIONS (Tables)",
     "shortName": "DISCONTINUED OPERATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails",
     "longName": "9955520 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails",
     "longName": "9955521 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Schedule of Segment Reporting Information by Segment (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Schedule of Segment Reporting Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-39",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "longName": "9955522 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "longName": "9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9955525 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "longName": "9955526 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Additional Information (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
     "longName": "9955527 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
     "longName": "9955528 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
     "longName": "9955529 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails",
     "longName": "9955530 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9955531 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
     "longName": "9955532 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-128",
      "name": "cdtx:PaymentsRelatedToCollaborativeAgreements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
     "longName": "9955533 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
     "longName": "9955534 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
     "longName": "9955535 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails",
     "longName": "9955536 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Balance Sheet Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://cidara.com/role/INCOMETAXESDetails",
     "longName": "9955537 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
     "longName": "9955538 - Disclosure - DISCONTINUED OPERATIONS - Additional Information (Details)",
     "shortName": "DISCONTINUED OPERATIONS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
     "longName": "9955539 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details)",
     "shortName": "DISCONTINUED OPERATIONS - Schedule of Operations from Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
     "longName": "9955540 - Disclosure - DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "shortName": "DISCONTINUED OPERATIONS - Schedule of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-156",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955541 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "cdtx:SaleOfStockConsiderationReceivablePerTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r728"
     ]
    },
    "cdtx_AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, forgiveness amount",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current, Forgiveness Amount",
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Current, Forgiveness Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued indirect tax liabilities",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r690",
      "r900"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r844",
      "r845",
      "r846",
      "r847",
      "r905",
      "r960"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Value of shares withheld to fund payroll taxes",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r766",
      "r776",
      "r808"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r801",
      "r809",
      "r813",
      "r821"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r396"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit losses",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r262",
      "r274"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded in the calculation of basic and diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r131",
      "r163",
      "r185",
      "r220",
      "r225",
      "r249",
      "r252",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r442",
      "r444",
      "r490",
      "r544",
      "r639",
      "r700",
      "r701",
      "r728",
      "r744",
      "r867",
      "r868",
      "r914"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r168",
      "r185",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r442",
      "r444",
      "r490",
      "r728",
      "r867",
      "r868",
      "r914"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r720"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets related to discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r52",
      "r69",
      "r104",
      "r157",
      "r158"
     ]
    },
    "cdtx_AuthorizedSharesForFutureStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "AuthorizedSharesForFutureStockAwardsMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized for future stock awards",
        "label": "Authorized Shares For Future Stock Awards [Member]",
        "documentation": "Authorized Shares For Future Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "THE COMPANY AND BASIS OF PRESENTATION",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r99",
      "r100"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of costs to obtain a contract with a customer",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r161",
      "r689"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market accounts",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r122"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r96",
      "r182"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r96"
     ]
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash provided by (used in) financing activities, discontinued operations",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash provided by (used in) investing activities, discontinued operations",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r96"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash provided by (used in) operating activities, discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r96"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r164",
      "r165",
      "r166",
      "r185",
      "r211",
      "r212",
      "r214",
      "r216",
      "r222",
      "r223",
      "r263",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r319",
      "r320",
      "r323",
      "r326",
      "r334",
      "r490",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r627",
      "r648",
      "r666",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r831",
      "r842",
      "r848"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r222",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r332",
      "r334",
      "r599",
      "r600",
      "r601",
      "r602",
      "r707",
      "r831",
      "r842"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrant (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "cdtx_ClassOfWarrantOrRightExercisesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ClassOfWarrantOrRightExercisesInPeriod",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, cashless exercises (in shares)",
        "label": "Class Of Warrant Or Right, Exercises In Period",
        "documentation": "Class Of Warrant Or Right, Exercises In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_ClinicalSupplyServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ClinicalSupplyServicesMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Supply Services",
        "label": "Clinical Supply Services [Member]",
        "documentation": "Clinical Supply Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "cdtx_CollaborativeArrangementCarryOverServicesAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementCarryOverServicesAgreementTerm",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, carry over services agreement term (in days)",
        "label": "Collaborative Arrangement, Carry Over Services Agreement Term",
        "documentation": "Collaborative Arrangement, Carry Over Services Agreement Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT AGREEMENTS AND CONTRACTS",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r139",
      "r148"
     ]
    },
    "cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementMaximumThirdPartyShareOfCost",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, maximum cost share",
        "label": "Collaborative Arrangement, Maximum Third Party Share Of Cost",
        "documentation": "Collaborative Arrangement, Maximum Third Party Share Of Cost"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, maximum cost share, forgiveness amount",
        "label": "Collaborative Arrangement, Maximum Third Party Share Of Cost, Forgiveness Amount",
        "documentation": "Collaborative Arrangement, Maximum Third Party Share Of Cost, Forgiveness Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementOtherServicesAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementOtherServicesAgreementTerm",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, other services agreement term (in days)",
        "label": "Collaborative Arrangement, Other Services Agreement Term",
        "documentation": "Collaborative Arrangement, Other Services Agreement Term"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment obligation, commercialization",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payments, Commercialization"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment obligation, development and regulatory",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payments, Development And Regulatory"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementTransactionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementTransactionValue",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, transaction, value",
        "label": "Collaborative Arrangement, Transaction, Value",
        "documentation": "Collaborative Arrangement, Transaction, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "cdtx_CollaborativeArrangementTransitionsServicesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CollaborativeArrangementTransitionsServicesTerm",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, transitions services term (in days)",
        "label": "Collaborative Arrangement, Transitions Services Term",
        "documentation": "Collaborative Arrangement, Transitions Services Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r124",
      "r546",
      "r626"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r296",
      "r297",
      "r683",
      "r861",
      "r863"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "cdtx_CommonStockDividendsInArrearsOrDefault": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CommonStockDividendsInArrearsOrDefault",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends in arrears or default",
        "label": "Common Stock Dividends In Arrears Or Default",
        "documentation": "Common stock dividends in arrears or default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r739",
      "r740",
      "r741",
      "r742",
      "r844",
      "r845",
      "r847",
      "r905",
      "r959",
      "r960"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r627"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "periodEndLabel": "Balance, ending (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r83",
      "r627",
      "r645",
      "r960",
      "r961"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 50,000,000 shares authorized at March\u00a031, 2025 and December\u00a031, 2024; 12,209,150 shares issued and outstanding at March\u00a031, 2025 and 10,946,635 shares issued and outstanding at December\u00a031, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r548",
      "r728"
     ]
    },
    "cdtx_CommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "CommonStockWarrantMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrant",
        "label": "Common Stock Warrant [Member]",
        "documentation": "Common Stock Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ComparabilityOfPriorYearFinancialData": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComparabilityOfPriorYearFinancialData",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Financial Data",
        "label": "Comparability of Prior Year Financial Data, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r170",
      "r172",
      "r178",
      "r539",
      "r557",
      "r558"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r694"
     ]
    },
    "cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Controlled Equity Sales Agreement, Cantor Fitzgerald and Company",
        "label": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]",
        "documentation": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Conversion Description [Axis]",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Name [Domain]",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares converted (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares issued (in shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum ownership following conversion (more than) (as a percent)",
        "label": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion",
        "documentation": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r320",
      "r323",
      "r739",
      "r740",
      "r741",
      "r742"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for each preferred stock (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r42",
      "r82",
      "r110",
      "r329"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r315",
      "r321",
      "r522",
      "r531",
      "r543",
      "r691",
      "r693"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38"
     ]
    },
    "cdtx_DirectTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "DirectTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct transaction costs",
        "label": "Direct Transaction Costs",
        "documentation": "Direct Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY INCENTIVE PLANS",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r357",
      "r388",
      "r389",
      "r391",
      "r716"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r21"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is disposed of other than by sale. For example, but not limited to, abandonment, in an exchange measured based on the recorded amount of the nonmonetary asset relinquished, or in a distribution to owners in a spinoff. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r103"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r158"
     ]
    },
    "cdtx_DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Gain (Loss) On Disposal",
        "documentation": "Disposal Group, Including Discontinued Operation, Gain (Loss) On Disposal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "cdtx_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Disposal Group, Including Discontinued Operation, Research And Development",
        "documentation": "Disposal Group, Including Discontinued Operation, Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r158"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on disposal",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r840",
      "r860"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DISCONTINUED OPERATIONS",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r102"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Basic net loss per common share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r209",
      "r211",
      "r214",
      "r215",
      "r216",
      "r219",
      "r431",
      "r440",
      "r467",
      "r468",
      "r540",
      "r559",
      "r695"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted net loss per common share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r211",
      "r214",
      "r215",
      "r216",
      "r219",
      "r431",
      "r440",
      "r467",
      "r468",
      "r540",
      "r559",
      "r695"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Earnings (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r218"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period to recognize unrecognized compensation cost (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated unrecognized share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation expense, options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Awards available under the ESPP",
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r152",
      "r174",
      "r175",
      "r176",
      "r191",
      "r192",
      "r193",
      "r196",
      "r203",
      "r205",
      "r207",
      "r221",
      "r267",
      "r273",
      "r287",
      "r336",
      "r414",
      "r415",
      "r427",
      "r428",
      "r429",
      "r432",
      "r439",
      "r440",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r466",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r501",
      "r518",
      "r556",
      "r585",
      "r586",
      "r587",
      "r605",
      "r666"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r481",
      "r720"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r481",
      "r720"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Hierarchy",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r480",
      "r481",
      "r483",
      "r526",
      "r527",
      "r528",
      "r705",
      "r706",
      "r710",
      "r711",
      "r712",
      "r720",
      "r722"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478",
      "r479",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r538",
      "r720",
      "r723"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEVEL 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r346",
      "r351",
      "r471",
      "r481",
      "r526",
      "r710",
      "r711",
      "r712",
      "r720"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEVEL 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r346",
      "r351",
      "r471",
      "r472",
      "r481",
      "r527",
      "r705",
      "r706",
      "r710",
      "r711",
      "r712",
      "r720"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEVEL 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r471",
      "r472",
      "r473",
      "r474",
      "r481",
      "r528",
      "r705",
      "r706",
      "r710",
      "r711",
      "r712",
      "r720",
      "r722"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r480",
      "r481",
      "r483",
      "r526",
      "r527",
      "r528",
      "r705",
      "r706",
      "r710",
      "r711",
      "r712",
      "r720",
      "r722"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease Obligations",
        "label": "Finance Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of finance lease liability",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease liability",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of finance lease liabilities",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r509"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use asset, net",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance lease right-of-use asset",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r508",
      "r727"
     ]
    },
    "cdtx_FinanceLeaseRightOfUseAssetAndLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "FinanceLeaseRightOfUseAssetAndLiabilitiesMember",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease Right-Of-Use Asset And Liabilities",
        "label": "Finance Lease Right-Of-Use Asset And Liabilities [Member]",
        "documentation": "Finance Lease Right-Of-Use Asset And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r809"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r650"
     ]
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Axis]",
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby letter of credit",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guarantor Obligations, Nature [Domain]",
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305"
     ]
    },
    "us-gaap_GuaranteesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuaranteesAbstract",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Letter of Credit",
        "label": "Guarantees [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuarantorObligationTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuarantorObligationTerm1",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby letter of credit, term (in years)",
        "label": "Guarantor Obligation, Term",
        "documentation": "Term of guarantee or group of similar guarantees, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "cdtx_GuarantorObligationsTerminationNoticeTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "GuarantorObligationsTerminationNoticeTerm",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby letter of credit, termination notice term (in days)",
        "label": "Guarantor Obligations, Termination Notice Term",
        "documentation": "Guarantor Obligations, Termination Notice Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r130",
      "r185",
      "r195",
      "r203",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r431",
      "r440",
      "r468",
      "r490",
      "r554",
      "r697",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r867"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per common share from continuing operations (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r126",
      "r179",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r211",
      "r214",
      "r215",
      "r431",
      "r440",
      "r468",
      "r540",
      "r926"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per common share from continuing operations (in dollars per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r179",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r211",
      "r214",
      "r215",
      "r216",
      "r440",
      "r468",
      "r540",
      "r926"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      },
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from discontinued operations, net of income taxes",
        "verboseLabel": "Loss from discontinued operations, net of income taxes",
        "totalLabel": "Loss from discontinued operations, net of income taxes",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r66",
      "r71",
      "r120"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net earnings (loss) per common share from discontinued operations (in dollars per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r179",
      "r212",
      "r214",
      "r215",
      "r924",
      "r926"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net earnings (loss) per common share from discontinued operations (in dollars per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r212",
      "r214",
      "r215"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r714"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r15",
      "r20",
      "r52",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r70",
      "r72",
      "r73",
      "r105"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r291",
      "r293",
      "r475",
      "r477",
      "r482",
      "r580",
      "r582",
      "r651",
      "r686",
      "r721",
      "r928"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r475",
      "r477",
      "r482",
      "r580",
      "r582",
      "r651",
      "r686",
      "r721",
      "r928"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r400",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r412",
      "r419",
      "r421",
      "r422",
      "r423",
      "r604",
      "r719"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax benefit (expense)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r146",
      "r206",
      "r207",
      "r220",
      "r233",
      "r252",
      "r403",
      "r404",
      "r420",
      "r560",
      "r719"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r401",
      "r402",
      "r409",
      "r410",
      "r411",
      "r413",
      "r598"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued indirect tax liabilities",
        "label": "Increase (Decrease) In Accrual for Taxes Other than Income Taxes",
        "documentation": "Increase (Decrease) In Accrual for Taxes Other than Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r839"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r839"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses, other current assets, and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r801",
      "r809",
      "r813",
      "r821"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r825"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r825"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r825"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r838",
      "r851"
     ]
    },
    "cdtx_JanssenPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "JanssenPharmaceuticalsIncMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Pharmaceuticals, Inc.",
        "label": "Janssen Pharmaceuticals, Inc. [Member]",
        "documentation": "Janssen Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Personnel costs",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "cdtx_LesseeFinanceLeaseMonthlyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LesseeFinanceLeaseMonthlyRate",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, monthly rate",
        "label": "Lessee, Finance Lease, Monthly Rate",
        "documentation": "Lessee, Finance Lease, Monthly Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LesseeFinanceLeaseOptionPurchaseEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LesseeFinanceLeaseOptionPurchaseEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, option, purchase equipment",
        "label": "Lessee, Finance Lease, Option, Purchase Equipment",
        "documentation": "Lessee, Finance Lease, Option, Purchase Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, term of contract (in months)",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease and Operating Lease",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "cdtx_LesseeOperatingLeaseAnnualRateIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LesseeOperatingLeaseAnnualRateIncrease",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage increase in base rent annual (as a percent)",
        "label": "Lessee, Operating Lease, Annual Rate Increase",
        "documentation": "Lessee, Operating Lease, Annual Rate Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental borrowing rate (as a percent)",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "cdtx_LesseeOperatingLeaseMonthlyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LesseeOperatingLeaseMonthlyRate",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base rent per month",
        "label": "Lessee, Operating Lease, Monthly Rate",
        "documentation": "Lessee, Operating Lease, Monthly Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LesseeOperatingLeaseOptionRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LesseeOperatingLeaseOptionRenewalTerm",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option renewal term (in years)",
        "label": "Lessee, Operating Lease, Option Renewal Term",
        "documentation": "Lessee, Operating Lease, Option Renewal Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term (in months)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease and short-term lease term included within operating lease cost (in days)",
        "label": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost",
        "documentation": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r185",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r443",
      "r444",
      "r445",
      "r490",
      "r625",
      "r696",
      "r744",
      "r867",
      "r914",
      "r915"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r125",
      "r550",
      "r728",
      "r843",
      "r859",
      "r909"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r160",
      "r185",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r443",
      "r444",
      "r445",
      "r490",
      "r728",
      "r867",
      "r914",
      "r915"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities related to discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r52",
      "r69",
      "r104",
      "r157",
      "r158"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Agreement",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LicenseOfIntellectualPropertyUponMilestonesAchievedMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License of Intellectual Property - upon milestone achieved",
        "label": "License Of Intellectual Property Upon Milestones Achieved [Member]",
        "documentation": "License Of Intellectual Property Upon Milestones Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LossOnAssignmentOfFinanceLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "LossOnAssignmentOfFinanceLease",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on assignment of finance lease",
        "label": "Loss On Assignment Of Finance Lease",
        "documentation": "Loss On Assignment Of Finance Lease"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r353",
      "r397",
      "r474",
      "r532",
      "r579",
      "r581",
      "r595",
      "r617",
      "r618",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r684",
      "r685",
      "r703",
      "r707",
      "r715",
      "r722",
      "r723",
      "r724",
      "r725",
      "r730",
      "r869",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "cdtx_MelintaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "MelintaTherapeuticsIncMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Melinta",
        "label": "Melinta Therapeutics Inc [Member]",
        "documentation": "Melinta Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_MilestoneAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "MilestoneAchievementMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "documentation": "Milestone Achievement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r353",
      "r397",
      "r474",
      "r532",
      "r579",
      "r581",
      "r595",
      "r617",
      "r618",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r684",
      "r685",
      "r703",
      "r707",
      "r715",
      "r722",
      "r723",
      "r724",
      "r730",
      "r869",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "MoreThanTenPercentVotingRightsClassesOfStockMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 10% of Voting Power",
        "label": "More Than Ten Percent Voting Rights Classes Of Stock [Member]",
        "documentation": "More than ten percent voting rights classes of stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "cdtx_MundipharmaMedicalCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "MundipharmaMedicalCompanyMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mundipharma",
        "label": "Mundipharma Medical Company [Member]",
        "documentation": "Mundipharma Medical Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "cdtx_NappPharmaceuticalGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "NappPharmaceuticalGroupLimitedMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Napp Pharmaceutical Group Limited",
        "label": "Napp Pharmaceutical Group Limited [Member]",
        "documentation": "Napp Pharmaceutical Group Limited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      },
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r98",
      "r127",
      "r158",
      "r169",
      "r171",
      "r176",
      "r185",
      "r195",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r213",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r431",
      "r440",
      "r468",
      "r490",
      "r555",
      "r647",
      "r664",
      "r665",
      "r743",
      "r867"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r208",
      "r219",
      "r259",
      "r260",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r286",
      "r287",
      "r292",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r488",
      "r489",
      "r498",
      "r499",
      "r500",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r535",
      "r536",
      "r537",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r208",
      "r219",
      "r259",
      "r260",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r286",
      "r287",
      "r292",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r488",
      "r489",
      "r498",
      "r499",
      "r500",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r535",
      "r536",
      "r537",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued and Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r767",
      "r777",
      "r801",
      "r809"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense), net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_NumberOfOperatingLeaseOptionsForExtension": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "NumberOfOperatingLeaseOptionsForExtension",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to extend",
        "label": "Number Of Operating Lease Options For Extension",
        "documentation": "Number Of Operating Lease Options For Extension"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_NumberOfVotesEntitlementForEachShareHeld": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "NumberOfVotesEntitlementForEachShareHeld",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes for each share held",
        "label": "Number Of Votes Entitlement For Each Share Held",
        "documentation": "Number of votes entitlement for each share held."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_OpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "OpenMarketSaleAgreementMember",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Market Sale Agreement",
        "label": "Open Market Sale Agreement [Member]",
        "documentation": "Open Market Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r697",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease cost",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease payments",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Obligations",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current portion of operating lease liability",
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liability",
        "verboseLabel": "Long-term operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r509"
     ]
    },
    "cdtx_OperatingLeaseRightOfUseAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "OperatingLeaseRightOfUseAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-Of-Use, Amortization",
        "documentation": "Operating Lease, Right-Of-Use, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESScheduleofSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use asset",
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r727"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash financing activities:",
        "label": "Other Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense, net",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other research and development costs",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "cdtx_OtherSegmentItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "OtherSegmentItemsAbstract",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items:",
        "label": "Other Segment Items [Abstract]",
        "documentation": "Other Segment Items"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r765",
      "r775",
      "r807"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r768",
      "r778",
      "r810"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r768",
      "r778",
      "r810"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance costs for private placement",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "cdtx_PaymentsRelatedToCollaborativeAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "PaymentsRelatedToCollaborativeAgreements",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments related to collaborative agreement",
        "label": "Payments Related To Collaborative Agreements",
        "documentation": "Payments Related To Collaborative Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment for shares withheld to fund payroll taxes",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preclinical and Clinical Trial Accruals",
        "label": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]",
        "documentation": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742",
      "r959",
      "r960"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r319"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r627"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r319"
     ]
    },
    "cdtx_PreferredStockSharesIssuedIncludingConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "PreferredStockSharesIssuedIncludingConversion",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued Including Conversion",
        "documentation": "Preferred Stock, Shares Issued Including Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "periodEndLabel": "Balance, ending (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r627",
      "r645",
      "r960",
      "r961"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r547",
      "r728"
     ]
    },
    "cdtx_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded Warrants",
        "label": "Prefunded Warrants [Member]",
        "documentation": "Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r534",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r688",
      "r708",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r864",
      "r865",
      "r871",
      "r927",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r534",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r688",
      "r708",
      "r729",
      "r730",
      "r731",
      "r733",
      "r734",
      "r864",
      "r865",
      "r871",
      "r927",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r512",
      "r542",
      "r553",
      "r728"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r141",
      "r145",
      "r552"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r345",
      "r353",
      "r383",
      "r384",
      "r385",
      "r397",
      "r474",
      "r529",
      "r530",
      "r532",
      "r579",
      "r581",
      "r595",
      "r617",
      "r618",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r684",
      "r685",
      "r703",
      "r707",
      "r715",
      "r722",
      "r723",
      "r724",
      "r725",
      "r730",
      "r737",
      "r862",
      "r869",
      "r908",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r345",
      "r353",
      "r383",
      "r384",
      "r385",
      "r397",
      "r474",
      "r529",
      "r530",
      "r532",
      "r579",
      "r581",
      "r595",
      "r617",
      "r618",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r684",
      "r685",
      "r703",
      "r707",
      "r715",
      "r722",
      "r723",
      "r724",
      "r725",
      "r730",
      "r737",
      "r862",
      "r869",
      "r908",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r352",
      "r519",
      "r520",
      "r545",
      "r551",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r644",
      "r646",
      "r671"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188",
      "r519",
      "r520",
      "r521",
      "r522",
      "r545",
      "r551",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r644",
      "r646",
      "r671"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r520",
      "r913"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r352",
      "r519",
      "r520",
      "r545",
      "r551",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r644",
      "r646",
      "r671",
      "r913"
     ]
    },
    "cdtx_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r315",
      "r321",
      "r522",
      "r531",
      "r543",
      "r692",
      "r693"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "negatedTerseLabel": "Research and development - Cloudbreak platform",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r686",
      "r700",
      "r922"
     ]
    },
    "cdtx_ResearchAndDevelopmentExpenseAcquiredInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ResearchAndDevelopmentExpenseAcquiredInProcess",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Research And Development Expense, Acquired In Process",
        "documentation": "Research And Development Expense, Acquired In Process"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "cdtx_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Services",
        "label": "Research And Development Services [Member]",
        "documentation": "Research And Development Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769",
      "r779",
      "r811"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash and money market accounts",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r841",
      "r923",
      "r925"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r841"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in Force",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees eliminated",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in force (as a percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Total Workforce Percent Impacted",
        "documentation": "Restructuring and Related Cost, Number of Positions Eliminated, Total Workforce Percent Impacted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r112",
      "r549",
      "r589",
      "r594",
      "r603",
      "r628",
      "r728"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r191",
      "r192",
      "r193",
      "r196",
      "r203",
      "r205",
      "r207",
      "r267",
      "r273",
      "r287",
      "r414",
      "r415",
      "r427",
      "r428",
      "r429",
      "r432",
      "r439",
      "r440",
      "r449",
      "r452",
      "r453",
      "r456",
      "r466",
      "r499",
      "r501",
      "r585",
      "r587",
      "r605",
      "r960"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Collaboration revenue",
        "terseLabel": "Revenue from collaborative agreement",
        "verboseLabel": "Total Revenue from Janssen Collaboration Agreement",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r904"
     ]
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities, forgiveness amount",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Forgiveness Amount",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Forgiveness Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition services",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Transition Services",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Transition Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r687"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "terseLabel": "Revenues generated in the U.S.",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r177",
      "r185",
      "r220",
      "r226",
      "r227",
      "r247",
      "r252",
      "r256",
      "r257",
      "r258",
      "r263",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r490",
      "r541",
      "r700",
      "r867"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RezafunginAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "RezafunginAssetsMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rezafungin Assets",
        "label": "Rezafungin Assets [Member]",
        "documentation": "Rezafungin Assets"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RezafunginMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "RezafunginMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofOperationsfromDiscontinuedOperationsDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rezafungin",
        "label": "Rezafungin [Member]",
        "documentation": "Rezafungin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Revenue",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "cdtx_SaleOfStockConsiderationReceivablePerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "SaleOfStockConsiderationReceivablePerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offerring price",
        "label": "Sale of Stock, Consideration Receivable Per Transaction",
        "documentation": "Sale of Stock, Consideration Receivable Per Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, net",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, gross",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSTables",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r15",
      "r20",
      "r52",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r70",
      "r72",
      "r73",
      "r105"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r122",
      "r925"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information by Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r114"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r107",
      "r109",
      "r111",
      "r112",
      "r164",
      "r165",
      "r166",
      "r222",
      "r319",
      "r320",
      "r321",
      "r323",
      "r326",
      "r332",
      "r334",
      "r599",
      "r600",
      "r601",
      "r602",
      "r707",
      "r831",
      "r842"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r82",
      "r83",
      "r109",
      "r111",
      "r112"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentContinuingOperationsMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing Operations",
        "label": "Continuing Operations [Member]",
        "documentation": "Component of an entity expected to operate in the foreseeable future."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r53",
      "r54",
      "r55"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r258",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r294",
      "r295",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r699",
      "r700",
      "r701",
      "r704",
      "r732",
      "r927",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities [Domain]",
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r255",
      "r257",
      "r698",
      "r699",
      "r702"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "cdtx_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_SeriesAConvertibleVotingPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "SeriesAConvertibleVotingPreferredStockMember",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "label": "Series A Convertible Voting Preferred Stock [Member]",
        "documentation": "Series A Convertible Voting Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r870"
     ]
    },
    "cdtx_SeriesXConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "SeriesXConvertiblePreferredStockMember",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series X Convertible Preferred Stock",
        "terseLabel": "Series X Convertible Preferred Stock",
        "label": "Series X Convertible Preferred Stock [Member]",
        "documentation": "Series X Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance payments and employee benefits",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "RSUs canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional awards were granted (in shares)",
        "terseLabel": "RSUs granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "RSUs vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of RSUs and PRSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend rate (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee payroll deduction under the stock plan (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Options canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of employee stock options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting power threshold (as a percent)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r361",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term for stock options to be granted (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r183"
     ]
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StandbyLettersOfCreditMember",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Letters of Credit",
        "label": "Standby Letters of Credit [Member]",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r866",
      "r957",
      "r958"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r156",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r258",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r290",
      "r294",
      "r295",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r699",
      "r700",
      "r701",
      "r704",
      "r732",
      "r927",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r164",
      "r165",
      "r166",
      "r185",
      "r211",
      "r212",
      "r214",
      "r216",
      "r222",
      "r223",
      "r263",
      "r306",
      "r308",
      "r309",
      "r310",
      "r313",
      "r314",
      "r319",
      "r320",
      "r323",
      "r326",
      "r334",
      "r490",
      "r599",
      "r600",
      "r601",
      "r602",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r627",
      "r648",
      "r666",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r831",
      "r842",
      "r848"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r83",
      "r86",
      "r87",
      "r152",
      "r174",
      "r175",
      "r176",
      "r191",
      "r192",
      "r193",
      "r196",
      "r203",
      "r205",
      "r207",
      "r221",
      "r267",
      "r273",
      "r287",
      "r336",
      "r414",
      "r415",
      "r427",
      "r428",
      "r429",
      "r432",
      "r439",
      "r440",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r466",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r501",
      "r518",
      "r556",
      "r585",
      "r586",
      "r587",
      "r605",
      "r666"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r221",
      "r501",
      "r534",
      "r597",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r666",
      "r738"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities [Axis]",
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r221",
      "r261",
      "r501",
      "r534",
      "r597",
      "r616",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r649",
      "r650",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r666",
      "r738"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r764",
      "r774",
      "r806"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options, RSUs and PRSUs issued and outstanding",
        "verboseLabel": "Common stock options and RSUs issued and outstanding",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon conversion of Series X convertible preferred stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r42",
      "r83",
      "r86",
      "r112",
      "r317"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r82",
      "r83",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r82",
      "r83",
      "r112"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r82",
      "r83",
      "r112",
      "r367"
     ]
    },
    "cdtx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r83",
      "r86",
      "r87",
      "r112"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance, beginning",
        "periodEndLabel": "Balance, ending",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r86",
      "r87",
      "r101",
      "r629",
      "r645",
      "r667",
      "r668",
      "r728",
      "r744",
      "r843",
      "r859",
      "r909",
      "r960"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r184",
      "r318",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r333",
      "r336",
      "r457",
      "r669",
      "r670",
      "r682"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r524"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r525"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flows:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reversal of indirect tax liabilities",
        "negatedTerseLabel": "Reversal of indirect tax liabilities",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect Taxes",
        "label": "Taxes Other than Income Taxes, Policy [Policy Text Block]",
        "documentation": "Taxes Other than Income Taxes, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r871"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r871"
     ]
    },
    "cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Aggregate Intrinsic Value (in thousands)",
        "label": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]",
        "documentation": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r856",
      "r857",
      "r858"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Point in Time:",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over Time:",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Employee Stock Purchase Plan",
        "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two Thousand Fifteen Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan",
        "label": "Two Thousand Twenty Four Equity Incentive Plan, Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Four Equity Incentive Plan, Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cidara.com/role/DISCONTINUEDOPERATIONSAdditionalInformationDetails",
      "http://cidara.com/role/DISCONTINUEDOPERATIONSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSScheduleofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect tax amounts, decrease resulting from settlement with taxing authorities",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r718"
     ]
    },
    "cdtx_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect tax amounts, income tax penalties and interest accrued, decrease resulting from settlement with taxing authorities",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Decreases Resulting From Settlements With Taxing Authorities",
        "documentation": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Decreases Resulting From Settlements With Taxing Authorities"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_UpfrontPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "UpfrontPaymentMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront Payment",
        "label": "Upfront Payment [Member]",
        "documentation": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r138",
      "r140",
      "r142",
      "r143"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants",
        "verboseLabel": "Common stock warrants, including pre-funded warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r739",
      "r740",
      "r741",
      "r742"
     ]
    },
    "cdtx_WarrantsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20250331",
     "localname": "WarrantsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, aggregate intrinsic value, outstanding",
        "label": "Warrants, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Warrants, Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute diluted net earnings (loss) per common share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r216"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute basic net earnings (loss) per common share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r216"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "12",
   "Subparagraph": "(f)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481410/810-10-15-12"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483478/205-10-45-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-15"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-16"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001610618-25-000047-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-25-000047-xbrl.zip
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MT;!U>[A-KQ1_/J+$"US:"?\*O_SIT_QW\=\XQ])\ :QA<;)(.5W]>+K).A?
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M<:CGSX!U5_<OBGHH2\3SP%*YVH<U3\U]AV(P"?]MLEOJ'.(/:VJAC-7Q%VS
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MWI05-)O,HVRD=?BU@NFD:!EUN,E>SG!U!!:Z#WS/AW?!-K-N+KL-M0L/[;'
MQ@Y,Y,Q>EYV+MEA0!SM7G^I?+@. C<T!P)663=I$C%:3CT2," -%2<3@FV#J
MAR28%F\$PTL<YF0V^C_G;/1\C//FH8SA'8WSUH'6TSZ.<9X-G'L:OVWLK5AN
MR:VRUE[6W-FLW8S[S(:F??>IL,O56K/<K"\GGJ_>9T[6^R[X#(WBK'M4L2&-
M7&^4F_)R^:S]3=Y=-K*[1=D&>[[=K)>5%97PTAN0F;&U"U7NAJWZ8;&URT;V
MP!9KAB2#!Z UE;3XRMVPWROSBV\[K7E .ZV=GV&_5Z)7=L/^I*F"?!-,ZY $
MDY]AGQ/!\!)\/_X!*V86./9!3U?#5V2UEG>TWK>=_>VT& #546SW#(O?TZ"5
M:]G#ZAGPO/?JE# A\9B'JH?'UDZ&GES+'D7/O++=+3>PV4H=60$[NPW6Z&ZQ
M\Y2!W$.3ZX[HR1Y;S[RR?= 3IB>TM4:YL:)3[0[H$?'TW#*V$XB.3*A%4TFN
MX2T<3L*?(EY^Z SK- 31XH<@+N&B8A>6BB F%AAVIE$Q;4DG8],GEKB?F*TX
M]120#P#'GGT=0C%!\ADO%<@U\!&:S499DWEIHEV(P /?5+2M+'7N5"37D(JT
M<KTA"E(?M2!U, I8Z5O ]\#43?\2*F1\V$N@>K!H^&V1)QZI3^!-QBUQ;0""
MEX#M30C:S#PAESH-52LWU>73DX^B7D;Q2&E)JAZ/E!0@)5DN*W4.2.ERBMAY
M:Z]&':26W;G>B-UBTR8OH-TRZ&9F#^Q8I<GE1FOYW#/G0F/'O'Y]Z)IVYTIO
M6ZS?'.@-P[4-M:SFUB'PH/1VD14Q6-0UO0!/>5<^#-LL=OW>D\7X@&#ZKJ(Y
M@Z3@TB9]09&N;>0@>^K8G5'.HXU8OG@\D5<B&%<P[J$+M>3#N)B>)VOE9GOO
M8G"G9UQF4GSRL<5R?%R92,<9$??%M.-7)Z?5*6# S8DBF"6RD2:4,.V>2D3'
MIFW$GN#YJ^WXU*O.'[8F5A\]K.'L8\=CD=(K%SM,F:_T\YMI^,.8VA)/15BH
MS1XA?8!YX*]_) &FQNG!I"Z</B=^XIJ1BDVM/6C)_;I,^FVBM6KUMM%7![JF
M-.J:UACHQK]ES#@*'QJZL^RL%UKINY3\7B$#V-<5L=[(Q$,Z2D(#0)$$?3JH
M13#J_-1WD2R7=\ !O)LKX7W=N^D^=J7GO]X^=A]N?SSWKI_*4N_N>CUAGGK!
MCFU0VZ,&WE]AXH0%GEGR5U@1R1E(4?E#&, ,\&O@.I<.X3'@'>F;XWF\[NY#
M8)/ ,&%'']<N,24!K2+&+1MEDG0F2ICDA@U;9.S1J_B7SW&I0]-FZV</?8X6
M%<D?W.R"U&;O"[^.F*HNJ]5:C3%/Y!9&;XYXKEI;-*_"+]1FE%NYXKNU#ZW]
MHJ%6E=PFDX^_L!66*S?5+Q=TF:*&R%XYQ<;X4GMIV H[."3C@R:1;.?B, PP
M=$';?X=Q0T^Z!7EE,%YDV7"2*I=35+3*$^ZRE@+N.^0]'Q6F'WJVY ^= "8Q
MO+)$WW6*]B2FN#$9#Q(_^@L4 OF8OJQ.!@.53VK#K,HT-=+2;'1;#9YS )9V
M,/8[,2OG?FGY.'8_P\LC?:5V0+W=JOUEB5_G4V8J^_-Y+.Y,R'+O))=34.@U
MVK^ Q+#ANAO2ZSZGWJF#>:?8;>9P7K:8W"FVE"4J)V^.RD72ZJOKC!)D\4J[
MKDOL%^:'WKY'=8SFQMH^OOTWTQ]>!QY  -RNU'?M9/D<RZX(CCD/CFD?D6.6
M.:.%)0*6+\_SQ!7<Z&Y^%\CKJ NSQ<,LALC"X:IA*N]",)W9X&71^>V\+]CG
MW6_A9+4:+HVXTFE8;P41*;5<U..)".A,Y/^>=2:.2)33YF$2?1_C6=N.49GY
M!($-]'*J[@Q[KXP;TN1W@;R.$H#CSQCF/ +X2#W*CO#PO,D =6LY8W1<CW][
MF'=39:L=' *R:QLW,S#>ALHF:T:;(F.Y[W)C17$94;*LL!2TU=C-DX*P1%&Y
M?>*KYQ=M!G,N^7^A-IC$%A/\Q!B9MNGY8?SR^#>=>>?<+;+_B5HP_TL$4>#?
M[AP\=V5AM=1IE.7FWBS,S\&(H*0M.N! E*1A'>QZ;NGQ0AF<GQN ?6E &S@#
MR;0-TZ6Z+_GD?>].V(4SZ#+5+5C2"VOJ%CR3]Z[QG\ +>Z0^4=^W:-PN]8<=
M> &Q'ESGU<3.0%YF[JZCJ5>7EWV%] 4,A)M0&!6Q!RUM/)51&KR5/3YK-5&<
MT'EX=.HL!=#W<1,.4#F!=[;>XD-,#R@B&R^[&FB6.DJ]K#3R\A<.<,WQ9,[$
M!=+;%C6R/[UA?A*8'7N7I3L=N9V)*BE.%@Y>4Y0&KC.*U0F8*)P5?#H;GV/*
MX#U;=T8409^9Q=MK54IFUX(+;<)OW2?NR6Y)G1R.[-1:J=,JU[7EDF-%H+HS
M42K%\4_N_2%U)9.1F_0A\DX^EB6;^GOE^)PZDZ=H^3H7&#8-22\B.49Q(DB:
MV?%%&-XYMK/@D*Q2#'*I(XLX)\>$D:>#NI8N4H<T546$-$]N,G NPGMXBY]Z
M?F1 ["[$S_K8>HL,CX$8VOP1HR9Y]XYFKLRM8NGA<JLMTA_.B(ZVR/QT=+1,
M*IC?L']_#)'=<$ZQQNC8*N$<[FV@GTG<YY#&^QSG9A;Y6(&WW&SEE;0J8HZ%
MIKVL#L("[2V35R,7-2%"B^*&D0!<H:R6X@2SP<"5K.DI*<I#TPXPZV;/ ]/4
MMT/Y5R$'.2V=G5;%)5I"N,^J[L*(L)3+@^/B!UW?=\U^P$K%/CN@A_#%KL/R
MMV,_)K,!A#D\:EEK[1/CS(3J GC"%T>S:8]:.:'9%I[6RLWEIAG<D^R9:+?B
M^.2S_!\ 1*3<J)'0;<Q%#R\AL.-<G[Q?RL6#7,.Q2<%PDP#U3#2 H7$_P%SR
M.9'P2,<H*>R76WA@L1/'YK.6W(OZ%,Q!+PZE'4$9Y49SV_6/5@.;J2QK.>2H
M"2US7CX47FW6Y_ID6,D^&;E:)>=5QS/EGHLOWM+ZAW/M5D)9%TNSS )+WE/9
MKUDBK&?WG$M-6>MY%L^N/T2;.\'^Y\C^::V;/-E?W?,4Y"#LCWUW:V5562X1
M4#SVY\;@XG>!O(X2@!. $X KQ"@!. $X ;A"C!* X^AX)H=>6XL-J3EJ [;C
MTLX$U<6)D7XAGJF'17]-;*5ML(,W%C7%KI/@1X[ +PV;3Z9/1<D"F/.*F!0\
M+O) W2?$]<;8H[)')@*\X"8DM.@]40BB-@M!U#?'18ZQ1,85:Q?8*'7D:N,0
M$9("A$$%ZQ:,==M'9-WF;JR;YQ(WLVX+6?<@9QMG'L*\E,RDS/;0F@0FD:N4
M5D_OGCZRP.U;4I024J#-P<KG16GJM==KZ].K1+X5W]QR//6=D?J6J6Q+:L)Q
M%[M1I=>54J=6U5IYJG21!G:A(0Z1$G;!.2%[!A9NB6O#[KUXFDC$KA)96S(_
M<EX(H_]5R] .%L<0B5Z"J?EFZI262FI>VC%HN>,R-LB61JFC5)5<S:%+3]\2
MQW[BV._,;&(F13PI\, :]AUV.0($BM3?W51.Y;*G/4/@1K>LE>D,!MY&"ZVV
M*,5_8S-3HPL;(R_T+ACUJ7L_"'%Q'_B>#Y 'N$1*)DWF;D+P;XJ]Y[C:9.0@
MN>C,Z\50O(;WA<M-;;E].]<UO$2QMZRDUCXA8VR*]N:XVKP8HU$K=;1R706^
M:"U7/N>:+SA1XY_8A5+XUS!?.S_!CWCTB+@OILT,E<8\7^D4JQX<C8449*$0
M<T^42D1'!4SL"6;5V(Y/O>H4H9OW$*VX\U/?Q=VO>29ZK8;K&CN>B81SY5*+
M]9+\_&8:_C!FZ\13(;:O:K-'2!^,?B#RM8_P!6!M'B#)G[AFY#=3:P]:<K\N
MDWZ;:*U:O6WTU8&N*8VZIC4&NO%O;* </32<FH=CX/M*WZ7D]PH9P+ZNB/5&
M)AY28!(: (HDZ--!;0-*N2'HYDIX7_=NNH]=Z?FOMX_=A]L?S[WKI[+4N[M>
M3\RG7K!C&U@CSI#@-^;/$K1YGWSXA[72PPH4U\0;2E\MY\WC=1L? IL$A@E+
M_RBED1OJ!E+9(DE6/<:D[4QH,%\0=FR1L4>OXE\^QY+:M-D&V$.?HT5%D@9W
MNZ!QV/O"KV?L4ZV%+!1E,D=OCKZNPE>?EC]O*M6FNOJK6E5>^?FZJ62YVI#;
MF:9:_WD]QT4IFU^^)?M[H^W:7AJVPC@-*>*@UNDV?@@KO@Y=4*K?8=S0DVZ!
MQ0U&U-^)JP\E52[/&4LIH7(*7S[59C_T;,D?.@%,87A+,;U5SDN&>I4\8E>I
M*?6\MKDMXE5\4&E9B)W+Q*U4.YUVFY+0+7IE?:IW:_J3I:HK!P'7%(O+C/0]
MPY@)<R&:HH+CKQJL]\-AJ&)S 9@%*[HPEQ3.+L_Y='5;]JJ*T)#S*\?)0412
M$/X9$/Y1RH$TE+7E0(Y.^,>V7?A18UWC/X'GAP$)WY%<"I2@F^!S3P_GX%/\
M7<=0!3O3,^U$H_95)M&<)CRF[9+[\]Q?:N;%_I+5ZI$)]\EW]-\K?8(4B1%N
M:GLLN7<+%1;CH.S8Q5SC_"-J7"= F5FBLVY:34WF^B#IG ]8C]T>91W=+).&
M5NHTV[QTS^)%W1]?:MXY=H5I\ID&MRC@+^XONX?TY.?*S+&DIV[X[[->Y-\0
MCH_XAOO!#X]V1UAP^,^U#%$O==1:7GV"Q+6JD]/(&DFY%XU@,8#6<KKM:6CD
M<DW-&SH&O\AD:&()C"2!-V%O[F!O)B':M8UM?-#$GFJ<V ["J#RT49F1.%H<
M$4=.AF6(9ZUZ[';6J3#]"\$ D(W%"<:.A^U/!]+817O2GS#I2/\(S#%&E I>
MI^ (!PKSA(^0Q4CJO?T$1'X_>(B@^F 1V[^-H;J*!]JESHI;RIQ<2A9F9'ZR
M,2V)I&ZIT]Q0\Z'0=B;7,C2ITU!^ZHX7QM^=OH_BE3"J0#Q(;Z8_Q+\##]9(
MW8)?C3FVH7E-QJ8/^_@3(U0A1*\!UO,V17IFD7-C%F&-\D)!6R1N*@I:IA0\
MW!16Z?$PSKK^H7ONX5DU*D&4JP/3)K9.PQCG)9BC>44U0QNC.P7F_>!K"$H6
MP5I%\'CV4^<E5B4,T8/&,[=11WJ%J@GK\_36YYR4E!B *LZ@$L ?($[I;G[\
M&5L,6VS.)"\D8OT(R6U60QV$Z/)]96%:%I10MIB6>Q *5F)93A@MM'E9P(.A
MZ6FZ&?4U%\?H>\C-!V(:/?OOIFW,VL0O4WZSU%GN B^LS(*2Q!8)F8XD6GGX
MVL>Q'\\F8Y1K _>1PA*BHRF@'=.ENB_YY%VR3-(W+9:N? E&[4%NNV!O]5G2
M^!/U?2N\T-ZUC1]VX 7$>G"=5]/#2KM94TB;[5*G7J[+YW$9YAQI*D?IO@<E
M;8PJM/([TQ(F\I[D<CTD]@OU\-((BR5X+$4@(8<O\-K(T5+EE.:1+Q/I.NP*
M< P*EYJO6(9#I,?MX GU;-W%H, -#?_MV3%D'Z> S2(/Q;'E^9%0VCN:V6EI
MNY764DJ=5KG=.+/['.R]2HM'CZ9GOX)AY+@3<8BYIR2-(6G23":ERMM!E0@^
M'>">^\[$DT)F8D>$LMQ<+KMY]#3-2S5/'UPZ)J81!^F]LN3X0RP]';@N)HR$
M#DJ9>2CA-^$GPH;=)UZTS$41'F[H@ +@C=L0'>#TWR/0V?F7MXJ#\'2TQ4M2
ME3!A3R!_=Z4</"YM+A^L7VR=D9,%!L9DPBIZLEMTNNYB8\M507EQ;II'M. A
MA#9>H@IA_6T&ZLSV"QZ\EIM-<669:[HZ2)VG(U%8"XO3M^K+Y4.*:B%S'%"(
MT'71QZ-Y)4NO9 \W(-97QWTF[]1CULGSD-AAM33VV2H&:(.!VUYV$(6!6U"B
MV91#O2/19!.I[1H8ON5Z<^^\?&'_YB)MDX7*F W<IS8=F'N%&,[90-D]QG [
M&EO.A-)'[$2REUG2Q@*MY79[GS*5PN;E7"3O1DC+M**4.HU6FQ,7Z5+CO/$]
MS9PB"V=LH&2.+,2@_<WTA]?1E?28)289SM/:^9VG"7.7&W6]>SPA UVET-A:
MJ:.6Y16-BHL:\.4XD'"_4$ARWQA"P6R/(YFS\Q4$$YRQ3/Q86%)9-D&$L5I
M@ME=H&8@&*PRV5Z^4U74H.O^YFJMJIR@F<S6 OO[F[!K>_N<)_=DZ-^"C1C9
M70.#&E\F/P +"1;J3E&0V1)IECJ*7&[7<[C/D@YY!3!]+XP*,S13.105MDJ=
M1KFA:3P3823]XQ5,FY R07SD"QW;=\E==[;37T(Y />M[L>'29A>+OWXT@BT
M4SS/RS')\:^+/02N/@2#U4M15?;LCTIRK:TP83<KGYVN#H!TZ5SAT*YM[%([
MM-T62?&%(*0\DS*S4-(BQ2@U/(_>)P^3+U>3ZR((@!< EN%) ]<921Y@(HU0
M%0<CJ<1I!-NO -H5A9BW<8&,B>R\7)X3!Q\'KV*3A5K2:E^EIO!VA);K88?,
M@G#\B=5IJ&X<.>I2?R)]B.)V'^'_R\[)/N<@J=O$GPLO;9&\:Z(D4Y\P&259
M9ADU%\&;%34%L&3/@LR.&99+27!:/O;N04DME\A;3J&0 T3>CK^R8X=OCA9Y
M"PN6YA%Y*VCE'N[+]XD%%J9E]O%[O<]'!.@[=773HQ@4\+"9MN2,43N)5,F]
M(P((S?L0F+<1E(U5U@%>:%?VKF8KX@"\T$B6.,!J&DGO_3?.V?MO,MG(G_/?
M\[R M4H(&W8!MJ2Q:[X2GTJ@8W1Z*5T/#W R=3]@+!%#&'LL92C0I-2:XBRJ
M$*1SB+.HU;2S3"-XP9S[PZ>SL9"YEN01Z2RWO[FP._!Y]J]-]C-Y<$U;-\?$
MBGET%3]BL6]1Z?LL2"-#JYLTI"'7^""-2S!J8U&(UJPW)"[U6-/9(;4,;$D[
M@-UAW2;7L2RL$G(9]WH.8.%&-XB?G6?RCO?<AHZ%H/CJN$\(]2_ &L9UHD!
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M6$BL/GI8P]G'CF<B'5RYF-]MOM+/;Z;A#V.:3CP5(N^J-GN$]#W'"OSUCR3
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MT W_?7/(X+=(2]]&2MS('"+02IU&O5FNU?.ZNB1H2O"YP(G B<#)?C@Y5HA
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MIY6]I@('U;1R4\GKYG\>"#U1%/MDM,I'9#%]E]$\X5$DGEUE::6YO;NA ^G
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MGM9' X""TAP;':R)9E&B+E'$;;?^'#QUU1$X$3CA)SJIUK9$)YEV0OE&C9O
M!0@\P+(<(XQ4/D[%&1O6?2.N<4?]^\%7QQU0TP_8&S.&,-NECBJ7ZZV]XY>"
MT 3S"YP(G B<Y(*3/%,_!7[SP>^QLYJ.!M5?B14P=RHT6Z0WTQ\.J65(OB,-
M8#_2F$Q<Q[(DG[RGRKL[6'K3>=/I:GHY=-Q.X$3@1.!$X$3@A%^<9 J&J_+F
MP^.N\9_ \T?4]KU'RFXS/3O/Y/TWU/J.A?#XZK@LYO"%>-2X=D9C:GL$W[LB
M'MZHE3IJ>_]@N* <P<T\>$0%PV\FR;!TRGU0P2#S(1C.]B",A8$K?40%'H1-
M<2%.N#@/) B<")P(G B<")R<#4X.Y)\].[,"'EB_HV='U3M66V',(K@?XZ]@
MP?T1F)[ITR?JOIHZ#8^2'ZGNO-CF.I--*76:[;HX"^:9U,Z&_<49U]ZB)+U#
M=VQ)HO(D2<[VY.Z.^I+E>.),[I(B80(G B<")P(G B<")P(G>YR3*BDO#8&5
MU;-U9T2_@:F5];Y00RMUY%I951JG/PH1YW%\46#:6Z?[$6"='P(\]EG<B0K#
MK:FMG;TJ7$ZAK>BB8=3U007$&4Z -:D1$.NO(1:&Z;+>PU&/6S"NT<BQ8%R.
M*#U1 /!DU,I'S";]->X\X5$DKEUEJZD'+#+7:.969*[XW"GTRNYZ13MB];E&
MBU6?:\CE1GO9LKLXLA5*12B5S$I%RZ%B7:.=0\4ZP7^"_RZ0_^J'KG+7K(55
M[MI-H2(%BPH6W2%(OE3=^V"5M9HR,&M=+C?KS3TBE<7GTSQ#[(+G!<]GKZ:W
ME*!Z.)Y7P'INEINM?<KIG9CE11]T,8JC48(<Q2B.1@ER%*,X&B7(48SB:)0@
M1S&*HU&"',4HCD8)<A2C.!HER%&,XFB4($<QBJ-1@AS%*(Y&"7(4HS@:)<A1
MC.)HE"!',8JC48(<Q2B.1C%R_.23OD7C:[OP(QX](NZ+:;-,HL9\TIM.;9^Z
M^>1UM:OU;9E="JL"3*E$=*S_2^P)=KZT'9]ZU?E+QXG51P]K./O8\5@!KRL7
MRSV;K_3SFVGXPSB5._%4E%15FSU"^IYC!?[Z1_@"4V/A%G;B)ZX9T]%,K3UH
MR?VZ3/IMHK5J];;15P>ZIC3JFM88Z,:_E58I?FCHQ@L?DQ=:Z;N4_%XA ]C7
M%;'>R,1#.DI" T"1!'TZJ$4PZOS4=Y$LEW?  ;R;*^%]W;OI/G:EY[_>/G8?
M;G\\]ZZ?RE+O[GH]89YXP7?WS[=/TO.]='U_=W-[]W1[@[\]W7^#C3S#'U][
M=]V[ZU[WF_3T#!]\O[U[?N)U+Q\"FP2&Z5/CX_(2TY&Z*I<VTYC<FI+GD78E
M5Z4HB_4N&,$<NK20MKJ8GOHE\& 2S[NAGNZ:K)AAUS:^$,_T[@</+O4 -:S:
MX3-,\L5R]-]G>:EJF!1KV@$UNG[T&;X"YB)C1+$;T%('Z!O(Y/M#]^Y?4O?N
M1OK2?>H]2?=?I8?'VR<@D>YS[_XN3FV-EKW R/!=]":VEMD*\&TKUJ"L%1AR
M_0 H81-=8:5(4T^!I 2LL:-8C(*UG))8_B%6OU$G7)L&<8GT/*0NH#3P3=T#
M&67KU;+DN)(_I-)UJ%;+TAOQX#,3EDHL:R*9MNZX8\?%'@GPAW0#^O.-N#3\
M7:>C/G4EI28K$CSW=V7E*X@-C_H>HUDVOSXD]@ME7=?6K@Q?\+< 5@"3:U4<
M$*]1,CV)2'T3M+\^M %P+Q,IL@HD1,(+>]G8=<:N27WB3J1KRPD,IKAB[.0
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M3&HP">+C%A '@-F!R9*VYOP(/.0:4_0B?"D8HZS3AR9]#>/6%@820W\.J")
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MNH%-/ A<AAL"<GZ"K118?<I9BZ(9Y))8G.NW.@6+/0XBLAB[#I8RC343ZR7
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MTC"\<2EL?(JU_]1!#9_\UX NOY:388\50\,479^[4%SU?U=?Q95[[O$LH3#
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M_'S6OND-H/66M\8AGX^+F' IEYQMDA@M4,;#@E_1O;PG"J$..8:,KO"UAQJ
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MR,,0B62=);8C2I"/RR'_F@'Q-X^T]+#^HV6W6RV[V\_CWSXK(+Z#S=X#'?M
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MG=E-T<X*+:C7Q3\#$P<Q4RL#H+4;@T[Q3Y6QQEJ-?FNT,P"TW0VJO?KE[P$
M;7U>"Y'&I>QZ1X8NAH7>"P3:A@OP-_H##OLI#,:Y<RV*3EN?T6/S!15^@B']
M55#1#+A5-/=,A#@KAPYW0)K:1*=MK:M]>+E$"Z6*70K[KUKBX@ #(H.!W1YT
M]@&@:@?IMEN/?SW]UN6$_]O.]BP]Y_TZJRLP[3,'MC@B^;+'5<HD(9)((J%
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MCI_,$-^ 2P;O1!0>ECM+"_QM,+,^?SF++"[X"%)400Z=P6^1=38/DBG5]5C
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MTB@LA%J?9(G?[' ]RM2K;R0N3_WI%0\%8PE_>G,WBD%UE8OX63-7N/*;>Y?
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M%J.CD^:Z27!:2TC"W* K!'!!O<6)9#ATNH($B.CRI+5;E 4#K"IR\9EH_(5
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MJ@O$Z.%><_#.!3Q*:V=9/(+L*Z4J_+2Z*+&,8Z0.3LX#6420GP6P$'/'/+M
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M"L*WSAQ[ F*+U+LJIB+4LERM&MMR6ZJNF?-E B1!"640X "D9=:OO[DR<S\
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MV0>&F%K.%-IV@KE+.G3G(-S;ZRWB>\@XF?.#G(4<BTU"+8P8P*Y.@4H5ZQ"
M$%W.4H:[4I2SI"QG D S6GTQCFY;C L,Y(P>'P]?,Y"TS/Z"GV5$RBS.ZHNR
MIXNR>WC;HG@ (_^WK"X1@_G2>1P# (VI5!CKVT!Q*8N(8V0,TB2>X9DC?0]
M OE%SX;,ZX*>1.MR3+/*^*;#W4D'76&+><?TLW))4H1'QZ*J'7,+XT:ZO13N
M&^6<$?*2,EQ9K ^V[\#PN56RW?*=C[QEOH@']%7 [*PLZ?LO?MX+]PX7/:%F
M.;=@HDOMMB@*^8(B)68>@M5#:H4G6CXD1H^ZY$HNLA_<L8"^NG@V9_RR2K?+
M=CK9];2WI_\[ _G4!2/.K<3@]^B'_!PXH?/@L DGB@-C='< Q<?1U_ WY*^U
M"3Z;G3NEG9H++>'Y)&:DU$_QE*>S_H2+K=M5H5ND$=T]M0<8^'ZG>[#$R!O
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M#]T.W6Y@62NO24]91HIW^JN_TZ\^\*^\)>\$YQXCR9$'U>*T/U0L:U'60ZF
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MJHAC_0*M$5VV7$UK?V3HHMF)#(,K1 \RRVC6>HW*U9W/HU1BB\S#GIDF ZY
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MV6P<%T#;UJXX'WB:.]BG^K9J&_@@FIC75C$U@L^)?L#ML/HVVQK)31FVB5&
M5!GFG1Y"BQ^,&6I>T23,#'@G&?NAG(" R-*\N3;Y2CND605:D.9%J#3> Y(2
MX&:E*9YL_HU%Z/?F:@N2E\-_V'EZ_(=?I,]6L$V4?K(0V,]5$" >7?#;Q\V
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M.](-=WM/!!NZB7=_'Q;^VWNU8?\U;/Z-C;F.N_*R%W9WCS:>V+KL!V_'$P;
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M@L5(,XC?,#+I=9PRZL/M(*=1< 5Y(S'U,0G)Y"7!4-!>X#4H+K#3:TD=UM2
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M9K*ZS(^#H?1P'D>%8><PQ!<!,RYD^GX)%@H]^"SCHTY'2O*<M/U")V9=<^4
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MKY7VZCJ9<(B8+%_&RFY9.!ZJ,<-".Z\KS@RR"3@OZ<HP-*/R!)AF-%))1=*
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M.@YD++VGB8S[M-2][>ZA["&6D>O<M"[NA&8#/"#V9H^-5@P54=$&<T3[,#&
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M?6ST%/Z=\,K2MQXUAR>/G.&-A.F# 3:@.ZF55#7M&>5[N)Y1WT8AS50.Q[6
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MM)W&?>%,,^%96MQ5,R?Q".O YO^(XR'\2>WUH,(H3CT> <YRIZ0, R- AIJ
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M94;+@1'-AE9$A<.U_FQRFNC\I$<6BA:R8=KWCIFQ#4JU5Q_HBL8F_8SLB*U
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M5A +Q"A#Z\:=3KKJYCMXW/4LY4WG21IM!>X1JOINW R4S80KEFF[UN@(WW/
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MT#:O"I'B0BUHD4OR%'+QJA/?\ZTZR4)V_2"HOP-2":"55&)]0U4L%DR='FF
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M+;EF$>?.NH;RMNH^G\PJY]*42P\-.WLED+ZIVD;P8YE"4Q"NY\M24K"2>G;
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MRY<+)C8VDM1D#0?B>8 %%K_8DF();YV<X=24S>WE?;-HUF,15K6#;)TS1\T
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MN&6$/9S60\(\%Y%9>B $D'I(?1[&8&DJ;-)@R\SL@U5'W>KBVDJ675;8L3$
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M@&B*XZ 0+0UKJUE:RE.%;L09=%/@CYZH/1 I>&T6Q@U MO]:;V?'?+N^)?X
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MTO'\8^7=:+U"RPXR?'L1[+BAE%,8@5W]OFYNZR/'<38;M32==GQQ:#$IN7;
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M"[B7@=^#) C=R$KT0'XYZ($R\T46.W$8%Q4;Y7SVNPJX@73J!D,RZ_/NO49
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M\CUP0XQ)$ 3]D7XS=I]XAJ,))CM3NI%WU@MVUL#BV\EX#\=B^FT^F;&>"9X
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M20=A,2C/SV6)4:"!1JJV M>:+Z!B&'UNM>6P;];Y)/PD7,=U@8>ZB!D (0X
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MC16K&\N/>?8=6^2CQ>=X9=V$?6[TU,*BK,]?KF4Y.7%%)&#.5=BE-MS.F^3
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MK.PMQ9WE-5>KN#CHX"*1:^Z#G"%AY8P5\W5@?\_-M/: 2Q2,7K_1,5H2.:D
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M[\RYW0_+/28"9 6$?Y(+@*13<JY$YN7CTIX'HB4;H@>5\J,J0O.Q2Q?D*[E
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M%'D\/$NT"Z,K(.X@M($[1[WV(8.S7))O0C7H-/$\DG@&K?$S27Z8B]Q]U6\
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ML VN7,G(,85&$U!W# 3>([D+^,93>IV>C/9P9F</B[Y1,$2+WA%TCY;Z1U*
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M-R#;;B>O/VCJOK;0$:J(5FW^5<)%BA=;>"?@ZO ';_CR6)'.QPCL_Q*PK\,
M9ER4"VY.IEA>_):W.=Q^7SL:PJF\I-,\?)]#S%2]3B(/(-&7HL/G5B @C,N=
M7@4XO+ZUM/!TNIP45KSO "L (S_NLZ,M0[!W3R 8%[@_A@D[5;*:,^;Y-*6(
MW^]#ZGI3A< ];( ! *MJ-2-9*91;% [KXFC;,N/EUF6POG6V_!!OC* UA<5)
M7QJRU83""NZE36QEZ5?'C,W:C[)H5F^MY^\0<KWSNNQ>WU5G21Y5#F]C$/)8
ME7< $EE:]0:WL-II!F5-1>XB\6KO:KY1[WLP^,KB5%P<S[9O,>BK>BVMWZ\Y
MCC0'WB4.\1ZEB+6A(*PF*XME_V X=26 /%5:#QG3-;B6IKPE[B6MA;SQ^#3@
M43P^/SN]\FJ4SQ##Z'.Y,5'..[&-N);6TG*7!;UYC>?+6JMJ)I_77U(+0+KZ
M=<TVC"6+<VGSJH @Y1!*R_-XOD\<$6*_PP*03,P>I@&=UPWPJ"K)L)'>@&$9
M]C< )+W'["L1\MS3/&S,U]E 5 :]I&!1-2"LIMQSY_8:KQF=:$W5L6-V<69A
M1J]N^NIF%^Z,R01_^N[_4$L#!!0    ( .N%J%J'4-'J?AH   '_   5
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M:,6,]$7;Q*5+H?7@[L&S2:'0\BSXSK6UTD [IP:3TYJ TC]UXGZ P2PEG>[
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MA@$>E+L!^E*T<4ART$75:V4* Q,R4\8Y!0*SD*W3_D? V[#$?BWDZDAY+9>
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M</1-<0/GTZ![M3>;P ?G/O7>3?&!97]"P.D<?YST:%(VD." 9VM!&)W!$J?
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M*"%VTM6*P\ =!-U&_>-9BK?'W","[4X3%?"$/HE02H-W68'2ECLG63FFJ,^
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MBZ,;F*ZZPZX!JI&Y=R>@ Y_Q[ZZX42NI-U@M[@874J!9H;]KLTH@,LE@N>)
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MR4.=)@]-DTUT4/OL\O?1.+W_Z(;OTW!1>>_/T;0__#"O&=W%3Z2K"(JKV)C
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M3 SP!Q6RUCF0ZO;/P[!.DRG5%-%@15F8<<O5E^^X'^M%]/^"R1X75<U 6,7
M>(NV' HDD:1T%+43$-=#MG_&'-.]1P/MK5R/*MU-OSO_[?7YR_-G9Z_?G_WV
M]L6+WU^\?O_N[/7S9Q>OW[\]>X8_Q]A]O1N<#[L2G9T;N_VU]&X/W.E&NN)8
M*UU&/QL-\-71W'-?+LV#;OWKT3"L>/L]_C1QH5NWOC/7L!21HQP(,1:7+B28
M\<X!]3)2Y&X.U<,F:^*O=PU= =7<6U:.995(0$>Y-%Y)@8-'<Q64U4PPC7_I
MZLV3JX]B7Q?0!^/RZMOG@Q#AT%?/D_$4=3'#[QQ_<N/IUU*]J_/$LO?6*.N
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M6?)!)6^3Z]3F98=VW*9GCU6>,S85)@U=TEACD**<^VFZ#K/OK;8>0UR=:G8
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M=6UPR)+(/H-Q68!*QA/K' <1 @JM4<8X:&G@Z;3A.9&D?PC'#5T#N+&E0Q>
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M=^(85A*MS@Q*,8$F(**0*]:!9M8(IFUBNO5!Q#8L!W>H_/'??<B$A.!:AYQ
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M'57IV/8EPPS& ,YSB:<N79?4@9HY6AN269'YYCDSTAO;XPHD'RF0 I5T"RF
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MEU#$4^FXN?K1"]&S%*"%_0VC_=.'F.FE_9#>%$;0<QGOZ[2+';T:@C\10[Z
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M54P5S<A:5ZPICDAW7^ZT350\OA;';F]F*!?Q6+H>2;69GWH[L\_+X]0=2#_
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M4GU0K^)@AY<B)ZI5D9G+*, %YUG.XP4E<J3C\9N&9]3SAUIC.E*\:<D_NBE
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MQ76 XP"C&3TG"'>@ "#H(ZR<E+ZKD^TYAT];DM>K:,DTW':D]2OE&<;&"9"
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MSSTG[W")*K)#&]EO7$QFG_R H;N1] 4M\#Q99P(<U2(.?@U9PT5.$V4(VFY
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MSI% 53^7*LRMO@W,6=3:HDD1KHT40*<>R,N(@:B$UT9 Z+OG)CM*UVR#+M5
M7A9?>^G@$!OL#!)]CA'-^O<46B)#!\:^FR=L]5JEQ]01/DTSIAMV=>IGR LU
MCACMKQ6(-TB,5CA]-^=)"0(KVFN/>4_*U1#"6>1Q:?K(*U_AZ7@ADT)O30*.
MU96K,1O4C]<1+"LJO!PMGS>^N5#D5DCS]-IKAJ7WYG1*=D>9N8GG1-0@9UI@
M\]V,0IYP^Y.SNXNL)L969U1Z3U=" :0QKT@2K@)) /!76*<P:'V0*$H!V >C
MSHU/1B.6\FHBF@DV1)51595\S^R(6+5H;&N:EP:_<^!\$M/K3].V!"XH[23(
M)>_U.>CU2;+A,+BC.G?5HJ4:;/E!5U01<'\8,-X=]JY'.+Q,$_'>5)3E@,!K
M7_.9? ;+5I-<!1/3$:RP&8E="D!3+D*+:D)N"F!]4Y6*7\_CD<>AX#WF1-EX
M58V5<$?]&,T$FWFERC3MB]]J\XT-5?SM6<G=((P1G(W\"W:K?OC6;H3PZ$FK
MP<,^??/&\=4,)PMWMC<"/V[_D/V^M"'BG_F'"8K^!WSZ??1M\(;1WX#P:?M8
M),;TX STE@)H\CFT)G4AAA%SK>0KC:M49V+$I5 E$[P8TOIXC$JWCY]9+3V2
MT2=\D?F5Y)_PE+1@RP!W^[57,OV]DK=*WCY4'84%O_52#<=LFF$63XDA.W.>
ML_I[-5I/\Z:0MR@ )UBB=,0/6/UT'%1J[>MZW<AFF@&?\0?ANRQMMZL ^VW,
MG?%H^\8L=N,M9=&%Q8X9,?3@KYTK7=_6/X7304VP8<O#>UCJ:MUU:L<<)'DY
M8'N3!#3WLY=MX\R_/QZ19[S'#^AQ<HT:NC<PWA.F%[KMTE8_?41.E4_ZOI-A
M(&<1$0K[0?YX0OZ(5>FR'HX9[[FE+C"V'P!.'+;9VA_I,>-8_'2,Z&?&BV2A
MP[Y H=C,Y!7F2TL2I2O#UV3A$H7L4@L+'30S8=]>7PK7K<*"EN,[E&WU!ZGF
MR2I@DOS=9[$$4Q@</O5M#%+#VL&HKTE'@A/I"7>AHIAKZ5\6A\HA6:8=S9D$
ML[8?V9:39FZ7%9_2*_:W.UM+M3D+%1_;^FQN>6D.6E;N[1,KS]%'(&W0<@[H
MT&4)0 %4R<"VIA"EGIM&>*&J1(E8 I"H%&/\:VR&].42]\K,=Q)3.+M=K@QI
M-:+BZ%6HP\H6JXFF[V>'_TC KJ\I@+\RTRB<] [P7%L\8F#Z_SPT\E_F[_^/
MFHLA/E  /JT#^7APX8.<MK)ZIR.I\;@B/E!RN)*=,,$>PKO6AZ*3DZSN<6D=
M^VN@R:)E^<U)$8BYY(@':_'JR>4+O\PF_GGB)&#&9,&RV$O6.MT;]V)#_(#1
M%=UYZ7E]TZW_]^_?J#*Y[?HCGSU=K%YW3Q[3"N;]].7LJ81G8E=?C<W7W@+;
M/[LEXCO.N".Z+3+/<^713;.<<I\#I<-?[\JCBE9&!8[T?HNN2<["R8;=JR!"
M(^K<(N.D [XZQ-7#&5/L7.(1-'UJ[5D1G#K_D_O'[RL,,UL0U3#P3_O:SQ.A
M1NCPM7F5AD,)B62B"1^PK6O%GI9\H2(BLKZSE#!)ZC_GGGV?CF,"G84 )PCL
MMA3 .]Y\"L#N$+8EV&% A40(!?!3IA]X,C=, 6AD=Q1B_[27XCV[.#L*O]GV
M.CHSU45O?/Q^Z>EKM0%%P#5=N<--XLU^LD:N(M5)IF#G5R<<8(N^DK^ Y\;8
MH?#@BVT[L.W+G:0FZ[,(:8@D0=HBRD3>3;S88L[TD0K='=PF]W0-1!(GAX<5
MXBT8U6!/R*@I?N/3T+=9-PIE8]-K/9F^,1MN=G@.(%\BSR1!S+#=]\#SIYYH
MY3ES5WTZ[=E6VT$?H=(-!WUFO0['N S+I87,CG++W=*?9[4XC :PTTN)U0$,
M?OWOIF)QA>3L-,YQ!&J^W IBA^P+8GD+O_U(]KHXKIBRM'#/LO^7EHT;[X_G
M-*G9*%([:#UI!C;S DAB$P^%[9U2 /S:G2 <8RS5)F6EI@$8Z5=!WD%47P2?
MT>FQ[KHDR(#UV!N-XBL[7$ ]E?H&I$_DBQY>*^4.CDQ)+CSJMX+>\X_]?.6W
MGA[CMY [>;2YM[F2]W::E\>'E:B)O13_#5]HFJMK/6W9\6A=8E4:6PO]W7-K
MD+;S=K_2*?,\GW;39 ?-KLMB<([5\^97H*8:IGX,/2@Z!+;7BY%<<>V5?(OC
MS"S[4I5?I2'6<+HON>^HTIW6_/0=S7OA$>9-:X=BMI@R"Z_%7T.5:,^3_5,7
MRQF#-;>1TMN'7QO2QQ3:6\3'9FT,_MC@/F .NA)!S/.0G)6IQD)+2,JO'6FO
M )N)WPE&J*<69U:&UYY>D\GS*2=?Q?^"Q0&O$!40B]>]#\3Z<W\X!B3HJ3@V
M6.D2/5,I@!AUO"8%\#"+_!0!PI^$PF*(,L5XA>Z&;/E$MP9KVT_.=]YP?!!)
M,[+@_Y1FJ"N4O=Z[*FS$L*W9,-Z^6&<Q[U_+&(TPNK4[I"7E6VO2476NEF7
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M21*?_.W":7;&H'4W7_!@2#H+NND+]>6SS\>2?/;/[@_NB8?;583X'+272%$
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M[/ZIP;K&!+0[&GYTK6EOU"T(5%I.B5W@CE2Y[IF5_?3[_0P%;Y=]DKR][^P
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MBZ/?I[:YJIOR[C_@0C4"@A!U 4/RXYKCE15B7FMU-0W)+V(N9WD4W/MAK 9
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M56^+99F-_".AV5!2KN@UQG%_]K:B8S]/;(3G)CR1 JBYEK/<#C3%PKM)+A1
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M/PEDW9HNTVBD[R!]5$P2%S/5*YAWK;5+!HH;$)2@]E@*X%PHA7SOZYA-O%=
M\OJ3]LDL)WW\.Y3>.?C1Z',,.:IT6[X"[>7HQ5-A\,\@VV.&*W?\7M&YF1C6
MNUO ^2NRG-($8V[E\AKZMF8%S</BJ3QY;Y"@MDOE 8'#-Y=V%<Z]UJW?)3^W
M84_]0.?*W['^+'QE7&UW%NJ;/[3J0[<[IU;;S].7[Z!6X2/\#UNNO+$AC>+
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MXT]@;MJUMS.Q$^?6U!/N4U&'/PT7Y*/7OS&Q42E0:U!Z6KAA%$L!5*/'(35
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M4/?3Q;U"#%V4NFY;^)(FZNZ;.H<FH0W6[VQ\6LCZ]!I=(A%9U9D]FLO'M.?
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M:'B-:JI';O#%2I7W_&<J)VLP@)T(!I#"2I:D=U88, #]Q^@!.?#L #6 :LL
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MWI-$2#& CW;C]%A7:@QS$G7K3CGBK=F][,M#W7G]G$GF/Y90<[!*'!?F3U9
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M]:?E6LE.V&EAU9W!9=YKWW=5!PCV\4CO<(\*75"7?NR/ 2U/WJ! @DD/#1A
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M2&*$Z/#YBH&?F&/"'S%WNLZ-<^D2+T6,"=L=V$.B/"!,-LY5OWYX*ZHV/KO
ME.L#/8TW=W'&7&UQ3A8>*.%@JY@7TV?GZDZ.,/,86K/\N>=$/[:)IUU=)G1B
M.\:2>TNPH=DG@M,%G9,[(MOVG5PWQ^,MT8C?^R'\&& [YGR\PH2QAZ+AE$V?
M^3>J8#3!GFF9'"(S@%=.B="56A0]7"FHGLBTA\\SS7NY72(#V/*R--+$$/\;
M>^\9U538K8M&05$0@S3I48HT >F"0 2EB1#I2(N(2!,0I+<@"DB7KK0@5:1$
MNM1(!VG2>TE Z9" A$#:B=\Y8X^[]_[NV7>/<<ZX^]YQ?KP_DK%6\K[OFO.9
MS[/67'.RK:%.>1X_-,?=&?<QI@#<-<$SO9V9[BF8.[H3;C=7(PE& 87-WVC6
M/Y17QJ9LL +H#-J*6WK)]%=*.M[CQ0U-YOU^6]]]QOL@+(YNY=5))@XXRT#6
MW^]8UDLDB22W%)#IJ>+\&N0<!3 ]-$(.3Q4%[YKLX^!;DJ:D:->0B%/PB/$&
M".2L2);$2U4XX]R:#9&C-@)*/9M<DA^/P<-M/J0XLIR_8GL;71MF"OG%:D,Y
M'ZKKV?;GQ'.P_(O:R<JM.:V+?WH">EN#(6-'\:XK-RKL\]C)4W =TPC[D/).
ME[U'0<S-4:M0*KW!O\98#GROYQ).5#GW&>IJYJ4CB!SO,\N2U)'L<)H/T]A5
M DFAM+@R2^E_UKAL:R)M0I3/*]<4&#,:RF5"'MN.:!;G!.; =]E6>:56D3T>
MM$ZA=!D$R[TQB)@>P>&.S)@X;\7B(]&GBTHJTPMU!R4=X#F:%=!;*<;ZUX76
M_@]T*0#?Z8:IB-G7 K^<[_6A7FUY+K45US5%GDZ)9SD7?&OX2)LTP')>VTB&
MXTH[K5]EL .*WMN$*\X#:;4UO-#:4V3Y+<I()G77AS<YIOKP)'DZ)73"5HT"
MB C".%HUQD D3T_ -;LO7_KU71 ,8?$DBD^YKB;.M9W"8I#<+9R8X0Z-44U^
MU:D15("!!?R8WV89(V#]S5)MJ>4);GNC#K;FNUH%9(S,T2%:29GG4P"R$S![
M*( "Z+B*<1G&.>&@KLF\&AK::H^YGX+T"_R(EZ:;38,8..0&N(/N.'6936'+
MI;5:V4P @%. 6+<!?PW"S!0$W>2RN[7-H,%JKHD_(NI((9Z,OUAO;DRRJP]7
M2'_,G?\E+CDTS+P73K\O@70")LYE=$&8;*SF_?TT/-E37/W$\IX;!;=Q4 !
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MF\C@5+/PX+>N4(9!1,Y,=KI@I:YPJ[?W(SHIJI)M:(?]$7$"XV^^H0"B$=2
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M.GQ9YBPK=@KYO$5J!7397_S>N'<(\'[5N-RBLF#DV-+2.=,(UN \3ZI-,U$
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M&P0W-1EZ91,3+(71/YZI(UG.#TW*7^ ^KJ_?_1X/:QJ^<VK> Z^&$5D<>RF
M.L:WH6*3" H Q8))&V#7-SJ0E>]>MJ[U7'/G)-\0P)8GSAG-$*D:*/S==J#D
MY]Z=XR7Q6)T7#3KWR]AEYW\AEA*!&^FA7#__D(0A#0E3/3]H&R(Y4L7R10
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MA)M$83PHP--O)9'&.9!M;:=\6J="[OMG!VY;K><&O%$_M%X-!9J5%,W^HXD
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M<+6(,VL= RJ*,?8LD(AD*4K'0B=+MVX(-^-(SSYV#^EAT7 ROZU;[4E1L$Z
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M_"^"AT,PY'X=7UC["Y8B&R@PI3G\MT@/_Z=U]'_VPJGL1+T51_*/6CGQ&5O
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M&;E&3V'N_;*I!X$V(ZC=;*HVJYF&W](MV4CH(/XXB(3^GU M&^CW0CS"4\[
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M<S!+8L 7+V)S;_^BZFG1:R'Y]GNE7LK-FE\NWG7PI>23.-*BPSD6P.=+96=
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MF'7PA9;WE@9)IT"JF$ 5>7_OI5_R*+78-)IX]WG9<LFQU;<\+<(A50+5+C+
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MIK[V#" O>-N8F1<;WY%:#T([9&RG6]U+-;TMZ%?'Q$D2\=00PT[L]D&Z/ M
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ME.Q?$>7VE5B[W(>21K?JT07R[%Q5TV5B%3RJP5O&GHVZ:0]/<ZPZ!XSEL8"
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M\QA9A;L7@/-&\V%&6_562[,JN59=L[P;(MFPGA7VG:0)VOJY/2&P#D2$WZ:
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M#:O5GH97=9#$&CQT*Z1<_,DN.HMKIDRNH^3T/Y2OC/S&,V #H<.MU,YUP+C
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MWXZ;#NU4:;CWX3*WB^W*?VUNXR .Y0V6DL\01A8>YY%VLZZJI*5="SXVCCS
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MD/AYT7'Z(R8:6;G5YA/F9]<^&\^YA)91[S@8]_M=CZC*-=22:?B+0$7-+29
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MG5/]LLH[WB69PH'&9\GY&35Z^P<>T!^V.PF5UN1YR+;=;MIWS)K-:8]12!^
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M6,(^R)^\H_[;XR<2<G S>"A.,'?41Q6EBXBH#M'G3[75[>WD+P[E6%S],R_
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M8)$JF9)U4K M2I#U&M>%4W'FU[I.D5K*EZ*UQPF\K4BB5$K+3KR;D\<W&$>
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M!PIP K\>U/$(;TC=M-,G<R&QRE7X=@*R#O<B^P\!I3B\EN7[+4=SY:R:]O)
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M2[^/^+T&+Y23'R.Y[*5D)@X[?.]"4\C,E F77R^X_^P5'(](;^:8MRK.R!'
M"S]?0K?U"KT]Z'MGR837H#(__"B;X.^%!M-#M8NG[WLI?375^0@.?B3<D5RK
M:?9J^;ST6R\RSV2WP$/<3OL1@$EBN+<HX:LODQ@#;[),-IUV)J2O^;ACE5F
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MBOC0""3=#I$DYA<9?PXPPX)B]N>N\1FWSTPOB*MWG;H[-73K.S@I9'410I2
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M!V.;"XDPVH57B'1XL<'QH40(1J"YKHYT*<BOSO/GC_LON>.,>[A>C=64>NN
MS2:%\4;8@^?:S$3[52@^O<DE?QW7L9M2>9/AU6-^:0X7GZ2>/_<X>XI4()R-
M,KPQODE/6>'&R-'?V7YUC6F#NQ=OW.1*K8UND73K,AB4QCO<J\6KD+E5"#UI
M(R.'>]=Q62<\/C8XR+NELX?S?8NH-!1E(4KN7!&,I6EA/ W*94;U$;:=&$AT
M7&#^]ATN5.>?:$SR<,-3O>(\%]5VG]^(%(A3+JK"CI),/0\+DX,"/Y= 8A5'
MA?RRGI=;?XDVM#!_PS9:=_L'?>*99UF4,B(_"1PB2\EM%)L'XW9BSC;%6V4%
M[OC&+M;790X9#]Y[ @0 5$4:)S_;!8#:5>;OU.%^O7KR,.EARD!97+4899S?
MGLN//D('?(G:FXN[.Q2#K(R".\!$H!&-=D(7MEV^VGZ8L2WS*/!8EO \^_K/
M_9,:M<"3S>V(/@3Q@CZ9T[)]G@WG686WP?CG%@P]5("Z9_$8=2Y77)ASYW[Z
MXO[2UYY627%/Z5DD.@-:A29NXY#4,TEAL,Q&%XP!^[FFQO=V5<Q^SKMS05<<
MZ1U8A!COWK8.UU[\3QKJ^?]EHZ>1R8L9VU=\25ID8+ =VW:)ICG6$B9X\:-X
MR)5PS6E@+0O@"!"$5$8^!$])FE-*E()S.8C)NZLW<4KO2)YR7,[!?YZE)RMK
MJ>]V:X7"QI'H*AHV[2W*15:*G:JI&&'MVR/?O=ER!%@K@WX"EWE%;H4 2;)D
MU=%B=HN+BK%RPF]TYB3Z)!Z%[G85,G%AS#C/E6PAN0]5-OHZ[>4+8Y+C)^$:
MD'&YU-$0;DJN)B-)VQ7T*8"W';=6O8LI3+7*L9H"-?[J2(.;W/SM?J'DG*2D
MWX]%;FY'76\/UN7&E[8W7K6+;0<LF?:U[#.(?&AVI'R$H'/ 3-H0UX-+68R(
M%YJ&R]S5X[\#G@O:5!,G3R]J!0PUA5[5=9#RSED;D??VU]_[]I-\E1(.=_MD
M)5Q2-7!B_7ZE8ZP2\]VKY+LWR!4;TH?T1*?%;0ULQG''/&*-8>BA7YF+\))V
MGGQ4U"]URU4@F6>F90(^!0>%V+[LJH]!G1\M> O*_#C3='6_=2"4\PC 4(27
MH(I2DD/D*U:55524#0RI#&&0]SX/EZ5JW?2"6W<H_L-_W%WL3[]WO2UH#(>^
MTI^LO*/K;/J/5INM'@'^=<T17'Z?HACV]RFJ_I]TNJ'B)(40$5QAATD$I%(N
M=I^BMJ.4PK1F,5FON?D$'WO._[4"]UUZ7%&[H[=]!NT):BE9S>"PD1Q5_.![
M/+W>J_M5HXIKLC)W->H\"!HWS9,='I@ ?/- ;\(XR6"\5]>.@%LS+RXL1;OD
M&_26J''\C3M/# /!?+KFC'%:$8AY^)0EP;2<\IH*:O\\="*%S[U-(RD,(\O2
MLW?AP9<8P&/3@62%/:%7]@VX&O1!5-AIHJ<,<ZN]2/E/Q=\W]&WNMZ1Y)%19
M6Y)&E"%Q<4K3?SWC^ \9M]V^X/VIC[-MB:I2(P#]31T>Z54:-$J2,S,ZX20&
M^/8]1#!UK/P(D%L+V=DX B2%D&AQ"C FXTQ)"I,6LVW[Y?/JA16=Y,'7'1VP
M-KR5"[(T3W8[ C@HP-<5CTNVW\-QNL&U,DB7(?XXEWBQD)M3;&@PD1!5%?8"
M[FX%'YH%'^S#N\)E[IC#JRXA5W^!2(?(18N@W0MTKO].:<">''_8#^1IS="\
M^;7#A?8%D.W]>6Z%0/60)P8=EQ_<2'WQY"GP;/P?$E:%S %%2R:SQHW\;C)I
MA;LLK, ?V:?)JC@(DO&2MX0\NLVR2.KQ '(1GJ8Q609*H0,82%R"VZ<SK 6?
M2PKY"X&N/8%WQF_;:+[@8_"VO^--8J=.PQD59UC]KTWLT*1;.KALO5ZD26;T
M_ 3=B9EJ]M2 OM1$MK<TUD0C9:%P#[D9%8+?Y#TB2;=Y?/#CXP7G<CQ/LF99
M-'\J:^WUU-$T_8&1)E K'&<C8ZD_XEB)'VKG;IK\F!FE_2;H,9:I:_Q*3VEK
MC-J?)E7NPP9[;^S"=#O&);E42>-],.8@>E]ZV]#.$^$\*JK"P6-7D-C@[]F-
M=Q$+U_;%0<G<%6C)^"I6J:Y?1P#+G[)R)^*<QQY7S]BHV;[<C89<T/3L#&4\
M;CW\GG@'?W=E=Z$M!_*SZFOQL./[LPVF=^Z_9)I+1D\.SA^/$-8E,^+U8@A:
MG";CFN+!*\6Y*!Z5W:'SP^\^3V=. L7?N<3CP&!X*SO_OO0S=&[<"1E(+V5W
MDY"]O*<B<J^#RZ-+/7%5D>X L:U&NN8&!U!/!+SJQL_:S/?"Z!)N,\5]S-H>
M[+GWXN&;O5-S42_IM(K^C.,GDZI2XD2N3&C>P3(CJC>MJ_KGYF8?,S7KJ4D"
M'E@BJ.-@0)@DM7\R"QK>""MJVHFY]6I^[>>,?66Z9T-?9KJ8-Z?*W5-#DDIH
MG[\!D8/)F&QE-BEX4S"S>$=FR>IA;42?H>#7OO+O2V?TKG*3CO=@]RA?D9C"
M9N!,_Y?0<A/N -^'H_O917FU]6_SQ9RD '_:TO14E<B4R;4#,KN*;4/,HF2*
M8C4R74O9F,F%Q/\Z-N>A-T?1UB SHP3]),-/X);Y/T$&X[_=SLEPT2V!SR =
M(5%0KF*9+;(N;O-Z;?2\ES:DW(999?XJOPQ;U\.HGVG2R_!X*$XO]P7U?(IU
M \ZOH3C S*P>+C\XKV^3+0A]Z^1W1L*I:\OYUE(R[+<(;84*4(J0#^"QR+*A
M*$_?3_CG D.1OFHR6UX29>E&>CG.\O+=YYJQPO=$1>,@P06AM,C#X$MT"T0?
M ::_D3HL)ZIOAAA_Z_5W><;$JC"C5\0VS29_1>+IRSJM9_--G-33P3C"9/="
MV4+"I[K:VHC?O E6$1YC8&6#WD1QQ]"1<Q*+.8R!+F3V!NRG'"E*[KX7D[O
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MA@DAH5-_IE[IZ4G>)2&ZS4W[31U&\U>W*MY,SX\ _=0N#7^5_%UTSQ3XBIA
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MYO/F '$K>14))?2W:O<. IN=WCV&^MOB!Y_"NFT(0$I.I@&$J5%C2.A:^Q'
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MG$4N"MBJ?M.U_B!*,<G%?!1EX(G8E]'&7IP;G]%^U+41CIC#Z,_E@::SI/>
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M$&4[IF2H&.H\8M0[C\FK&A<6N_;C_G-;(5D3>J7<(P#;"TH.? V,!9$%D4<
M3AT1)])#>*N>-B/9GI(5$HP^ K 0TPE[]N/%%H(&$B.E8I;>4LK,\@!5L[')
M5[0E2X,"CY3GR JO5KO@]GG-2<_* >L=VS3"A8>CGVO-F"*Y@$\O\O>IB(SO
MRY'5>0F!1X \>"P$YWD$(!N#<6O0_X.]]XQJLNO6A8,@14I$I4D)"HB"@")-
M6D"DB0B"="%*$3!"1'I+*-*;@(""% $5I$203B! *"(B5:H00E.IB;1;4CCA
M&=\8WQG[W7N?\>ZQSWCVV>?\F+^XL[CO5:YY76O-->?D#UHX393>4/,!B*3
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M&T]>A?KX=@4J'("(AJ@I"*X^*P@530DLKHSA^,VN9^^P,HH)3A8NO'.&/]F
MZ7=0-C6U, S*IX!^BJ_O:5]J(J*CWY(4]G4SOD1<6$-X_(AP-)$3_.*?H:&G
MM7_,6&YWF5J-Y*K=C*K%<GU?S7Z3BPL</ST6*?-EQ0 BFL9[QT58[\KH%JR&
M_JZ+^=&HN;H\L6$?-3OHR9#+-:.U/QDE9KY5%HZE-D=KG+W<>)/C"+N(-OH>
M$4'A32=8'(!B/%Q)T&AU_:)5X^:!CR/S\1NG<,+-SJ[7)N]"FB[=DE[/R8_
M@N5D)1H:B)!HUSPK><.+V1K-5ZJN7C2\F6821*+":6Q]9#7X5-3.S@#.3J()
MD[&<,=?4$*?3*)ZA^TPJ,0_$+_*< 7:-CH?IR*]-8PE.*,E.N(:LT0M+R^K6
M^I>N8:FYR3S\S,)<;"([JS1A8(>XT!4DG%GU!OBAU3BR*7926_HAMYZ-R36+
MV/O;HJ<! G8N <H\&2<B28K8!]=,DPY S^#=;^GM"Z^><U?/3U Z*]-S+Y2G
M[^B P%G/A@+P-RK4K.9;>2&FJBEZ=_A^DUI"(%-JPPX'%^N^13;% 4HTQD]-
MM^^'[-KR)2C]4CIK4CWM3I/, _UD$W/683#RG5YQ'T/*TMN/=E.]R3MD _1Z
M7)RS'NU]8_NIG?NQ?+_  Q5A0_%!EC4J#]!W>&IG@W7+E=2O_MA(O)52.H X
MIBNQ,Y;N(Y'['&3?85#6L" )X@JR>AO@3V,/]^"*<1)I)-;!*^X[WO;72'Y?
MI?7;:?E\DB"/63 OU!9$O578"J%SR(B.$(:T6<F7%$..+V$8U&1PG=)5 ?Q7
M<-"N#&1WAYJ_4_(H#Q)ORV$V\_Y4?=Z3M N/+Y6S_K%[Q3TQR(*];;W0K<IX
MG+GQ;1KJUP:45/%_ZWD0A1O(>@"FG)I:$=;G% 1^GYAU<GZD+*7_*YZZIG7D
MO/#E+J0$??PL:+PK>%;40VE8K.K=)],3JX729'@7+$-VOIN0?[?D49#5;'X5
MEG+*_)#%^.9%$4*UEX:09_NXDXTO%_K%^^GV&0J%.3$=>6R@X=81#)PWAYT2
M;/HCL8\LZB(WE%J@.-+&-U%H_.L_APGC[@Z-M^?7/5G97;&H7'NT<\0KL>GC
M$12I'?81>RSD>JLLX$30\+ +&%4HLTN;73^1OI\.>XDBVD&BLU!3FDRD4=ZE
MM2]/?F69GR<GLP:T:\YAEQS^2KQ.;=(46<UG]($=!9H[ZS0%2- 84;(T"OXU
MDW2W [PQ>Y4_2H7IPMT?2P,Z1BRN4;FR5>GD6NI%*B/?V[,\02IOMD9VC$5@
M]!>L ?R=A%/"U!&G'F8G&,EF72EI#^C8O+O_S!MFCVI7:Y68"3&CIE%X2O"W
M/!'E! \E=YLXUTNY!>FKB58_4B@\_KL-1'2/, )'.T:T+,CNSBCHD^B:?<-R
MJ4^-L]D),0_R%W(FP0+H_2Y'$?2?&YC8ZW //*DC6R0^%5]VA*M74.IQ:)0E
MF#I;[RH^?EC/W;HLV!;Z)=UDGTY(3<KIXZKU3PF+K93UUV2W ,2N'A$Z)<NK
M8=>MFNA!QV3/GNP9]4FOSYWO2E>\PGO11>*I]Y-R)\Z>O_BE!\0PFDW1&EOW
MA4V/T(Y=EHP*T9Y7"W7"\69W?6LIC3#[@'*>5E/39]1_=:4[ADOUHZ<"@TD[
MZ@C*#09<J(\[2T+'UAK,#WKTV9RK+2F('@/QO*C L#(?@%Y(5=T>C>B)WVM1
MIK'&YQ,C9BL.0)U^FO*SR%Z)VDJ%N<:[;*=2+KU"_-2WV!OXM1F%D2D.D,0U
M(2,+?HWMWTIYUU&W6^=7<D*EZ'98P;%O!>!V1 K^ [@+-7$ ,AW!F,/A[@L5
MQV99&O/O5(_T=]7FR%IDS@LP,#QNB[X?F6^!?D1'EC.7("=;SQW1DM2O;1N0
MW.N'H?DL/^!M^SR\3Y@@Y$^E73CU5RH]#6T>((9L&,!B1O^-/VUJBB\N1+!$
M7_-EZ7>4QZ2[7U>%A8R#G\U%Y^F>K&>?+N>G"RR'01^[E7B<4^;]\!GGGLH3
M*UQ]Q?R_0/:/_P9V=S-)4SC :EXQMP4=C[GZ)B!M:N;+!]S[R9XG58W\%U^W
MM_<(\ S1=:T:1?>P6#:%$<CU=M$L(V[=J@Z^[FRR9C85],&1;594BI_4?K5'
MD?#7<9QBB!!)J4%.0<.I4X2[^G<&5[ZK_'>]NR>S9BX]Z&7R>N4%"QG2@J31
M+A[.FE69>?:/A/PX2^G72\@O3;4YM9\$]?Q?$(LWOEY2=6SH@TR =_L ;Z9]
M\%.,22""L'KAC9WN,,7,XWZJ<GJ+XZR2)WE"[*KZ^-K,*0;@(\LZ SF(HD:,
M3?ZA3[ICJY?D3NZ;T<<9JHE?1LN)#W _:!.XV)D^KCCLCB+:(N+\O&V$[0AC
MX3*O$/Q-:7(U^F)OM9X4MPYVN@HYG</>L]$IM63(B&85$QV'SN?'M/*36B/]
M"^'[S+ET+OZ0-UBZV3F@F"$2]%E?/0QU# 1(XJ!$6WST_ML65_<R0-)A<'L2
M]F@J//MJ)WOD5J";LK+*7-!X'0"A'?,EJP.K#L92^.X8PXPB]Z/=M6Z[E@<@
M.2?QL/.2'P846Q;0@"1Z[0"TT'_</9VB,NSC?*(<[SXXSVLE $IJ=;RW?G71
M1T4D8QYZ'#67A&()T4<\R./_YCO TG?R<IZV\G3(CN@]1YW?<Y&?5K-!^UMM
M* A2D&**::HAIB3[0+AG;+LE\H25:%>S%2098EG"\Z2;HN>EPVZ:%1?X3K3-
M8\__I<!-QLM]V1\0^3J;+6O<8AL\G@B(9B$#V!>CCWHE-RPWO$#=ATP+SIVK
M0KVA*).$9[Z^]!/+#EYG=.!]]G7N.(.AO:!TVE_E%"_K(B^Y8R$'($]\1#4>
M,%O0(\FV>,&?]$O,T*+WJWHM"++7/CAOXXZS*982#D" #+@3S_[+RUU3@LB;
M5+9:]X@X,]-W,3-Y0X@X^)[PUXT?+4@%[#C&OSCD,E&S<;X_R#52;ZA"O*4Y
M34%V7L&LOU9_5D6(80S+B'H$GD[OSJ_53T#$3,LI0!@9EVR )P*?XHHL.= J
M+"<,##C3GX%O[&Q.F]..P5C6M8E6!D2'N )8P)/ Y>107\^0QC,9SYC9V:._
MGS( F\I?S@;D_]KOT\RA)J,\T0*T/LV+5<EVT_VHMJ18A+J&PE)1LOQ2PG2$
MEV#$EX"V1ULP#(R==CX OB 9[H/F XS,4BP&:\]3/GF>C #KZ;%D^%ZU-/\D
M&D^[5[931F-]1PKR,,*U*@ (7XF=]I&7OG#HY?:Z^J@)L>[(JQS#EYTFZ'!H
M4O)?(*CE_[#B0MQA][0%6"(X _5JR9(AI\=K5E>ET=&:/-RSUTE&XJHWN?MB
MF$Y4OA>PR^,_KKW<XA@/^L-,IK$9DJ_:6W_7 3]%RYQ+4[K>D&+5]" N5E2%
M\PQ3Y(!HLC2.8DA?*/I$N)M5D1804]E3_@?ULZ)4A]TNY@#TZ"QSS^#X+U\Z
M,OVH1+6?0HJY!VDL+6<L]+-8C!;$%==76TN$#8@*W#EQN2,M..^HZ\,#4#5T
M??RUVUY63Y?(F<;D8>87TY- R]++CE(U)^US-LF73CTQX2&KZ8*0EQ_":NO7
M!X@#1BGV)*6X2CL 9>R6O6)O@N/N.2GJ:U]MN'2$\<2I5Y%;OOV>AR'2#Y'G
M=+Q.SE*4B,2/5C"U/N4;T_)7(F"@A;?PG7WK-+?/!@EGE2WN/T,=ZR3)A6&4
M%V2.;>F.*\A +881)_L:/C;5Z2=;?%*YIR\FBKS#\&>5C\*[V=8O)4U1(C&Y
M&7#@/<+F_%5Z%->S(10>NUW?\=H$854H#\RFUU^^XR/>/5V'R259V5",0RKQ
M=T^X0^0\9 (ZQQ>[K38C;Q+5*EQE5)*H]\.DVB@X=HMR^U.1%&[4*A88H+%N
M$=7N#IZK&12T(WY]^^6MAB["=O4>$Z^(7>X[,;%INF(H\L%.K<Z]K2VU==^%
M\*A+^H?Z2[4?Q=B62RRFQEI8"#:*/X.>WK'>K'C[./7[]8T@J0;Q\666!.A<
M;%.(*F<?8#7O,;WZ^<ZT;(5SZ2/D_69O/2-PEDJ;^CP&:TV?UU:T(2RKQ C%
M> [&;[V*/%/;<(1GR%? 0U;T*+\ XQ=N+XH*"U3Y,(U+";I;QDF;BFT]1DWH
M\M^CR7Z;JVW4Y?5:,2J[F*C=EC:E_*2WYRJ_T)TL&/&VW!29@,G,WDM2EU37
M%*IO2%DW*@VXO_;Z)7T^63Z84.+]R4I?Z0_<T+T'(!;ZZ"'DICMY%[I@G#+S
M@\19[Y][Y7NBZVI^Y2_,MYRNBB6.HP%]&KL:,09&XGD374;8/!'@V>'886RV
M<?YM/,<%T>K.M1_B#&T:;HS;S/%_>MJ@1-/-R0/0O%+#U*T,$M?GJ5_WW?<>
M5ADY<9MJB7UY:>'_1.6KB6;&*I('&)H#"ZW@C(@_DB@:Z(<WDT0_COBJN#XO
M69GFCFO;*>#Z^B\C!;!*!Z"Y>MAO R0="B;\$%1)Q6':%)YX)XE]KF*Y?@X1
MXU6)74CPX39\3ZFVMKYIR!63/VL0"3E_5%M%4C0>*.IJ,ED_S.C)FF+D88ZK
MW\_,>#O-WB<G/Z30+,![BZG$>2KM,LO[-#^R*<NJW!J=<IR+)*;0NJ9AU",M
MW5CN$#GR#>0XI.I=C"BQM90PHZU^A@#/B#9__XLYV"56-44" 9(2@_K>J&/>
MD-X6V]6F#W(L -[-JQ^I,>HM(O9T7LW4.1=YV4FH^9(W4_']WUS7?OA__G[O
M09AF]7\TAN$_R1@C@'$BM -2PQ+N2;FPH''95U@>\5+@UN2]9SYI2C1>D=K?
M[];H$X:IMXKZ\@#D=IW4GQ(W[3!TOR97QL.SX/>&S-(34"]3-(,R!]%[JG4Q
M;U[:VL&]V,!1N[$X->)]BIG)C=^;IY#?8*SJ? %C30.=,/#$]POM>AA+,=J?
M_O.*-T)(?H@=2Z'T4B[#AUE_ON.!?F(D#BO<*K1"XR#IUD\I5.AIO,EB('CM
M.>M,AJ-[-A,A1 -P0A[7V#M-CDQ<=Y"T@6YS><?LXCGH4J'R9_!0$K+H (1#
MA-!%3.$[ I["!B7H4Y3VVA#[4DAANC!+I_$()>3D>L+4EI:"BK:PN_1Y$:$.
M?+Q#.I=?%F+77#NL#F5GDQA:>[#E^4Z4VGU/J3#?U' 7/6XO:5@S6--LK-HQ
M(_.HPM'Z?L3EJ.NWPT#;1S!PFF#PG#*5!\I%GZ?TY79L9X #R+E!R@QWJOB9
M-;@29+Q]#0YO]GZ> =8S_V4O:_;\46:,:N*=QKSE-Z=NVYS^9[8\!6;/ZJ7C
M]@NELA[4/C_**$Z)B:<$TS]!>67*-8H^0IL";JH3IY'8T#<UO$K^IO+]RUUG
M DV=0Q)+*IYY#<93,]"=^*D4;1)J38SLUTZZ(3BP;@RU_W9NW!'NM50S]ONS
M<5=1IN4Q U=CG'B$8#R(6EV(H7^5?X\<&VTP'[RF#INC:B,4R!E'#.R.P&TN
M;^E*'8#8P>.U04=!/'\T#O/K?@O14([3%'(;_(4X +&]C#"*+&4"*;[TNQ[C
M%Q2GHW097X$L +9ZFEAP$+:'#N=(FN^84PO=20*>LI6"QPK\1(JW04_@Q.D%
MR41U8WI[%ZD5>2/MO]O?3O.?QFO7C'MF'HV?E>C]DV&(%_,,Q3R#"<S3<0W[
M ,*YB@13<VE"/_/$Z[-'8"/;TG;!/V7%M\2371*9+1^]>A:Z.K)*>HV:RX;5
M?BYA[+$LX *)2#730>L"BC"%JAVG@OWP@,5A6I93#&09W9 ],A>%C92U1B::
MNHFHDP0#TCNS_'_C!\XTI!$\<%*B4<[>F2#]9A6AQH7&_1-_>W6 _[;6@2%*
M1M<RJ#01:5E>/S:V;F9Z587B@\715WLKILXSDA)HQX;(,@!L+KET#L4-0'#[
M)M$A5TMTSN4KYH:YI!F]>?#L4]NBT_W;KW9_P?(RJ)S(64CU!/6])NN,FQ^G
M.V(^5Y$V76P_ZSF1QK#5;0 ]GZHWTRGDJH+^4;G_.51I-]CH11Y[K+A;<;*N
MU.>VN0BPZ(^J E:WPVW(7Z@)H]W6R%UM(*ET5;D5XA%L/.8Q_Z'YM^OOI?K8
M&\+%6GK"'U3,M/;0.>6//'W5/LE<G$M;6?'G[F(Z;[_H^)A':S$MV&K#9"WR
M,-\AT202ZLKO XD3$8[I#.J)4T\RMZ@9G>-N26R^4]$D+[SZ$:0$X=!>\](Z
M1:&KGZ-/ 8%Y!+>M>_T'( &7.9+)6?K0S\V#T)&F'/A$[8F>BGDOSS88AZ=K
M*G37F9"0JR2(3B.9=T#=_M:C3_AF3R:"<NC(GG<R%?ZY5135?A'K.B#D[K>;
MZ<#;0$RL,E[.:>$BC=DP#RLIYRQS8GZ$<6DMMX:2]BC<$.U1Q:ZL=CPW0L%#
MLM?4HQ;.':C\,KT1T^G6/:Q$JD\4H=."(AQ-<HAB\V \^UR%4_F4](OL!9-&
MPP6N_S_9=RY2<05/O &=DB30WI1. .#N7:O31^IS.,;V,?O>W^NZ>MWN'!<4
M0USTKO&V1L^#@?,L.#3;G^H4@2FW()F"B\-3T[><(B0V;GRL.^6[F VB5A9B
M13!0>L<@@1&"\,/N'SWYX.V^)*8-P_O1G^<[W.WN3]=9/3#5;A=SGQ/)V( <
MXG4MA'.G9#,E$2-6 3@:? Y]Z;-KK'63R]]3LF]"CZ72>UT+4EACU:?)2 ?9
M;.2 P]6A16QZ]R_"6\-L2-7JH,+)5R#_*/NVTJ\, Z9PO$)^_"S'N,^J&AG,
M\W-<*2M5G&A0/X0D"3&;,3SZS5K ]?[_FC#+_VQ[OS<56EGZ:&RO;G!FNHJI
M2_W^X$)J.W_9*5.6W #RKA_@0C(RJ:LBF837&#N.3<%4SR_76$P TL^L6%XK
M+FIJTL?/C3: 5!N^7P5CU"%\%.I U+J=R''/.:;7[=3 <_7KY=%C^\GQ(,H&
M0'>D3#: :V5H#(T;S O/X[F\23:9YO%ET/1;[[X9?#EZYVMH62_&@_Z8'0D5
M36OW)OZ8MZ]=)[G:97X[DVYRN9)Y)HG[65W@)Y5U6,4=4Y9Y6A&9@38.8ZCE
M5.M$<I!.9>^B&PDLN'W<RWN6U]@O-;"^,1#W2L__6H1*AM5;K2U5ZLK%7537
MJ6@M\NSCK"MS5C0XQ6QV-Y!IS:MM<=NI"SE\F,O$5H["4[8PCK/W$ =2YZ2E
M6S276>R"+VS_J7DI@)/[6ME>#Y)GG:;HI#JD'X8IC[T,1@<Z7 80FAE%?VXB
MAXKP"8V4KTI)R55)[U[E?O?J0F:NTL"#(5:+*(^?V7Y5BYZ_L34R8OE]7Z_4
M!ZA\9?;Z*?T5>0;YZ0#$3+N@[Y@G ?B^GJU(]8OLK2=?L)^826>[YEWC.W #
M1!R(01$MT6%Y*AA,I-FHKPES.7=9\=12?N]ER:/FO?)"R9APAZ[#5+?C@# )
M>KNQBKC7F7MZ?GE63E6WR;^&09[OS-L[+&DJ3-F_P;$PHF%^F(/*:$7EFD^+
M>0<;AZ:Y[4^K9L?G&Y+!;)8ZS:\>:[4)627]=>%5 K RPWQ$, $'H-N#%9GR
MLF)C,I8[N5OMECJ\0\F=D H0,A'P[[9E213+,V:Y.^);$Q:54;/:L,'D_(,A
M_F3BW,XV.@T[]PY?JS&^MD5\(,RN%[\/.0%TN=94CU8X<U>DZ7_H.[?17'4V
MK. )_ZM$[]]<]?1)D :0B&2[O&G">,HC3Y^XA:3%9OMKH;*&X@)_;,7QN8US
M&S2QX59'^E-7YN4Z\A-G>0 4R0Z6;HUI41HITGEO&%2EK=Y]I;88(AT2D^AW
MBF%/CG(2O,LV(JM@++=@U7F>N;3$X:-)H3N?E]($R%%SY)+7EMKQ&SO\..>-
MA9TC_$YUT2KWDQSC%5E3"Q@LM-I 7!'5%#%"#NPH8*)+W$GHD\A,=SGZ%*SF
MF5H4KZA[T:NW(S'?=KR XP!T/ !E3'*("2V"\UYZ:&NQ+8/P=G\2?ICXS>7>
M86K43=HQ:;(@>JUE 0$.L0;,W]C; -[K1HHSM4V\=<.53BYNGT0WN'NW'@<<
M-1CX<A3YV2H9.9''DC*OO]9%XL,-KZ2ZE?J^:<Z9?'[*1";S[G$#\K32#DT*
M](8LA!S:Q=;RM;4(=D-^$E=OV Y8?:R[:#;U2[5$'(R)@B3.J0BHH!^C^_#
M66BGL!X9=P#BQO"(^RW<&'E7_^U^ZIT_W38X/4+R8ZOCYYA5TV$E?VNH)@-
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M-HS,L:?4:;Z" 1?!;=4%J6C&Y'Q'(=3"*)8(@,-A.R('H#8([3,FG28467
M&C(=A1*M\RGV$.*B, LM/OHP>4#G8?9)G2MC!R "$7($NZ)Q  J#4C-" XD#
M\\Q9)+LV5;Z$&I@R6=JZUJ@9<=6OM5M 0#@)Z8/"/5.0VY<Z'4-C/WD 2D /
MHB*PG&* ,O%=!XTM^D_M^1HU_K7,]4&Q&\>=O$QO25OTKLW0I,N"X*C!F/XO
M%573MW5Y4N__4PGV3A_> L3PL<1#G86?_/%!K!N;&V!J&VNS56P-94Y]B7#G
M@_@$!D>*A'MGDZ4.$Z"U*'<["(]N"S\85J-*FM6E#6^,W5W+EC2KC&$2.FY
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M]_'\(:ZD^O:%4-)'W=/ZL;K?XQX.3R? <V(9H J#84S.0B5S+EH:OY$Q?SN
M_;OVK\12[QO"<E!$._0?<2@7:DU-F9:>#=KOVZ7_/5W[4(LZKJ-IX0Y+#H)D
M+E1O 47L %3E-WX TD(_^=L_!YQ#4T:U0Y%@VF">>B,I)M&G_]:J74.\BH.1
M_0T#\X?G+?[H,X;?!5-4H;N^=-)WCJZH(U^6T9F0.V(JO1U:/1 Q[D#R'4V2
MP?VQM/4HX/3R ;[R&/(S-HL<#82NZ9 #T.M1Z("F+LQE2'26OO52/:SVY6S
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MR4)$CWY:M'&RNB; [WSII_:FO5EB$2=U_ _ZV]WV&_(93:]';^LZNOW39.T
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M=^LG+[81)RR0-J?#Z!6X&ZW>\E++49O2-,D^BU=S:O';YQ" JU-9@_U02PV
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M_\K7F +^>_'Z+\H#-YR0&QK2)/(;A@(-DH"=%,4-QW#<63)?AC2!L-(K).!
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M;%-F*,C#M)=Q3;=LXFH,+=USH]57-@T&G7#T(^9HXN4^D<&7OV1 =-_%3I&
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MC'$I)(X:2+U %AE3XR3,FA)M,F6E,@XQHR)2]R;LS]]YKN[5@<P'\P:BM/'
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M*?U.NCET[7!(FE=) CJYNQ)^D]H'KD(D(Y^A7T/QJ8'9=:>:+WN$#Y<&QM
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M=GC]K<KL6*R7)C>Y<7*:GO7OPF:FD4X+\:^QV1YFGDS$DL#RRT$5Y"*%@WZ
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MMM].WJ.[<F3>7*@.X5PVGH3KMYI=G;2(ND?@"DR4$<5(^<C>[*EAR]^.H\C
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M'=E_=>/N)NL353'P!!7=T5 G;+92IYG]6X,5AK<:)<%1.Q7?FFL6)S>NX6F
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M+!\4$W_#L:=X]_Q*I>^UAY0OW#-H:ZHC9,:BC-7!0(A;="))'>(YZME& O:
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M#Q.[&L R\CWZ!TCJ:1X:X#SX)'1R $V-3/^YP!C.$?AA+R5>'S&AR$Q?*X9
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MA8Y*WF7]U%,2;5?/)^%:[>BE8#0-T MLA^UN^]  GPJ"E=;-:0!1)EWZ!OH
MH_"/3? #F7;CUT*".'>_P69 #ZM__D2^7[53)49C:8"88(E5ZJ4Q[?>%M:6
M=UVB[Y\SG^;F3KX9XE]R".XR8EZ;9X&>FU[S7T85-X61VS]KS7AILAUC4G_5
MU]MC18#-CE)U!V(I,1?H,$TF!\",5&$B8G&W+O;EQ98PU?9&A7(?/Y7B*;B(
MTQ>O+?:.J#8 S&8MIKVCA=GT;;G35EWF8C$ZX7O)XRIO%'V7)(ZLSLTL/*V=
MO/U[PV!OG>C^N$B]]NI:UDO]*1[_">>+GE["6L^@;6Z3&H+DA_B>+O=+FV3%
MXH(=[[,UMQ[F5U:M" %%D.IL;,QPF5;**RH?&CM165_36C>FUE):0JG6^1#@
M^%2L7P,C3I9<! .)>9W(&J<N0^-GV>#:VOVLCD"8QEUZMGX$%%&U"3OA:<0:
MW77E-MN"BFTP7:Z*9-0K@2+>NCX9L[VAJ@HQ6ENN.N0CW%[,C**>G?U,8"NL
M_J,U=P[VK-6],VI,?$5]*J+':AL.I/Z L?H-:$E[@.MV3'TB?(JL"M\"OR;^
M2"[FA:L1Y4GB/T+UYA:3XS*5,A$JGTEW@GWTA_LNYB3+G^%F]-7J/GE#2")S
M0Y,D1@QH#V>&=86S188P5CF0[')&%8;?347/%_0]TA01$;4?%?SN_.CW@''I
MY:6=QFF-[O1K-]*M/#EO,6NZIA&S-NDA:UMCH*89,29]H;$N1_6#RQL]KJ$&
M7S^1"V^33HDT%)<N;4X)].P'(V+]%D[/WQW5*6@.N![2=TGD3:6O</L+91K@
MV>2$XC*N<I/5=#0XIY6)JZHA<$)_<F%,/+?8S:JN/B)O?C6@.L@LPZNE<S#D
M8O$3Z 6;V*#WBT:@P!#L?*H?F'UUXM TQZM</G00VA@G]SWL+:?=A3!2$/E&
M;:-S;C7AQ"I#A-JY%$:-Q="2A8+0.7O0*^0S<-))U0^%M54'^=0M"\MB08D=
MJ>=Y<Q_$X@ZW]2@I&MR_@Y]8@6.B22=F]LT#3&JK!<-PMP% TB>@ZUY!# IK
M#RJ;Z]NQ!7Y(DN=)_MB:G_K2]BO,_"<%FE*%1^_%X66[W*)KA_T\)1^(B-QK
MO7UFF3(43M\\+]+B=AK)9$HQV.F=QJD%EYS+^/S]ZX?J76U:";W=!E?:?GR
M%#,Q1M[3M/O26DOY&"YF0'#"WOM0:O=F)O]2&3R.T/BP9X &.&Y2OFMO@;LZ
M1HGK?)R]6)?S^P/V6EUK)3ZPH4#55K$&,KE6E\Q+*48Z@V.I-XA&98$!MPD
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M?7N\% [@,$'^12CGM!$?-/JUOT+8C84'#!A5S$CIY^LOP[5=REUC+IS%*)]
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M0I*!!.G+;$A(&QJSD]#.M(][0C.=D?0[AA_:=3F [CN-B\4_@N])I^%9+[Z
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MQ=UB18,V>KX$_=?V\RSKJD)ELU]C^83D9Q[?NZ-R'Z9X_+(.W4@-L0SXWZF
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M"]9Q(GJ6,P]-K,/2C^"Z\$-MZ])P#/W\S]%[?VS;WJ]/&)Q%1=;_KJ)98LE
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M,C+YXN5(6*G&P@&T)OQS\MXHPQN,,M]TH'$0_%MX%L=:"NTL(^T*!>-^,U;
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M]HAMS^C)QFF-?*N'%:O!U4PH,4]%;;"^@L1\Y=YHH[Q/\+QB._.RF[1T:UP
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M-] 07+=O-0K* %LKS$3?.R>AU08K!_+^=XCU_)=;#X4A[?8&NWCF*QVAZ@2
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M4TH  (\ED(PF1M]T$Q5*[\#+,]>"(KC+W2KXR'H6;HSB[Z&=#^7A3O3'FHU
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M8>%_C/(DI>V*8><\RTK]!P_H#>^@.7-[YMIJ4TW@V^O+85FD5P/X$)JK]3_
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M$.M']BG')!NEJU-M*C(R IPNP*L=)!, %LG@"V[XUGJ@*[X;= 1VAUV<-!$
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M>=6%G95[0+GK]6=A1<E-NIJWIP6!1K+BD@Y6#T\:?78XA^J:SR]\,HX5Z#:
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M1?&4;V[FNTZ=V/Y$W)>U$J#UJX"220<'W70N(FVP5ZWE16[D<<#CCNOWX00
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M&VZOU]G7Y92&@[ZK\B% '9EUH'T01G"GTF2W_N*BLX%^7 ;LR)'UQ4-?.'H
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MI*5?95UR:YW4L@O;RK5;R(,,8'G0AA581O32J()6XHQ!ZAX)9%;NO7]SKF9
M<"-PR+=G#YQ[=-) >NUH[ @"*D2&^X44,@>G=A_'/.<\*>%UN^Y;J*;N/\ K
MC40=O5B_K!=@:=RY]#U;J:HZ'08.WX5^0JW5_)O;$5(3POBSN6P1=F&A3U_7
M-]]J\/><[IN4*(KS03_^/0V0E(L"[8BZTL7/0Y/D[B1^-%'TI&,,!*_L%U*8
M-(:=2,:/%K;A%L@?J-?^OC_IID8[S17+"-  /?%H((G1&K;Q P%/_4WL(>L0
MA/! .B? T!=[3H*O2.R"8C0D:[&*=-SB=*X.HTCW]<[S'W*P5QDMZH#"(<HD
M-GIR^E73EPT9VN<^7HAIE'%>=F=RFF;=E'#^.:->47YDTWXELE8)%!YRUMO=
MG1G33ZQ8(?C1 "8I-6NP1(VSE&3HA4T8OYI#*3B@T!%1<OM0=ZWFX(OMEH5%
MG0.CW]E)T=,<.NLE(1:ET!X0LT*)>DE2.WRJW+7-^L^<7KDH\G<G'3H#^ C3
M(2"TZ$X2[LPN.JJDZY&NSTA:^?CU08\0[U#/3_T8L"Y$@5+?*(76O5:!,XUI
MYFUTD9G^] 6C>R3,VINT=4Y@NKXLH</,J?J2>7@]:(RX$WCB@DWF^D78$'E"
MK)-86*=(YY>2.0BZC*WNC/U+I! ]&[,;C:F;K]-E>1^WWK7^*^@,/R[1Z*]:
MV/3V\D-4&^)4NWVNP8KS=/_M6[_SU]Y=9?QR]7@%$,R9-;%[1W%R.B53T<^?
MW<;R]SN=_/#VG )>EF*EJ\1H@@0>/R%23ZCZ\:R,,O$CA??>[KZRZ"$P)8#P
MIM%,6KRZ9F$E/KMK/([QE&+D:+]1QM]3 UV@_<CRZJ\XG@>"LKA\N&_^;,^"
MW2\+"XWA4]=R$[H'8EM"3YU>3/1$S4,,2(+D6ZC# E?72ID=Y^_O'P;:JV4L
MJ\=-OBPAQ/<U.V#=,75HX&F"D>ZP)%DQMZGZJZM N6IE]F<Q!L]V7W6CR6K8
MTF*6. V0;:=- S2OTFM+$:ICN'N\<)651U_U#83*QIT\DGWYJ6YOB?N5;51V
M%T0*)UU!DB-#T^XCZP;A^,Y?XY\XKJ=>$GK5$A3:V@UYY:] 5 4G@S@UKCF!
M+C?"I)%WX +5V0'7/UA9G'UN\?0Z9E!7]"^DZ6V$*DEZ" ,HINH%AN)=<T E
MWFL^JSN;3PMP50X$@4"!9R3+PY\-8X:X_28: )'@%"V&@&O4_C\[W/Z__A-?
M!MY5<M<F F5#:8"$+-$5B!7)#?*FN0F5MK06KZKMP)2SI:%[DI\2>I.]&QMZ
M3ZA.:+2)<7%OQV+)@*T]M08J7^[J;9NED/A,^,LH\TLM/_'L*Q\&S[O$Q-%_
M'?5:0+TS+-YR[\.K=ZIUKKZ;TJ<Y'>Q.3 0*/6>8&$>;,O[5>:Z)K0@5QY%Y
M:UJQ.(L.">!W:HC2%P[Q)29\N]\QW,Y%=!*+,!MZ3!@C\1+TGV+S*,=AQ1>B
M2BT[QK19O%7;O2M?99N).E[U,.<_&O  _8)W?OSCVX\$;'%65IL\.+8,ZM&]
MU=/8RT>26RW[4W"DD Y;_)8E?C6>H/6_.]\=X$V=!_3QT5C,1#&+$5QM[%QR
M2MR=:(,.(EL&/S&Z4 FB_:O(B+NP:F)NAUZJ%SG!/&'$";X_ B+!JA(VJK!6
M:@(^OC-^*K(->)G\\$)-B4'!#%C;K7JJ["N[Q3WA5W**(-G-:(+B$KP=H]@%
MNB*I)A0BTN>8M&#@,GIWJQQSEW U10@DA@$73)P@L$"J8;X.'7.:AO93Z[SJ
M*RJ70KALXL@';/KI*8:F@;JB:R&J=J3S9-6RYIHZGO3#+MY+1M)6/ZOO7/#P
MO*BDT6'>O(W<9Q@';<\;44Y/;/WKS O;"]>;+(<I*PAGN&E8VW#[4]LN)D4G
M/.@&F9$&.,]%%7[7W3;@H?#UH66?K).GD&28,P#VGCTSZY;\0$@5=@A_!0O]
M^+V#*FL!>5BL\ZTO85:7M5&45/"KZ ZHL1M^#ZS^SV8/Q'\U>R"U)3:]K0WT
MY)]N-MC8-#<TL47U>-SVY%JU+%^K*#=R39EK0 Z3CRA%R-<DMC!,_G:60&!<
M6,C-MYCU$(RK-#/@2L&34]L]0@4#(:JDJY"[#;CCUB+YGWHHGNFG>_EJ@UZ#
M/[D_)<WN^/+NU2@DD;S$W-]Z<9R2*+!*P!P79?QM8 [K5<.)4L(9J=%Z:_C$
M#OO1%&U_GAP2\O?NTQ=A@]>8Q/L\&VQ4Z#FPO5 );#<P0:/:K1 7-GF&G]D8
M>+)$Z*>^N'*]VL)PV AI^,T\D\"#OXP5C<08-]X_AHHU":T?B#B_H4ML>Z%K
MR#L*AX(E15-O5.P'<W[./;2W<XG0+;WQ_&>T2J(!I&G9?>;@[NB>2#5V*'+7
MM^/)4UL; _RSF3ES9UF@S8_:6^6=>M*I@I0YY.\CSY&6-D]$3-5H>7-SL.]"
MV3CD+B6:"J3'IL&(S7'T#5];UX"[)_=XN9 2OT1Q3+NCQF>-HP/4CLFR! W
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MY8"0C+V6J8:J*KF$6&V?\#2L)"H<N/0C,P2HN)'P[]Y=>PBZP.W)SJ8!4#%
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M_3-V<A5VS8S"Z]7>EDL>A S#5-%G"A/S0T34BO=RV6=1%=]?ED\_;I3XKI]
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M!WS.PM'S#-C?_R4L;15L1V8>00]#60ER@]Q,.7HUR<L-*HQVA I.PF3R"C:
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M:,_Y[U9SI)8D;+EK@5J'V.?.>_0 2V#BSZA"NE8?*6\LW417J&R5EIGY;2S
ML_<7NMG^]+=Y!H@:3T!X'#62"C>Q"BU5I$=)#ST*Y?H@72^O !;#8O!KC30
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M"LPJPI0[LNNE!Y9@8B"]@-J Q)(\(2Z-58WQ2]1X+SSN<FK($YV9LP:SN<K
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M?8)MR)F!=QAH .%\:WK]&J,3@P_.)GBZED@4 5+"K]( PZ^*D7\8J;J&=33
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M3J',V>8C@"S_8L4*<5E@^Q#<H2(I*#SL*W!CX_4T<5[?$33G*P[["G6U0L3
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M)?*BL&M:F-U3Q%[:(9[9L8'F)F'#TO&&C?XI3J3=N$)Z <'J?2UROR;?G*8
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MNI2PYF)FH'?"BY#POJ:675V(G;"N4/@A54.*]4:(#Y?B4$Z)>U$1C_D-J5A
M0W+0PL TK6WED@,_["_N/_77Y];\])<*K:#4.+TZVZVNHR^"&O+2=WJ^06 T
M)]U3+?M<7LF7^Y?( 3@HQT1,G'#K><V4NPQ X_9MT0@&H/B7NOO\='(FL3?^
MTG^E#%0]L!'P?8,H@9759LK^H8%C'4%5'XY]W)"Q4NRW&6MU]!+D)71Z[7)T
MUSD<82'TX "KH8[9T_1*IU.ZLE75#C^KR-.U &6'\95,5'=DX_;OIN#B;6PS
MY(\(TO5-/5[G%.JW3\H[\W^T,9AKZV5&1UB.FF7A"_WKJ>!&W$MO),U?Q[-/
M1T)"UG9/N\Y?)(_I*2V6G7L^E%G^P$%"%8^^>E=/\(I:*>.?>?7"\.$$TM3@
M5EV=5*X$7V ]UZD.]WXK*;=TH_B86ZGI_AF-$44A([(WK?O@T5D[+.=R4L:'
MXL13GC#[<^3VF4%__^+3GT$2)C G!((3?KBN,B-Y(+>PZUQB+.VKZ6F(+ ,H
M#4 0+D. 4;(+R=8N6"5MN0[,5?]A6+F_1FEMR'<"E@>>;$@#V4,8@&AMRRJ%
MRG3VO3=1N9"I5 :PYIRYEP&4I2$I9B?4!>A?1$.N)X%H K>EK$>4O3$#N*-9
MP70JA__RMD69?N2&IK -69GTL@)SNS1U)##,*'[%-&Q'OO9,9<B57B/X6["[
M20)QA,9"V%TKMCMI4[<FY9'J;!?P@VSU'4+CQ8(&J%8LE849=N>FH[49@ -V
MZQPB D+:4<.LD]L4ALJ-<0,KA20150-I@<S:0;[=3^$VN7SQ#\4:L)B?6TF1
MZ42O*;FHAB/^!*3.^>ZO^?Z^/)2XDX8,0/;0P>R6D(G4.\8VY 102)+JR'QX
M+)9\^3H#B /@A? ^7J(1X2A>39_;1S[0PU3*[J(8G??*<]2L,$Z(LQW!&KI#
M>/S>]4.)8*/T$E8 CD54HQ[1CI;-G\>$?A;0H(>3:ID.L47RKM '(:5K1^_B
MO//6@JW:A3F78#IW\:6:JRT4H^^5Q?,#>@B>QHS<B3=GZ][<NK0K9;(68@.
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M["J]K,%-76[VHH-WG473P!-+N;2$PI/OI I,2\][-(*K9-ECYQI'KA2D-#$
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M@H7]\"AX#[9<N,5KM(/_%@$3)5HWW'MZV<NL;5,G$NXL\:A'8F6'_8:.V[*
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M3QU 8.;B@P=(0S=R&D?D%G_<GGN=$]WV1\8Y67 )Y%-\2P7$+E(\L3;J%CD
M/ZYQM(7B'SDJ<T=1LG1OO;SF_%F!8Z/&,CZ(J'Q8 3."J:87(N;@_0R D-O
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M:@ \.>E7O6M*2T/D0,3#T\I)*23Q_RI%A;-3CBRC%U_6X$"]$ AY?_6C2.5
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MI6"FH1Z!/@ANWWRDN9NF,:2H]LYK0QK+.7+]^N0O/C\,2'-?ENXGZ4LLVLW
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M<$5%T"I=7S6'7JU7A;/"AAUSDPU!UQG<X08=\$:8]'RGG X8^NSRBN'G5.B
M[@P4-<H,M7]4_M 2"H\#3M30PG-K:*<8?H&$ _U]09"Z%@#&B-Y/?Z-^0"PE
M6R%F6C;H@)C!/Y2,#X_<8?H*_J7PE\)?"G\I_ <*YZ$43C#1@&1,UJ (X6/*
M9D#,[;-4/;(U6:2-, 61)C4.2+JVQ;1N2*2I2TXA[!B$371&IPTYD32+B5#3
MF1%3D/*\.S2$7<<AW>[T7GAT[%,Y0,6',Y8!=%5T0#QP!DSF11#'G/?MB,<8
MP*=$@M !]Q@1PS?TL]_ LVA0A3N57=^=PF-#!Q#0?RC8#X@ [(71!#/)BG3
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M[+W^&GE1J3#N-4+(V$1^N$)$?O2;H19'Z'\J)_M_6&Z9BPFG'!KY=GC0EI_
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M=/)E[W;U?=P9K"<I^93I@9930(QSB73L@OLJC3E]?<1&H@CQE0@.!G.L:2C
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M)TP,V D'(8;C#=*C930NHE[P=J4J.$HG=G6<P?VP\<$M1U!?E:SJT&P1"G2
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MOS4#S^DCU$CX"9C<*+<A?J/5E:M_Q]\B3^>+Y+K:V&.^(;/2$IO]R0*V*NX
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M9J=$47*(]+V(F@W)PB)[#M0QV@V,>7/!]Q\64S<K)JVU!_79HXJ*3IT)>J5
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M*,D'23931'DQ2=EE3U^\1(X;$_4B**YT0!CZX';53& +>$_AG[,0_^L2EQO
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M2(%M*CF&?:ZN'BY/NNQ\Q4HW<QY=;;:_GV3?<<5O\16YAS6HI'['97NX]TZ
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M/2JFLW?\N%5,B%@8VA!C(DVIXHN8[[/)W:] N-M./6("_?OW4>&SS$.C5.P
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MK+0N-U??J.@Z]X2/^WZK"<L[@&!K=LKHYYKJ= CY'&1A'JF&U7^4X:[M$E!
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M/Q?]#%0NC/YZT J )YMS\@7*3C   GQ'=V0\*CJZF/9"5^4H9\>2JOWOV74
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MJ=E]&G17M9R^]QF4!MJ#1&E4D7C(S%S#H4@R(9PIV5FU[GE1Z\\9 ]^5^\P
M7(4((]K<X#(:+4D+\1$I564SD>(34#O3HW>01)EX+69BD=I"+T2CN<TLR?(X
MY-F!JXI_&S[^C!6JHM2_%W__YR2Z%,9'\0C8."1%T:J4_[[6!P-G<+^K#VSA
MC]Q#XP_38OV6LC=QBT]![GMP, /PQ&W[WFT#PXY?T*UY4#H#,&H,TD$LQ#,
M; X$W:UU7US&3Y)-0/910;08ZQ:1CD<0%U913"JW^=?\=BCE=B;\K*T5]AQ6
MXL^?^D[P[F-PN2 H+-B9$-I: 5,DVRQ"V-N+BG/7?V-J1][9//, 13O0E;FZ
M42>ZB&J+<M%-TK>-TFLS-'[,_>9_>()*-$S3]%7AJG)#S#0&DT0AVW?WUH?0
MM&;TG/<"@GP-U76BD HBQK^73(;A%=9].5X=PN:MO][KR=^"^VX#"<^'(]<6
ML5NI*$OM*W%[G8I=>8^\'G1<WHDGLW.3I]:8+FVSVPS$@7A=#.::<SHUD5,_
MZF'R4=#Q].=+#$!M2',0G<.,^&A#]"X!\JYT#2$'K@G6V;A$S5N^:@]Z]IT!
M4)7'FQ;H]>"G@YE9;KF8*,TJH%-J(GOO%IV&WG5R0;3QPGE+NVN6$!_-;JL<
M*WFNFWHE=%NM?6;9?(?,A!>[I9=8\D<C?OSRY,SE4D,Z&H%W45^9\N0KFIT!
M6'Q.[Z-?J$D^B77]@2G]=4;3!3S  ,2=1H%I^7(28_]>P\"\*P-0&O^HP9%)
M NK#>2YI!J,?QN&=[GOZD.Y5\[-2H['T6?29+30',$+S].\#X$P.:>*QKW[:
M/)#;===ZMN)UM>DK?5[(?SH_^2@["]@S?[%<5.67WP(03T/U1U_;F;^HK;M?
M] V@V&/<(]F,4 :>A4DO,7F!/"H-#J]M&,)&\:LD*O]V\*E_SK)VY?NI<\[J
M4\V(]@1:%?HO'Y%)G"S;3+6R<A>3>=8PJA(2#^[8^[D\]V2T6!*U0D,D4*:+
M7>Y8DC*\"USO5-C^F=.Q2Y_W.9]X4_!*Z+C9 A<^C% &G68E-32".9HP-A]4
M;F^J*G:37V7;9WX[/G,^YX]I*O4F<$:-_A["!R)H[C [QTP>!V)>\9481FB9
M:A$E8ZV:SXH)J";J>UXQ'/%7XXD#\X48Q9I/AE9!IM:.,[PEGS[/+4,>' %;
M(&Q43ZY.5#A<@/A<)D\Y6)6CHWSYC,_IB 4]/K(_Q2=@S826AW /UNV8--83
MO^WJ&>#]7UB<(=<7,1E6RE,O-Q(K28VPW;R G8:V'H,BE39C):TJQDX93]OD
M]]F)W34%_F>V (DJH6KA=N(M.T6!(=MKG:GIRUC[J,[RS'R%S,:S]^:^VC?;
M.'+A!;NDNVRFW^85]/_M#TT=OS13-6)SK'*4B]""5.VT8L_#AY'GE!!L 7[=
M:@ZU[^$3;W@#ZQ3MUQ)FZB5!3_;##:\EOQ R?Q&B<!;5BB0;@6K]:2=;I! +
MP5@&X%+._R732ZVI&#TUVKBA_5!*^OM?(,$4/#VL3Y8G)CTA(L)E4O\;A1F*
M@&5NPRIZ B+6_K#.G7*'%BH?0R@GJ-8_R4,4&;*B);I>Y6U>->O3IN0,[Z9/
MF1D9L^^XEB!Q<$E:,L(5*2+#@9,[%4"!F+/)<SX;\A(;MFG\LZ0Y<9SV;ZD]
MV7E)[@.3_X?F(Y8@7%@R])F-J8M=]?BUW=F<%]LL8TJ$D>7O1DEO9<VP;L'#
M!$GN6V_'-R3*AK>Q.X^/9N@<P?3BQ=1))OP=RP9(8K3L)@F* C,;:;K#S'"-
MWT(I3_$RU>3>O1VG=KN[/7L:@#*5__,UJ!#Z22HK.8%B$A -)B#"EGXV58QU
M*(*]MF2J]^U4[FGP?CW/*GFR_DW3;ICKLWGP=DV&JN<3J>>NX%<HM,_;W O4
M?X_ OL-'SF\/\<6X#T,J7M4&_03XVQ]5T$#."&?0-/K?KA^Y#@KT7(#1H-R)
M'66V^XKS^G-SZ$]_3\-OT8=!_.IFS'X@T8KDJJ'<XGWY';ZTS++I<Q^RSE&3
MOAT (HS_NAUFW)\J43?,-G<]-ODWD;=_TQ/JR=W?)P(P>7\LO!4A_F;$1U,
MC3I 9323QE*>0KDEK'PK=^DM*QYKRL3*^=W-A9VXJV,#'.M*^EWOOK?-OPS^
M>3@$Y_V?QU_2 =(+:/R#_$WLA9Q8I0F]TE&ZSWRMRKF M C;VQUW>^?2Z2%I
MCZ),WCF^##G;>PTMC7@-(HMG5>&X!%VS;I.UO9T(KA>5.^F7&E]R?5Z3B)'[
M7:C!NY<T^7/IYLM-BD-9>ET^ ["VJ^HL./E]RZJJF0&0VP49J$L263ILU2JB
M=CH:2)FE5@."R9;]*^)'CWO%61+(4PGP/Y#*I]$4*_*9X?OH9AN!9U6-^M'!
M%K(?1KO?48EQNN<T:$1(F.T5LC,Q@^0]88P_!D4U<0;=EG *_56G<$,]DYBE
MNV2[1(#2V0N)C8NORV=<CS/1L=4_)NPHMZHN['$_6'M=6%-GW\ACY356G'=,
MU_%,?F(Y<WR$+$%70K?>+PY/ SN.:],6\<[/)\R>)TO64X+*6C<:O:*^V<=[
MVQ[:\E DX%.VO+32)NY;%=][KJ<5FY?'&XW>$E1*V=8]!<1I35?@;?&6XVNK
MAX<T5:&Q%5>B.IKTC9"'CD4[HS\**P]JPLR$U=<&6!(-_>,GM.':_^QPDYM<
M.,(U?"0=(C5C.78]_)'DB4Q-!V"6&RFC9R1W_C21U^M<CLO4B8BGZOFH-C19
MLB36F?(F0%[VUP1])%WS#!SRQ7ZWA.!&JT&MQJ+W\X[3[="S]>@4R#(#H'5\
M,COJYO]JG_7_A^/$KC-^A")+U:)]@S$U;B>"\P#)Y2*,?7]PKT9<\VI@RO5/
MU5S<HM9&'AT/>J\XB-;TV5*%:'543Q&7MX?=*)8 7;U,2[7H80Z77?W FO#S
M8Q)-CH^WC!YI'AR>YLU.C+^U@9^9\IK-J-I(1O,S *8!\5M5%,D ,%,^)L\C
MLPT\2]TPN2%+%D3^[Z&^"!5)R;+Q4Q5L2;&=B9V),+ M+1ZN !,CKRW)?814
M'<:I*Q=8D$<1-9NVHL2PIOQ9<(H=L>GQ%CQ0_(7F?] K*8*HVA\%UU<DU#:2
M6VR:E:ZZ")R/AR 1QHNHL_0.--]W6D&+"-6)B.YL!(JX6;YL5)WU$IO1=A>Y
M/S(S\^=A1?*?4O&PM)C 7C7OQ&!_TA]:"A3D"HYH4,Z*0$F&PVP6Y_24W8&&
M:1R/KC_3Z6F5^48M>',J)"=TM.5C=F30[Y@[>G-6.<RL(4\KD"R=R*188I,T
MW<C.!+,E8*RF2 "E'5&M&[,OQX,)B ?;*&"P[:1VONJ8W&B9>7LM(9=+#9?X
MI/+EXW+-$F!JM!2$&U<HG0<<WG*1W+/P5Q-H5:5M7VKCXM528<\B[V2.NV'_
MRZ)<6*<[P!%@OR-\$_W6X+#2+:<6BYKOK#;%UZ4>.,!0%#YXK^7.%@J'B/)V
MA5^+[FSPCT25>KR&YF?I0?/^5*8Y-,P)O]O:Y=FMHGP].&;&7/T]2]I%B%>%
ME)2*6S%Z'C:RR !,IW9BP/@E'#BV<D-8GVQE3,"Y<%OD5M)JG$X"+%('IJL.
M=3\M[][-H[6@G1 7Z1,(5B7D6;+5L]'J&8J-']8XT=U.STCNYK4T099+'OI.
MAN_N7Q+5#I;5_B]XXE3+0 ,#T%J/5C2YD[M:YXH]DI-;UH4*A<_?[>LSX3AB
M)Z-Q$5M:1(YVM' --AI8U=.I!F+9I%]1J\EDM:Q3<*E+Y$E-N@H4B;,ZHZ"E
MF.PX%T4QBC((ZG=#[&&7>^,;N9S'J+5'.8LT$9($N918C!.(: )3]&$ZHTUF
M>62_);RE_P=UQ=?V8YB7(:)FKY9D%.X9??CD^?/6\V,S_ %%@9Q**B*KY))U
MVQO"D_(AF,W:XZ])KKOZEVR-M!5N&_]/>]Z_NZL>=6P9U3B3@K$HV#-0HY_U
M]%#PLJJ!)J?3_HN_\&IWHX5GO/IG)G]0AI!L O:JEI+C@[M"W08!R"TYB@8Y
M@F1'0V[!.''1>,5G$XOHAH; ZDCQ1,Y*S>=G$K@C6]=6J)M_5:7LM_N-K/K$
MZ4^7O<K,>W)](;YHL57(:?H@_#H!BU]:&HZM$PY/D@RK80"XNO*L++ID\@^N
MFU2?:A!L/\T Z,*UDGJ72H.5M7EW7NE<OE;20F( C):/<I</_:@7(8F:KZ9
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M-K^/%OGYQ%B+#?#_6;,SQ72<QJ.1K<)CX$X.U>JEB0^1P-W>%Z&-BAM^YZS
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M-:[*2U ^X-=Q7!HI@U@O=S^;@0,=JLB:G@38P *-DCVI!%(- ](.1BU<B[>
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MO1]7OP5)0_!6%^+O8;YWIR$A\B7%L]G<1+8O.?&M(NQGM;M2\U*385PNUTF
MSPJ9-F#5S(T+VLG2U8R/QGZI]U>_< \PJ.[!8Q&N1E&U,(8P%=>NQ5>_??4C
M)W[GMZ%V;LZV LV]6N,+2GR>>QCQKYB 4VIQ5<1&?HO U]H/M$OY84*:+\^#
MA0>3COWQQELH#SR;3F>#YG?7Y\Z+>PP\-I:I7+DZR51: !%*_[L . MV"U-T
ML */=O/=(? /Z#9%_K5&_!U@%J%[)%F7I;T+W@2V>Z!VE@YBU7D*9K?GA<K^
M*'Q=U&JNG,AC8D^FD[G_E^'G>^VQ  %E=7 <_C499]X^Q09WK1AA_1GB2YWO
M=%(A41%-@_RO,SZ>]GY[(C.LHM+690:4#-:.:H*7+)QSKXCB'C?K,W\M,)C1
MNK*0GVK2DAG,WX5C<1G?7JA,B^Q<^U;RLJ[&XO5AL5P*'J",%S\*MJPF<\:4
MDZJ!!N[J;P*^P[+Y7E?PL6$E(5<Q41]#H&CX?0SGI]T]'P+8)+:4OCG#@]>5
MV7N-B>\KOJ^:K,39PXP"<C#'!Q^#FF?O/?[BDJ27W>#@*.AT6-S6C[V(TYM9
M@)M[*4>*<6NRR+CEN2K^1JV-&T;MYJ?EH5X%N97""F9TG.Q=63JHF\2K!;2X
MKM(\ \"'05@1X2C)*D@LVF[F88)B8;Z6YYU[L6.7 P: 7LQ0L0MX*[2FH$.:
M'>LH^< 4:8_>_YEPN6$<;GRF36B_8R+(O56;87^#7WS) Q6^0EW;/1)]%C2<
MGBB5Y,%B91483H<I% [DJY63Z7GZHJ[,1[R'(R-I[.R?/[@TXFX-WE&HR+(V
M-?J>EB(M/).7@DSMF096 C]+[4'M5:JI_)14M;)^WK2?>"VK2K0"IH1HX$#8
ML)EN"*\Z7_ZVBY2;NZ\RRN>+.TN$6G]-4.1,^ E\%#I- BSYS ,)Z3[Q5UW*
MY3G!%R'K^TI<KX;:_% Z+XH6F;?%CZ(>IX&QE)CT,9L=Q^NP* 4%YV?"'NF_
M9M^&\@4!M4OQ$CF8ZG.[TH5P?V@PWHA1)4_5*LQ6=6 VOFO-ER/I7/A,[I0.
M\ -P1_RPX_0/NAH6 7T%8M*R9VFC7NX*L;_WEO\A-?;LF=$*Q&<Z["^45EI=
MLZ$RH.::[W3][_7H>UXE,2F'[8E&KV/B'T R20 NO*<O9F-%,Z_8.=7[T47>
MH%]#:-9L[Q,*7M=W>!T P>#-VH1+#ZL_1Z(A"1 95=EEN2L4TG"G0$%43[=8
M?L$6:O3M HQ3<$W3O(6E7_R\4R/]!O7:4RXI<=Y*YGUH[SV[;T]A[5!J6!24
M/D1AJ49L;*M&YIZX\)RSXEKOJ80ETLK._99QBG._FB()(+?WABE378C+#)O\
M E:2\L^6%>\ZD9QHP']IV._$JZ;YO5.:EQ&\[16V=V=]7@@\OZ \-_? WBXM
MO%0;+[^\^+2NLLYL1(ASR.)&, =D$#P*J=IH.\6.HO-) .WJ:X1R]_8C(Z?%
MP%[&_T3>>T8U%75=HU%4E"K2I"M%% 0L]!91 0$Q D+H41%I B(@14@4*=(%
M!!24" A(#;V3@/2.M$ HH?= 0@F!M"^^[_WN&.]S[[A_OQ]W9.P_9YR<W=::
M:\YS]MJ[.Z/E2SE-'*4,Y:48$CBW#@ER2LYRUAI3RN^,J,J;-X_*5CFY#\T^
MG]6*^OAQB$P2LO@S^@<+(:E0]H$W!Q525GUNJQ6V3*KL>L&.Y)%.FP<O21_;
MTL"A^W6^6FXF5<,^:U$1]8W)SV,-5 $5PFR)IQF4XB<-"V=5,E9R0J8_^;M=
MO5PL7>["L3UOK=4<?]=KY.<Z1 4ZAJT:0W44RW.RD5P'5GI;__9)U]8VLI3/
MJ*\Z8\YAWG\_Z%9=C]K+#$'(1''(^4'U1Q=J/YZ(:#6LE,G7<$X:0Z;:(#3@
M@22_A=4034C!E?1,4HW>V &SA6-5.3+.ZN*)Q+OY@R>13@S<28)UI<YAR6>-
MZ8"L=F\8GC'-H36]!:[P\YX_G5]IAH_L$[WBU:*99!'E8:P9RU_?*@W#6@Q0
M2T9X3VKH%09Y>5XOI7<QR/9:"]8<9I/A_M#W5:=X<60QATV>)^-9W^+_'PE0
MJPI;^H3>%M2918(_X>7O8Z]1]OR:2;?K4\2 !N3"=X? @P-$9J,Q&1:D\!<G
M&7SSP!BZ*"9I,>Y^(2D.)S_-^?H<L=A;4,GUN4VHC86=9D($^\I%367P(]Y"
M/3DU9PRJ[=CC-01O&FPZXR-VVF7V*=G&=MHV(&#UJ:XM[64Y@RW5!^4>=J;6
MBG.)?+^T&-+6 [O#O I1I-B3$ N<&*8%?F+5<H/ RI3+LUSKCY<B58+*?F[T
M&2PM2L)_(O[")T%S?=C34%X;E^.0@LWZT'#R8]:/RPT ONMQ#4].K"=.+-1X
M^6LRA8&B(*O'<I3!V^?,R$Z?M&MTH-MIV*5A\E3]IL.D["H$8T34]\0PM5L(
M+OC_=O9T>BYWNL&%YO]&!/MV1\GKL"Q&-'DW B>R.!@)9X>J^*<^A CZIPWT
MXEYN]_",E?!)>*R^.?V8A%&SY= VE=W88:+-0-B4=CBLIS?K*S-$QAK+B.D"
M6RM?9#_L\?C__2CO'1<A<J?D['RA6>A-1;LIW/ F343LGIERL\,&NM>K-T%W
M:O:M:<7:_E8:^DF04[$+4IL:0Y.1L;&WSCD*-> =]3KWM+%&,N3&9D+BV4M/
MXSHS$4/Q$3 1'Y1@$!?H4XT)-7R<U> E\L.CG2L/RB5--L[9QK_D/:(#R'9!
M[L-(E: '-<BA1,A6L/J0M8YFETF>QK=OQ(P[W<T#G,(?((^#N$E61;;0-O62
M\,O.!UJ! ]N[F'-GSG$ ?6[2AK,2:/B2/E/O%IFJL3S2 55)\WIB06:ZQ9^G
M4H-W^W/>%:Y7'(ST^VG;$M!MG@(T-)9'L4F4U>8!)@ CI]S_W)R/L&L0X-7X
M_F>%=YRJ_=@&\A+#[%]O'ON%YS2.!-DY%;AQ=3:NXUX,=6R=,2QJF)(>N7H;
M!P%2SI$^H\YHRSLC)9LJ4ORO.R;*%OI>_"*1K4=B%KO!]HA#[6(7 DG1(7L'
M71W1U- BPDN,"R&?#N_EW7-4?[ 3QY-ZIW#0#)[KELV+*_T;>B/A,"CY@%9_
MH-F7I09UW@0/R$")=("K;;U-;F'Q6%552D0OJAR"NUE D2481X14_<[T9+.W
MBW:"7!9/&?!S1SY[>N+9]S/LB8 NB8M 2]JX6*4DZ@1%R-FG]GDM@:\ Q_OU
MJT<<[V.5GE;-Q4LGIN%WW/:RY[<_Y@>9DNI^64[^Z0\N<(V6/;)J<WV!E2"?
MMNO4#D'6,$8BP=_P>,\0'_%I/O9767G UK; $[C<KXDNT$^-L\>+XQ4=)GDR
MHP%CWY$*(SN!(E;:0'Z0;(>Z7+=IC41P.H/7GHAO<OB#9*$-0J]1\P_ZG>SK
M1G$^Z3QPZFTS-W/J4I\*;]Q%XC75%LW?1Q&FKMC.^$E@FUA%TX_X2+FJ=Y[G
M761??_* =DDX.VXT+#S?>+)8 M+DLLO; I.-_2'SVA$%)$A[17?NY+2=T*:[
MSK. QS=U]?3/LG+6_CI_=FE5V *+2R _\==84'GO@$\-]5@:%UQ84=OVU(P4
MCY)Z=#=VWNBF*N[]B97J0C-N$+>@3_:VRXB1+SHG3O!B4%:UN>8C\1P"7](X
M*#W=QB78,[?Z70UT%D46I@V#X4**-E2A-M;S!/G$2 G;NYE\VQ>\4$_GK1Z=
MZ&#NJV7*"1:#G&)()!6*!$PZJM%LP5LH]QMOXGKOY?D7R3,O+@7BG@CLSVJY
MC0-=Z("I"XMS\5&7\ ,165,;@8C)\96%A:,)W?.O<(\+0SJ9U+HZ]*WWO+[Z
M$.P'HL;V:8U5VIU7^D4T,Y\3=O_:00K!Y0=^(\M^T\>!4;NP2=1B.ZH3R]1;
M&"VVU60X "N?M;Z>/JH\U+/VFF.<&74I1*T#5 1.-_W^N_^/:[^8>7B;:?MP
M;* \(:5%E\="WX"$6D =717LI(;]P^]<E-.E_YVIM"@610<L_703(_*D,T)E
M&O7[1^I#V';\LCT12,5$#.Y&'M6PT $HAV#PZNT6E//@I#'06>&\B_5WY-5@
M=A_RRQI+BS90@[QE=5![Y[-XUQS\*I&?Y#E'E>X9WTIOQZ1?L"<>9$@RE?]Z
M0#*)-^U46Q7F/$&MUC0@\,\/=IQS&@FR6=!2:#W.:?2>['3*'V1CZ<E\H6O^
M],2I%S&P\PA3TFFRI_]-"E.N"U1];+L2==X%7]Q8D_JX_TU-NO\%SSO]M>]5
M/#O5EE;*\D!<![HRIHWOY,8/*8_6%]Y\>WEP.>97MDEPOI9H%$:++Z7F*$.*
M[ H=F!4CJ01GN8GR11EIR3YQN9S886"M&_X$L"P0^>H\Z-1WKO7VP,&M>PN]
MV O009HZ?GI8$3LI>Z.*S6!2&%]W5JNF$$[B0@A3*X#._4*+]HCL=:C K<',
M=>T7X;O.&&"E(4G _-6-QV?4 (D@490NM%F,4YYR$Y]D,JXD]#:L4<='*ER-
M_W3QW[?97&MM=:+9S$T^3\R!%2\**2"W'=019"G 4CJ"#K#Z4DY^I]BT;8<4
M<7>7>Q=@2W*8"_MC'?02?[U<Y'?]\C>'=?(^8J+@WY?9.;M[<SL=[$Y&,N,K
MX_@9RYXS*G=M@AZA=#X<F$%>=M,!IT_A;8*45#;9YP@?JJ>H24O*+5XU0HW8
MAN7MU9(M&(<K@9 B$ZM>:4X'S$T=[]Z>;]05SD5*GXM)^PCRR\'Y,&RC85];
MA-3R.A7.%^1XW>GJ<?LL)V(G#65/D6+"D,"ZX;I3DF\?9U_;NN]Z%M&-"K%G
M0I)Z"=%ZPU&-"QM[N,#0"7)IH6=R)"[AL]8$Q\'Q+N QX")OQC-R <]O7TA6
MS=&/QJLY$*[H#NN_22,K4S!?]*P<]#$4C=U](\J@BHBOJ/W[OL<HR!>QJD/*
M]XA8U.:* I5+Y,TR; ="W*0L^!%2*5&+= !$@@[XU4<5HF;XR %;&5R$PL^1
M[L3^W<S% GVK2#9VM_M"14-@F62B<= ]QKBP5(1C%\-^E77D2Q[?EY/@7+B\
M]!B$!(B%!4_B]6D/L!]@6\P,I9MU 2G @,Y/L&[7$=@6)S\M)J4D&H814X,^
MC%FX]GJCG'R#LA"L0F9=(ZK#MG8R9VVL[[&/[:-OV3W\Q-37J_DI)SY(YKW6
M37M]1ITR%:'WYC0R+U ST[8EKJC)G+K/F6M V<0 GP./E!'_W,V/#L@Q1<<Q
MP,:0X9Y"<PK'FP$,'MEJZ$X'N" (P.ZX+,A&>S$=((]>8]#HG__BFX98&.V*
M::?S^"U^S9//XH%=4/-=.$XWTYYD0PPG.!%C'NJV'R$_H0PN?]ZQ?>>P3&$/
M!C.&!TL')#HLP,BL= ".!R%*+=*^:LE@1I.><_TZBG0 V]JQW%%I4IO*><T:
MU@')ERUB#<Q9-,D8PFS.U978%@CHSU_T3MG\<Y?APE8>!U,+OY'^6<-9:SML
M3GRMHF>L]MFQ1E;^J 6"Z ^.R*5(42MYKH?2 KN3WI\7<V?K$'V>YUH5VN(Q
MZNW[5R&"J9]H8R<+/IM*>*WP:7\PNQY\PPT-)AJ0;!2C)6&5TN'CTWO+W<2G
MI./TS/@>Y$_J=^A9B@+)HV*6I &N)%B4KI>[V^ ^3W=%!1:<I5F.PA^!WK@)
MFF:'?"G4J3Z65?(T:^ R$LNH5W4EQ$CPOQW]DKYOY EJ.[2^FH4,HDK^I^Z@
MX!FC&@?KML8?4C\P1DJ_U_XVXQ*-GY_",#$"PWC^>%$C5VHHT73 *[+*MXZ=
M XC\]K>=X2:&8%&C Z3<6K'$TQ J0\-C*=R'M =GZ8#2XL%=PV--+8A#:C[F
M&$6]!D]<P$,PPOH6$1KAD3.>^/ND?B1KD <IL_"^$I##O\*L@<EUVFU3\9D^
M;-;V/(#BA@-.ZA/-Q9@R:]%*D_-(@MV2_2.YW;]6;0^D>#\)??VLHJSQU"L1
M&IM5*[/"*Z,S$F4"*CNHY1#Z,[=9]'!IP_@5%@2$F,V)_7_F&P4P4WC@H&]!
M1G.%U-@EK9PV(4+'LN^KX-=C*#(GQ1\/"H4*BK&ZI8T&VI=CLBMO& LEW.HZ
M?\V"1<_OY,WOA!T[GX75E-UVNQDZ8/TA?MF"1S7W5T&WKFJQ/?RY="ET-!H/
M11N,*(E%I<3^UD)]K??-:=S[M<M=XZ\;=7]0=SF.63@&/:C-3:W1O(9O?<B
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MF[C>I>VIT60?4WU;ICBW'3$^Z*08JR9P_EN5$8C;9I/_BOCX.)\S3A$1G_Q
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MB5Y@G7(Q7*]18,>57ORLU_.W!P!L8Q)FF@:OP3XQ8"5,73H\W:*&<#VPLEC
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M/MW>DT)^%G^N];6O&6I.;.>=HF9&TF ML(2]S? W7W:V8+LNL&]+\+,PQT$
MY>(/3Y]@=2/JBY-G"O-KTWR92_H ^:,Q!2$Z+5>:/*)DXW(,QH)&_)Q0$:TF
M?UHGAT)BWDD,:BL$,>,C.G#*LIX7+"MLF\_6C,K9]-9]U+I;?5:"FG+J';@_
M,)["_:C')L^-\Q/WE(W3<MRB@=5WSK?<EX"?$55KQ2[/988L\F2%5?ORF.)3
MM:\D)NT4P (KM)^2W,@G_(5:ZAGNUO3.=V'SJ\T;G3?1[)F7EO@^7;!9L\S?
M9@]6+R@K*/AM;O+^Y],3ZX^R<HL#DW]L&*[J<9\(:];M9#?6!7:.;?M+=RA,
M##;#^:H,#M[+:VH4]_D9^>:Y3]Z&!3Z8> KWQ8#>N'6YP^;2E M]BKT(9US<
M*_J\7$X(QQ_&M$&3B?V\.9IV@3>70RM5R]1$[6+R<6XFC^P.P <5X*,,.[P3
MT0L/:9YX$7QFP"C6],7NRICG=X/7F]]QIP %=5L_G9C4V@/YFGZNSU[]N[U?
M;-TC<N]1_3WA<32+@ CHN0R5-\PPL5#>I:%B-#,B.SPWWR0J!GP_*'I1@22M
M$*;TKEL:OQJIQ,FIAX-7V-ZM2<@K7TXHH^W=/"R8Y65,M:>_-ZC)($AG89/J
M>EJ-K/6C8#*<^-SZ7GPN9U-PA*ZOOM"GF( G@X*VP.2>O$H?7II+,+IFSH%D
M]$=0Y8,BJQWWG9',X?T&\RG>QDMS@8F@ZP9+99))H^@>8 V6@:',_=G2L0BE
ME.'&QPERQ4V)'Z2)G]B;ISZ#G:7E;P'F/K8'Q]H+$"2(^GA$NV=4]Z+"^9E9
MT,FI=M;U&PG";\JY]S3BTUU.L1=6$L;+LTW'D@VZ2VIFZ("':WVE)=5G+%T5
M1TL2#=92,W[4#"T YS*TV1N'H#P;F+%I8Q8W,+FXE<TS2@HC_(Y/'CBG=& .
M+BVM'BYRWRHJ7JRLK(E]'G[VL8Q>U(T"!NPS72SD>>X6_+RHP 9&<GA5<Z:<
M(J4IX[=L<]0$6?COO<NU%<90<]]1F(Q+C:-TP/RS (AS_3NX+)E?PT_-O8ZL
MKQ6X@!R(?:M7B&;BV9#-R@E,=KAH/*/ON;D44&M;PQJ2KU[K;S48;(.D3FT3
MU6"?X.R::@2SUF%GY)41B=%77W>,VXH2M&^("+\IWC\6CCKR_"_.L(8&QQPK
MQ.Y4;C[WCSIND?\*:TY>I)D3'7GRP87W2&]*R[Z]Y+Q1,^Z2KX1V.BR\O0R+
M .)!\-/^X,?AY#;K'&RT8]A'N<H$5C<+B=S]T]_J<"CF6G'DKY"+N&=Q%QTL
M,V/O2GK]-C=G @#4 3*&5POM<SP7#)?G=BGR)^5575U5R+3#_!6L  U  BWF
MIK*C/LG]BB).<[GG6Y4:??(>/:G#ED<N.GLLZK8J1GJ;#)^J8>CT9OC6NXHE
M.N!%_&W/7#I 0^!PB@3&[)N;MHW]+'YDH:]]^VKSXDK!<Q=I^>.\O2K$GN;J
MW& S\!R%?=BQ"G]0%._G%5_E"GXENA#D<_H]X.I6 6"G>Z5),$KVVFBR@;?Q
M3$8L"T_IZ)C,39.HM1#D8Q**?)91[3@IH9B$H''';Z%PURZ RA@-.)JUGQB[
MB1JTI4[OB[AM'%\;+E2_M9J[1:0A%]E>,G-^-26J?MW3.ZS"C-GYN#7<U.2:
M1Y'N!0EE.@.=R4Y$NQAEB/-D1?_NT!5<G>K [9CO@>APZ%^QLD.*PJ#@E/]'
MV@7LEL*5?CGM06HZ,0;WTGVJ<8EV^/ M(OMWGN!(+,@5WD1[9L,4T?8,F6^J
MDI=5A36N:CKV4P6% %D91F1,41INE*+F41%$OJ_4BJY=E9WD)7)Z^L69N+P<
M+VQES=84@P1QN?_49="L_UKH/PFZ[4'FQ 1A;URB S(B8UX=;MI/ZG(4S4!>
M89O>8?M$F3GP6#,OZDRQ6U.3)ZQM5V&R=4Z,<AL;=F!\:1,[]8>X@X/Z3=#Z
M*Y;,IVKZ@JC3JUJ;\YQQLU=+J9E(+2EX:*60G?S*\8'/Q(ZU'ACYN3;6,?5'
M@;J/0*=I(.<HLE&0Q+P(W%)8%!%K/[0^;*V)-RM+69K1<4YE]?1[N5SSS"HJ
MGR7P?$N]5P<H\V.;GF4>F$O.'75$04(TQ&3AC@<.*:VL[_/\=3=Y"ZL11C,[
M4Y#D7H9,;5%66A1,)51_1\1_E?L2RK3EQX;^$&1-,EOPG*SI'$^YO9%0\E/<
M9DK.R.C;W^H41S9.MA@6.$%I^RU-GEI2.6'1XN[[31D0+9EF]ZN?U.6@@?P%
M+WZY#F0808="#$V.-DGZ&$!-K.#=VZD2"LV8ZP"&JV9+LKTU?<RROVY1>&[/
MHIB?>_FFO["\>&I%+][<P6+3(LVH:<H=:M_$609\"1=SA7!KG_-W:A-L.*>D
MMI H&WGWPTKEF\9W>(W2.X\TDNSAEO;,>(]O^,,_UI (1?\T.95'H??.>Z=X
M+'\]?"E9IOUK'!>$"]#S=;PJ>V4F?JSTR<9PJUF>W:R+)/;'O\,[2S7N1EW]
M>?+_*IP_Z #GG4DQFB!3>_U;AE.=@Q Y)Z^'P1.H/X@_2'[!4XVCG;,=-Z>*
M_; 5C.%#D4R@#$8<ZD2&D#VI\D:(JN#T+3H@2*&WYMW^%%IK<_AW,;5)UV@"
M.X/;0ZT$E/66EK5KND;LB-D@QS'$R;?_6J E$4FJPL-:X8)!\CY KJDN?.%1
MJ>U4J4'Q4H>*Q'D]KXZSEPYY]^S3Z8!3JU5_&T'/"JQ(1,^*R1G]-]5[ZSHS
M(:KN.6W-WC%.GO,01Q,[12^EUPR_3(Z7%DA^6G'NVL(_E'I".W#HHZE !Y'\
M),(O'?<2?;FJ@Q)H=[[U^8I[&85=E[\0DH'AG$I[38RX#P+%/P8W$G"C1(WR
MH9:<(M/D?0['IYQ([!_D:%:49=HHOYR:%7=TSPW5C:@2\<0OJ79@[$O$GK8=
M*9)\FN34-BN*I\7/_P#3N"P544JY:48*U<:!.Q6K"92VI5?'WLTGFT#$ -(U
M.H"%OSG)WY/L1/;K0R;NX2".9&T5<?F9!FSN0-W.<)-VE%1D\57U-\DC=$"$
M3(9Y2+;=<Y<10Q<K:[+UE/U4@#"L;2>4=I'4,K^738(_LNGU=<?WY;T8 AYF
M>W4!,[?9@YJ*&+.DY-.]8U4)%YF9M(:Q@=-<&?*@OOLB\+ _.%M7QC*J$A@A
MRRF0/%=Q)N-*6I+=VW\TQHND3V;WEYC/+78O<@7SB\J.%7_5E/./%JGT4%<-
M=;H.Q+P4(22D':M'R;B.YUO-9M?]#6UYAK]!]'>^BE! %VH6+NIOH><&XTPZ
ME6O<Y'*+65Y%FY<^30K;*OYLCM;Z*NP=<ANB9?N/M&+FT\0^F79Z9D@DZ;,U
M!WIP?S@&3SVQ^%)F_KO0+#FA\]].6^ODA[J2R]@GM+>NJQ\H0M281G9\M$7-
M>+0M*=KN_7;XYF.,Q =4D[#A#<X&/HDRWLU9+3R*<H7&@M8$$A%E,)?)7A=B
MO$+?[F&^W=2;VS'[7<4;LC)53O\:/A76,H_WH6:(LLAV'=V>]]QBRO5G[3B_
M@>F,7"3H?;^4,6LG[R[=;67Q *-M,_#*X:V_0)=P5!=!@<+MJ8L<DTJ_1_@Q
MF_2\S\K=HXAO/2GC0UMDYRCWMMM6@6S>9FT<%.KN[@%'F_70 >#==J.)=[R]
M[[9W@OD.4;HY6_[QS:A)A18Z@&D'6.6.<?=NTU!F-SQZ$G I1N7+Q]"NN40C
M!PE527"-B:[WDT+UX16&:K5A#<W\F+=5BC>)3YB#"0 =@$P4V]&5<9YI?V_;
M]&\>^WBD;3]U75SB%#GDU^&5QL1>VKD<%Q%,%;;MW&K58+^P^H/8KGVVET^!
M.VED^RA,AGS3Q=T_UJ)OI25ZRWRUBEVO]2(+:-6N=,#M 1HGY0P^HH7]EHTG
M^T0-Q@E@NZ'R2K(.+L*D#&"B)@/\.@(0][.B5K\OF]HR.':A7MAU+27#F"?/
MZR]E1<FP#_[05H&VS?*0ZDH&$5:N_*(7Q[<?;4:Z+W#K:,""LZ6@GJ];M3H"
M2H#-= #^D2?K6OUW/VTI@MQJY*78CZRJ<F%?/+>6-,K$MI.U#PYF>-$@?OLO
M:I=E)=J*$QTGHK"6A;IJ0+M@B\&5^,__MA]NT;Y.<5\T!EF/4"#\$5L>/QZJ
MOQ"\X5-CKOLXZO[&V2-8O>PF._\C6N??HNN:@QI;U826%?>I!M>P@=L=7F#G
MWQGBQ0]DWO@]6&]=GK"5LD)GLAJ^VS@8)]OW+CNLPF*Q9:!0I(*;V69U:@7)
MP:Y6K38#(Y4B,$7>X9)8.;00V$FR]7N/FOMASX^GE?&N1@;I^R[XBS_==.3]
M71%)P(!^3$:4RD)L_X+_=S?2JHU2G\L&/R_F6=Y#C[VB.1^Q+C"L:F6J4U1Y
M[&!*04 _$V/?OZ*;VYH5;N3;?((G<O2I0WG4<8C_'![Q85:V\(N-.Q T*=4'
M%\<]P%ON=3X\*,:0>HE=)%:"PD)-FYO&((O+K0UU\75"JP+EX:5PH*)&TI=$
M76E G)>^)L%0-3"I\ATR#6;W<.-Q=E)![984LTRBGXM*,=;=O6E?OUOL]+-W
M=$"<Z#E+O5T,-9V#4T?].^TNZNDW"UV9YENE+::WSB(^TP&.GA.=IB2WA:^:
MSQ;5<#9F519DCG17VM.P"=Y;#T@M3\\!Y/75!B\B$(4-MQ"/"F,N[7B.$D@V
M"O^+O?>,:NK[VD6CHB@*D2XJH (B72G2B>(/$!"0WHD*2 ?I 4*B($6J@(#2
M(AVD1$H ::$C(""]20F]DU!"(.W$_[GEO?_[Y;UGG''?<<8X'^:7/=8>>ZV]
MUISS>=9:<\Z.%T6C)9'Q(NDSY0CL6@^<YH\7LF!<.),FE7S,_-4_$ O%"$E-
MN_&03?977M"*)H;X5WHU].QH; 2>'>O0'FS"#39M2.^LS_\Q2S^=S6RIWIX;
M^<[M%VCZE>*2G,QA&7O[43TI:S!=;ZM\K98<D1H$+PUB[T=;@D<\6D[.M8.Q
M>OG8^0Y&B8Z>);2\JZ\<BMF!'%_[1O.?+!LJ0&E)KNM-L"?8:LZ\M<A"Q\67
MP<KR6>S-[S^SDT=CV&\=T1F-FOBZC)9^<E;,\WLI27IX?L ,LO]#L<ER8I5T
MRBL(V:-<FE_8NPKN]\?,>A';>5PX'I:QS+9D_;QD<FZRHI0;2+E4EC<S)[+%
M(]^(1M&O1G7K:3N L \3'_W52Y6H:;D___#U%@2,R<%%2@RGM4+0R</$I-H%
M;UXFR@U"$ 8<_O(W5*:P'%'8I?V]QR%Y0'*W.\7V7<\AX 5 :)Y9A7L=SM8H
MY(_9NSH=7*)7UWJB.Q';/>OC_DL9GEV>$K7\*5_(6W,SR#-7EXT<\^J3FXNE
MME\%SJ;L;^*2D=5&OQ&E(&\'9[T^]KF4JKK_8SOI3C,*"PR#8^BQ*N\P\ZC@
M6J)PVPV)ZA,8.'WE*\VP^JUQ=>DJN\"BUHL_E%D(LPOX!!">%9Y_5RP\Z0RM
M#%0&KP3QRD)-R6%01ARGT8^QZKYH!(.S_Q4;<,6='M?=P(K()3HJH+)7N63
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M]7/D/23"<!^,H0(^4!Y ^1KK1Y0D."-]G'8MC^OA>!?-'[B8$P/UEH<7)"]
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M?&1.]#;"\0"__?S'?(5W1J#I, * =IO?G@&=A2I1 >\E?K5/.U(!T^#I.N)
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M2?;'7[OL$:XE0B279? ,%4#1/:M'/#\#WSZR; 5=@(E"P!C*.QP0DXG/55)
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M6?I=,W\F>]H;-7P_KG#6W(PW/\!CQYPH4M@MXA+L\D_6#2#[E-J*$"*R?&E
M5?',Q\>"C(,&P*(35@VLQPXSUD0[5NK),-2\L&5;NSVOY3CE5W=(>Q_3EUO
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MS=@#*W+R4O%N<O.6R)YXT4(YW 5A=_%^Y4 /UH7XF2J*KH@9%8#4!I/91/9
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MFS<E0QU"S^*':D8S,NKV1]3R]HO.!C%O87V]W@GX1E,"8%/1XYP928-_! L
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MKYVE) HM,/NGD?E?,/^ :*'S%F.#\>S*O"C/ ES"5Y$^D@:,8C5D-SWWC</
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MF_?M"F ]T*35ADW#JWD3Y[1F.FV0U&\S>F('<QX,]&+-&8/X S[5S0X6S(G
M3J?>BRD=1IQ4T*,CM8E7="G>:(HN+\LW%]MP$<DW>?G1EDLJGEX1RKR64K"3
MB/1[CES>J$ >JM37V6$K71U?QUF(<UV3#[SIWP^$3/2#D4]P6@3 =P*  W\+
M(L4:;[%11W^W4CB#[-L?2NW R:IOOT!-2D+9]IHCVZ\G^MULO!&9><.8$WEZ
MM% ]-@%,1@!,6NKB&!RWYT/A!T]:A F %R5@'$/M 2N6V0RO61%$3'0%\>'2
MQ_N=X#-!2V8"X)MA!3[<- )$#D:)X_@]E.5AB[!S_6$#BW'IUZ^IBZ5,8@ \
M-<0AQE-KHAQ-1TI;))&(SNH^\HEPSI^M$G7C2:)+LHN#IQ;]MA,ON*F*$KST
M(YJ=>QN^[LU4F5;/8'4P#A!&9%+A.31[&</:J!J*(6.<XU5.78R> $5[95YI
MDT ++XVE)1-M2#2T*0Y@$S/W6/NJ$DW/Y+M!S'VC3Q!!7"B4Q9NBXYZG?'VH
M"$2W[*Z0>"WW4Y!LWW7@O6[K.FD*7B?  FV\3P4;.A$#1#<O A&Q-.CY!>5P
MF1.'A@3]D1']B%N+G8'\UH.)VAHW& \.@^AUDSGY/XWRGP[C0(M1>W^XAF?,
M/ B ,.547#%HY8\R/VR2>IL 4$M!9J(%$5'O0)>@/Y)3$!]J'958'X>9-\U[
M^$GU!'R*!#".9GQW\S-JAH[^P0\0  RR".RC\@8"H.YUF]#?IH,VZ3++7D$:
M'R#NA>9;&8PC+FMA3Y!_W%O>?CG)3K*G_NA#?IDIR//@K:3)"%SI(3P1MJDV
M6B]PCP#X0@!L"D[("^[6(C6Z.%I\;0IB=\:WU"?+O)Q<G5A@VZ65Q?28K=9&
MDU=Z/U2%:4,I>"/0_2>]N(]X+GO8I=KY:VCK3L\V[O&:6TE;<J4R-_K97G#S
MFR^V/7WB^O&9>U3P!G'@05$56%O,';2;CKIM0\/(2NH3AEZW 2X73&7F*R$X
MDJ-P6DN[U.E4&>XCU6(.UCC+G6U16](1[)!_>%Y>7S1MS_&&5&IV_O&WKHPO
MKWF-(@<PGA":^K9[T<L;M-EU>SK*N[F#F"6&AM-?PGU_CW(.AEUM T&\D49A
MUB,>Y&@KVY7:W:,K0=)QLRV;$D^T*3L*967[CJ7W3C*KP.TSH"O1S%!N.P;3
M,ZA)BJ.T7XYD%"X+?ZJ,J=;G;#ALVS4;J3AC%;[M5MZ'(P#&"[*\03W3%%UT
M+*+@3M_NI,;\1YYE U']0L[<SQ:0G8K!O15IH+]-'IP889.6(W\;I;/CDDI7
MT)R8=VC$8D:LQQVTPZ:@B@M?$H#_I;?FX'-#@3OS-UM3_R=7VYI^ZXF"=B(!
ML-);;&0H2.7"6?']B "8$L3K%"P.X@(7\88'%3T59YJQ = DT#EMXK'1_^@T
MSXR6C;!?$=]!VD#<9:V=$CR&'D4<[7[Z4TT"(!@;^]MT"2H <4#*M&.,\U%A
MX:7O0++.$>R?6X9)VH49+NTH=:3,H.HC1+'T"[/N73+6'G6)-M([D6G.QK_K
M0%S6J(I@F'5F4!VLEJ5U*3,2SI2KS!^O<W_&9-*\VC_36^^GUOJG^[T18:ML
M<A01'3)I:49J7F?B+;/3DD_]+9*/5_P-%^ S% OK772F2G?44+/!\UKM?*$G
MMTNQ/8KD!O*\+_T ;HZ3VVO@:<X38;3KLGAHTP@:UC'M%8I5L[$7Z X93P#4
MT]VX_2+^!J"\+,J-BKU76A5/-8,*?HI.1YHN/QXO_]HVBI5[)Q+2]=-4H]Z&
MCF7)AQ^R?:1BR*G[1739]L"741B1V)J1*5VT:UJ/B+VT 6,L5>8!.V9H1(DG
MFL[K8/AW6R1>PELHK;F$/:R&O^%YH>- *BCK-H.],A^J-K$\CWU&M*S&P*)%
M!S=Q-7='>2 8S *=R. 9AYAAO-!^:DA\X3N=E_CQ'W/S^D]5ZD7XR=NY5F[+
M]ESQBZD]]@J"6;D$XZ_]?MJSWX%$QQ^/L,IGE.Z+C$AN=:8)8@'T18JC#PX*
M!M<F_A  )7ARK:%,P7@8[#A["T2'%T4K+)TDW,Q=( "NFFS755ZMPJ5_B+_A
M2Q$=\.[7%1F2-",P.!5,!Y&"5QMAF>1!%&A?S83.E/(7+(/77?[H.-L\Y,?M
MQI,$N;UM^SHQ.E\OT^5DM)BYLUD^;U?=FI_K+V+J9J$^8\G\";M34#G-=DF>
M,450MEB_A*<)LN\(56&#VVWVY\-%]UR\ET]:T"#DNDFRU@3$U?I*-@U3$LVC
MURV2$@LE9Y2+QEX49$9IV,>XIAJ/,,T1Y:OVL2B-KO.<9H2C-5>SD[ZWJ!#Y
M?%IF<\@"PZ-E22@"5$W?N2NSX!5Z/&#6*0_^<#S@.>2RYR+M^&A/*VS56H7W
M.L"<-*: _P01B1]I8QZ!V8"G71;A42VDCCR!ERNO:^^*=;T)'+-YF/C0.J \
MGJ2&]E)68,K0B$.I7=_6;,T^_F'17%IQMUWB\8Y_+5*[RU("9=1I(?@,M19)
M']9B(/=IUGY\HS>.1)@2;>M&=?_]:E/"2)XA^@M&%2*'5I!262( 6(PW69VS
MNS,'I7M&AEH*Q])(MZ.>S?.T\0/?PRA:#)=&#?VB[PVDS(+WODR^_P!TVFFL
M2 "]U)U*O8_.6S3+C""Z[C***.E6MP/;^EC#F\:)S#_NQH2%O7XQ[WWU4A1U
M:E-"LEBX ]Z/7^&6BIS#C#W4=B23'N;@$@)BEGXX I%>-J.955>M$U8(B1\W
MT<WA_Q$R6!5L60+FPD]F5M$':G18.';/7?WM!!%> M&WGZ!7A@UZ8^R6Y3Q>
MF8MYK@8#KCQSCS@&3E8OC1$ />(!\F(E);\F3 <B^_+GS.7ZM5#6CO4E4E(,
M?FECZB-/ZU#S0\<X<N'N[M;,M29_1-.0&C/??_;3T0M<X/]/N'H@X6NTKKNS
MN]RO.R5XDDN,PIW[;(_OME*8-]/9%YIS5ZI[59LU,W[7B'F0UW295!80=RYN
M>1WS&/J#APWWM>:#SDYTKG?\ +7)]G-4F(VE;O*-%9^XE82H(/H'4BJI#3HZ
MPALCEKK8)F8;65D9IQ2HW<GDBF:N"9^-]^3EYP8?5394"HS6WH&JB$6T$?*I
M[C<TL(L8:^+8;]X=]JC1]F#_!8D,O<]VVI%95& .H<-5*M^6.8%]\"C3UA[)
M)Q=P'/!D<YK2U4/-*-RA+^8HPP,/!%T^;,,7LC+91*&WMY4YT7<6&I/-QE;&
M^/R6'6:&!-=D%WJWOC??@7F1*JX#W=&"G:YHF?8FEF!&EUCMRJ ^,TR'[-@=
M]%(;#)<$>\E->N+?R,,[)L[:E2'UZE9RAF6O2#N;%76&U]5'8CY\ :R"(!U#
M_J+..(6ZO?F%ME6<AT#]4X?G55K]AS!O?35F@7^[ASBQ *L3W$W.@B)\Z<.D
MN1T?MDZL3HC9U >-]SR+3K2^_VNEWJJ1 DL=H!R: Y>&+9YF4!( .?9+]%BZ
M8*SP'/P5/?H6* SNN,_I:,DUA!4L0D/][^CB?_OLE_/%64"Z8NUHYL7H%^\#
MC?]YE@06P8_!D'IP +3_?(6'U5%XGAV]]C;J+C?W)S:9Y1<IJNE1WU?UA"5[
M%>Z_T(W< "&-^I58NTS]8[MU@Y5OHAVM_'\:'3P^!8GKWNF/IS3YR),G [SO
MJT>QX<&<N@AGL(=*_'Z'<WDX*GILP:<7XBSJXO2*GFGHVX^J;UO"6@'7_JTE
MB8K?+)A\. B^D 8Z> NN\<*%$  G>WN!F5G/]-4N41_,3P.7GE<@F]O'Y?.C
MZ@;<I<_-))JBFG8D>Q& :[^>&149!4*GY@]T[F9B:!!$W=CDUY/^N6M6#Q_:
M<<Y#?+E[K7=&_;)6D.O9V/3_N'PQ\I5B?1#+Y-AQFGF%6%N"T,TY%<GN7$,S
M@S>BZ)4I#JU$\0=[X!S#3/0MVQX[K!-R?1$1TB*[MH*N42UERY6S_1# JXH_
M;,1:5Q3 ''5#7%#!"^+A1\*.GHUC?&&[TQ#7<HOR&V=CSWR_T68BY=&V)RIH
M4A1%-Y!'40"V/$_K'?SX=\MMQW4SS3+[JAEUQ7Q1LENO]*@8-.%<:;>+\IAE
M=FRKDF7ZG^.]U)XE!)T,S2*2UW/ PJ 6' /Z#O* /@1(HWAG4?82 =!5U7<C
M,3GWI_JF&<H-@:J@(@""$F%]-3I$%?OIXC+:BBM2B(:0P3BA:(]1ZB_PAJF/
M2L_>WTJJHM&Y-ZX=[AE]YO2!ZGOO.C/;%_F,P]E: B#O^N^(L*8FP;,[3;AX
MV,HTE(M82/, 5\%"6%H"X%,21/7< ?A+_GSBQ&IH'PO"**-IGHR)E-^=?3"C
M%2&W*[9DEQ<>L&K"=JE@,N*L8F&B$\Z\29QX+MS>,:>=\MT%8>5JIW$ENE9"
MIMH-B/HW>9[WWKH&_Q(N!^^7G3U>C\446[Y57JD(4M1$!2_5[^IB'G@'+Q9T
M[C/4!RH*9_?=]4I)SQ)^V\<4)/.IX?H!..3A*S:0Y++T:2L4@JY8U.VNF#(X
M"9_ WX H(5OFY)"_6OD'E=)S%(?)4E3XNE#Y%B;F-N;"M-9*W>["?L:'V'LP
MF#8! ,YNAE<G"W87S$Z<X\1\<PB =L5W="^9E870B<N#URP^*O8!GZII*$&W
MOX95@'Q;P"?DR./Z]S!'E_ F[K0$;?O\Z3G3!Z>T'.J/]OD,1>ZSRW*E41]+
MHXLPCR#0, S]?;3W/&7-=NRL)3K8S%YYZ!)//M.[Z'IKV0X>6+AOC,()'['R
M=WE/ -3L=]WRH&.UB'T0-+[U:]!L=$<@0OAWO?ZN1]PG81;#V7:YE?'1\A+'
MG-7D59Q98Z*9O+S#6>X9 6 9"O_WGVJ@8F=2%Y2K43.+M/<RN,+%/' WCEUV
M=RTZ.$,F>U$E7( N"3Y!"F>%<8H=/Y394GF9='( U@^YK(?<C0G_ZN/J.''/
MX'LRW;48V>5^L8YN*KGGZ_:\S_2GO\K79?8]+&X>R7R8<E;G;PA.SZP?H:,_
MJ4+KEUM"MW4>O8E\[$LO=#9% /!NP3APC!64N'+X:V^0/9"DW=[1E3DLO*;>
M_JB_,?"@[P5I]W7 Q^C WHUG/#Z7?=($J8O B7^&!&[]2O5<>ZXT*?&"4HXB
MNT(9783"?(>1K0TOHC):<;%B1?"=#R+K#5([0IP?<B'^Q]M1ZQ%GXAT@'IA]
M;%"3:/U[K!H2IH_*W41]$*U5T/8I>!VMS@KY1G4-"5@/_;XNF!+; 2)1%H6.
MPMEK8H$0Z^&1#CS'L)92>62LZ*QA?:GV-8%/+*O3CR4W*'2:"HMT^'%S%?W8
MGQ7]EU=:]R('L;%%,(?G#- !^+4I'[JLV6L$ '3 AQ7+> >OTP;&7+& ;5PS
MJL$/F^J<-"-I$.>>J;:NA0ZL\M(_]4RGNX;[A3_Q"N4$&6?>%^X'+61 KTU
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M(E91QU=CG]_BO@;G4>\,[Z?EV'TC"F+VL9#910"\A]7$H<>0"'47IG9/2/_
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M*)1P-XQ-D:80C%[^?JI,!8]![?2D^I,-?5DZ^'V6:F.HH.EI^1Y2D'+F=K@
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MS98Q:1"S=UV_;G5X04-CROG0TUNC-E]BIQH 1K70'\I4:+\%\3!67Z].,,/
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M0V_/)WYR-3P5>S&GNWW7 *J)O9W!@/=;#(2Q7-7-W4B1S\]YQ18C_ 8DB^Q
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M(T_1DV!,*_@L:OUA* 5P@1U!](_%VT@&@0]O/*( /EP:(*L8-TYX28P1MBF
MAW9[&DG'^KL*%, _7NHP[R/4P&[)G7Z=?&,8VI:WF1QO/7726TFLO2*][*,@
M$(%%_:L?M1Y=F&,:AQ@]&*ZP$ITV=TH-;/"IJEKX\M&#/]BD]ZH>@$8PT61W
MOXD:.L2SWJM6T5PWLW*^_=,^1/'02X0 X!78)!<%T*S/#'D(I.]Y=2R'X\I)
M_9*.7'FB1;?_6U/@:K-.\/2XPE,+V:-1:#C! =ZB>HB8='_V$XL,.9I09L)*
MZAD_\X:8-!0F1:U*2;1R6C'-).G=GP]IW0&<[J)NE7ROQF]0 .>3RQ!MMR7?
MSEURO1=\A.KC^JIC6'95(V?WIP-A=,H*U@>J1H97E"^HV"XE![DNK(*%+0C/
M(Z8K("WM@Q,YVYHB>PH#7D--::08U,LY>EBWZK6&JF&)'#31H,#UWG>4UY7H
MU:GTTLYW" D^+25/+1'!M)L X*,QVG:F2WG11-I%T.5NLKGSJ6O'!\6!7T+A
MB<KP1C"(/(,HEX^%.\72X\&Z&&#D/"9X-B5 O./W\/3T?6'U6,>G-H9Z3,IH
M%%0)0]K[2 ;B;1^-N"43G@[+U%N(?<VUMY$I;<_?O>3I:9R6X?>-J7\.+\ 4
M=>&##=9HP;I$M6517,S(2G/\R7@<%A<05$W^TF!PX3C>Y5!^T2%6!A5, 3 U
MJ"W..+_Z\&2PR+XQ/;UUF3^!Y1KQR9MOOH)GQIKND?)0\VEU U%-$HC(N7-$
M1]1E,E^?2+KW]6)!N>&^*)E>0>T^;H7^HYN;)X)!R3.KY!ND$+@+<%);AQ&X
MY-MI)03E<1=5'O/7/+\RZ840%H/8^EQ?R'GY8.W".R$J[16#W'T*9X :XH-@
M40)H6;$ CNOO:2KXM>QM,K+E+][=S/%';WA[@NC(;!"O>63;#'<+[%H9X4)P
M3MO* T[7_O:$ 8%JK)*4O4BM2)[V5OX9[G^^,$$ZXU[G<D @TU$YB,AY@@9\
M'$P!N.VN<YZ>5V-YRE>$N@+)UL*DI_F:]V>[?K?0X@NWJXOC3^&+^Y:!I]TO
MUL9(3BF1M;XG4E$<0@$</JEH/LZWUPDS?):F=3V"\[G>@W.OF/6+!AC@W=4Y
M5+?/ 9T"BN_=_Z_&J_^_#Z@D-:@!I!)O5&A=#OPRD15Z:IV/VU+]46!1)1QL
M"8WKG#&((':$\K&V7$?_0M#![6*C@#Q%@MB,<.XP<U,IY]/OWUXFK*J!I*+#
M)<:5W3;2HI:Y>DBER.\C(*>!,,\G4U^\Y<("1/D+8GO48'5$UB%Q&> ',MW/
M4A.+9S(N:KKI3+O&R40M$6Q^6X=V;%5 /4P>'HPR+-1)+LBI,B.*G\P=@H1
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MVMU/S,3F$7CAN0X*@'F.W\6GSOWC]C&3M$OO^"[0S4\TCKT')Z11@QR$3U
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M;[INZS;&<.J\X@U 1_QMLP%R9CH+(2P<(=XKBQ1,X1-.D$L-M0WEO2UN\86
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M?KM7I?TJ0&OI(8'Y\[* Z,^I/U>DHM)(.]@"F:_S>S&&:F;J?_:"3#EICYG
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MFXJ7)0MM 'NN'\+8MR3[@ED,+%<7_JOWJ?^?\1\8K$;ZH]O>!C?*&JL;F..
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M&MF?YZUQPM>Z;=2YJ%L=+<^/X9$.&11 FQ+Q[YXTN_D]XA5S.+9N WIK'L2
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M0L<^//TRG2&:7O,TZ!"96P%DVH"Q#7T;.K22&] <=FVY,C%^/^X1KY:(\TW
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M=DB/4@7-%UP23)UK/0I^_V3N]<6N;ZY_7I"];TU6BI!63E,UGNG"O1'??"@
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M!;3=<I^ :Y6G?+>'8&&5[9#,):R9_(D:@@[V6WR<"C 21XS_UWSR9%C_4*
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M5832,/Z+A1/:"][$W)<\/[5M]1\X>6TT.[VSJB.4M;7RXQ9JN!>O8?%I&(%
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MN&3'5XD?Y]*[H2F$ C0L,M33.T/X*C8]"C$O,OM]*\M-18[^LUSA5'$,2:&
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M\Y01,V?\S9I;@1$4+66#RZA8_YJ42U1 C2ACV,?I?BH :P)_W4C?G12;M8;
MN&L+08RQY&:P4-08?;3!Z@L&.]9+ #T-,)^HELSF'D&J^(T'Z0[VPHAYK6ZR
MHIV-3':4Z:=_-G >(%U?TG8[")4!NWR(9 F]BP-'^S%]K/"HW7XIW#<P%SIS
MQ>FGZU:WHQ@+T?BZ;$N1"5F;]B N+#Z-I7#*UM,"*@2: 'Q)>D7.)+'BP.A%
M1)%*=$V3K+'[X\W3J)Q/7F#WFR52M1_HZD4<@]D@&<#OH"2$-C]T5)NE)5HO
M4:;L<%Q>U+RS\Q;#;[:E<]&G7Q'3R'@(FR(R"L9RM,3A,FTZ._=HMJGX8QN?
MXVSHCPGA\J%P^A:H&O0GA:L%M[Y[$>7*]-#I_19VX6>?]HJ7:KHNOB.O.)H*
M"*XWEB<L89?Z+':/7BR>SOW5J+9KT$18NQYR9?H(3&2@$<O& "$#ST+@02,3
M(=R>%<WF@AG!]DD.-)KX5L!EE'' QO4XT3]A1L1!E4ZU#^3^+]>>E%$NVE(!
MUSR[J0 \;3[G8K=>(;M+#FB4^*!*MO15?0;E0Y@!\0%T&,ERC48UCDI)D8I:
MPL?WQZ^UU#2/^VY4K,7I?_AQDGQ'9+?]'"H20@]KUSY2H[GI;$%'<L].60#7
M0E/4QB#>&4@_)\F*DCE<QW_XNR4P(9Y&HP(C9/;)$S_B>1KP3P<*D+>19+&L
M,E8*[MKJJ7[@F]8*F K!N@"OWJI(K@0Y@/E)(83VHD!$Y^F72*=BF]]W7' N
M5AR%12E6WK?U'SNP:)Q.S_B:V1C>VLKIA?F;_BF_>4VA*R[XZUFX#B=[6MI[
M4QW.2__9G1/W$8E+U; HV$M)7_ N,<'H?NOHN@IW<&*2XJOY'I.;33F"[GV6
MFY^^MF_#P351%>Y/H]925@MT[BG^7KI")Y -N)1;#&!]:FYZ=]2:;O)+QW^C
MCHQ5G;".U3,@D%$KV.&&,E?^%VGXJ(8TW[?/$HIE<DK7])>D+PY?4*,;:]QC
M(%C=QZI$*R)9-Z8PTT;C[F.SBVPSG$^>'TN4:/6+UV[DO<RR\Z.OR-[XCV:G
M<*W F6$O8$RD:X0T#(27X$VTK,GH.I]UH.><KWPF?F\^5I2E4,$ME.3Y=/SU
MMN^#FM#!L%9L<*55_<E_\Z5_D'@V\5:@S<ART7IW?-FNK15.L<\A6N8DW]7V
MQD.1?5,'2]X'#QV3%ATFUEH\XKB3,CU8+0;P_]FOA/YG#@X$?;(]=*EZI./+
MLR'L2/OJVWZ)VS4TS.SSVU"</O=?V'O/J":_;UTT2).N M()"D@'I4J-J#01
M*=);I(F(]%ZC(" @74!! >D]4D/O'0$I4D+O(@022@@D)#?\]KT?SG^/>\8=
M^^QSQSGC[ \K7Y*1=ZZUYGR>^;RKS#*2SGYFB<>+41L!Q$SK7U<-\_!LRZNZ
M%XP2E)"5,**>BYO9!D5[0^&*.IB6;/KC]NBF]NA@'1[)$>?<W5,##?LH2JGF
M/5,,SV%0@G[V8P(@TND""OE38$64R,^]\,S:IB7>=LF;*0EV"-U_K<QA-9I9
M"'\%#ZF+S':FBXLK=Z:]63_^82U&AM70"$"N!P#0DX<:^F<_N2A08D1):"%U
M/X3R[9J+?R]#%8&M,)$KIHLP4MNG5"35#[I)!H%+EN<F."E=1! !H"9\0 !0
M9V8C"^OBII<WM,?G]D-C]:W=L(H8QSX5!HQ&KI.*\M2R*<J0 E*WI.4]<T=G
M4E'@@"/EO;#\SD>3_.?)FRX"GK;[T!>Y,<)/_K\,^7_DO2M28EX1KU5(5 8V
M_@3 \=.Z@[H5<+T?+D5' -^%(D+L%Z>*GK'7R'Y<;*#N1> C B"'>K)\C!8R
M ,LG &;R0>> "H5'_[G.4_E\C:57EYA;3%:XX:PJX7]D_0S.KHWX:IH$WX3?
M9;A/]HO21,U_#"=KTJE[+G@N<8%SP]]IUHV"L+:PH%XJSB"C/I2?G-0(B]/E
M,6ZFC2YLT#> 4@&^AO^3=[$QFQA,(:2=J0[<*FUK:]]I#TK_9-:CW\BH ]_
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M-4[!9_?5L5$&)L'_ZE<:S+<]^XSUR,O )V_<>@F\%1H^KL;\)4=?+< -P5*
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M+4[*#..S-O\NP+G4:8;F_J0XB=OBSVO)+-LBS4EOH["SYS \^_#*]@43A($
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M;)#7!^\(@'K*<#P))L\$4X 2'^OA)H-A)=#QWVX63DHW5WXW_1%)/LK_:OZ
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M-LDKN"!?YJ6Q=7CYPPKV4#O+Q<:)M=G)A;6947_@M,9=ZI^ XJ</E+U,9@Q
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MT"DR8)L1=Y<,L'F?OAUXZ-MD3:2HY 5N=#&I4U]Z89=J=^,7+@V\Y)](,F%
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M<CZ!S0S[FL*-H[U?-9W&^?YPF2BLB]YR?VC=XWI!\1P; +(9*-"JN+ [3JP
MN3%DJ=RJP3F@JYX$E'WK&+HU4K*]<::Z9\%BON25HJ3ZEN9WW9\(:_"/""AG
M*2)1%?:XVDHV<[_*]\RIM0_A!-=A[D0XFA@(@$(Z\0J0FS!>)](I=99A(8S
MF\?24NMV]'']\RK=8O1TD*2$*':L:!2%>>7@_<)V5WR,^'KR<!]T]Z=;V9.G
MS3LZWYZ?B?.<+@\+9 $_^:ME"JBM):Q9":H 47E5!F&:KQ>32%9O+IA:&<KY
MPH3 $;6(A7A7PKFY>Q#-4@MMI>.\P0[^9$# ]61H[MC*(AO5P2L;,H!6%@>?
MS7Q?CJD.\1ZWL[17$JP9R@<]6(Q:>-NHTX) W^T[MLIKUJ9^:LS;P29LU$0K
M@ >??--A^S;X\2J/ZX=B9^Q8U<<9"P034]NC@:;<.)[M+79H-X*NP:EA%<:\
MJ[;5HV_GBE4ZN2=U\EI.1X@2G!XZ Z0FW/]T#M/ 8[ONN>@\NF.^<5A?UD<(
M;(QJ55=']\6?8\4%M9F;U@O(U!LTQLS:D  =30\Q9H0SU"B.VL;=XGA8ZV>'
M"U75Q;(V/Z*-7Y(!R+OS)&%*]S=:X[@20.+ Q;K(QOAI9Z3&3KY00P3P(I8K
M;M&-P2@:QX4E"E8^]7P"EV.2X6INNR,T6/'CZ9B(RF6:"(T@MT?9XW!68@1)
M!F<QQ]G.$KMSSRI3OQ%V)_;VIR%X2,*2+L<5K@V:L#M)ST]V6J4>(#!!S21A
M' S#8(9>CKV8L6\Q9+LM^OK;CD0(E4G9+&N-$!]]% H<+X>,@IV2!9_&N0FI
M?\HW% OCCYN[Z6-Z5S!52##Q!H"X]Q:AK"I#^11V#9&:+-%0_NL+?*H3]F\'
M4LF *J\C_MP>N!R!F,U'GI#K+2YLA>-\#17DIF-Z@;./_*S5B\2IU^HDN@C2
M> L"+R;$:'WK61UK.7&XJ1;/F^-:3J-$D!CV[C7O-*_4+U7?GB&-']POM;M_
MBLBMQT;E]G\#(:2%M&+P),.Q64ZB3Q.%[VLW9<-?0D&P[@G",3*@K!IY*-Y/
M-_3G'/56US (4]SXAU5E9\*% 8A$T;CL37>+-ND+=7HY+T2[;\<%+H6H!<;@
M<J[A]O"W<;%SG,\@G XHHRBI,L=+K6ISH(FGC^RX#4JQV2ZKP*><3:!A58%D
M@M[0;K!"6].3R/!K#BXP:=!9WJSOGF,9@(V?_X5#Y[_MM_W3VH<:R3@ZFCBS
M9;G.];-XK6Y/B?QV)CGCE\]!*,%A?V[*\&-7@(Q^,C5M[!NHD]@))W$I8.,I
M&OS=!S( =:T0AHD!H<)ACLC#"\KN)#;E=#* JT@8"\>=AQ,RLQ#$*"G$[DF7
M23+ @>5 82N2#,!>_ %;439KY>DDG$',CSTK:2\KQM!=&][PH]N6EBL^2/'X
MZ5M9R[VPLP7.!9V$B/G-@B)(K.B9-\(R8">>NY5QVQ:7'3-TY^Y8YX7<6."S
MI=ZX:R ^5%CV.1D6?KVWUI#G<0;!S>>/S*]63'@;:#]G#H#$U?[D[?5J@?.C
M;EJ1+^,R6Y2XG7S) (Z!$#I?NU49JQTPA4TU:[]+OUJ'NS9__DUR,/#J6'3#
M'6Y\+UOLP3.^.S<&/6-]#?*0MLC=V(1TIP=YR*E,599YA_58#$_G[ P<8S8'
M3EA"C)4F<R?$7PK*-Y8LR.0Q0=E(+ 4/FQK'48/U<>%8OT;B.Y!MSM- T\PY
M=O0&*?W]#^=3-]&RL4*QET)/FM(J/=ZD^I20.@@=)PD/J8+Q//[E]P?@;X:]
MZR>#E$HW2Z>N*&?6>&B2LA+9?X(!>_IJG%@W' Q6\.":C8T[JIA;M+;FN0Z?
ML]20Y#=_ZJG1F)GO)>:?31)[M,D &;E&I7S?X288RT&V!)Z%8(F)[ZB?(P.>
MPDY?M&W"*#R=O#1C)/9*^/GQ$U^_!WB<U#95384&TA\N-0D07^P5J$M!)T <
MI+,_B[;]71^W/U6PT+VOYWB7RP'?,ITY1F/?A"IR_9JEU..; GW[.6[YQ'IV
M3M0J99K6_"/YKA;[P2>\'6D0?(8D QV2!Y4K-!N8&C%;NMW;*PV<,(TQZ)!6
MUMHQ6TH0?Z=DG:,B?[N*BWHW.X8P.HR836F20W^($JV>S4EL$@(_NR3].OT,
MM^NCVA=>9M_TXI(6R(#3TIM*\T.(V0Q$Y7XT2<V1)(X&MED#YUC"%QBDQK5T
M&JJG;$2UP.G?$K0FOEWB4A8PG--0GWP;8_@"4&&V"(MM$H/<I1"+1.B@P#G<
M$_1D!Z?Z,9P>*LJV::1B_^&8<]GM7J^X#[>%"K?GIXH_^0EHOIM;7F? V&#U
MT?'(-G@XB NB663E>"ES6D>O]INKK+B,4%&4XR+].\\8+25Z#[V6YRPC]!+-
M".N<"7OI"?BL8>;<P</(G@?5KW8WK+\CU2W]C".$/P3\^/ES]DG\HI?O4N-2
MR.FF%7C?%DZ,A?":<X.? K$P8GT]O)_C;^T8#\W)O6.L=8Q^IR\>R;:(TT$%
MJ9GS*\F)9F-<;QJ=CP,83_IJ@*:(+OUKOZ99T0C*3O?WX;_X??U#J^KY\[>>
MQ']E!IE7_M<2KORCXG^W[Z?)2;9=*.BV]@#DTL)#0(^W)NU)>--TE'N+2[1;
MI7XTM+/ >0+6=];+-]/%6KG*WX%?F=E+BV52"-N/P&27(.F;3O?*$?:]8E6F
M;QN(Y-7Z*N+5:JUR=QWX YF7&H.P<L3HQ^HTX\USB6R2RND)9>>Z+(_'WC11
MTNW#@*S)@%N*"R$.T';$)T;@<51XA[I<).\6[\WZTHUH%H&,O,#=*X?5FOV!
M8S_N_!]$*/T3.Q$_*-/M\L9IG^-OYG@M&D$6$33ZQ4Y72FY_9GZ&3TW]LI':
MM:[ECUB70(-:D"Q0<8*YOH4V8EA5I;#]PSUGOS953,O )X]+Q\+:O#3H^,PF
M_M;1[LUL$=P3%(B[4$ 0W9%8=GR-^.X1>R<I\D-#5#OPH_L7,H#])(\1S;4/
MWZ=%!S?MJR9WM8)S,L;ZV6[1M5F)4P;1;7_J6S,3=+%R1![M!:D?D9MRAX!/
M5>HE+CT^()S(5EOBR>E,!"WAZI!HJDZ/9.2\X4L\-?#5T5'TE6"*6J' R@F6
MC4_H-_OWG#.6JEU/'SR04Y334F]1&L\!HGDXL9O$=R2N^&Q9M.J3Z^'+Z??[
MRR1?)][J,@;QYYFM])[EYA(Z%P("0:0I3-MA*.]'MA NR,>UKU<^O4!R?/_$
M3XJ.:"KN!3F!<.+[SYH$NR9T6E,\48E,/6XVM1G;,T(!'O=.K0;X:#5W?O4*
MUKE!Y,+H- .CFN1G?) T_K"[20DWQY0?&X@&7]N88ND?6T1NQ.,%<%$H4!N3
MD2D:$;FYI7K2?R:XH@XB?>4^H]W;%.X+5-^Y/YY0'Z::(#4CJ^1K4: S/T&,
MA.L#2'_S;:///PP6B_1MA%@UI@ S$8DJG[7]%><0QBX8NMGE=23&KW,TOSV;
M#KV(231XY.E>P&GA?GEX>9_I[#%M&F_+PR"S000S&3#[#GE*G6,5B8XG/$*_
M[W@C57M2ZDLUGOG=J3W_ES2PQS1]A;DL@QD2W]1/D2@-FA0MWJ#SHZ7*W*LV
M@R\N'' F'2Z)+H02%[_BQ_+_5Y(@NEXR 'V+ MA!<#R#$QEPJ.;RDY^.I!'H
M1PS2(0-R8P[P_UO^K\'Y\R^F!8D_+^'*[>[]2OE#U+-_6?.@7D(\16P'YO @
MUKG?4T:%:-,+> :)E0SH7H4X4Y2+/85KY&8<FOSC3UW_TUA9(/!9-EL-1@@7
M*'WFYZ#+3X\)$W";6RB_9JSOUF!"%8O,FW^"@.IO^V\*3,.SXJO+%.'?D2P4
M^GJ-)$PX/YH0A;'Y,OB [7$ A7('*^^[00^TP1>-7-_0-4)C3,'/"%+O_%OU
M4PS&*C*E'(Q2MLR1DWF8G."2$[V&198]FQ(Z J;^9$ +&3!IAA)K!U_@E3ZC
M]7;5Q(;'MXXVKU:-[;*Z18Z=E\O42+BXG6 A-XVWW#:L#8D31;9L\02,"0BX
M;-$ZLR2KMY[-'O/<?/0\)='6FWVN&*\*'2(#RB6XH0*XU(;;N2UZ'/)/HMD$
M%Y:^0ZE NUWE02-/=,IRDE0_KQ0>*FA!V&<1N/.^[U%9.O@S<\@0=]E@[8NB
M-4/6CK9@@]'RYSJU++OF^*B6&>&/F/3(BM(@_:0/0SXJ][:D\FS%S978KB3G
M/_?0.5Z<;FA7))9I959;^$<ECC[*DWU1YFS;.NDLP(,1"7-6UMI^G,8Q&Z;$
MF.=5PGQ"Z W[;$YE_L;=.??Q_0Z!DX/>((9K918N-V]N?Q>6$N4WZXYR NAU
M*:G4):95(9P1$_IMH'(B(F*AGR P(^YJL2'@M9ED@$@3ZIPR75L20$P70#Z'
MN=M/'+P=&3XPQ=92*!IH-D/]\I K?!<)(.C>1DTN,\FGE'3+U5VB86?ENE:2
M=XKYAK1F)SMS+!E ,X_+F7-\[(W@)Y@\Q4&[SFDZV#WQ@7[J>$<EI/?4A8O^
MTJ43 EE%?035]#D6XFDL&8"H!A*<$W$!TFW 0Z$-,@#F!L*-F/='%6+=F[?"
MH=PXWMD?JG*H(.VP =YO&0&9WF-7GE,E:W_IX6,. 0  5 _:(95X:=*8U7D<
M!G-LI_40&=(7*24XE-=HT;*=]?VS]AMU;^KG"WLDGL.TBASYY'0PSEK(U;J.
MELWX?MH?J[;=/R"B:,.4^?N$1S8H)N:>]G3Z%?5:U_QK_.O-F!K5KV^0*CHS
M8N]]7K1>D2P^[</Z.>U.GS#C,8U=;N#+7)9DD*,1[GQ?<U^HGX!@_YNF1HQ1
M?,4KV_+T:Y_*T^024/Z3PML7.M@$WC,DA3>KFJ51.OT%* !7K%N+070">;Y4
M\>0DW(^/R'A^,E(O;N?FUY,3/ 9O[LR&Q"=UP8L:[/#\A#.XD+I6%R1C@U)P
M0/&4GD]0 3'"!'O?5KB>^-Y37#C9_U$X& #MDRJ%M@'1QK&)83QNY0$%!'F,
M;/@ZULS+?9OP@_'C#38/$1VPR$NJ1DWAX"D ]./82<QRVQ!.8M:O#71J4O=1
M[2!$K0#<?B[L1H7IH"(HU'QSK1?F%"_Z( CKB2O\T$QJVFFI>]\ <5@*TKOC
MN2=+A4DDG)9N]9@@T&.6F@K>SN';K-LG:^])O?7A5^%-VYHB@=[R1+Q6CHAO
M+VUSD6O 5'AISU_XJDD#M&:"PBAO@:U2W)Z800#G%\/R-.>Z\WVZ4+85E7?G
MX?<FM^']3HKQB94 J 7E1NZM?/18HKJ"_]GW5RPF>ETE74:N:4FBZZD[9VA5
MGE1XPX>+"&44(J=:,-8D1_#'L'_J3:DXJ]M,][TV^_I!:*=NWVA3+[$$Y #D
M(L#<&8 G"7I-N"!B\L6(OA_?D"M0]Y1RO_0+P7U2=<M;V2^H=GG_5DW.FT<5
MN>,4R8"4I#&02A])KP2.$TF(?X)"QB#X=C-[1H?+UMT>5F9@;VYF#0:E.C'K
M*5F?7$CII?4&:1<4K;B?F^F^7&,?_4+\:6BE[M;UM&VUA=L,D;I)NHX:7-:!
M9W9SD]O]MS:NS9:Z=UK1#I5X2] -N\T/O\N:U[Y[EL;K&-2:SA28%3@RTE#-
M1)6 RCW=Q1\6XI>XF6&Q%G"QU$H\W\7AL?5=;J$, #QWLMOIS4K_C7J1F E9
M'[67XC1W#Q,<)^X):R6]\S6AB1TQ5!ZTZ$!/=O)VV?G<8HQ3LEG[H]*%ZV)E
M]?9BC4MZM[I-"(M8/IN%13=C->,^TY6NR50N@!#73_%C[>P/I!8LQD45& >N
MT)Z:?608N!0MM9"\S6WJJ]M_B?(HD(0KP7_D_UZ=T4\4Z\G*'1?TG9"I82[&
M#02[BXP4M[-MN K9L.;2) 3_I-S&]ZGB>9UD!/^+4$&^\#6#RHC9J@0E$:<L
ML^/:7)+!CL><+S3&-Z1]?)&&VKSWR743('CF"T&\NCJ9.]^OQBE-^ZL0U=-_
M=<MU@;/W<E:<EOPSCTO,@4MI+@'"=6%WL][I[M1=4H0DR.S^D7K?=]LRP.I!
MJ^9GC8T*Z@86E&QUU?8#\P9/P]'OT\*W3K)1J;'S=O2>U#QK*I%XR:>O5'Z0
ML[HRX;RHT[39<5,NJ:T_RG"4+E1%IUE$UEJWAU\"A!A1)]Z0VEB("9A>=C*Y
M2J^M?2SXR"&Z\06\4V:?NX0]4HS/ 128_&\.):AN/J.*ZIH''27R-VNH3D/9
MG+:4JS5C;-=0"2$).+D+!F7>%TJPK_;E8A7O-@?L@/^^-@55'DLE9C8)%UJW
M^4/1;FI&FQ89]7BE0G!(#DNH=2>>N2\';UM!A9RQNI8_T?O$\UP[C;B5'N_;
M F[A,28R@&$'M45D\@7N#\$B?)-64!L.U?6/@MG:PR6[Z%-!+3J>I*-]S!6<
MK3 F1R"3CPN>GTZO(JM,ZKJ[^R,V(ZXK!0^YS53#>_UKWT.L.)Y^XH)::,H/
MPX/E!K\=2J8SA7;,G8UHW]DQO'&^O5ABI72(P*(["+V"$[,:+MTE@MI\_<RJ
MF3Z+V]C43O9[/LCRXI%NE69T"HPHRW= $<^-^L_=Y@XWC. &EJ&;O9B\=RQZ
MI(9915JU^ *F64.CNK8>U(!+MD&EBDA\-=%(@7=/W?NCL^E:K_W6MB[EW396
M)R_)WBL3^%$<*1G"%SK\9,VP(6)3*B]!*6/ZQT/==R(N%3O=Q7^.T(%O'K@N
MK,_X;700GKSV@;\$N799(:_CC/B27TU#'.Q><3W,%@A1?U>"..V?<P.=D#$1
M^2F((\>VY%2OO._"+GO@!&=4+U+&H+;G(FI?D\3S;53V@<*MB@;2=,+8K4%<
M:N[P69U(P=SD3@\AI-A[.[,)+Y"=FUOZ!,E^.#B](K$*(6WA[B[Q\PD(C5 7
M( /ZQRAJ%ZE#D)B7GM3'YF% ;;P][I$YC)+PA:&]^UJO#[,J'HL,V[H?/#J!
M;U;>=%-X,@F7QFM ;O1#E=<F<B))3([GE&2Q^HK2LD'>U0H[]0]?MCWD#^=3
M4MWVY\LI MG!QZ]#V ?6Y=Q/K5;S+,?GF8PIG/DVI./,[?$HRE/%7]&!KUHH
M'\Q ]^R;BUF6<L/KC[Z^)O7[MP>WOAT^;F5(?82N6.W'OAX1^E8V;^>DN&8'
M3;01PZH08RO@XV2 ?E0;S[96(>YP55)?@84CNT0I!HC]U J":LS#A^]:;<_H
MOQRQKG&Q9^;Z'.)%Y^:T;ZPZNIGT]9$OGR)W>_#I;=N*.RZ\DE0,:0_K(=\7
MYO\8C-6Z"R^^KXUJ<XEE  XR?\D,M[<]^HDF[4@%@NA/BCGU^)MC0A\>'ZA_
M'ZS"U/!IVDC"4C:I._[3J4LO=W,9V.[Z5C]'2LZAGFK*O_203UG3:F\HM]0\
M9RFKQVOW[M8)SX3(/\ID6'1[GKJ7[^([Q;S(/3^8Y<EK0/U6U]J>BUGE%LV_
M.,@8\?HB4J96<<V@(F)C8T3XQ?=Y)5^N/EDJN;]Q8I_?P5T*D;DT)=>Q+UD?
MPJN3VPY!XL\7D@$1K7C-K+;P.47%7>+0+;JA(_]>("5;*/[1O[Q$\2_#(C9
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MYRJDNUIS1?Z*4>F5CAE]"T^^\LJ>,*.7L]1C?Y3;L- 4ECH?,/%PH_8:HZO
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ME0VZ_X(-^LUC'69VN6"7#5HW/G?8^X8=; ?:^^<)_G6$:$XYC TJ6FM:BYF
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MPDE6HX629W?7 'S8:@$V>WA*6-.^EEOA2\M*<9CTO*%1+VYANQDQ6DV$A]:
M@X,_T=)Q38%CR2O4P[KU=B,STC,;O&,G0D/\CCSAW:,-FX,NYY([+6GM%'IC
MLF=3OZWM1,Z7+Q8Q7_7%(QZT,K/"))=/$?MW!QS+;+ $=".\)O57\!V3K=%5
MI@_4"-!A^/JC.D4VJ# 9O7M# FD+,.(^,O4=0"=P_(L7SD[49629!;@X7YJX
MUG#KIO%'-N@([[!.,=P577\).SWXY_-V9P#WGZ-)VV9Q!;!!\AS?V*#A:N \
M/A_=!$0O _ R)@H"#)% -FBEC2E(6W! ?$$>I8R7#IAJ@S]-K!J)<A[1@+P&
ML81VSM$%NWI9 QG@=X%IN!N;9]O &Y@A-BB&L&Z,!":\IT5@'MG:$:4+ T[C
M]Y]6<!B /OVV,#W,HF%7"+_"T-MP!L^ZT1*T=6WG.)H/NFP_ -U,O\HH9(8
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M,#;H12.+#[L\:EBZCB[6'9Q]V.G1\_[M4LP]G"?]+*H'H&P E087(L\Q 8;
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MY-7!>OE9PTS=#5>? =G5;((=^.E_2!<KV2 (;<F8YCHY;MN$7VDK[=L<%@N
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MTM*G%Y\?<-VV@</"]]2^EU-6AK<FTXU!>TWV1F54NYM^U-].GM'ZJK!!1",
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M"2"OE).S=V5V:UL^*\3*V:DAV:#RS/2\_(V]G-92?)NS6(3;W[< 5-U#P;S
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MJJQV:@$;Q+G^.%5R,SL74,59[)5 Z'(K'3&!ZH,?D2//_'D/==G4UDV]IG(
M7:;;>^*ZM?73 *Z$KI_!Q+&-J&F4$KK>!$NT05ZC"+] $^W8(, #.-JKY8Y"
MR[4SU!&4QW0M]UW'00)-#MH(H1FB^!?KSE9&N,^]+*1>ZM*@JVI8QG\+MVB#
M-4)+>QCOL4T(.D\G\V0^O:HW(A&!L_@]?).YZ)6VEIN#_0J]C%(!S-CE&DYR
M#M'GEV[W5',5+=8^R)8K27'E[;-K" W.6='YK\/UG)Q14R@QX*.6VHJD>#[;
MA;I3Y,\]+PJ4)!SL#+4H08*.[YTL9UJL@W\^#K0I_PFER>,:M: 1@>:?IB1T
M&+:%CVQ^CW>JIJCH'1(?.!NG%HN3VGO^5X*Y!4<4+8+:1(-F(_EH,U]I?I<V
M! S]C]>4AA@I]7Z+[@J*ESEP."2@Y;S)[/N"J[EGMG"[<-R]^+53&T;EFSU]
MX'AX&:Z1\%P=,E)LH1RI??DZE.KTIF/BNO3IAZ\^?'D=&F>[3Z)" \-'[F$(
M.>O7#=T/M2/OGTW,47$/ZM0Q\YC6RZAQ.&?T>O,Q\Q%FV9L.IG&V$+@WL<?\
M\5PUI@$%TIV'$RUDCMB>J)9B@VPZNN=<91+C+K6*ZLK34:R>.B&:\!2:MYW(
M ^LOJ77J,W([\&[F5G;D&_YOTV4BFF23>LYRH?.UHGD]-@!:&-8P,G#8NM&(
MDNE'WO_HNCL1'R#!2D%SC]G>;?(JDCX4"C@-[;BD=;\5@-WM/\@&A0E3X+?)
M,(84=!0]TB! 75O)*-Y)=SPE/T;7FA*G;,=YI@X!9O>16XIF^?*$HH?$!]45
M^UG\X58MA^,RK<PM:90OY1_J,]@PQUWJ'P\"8 =[KI<YHV&RBC5R6.F)S"!?
MQW(PM,A#SS5=M\7F7F[972!8!DMV/.1RDHMTO)GJ=?&B!\C*,^126R'D)Y9\
M<XUGZ4Z3#2 "OFOAC[/O83U*:X67)-&1N,[89Y#E<-U!Y>4@.A^-=XZ(BIQ2
M%G7]3<N'#14,K9]4>E?WRXWG4.:+?9P/_A_>WC.LJ3!:%XRB(B(@33I!:0HB
M2E=*1$6:B("(@! 5D!(A(BVT1$%Z!P$%) HBG4A'6NA%I)=0I ;I):&$#6D3
MS_ESS[TS]\X\,W=^Y$^>)WM_>WVKO&_VM]YU3?_5' '481R%:KZ-?8EF"Q#!
M$@XBZL'/:A\D%VJDX*P"W#K4EA\*6!Z3=G*02Q9FJV=W6;.*,=3W(M=CC4V=
M:21!;S*%D>'V8&W8<QM*Z)#)ZIB]<O:?N5;.BBYCM+O-IJM<XF+'FM3.GE(,
MCM[#=&TS\M='!O5*(ZI$%-)!+:J,2C]+<LVV.H2XD2T^I<K5:5G9E5P/ACYG
M.+IR@"4=Q'+0;,P+@*UU1CPW%?#=3Z2%DHO=3*KOHB;^E+G3IA$,^\+GT2%(
M 02YQ1O),_#*DQ7V^?K?-%G^]S#Q"+VS@43+QY$A3KD%WM4I,30KOGM/]SY7
M6V!G4I?S9B<Z24>,768B-/8T8PE!#)0=F+G@3)NB8DB!,W9;'?T7B'$'/S$C
MA9HZ5ST_RB].P87CKVS^K+EEX=Z])UI)1&W($CCF<6T<$\N&8P&Z<YO2EJ,2
M#;7WZNJJ.2Z8QX><()]AT(R@Q "C6@!%L+A/Z$B2M>Q>4 ^&R=[S3G#F"K[(
M\5).$/U"UV^*4]Y1Q"LEY3#'[N;UY90T.?@.[6/ 8\:/4R@0@E:^5OK\9Y7=
M#MPU%=S/ZF37HF[A<V7QOV<?IAN_@,43.BF\L%OU(^<AYQ!,#X=>=3>CC4=,
MB9V-';'RR[:*9!#MMQ88F"^",<A5U&8F':0]&/U:YYF$T]""S\FRC6\B!5^$
MF;J?9Y[B&,16ZFZH$W;P\U>Q& 1$.ZXU\\)@L>B12IG/SI9XA*$&7$#RS2/A
M:Z!%=KVNHF5R^*ZQ+1:W]!02>/6)\_ 1I<$XER8<<)^ :\>P3@%A+;5%-ZM2
MKT\MZ<8/UG28C.Q$*ZB)UVB>+F$FY5"SL/-I 9S?@3 :)QT$Z-$FD%60EV3X
MA/=+U?^0]/G3<7VV&(E$-:LC968 (?QT:ECT-C5NP1YV8ZZ_>UDF-?0^"G'.
M8F6I\3/#3#FH;D[",C4LFP'DN4W"#RX(M!9"TXQ0-BUA6%66/>,=5R$(*VKN
MZPP7T>==@-%"W'EGV-Q4H*B3ZWQ%+!VT.3RK$;EQ7FD'?^-0*V,Q_J3O&.-*
M)Z'#XB.3ZARA!SXWO3?DVCM*?ORR&.FX\)JCBD$!ZSE(0M2/>_!)\?;:$9I$
MW2=/N9,7?(M<Q[^EPB\'%M8'CHI:.PIGO#V]#M5&3H)+L:W&( KKJ(;E'/4<
M@'HT^/?=>*>/1H\&7*;-Y'WLGYCY=_P:9H7D.OV-S=QI3#]*VXR*?VU-!SWH
M',@\22W5$D3@YFV68Q?'[H5]7]VZT%@Y<LLZ7$I<EE]'^O>58[+E-YJW3H,A
MB&S:F?(OXVN).O-T$ CJ0CKS^BI\7Z+<^^!T:4_G*%;F$$PR!(0<R=J4I]6$
MCMR\_EQG$VM]E.=8DV_915XAGHP0B9K#<#6!A<8M $=FIH@/TS@0F>NW"+LK
MM6/IWWM]7?,D]]MB&B_US(].?PB="NY$7M>!3V-<2)6;AS35,[9D$@RY_(W6
MBZW,?<^HG++6-4I=CH,4;?L@Z\]2Q.3TYVJ[XNZMW_5.S)W3ZQ(0(*6OKP<J
M]/GW_,175E3'Y*3X?I2Y%ZGPNXT 8KJA#"R36==3K<";NG/H<KU?U8F]S@K!
M;XGU\O&H<QRC.LBOR&$P>X N$3;7@9V79X5.K$Y^_WXQO!\EWLGW0>)Q@N%%
MQ3=?8C.6>;V2\_.;X;G]E,K[:7Z]+7#C8<H>)0X$Q#"V^18!$NIU>:->;G[S
M3ON,X0?5.(4):_W8%8.ZA*V'2.5>)PC!?//BPB&W%>#EGSN1M&MD5Y S$KP2
MP_.,#IHU3R9(DS0)Z":(H*T+5CC <$ZH*_$/F[IQ[2ASBH3TDN_%&KW6YPBF
M)>&DZ+<N<9MMLZ#*V9!UGSE9+$OGPI30^'MWX/4=(2-6>[VBBR U ;9,O4X1
M(_O9\D@?+$43.Y<FV3<Y11-<GH:<H<D"CGC5]W+U^O,VMZ"K0XG1 MZ&)X*%
MLA.,95K%8^>"6$X(4D:HY9!78,#6ZE4C,QWTWI#,3>:V3C2N9NQ%8';?3EN"
M7<^.A9N/X[:PG? ^YA8C>$S74PT7H*(K,W9"E^7DMBCUE"P=[_OOUNX@@ZK_
M23XP4WCGH"%'#ZKG_[7)3#[ ^)>$_*RO?'\E,332XEEGXQ.F?9X7%[/P\F6;
MN9^'*"*M'-)7G:@YJ-I>; -8'=E-!U5V4A1/8B,N,M9C]N\4>.B[<FHVR5BZ
MAQVRG+351P>]>H$UK)<F#B#*2:]1D6%WR-=H7;6C[/%N!\O=7,CMWG&M@U2<
MH\"*.Y07U:RJQ0DH+H2@8Z?:,X6&]TGEB;^MTU?N9CZ>O[K9^&D2(D/V6.@,
M]<2<HO7.W!BL,#SMV2 SW)H6V>SL5F<7S2_Q K39+4TLOF[Z.D>*)BO5N W8
M:2@]6I>H:D#/Q*7202^WIQ1;1-6 WF\(_]O Y2R$ZD.<?>+ERABM)<ZKQY7"
M7AL^DD]LF&J$;9]Z5J"OQI1HA%1$,C#ECB>-@1PPG[![F5;4$PS#!@48UP-P
MLN;LG>]]8[@CZB]G61EAA;N_^B\S3Y_#4-@_O\P?C$[$P=LE#V/3/ KPPRB&
M*1+"B PRJD[8G>\H]OCF]-@'J3SB^O%;F:7>CXE"IJ"LER=*10MR M?[E3@
MF:TXC[R+,!0[QI-\$>E<I/RH-CZ0,RL<3%YK1/Y3L7#4!.,/VN1,C;EU)3O#
ME-0]T_R?+#K1!J]$WW7Z77/A=<F#TY!+ I@?*"?Y<7 34@)PS4># "M-\792
MZ6$M:GQ+X/S?3DJIN_A&Z]F83GZU98%3D@*FD1\J:X;-)? B'%^0/ '/"+D=
M6-;O#?-R)LI"FC-/2Y,O*]=_[-8_MY.[IZDMGK8I.P<9AY)\@6Z"ZL)H;W]$
M@-*114BEK(!8/6I35C_U]U.E^Z8W+"-.*"RRJZ:1=RK2(LOCH$WAU06!I^%7
MM7J<E:9\?)WZJ]7Z3KE#T5 VE%L_,Q"%9P]C2VUJX-;%518_$&+&%6]?()M^
M^L99$1*250Y.EW 3V,<,L$%IVJK8_>;_X.-AL\<AB]@ "!U4FLC8+0/3K+"&
MB&C12:2\F4'CEJ"9]?HAN +*J^%.!YWIG\=&:%B0Y#<9.$H CNQ>.K3U;I=V
MHQ97JZT'[V$^:C&X2K.N)R;25BD0;$TH$F4;OEB627*U6K;BEH!Q;8G#XS_U
MX[0Z&G"D/#HHZ360\.__4 SU/&Q'D>3W;Z(>:^O"4O#<,I;V.X@Z_;WVT9\>
M8:>A:R;4!9YWF0H>)L9IYD_YX+LC7G*"!G#L_/>P/UHJ#(_*1SCJCTE6$3J#
M,/4Z=D*\?-6I+6WZ<0N/=A;5-*M=M;Y8_&!DWJK4]Q"GPE5/)]>K&C<6G/"*
M; H[.@F.V@?1IF?A4W]XS6)?WY)P<)DE&$."%1 JZX9EA#W2)'HB3<TK=$3:
M><RF7N\>]?URHHK=N,52]<9Z\5,&FPPB\$[7?[]\$>?ZQ>?I3MREF,Z!PFL4
MF)5*,O3%/A9J=K/^5WI!K2?$" 63GSR@"3#*:NL8BA#!@'GZU-*S.W#:$%DZ
MZ>\'_LX/Y'+L%#^F.X;9MIH!Q7-A-T/>CA:[;F?7U92FW&?]8,E4X1!9I0JZ
MIZ?I)TAM!=X1PII1W&F3<%X 9HS[6ZYK[=WX7N\%6U"SQ[ :.!EYE7)AZ$HE
M)F:&;6B[.+MV>*M>V]%5LR+J0Z)*C8Z]>(U8@N7S8:\1) Z5&5II15)(G1A:
M7Z2#YM#?H670S1 860>!>3S@6L_*\1YG--P^D"9WZRFSZ(LO1EG\!*U7^YHW
M+9;B.B&'5S,U&*X3=,!P'5'L2PHKP;H)>W:?-6K[#&!A- "_>G''(:WC7/1J
MO#?ZU5O4&8H]L$P'20YWHDG7;.F@U3MC'R81!8]WZ:"A^(6T;/4#:!+DS2L4
M_M<L[2=FAY=P$(N=RT430H!U6\(R119:A7)8XQX/S"7[.Z;_[3)#SI8+.PIT
M/-"$;0F!@1U&.B^!44*00@$>=%#B*KZ?S"^/VONZJCO3UL+AB.I%?4KFQQ1Z
M>#W%)D$\Q)+Z0F]<CUD3$OW$NP/=%"$'HEHA 0_K""B*&'9J1J=>D5I-AFY,
MU;=/QV3>P8O6%:[_M_?X-XY(%[*XH@PE,T_002NUOXHR''EJL8.Q85C#-.L)
M2#LX%WV*=A'5,@G8S<_RHQSI( <4;"HP>P/I\_EO0)L=<G1ZN.2D!TH$ZXQF
MHO7?]%0 ,DGZ7D+)<J[?QL42UQR$W2;USORD28F]OM6]4$X'V76?EY_PG]_]
M.5GXW3YIG-F/D@WDX+NUU (\1RH;/,S((BGY!:=U1GY>=G1>>O5 DTM#V!]L
M-59 9>Q0:!HVI8K6P)]7-V#N6!*UH]5>QXB<4LL<O!RF]?)217_/E<G)CD6_
M#^<WCI&F;:D$9M(8@;FS5]O37_7G@,:]G@]#^T9?^M\E+=8F8N(>" 5YS[VL
MQ[?6=F[ YOO/MF;=HW$TAHCO3&X__*'*9\IUPTZQXRDW+NCZ%"\!TO$Q0'X.
M'&.!@[)ZS58"R!D$QK.PQ^?-V&9(X+N/;I)@,>X^4+=4R*4.%X51+2QN?^7\
MAZS%BD L9GV$6C6"@93O31469SHF</>4JTU7<$>35J&\%#G&^C].4>X"(5\1
M;MM-)BLJD\E=048&KHB;UODG4F5<1\Y=I\[O8W+KN?%WB$)S;LD+W@\3UVJY
MIKL*!^V=WLP%"BD#V83=YMV 6\39,$8M_F796SA[Q[Z:Z[)#=->\S[F;^!OM
MG-$I%X;\)F<#)X5SP(4%=0RG383<HTFCFHWK!>8U75PA+9DB=<3$6^VBAR4A
MR74)(QT&ZM<.9(YM)O1ZH<MG&4RW!2Q4;P2?+[YC4$.(Q7I[3^JZOZX^?\!&
M!VF,/2RXD]F4Q_SE1I/JOZ/5)XB ?#;@)J="OO5S#%/?4+96K;K[K:\M<"YO
M+2IXX.31$O8JY7EV+R%U@5;Z_8F-NO%\K\L3UZW:ZTY2%\",Y')):76';&[P
MX&"=ZO=^),>H3]#ZB,HQ!8^P56"0.E\"N0TI30:3PDB:[W&S#KL!6-6>VU,^
M<YM]US.$_2Q:L002]"@'=?B:#CJ0"USVRAU'U+4:.^9-Z09^7U.IDZ[^]":Q
M8_W7CSTQ7$2 (2!-8)V'!'D9\P#!35K@JF$EH+I*CJ<^&O%DP.>E!$AS_;)M
MNIOQW4>"^?P[Q5 **YB1*UHG4&O)=-!?1K'Y4[GOL]%#7*8)RL_7 >5D#AKG
M9O701&#<)LJ9'!GF38W H>Y[KT,34HZN?B7?HKP0]'D?<,/Q6W^QS4;YD.<>
MY]3D76:/E0)51=$:Z4FLG=8)BO!0XPF*\A!%,D?]0=5<CX<GGLWC]?BNA'B5
M'HB]Z=BV=3MRL\\P,-I^ML(D:@JUCMNY@8V;K82_0SDB-N>))]O;2>5O,NT%
M[Z5%2;9*N3>4W<Y:KA/.$&8*AEY_BFI^4CSV-X4CE*L;GBF19'-ZT6_S_*(C
ML8 .JLC=D"<*+<2U8W@0"W!>Q(-.G;H,);8"Z)^[ ]8%!5G56V=*0!OC&,>A
M(JP#^#CP&*>=MCO?L';G=)!E;LK0UM+C#H%,XT\'W$D9Q"GAQ^?JPI0R&V*6
M':X^*59/U3I&FT$R ?,8:\#/$-;/"D0N1_E;DRQ"Y[$_A0M'&SY9:)8A,#F%
M!'1G<0X"@C]5*1TL_WY2ZW.1_M4$G[,A81\2M\(+':5![/X+6(^*NNS [U9/
M?TP.WT[D7$UF/AK[-9PCF&^U]("0MUK]9I3'Y.'#_XU'F(\M0*I2HS :?&1%
M8(;6<B]TR]J^S/+<7%[:HXAPS5B<"[$?D.)HG9:]#Q@6 $W:PFDS^7GZ3K@3
M#O@@L9IHT:;2EVKK.T=GCASQ/JU/&J\%7"*JOI=(?N9J.M!Y]K="Z>]O&J\"
M@PN2-F1W6TG>U&_*V^/HIS@M<,!=0L>72;-I(?15T G2CIUSHMCBE=(:\^:S
MS +,B3).E8+)/-7.UMM3N^1.\QMF(;6JJ#KC]2ZJ(A$2ZMDO@$#207?'7F6-
M*-6M6+%&.7]0J$V@D(/'W\)VRTG7&^L!;O)S!&;^5;6\U*= R=[$0G0]P2V%
M1>O[M58:LVWN @=P.>5=44>:8ROV!"*,$86U6C8YQ1LLP@[]QBG2";,BWF\5
MUV[B>ND@EJGV=3(20$*%*V +JY7:*E_BGUUY1<IYCY('RRB4G-(5,;8:>@\=
M$Y_XWLB US^5TTA<6T6T[5TJQYC!I3SYDI2.CH6_M,7K%6$KQR!#Y1\^O%@\
MXDE**H-H48P1*&=YX%+*IZPNY/!\_ZDN[:@;QGO/&V_KDLV2[ZSQ6*QH=J:3
M? -B&KV'RWU;MCH%2+U(;U2SPC,4#^4I\&EA/6')1KDV-'Y_VEU=;_93)%9G
M[5#8R>S[@<OV: -*VT ?EY'2_:V!:P @DXRIT1IW"%$+H75X%'C&R6^K^'7T
MJY<_TBS3+G][,VP0T)5T5A<4C?Y4^[(1ZV#)4PCZU7J",UY'UM&YTXHR#U3,
M5H6,Q11JYTVYH AQ=7H"GM=ST\/"I$&!'S\U;N?:[G-E1IX?E$\PT.CM;; ^
M_#1;?O)S,9;"(]M6BM#D#;AQ]NB+UUODJNLA/S\>GOY#WBUYGV\31UCNQ/+2
MSDT L"8_D]'<FI'L%!JG%QMVB],F3*$V2*,W@RGSI"^&PHUM![/(;2BS,;5Z
M6QP9M[&(S^9+U:P=\,F$);#FF93J_U4I]!'#*Y/:GZ[F//@LM?TKI6%CZZX,
MQ/EFA-O,YXK217 9NGF$D2(M;@UL*8WO;7KK-0X7@KJV<$8]ISPE5 9#^"6>
MWY--H];72^<@TDD.1)N^KV==W7,D?*H\?@AE?= KW$D:?E-JMIYVQ(750KEA
M)H]#HZS^QC6#PPPF_TZWKTGER'WZ4]97O&-]>>7VCS^; [Q,$-G'B#"9_N0
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M[2PMX]]M-M%J_R$QT[P .=23?P_9>%3'N$CAZM%A<!MJ)QYZ&C6>[T,'?66
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M$A8.&-U@( CX1G VLN\(0DH^#+,@MB_ZNU6>^VGHI?'Q6;_.OEMQ;"LHP(3
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M4+Z>]EQ_3$=M8Y=]MOY^[FW1/IL.JC4^0OUBT?Q =EM8=HLXV86HFV($ET-
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MR-]\+P\1?JI@,=]P#R%1*)X5VP&:'>F(NI7YDXVXB5WRU+KWQW6^(42.+O5
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M0+@=S">R7Y0D/,<\WS8]KEJMUVUP"1J Q:#^GF0&GZ#&$*G18INQ@&-74(W
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ML37&VX]0I[HN,$[W=I)*FK) +[JEVW#@[XS)9>/IO1J6]^&D-;KWJ.F;CTQ
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MX+4E$&)(2<R$,'MM)Y6SWHF\JOX*:=H2-5KX=B>'LO 29J&(S=Q\0W%PTS7
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M[1;8D-0<5SAZ1BU9XL(1/.K8%0LD/\PP06W%J1<O1'V#MBBOCUYVG$%Z+UI
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M)L#,9@^?K"!^C9\9-0>Y!=.EOBZ06_Q5,66&^>8Z_.XD2IPS+!*\^;/Z0_>
M9]N)0 E-/[-PTY<_KQVHW),:V;&.)6W6+O G&9,JE=ZL5Q@,>E$.0" R.RF!
M:-!$U?$-:']C:CK4DQ&NJ[UO*31P<\9XG_' RD;K400W9*D4Z''99!BLHN<J
M[\BCD)<DP4WVXD_DL>GU8.)Y/7FE=13_*/O."^K(4[7/^ 0*$H;MS)0@<^$1
M(3SYOA&-/&&#U)>P;Q9(7-9.2_%V0F"#4-71>M,T64;FC";'*JV09C#&5(=
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MS=;D"!Y49RI2,OW)X>CS=?EDDYYN'QG\QB556G@BW64L=F$48RC>#G8XA3V
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M19'^?^WA_X-JKG]NI/QSM?IAZ#\5M*^]MT)M@Q?3@3[&N ,SJ+T8/)'QAW
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M%4N#"\5ZU*^:T>I--> VKPWSH;8?/%5_:Z2(%'&XF&ZQUW/%UW-/_LM^&J>
M37'F9Z$7[?<<UY5\;_ZK^KC_55X8;_V&4H"#BEJ8O3LE?:[C77HSTIIS-L\^
M>7V\KW9%Y.9KYVBY/=8AM))] W!+=!F\NWRHN=XMK%)@:9@A2<B=28L2??Q
MG4/X)M-K)7OU=[\KK0SRD\&9^'C-RKY=DRO2/#(;,D'HH7F:%N$SK[]FO@;-
M $^16U&,\)D2-\2)MIFAI 89/PX=1QX)[?(P^Q>.]^042B4>(=Y%@T^!-MOW
MDPZ+,KWK88&/^)\CQVG< &H]'!E?+G''N3_7L+=U.M_$=/K3K7!6"X/[SP$
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MKTX>9E3Y_(GYX3_8>A?)O]:P^Y,&J_R8E(>:R_?K@>(D.PXI:CXB_[&(G0T
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MZ ^<]KR40>7A%_@T @V,#__>JLQ?#4YO!^D9*SI^^K+/T[-,GKMCGQ#&& H
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M2#%D5I@.*05V#0UF\507U3>NLO^LU&]NV@RUZLQ""6NR6MP_16=7YEL)=Z<
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M *";*C.]*P#OA+^!,A/;<F^D+7DS;T#%OR?6=5W)=ZO\\.'093(AUS&AB%[
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MB6.^"WP>PAV\6"(('>KBTXZ(:7Z,G9H*>OA.^8U4VWN.H8%DM* /-XFC8Y&
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MG<T]=S!+4-T]/,OXS=7^"VE%]U^M?Z3SE?+0X[WZ_&2DI:VV=&.]7->!V+8
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MR<5"HCWF=$-*H=^%W>B98:#$D9Q>8_I97=PY";T=VYRTE?FSH 4$19Z(7O@
ML;A1YH@ID\-Q/*M+;DJ9$;\S7^-3PSC(J')G\'8$Y)30EF(-<D6^C7[61074
M".I@X.\EHL@ )'H^$F<S11+%/;*\RZPPXM%I&^*YQ\%U)ZCHH;_#SGSB/*92
MT%71VMQ6DG(%G+2VK(L]CP''PNBQU<AHASL_E$-T/DIE3#WH$S:D$PXO6VX$
M!+R 8@!%0W2!($>:0=*,<OE#T!BE@Y$*^'JE@N9P2WZ"OD,%E2[L5L\E+'WR
MB*L%+:3!]OY1=Z4ARC=4P BSS=/E%;ZZ><I%V#UW;>VQVGD*>C,83N*RHAB
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MBD+I\<LC[,"Q\+I)..@[HJM9<A$9I7DUJ'C+H%HIY)--(K:9\'D?K$?G]<Q
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MS!X!SUWOE^BX?F&K)C)"]YZIR5,;=*U@5TWHWBPL;EZS#O8Z&SA?D%I37W.
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M%C_06=C"-R%68AJ>"=VJJ89+K\)E=0>:E5ZVWG(.:S28_,.6G**LZT'ZL@3
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M &YXI'YN8E(;4JNL;Y;1UY_U!X=61:@UEFGMX@.8I/-JE$&"2(_=8W6$$ V
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M<&:>TV;M=ORXX-JC'"9-5AK Y8^*RV6'1,A V:-E=J88:$'$)7+OQ<D>KYU
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M=>CNQ&?H9,NQ1A*<HD7J-QW!>VXOHAPG)0TR@V/&K3^$R%B]E"BV=7V1W.
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MTX PN<;)>Z/J722_A1DY![4O^I]VKS?YG?ER1QID/@A<3!@T_>UE-0$>9 #
M4A9@G]!^U!(:F7TPE[S?4N+F%^:IZN0P:U3=I>XAO]HAWWIXXHQ7^ YBRDYA
M$N8!C#,M/R4D910=]^N&SQ$K:,,':5>5D+J45]B@5I"7MU!,+MI-IW,8Z(3F
M'KPB>>+<G[7[/#Z*.*XW=)-LI+#W6#B3+4U=S$I _M4D=\;1$"7\EKK?- .
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MT;1 ["& C@8CK8CK5G!3DM0BY8<)^]GH< L+54@< !KZ1:%WM/T3/.S&]OC
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M]V&1L)0-$[ZU* TI&LZ_IA]JX5C^G?SW25\.6J\^'5W65(SQ8;XO;R%&0R_
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M32D*"DU?W?"J:/%:\]N(P.IE82M[<ZP^++1,-#1KPOP/N@2L3![]SSPN VM
MQ['?"O(IAI4MJ!*PX0=2WR\5&>62&P\;DP*^#:)2HRS.';LN_9 (+WE:\<ZF
M<LGFR>*WH\U'..!,1*M=1:&G0\+ZU;.+_;&;6[4S\'?/V2+R;AM3.E"W?RR
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M![%6'2]3GO+K/E3^)53OQ,#6<U#+*3%4\U>!P8W]X[UOQY8'W(5*YQLB_["
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M<=CS/PX9A&*BL#,O01M^T^HLX-'O40I'\RM_CERUTT1U8GI\48^O6 5COE'
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M80%[1Q@EE?CQ\-GC98H)\)=?R5'1;RO$K(SW&/\P(B+4RH"KAKN^"]V:6PQ
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M$D4<0:=LW_1'.ARG;)R+'E..4EP'4\W#3[L5?C]I?Z]A:;PLD76-T[/WA<5
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M:]ZBW)Q*U(M2C!^KE6)T\2J(6A<G3EBDKN'''_I77$.=+//'H!*6PYOX.*Q
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MS,ND&]#\+8OJG0_N43HE\BAU>3IUR?V>H\?PV0"T-[I'-'#+<4&0*BD6.G"
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M8J#TZUHDY2(^RO9(SQ@3B)R.+0LRNY%R4V@C_=SCE+V5>6SGGF&(5V'>0[D
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M9^^3_QL8@0,3H*BQ0$KT;RH@Y>%-2W0Q*UG^H'5SHN8RL@14K^;;JK0JU#S
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M(>H5$>Z_IT8-ZRJSHV=3GTVNSJA_>KXI*LUCT>WE.BS1SG6"X6%'.<-9IP(
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M5 W>/G>:(^1 <'/ 9VQIHU#D_K;LO(:@4.2U*,3XR=HVG/'K-1+3-)F_L3*
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MH9275.<9$5/\W0$&<KK^]OV:]]KLQ97YQQ,-YJ8DOWLDAK$_@Y?CUIVFH:.
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MQ3E%S'#PG'W7?#XY\A!OKS;B+K)1%S:WI 2G<XR"JE;3E?/!26 "B!TX:J"
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ME@4Y!6\7+78_6YEB_?"VPMA;3M[G7X\?^,O/?NP99/$'!4-X0T&2\QB*0>'
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M7WA)&X7<$J+'I!222N$.<YS8<1U?4,2>>-2VM7^J>GE-<]]F_KM!(Y[ "EB
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M!C(3B@( +E+_LI-]\O<#2K,XK^&@:*2^@0G4%"]]9H&?^X]OB(KW0'"R^A1
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M9.7V:\OM.,>&!DOX&/*30$"\"&VUQNW2?%&?F[*(H@*J(@LF,@::7,8X) Z
MA=YNG[1T'J][-!%EK>X. H5($>LQ[8+Q3AC#'@03\5%5X BS?[3!]-ZXD+V%
M3<%7N;<,3U\5_7ZG, 9>E]EC(TCBXW'W)BHTK@?)8,_GR5N[F(GY>>,RV7L
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M5\9UO*'"^[HOO :Z)]@ZN10 _ZE@9ZJ4EN""J[:9-Q2L:W5K6D_O$F8U-@2
M^=VPX^BZO</?UL0'F/*3F#GS!2G7WP7BOR2"UN/J6>\T(N_BL=B5;E3-=(@]
M%A@IW-;4D+'F<;5A? 6<:LESYYFGXU. N6CR7-M;N6^^%POD$A-T-&VX^T98
MB*I8PP]V0\L!8_F8T6S^'Y,'6EDN2JIZ0VU,]4J7>-@9N=C;:F\JMA<B0RB
M*[4@*B$>)UJCT5X9OFB?0Z0(XZTG,6:)[T0=V&82#VP+7\&9CN ,+^WHQG9;
M:4E903?8O]5XW%PRI&7I]V8_[['Q9K=*=$-98;*&SOC'@V)>40R]A^IK57=G
M_CDCM_?X*NQ<QR+MWM$6T:,2_J*W6+6P)C@I@-AWCYEU7L2>/]S&MPR":=$0
MS#8AW/8_Z68P7EPCQ1.<YG[.9WG\1BF/N(/[$1BS/A;T8OA#@1#? &J7 5%-
MV[J]8LVUL;E<-^0)H $"4F>R0H$DUF_R+6VDJNV]M,?:+#C(,S?EVSV1JW$7
MAFTJ_[=?!9J_?XU;X$X%6^3=L\P>8/KB*XKC&C>^R?')_'O64<'&A>_[8T M
MKRWL-+HVK>L[[)J_&5+?_<I.A36OTEN/Q2P"V$,@6MYULW,TS.S3ZN7 $,O3
MC(!+>5&]6%!LJ^I2IFD3]DI;X:;BOE>-:UKBG CPGNT[>9HZ.S?, 2X6[X>U
M[^6+#U>37 ;N&3@;ZB2MS^V"+Y^Z5K+%;8F8W7W!0#=MBX8+^D/[KQP:HD<N
M;]E=#;L3GJS?%K5F>L8>XPW)06&>')RJR$0@CE?\*(#"Q%'6MZ5?<;6(/[6<
MBU)*"@N2!\Y;"E0&U!6U(4\!1-JQ3;8:@,+=6TWR%OP_G-N13H86=YUXIQ#0
M>2R-]NTZ7, H#0G_.YW<NA[+,MPOK>B[8X<NE91HNN^JWWM#'7=">.+XJ*F\
M;>!CK!A"D)Q8/.M:+Q<\5'9CZF7FYN C!=AG>DXS#WWCVM%:0B;IP38_/__+
M6<M]3P>V7G:)H3NR5R5HDPQHFIRB.C&(^%;9E0'/ZYB1B",$FY9GIU.PV)ED
M843"HXOV]A^\WIZ9'P,XP7>004\P?J%U9<% *ZQ3>('K"<UC1>ZS3[<-K]K7
MZ?7]X%G]<)Y!%&R@\SF GJO/#<('$\)[GN[6007QSOJMFF$-;5-2Z$3#7',O
M+1\K[HA:!*>%%"ZVY/<V[K%7@Z(2H[PSM=OYOC[\+X?Y_D+"X;70;E2TD,1$
MD#(:<IG*S]Q4WJJE*2Z^: P?,O.*\=/E*^F^?%>L[29*$;Z4O7CH V$#[?0=
M4 #Z(GE"QV8&>RZ@)B;8GI)"VW([#I9L9*9@:]7_8-S35U#O<-%P?,]>;L37
M]V8OYZ/S^G>J:.X=B]40)5?B+_EO_[1&L;B=02(\KB4/)@7?Q*E^TNE0U1>Y
M?.G"78W:BW-Y4>NUP,@<5JQYW>N"ESF2OXYCK6;N&#Y_7MRMAJ5_5FXE_V*0
M]O(E';KW.M8,Z6.C6L_]\_MS>#%J1M^706PN*G2O@OLG9?+J68ZDN^5I6K1>
MD[GQH6B( "-KN)I^/OZ=SA %X+C8^[IAIRI.\LN7<ZTU_8NU)]V@4+)<>%>[
M!%8&]Z1%K@\[I_O<9]M<\Z/&BX<F="$_]V^_CCI6(1*ID:,D2$,#'*+V&BK$
MRV<@O'U/>4.NF_B5N'U=&LR_%PQ'6G/S_+UQO:V6W"8->S\NEBZ%#G!\EMA7
MF)[Y!>"0L01WI@"$6"-1]*V"RP^6=9$^F^V_7B,6K_Z6H #:)\LR2-_:KP+#
M*(":HIBZNX6'2&DI>,U>Q,[ZDX<!0FC+3#*M642;D$,#!/%  D9(:9,VQ!!P
M]7A#K&%OZ@(?!A4--IG:YYKE-WGN>PD39?EM[&%9!]WQ!M?.,;YLR5;& D^[
M#/\(8=\_S'A3X@5=Z4IX*&O#\U5SY_/IF3IL_+Z\W^U^^2>B45J7XHJNO>>E
M,Z]4_)"6:3@)A[Q'*+5/ZXNAD#NO.?KM5'ZU\^'-*8">G.LHVSM:569NT5]C
M5W\W?8A/H7FA?YL'<%QN2$.$8B ]!^>W-20Q/RMG4]\7U49[^[MOO+L12]O(
M+"RIR!G2(=)@=9I,9HI>.=B%A,*$, 5R'IG6$RP]I:QB/)P"0#Q_'WQ)88\"
MJ([OCH )D(?)'*/09UJ!T:SUB_VWZ;@1<BKU_DNW3<A[]OR#7-?GM'8VUIK*
M*W@?J!_#,H/7#-^!ZDX^P%\B+[O.*H5[U%E+[FG(U'I,?'G(H=4H?22Q]RME
MX"[H]DF_']9D!10"8]S$913%*L3ONO$WD8<OHAPS@@\]I!K81-BZDI-D>U\!
M:8A<&,VNV?H&I:YT-67%?*]2Z,_8TN@M-F9V&B'[4Q<$FL<F+@M,';Y.4_AJ
M EZ'W(TB0*6X'(=X&D]ATMU%0B[?0:!.&P)SUX+XN)H+>EC);K02]KM@^[;4
M<$5_ZNAIXK?!^BF:,)T7-!56AXN_H62#$70_Z=T>_,@":5RQW6M2(B$=^WD\
M^1,GPI03?&V9-4:(%I/S94IE([95.=\.:>VA:=[PX?XQV,L-KHD]G[;LH2Y3
M&ZPW8EX%N[+>YY.A>":7Q.+87CQN_R#J9GUNB97+E5<+$%M-1Y?+\Z(G[!=6
M[F];9#$!:K2\K2!]!^%6ZU]25?SB6V6*[5H\K-ULG69U><[HP:(9>R\!>4VQ
MKY?30M1D*KKSW32D?]5FOW@6IJY!, [C#__CU6+O=/&5/X_ M.%_ .L'OFS9
M+Z25V8\>&:EFF8M_N^WS5SC<;"*W/H#[[I_274;>%>'FA[Z)7*,ADA?#3!)T
M*@2EA32+*U_W MG51)8"1 S9\$5:&,* 7'2IZ^6Y*T*=,T[E_LY]"X+8BI81
M]!Y<?_K+$SY;N4/5%$B)]E6C]L[Z]7E.L!(R2 \3'^H;;2MBC36/SM]NN&^U
MT$<!&(4QKE_L-<U3/>_^[>JS5]H2.\_^JNA) GO:;_\*XG624;M?L=7,E2_
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M@_Q;%Z\U?& 0C[O1+H'/75JD_7,=%4&TSMWD:/Q3Y9KQ2?%']P3#,P/ID<8
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M$>PWY C<*DGU/U;RO?(MZYDN\RF]/0K EJU"G^"B?::C1?)S3L+#_O90 -^
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M$=&J9[%QGB]N-:K%L+^=WLJ&N5./4D6M;K8+PZ=C%\FI.F9:*,\\"B 5+J5
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M"B\\-O)25KYZD6D?M?3I]9,%(#Z2;>2W^?;P]'B [GW2.;+9 +SS 6IU5T.
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M_:^@RQ(%<&9^?&9DI"<Y<P/^%B(%WCCC-D-Y0/?[#T$W0"]9/_HM?D/T&5[
M9W;R31Z=>4QM50ROW$B3K8[\\NF+F8^CX^Y=J%'R67;>=J);AGI<_OF'2@DZ
M7ND[=1.W22Q!7/]M'\7V!?R_];0[72C<OW*-HY)//F45MQRE4:=4(A=[[*,Z
M7#[R^PR11**RNC41LA+5+B3J"=H*;Q?WT@F6D)<GW6B=;K%D(VS?U^6Q_?7^
MC4!U8H#L"ME:,0#4H4X^&%;AU)!'X ;PM0C6PC"9*^EU(U6UW<F$OC^7-\X9
M-,T:\E=E'("6LO@:/AR-1"Y<^X8U:.L!<FXD:=4V3_(K&R%41%D&?UI[NZ]^
MH[OX_/U@3'#=S:>!$N+KQV]EIL_:4QRVS,J,5?_.C6N5D5@+_Y.._"W7CPO&
M;$WZ>E_)76G3 QW-C;37EP8<"FMD*REAV3;I@P6UN%H+5G_D"YEZ+_(0[5]C
M3M"&T:WZCNS# 84N?MQ>(A=#A+7U5OUX>V'!L %035PLP4HI2LT7*]ZCDE-7
MK F[&OAH_X/N-0E@4.R'SB=O2BM_*>9T<YV!RUP4,W I 5^WKVSYV@<PS_VY
M?W7P.W^)N<GN?>'V\U@XD6-CF;4;R&&##UE"Q*[6Q$8Z5F7L[4DGOD[D_HP2
M'4(<[ DU[5CTC1:O7?>93$MN1\&/?TW9'7&^V#U (HBW4;4CN\""(%F,>XXR
MWN1UI<7.6[4J?1+BXH%J<QIS^Q6C=<F29_./K@J\:"\FI9"O^D<OZW2JLYIB
M/6*'PR.6%UW\&Y[*RTAJS[#O7;5_M2<>XY %'N" 32[6(G8W?,\1C3$)4T<?
MT"R3\]4/^4>-M^=D/5?P(7R$D"54GR#S2E$W 7C%/VB@/HT^/W7!BZ[^K\QB
M++9/6T?DPP7UG9>0)',_2-HQR4<NI2G?UYGJ0Y!I$S0H G+X*?@.N<L*3D[L
MAQ1,GM9@F<G&\5_A,_J&5$YY=^<HHR:?O&.X<2I,Y;14PAD&2@;]]\)O!X;T
M5!*;^>5?S$"1HZWP,O]MK7C[$09"C&QF)?E;_X/T(DT\%>:YJ;ZM0HT<X7CX
M +$!J]4?)T)J;7WN@=D9,KP"<?5[8SX^2&/MFR17K:>[Y&XPG"5@G[L%T=NB
M\BHX@ZNB@=\*D,<_TQ:K,.78.B&U+QPK9#)T631VYN_\Y^1-%7#ROZ3,IR]N
M$!S[!/PHG?H@7S\9=QL'VX")LG>2<<?<^H@DOJ!%-I ]?%;5!B/S_D"[(K"$
M\UMM&!KDZ[M1K'CX2?QE(G.<(>]%UL%'R*):*DN]A%CA6;3%(U>"X3UVLNT]
M::\M;+03M7N".\:T=SO?TA[&>'&"4V"CP,,D&0:J-7#QQ"F4;FD)84)$V75_
M!2Y* 5AOWR#4%5[8+$<,(_%\P!2-6QA8/N$\>=*.WX,!W-R*.3Y)5O2\P*J>
M.6"?REO_KGSHP_V.#9<.A;/2"\\N*)]'*:&6BE"'%NU"\!DU"F#K/G)T!XX_
MB2:-$DO&/2W\&\:,(:*]1A+3+KZZ2>!UY[T]@C1>?*GHHP^2'>_M2U.R/3ND
M]<IS/ZAG=O3[M5G%F* .\%9V$%7STU-;DB8:2+A$ >RUUHV 'Q8T-!.M5&ZX
MS@9:DA]'+XGO\F-:^H#,06S+<T=3H+J#6H+;Z6/PG/U?O;"[MJT7<4A[4@U,
MPR:(!G]?,;^04TAX4NP*W^M'2A<^E\A(J^X^]<Y1XAKA&B</P0\]X9= NPQ4
MM,KK#4JGWAN2M#*$=\\BI2GM[4).@..G&9M]@34^*WGK;F>GDCQHXR23P+DC
M"D!N<?>$0+>%XF@5=UXYB.:KKRIW>WO&?%QCG?=1>T5B_-']-V]LE.B>";RV
M!-:F[3I3 !=WOB"B0(P*>]9Z"*U$QY:ZI)77O;S/6I:]:&XR\B>>G&/<B!'J
M_E?Y%>0V%,_B(K<%OQ(D>2GS>H&4FU#G8<]33B!V^:VT:@8T"NZ,G)WK:Q><
M\)&"+J=]/#C*?G"EH:G>]Z:HMD!,183(]@7Y'7%>!?WY^D6,EN[7Y)(#"!S/
M, JO/NASPF,QSEI8K2Z=*\5^5JYL?;?SEN^$77US4?&;8,B+]MND0E\#:UP$
MJ=9=@]UU]N@,^+'",Z\VCF>.R:+C>H!B#I^V^(OD+ ?[=E@I*::=!A^-\\.[
ME?K[]30T>QRO_2R[?@0M'!)-+/?@U/W@$'M!67M3=F"]"3Z;CQ,<)ZN[V?=F
MG*]44UKABC76%7TP=1)X_G+[8KK 19:=' "_H=7-0\++G]-Q>P%S1WZ_;D!^
MZW'7UAMNG)U0[9U#Q6VZ7W@MWR]U*?ENJ4J$VQD)[>RZ+54.DM_BGW(&LMD
M=Y6"L:QH2"^2G2B&%:PO"4:[F7C=4F#<6[N"U6=>D56]>&'5)KNI[UZ_Z,:G
M_T-2RFZ#($&>FX(#?2/5;B"WF-&+/%H<>HE=/Z9.GFN0.Q;E;J_NBF(8_P30
MC.,SH]OC=HY//1^3.0LJ2J>/3G,""?ZPH7;&L2":%<,H+^E<"H#1=/K*88W"
MSV=_#OOYGU-O[',V+4*X2NY%78(I$-G'B2;+#R>?E*A/]DA[R*C5SB9Q0=)<
M]B!:\,Y[J-7)("I4V=ZB (Z^J@S_V["! OA>N4D!'%,  50=;N <KC<)=K,>
M0BM4U"E--L![</,F'6+ CVDPYE\RCN-,FR,%,W9WDC"PU7[^).6!I=77O4'6
MA"OD?A2GQF4B5.,Z5JN53S'>T4.]Z?9"O^R$4FPIEU$DTR7@!A/,J+]HDXO+
MR%-!T*[B7Z$R14W=<=,S&3QPE3/F38E\;8S2#:$Z]K;L!M[39 *@!.N\%[A,
M>K/***9O\ "C\3I2M%%K@"A8=K2 D@,]^[>]J#ZN%0L+>?70N.YKKI-(GQS6
M1N09:YX2UQG42GNA*Q:5=OPB#4O%]^@CG?5P(M>Y@4T4GQI7I76\]++!+=;;
M\+<W?K\G*D611$8/4+5'T?R=8\L7UBB ]D_ '4@F F/*O+B'C"$S_:H82%I6
MOP6\Y3LOO_L%IDH/2]S$@7YG:,5^WH+2><,7;S(<E>23#Y!_]18#49LJB_T0
M-"2I8=L&&4_5B46S/:D@@$^+Q,\K!)M0T8W2<N-VV6/F4_ ,%Y8"('(2=)*H
M1UU)>QO=Y.X[8/=$15+KIK-ZD^3I%%<[US9*'JJS#(L_="Z =:NHO979K5MR
M?'AA^K*!#WY_1"T<E"HYYQMXX=A6##?HR,+U@Y6YA)?>\I'(H<(RY-O/*J$Z
M@I0_;V)W72N'5;NJG.'5_K4HW#SD:;S>&!3J=.U%_?OU-^* FR7B1USC,0N%
MN.E]:B14OMVP%MI @J-'J%!^G43,,.Q#\FVZOREO-E$5@T=)?GP*/[Q&W#GJ
M0MVA=CP-Q^ZZR-?J5GE[L+=0[HX]OK!1FY8"N(881#W8UQ#SUQCIE42G$\&Y
MW<O:CEJCJQ//K;M^Y'ZZH _]3G=9=D"Y+.7T1E$;REQ=O0(LB,1;"D&Q?W&-
M&.?=C?*M9N?(\KK,ENP'ORMSR4,-45JS/)7_%WOO%=74&[U_1E&0WD2D*UT0
M$&DB)2K2!02D-Q41(4*D!P@$1$"Z@H" $.D@)=)[0@]-D"XU%.DMH81 "L/W
M-W,S<S$S-[/^<^'%YRXKYYSWG/WL_9SUGKUI_=EI!)$/<'X?537/!?8&(3-W
M@YNQ!16AROJ]2A41Z,]NM]BW]Z6=QTO6C"[[X5.OU%740Z@5%M6&5*^/@+%#
MC#1PC)WB+Z/=3 TC5I9-/,VLQI*YUJ(),/P*.:U9!0ON:/3K$HADU5UD-$$_
MC5;YZ+V1?J^;M)UR$S[W\SDU)R!B ZW:6W2O[T<C:JL@TR#=T\#4UY>L<*@^
MB@.'O&PD*)5")'6,1+GD;U7':(KMAKF_? CO0]*=!QN(]&R8PDOHZ*+0X!3&
M D2S?^C2UBB5"E(O":YCV0*4Y^\PF^3YM")J8$YG@&@+&)<Z-<2FZWX\9D?E
MJS5/>XBX2XYO7 95P5)3Q8R/_]K.!2(U@6<YI<YCZ8IT>;/DDGZ\<W.%9B)/
MQ (XD3VVCL\L5>W 1C\KV5\9%"2 \1[([3>)?5E=6[(/.B0.Y2BT!#[!3J0I
MYI9L7FNTA]/MIFSN.T4+\^=_#9'<S\5'$GXM#GV$URI%JIHM-.0U5%<TCWY7
MRE>4&A@VO+N1Y;OPXV^\[V&WW%X6YW^O^]9]&[_<A:0N4>>66VJ/3/2UO?V3
M8+ C7"_P@+D>P7-NVFF_KV-J]CKV+D"4GL08_!R=U*^TL8%FEA]3/QHPU'TI
MS& 5):8L;ZJ_=37S:-6<=V_;-9^$^ALX1.)0,4^97&0.E__[5MNOS#]>;K(_
M'(<>WYI%.<Z)JG'BG0C^EW2$V%QB/%O]7*SRQ'!2]N=&^++AB' C07/10)/S
MEDN9O[O'Z$ X;LC=],2B@8)N; Z8W.['[D.^Z0B-7IOZN#TLIZ6]8%Z0T&9!
M.B\71K0MEO)A*["T#?Y[(XZ3S9R(C<HB"$*>&.-K<O<*9$J'##K8HM :E^B"
MEQT$7$1^)EG:S'X9PFD+2</V18+?$Y;-$QYB[5'%>FV"5:.[TGQ1K1>$7HL=
M(H;. THKZ3Q%0(-*./HT7H#?.@AT"<?^.2\SO9_^UQF_XUR.;7!TF-8$ NJ$
M_?#]_^IFR/_XQ_\=S<QX]'\^?3$GF+NL]IMC9-=]C9K!5.%(UQZ="XN.?^Y1
M90V4S"CL?7EF*.$Z4-3;-2>0CJD"[^074P85UQ;A76[TSZ*']+TX:MJ[*,DO
M\];Z(7_B< ?)3LI4WU_$!@'%2%?9%Y[X%ICAOE3J<*H_VN!LZCWL_2 -X[4H
M)QPLRH2IB]ODG7N-P33$E3;+O\UUYHEW K:3]F1(EZ+WQ\CO*9>TWXGR4\76
M*W>XIN;#]I(4@7K#?2:$XUWMVX[8;6@4\7'P.+\0&7$D:10!IR<!B_FX5YW\
M/X\%Y1"*+W$!1%Z&&UY?:;JHTRVY@YD*7)!";!]@RX<ZVA\WCJ]Y^17/==]+
M60RY)$.4 !AOQ>*2[(;>!_- +!9K8J8(-AV-[J'NA(-K[5."=UE_-UU(4=_6
M+4_\YF8H+;O5M'O+WM/03E%[;8_$$4E10YY+%JH()AE #%Q$D)(0Y^GBC\3D
M&>!QV0NHY?_,"I LD(FKEMG)+DAC1/S/J("T.MAI,:?RGQ:OT>A=^?^C7:24
MT+[;?^TB$SS<BKY+Q"8EA=!81P>O*#\\\B.= 09^9!U^GWP\N>RULO?_L-ON
M2"#*@1XJBPOK$.N@2(\":ZHCTL3.B\TW*0*97M6[<<GUO<OW2K(N8?G#L4/M
MM>H\V+D$O'O,R^LVTR<C^C_EK@'EJF1/OF;I;AG"&[BCR 7PV5*)_SGZ&4!N
M 3A=V(Z\2?X*<S606WX=5=AR'(G8-0_,3+M2==??J_5O$$;6L\_($];D\!0"
MQJ\2I):D+BLHXC*17V:H]!V+-(3]6&4WFWPS_\)^6@9.UKNFFZ4T%,Y:NIK[
MGH;'M5]?K6F,<HK65#-+#KT4R(U3,\5S$7A*,"U_*8":> NW+C>P>]DR22C>
M[*E:2''X\F6CG)G^_M'3HV)KD[7-XX,#=0M"!?$!!('_0?[>K+P(#+,^ WP\
MC+LXZZ_$>>HVAM>_FTIMD\:A]YE;_()?B-?GV)\<I\I7@VW?9*35ABC)]JK_
MG518D FGL!'L"EHB/Y#4"M<51Y[WW%ZD&_G\NXF\)C0>59Y3/7+G:4(&L6?"
M="WUN[$FAXA 5I8$86[9: J&[Q[C00=,?O21B;S_K4K?A:'N[B\P7S/:L]FX
MHFW?ANZ9)^#>IMP13_ 4_+*%#F7D#! >GI\1E.6<<BD"&N"OXK<VXPX::79:
M #)!'XT8IBZYL:'M?HJ]>T^YG&S6Z&Z;D-S2S>A/1VD[ UQ,.=@1:GUZDE'G
M=C]N\<D9H&'-#5TK:\I3)*Z>"1LHMNK]Y;,.32,J=Y\!^%!@-9LE@?!ML2IL
M6>;8\?[@\/8%:^IP*L>0?5FING+Z .Y33@J=V1E =%B)'+X#Q ><ZK<CF7XW
MT^>B\R%^VI7#\G\&S2?:+T>H9A724>ON&HE6J8M I;#H;F8&.#.AZ0EE8H3[
MU;<9<HYEL,_@:*.B^;)8[%*RSOR76QIO9K!^5W2)NF99_^U'.'^*^E'_I^:!
M2 -R&52MG/)+H"8E"1>H7P'*Y#1NU/^]K,(PHVAK4R'@W>C^(JMI4*YZ<AT6
MJDJ3#97#EB5$D)0<R1DY?R*NX9'>B=L,70D#VP/!K\42 \8QK!"P+LXWP2-O
M*\"M'%%@*SU5)O/"ZJ7';NF5<U\]7?JM)- UL) L)&%LG+=A]!JBGD2$05G'
MJJ_7W")9GKXM#<W[V?"S7JZ[T_D%+<]%R&9>0L!YF3E&. ,44WZ?!WCC8$:V
MG0N<69Z8MGW8O]5)+[+3/7X790]X^EU\4.7;-^86*=@+5&AMP/<Q(>SE$D.!
MX%ZP=%XD\*@W_U:"6WUY_Q+G]C'V8"DU\C".OC/K>EWCB'R*E*,SZ':MQ\R*
M[Z<<ZB<,OAM6AA+61SNCIS7;(*Y[&V< 9K+?OL+_=1@:$6U^BMZ6)=K90F9=
MO.8)G)WL3V:^\ZK**9Z\N(05CFM]GK?/$?#J\ZEN[H9B.G628X&EYE_+J0<I
M$SAWJ4KYIS\:A,^E1GCU.XXSPCOANHO<AO5NJG.I2Y6'2/XAO;S11O)S;8XR
M726;&8VAW<!<"8^5G&*C_CT[(_XJ<AV2UFX]U_3<T.T/7J](>?]&U";\WL;*
MVUFCWZQ[#C+KJ.LD,-$R>#+=!<M4MV3'OKB;*LSHFW)<9=.*'Y9U]L\UGVDT
M_4+G+\2U[G$X@/D);VV*6?:=OQ"B9^,[-B;#=EY7U8O2)[Q]V1+81J'&'G?L
M\'DC&-_4WK^65>@WM7W#\DO=<0;5*M@K24\Q=EQ[U&ED.7F6E].^D)GX%'HK
M8UF[]0S #K$?N#6V&NY^VX_E0GU46,[?PUD+=]@T(A;UTF%Z68,@D+WIP*0N
MG%%&+2G9^ZJF.7%:FZB2%/4\^2JG"2\;TVCOV^5HLB#B+B&9*$^2);1 99JM
M%HA\AF<  $_/M+[++%-H7M3GK\R>H'OS;&YN4N=B/6+^S22P+$&(D$:$000'
M6UV C/8P?L((F=)?.&4U_>1GZ:_VJJH?NUQKKL[W-K^O(OW^\QCYA[!JO[C1
M9W;IZ1M^%S<@2PXUFLT>Z/DA0\G=H0A8%:HC(>R@!OT!*O(B;_YN,M%Y2*W5
M=/QQ9=4]FM^\)A!FO#\AZ#P>N1'14+E%7 &H\?MGL'3X2N?[!_NTO&_]N3AO
M7SAY@'[8Y6+XNW@(&1>TI1^,DN[VD;GGZ5]XK 8^Y8_3O/KL2[#N9I;Z))(S
M>'9>'F<>FE?;H)Y:LLG):2ZN[B)%O:A^_].C:V]#/&*7 9.SUIRDJU0+\14Y
MVC"/I0;YM&CJQ.YCH_J#)>"<"FMR C$\'-J+U8<3;J5&M?V%O7'%G$KKG1YT
M.52DML&X74=< ^ AI<%30M=\*[,"%5Z+"7^)>&RBN^GQ2Y.G5(UC-!EF'Y:9
M&8#XD8JI6R9[JW,36I:EM/%$<JX\,S/A4=^F#(-+_]_\SMYJ](5W[M)Y NU7
MZ#B,Q%SCRZ+)FJ/>!/DXQ9'N<=4FD&7BE21BT8^KS#UT:Q0!DA0VM;U%JGJ/
M%A*,?E@#Y;J<]T USUMZ;=53S3+)SL"U[(J$Q]$1;')3H[EP2,;H\7_?V6A_
M"IZ T<,6P=!+.,.HJ_;NN8RHF6T +SE'(//!\7,NX(+/2;A 9QEL&=R!"8=?
M=C,Q58@O$Y84\A0^L+VMC(]5;<!W!?^:_$S0QNL3C!8<>#67R,SMLI:$"*Y7
MZ2K9@9Z;\8MA''%YXO<<8V6XEJ\6=VGEKY3:9=B_*=:MM[ZO:S\TSI^P"&2T
M@BBUGQJ&%6H)_AQU>UD=^F#]8[;V<JC#-X'JG3',I7.=%T+/W_R9OM<Q:FOM
MRM+#Z4M(%(E^D+;0_#:_]@S0-"J(,@!EXB8[4 RD)\,V.N=7XUR^\7>79?XQ
MCZ,CSZ<CK3. BX[\;/Z.HY5[9F]T=*&$T>M2?Y^UG0:L8?\C[F+<RI?AN[LV
MD!=IN\QU7]C? 9]*'NSA1PB]95"_B6:YI0CLRF#HPJ^Z:],,J=]I]\RL&*I8
MLSY\H>+B9:%51J]K1Z)>PM[;<XZ-4/I;K]VUO=G#.<G)^7F-TO!+J'##SJ)+
M9FIO\;C[X^%7DN/BV'B2'E.M7JKIS!4S_"Y5KW?/"6?8-\=H<UL<W)D<D,PE
MGQYD.-H!VY?>@!UM<5)") \XSZ,@/)<R *PY \3O-'O(IQO"Y>PW=GRQ32>O
M!BL?_Q47 TD<41%"-WX%Y]K8H)W!5UFE>W(>?&P0HZ,&K#8?+/EMKV$QRWQC
M?L$RV,RLLH!H%GOJ1-J^^.A74<D?^4+O<9@DX><GU$%[<K$6%7B3?1(MU+;1
M&9T0VDA2YT'%&/_$,27Y@)T@(=N^K[Q-#Y@RT!L.@. .6/5@*/&>/031AF$Q
M.="JJV]BBX%7J<*=ZA\X)BH;/_3X)O/ WS2=+(HU>N_M$*G.,4I26IR1V29S
M&FGPU=2E[Y^X6E;P9*8EW Y(FJA/^'@&J-QK'XJQSAXCF2[,2&F8@%'^#(G3
MOT3O@R%V]&> UJA\[+,OV57FDS6[T83BHB'OO<+@PD\0(H6.:Z&@-D&7\,(-
MMGP&X-RDZ?E9\[[[S0NVK LP6;,9/M\?WY9_'/WWN=Y"YN=-8\KXO+R!TR,0
M?3Z&?MSVN1&^'MJJB#NN&HTFCB["MXG8O052@LP'5;$7>79WDY6>RT_R&)D=
MY-TFJ&=4&$,$\'Z$0"P&S5T8JZJR> ;8WF-U?6_6U$QTZT0^3WDH#!?JZ;F[
MR0QPO'Z=X]F)R]@:1@MYE(]R2'WI[-^1^@O8L'6NLW_/ &\1[_T<^-2O;-[7
M2KV>:C^Z8J=M&(M;[0D)XP^RXFK=R:PY6-OV(KI 0*WSE^L(/CCI53##9CJ]
M0EG-W%QS./\=-*O.Q22>[#Y2*\.%00BBI>074H@R"&14EYKC07$0@$9C>SH=
M]D6@P C <^H4P?('AV+1'^>9S*=M3H_EDPN2CVU@GY<$JB-WEK'G;A_#5-.B
MTF8O3)G#V1U534^KIPC3N@[F0Y<5 9<]=:9U>_AHA'+)8=Y  6N2$-R6$%H&
M"LBGU'A*W\Z>E!&M3Z$W>WHUX4YBT^ JVJ/ZN'RTS:&2LVTO<CK=E5LF5/ZP
M)2X,K;#5'^#XHL?I8 [_>?,.Z(]K[IMBM1F2&A!!8)7L3_9^J'G5A.NDX0QP
M^<+H'I*),I)%1\C.U6(#%2W#U3AVI2RI&8*X%>."T\HQ%-J@A:GRZB$^Z*,Q
M)?W '_;T5U:#R^J.JY261L3(!P[64#."V (B;MHI!;YLQ^I3HG\K%K^!3_LN
MVV"7MQLUMA#?N5R8[P)5(8 7ASY0..JP:^'R72/>(#]_H5JK5ZD,VU91_EQ?
M$XT\@^[3B5,V[QH-8A3/S>6-,B+Z6C-BWQ"SZCU^<HOX#.8:/ 2L/NZD&?YB
M,TTH-(!?\/S>X<\O@J[_HBRP&TT&(>0(Q41%Z#W"U \K5WMY[/26TL2[#,AK
MHE-7@V7_M6EH,:=JHO_@7= MS0;1YM%#D*E.K_#H/FA<C5GR/(?ZD-34Z<F9
M;WUNY>SOJ6KZ2.<0(]7MH?61HZ[N GN3(XTHTGLP;"OL#+ NFH.EA!82+!Z.
M'KI)3+T]_*4^)^56-I8H%'=5HEQ7>.%"KW))U>,ZEF83QIY-L\@B5>X95N*\
M$W^C3&-/7S3>=_4(E@%41BTDH_;5H.?6""$))G,?;6&PIG#ZN2W8!>\=O6FE
M%#4AR^C N%P5(<C?! _\; ^0^Q@6_E\JQ[SWFXY;>T\"DN.\B@31GF< MWKX
M@)EP:-2KY\IB!9+(L>H9@Y?M2]V4"9X9R0^R!F"/ZXG*++$<3JHLVHZF-L=?
MECD:R7S]'QI<]<#.L"[+DP2\-#D?2KN$B."GQIXO$'B91Y_UY?23"IWR51''
M!A[WB<OL?C3Q!(3@^4*%DT0F26(X^HXS #=)EJJO5G36H?J-S?;HHX4.N0LD
MACMY^&E@BX,I1!]O1#!> /),$YHZ*"R1>I,[5M/T,8%-(9]3M;0Z[9U3^ZH8
MW)95+4I_,?B=KU5._]5HL^%NL]"%]RK1C95>B25\PIF45Z9ZM*,!724PA] #
MBPX805RLW>@ZY/7$GLVD=KC/9Q:E +=#MEHTU>J48+&%[1KO+OJIY!IJV@M?
M/QZL NGHX+]"X/D!"14E:OBGQR?)XV7\A0 <#TP0*T6SG?54R#MW@\MPG-M&
M6/TN[AB,/0E8$>VK+-CNOWTN;ZAW/3&G%E[8M87"T&"V]HU% ?J-:9[&[<"/
M@G.J,9.,DDY_ J_)MTSI*KM-,5N6:.\YQ3A<(#<M/K9GFD2\'H^=OC>RAQ#[
MG)>R\!7:('R[,['S[]]O?R?7$K:/<:+'>%;"T!+X$NEQ36-DQ_1GH\-U0>G<
M%R\X1B[T=_=U*LY^>G"][[-#8?( 86\1'JXNY@(J)" Z3H-;7#]\G< #=EC5
M])3F-7;SN U-\/$_MAK7SP"+H5KJOTR#%/?/ )&JJ9T"=9%M:LR:24\3NF4W
MX]FAYN:*2?+[WUZ)7P:8P&8D:+P<I"D#]NPXFAT#XC-7 :Z:S/OZ HPNDS"7
MD!ZF[N2K(LU7C.;%+U:Q=C_SGI7<;)'YSU#GN=+ZTX1(O4IC6JBSJ+-@#9;M
ME;S)WVE1NQ%@EQ)9.//'9>*=I>7,]W@>&\N4>[G&PV;/ #0_?\3E EW&W5;6
MR+".8ONG^"!^2K#V@$!=X0X_AE:5&LG^6YJ9)*HN%)>=T"LV4%,+E.R3[7F]
MPHGQ$/!%!/?!*H.3SW.%YF[<4HNB2IES5PJQIG[%N/'>E&'_N\"W-,"]Q$"Z
MPSD0WI7@L604Q4(X-L.NX2.C%U.4<Y -R 8?K5C UX^]*R'UEQCKA^X-*6R,
MLT8_34S9QXS6G9P!VB0,&K13W^QL84@)@T8A6;?'S@ O8=- ,X+%4E.*.L.D
MF'DE,O6#N==':37 <]6Z0\FL&'O4N7I>(] 4DTP(@040> <^T0'$S^/"#;)\
M5IUD77^Y+W3\TX]:FI<8O6-X-*9J[SQ<XO8*47%0%?X:Z:SK-KKXM+(Y*L=W
M<^S%0J%MPA8>>1N^I_RISH76M-<F1CC>WY1'2'YX"K@\F^(8.AXEUI OO&9P
M"QB@ I1.)<%]_GBX<O#FM$PV'FR!AWJ/U;7^>R$''@*X8I@.XR31UD,DH2S1
MT;*1";_&"*V(K9<[;"4YGV@!3C8TRMV:GK":XYV61> UJ!H2R]D1V-"L7[+5
M:F5K-V/34]'%SL+%[ADFA)KC>7C=<?"=Y(817W O[ I2V-7$]?YQ:/7)7O[+
M_5EK^5JP)+^^<NBHAWI9DC60"?AZ*,*!%GQY+1S*5[A1UW\,ME7K:G_U?"?%
MW-F6R&H&Q"AN^LS/P19[(W=AD:.@PWO@/[ %N[U6S'OLS-:=#!C+EERFUBGU
M%O6SVQX"/D]I#U^_F$;:_2<XL-X_4.5SF:07($NEHW1+?@7?#!YT8*)(0JH,
M<4K14#5R<=G&,)JC;'+&_>;^.&]/[EM/B6]R[#UJ01(K8A*_B_ Q1G^3HXQ7
M<N\'O4H_J?,:*5D$$B0F25'J%\X /\.'*#'6Q,IZHV@,53,[#HDVJL:5QY!K
MP"^$]-_"05F,L:T7O=B+52],*@R92'M4[J*HTZJ%<W:)P!Z'D#/ _N-FJC/
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M?$>:-2=]WIN9]Z,67676%:&*TDW-045[A["&,F7/OKU39&2O0R5B!X9%#BW
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MUN#8HHKI733==GOR(-V^(2TQ6\H]91VLKU2E7IB#U!D[$N"C_#H#7%65 9=
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MM>$R04P+FL>**@1 !BZ>I@?$K_90XPR)KAEMYOK>IUN;O"]G+[Y6;BOB= Z
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MY('1H"MAHB[<!D,5)9"+[+)J^E107U\7Y%A].WS7>8!]+C'H+4O3^[A1>,M
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MN[ISGP2)7'(]ZB1;$>%,'<@HA47!Y-OUV2(6.]_?/$YV0JL3=D/?(T5PO1W
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M NMLU]@-YH<]O^F9K_48O0+'GF6U<FRB:,G4HE%E-I;S"S7;Z4+;MHNJ946
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MKC%*NI>XPGCWKM1XLH%$<N!=U'/2TZ]D_3%XC06>MZ%@P_-71>S#L476JIW
M++2OJ'?JP6J06<WV;F<AC-+7VCRZ<2QJ-(_D@^I2\FLTW^SH$V_ 6 @%GV@
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MM0LQ$#9\75:-U<<#BA -<.=:R6A$(ZR(C5+Z/;[U.EDF6BW#?,_S<7R;P#=
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M%IVYLG%GD_)9?F4QOGVMK:H.,[WP\U6"INF1R_5CI:/XTV'/?;CG&@W Y92
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M6>+7Z#W5W1'KS6E27I0^G94=);_*&\1SGH=8V3;IIO/5/K/6'4V^>.?K$P-
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M(@T;+@Y<X=)M]^=Q+1^>L2\^M2BR@_W*%:VJR@U&"I%&Y/#QN>9N9N<N,!N
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M5!]XNUB7+F);O2T&PO0S4AEAVXW1('=TCKC]^K/F1F5OA$2NV8L50GE>1ZZ
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MP3W)N^'C935$1BHCZ,!- U#JDEM#B4?DZ-S_.O'<AJ@Q+GLY]^?G:GQ/]5]
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M^,8^,6@U0+6\]1U-U_ZK;/?X7&0@7LZ"QN",I_JRKDQH=#$MVG8*6G>L:&N
M^U6.7 +MYW"%ED!0HO,FH&GWA11:6?V)6]Q.&8%*--MOQ+BFNSO-^;$E(5^
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M38OC9DN*U-F;:X )M.-]AKMO\V0TI[/_"4T_-R)@YE."#.A:Q9W"^L_9Y5(
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MI ;T&Q-E+=]]V3T>0%IJ/JG._^V)_XX%'QQP $>@13_T*;RTLV/!4F^T1%6
M_K<[, 8=-#3P5Z-6S9B]/,X\*$,P"P?CMZ*W[(QOR1?.M9$M;F+:B@ &;>U9
M4T4;F.!A3[D"7:(W^Z+>BU[><Q(EU"_>S+K!ZW@%S'X'E&5?]GFA8J%)*U^\
M@%)Q#AM+*R7))II9?'@4D!GV^,J7]:>1LG*+=CS1QI.5 _=6V&)@^SS^OXY)
MOELGZF#30X[,I">UQL3G)+K:]KELZNL:HJ1R>WJF_KQPB/*2>T3#8QVF^+:/
M_#G95T6AJQ4I_F_,M#N<\ !GV2)I[(YL+FK/5<]_KO;^Z]-Y>4 :"4H4S$>:
M5NG^RSM5CD'[Q0T&7:,$<<$._OS>=\Z GV3:AM*:T8W/RNSY-$=EP=E;D@MW
M):H3A]4>D1:@BC49FZX>T/Z?QOA' ?NLG8E3/+'MZ?:5),E4WW]'ZD3JM./4
M->+L&K'.4927E=->$O#/!C1>+'NV(7"F:33A+PGCA)YIMT20[04H/;6PW6EN
M^W*O;M<\4)&/48AY%/HN*C 7\6[#QR-US1O]OB8*_6>FQJ^3(N7]LM1F4I,B
MHWJ=S&\=%:,;#'J.8)W*X1WKIN;ZX+Z_C'-"G1T!4D,^%?3^P,I@H\PZ&IPI
M)RD1D#'3GHZ3J"$"EK9-7F+S0O!:>TD2#;GV>X&"U9(Q?][XI!:[O& 3TS=O
M6HID:ZO&#I;8GTB_HI/HB"6L<NL[V #*6:1V#=,QM;)D1(!"30@(XP@C CJ'
MR""*'U2P'UMBI3.])MN+_S@SNAO>XAO=GS2Y<H_!LWR\!L8CVE<\_I]V_C("
M/28.U:>LWY[VA Q_JY8_'R)35W2]"V* LQ2:@1UMEG9O[ZTI? ZF4F7R /K?
M["U-\[_]6.!' RYGH9\BH:8.ZQ$$<\ZC8D!]XU\XOV,B1G*5589H$WO]\MGI
M645/&'>?.FF($N?/**IG.N."1R8L9>X4M8*"&6PYM74QEI$W71*LN:DU?21F
M)86T34/PPC0D1,#0[N(@GLV$","ZEV5X];_ *DAOH-:2B[YWF1K.=0/1I2-7
M;OF_PHIQ#<)%H)N#O\<XEH;;Y2OD]E)MF;%8OUP( IN^]3PC E2/4/Q6C ^L
MQ5!3!]&?$=1P]X428S!6)!(<6ED.79&W+F>@_250U7SCNI_XUI&V_LS'V%B3
MJS!2ME!DC"_S*E+$-+KTED#OLK[ZP,Z#GN,E"=VAH$T"C&?6-4&7)(-E08O:
M2VIS3L-N#^_I$)@.LSYH##'D>GZ@>7T$C"_+W-8'WA]Q%)>36!41%,ZB:Y=%
MN(\=B7E>V_TO\<IP[,C9;3Z:]VNL>+'Y=ZI'/\R%V<UEC\J;$'(A>55/![\(
MB<\)O)0PCBQ.<]#DF.W4JV-!F49=/@T[ZGMD#+2J=2H>E,"5+T2SX:KW->+:
MS)\2 9_-F;4GED"/FE,Z(O,P ()[Z@4(SCP&I)Z&EMM+%TM7HN+;--<46%[?
M(7\^6""^_4:;R^.$4/^Y:;<MK!^)U0_/W9JH-ULKL[ KF'L[,ZWYX8O8-"]5
MJ,;:"FW+KO$W$@7("!%0(\:AIGX(CZXV48&M[<Y5^,3_%7T6<33@@K[NQT $
MM"5CH!L@5#KJHG1^>Y?+Y@!XD#]3X^HV,RFWG85-C!(3"4&!3O)"W<F/9FB>
MOJ.KK[#ZZYSQADZ3[.<.5%-M;->]1 )%Z'*KKZB+M ZV_:LW'"S/%4119!Y]
M2#8,@@Q5*3)HD2@R^J/OR HGM6U2+:G?<]?_^DI0_<C<^X,SD_7N]*"#=33W
MH>1&<<W5%W'6)_%LG5 4U^^;/2_5,A5=2 D]K(VXYN-1H@IXE!GVO[?2=Z-+
M-L$BC38NBS*^[UC@"DXY*^4D-0  [Q6>O'C.S1ZVN;'I?/"O\4K\:47%AK82
M,.\"B(G=Q)=V4S/5<B5@<<?M0'FL4N12LC??L#N4PYQ\QK+7XD-<8?6S?\YM
M9;1NIOY7_&+HS57S,C<RLPP3%_S;3?*"A3===;V1'LO6GDY;XN0$?U[86:C@
MR!?_[%]8SD))TKKCPPK8_/>%5U1!:.VD&29B[(U3T]*%5M+T?IN9\JH_PQ[\
M?"?)"2:=\!>SS?TO@_=,1_!:&(?$@&&X28;XQ&[:B[$,D891IYVU*P]*^SPF
MZ>E9T1DB^9?+_]/,7;$FBRRX3X5>,)-1]P?#[I?4&YHWEA760J*?VTY_$+U%
MVNRZ;1ZIR*&[P\&Z=W^=5.[C4D+8HZN2\PA0]@0G@-$E,."1/(C=]%W$;GA0
M;?<T/%W B0"\<+JX]-HT3S?M -'+/G59-H+S<)93X,)XYT^X)18D]KIV'/G(
MI/ZZH(*0R42 YA%9=9ZFHJ*[.U5\8]RL&OL=I9PT(T/^? X5/G\! 05L30A<
MVT605:(Y9VNTK6$EK.O@^0\FJ=[;'9_2C0&HS+IH<OQK3'>TB#B;&:EAB$[M
M*-KJCTOP#6KE06XG%K*8F'TS.4Z+%09ME=&X%Q2*5AOFCX8;M1E&-E!-467L
M0K_!Y74J;9*F3W6<?2/MKQQC,"9.8?:P#]H_\]UA]Y[.P:RI,IW4F+M@M[_<
M #@;:HP(%</M5S9L.ZKVO=ZIJ_AA%?E+6<J*E_T.>/$%TW]L73)O.*7#7E_H
MSXIG[  R'76 =-C*,JYNP2A;>?FJ3F3'].CIC;_EC1LB:2YQ__8?=,B(K[.>
M=;M=0?IOFGBFJ!BZ"GR2XCB7+B*#W)>3=C4> VAK0:Y",L'5;-Y4T0YZF^5!
MFB=Y3/Y*Q=,%DBU[9/@2E4A' L1A1%Q 77_41;/22*,"7.O.]BTFY@73QC^K
M*N: =L\S8^:ZIX\1M)O29MT0_I/S1R8'UC=+-M(>#N/5*=2RMB:DB]5.T[I6
M'VH?\ZNS[;"QNOT#TP9/O;$*K4F.HR9FN(:75;6ZP<&.J@S.ON1"27.C[FIR
M[X:%BX47D%6(!O'*\/N2PY^XA]=N%/+G%A09;GC0H>T-$LY]OW&S"#OE&&:]
M3J&LN$/&2^T+95/%Q2]R?-0*ZU;':H3GS_>G"Z,FM8.-N !Q0?J\F%OX1S3/
MLC/_,]XRRX^) !9;3@9; Y-)L3F.W.L=XA2U"Z*6+#.-$<L\>?_<CVE;P'!=
M4L]S$ &M5<U$ -,+#G=& _5QP:IPL89?#0'GXX2=DY'B4+32]4##^KR.,G);
MSX.I+7/^8;&+J5 Z$S/[)YWWW[^W,OK$?@?!*NN_^:A4@<!$YD\$;'A@U@E4
M)40 KGYDJ-%[L8S!3*XZ<DF(SZ#NU2$K&]M4KKOII]J@=R]ZV2^&;NXRO&&:
MG$!9I4QZ)M(:&[<%J]BDMO':/Q?\XP7P20*DA:V %IV]: @A,&K$ @I]5<5+
M?,FZI,G"* ,5)X[F3+M$B8"W#5&^S6;92_X2CS(+[8VK$L)M)XV#5ILB?U]N
MEEH9#OD:A3*0.(6M':&_^-V9$$Z8:.\T?G#<SRXH@8H0?0[\I$!O]@# H"_<
MM RCQNG;9DY478J $_3F6"'S8%(ILNO^.Z("@O"W&)8%KYGV;")@ROB?=?RD
MKF]L7IIL!>&,S1]B<LLN*RY_7 :"4E<N$P<."6X.-CZ[%]\W?":S#>WOUI=D
M>^H;/)DW41:-,^GA8/8))KM9K(M[GS-.IE3_Y%^L]/^]*B!IP]O@+(@ "L]6
M4=S'"[4+/CAVX"2=YV_7B(;$GGFS\:8L7P:B3631EP=\2!B]3+=C+$NML/E1
M?FUO)BYB.5<=JOUR6*P^<#SW_'^"L3YUW?(^I9<UQAC*R3/BEIPKSQUP?O[(
MM*"'JNH[N[/WR4^J+0&0 O9N_!+TF7?6EH=/R4]7EK0NMR2Y=A:S/N5!GFB?
MH?^&$KAZZ<SKBJ2]@R4!-4.M7L'#VE>1X <_H@$TNEJVYVNI2P(,32-5%&8:
MO;T4+C:B_6QWG%]8\3K;7CO^9YE>-ATBTV7:N/BEHJ(!D^[S/#Q/W*Q@^XLH
MB8/EMD]!EO>TO/ADI'K+7#/CX_=D&@QS,C=._#A''(X&@#>JRRN_6 0S;A1F
M ?10CPH=:SQ4]?7E%1ET6-:YJ)!TH$"XWA*"?BLI=EOZI$9BV?G7]PER\-P7
M><N6EO5A@Y'Z,F8<CR+V)+;>NNE=?5#8G[@SP3]9/FG/K[-_]!Q0*<6-MA.8
M8NB-)MWF[LU:Z9\?2*G1:-<%VT]$_@,Z^LUV(^X"ZCHS4H?%ZRIQP!\ZBFS9
M]2)#TC6S%79V-X**]2>&NF&PVY^CF+_QW__D#V 'W%#_;X2#SI/9;-+ ;37%
MAZ7%+1@.II,WL8B[4U _42PR9UGQ%T)T?N1 XHUNBK^:\IFIO_/3%,IS@V:#
MIXOH+VG,6.OF@HTDI7*JDX+<6.&29<K;%M4I=("W--<+I$K3"@E;9B1X]:8K
MB9A]Q3^H5E=8?8LG#73!CHY7L)ID0Q[Z\_T5K *>]_Z\592 2\40^I<\ ]Q%
M:""2WVH>?\^;J6U_M,I.8SE3V[-O8BS<E.L5U0ES2U4:?5-AS2\LF&>4Q?LO
MX#785)74M]3XN[&8A4,@/#'!FC?M?=IFYU7R)%)0F3,Q\?QZIAE.RJ8V:RO1
M/G$+I^T(W!O"C4K,^DGT25D,;ZQO7L^!)^S=U$Q=><3Y)%01\JPAT:!.8AB<
M>455LBW^*>':L[>,Y^5)^5^_V;%AT9I:B)FUSLY,6/!>;T5_[L<@V_5CM[4(
MTY/BT.H&Y)@Q2+!'Y<$;RA226)]C2_,01<87_R$_[6"\ASU?VUD3O7G?%H;=
M5.$] GAF7X]?XV(CW$:TK83+:^ZF[R!V&H)K!Z?A1("DC-?%=G3#9%H5>L/O
M_DBCNC5,S%=C4*^2VO+9U-\X<*VE0)T*RXK+OC&#N_Q(ZW^E'/^KF=,N:TY'
MG2YQA3N)5.USV=?X<<3NS#T,R&^3"GFO+\K(S,)R:RCE7=-\F/2LKZ#^:.6%
M(Y]F=7E%D..N4):A11!97V@6@.8GHW78X_GSW_I)W)G_IS14?G^DQ\%E.MJH
M^"ZQ7C\#6C#]_)Z3X)J1Y3MJ<LKL*"KSG[>-_\;8+5$]/'R-#-6T\:20%W,<
MC@\FQT=^ -TD<,SCA3 _,)==I>+ARGR>%5_;++TR+=.%D)8I=!I>VV9S#$(B
M3C^/?_O^5URXJ=[8L22:J9YG9_&5QN'"(!W.C5,C FZ/R#GMG6H34)-5R=7U
M36.R92*>O(4W>ENNEV_/-]&%W8U:.-;_M\&?_$V$#&B.L8K[1U>JU&)+$?&.
M3[3@ LN68E^^):X@N+R7D%@SO>UY_/3FC1R\3AT1X%]$_X+C/R!03\[$\->0
MVQFL2F;&5[I/T#M1\D.Q=JXRJ6 '2>P+O.VU5483S;$2\8_,,$'AC*:*'YZ=
M+C#N6$F(WEMG\$CQO]-&Q;=0Q!U9D<4B=/D6@7=$K*@I@S#HBV 0=92CGGCK
M? 6H11) P:%C=4Y'XT&CT;VC? 46D9_UX$\2$=7K9+8MVW&=5WP,JJTGUF3<
M;UH>=J'16-/\^[NU3+B1OO*L#0ME=F"/'/_<_^$@XO\;8^3H[-#_JB)[P/ND
M*V=>A9F_\%.LBAR@0&"M;(:G@S5R! =N987O7]L^]:J=3D]5R,Q,UZX[ %_<
MCVL:LVSP>&RB?V*<%N1]H047*4="562-G$:*'(6H&@_ Z39O^,&U4F6OAHYW
M93KJ':2#XWQA^5-_1!/OCI I;(G*1&N,]]@VD^!),S>>; HLFO%O/5H^0'TL
M4EY-4HBX:T<^%S=9QE%NFM="! 34HUN) &:OGP\NLY$T8\R]5M9QRH>O6I$Z
M+3])5WCIF-<IWI1\!#5&.B):CD'T7F5@C%/">51=@<FFAZK+NJF4EN9/#I43
M]DF*',(H@M(]?*6B!FM5_V?=5O*)^C6;RS/:-W[N*]*K 7#7RV)A,:JW<MTA
MLI*DDE/A=Z+>/-PA IIX(LZ#KC55=(&NP1F7T)2SF^#V)*M ,<6W=16542S<
M#O#BXI^<-$XA32]A,>K'DROF*7\YFI\-T2G&, X'9E$&ZWX%EWR0N.)KLCSN
M2W*6+\WL'QW+<4HD$9XOQ_)^8O W[.FC)W7>F-ON)0(LN9CM66L"C].I[9^)
M'=@RO60VBU+^4F/Q;(.%C;.#>GR]GJL]57+)9A>R' DR]$Y^7>-9GS3"]ZA&
MQOA)_@K[;B\9AM'C=,RR0IUP*^:C?.]>$N3+OCX14+G>SE:B[D#?F=#F@1!\
MUBJJF+)\:?'B^^E?@2HL)%(,=MW+Q\S5N.ENTAL3SUE!V*.S4 I__[A8L+PY
M^$(!SXUQ+VMM\MEJ;T^R_N&9UR(LM"=80O>8H8B:XM'U %%R8-VV27K%K#-N
M<($F^-ZDT,_QGT\JU1E7U/A%NP7XK0SO.#,B^$WR',>;N7 6.^,GGGB:I$H0
M"UP2F]>USXP+7&+$-@[S>I@)_ U;C1\#WMF-] 3<<6:F:1H5/\KK8,)I70$*
M7DXRC"<4)WC&-1VY.HNOB_A^<F;Y!_*5LSG26^1JGQ9V2?5QFUB-K@N%49A#
MB7".R4=HN/)*U!UA=D"8$M.G*(&\RVJ'A5$"U<9)]:^K6DA=1.G2?OOZ*VW*
MG_R?6@ >C%3Y0[F3)GZ^\#Z5^I%F-8*9;+1KLO&P+-_"<$%EN-7B!9OX-^E7
MG9:?WEC>)G&XT<T\X.J)YI(ES<79MT/JL+QW-A,OD'V[#,CW&89%M'?1SP !
MSVH8?V 5".K-QD3 +S+"".,:Z/?@553?WB8"J"O1]-O5M\H@IBR686S8-7E'
M5M7M*DO0X]X;7[@/9BV1A^$G<=&P0\2*=7%!FQD1T/ML%J^'M6Q#WAIQ*]$T
M'O?KM"JTW(F]3#.2G<VW:,O@"9#^9#0OC#M>X+JV];#=&/N@J6HKHI(6S+N7
M]H=''^4;1>6UOMMI_Q6GV5H]L54]_. 0S-J5H?^$!P @>R$G, 'GP9"V$#B&
M+"N27Y1/.+TWFY0\SZDWU92).7QJ<STBK1V@_W&N- H=8.6PE*YWGOHP&LO3
M=GX:S(ME3&BP$OYR%SXS\>V^8L1[X ZC;!0U#<]$G:_(23S.KMA^>+,:*5 C
MJ0-*2'-XILCBU/['C>)\\B^:W(]VHWZ]NXS52U-+DMX+!DY3JZTLER&WLOK&
MZ_>6(%2X3@2,IYP;[.IA$MNJ063[QXXB+T;=DG<EE-]'0=G>? JK# O2:)&D
ME$2H)O)FL:9R-+FSJO>V%P(C2FFZ0!R-9 L<+Z:@:3S554V09ABKBDQ>!?EX
M6'JI0.*H'S?$MOGW0%F86N+8SZ&Q[,A#>N%AUO+C]>N3G^%4N!A,="N2^0(<
M5I*LCS5;*1-?'9]//XFMLPS2?^O2S1N5G7)2],W;7I5IYOSR5G@CCX"3K^5"
M>AB0 1?)7K(XX#2C:QO\_HLG;[[<:P=2DOT( W6Y#H]?O6(C@O^&MXR8R2@_
M/J^[DTO1GQMU,=-<KQNC5L#Y,^WVCIE)HGW C>6OINS47G+0280CC!YBZ"7R
M"G,<$4D[*4+IRM@C'$HR?238A[BM@2_(*?+ -_^QGQV0S#3 $P$]^P\O\X#,
M"@5L=[&.!>D> _V4 W<1V_GJWT_GP@Z*MGO$:69<7]95)<F$>U<.80?H;X)U
M'>]=IVTEFVA"M#4#9*D6FRE0FZ)>-FIC'/=OB8^O9JJ)_07_Z9RB$W6-X)0Q
M\/>R;*E.IVYVB!11&LV)/UH-4"G)C ]GIEV(:?REJ75+ZIP@KMJ7:=X<]U"]
M7L</4@CL+&1=:\KS@KY.UAZ'_1PMMF")75I[$8I,25L?;8*4I30["I'ICS6*
M+,Y<F#P_YF#3:+2K8C-4655F,RH?>BLU-^-NPP=E531+'6C>5<34;QT[ZG9^
M%2R>45!QE 83 ;Z5%B].!SP(/-BN+XL@RN90=X'C:$5%L.17I</<26X!&L&G
MW+'/2=DG S?3[_A=PRMCVFTCH=DX#Y/0URH<QP$S30V6))];'*]S7AP@6/>1
M['@60BM.QG<A5=-$\\[F:<&3@-7[J/+.^Q$WV)*Y)0SO?!Q7W1*>*6G$?PE7
M+SI&]_\Y@E![A6M@G4)LBNTD!;SSS/)^4&X5-R1*;;30]LC2I@GP=1$!]++B
MF!5#1)M"@:\_NN==M5Z 49(2<\\U<<M9]^,RULLHO+QKWB:2%T.=[[$%Y&KZ
M$%,#$?H>3#HEQ4>XR9\8RL/%U QU!*EWIV9Y 4EDVPM_!+,1 0JV5W72>=SH
M>2?8IJQO$K&Z)?3F_6K]Z/IO(N#9+%P=*]EN3C51Z<MC.(;LSM_:X_D=LG/0
MG-09\"E>ARF!=(VGY"TN^B0,Y[HHIZ,NHX-5K#=7FGD?19Y32S[7:COLSU/+
M%X:-1EVH.;HN);8+/7=Z7P'MC:RM#=GOK+=-_' 1L>(K@#HB J:)@,63U$7T
MCCNF.E7LX3,V4U.3XD2AF'X6Y;D&I#SS;EB0)S5" KFT:CL8UPMJW.!:D@SF
MP11ZQ1_/, Z96L$BVOM!.]$GM3PPTXAW=6A*OR$TC:QEL6*.G?G#@(]GR0Y:
M_92_O",OQT7O!VB^I5:'KU\(X 6&&RV6:.AF<)_>CQ?+RGE6CZK7?JTJ^[XZ
MGFU[_K1#]?G"*5G8)A'@H!E,X,1T!QPA:&V-U=.^Y,_8WZ+YD=?RRTE?W^*K
M_S4%;NYC]M$/$8Y\%35+JAKJG4YE.*[77N$=QHC/1S(#$+W:"^%4Z[3WAPXV
M4\A:+17\C0\UZ1QPLCR<>7>'))"G)E 5.7=BQQLESSMC6,08#OO^@CNZP1#"
M7+8RCK >L#^!'-=(B[F"+O[D:QZ6TIP8XIXMEJ@M_DU=,G-JXT!H-1K1/1BS
MI%>$TO7TT8DYY%_5@BX_V$!MU6-P53/D@$ET-:*!"&B1B[XJ(LR-;-C[=MR8
MO298OJF2I'B=09BIYSU>O7=R+9TNH,J\+D>912+@<Y70_5&3N-=8W\Y*UZEN
M=M&[_%: KXNJU(SG:6C50QI4>&N29QOHCA>XVX^^/$2Q(>JT+TV E_;5"E6?
M!\FGKQP:TH$#/IZ[<IF;K#6M9IZF<:\KDK75E.'ATT+#>9&O\YU+E1: EBUR
M U:Z.'A_5H585)RVKSO$6W/!8)=VL8S."]8N?;=@2;(1&]_GK:OPH'@FS;2\
MU3D9N/?\K\ 47&4IDJ^-U30IJBI_9C/AD;-UW=='@V_E5([8)Q,) T@*#!:G
MODAENB%M,8[\^_X",;5\> JS:/@STR"UGW0(8S(JZ]I'U<F*%+'P8= A)?BN
MBMF7S\F+.Y8O_FYEGPL+9/J,K9C,G1LQMR^L?[0[K9@40Z,\%X-+X E?O7[/
M6;M6LH4^_/1L;^\3> DZFA7S,)(W<D)Y]J:^[E?Y#?FC4OI.R#4\[5(T]6!V
M<_!1_P/;/@47&SMVG9:IQ9AOUYYX=RN@Q=>XRA/#Q2D&:7 A;4D1 \[S7/6&
M"];/9]B8V$B.*".C3PMY[,S<C>-%W!^[31UO((6\5&$,]D@.PG28D(EJ4*G(
MNZ3G/,H\;!^ZE+2^LTUF>9;ZH$^2<);NA<)I:4+5%PK ED'*_BOL+GCQ#W9C
MPB$A]9X=9:C3+FGKTD,.48:+-R?#S^4_,"B$S@:F-H1:$C;.)W,)P^ED^'LP
M#,RT810ODVOG6>\FX )SL;+_6HOJ(Q?\24?>TWH^YFJ<8@\L7$NI*>"'9I5O
M$L1P>8N@$ _,P!+'AQD->JKA>W.\L2*G\7?N\LQ2OO&[@:M:Y/JB+HV#F83H
M))#4*WO(ZO ?S96/F[!<5;@8OS_IMV3%R^#/1V5UR^RPN&C#YL@LT:TM87WF
M94M6,&OMO1=O."\KH@2^8PV"=X#,A$D_2A@UJC,'M37,EPZUS[C?_X/'F<&9
MA$2#S,7X )69)US/?.@J/^ &+!H39_O7N?7V/^?69@>#,I]?072Z_07^6%\6
M(.^VNSG.=,:PD,S4"0FS@/;+.6<_KF5>9@,Y[$%TC3PVEC<;K#+L]$^Y[,8>
M(+]V1?E;R+]] N!-\_HKD);8E5ZQ'WQDD2$[SY'0J]MG%=8SN]_2M7R?APZ]
M:P,\3G0U[Z[:!-X?%=_EE#-0;PX@ C1BU$H&&D)>DIF#738GD*;8O%V%/!5L
M0[LDJV0X'R=9%"-K4DEE8?*I2DH6N!%;L1=6<\&TI85P@LL/BYVAMMNQLX(G
M'P\C@[*UG+W/OCUTW1S0P64M[%[K/BG%4"?",C:KSZTZBQW%4_1CBD5C#U=^
MDP1X<8 M]!/W[4RLQY'K=:!WF1_+<&Q<\CC/)?!G()^7I7[3R/ZDWK#C^&*3
M374\@_"?W_'NUR/S?HDG8^3\N!!M(NY\[=^7S3A*O[_>B@L8O:'SP9HMB@0"
M4YT=;Y3,QD%;??#22HE6.0H/4O:PTR;9_ .K,;$,E"D&7_W:&^$/QF@N%?_U
M'YLVF[G'1N+ZV6T#[<CSFC/.[F7-+YPL.$\H.^'^A&-E9=REL;*:,J%!6]X:
M?\,"I[E\VDX$L&VIY&T0'E:GG2B$+B0]%T(I;"#?E2[OB$+;@&1>3J/+DYUE
M+%[=G1[;1<:;A\5W]0UXX/P4$BUO,"\+CV2MOLA.YL+M+I..(!Q>5KIMY^9Q
M5\AV9Z8OUF2NG6GZ:P2^CZ!#Y[7BK,SMMI9CIJARC!?6K7D6MO'12G\L8?KH
M(J=1[^,S^EOQD\Z/ VMI9RW%%5I/?$K3%\T>3IJD"9284]@NU:?=M%;AU0/\
MXKWF&G% 9ER^1',&V((<[_(1_.WT3BT%H-!X%=>^QYL?V4$MXSB/>0YDXF*C
M2VG"I*(3AX[[P[<_%WX$+P$L(IR?=?M,5>*:%BD&/$V&1TV"92X96=7E;:*4
M=>;T F+?NY,K*;/33S0B3NX2 ;&08B)@ZHK<'[W6:\.!%ZL3L<].LK&7"96C
M*KG&FD)C"2YUK^KNZ]TNE?\[9")UPE@<=Q+&:8"GC;"ZJ)&<1X?+;0W^ Q6^
MA0_3F<*%"$.#J\&QMV(%U[FV6:Y9HJ5*1SL)$L-PLI\J)=N)F?UJD?'&"TH'
M$>5MF"MUYRO0W6PG\MF<IA(G7C*_2> 8=6N8>T[G)2SHR!/42OTSX,TU^>L8
MOZHQ_*U@&E;\#4PFM+KZO%$=6I[9],5:B;:G[P<E.>\-KGBES1EW6!T1T,Y4
M83"-QA !(<!WF)IP BNN?9DF4E8!RWHTMQG7AYY^9UMJ9B3Y-<\!&A/:YL_&
MX6.3E^DWI9FK@@EI*<E<L-UU9ZE ,=/P]<A(.8'[HQK'-:=K6L^IJ[#0)=_2
MC(S-FHGJ&H=JS"P*?/^E[*82K>&=+ "UG #T9*DJN'MQ/\AQ-R-J?IX#_-ZY
M(T.;X54+@ Q @@J=ULU./$4 D=;ES37IB9*KHSWG:KLQ=N=@5!Y"F/SM(:\#
M?9!>KQ3[$6/< B+4F*PC\J&Z9GOB/Q-:GO:]M8/_N-_N?XO977<XQ.F8[PMH
M17$<M,,F0@@37VK^MR%RA8E-C_.&(=CR?AJ/>(GZ39SI"8@#KH39;S>3H" "
MZ.RYIB?B^E? ?#&\=7#ZB/OE&U1N$H<Y8[0#]$Y1BM0E$>]IOT+7N6:R""K(
M$"+ 0N\JW70,W+$570;F-W!DO@53/4-H\92[0WU-VMFHH) ,0"Q-/F.Z>,9C
M#P\\Z,_&ZFD&X[@D+BGM\64&D-/KF6Z<QGBCIB/CCHW#UU:&FALTSO/&U33E
M:_4B-_$O,>L= GSUF+URQT)%EFOR]'>PZ[DKW*+KL[?/#!;6.P8#D#<P9I'(
MDK?B5'[O#T7V2BL'*Y]^/= S^M061<;.;EU13+B' _:?A&'2RC +*GE3]A]R
MHO+>):R1)W_\O"C]-H":#) +U>/R5?BX>>G-HFJ^G38!K,8.=C13X25J*M([
M?*)/W QBF=_"[AMYUK)T]Y1$=_V6M<"NMYB3C@%;2W"Q\Z@CRJI&[=Y_2;;J
M=,LP+!$P4_ ZC0T3%CQEHN7,['%&)KZ%I+I,Q],LIM+)V+E1<-AO*<ZYYMM7
M;[K*[GE;"RXL\_UJ(;@G-:B?>.#IA:;%&LK&MN%<RY$4W2CEL49006NAT1[*
MG$Y>Z<B*6S3]W0U7H"CN<@$$@/[>0)TTG%"IBAMX^76[/"2E#*SCX<EK\NK>
MV<WK7D"C0$M\P6XCP[;#70</D"H4U6^FHW_&A(P@0[!D@;)\^;TNA5 ?ZFC/
M^^#ZJXKU*/MMF'3%[SA_LL4PQU+# 8?Q#N1C^;W4*'H":_^BP245Y$RCX9^Q
MPEO8N?8'A;/%_B]Z>.DD29V>Q:6E&'03[F TXB^4X&_3]7X-.50B0NHI0B=D
M3%X%[OZE?N'XT\93-[V^EL,8&8$;6-C5[$)3BW.0*8XY'MD)O\Q.I*?+_Q5
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MK\ M.Z6.C0%V*#W+3%5+M,T5JI#1KI7KN_#NZN*G3(=FKG_9\WBN3L3AU5,
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M!6EF1 6EX[>"#CC.Y$:@$$$_)/ &!,P$UY/MSH78<%>3CCD^GGOK'09J[]4
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MIF/3Y;LGY]D:QCNM;S9$#4;^:KO-+5?E&#@7\L&VWQOU#6&OS^E4>PJX1K;
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MJ)P[;:_+T3$^SU7''J]$LY-3#(F>B:)9/U9Y#U,COLF2!IDM]YG[HW7^Y!=
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MP%7?#A2OB[H2N)+SI]+9'D@#?&U!M ,YT8,4L0)8M,G'QL/C_H2+-@$OK7!
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M+3?"6 N2RVE]ABB:<IS!\RWX#5]?@ER4GO*VTA*Q\.L3:7]UA@_/"ZZ,I=(
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MJ-1VQW5I)8R^:3 LL\Z1Q.VY%E%F@@[2R<H2<BZKCG<S0/BZ)=N,L,W7I#G
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M.9&9H0DE3;-R@M@G=+X:J?//_[16/AP,:1SE"T+2E6_(]/GAC&&5:%:LCJ_
ME/!0IV2+GI_IW]<8OPY5Z4UII97#BQM_YVM200'0<J?'S9JZB[50MNP2EW>Q
M4Q:-^;E"Q9T/^6,5O[D:6Q"9*?X>"H>DN),+L.ET>Y0U4E?<5?LCYI[F?$3
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MI>1@EP\]"H(R$4^S\@W/*&[*E5]D-(EU?0]8,VM0)GOAT:'/')QFY42Q3Z)
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M7>\6.8!V&<SV3_R-WUPXF!^<O444R4<\46N 9[S=L&MOQ'*P3YG6NR?RKGA
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MD)'-J*K\(Q%)%,6;[F(LQPY,4\DI)%>RUQR;Y];S$8HVJ?[>1F"/&M:9VP7
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MNHRSX_!3,=3LUT2YW*[DU7Q8T8;W#]SR84X ]=)SB_J_YFR8\"R3U%^+,NE
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M=(-J1N15V-36N=^ZGG/&]B6 %3^\9!>)TGB]$E7^*WYQ80':38FH]NN%J-
MH!VM/A+=UL2>=(J$C-( AYQ%AF0P7>2@FT'T>*8!!HQ,ZQQF_+AG>8,Q^J&R
M#;@<E?#+(3TPJMVRESC#X6A"7!9FV<<J.]66+\;>@:N)U3?<21=PK5/B&T S
M.?0HSZ@63"AYM)_%-Z%*CAB3?7!R)]@VT 4JH2.V<5ULM(Z%=*F.;L+<"E9B
MX96\FJ5;.L/.D:"\R@6([EBO*$<EB!GDT&.O&[=O+A:1H99P'W;G_;F7*,NO
M3"#,O<O$<DH73K5H[N="/C?5%(G6/Q1!=FQASK?@F;[).IWQFI:JN8_%E!Q<
M?MR8\'C"K=^KPZ;'>[_)BKO)!YA/52/BHN$:^60,X0#=,+(Q)5LZ@8#S,41$
M\?TX1-D2*QM1#'#=471YG4XZ#?#FK>BCEG\U5M;M9>*DL_(S9HH2M!EUR(/<
MSJ"S>(>#'K'6EXH:G8M/C1W?96/I2!,DZ@YAWTQ?&?3P_0)63"^I#[-_^D<H
M])D$:TQ?O?,8VPPD 'B>[)AG_),,U:7VUB6+,W22<A>ZN,[Q>]F,Z#N/3(XX
M]*?ZH*X6UC+3B08S9%D[AEKWD?IT24YDW7_=:L'"1=L_1@"<?4?+M(BB1P>/
M>H;F?=3K,=GRJ;N+5P/&P(.%7(L.F39!_'<](])R]K1,'>84 &3?6:9O%<#+
M@TY[1G:W/M\_^Z9S]>D'UIQE7==D2"/N-$6[9'BK3(P=.S%]G/"PDDLK[@_J
M\E&!N"*DA2>B+*M;+A;I4J::ER6"A7@O@?YM! &=SX#7AQ!\B!$@,+"UTL7A
MQMM@O8#5Y?5PV;4K=M$ 'JFX=EUWW+^/+7A!'&M68*;<BQ70TD]O^MES%A.W
M"<MB.9Y:[FKUY8YRS,Z:>VKL63D=T_V@-R5\Z^"FM_Z&"'&H60W$KEK$L7R8
M";P\HBKD&BZ:>"GU\OV P5N%3P#,]Y<.1M&-&D5.-(!=[77W_IZ?'38^HTUZ
MX"311TFBU6V>-?J-?:??:+)G9)C!7#'3'2:A+>X,U0E/0,UV<F@QO<*XYH:+
M@W7<WS'+-7)%XV7=3LW_.M]J5G*0%.LME9O_S6]"[PB[1P,H.]:VD>R[0;\C
MBUI^;7&L^J#"[ :=X690R[^8]9C2O!<7_DBJSV]VL[L-[^8C,:6S?$%P\'%0
M!OFI34T(N$'!S<_F F_MQ&W.7S];*DYIN40M??,3FA6;Z,-WA'EX>VCK-Y.V
MK;NP\[$"6?ZWO%Z6U.1*57>HIN?#N0C ZN\KAY)C(07MB38***C3NZW3F4E-
M[]J[S&+&)!;S]EV@666[Q17U-3BB!@J30C7>;T5M6B!7_GE:_F^71$9AOYK-
MP9%U(+?TM6>H=X.;IS^]V!'5QIHI4;ITV)^X:^<AV<E(,"'[DWVFPS/ZB@[E
MSW'>82?YA=VR^R1%5-&?>FR%0;J67'?@P=  .0=B&G!S&B"NE4P'%>L8NE;H
M7"O]?ROV^(@6$.C:9RO"'<<#<6A U.=<BAK=ZHN'ES.&"C$P:M5Z,!>X\XWR
M8K*^D+P^ZWLX:O(O!-NQ1N6<,)]]]U$6>R64>'_LJ^\#YP0C0LD2D@%Q">9E
M3?;%:P.'S(<61OB,@Z6&1E?8FLM<_&<Z4B>=M&O<K"W^<W+#9_]_*1B5_&\I
MCDK5U2/P=<15Q6A9#6T04S3+_\>3S@_+PJV]*%S'YQ-^@W]7SL);_JOT4LO,
M"?'8PA2U=1*O&GD:O5S+OO-+W>(E@T+"C0X'(?;;6ER&\V-#"+83_12R;Y[5
M_B'[.,#IP1TYK/=VY^(-V3LM)1VR4XJC>>2EF:U A$3/1:IX_XMA^2M"SV9N
MM<GC-A,CXT-)4L*#YNK +EQ0H5J1YN:F-\<& Y$!3PTGS#TG[(<,&=>/;!7<
M=X"FMPF%BI_A]194_/B06:?O@6*/)^IW'^6S AL-4 VB1L76:$O-1'\H$^-8
MU90+"7$J*#N^*\XV^$OC_T8;05[F!Z'HXVX1XQM>S-5(1Y*VTOB-, [%>6SU
MR8$9VTYMX^LRS2ZK-, ,#9"45M=@"KQW'/W_$/== 4UVV[910%2:2*]1 1M-
MJ=(2$0$1(0("4J,BTJ2W ($(2)$J(*"TJ/0:D5Y#1T!ZKZ'WDE!"@"3<^.^S
M]SW_V?>><]_NPWH+87W?FF6,S#GF\KMMS4]'GNYWWR@;\,.X72^OKU80G8YW
MZD]4% 8\VW7N'51:V=+"(9L3H0S;<.EOZ_BDF<("1:<"X[==X 3_YLNM%P"I
MW^ZO>QIFC\//$!#9!+\]E?!F@ZTL,RW\AY=)&D*@-W>KS,9^\CKOQFC. =^9
M [ R.4E1D7/Y/CZ+<E%>&;$>$<>HS]VE)Q'<5<:9G\H'L6+$GR[1'BZ>H OU
MV/;-9*^YHU?@B4O6$E]>\<:[% J@ABZKSSU#O 9RKB8"+TB9,;AK*A<TBC:5
MIPWFI)!QR*N2E9$%C,YCQX:U/X-US_]2O&07W.=W'@9L(HOP"PZXG7<CO7!L
M&=G]E2,;P,.\/29Q8;7T""6GL25. "];.;K<A5J2$Q0%&N274 W@">$V;O4/
M0N3N?N*#Y>4>LM^UI?&^!,4S>]5Q?<S=WIC6W@FJYOHS6+/E;YD;QMJYA1)!
M/TNBYJSV>-/H;LMX^,=JJS^QNEZ#X(0Q-<^ !T>Z6N2URO,=,CZQB'=S*3W^
MT7SKF-D4%8*V @:3.8;2T8-$X;=BZ0HQVY8)L[?XSAOQO1,894N"Q"O7E:)C
MTOU.D+Y^;TX!3=.>ICC9=V[V)BT>'Y_;CGX\&IB<3+]V+?8QO."W\F1I2EI6
M>>W?;MJQ-D"$@A>I<A&CI<CC,YE&V1>DE_6IAV:1;O!3P D=HD-\!+$I1H$N
MUV\[MO%=O4(H!.7Y,6)@Q]"2ILM'*$X3>J;J:\P2*9[3R*:JWK&5>6@0\>JL
MDKK6B'N7ECQY0=\J;,:S6?[S_-/[AU>BF^K+"M<W!$<3%UT'!D3!X-]'^-X%
M5+3;R?.M0C^:=8\17&0NO:PEL_K7LQB 83I1!+<3JNA^[OOQ8: 8D1?_.X"U
M.J5K)9@A5I+;@I._SJ[F^W=2%^@ACKTF&^:(G^$.SO=QS'[>>O8HD4."6K4[
M[9S&0NQ]U#?P' P..@5\&U0Y!3003@%MN3 TWA?+%"V]=I#JJ7SBD7E//Q91
M;JK^,8\5GGN%#[#U'(/M0%]$K.J? CHC,:< OIS(!1J./I>2N-A=(G,A3J'%
M&!H&.D^HI_"L(=$RA>N#8D]-C7\)/GC &Q$U7YN.UR0DSH$O$H5,^*Q:O-\D
M>N'7,DZ4I@?43K2G>%GZYNL&U0G0N4C:1D\0RX]!Q6BFJ8(/HL@)(?LF2+UL
M@HCDIEW$OS%UW4/+Z^4VXD..,Q%ZTS(]/[L6@/[NPK]$1>%FZ::F/1NL3]M]
M>"1+>&FH%&.U8*@M_5E?"Q6<3"!.O?FC=&M/U%/SMC"-BY%5KZ^XF[(;[',>
MHC0&$&^ P=[\N58YXS"[CMK2+S<"(!53Y>T&]-GG=!G/\S*'';#TTL:HK-W<
M3FU)6]OL7YJA)640J1:4^'DJ<#11X6Y/N0H.-(,J8,F5-+_HE8:0S9G.2#Z$
M3333&IFKMJ]6*$=]GHG9]I']*WGG/8L0V(2)]Z*DZ[L\C1[AFM$_=UL&SPA1
MCG'GPL2%L:6D$0U1?U#F*TLNHK!)(_H<G 5+7MCB9@JQ%RD*.;M4H26!"PSY
M6,+4,!"KU[\:G!R5KY= ^DQFFX*+$IQYY2/\#(IS.O U.2>M'\^J^3;PGL29
MJRYT^:KC[0A'-Z*N_4S8:9+?N%.]JSXEIAS#]*(Q^*!7)V8#:J;OJP(I&RY8
M+JTK#]X=L)P4Y& .4></@E#[VF9>7\ZJ@":^LF#KG,4CD*[A WZ*<,41M_W:
MD#9YQ;L_>A,]80F[3*^B5*@(AH'D/B"G *%7"-D<'=)Y/)48EV\VW93Q\$%*
M$'5T-2,7\NO$W:3]7DZ_#C037#G35CC;.F;UN !7,;XCNOQ)4,(#9$[ZW*L3
M]:752[;Y%, ,.P7@/4N1#ZL(FJ2RLE#RR, U2Y^@C@ESZP4G$NP7M2=7[N%K
M2G1RJ5O-;T?\.D;,80)G"8C95)YFK,S^CXKG$\I$Q^%)W"O(@CG; O1(*9KF
M%# FC=XW:_4I!4F4E6"ULC](]TG1>9:%S2\K9(%76YN($8]HKY3+,V7"%WSF
M23QMZ')PH..^J!J#;O=;<P'I&DN5\T47@.;J*\:V&\([GHBJ+ZL_]LJGT(N^
M4*B$WQB[;!H_CO8=T<N1"N*8/D-=>?&>J?RO+W@%4S_]_6F#H=))K5=M/L(G
MSQU%5LQB)WO\^T?[ AL+#K0>*V2[:HDLB*:%<#CB%N8.V@*2T$2AZF<>W1Q)
M%K%+#S?:I^]:^>W@G9..*(D*&7X5-[IE,\_@,3)C9V?2Q<5/76E69$%WR5"@
M?);*E\''/7JS"]NN/31"!EZ8Y FRGWN39/.JE^1J=2OZ[:O:DL;SQ>1)_ML/
MGX:64__1L<73LKEM;1EFH*\^)G<?HWYGGM@@?BUA%\@U?QI2KZ'R-^)PV7]*
M["JU@PY$Y4P*8S&U^6T\3.X7,3<29&FZ0QO/YSI0W?EYC1$J0\9US<038T^B
M/RDZ<\.ODU"UX *3^5$M''>>*<T<W:,G$"3ADCIH1?K U\5/EF XAP@=7!LD
MA&B>P"=\)$T>B0F];].@WN,1\](951+._RZOK+J/GN[3'7'0+*S?6V+Z>R$_
M<W@_W\SG<>V@X_>]3=15'Z_Y*4-OB?B_?F;<9;1+&R"S$4Q4<9D[X6_WT3=:
M./S?'R*MXRN"V_[H\Z;Y:&TW;@Z.-S%]KUCFWNNTRZ^B(*N_1[Y"5)BQ$C*D
MG@86ISDX=Z(4F18N<DFU*OF5R,.;79>U >O:=GWK417?QPG1ZK4#!YQ^_19>
M+,J*)E\\T^F9XZ]$*3$\&?S$:Z@[._0FXYC_U@D;!1NS04_.3R&$4%X%_WT1
MH?!X1'?9TQP:\TD_/LIDWC/@%2%R5LFJ>>!'Q$R#P2U.I]BS7#RKG$Q-]3 2
MTD]:&9O $QT"O?0PB:T'*1ENDA]T7:F@Y=,K6BK!GQ735PXXN8Z;JM"<<#EL
M;\OYR^*75A.2OBJ_CWW=$JK$UL:EWC=BB[,OJDG8$HQ;?6F'!)+Y5KGM9K3F
M2;>76%^K6K@D2E3\>-0A=SQ?FXSW&X;KX"SFV] +D\F1CWN;A.N%>;BL$$)C
M[\+.6ME,?(V]?])6!X20$NLYUA(UG)G>SWJQ+HJV_MZ[,1^U!)D7'GR[.3NX
M]:J\+$#!#O9)T*G)GYG5#< (R(N,6]ZHF-&L,<WN1)=Y$A-Z@\$' V#2+6/*
MUL'L<&%L191TG:3AR#ZZ?%W^Y;D!QU)-8(+*.5X!@!=@E\']D_IC6WY[TD)"
MR?*NYC;H:?T'T&6_<0.( Z@K$Y9TAX_EO>C-VY3 4O2+B7BQ'E4$:3T%7*P5
M7>@V>3)TT"V^E7ALTYVQX2RBQ37%0^!R_46;,FKT^#\L4*A@*M'$EP1)1?]=
M1%D-@Y!5[7G(M10FWT>C@^MMQC 1'P^\&E14?TE*M^!MFKNVEQ'.> :PQ 51
M4[3B'=G*+#"0^3%YO^9J$+N4:5P0%>#UR<6KVVTV!S:DSD9QKU8\9 ]DB842
MTU;"P1NMZ'U3Z0UHJ2$Q!LB)& U'K#ZH**CG@ME!<'68\*U]C'B+H<92M]=*
MIZ<8J\5+^\ @\\"R_U8/HB?D??>/'L0RUS@?J8G95?2<A8:< N9$2/%O]U],
M<I.;=L>?[QO8" '(U&%+"$O@AR3H>[A2#HREE<-IE7LFT>O6H[(+U%>'HV_3
MO7!@2%,(.-\KO0\.@M_*A-U0+NMW,X$6VR1,OG_J%7U]JMAB[Z[@+D3ON;D,
M07H6'5I!YSH/9)J$3M]LGV!+XWK$=P;664S5ES2@2UK,*$=@EW6B*[\?*Z3Y
MX,+Q$8Z,Z\;L0;-<;B@66/C3*N9:+KO0!;T&ZK8%>HVU-(!@5'SJB2W&%H^X
ML"E0[G5YQ&=U88B;/DBX.%2/W/%"_O!L':01? [.@5V?*X(KS9W8T671^/7]
MWGM\9IWJU^\&X'V[W.'29%$?K<K! YY'C@4.'*_+#\_S\7I?LI,3;NORP>SV
M#4B4%N'+T+-I*K.Y9#J80J.,X8@A/U?PL'W\S/+<-Y]L!2],2A5\96DC#8"Z
M1="<SP=SDT<G$DJRC;6L7KJ^P%A%P8CEUBUW\^IG&M]-*86BG/\HE!'!QJ",
MQ)$9EG+9\Y.?(%*#:DPD5T_A8T,M1PIE-4B326S%K@6 +W6<]T>QV]QY>M/T
M[73)=_]#'X,\:.V*+W(^8J#T#QV,HFI'\UTG(' AFMCV4%&1+46A7),=,X,7
MX_3Z_@9RD^]FJ6(:7D *78"E3._)3--P\+"[-8]RR<A#!J&(B2>XC#A-HL!K
MJ\MG88*!;=IJDN9'\RB:5?-[@WZ-*!N#B<(BS]NF:IS?#O2&(9571IFS_'Z#
MZ:62%VL"FSRV;O,UF)IJR5O]I7$R4*SM[-TAUW#ON71N;)-K/F/.SH[4*I](
M34RL7S<2=W@K5KB5!$^P[CD(E]N*L)AD6T$7GP):F1@(AHW<%,))>M7U8,B^
M[,+U\3^M_P;/]()=SES]%" _.GRW[6-;3%LXK_79O)P&@!O VS"-D([W)G@M
MB+XRTS/ =M>.[J8.:-$/-"[+'GY66[\ RG@]4@2M_9302_S]R;>5HQ]S3&)*
M1=CMA,\ <<O(C-49_M2RYYOBBANI#P!:/XO5Z+C1:H(.BL[^F!2?E2V64X @
M5<LIX& )2 Z.+\Z#,V"O%\_E@YFF8"[3;N$:]?UL934=YP0;S99B N\VKFMT
MN\U<P]9_F>]EFK9.*JR8**W)8.ZB_=Q1I4S-T*G">'^58DR#G]AWB 5FIP"O
M"_7(%=> OTL^4#*D?!%Q18$%]%FB>L"$9K[H;;=@W%.K%Y<=38\=:-I\G3>@
M*C!H,[=5H!N/%H]Z^0E_LG7FR\#?5A-T_]1^>Q^W33XK21K8G1&N,?J4\?&W
M?__0 0V$VB#.$UD:M3;-3-/%J.%1W#$.?X.5)@=7E_H)#QATI.]=B-UB'HV8
M^YC:B!YOLXLB,./"S0F-A;#OZUJ@ 4Q3@MZ1O/N0TZ_8[CU>!Y'%RRPV]ZAH
M@J")>!."F?1<M>.%)D'1&MMI[>(54N/U*1\+MC5Y4/2?$?$,X"<E 4UM-)-\
M=;4OF6E_L,:CG&LFVKNK.8A(4-TIX 7N%)#1-UH*_]MD*I0RQ?P]9N21;7?7
M:N :BG[/$NOAV2Y;=)')Y8RLC!QE]G;>HLC0?9]N<9V0+7;9&"F6UJI$[SN-
M7+KG%_I&7,+=+"!Y!L1N"R'NE!T[5*/XKF(X7HGR'S@H?&^TM9T<*=U*[D?O
M.@,OH#?FQ4DWC8]9&LGT_;54WU33K640+P=?O7$+Z?:Z\WPQM4=C8^=9K09E
M0^:B./:XHO4)QXD#,Z% HRFOW>Q/*N> MW\8+%HMGZOX%)?/M:_EIW91?+R'
MSQCQ90%<#@G>.07\)(HO\('.58* M1CYG!NV=_]9CT$]PXZV[5 3DIOQQZ4@
MH4'15[%W=E4\/7EU[_ODYU]2IMU;EQ"N2.+<?AE[*]WH5<SC6H<S!M0O IAT
MS%\B3L2)XD.HM&W'"Y,%19-AC<Z*=U?&F9O\-VDL>5KO[6.(W?R%H!K.4\ %
M/UG;4P ;^3HLH0M26H*@7@LS8-"X&O,FX4G.T^?U4[P*OGU.-,Y_:GUQ\U@4
M*9 "N",.]AU#:F4S81#-<*W^TA-?B3:0 9UUDYA/W%]%&"/9_ZE95[?4DG82
MUW\*^)PZ=5M\&>K1UOZ?*#8*^5_N08>JF?Y7A98K^7_677WR';U^G('F>4]:
M;16+1#>U]\KC49:SZ$ES)16CZG#(C]H?3RL,Q00BWF!>"$4#'!Y(^%!,[0DA
M4<8?VZ6#@[[W:YR'%,>_V<W<^WZ3\P+CZF1>8%POIS1J 17DQTJ(YZ6;UV+G
M>](8PQK1RQO*])3O_!^]NF<CF::/2/N5@>7!#W;CYV\0):71-[M\MTV+Y8Z'
M,K==\),[5<:N>VX^I!'%A0<XPV9@Y Q#\1#Q01IO)3IVW&^484$M;A($<J>)
M.N!:55ZT2-K%C.-'FE5)F8IZ681KZYIHFL)\#NLEB>:4ZU-W3\9<UK-CU;P4
MD_"^)GA+@D4A5&FZ]_U6K)7<M1&OPD'PMMIZ^F[18!.(M@].F\T#9%HSF- O
MX?W9\%G,URA:Q+=#.L-8;V52/1MU=&E[H:L>XU\%%2>J4LY[ *M.\LK>3:O_
MBOKD=\<N@9^'A()?S;5-U!D;,QE+UW2^V_25A.T@/LJ-BK>IP.Q;@N>>[9-T
M]D.BT8L/<4!2H -B7\\PBMR"V%5;^=,U=@HXIG;?E >'*H)Q LV'D"SSY@(;
MR9#2+UM36W*F$HLO H.W-C1FHP&K4$:W-P.U"A8DY(N!TF6@O(:?!X#E3[.U
MY]9#WW&-^EP_S^OFNV%F/,0"6.]6\IP"2:_1&!SJMIKDY<:#!CU[JGWMA01A
MGSX?^4K+6S: +$>0;./G*AM.;)&W#U=4SBZOK8FZ=04.[^QL80Y,\^;_7K,F
M8&3QVITQXDYG\Y7 L='/ML@28#/?JZ,=,<4;#B5R4TTS7E^?G *J>/*B&W0C
M!^S2A[*MK(8YD8P@N74T"_F.71(HW,[2=3921N048"NBZX6Z#@#(D"I%:Z,3
MXTU'D_SZ_:Z'-*)+#P.D:SY;5I87_PBSB:69(C]/\/U-"Z='-M5_P_8&22'.
MK=ED6WO;UR>^SO:,<_!75AH[O#&U!Y4GFJO&X1L('E'?8@H6:)Z_9J[WNX6:
M[]>9H>0&IF*=>LRBCR"&KQ[8_*V\D.+6'K'X)K!LETF&)'-4@,C.GU9^<]F3
MZT8SL)+V-"5"D B3HV5N#W;2D2PZX!5!>_+U"M%NR!']!AHL'YPUN@?3'C.5
M=!1F'51G1VPD53ZAQ.S5ZC>)5M_'E"U>VC'$I]#]%/9Q.Q]:[Z]^-N4M4M;$
M9&?JBUF1>3*IO8N?>42T_BQY$"1<BN-%CD_(?I"%V"#NM@BX)0\E* &$^N+Z
M_-/D4":$$MQD$X@5*Y:KR$U.S5EGF53T2"CWO"7Y:S/C5E-<4$?'C2CA*IRG
M?RD3OTU3>PNW?GG^V^S;):C?(<//X9V^C6P=UL 21+,C_;H.YCG,8,RTS5/
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M^^$A^);T8"*VXNAB\J(]&MRV7$[!(5>4%,AUZ10^K2K9DG9ML%;HVXSM<=F
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M43A6X/GS=[+>:9]0A2%6=LC[_5 9<[^1M.O]%B=J9=A LX&"$$QEDL:SFZ<
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M(S^5'%ZH<&AR[Z/?T0!0=FYB]:M TX(PM\.A*Y2<_HKJL83%L!M\\Y([.VV
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M\+ +R2//:FX]^;KD=<G5K=DIJ5SWDK\YDM95M8$_L&R:Y1;NS]YU>V&8X0+
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M@\-IA!M5I_8DP'R JHMPSJ?V+ZAH*!,?YO'E8I#YR*[6)?&,GHL=B!_FA(&
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M9F/<^H.<+B(@!JABA.60)1PL3J;&OX_%)U/TY.K7V,RWH!"Z78N>(^NF !K
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M0:[LPF0M_$JBOUQ[RFE/8T+*>/G-/U<Y-)8^C,'?5LQ69V>C )/EG4,SS-U
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M/O;966SD\3]F[W"%3>5>_.9_0;]8U0@//\M3:&<4_A1T![ZW^/ZZE.$JI 0
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M\YP(60(2M:7!#!M)G-%2\L%^@C56\]FRB^%KW@J$DE=GR5/(IKUKS!ZP[NC
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MQO?O_"PZWT0C_-7X[, XHW%=[MZ/2I%W[B!OEO[(74L#E- 0+P2!4-8"XO0
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M;=$$+>R'TBJ]-@VF-5+?5;_WRE(S-<1%?$0[F+:1D^AC9@'6X]I9+E4-=/%
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M)AIO.R*%^L;O-$39O /)<F99GR#W2UR(<]9NN=!;^$]R.ERWL@:%^L]6GO3
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MT@ZX26'MJW/F'(N5;>5/ZV_2]G*B$=PAP4!5*VL#,QV]P53O4A$M>3_,P3E
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M$0H8^GCXL+I0!O')DK]^0FSHZ>BT0&5]WU4YUQM_GP5&T)URA8=FD7O]T6?
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MI3@#OX5&I$X)7M:7IUZX-Z@$]/R3I^Q7^VTBI>%RXQ/BB4.1)66<CQW1BC1
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M2GHI<Z/MOO.2@]/OV(("F5-)^L73C,SMQ_ \QVSN_H?)QO'L35=@RB&OP5L
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M20426$\)%>GB]44HN63>@*^G8XV)[7KP"S[[G%(K+L/_:D+D+0B4/R%DR_.
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M:NYRY%BO].$Q7['Z4XG'0&3P,D&C&]=ISN *23&L><H@XAZUK_OMF2-TEM8
M>!;LK=\)BE@"8O-^S2-V6"LE.KF?S%3'RB\V%8N:M= KSD5 .S=V4_'NU)E_
M-K?'\'1=W\6^*2LL1YS+8EZ:[V=&FC.Z>EL2O]Z)AND?1"<TEF]WM_2LGG4[
MT*RHA(H<.!Y:).@=]=:,)[8G&5X[=VYY$=AGV2V'$AP$69H#$-M+')/-AL7*
MHTO8 %W(RT!:"\IT+#D4?V3^HFJY1902"9<X0Q(M0%]5BNU1PG[S\",5)'Q?
MD)[XE<\;'$0"K.N-PO?Z@02 ?OC_\J&6VG(AD8\$R TB"GB!_F[)2V#GP*%P
MFE."^\3OYCI_O@;'YW$S]](\VC\3F5<19#:W/KR![6S#+#U$ES8O<4])9$\;
MEXE8F889+&\8L%AWKZK*/;^X"$5*_%J 1"['AI<BM7(S!.+7[T7%\\29PM$C
MB$0]0G*S10&V8/D@^$H-&K:9>JVZL8Y6JKO_E;9*CL@U>>)$8>[Y_*+QP?3I
M'4S$3CDBZW@:>0.5+1KL=Q\5Q"ZWO]4IE;QI["OBR:Y9]88=],3B&?*]?N&0
MRM-R\J;;B9[?Y1(D <JTH-O;>]T@>P3'I[FMZ&?,63-F/9[0_*7D)H-75D%-
MW9<909$;3SF;IJN)__,@U)2.PPJBF$ 3DY@\<&P3YL-,*'G&@T*LY,>N+&IJ
M3!6T5#->YZT)8(DZB/OQOJ;(ZQ%2;94$"$OPFS;:3%Y&7KH[XBK@>&6RJ[O0
MB7%1/9AG/>PQ/[5Q\+!T'T"_QJ\??J2 ?TS<)P$NY%\?'\Z+MN_D[7CQQ]:$
M=67 \I>ZXQ=?2#8]V& +V]6= $#GRB*2=.4(NG\?F+WU29%]LG.#1RU0<>QS
MS9[NO(,MM0)C1G_1+;^ 5F-"#7S=&>M$ ICFDI\A3G^LE09]RT\$%1-=^O)=
M'B%7'RCZW%"!!_44&.PSB;.%]FZ@UHA-JB1 SKVL1?V )#QB\]WG'=72!LWB
M[>QFT2X2H/(PT,=VU5?3M'7B=*;L]/K<ZKNZ^B#EVZ?4M+QKN^K*=8)9!XFH
MK=!685L@%=P6%"936^W@[>+P[$ROO_9Q3KVE3.TK&ZVH!X?F.G@^K%0VGGT<
MO.]J7(S[77Z?Z=7T$4_%^_JVF<ANP<Y6"K*UF,&K7IB2Q=F+M\F'B9FSR=MO
MX$$'C>5_QZ9!#@Y/C,8W*E$>(6XMBJ;U.IR-)L^_ZH:U.50V55OBZME.RU(Q
MIECC8A\1%$NQ=ZFRQ92$#4YM[O' RZ*"#[6@L(,/*I^_3K5,?3MNWU$TVR]M
MT@/J^L8=)>^+.B;'8]=T4[=:XR$,::?MQ[>)-N?ZDY/H:?_3(,(/^6?V<URM
M7-.=,BL(!Y]^]X<']_GY1QP_@A6'%<Q-_E4_0C)$D>#2LL^O#U@?_2UEXVKZ
MVOWP(.]:GP.X<9'R)"WA\"QJ4ISSB0G##16-F@G*ES^(DY?[*C)R':DXKWAJ
M(EUZVGQ=Z<]WP.1MB*^'1V9RG,;>\E%%;07*W]XSLQKH5\[R_!@W".1UJB^\
MK43[)^9ICQT29.^OORQ??[WO6/C\E'"DQRQ1,#A& A1)%N1IF//TMS(0I\WH
M4?2=T32=%R&I9>J>%I<B#(5_!>?PNP"_U_Q:RUC6A3) NL'S-%U&FB$GB:$*
MJ,6@[DT/>$,L,F'Y_?<@<K2^6N-)2YAK06#($B:>8X7^X@1T\;BX#_X91$M/
MO8BU6;T?SCB[6^M1S/P'Y9\W+,HA*9-6+.(=<KGQH01[*W&:X%%7KDCMX4H8
MY(1K'LEG5-=$:E8'3%V9I7Q<XE2>_;L-^*T$"H3VAJ^"<%<7_E%F\1)PZBZ:
M+K# +FG]MJA#3L,;X(H;+2A="WV&#\O@(=.QPS QPJZ[9<)FL#7_^^<%A]K0
M?O.JPW9.T*I'P/Q;M-)B%S'8UEO(O9'715S+L^EM<]F[ -4KS]N1V'? &JI.
M8\VOK3(HO\IE-FO426-@'S@H,8^A_F%3R)$JY2OG IZ(4]&96.(K\LU@F#/)
MIB6F N0@>G[=1YI\Z:#,BUL2-21 .&53>1>;XG*"'S1X:*H'HXKBV8D7J;NR
M"2]9N#S-WC6YGFWS[?0+A<.=HTM4"REK($OCO4&@-AH1:).^!1L350ATZM5I
M&47OI$<X[:5<N+>:$Y+@ZU4^AF3_T$U.VZ.)=B*Z)R<2+V22?' X*8%=Z,#^
M7(VF6C5'7O%8(0'8[8MSL?R=?;%5-9M\C?67/"ZK^%2RW0G6>)PVAG^%ZFFS
M'[Z&4%V)MM$8>Z9@3Z-N*9&WWI2BQ/;N;C@5KZ6<LDO*W3%7(#5QBLA=A<Y/
M+5BR3;E@^YPW*3QF\#)&]WOTLK]SV<_3M19O:$PS$#7=)L\T<8I4;,]@,Q!:
ML;TL_],QPWYM(XHS-$F:(G"J:B[JX\DX5!X.NG=6-$7F%'U"J@\4BJ998<G\
MO4OG"%.SCA^S-8CJ[SLSP"4*)NPEF(&7H?X5IO8R6Q%$<=\DW]>[:P06V1:%
ME]3I+D<5=SX*Z+11Y'E Z7P\N;)00'VT7O"*H.9UH2]F)G,[4U_?.(M_<KK/
M(DXE5+^#E[,?^#?K)EB> ]NW@D/<AHS9XG7+5=W1JIR3XTA_6N;^0JIOWN@H
M@'1I9HN>QEPNG&L)_C5^+$5_D:@BBW:<;H=3/_-=/F3$BT]^SOEY$*5?ZV6%
M39<,:'G^X?E[PU?;7P07X/:"@]8#RV5%%T_>!.=%BRS1'K"LI^-CG@^-^(8C
M4U#0N4A-%%7(:3GMMA]CU7BIA+%WU=G>^T"!ZV^+#F37@<E/N6;+\^4E?70C
M5UB#?TT>N-I*I*H>7"FI[.%^GIH8QL^]?L<279*>]WJ:G+\;6),I*5WW'2(T
M.I8%J[,,]S<30YFE6B,_S$TD;2<+0GTP9WZ>6DV?1"YM2<_&C;7(8GS)B0@-
MUFL\B"[>O8GX!+(]%D]4_;D>?MVA_>M;5AZ+MMZA0S-[.Q*@.K/C,'SNG1$L
M/Y'Y6VN8.B<F^D'0^ZAU 0)B$_;'K\^K-2\?.]"]1,->DC(=6N-Q;VA5>:$P
MG-I"X]4E_R$J-I.8TY9#*<[TC'1Q$H"'\RF347&Y^5X](@1ZY,4E1PY>5K*7
M]CH3C<P\>HVW) '>>\,)C)/+?DP3OU ]R/+5'Z</+&'$,=ACXYJ26[)B+W8O
MR:E>4YF..$7,T?2D (/\V+ A\SH3]T*.B!W>QL9OVP8%&\6B1$TN>\H!RNQ2
M5CXD'\T?R_ 0CZ4(>_B:IYDSX\17OLD$OP7HMNYJ)JT?*[1C!MN YGC=,EE6
MX@-BR3U&&!E)3C=9/,LP2IA5$-(T6SSGFL:Q0_OHJ\AW.Q]+H&X SMH3U?B[
M,B_P8 )0V*V/W]3\'/KJQ_U)5O"F>:KL<)A@GM\@G.(T'Y58/D.W;QR:N'%O
M5;MPTZIO_5*:Z[F7_C>\\+_IPT"LDH,;/?M>K0PB0H(2I[Z?/!V?%#T?_X/2
M638A(>W8;!"G"['>ZP)>D:C?'\W+&.GQWOC=9Q5-OI'X)%#P!^(PV06ZD;/&
M+]KUF?#*_.#K*<I:.*-MQ;-BL2@6GS+GF<6$:8D@,+_DV?@!"1 J8B3 5PN'
MXA]O+#&A64.(K,21%+[D3J23*)YG]5[MF3O#T,>8ZX81930N[7,*SY8K^LJ2
M,9N&'.JH%QWM?%)C098CDA/M^+V\Z6>JR^;7\)_(;.,J&NIUA5CZ98>W;BH)
MI7@_PUEC7^CE@2X'\2BNRP51>X;WPC(1.\2@ COE7H]( ,9IXI)YG.CB=P)(
MY3P](QG'CY5<[5#UT>&<#L<KNOT4.;5/;=":4YPH*@8 Y,1N0,#M\! /O_OH
ML\A6#C-LZ-O #G:YA81A"T><^JSA,]@5>!!#P/.]F!Y*WR;S1_\&+QZY )E)
M@+U<Q(76:YE)K1V; G5ABX'7'GMN>V6;-L@'.'FL2AN(C@18X4.5!J6(Y!28
M=*AUN0D>ZKV'=_=0,E[C8=X71<NOJ1'25] U;6I^C>(>0)!R^C<!_ID&YI\X
M4VC?]6GH7AZ<&/.ZGP0(<MSJRJS<J/WY,9IO(>66M@I[5/+'.9Q*PWQL=U[=
MOMVYQ#F[0+FMYA )D/*L>(4K'95@,*(9YL<+"1DW1%L7\ Q^20E>".SE"*,)
MYN'UIW_:_?QVE^)O2& [XAKQ$=9<#VM3IB0?6?1&V,U49&DE-_I=512^1_IN
M.!O_%<WG3F:A..%/9+N&]T1U]]/ ;WQBG2.FF7&LN!5T\FYM\7%&BJQ2?WNR
M>PUI!&22& ;X2*%[0IX]S?>11!W4E>XF_'[<;D\I:IOT-L:)QMGYU<Z9B_%\
M4HGV8;:I/KB^<[5 \!S16XYSAO;QC4/W'[,2(U+*L3P8<U1W9=:<W9*$%)?P
M--AA+5XM,O*G90R?@&0/>XX(LS)@N.#VSCN0H^8Y;R.8$'*/S$\Z^HT03:*2
M P>Q.8L$&+EBI2IB%(LC([&J>&$S:P)^^&?K=5L'5#GF%UHS0+QOW8':WE*L
MG2=I]H@WS+>73E^N2XL D^?$>BN,NQXR&-@.@$MV4^*,F\HEE<5BA3(;#7ZO
MT_GK8?Y'&<$&LUOGCO5>.6\C+'C]HG4:?RP/BB/K]*:<!Y[0'>5O:G/JKB0
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MO^.GP(>;RU GAD80IY.]!C/;O3?'V#_JU8>+&M$>L&S)5JDH"5< +7=,@)U
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MX&:H[G1'=1'\50:@B6R]*;\](?MKQWD'>%8[8-[0:T'6M]1F]F%EXQNO7U(
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M8X UJ.&(!SR;:KQ+J6$J,"5U[?E"8N=&>[%K^1=[-(&:TE/R1W_I'9DTS1G
MOC%* .J3$PCT5@NB;WL'JK!=?-#Y2#ES/IS[T[;W]W#+CQI'QSX1DPS_/8Y8
M9G:Z2NV.3'BAVM=@M>MI0M_NB*F8;"G9$8I"_\-675:PZ3)5@%'4QE44,5N%
M.!S5/A#-0?!?T(V\3&#;[(S*:#MY\T \X5ID=MMCG7E] 5\WWF9!5L\D)V9\
M[Y-#KD8JU(P6S)#*;BC27LSOF*@]1"P5LKCU!S1#RUT3:$68Q;K@RTP47&0
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MJTJ/9&K$K)OK%Q[.+DLON;,%, ".H>R4W"J$W8S7NFY<.XC;5ZN6 ;C7Z)\
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M]3.#;,%!PL"6>M@$R #9YF\K2T[Z*GEDVQ1,G$I?^U[R,FPSA9\^,::[J<$
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M98VI9?7"\@5/:_]XCBP $V!OZ^2//)[KD))LDF+IK*V$*=N1&B;=L*J2@G=
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M .T-;-Q8B!)G %[_FF_D)SWWK2$O$%\,F9WRPGJTR 5<LM9/T?P8O0R9W6<
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M*$)-C-90AO5<5T][?EV[J!7Y;M#"L,$!DR+2&N++GXC6U$7OBAOM%5N^>)=
M&$]>QV008$#<**$P'N=[\"0KXT4#V_RU!Q-@">AK(4)/U#\N&UZT3_U1;.$4
MP^I*G!1G^# IA:L>\&"A!"=UF89C0$T:XB<J@W?TQ[LU+!T3B7/B9#4""W]A
M5^1.MO5U0=Y(8K_9=.+_TV:QVTRP:9=VT/TF7F2S!5*@*D;1GW^\]/%(KC'N
M]%!OW<;F7<9KP"!TLAPRVY8*ZM2BPW)UBLG/,,)2*WWD/.*A.S^8L^_,G96
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MS:!^U@W9L<B\]@,#NYKSAJIQ&*Y38Y1XL&?..*YQSUTW)J1+K%RJ?ZULL]W
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M[[FZE-C[ND-@'8PI$3A55^+T%;51AM]FHG/ZQ)R4B0D &:X 5XU+>?B.PA7
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M)QLIO]F%=.BX,@K9Y6).G$^51]USZ[)5;'0T%4XT-DLXQ]<7>S>/C;E.>*B
M/FUR,A5@&4&)3VF9G =_W .SGRJ,#YNA0Y[65:7[5PCI-]*]$N<U+\G\,(QZ
MEG)TK\?=O#39S2F>0<_%UU=^#)>?R>'KA?5Q5J2_DWZ3,?X<C;3T+681K7?)
M]OCX[%2K.Z,"E:SV/SY>W-5%;.4L(%'G0FV'^>]@%YL6T>!ETHODN)2T8-#G
M7TE5MV]IMP5=_ F_A:=<\C<"X40(X,CF(,)*^#=K>VFL8^&O78WZA1)V%4,.
MH-03<Q'E91V-W1TLF@)9LN<*RAQL:;4/H *8NN>8:P+@K\<[[/G\)JPG]ZD
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M^C_&;QK:<EM\ZS6R'@4']I*M23$:Y$KAFG05]'[#'WL3D1,7AXPO6^V6%1/
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M_\$>#=I_$;F)(AXO'=U.F36OKK.;/.@K^]VE0C%EL*'0I.M,3S"_]9HMJA#
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M>OE@^%NWURQZ.6P_0!9(2V[LUTLR'?96"CE,\2R&2NY!OW,=:3^AQ_+8U4K
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MSEI_PY"Q.T6_2!?7U)N8V\\YLHNMBHX./R8^(&=5;>U.7U]ND3\1KLI+7AN
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M=]S8]K S)JL'?C3@?W81?F&&(-C&H_')>=Y6T;_\_M5(J(#?0(Q; @'53A'
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ME#VK?_[((DEY;;[ C[$2QQ@PS--5QTI3Z?,$7Z.JV &H[QO<H^C3\$9##=W
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M[:WQ$NSS)R[PU+^) J=6Y!LG/C4:&5]MO(7C6=.NG6B4MV?75/@D?\R4>WQ
MO\:4L\@NF3*/P+GXBLV,GDRN99>([6!@EI&P:#C/+BW<)<=ONZIR$8+T?R7T
M)_%94>8F;I[WN+9?0:>,F*>('L:$>+);!O3AH6+)[WY8W-#/R@FG7P0X_U(!
M;M@;DV9QTKT)=^@Y@N^+QLJ[Q]/1N=[GHWE-GH8J7(LV2>P6\K6OR?,3^P?%
MA:_OOG<7*Y7$"-L(.QK*8(ZE3:@ .P@\P/4_:WW]3UF=(K('JC(/Q%$!R?^L
MV-A:V/)))26OV.A#4TE#WUY3@83-($KK M%QW!C_Y=DR8EJPA9^QV=[E"MN0
M#+"H93KCN5H6/.2<4B,%)[@6L+" *RIHMS"O$N:P$$JY%M/)S_/OI'KY,0_F
MBT6S9H^"T^,LZG\]ZV<Q-;^Z&.-G<SE[.U<\P9.XXE2,#W,=J9F-\8.R;D1E
MI0MLX)%35L8)>(E;?NGPN:E(F^EF._*W5]"SI/>$J,4939N<MA'=2[8KMZ*?
M%A,P?B"+"U/@ZHD@5?B*&0%BD=SQN,'XR5YL?BIYKK7&!KQM/UT%?DT3 7R$
M!UJ"EU ^]_-P]Z*.A5E/@]7-_BO6_23A;S%?]TY''I9<ARLE3 ^MS8R%F<>I
M0SVHP)EQ7$TWXBSI'BYX-2'WC2?/;L0=$_\B9I:!QY&+3 P6+RMLKC)WV*09
M!Y+<"7&%7J.=\^?&[I!8B[WD3@8/SN]4W<R02_..BRW2N?,APW?9 ^KEUDE'
MPX3Q97,XE\.5D<DM ^4DGZK&:WMY&F]/"9T^_RJ6Y<&S3FL_+T*Z-\[-$!N2
M;[.TA9%OF_ );W6!P?B[Z[_W)52]U_C#4:9*&!1U<-S0'?!#ED04YE?&Z((S
M0O,"9DY*Q@)8L?-13!DO>)(RB<N;;!I__,N/26=]DT(753C4L/[($.O1$KA6
M]"FZ&>V+MLDQWWX)K@KM:6\Z#< <=T-X8CJ@H7]TLQ^B%*L3WN$+2I:)>YG/
M^5YX0NOO[];P.<5A=S%13--\U8D2GP\;=GF%K.E>02]L)[V43%OS"?06?"68
MK^*@,5L> U_(HO$]>]/RG21BE232'LDR2=#$9^%6X_*Z7OVJK/I^+>I;=>>^
MM4+OMC3$U+@74I'F0P5(,OF1KW&RC1_J9T_<+"P?L,Z&I2^]#$+<O[_IXR&[
M#N-N5B0$+:$Z)2YX.3T>QD"=JQZPI6C'JPFZ?LTTZ?L%?)3N45%_ >W7X3.K
M654C;/9G>9+8=EX\4[\>&'[SQ^G___7_^<6$Y+A3.@]"\M#]/^W<:S2;>1H
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MIP@-HTCF- 4:47P'QV\ 15G2MZNC-C%!-3EF79'QQ<2MMIG."A&+/S!TFH(
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M8$II"CG+@C3.?)%DH8XR#E(:62$;VJH^,MBEWB89ZRGI,%[]BNH4!3-EM09
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M=@$-'8HC&X#/RQS657NWU7KK\AF -U<Z#,H_:.'7K_ZCH&*XGF]P:,L[U S
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M3SDJQQGW47;'F_@"RE%A#F^<''_,W&NX6G[E"TZE!?Y5>B6K@AN$+8^].T'
M$N?R8VH)@Y:R<?#RJ-S#"_&Y(IMICJVT1HMAGTA6Z]W1 2=;TOK$Z:Y:O<]9
MA"2NE@OY\[)I3M<YGZS]?-7(Z)8LY@]- M:O\P4OJV7.VP/+4AU$\(+.53&N
M9DLI(C_D$?%@AL(,HC1D, U]^5. <.#Y* ZIUN'A"+R-K.(;!L!SFUFPW'!W
M >@^-P8[>\=3I!$?>3O@30U-A\_=BG$-JT#R"CK,7H#M-*WY;<X]W\GD& 1H
MWFZ2[$(YDT^66=QG'#A[(T2.24X72QH'JYVHTT@D+ H&8;):X.+3O*SJ/;UQ
MY;Z3 XR\(+5T@2)\81H-.BWUL+/I1&"SA: K:UL=R.TM)BVY[*H%G1QUNI)!
M0X+MU T:?-CN5/PCGA=U(.XF?UY5Y2=5^BM<=TLG(4VR+(:4!PPBDJH3<11"
MP@GC:<+2#!EUC.BA-;)2?KK^_?H3",T.O/N@Z5='QP*;*:4BVL1652*MHGL!
M:LH@'*&GN8:(C@ZY^RA->L"M(?+^X;;.*Q/?*/BTN=Z.D1?Q+ J@CP+5.H*I
MB"@+89AD(F#8PX&9FI_/TLC6H,E')YIYZ^0P;_V,DN0.YDO/]DP["V8FZNR+
M R,5'G>'V5O? _CT-N7%W0'H++/_<&2+<-U=P:G\VYSBA=P#7;4_WA=RJW-)
M:;'B3<'RYB+_UFG'2<0BP1!D?BH=J$CXD* DA6GL$49B3+E'M<-R=CR,;$H[
M3#5- M;_J/D"-6-XH7E"=0[4&N&U\0$TLX)=["Y/8,<W33 ,BD0X ]4@+#8^
MN';AK]% -@MSG0=/;SC+<NCIPE;GR;X3GCIS*/,PU/6_JM?+/PI6NDN0,AAR
MLM2H7^0R6H$/ZL?M]K&N5M/T&6R<KN8<T7T.E G(PW&PD? UL^WC0NLXP<D"
M,:N8FPF=R:)P%L)WXW(VKSMI!/GK,J\>%Z]?Y(<URZ2?Z65)"&F848APA"!)
M P$S0C'C-/3B1.OJRC"IL>-TQQL^/C4,@$)R<%;;PBYH&AZC,RC,C,>)=H0M
M;?#%)0IG-6RT1,-IDT8M5,YMRWA$4,-6C-T1WK+]XA%)!EHN'GO#MC^U=,9N
MRE*Z:1]6A:J&6/?Z:FH@;UJ&J8?6#1[KK-\9B\/$XSZ#"57;Z"P.I&7+(NAE
M+ DID>:-:UW-.9./D6V?8JC^L*5O0)LKX:7B :QR5=USVU6Q_N6F)VG=DOU'
MZ2Z4-?M_,6V!;3<EFC'(\8$V##S6V#4<@8:EMM?DNBCZ12_0#NNCG8F-L\[;
M=EQ,W)/[+*@.NW6?-YQE"9!F?_IICLE\49=;NUH5A>J9C'T>>CP+841CE;+G
M19#X 86$42HP#ABB1MUB3U(:>SO9QE(66\*&E3Y.0J1G;IP(;KC/:V7NT+P
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MR\BPFI?=^[PN>%[7.NRR4?_:L%!>#V1ZELX1$&9F:X<H:*B"'S])\?]R 11
M35;I!;BLJF).Y%>G4MGDMNL.N^V\H"&]J\IU/92FK4LW+/)!U3F-5RRO\TIP
MN<J,JD]LFYO\MZNJK*1R2/,BU3[+TC"-(4M2#E&(0XA%+&#$8R9\[/$P]4Q<
ML %ZHV<OM=2;PB07ZSNYRRT']LT/AJ",A9\FB ?0%QZ"*(U"2 A*H4_"*"$D
M9>KDV+@6LT- K:LM_XP7*M/NHE-(>304PYC20 @?,D8%1)C+/0'&"'()KF D
M#7T1FQ9+=HZA<3GD#8)\Y(]0;TUR"(C9NK15T*^-@K;57CK$'=[DUI/2U87M
M 6K3WLO6$_W@^K7F:Q:WK$]=X;K"1?%Z^R*]W#87<!/7NN?%TRP-1>KAE, D
M%*HI!8LA$7$&1<B(%Q+L!R33OC9MQ\/(:];N14O<37.CBB^@KI" LN4,X#5K
M0-)Z:E)M\*NN&3EG*OI-RT0 F[K!)R^QUBP!Q=,ZY;?<AE2!8FM\1 VN&(^/
MK-V=X7$0-KO\>QXVO;=Y+8>>[GKN>;+OW+<]<RB[_4E;Y+8]CA \C8* !3!.
M,58MB!!,"0E@E""">.3+/QE=0=L9?70[WFDY^X=1H>OC8#":"HI] N.08]64
MG$/B91P*=5;N9V&,:#B3TT*6H\/1I7(>(.O+=,H)EEM>V%:+=H&7GNMKC8'9
MRM.2&>$LZZ@ CGS8W;$G]5B/BK7OGQY_R,SR,#Z?K0/YU]_IHS)SG_$3GS$_
MB#CU8YB%F$(4^Q225(5"!)<[^#"*6:#E:IXB,/9Y4DL2K&D"151/H4YBTJ]3
M+B0U4RM#(;65:TB2GKON\M5&M>0/6XTZ.> D2C4DSEJO!I^SK2$X9S?Y_YGG
M\K_R2^9E-<O")$D9I5 N\:E*_?0@YGX",4,,1:H<EEG^UR&)D=7K\S*']47C
M>4L/\(&6>[K0:(9LSA+8,$HC:<%Y#A4UL";GLL+>*5&<U<X[(#!Q5;Q3 A[6
MNSOYI,,8RZ_X^_QI]73_."^8NA+=I)+?"G5U^K#PE=P!\3!"*<3"BR#*P@QF
M$<4PI"C*@B!(2!2>'7(Q8FG:",QZ=W,!GAHFZP(13;CVS )U;B;HC$#,:+ [
MB\NT'(*:Q;K*0WNA2*6\*#;/+![G9@H<1&Y&FPKG@1RW4^(FMF.%GE6HQXS2
MVT=^K)#1"@39C6RQCOV6%YPN'W)5?+Y3)*DY&)>_N.,Y7JCLF<OMNGG9E.#Y
MP)M>'ZIKVVJA,HQ59LU77E6+IFNB*@LGAY!_: O<JW%F+)7;/>F:0A*G 42<
M)S"- A5U23CF48"XKW_,,#G[(Z^/-SF;2XDJ5<&Z7?.:.(Y**E&_>UX+5*?<
M;!SDMBK2!6"M5*KA92,54!\S*#=RU56SU5CJ;W@KF8%AG_ZCT5B'W_6G8+9F
M=T79JTC7YA>I7][M? IKD<#E^E/82 4V8C7)K1W!F@*BC6C@\D_R,1AX!._Z
MH[#S'M[QQV'F;[S9W/3Z)M-S-9T?\V:([_@\;\>%9=,<=??[7KY[^7TNC8](
M,YIY'$8\C*7[@AA,4>#!T//EIAWSD&&CBQ0[HX_L7=2T@"(&OBERAK<7=H'0
MBZ59BV>V8NI+9MX-YY@$KKK@[(P];?>;8V(==+TY^I"=&K5])NK=3*<\8%NL
M+L%!R#,40Y'&H52K+(%9+!CTXS!-",>1_+.)6O52&UG-6MKM]KU#W;"\GQYR
M>GKH# \SO3P#"F-%U1+1D>+VTYI4D;7$WE=LO9=&*C!6GBJPTI91N?[."SJ7
MJ_R)2BKKO]\5<\IG* R%4.=;7A(R=9O&@ZG@&!+L)Q[V,8\I<EI%S"G[(YNB
MEB7 6YH3%0QS.\-Z%N[]SIN9R=0I_54.U/[:5/?:R-1;X&O]%*A%F["RURA3
M,E7Y+K?,OZ\:7:-,C'$AKG&XL+S0B<M'N2%5_Z?J@+W@!:^;IY65'%R2//[W
MN^5B3E]G(@Z9ET448J0J77JA_"E#$21>Y-$$A\C+C*Y^G</,V">\DJ9*2"X?
M08=T'87:\E?_W?!VZ#GXZZT@4Z%J>("KH%3P[6-ZL0_HB:<:!L&W]O_O^?<*
M_"RMP3\=^MXNH'-U.?4<5J:]O>H M(/KK2[&?&^%A3\O\Z;<[1?IN'Y<%NJE
MF:!$&DX4PH1G 41^$L#49Q@F?N"AA 6")T8V=5KVQTZA6ZFT777U7!4+?B_E
M@(_.HR/O_LUFQ[UW[Z:P[T8N^>/F:VCO@'Y3LH)66)<55-YDEMY]O=ZCS+\O
MAW^4B9FN\FXO%[;E');/O*A>[Z3^5G+)5#P\*^*?>36+&46>SU/(_9BJ<EK2
MH8^X7(N\..;4QTF,4[-:#J>)C;Q4K$G7WB-?T[T .3<L=]<+F)Z5=P6#F4U>
M4Y6NLJ); W&]!>)S#Q 6%^6')71V2[Z'U,17Y(>%/KP?K_&.;8'*3>NX621$
M&JN3W( (=0TRBR%)4O53&,4"A9B'J4DMIL[81GIK7GOI7KUBWP:O"X*><EJ*
M9J:+GS3DL:A)><"YLXJ4VY$GKD=Y(-)A-<K#1RP51J6H2AUL3XVNF]LX,X1H
MEO$80RX0@@BG#)( IQ E-$NR2*11%L]R_J#>N3>H\'J4FM8GES6?W %-_:5
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M$-!;XVQFBEH.FIYO/0UI-RR#O3?:&:I;Q*WY[NP#WGK"#")2;SUQ=O&K-YM
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M63C.-E7A9BDA@HI4>M<HEFHO.($9%R$DOD@R@5(/14:%UBQX&-D8-!R!HBV
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MJK-%^8.:Q"_\>5FHJFLWN5@63[5G+]WYYH_;+Y-33L+8HS#T8@Y10D)(DB"
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M2[Q[&<TTC\[A=.CYLF\%LN&N]Q2^%Z##*/A#<@IJ5D&U!"=?&B6ISSV,SC(
M';(V<;J@>U /<PM'H&%IC!>X+&_%W[$:M[HMOJAKYYUF&;/ 0WY X@"&B4=4
MWXH8DA3'D"(68I1XOD>->G,/$1S9:+9T2[#<ZWMD===Z$#U->^@0$T,;IRBK
M<X^6MOQV0$U]IT.00Y.E*:DK,S1$;EK3HBG\@;G0?<]\!_%YF7]9+;COD<B7
MIN6^>,HK]G&!'W3W%"<'&%F/)5VH" -%&?H[*ZTJC#'/51Q0?P]R&HCA78D3
M#,ST5D]\\$UQX>ABT:"45MN;TZ-.MN$9%*R[!1I^V&X=_F6%E7+S3FX'\G#*
ML8^@CPF%B'LQS+C'82277!ZB-$TCHUX$AR3&CWSEC+R"3[R2;ZM5YJK@;&ZX
M/SF"C-ZJ>IZ\9OJXI35*YLMI41PME$<(3+HTGA9P?S'L>=)J^5,Q#;Z\?'FH
MZPNJ]/'+I\I@]3OZ_@2+7QVIDO];5T-KZECNUJ?I/VO11T-K"3P;"/,5\'P,
M3%? 7B%M%\#C@TZY_O6*M;?\]3\[4AFR\E1)FOH_JKW 9<[NY >BXI,?EJI8
MVHS[*8D83R'SXQ2BE A(>(SD2AJ&"0J]+,/FO7\=,SFRH:@)U^TJP+>&H&F5
MF3$F1F_Y?FNXS<R1"=+NJW>= <54E;IL6'Q?5;G. -FX M<YM,S=H$XLX0NG
M2[F:OM[DS.1H\?0(8[M"1B>-/8(.^SAN9#0S*]WN[&NB%T"258WP5+E;=X>5
MP^)9^3<]PT[FX0R+UO5Q-)X^MX_*AWGYO"SQHBY=7M[DZOZJ)/=!9<ZHZS,K
MSMKTFF6N_KQ\XBK?HBG.A^470OG71\XK:00NF=Q1R\?P0KV]6*I$C'*;8BY$
M%&,<,.GZA!2B1 0P"P,/\B"+4(S"-/",BH>\@0QC1RDZ[4:ZS(,M][;M6J:;
M9DV7ZGU/GIEI7(O0-&@HE55LI3@UC1/UB)D<6^?]9::3X(UZTTP^1:?[VDS/
MRKF+UYE%&+9&*V7,8QE25["EUX PBB#V< *)_#1#AI* ":, MWL6)UQZNI[>
MW;*2LSO'B\6KM&6'Q5/6@@#UC8,KO*"K11/ND@/)+<.< JRN9ZA7Y5.?>04^
M+4O5SZ9HJE3;+FC.IMYTO7J+"35;CKIS>:KHS=Z\;3E6+ZUYWL[21.N5:VR=
M+T?.&'RCU<8UP*<7$^>4S&,)=4"X[D^Q>+W#<_9[>;7\RA=U^_8V3]RX+*K)
MF*,G778/%UJ>@&(*O)1_K74:YZHK8</=.C5>/T1AA-]PT&(LZ,R,HR5J(Y1'
MM<'#*NYA1&BR2(B-^-W8B-7[=@YGG0S9U%V\?>'%_?R)MTG&)!-)% L$?1)P
MB-(@A5G@^Q )P@0-$ X\9N(WGJ0TLBU1Q("B9E@%Y#0R>FZ5$WG-#$"')%BN
MQ1XA)7I0-$?.R6DZD_H8@^+NNPK#+YR11-%^A*:Y$Y/H6B==P"(A0DN]SA3*
M/OW!G1KUB'!><L.4RM$CQ-%4!C<%?3>Q%[4LWN17^'E>X47[X7B(>CP+,D@I
MB^2*Y3-("!&0(X]R%".,A%FQN3YJ8^<4;&C7#AR\R4%+WK#67"]B>BN9,QP,
M#_OW()AO(!AA2=.2T57EN5Y:TQ:?TQ'[H/Z<UDN6E;+JRE!\][:[-"*T+6CJ
M91E/<"35.TA"B*0S"NL*&A'WTU"( !.F=3==D][(6OYIF3] ^=X3$/\_=^_:
MW#B.)(K^%4:<B'.Z(XR]?("O/9_<+E>/8ZO+WBIWS^WH#PH0#Y=V9,E#RN[R
M_/H#@)1$R1*%A #*/1L[72X7B7R F<A,Y*/%(Y@I1(+9"A-@3ZPCS#,3=X<L
M@0E\!WA/CXL-=(<=K\S(=-7GZ@BT<;M;F9'^IJ>5X6MPX[;-MWE\N),6\[)^
MG(.*8_:^/$[*W_117R1(P'RIZT$@Q3#[B3YN_9Y,+_ 8/DBJT\*70:JLS.+]
M*XYF' \2U#>1AQ]T,]51KM*EA<8L+4M&0S58KD*84(X*'*6(JL8N81*%. &5
M\A^$Y/M6;W?@X2GYMP>Y97B#YH('P(LP._)/GOKXAC1/HQ\W<,XZ__$-N<>&
M0+Y] 2; E"V_3SX_*TOZ5FPW?^JFOWY<U-??EWS>R+],(IY&N$@R1--2(%S2
M!)&8"U3D.199FE >&DT^@('U'472>*C;VD4+6[5\X JXX>D*9.*PD/MC#3 6
MU7+E5NQV@UM-M@XD'L$:$2^<8@NJ>_7J*Z8S<&P+_NB<,U:>=@QH-:EZ5ZG'
M-$R22*M(X&JCZ$L["E?*T_+MDWIOZ*EBGZ39>K/DC\U$\C?/2QRC,,4<85[%
MJ A)*O\3\H30*BEBT.W67BB^;\E7;26Z>78*;J ! ^V?_2PRLWU.)ARF!6UH
MMNV?L9\FMTTS=F"<HU/&?C(/M,<X\+"=:'[F?_9F6=2+N?R1MI4Y^UNYT[C$
M99J%*"4Q13BC):I*7J(D9C$EH8A9!8K^01'P+-!?.)6@9Z_!3=.HI&J57KC^
MW263UI#\97\0RQ;&,)D'\]Y,'?CD*-!>XG\>YM4X3?5MF>%(Q8#!CZI];)FS
MJYBLU[&,K/!:#=S9.PR7XH2+)"\1BY5ZBD*,*EPF*,P9QB7A49:DH-C*85B^
MHRL:<G!YVO#@(5X91E;<<  86SE O(=K1P/Z7 58!B"-&V(Y3O*;((O!*W;2
MO)N;VR7S3W*<T*((<Y3%0A5-)!21")<H)BGEG(1E&$I#0[5F,)/D W! 4KR&
M9OPAKTH3YGP9S%1I@G2U KIX?%QTG?AT3SZF.A_6[3_JWP+;\QWBH9F$.^ ,
M3+K?5@!<K&HXW,GU$:H<R?0A**/*\Q%2=V7YV..6I_*J6*OOIN@V[E5&<L8K
MC))*9-)E4&-A0\Y0+I(X%#2K> +JK'D0TLC.OL5P[<-,,CR,79!^FKOO>)[U
M48I<';X'X8Q[]!XC]\W!>_0%BSD3_$EN]C?2\,N'FK>KZT$6]9/JQ-OK8$.*
M,!52/E&2)@3A,@X1P4F)2BY%F;*"5LRHJAX$U;<8]X#JMA+ *TL8!X?EVAM?
M@#(.9PELO@64Q%/F7QC#&F\^!I3\K?D9X)?MSN]NWF9;.S?7#0=5;^ZKYV:Y
M>.3U;BRJ*.2)GC*,HK*4YCDGJFEG6J (XRREF,1Y83.7UA"\]RB@1D9WHGF8
MZTQ+J_FUILPT._S]L0BF+5;<Z8I[6TS:\0 K7/P&]>P8X79ZKBGP<\S6!3+F
MP.1=Z"KPG,.ND [2?ZOWBN\4"%##K3XIP])\ A4P,5W5EKKKG+4';:NTP/XZ
MHR4#[D&^GP*X[Y]A7[2:;7D]7TZ7KS?J=%;C+5[X![(DW<#+25KE>53E%"5A
M+/W@- U15>4IRG"!$UR*&$=&1^8Q0)X%HP4=]&"K^:@DN#J2'@YCUK 0N60!
M,'9E23UH2JP):5:38@<7'FU:K EY_8FQ1L_;6;UMHR'5-$8==_N;$7WFRUMQ
M3[Y?+I?UM'I>JEXE]PMIER]J=>'58C<IXC*.HXJA5*ATEC#*$>%1A5)<)'&2
M)414H 9TSC#SK YTPQUM"K)^-[+%&LD+'?Q>B&"J*0J6Y#L'WI2[VR5!!2["
MJD1EB4N$\PRC@G".1,1"N7E%1$@R>>%UM7C7^]3'\-]TIT@H"IJ2$F65ZF6=
M<(%(2F-$LS@IY:^H_ -R_W,>>8+?&/VU=LG,<ST+[V'G>HMB\(-"\L>6_P>Z
M*U[H/F.2_Q+9BZ"/KDJ2OB-N:^2<L\Z1&^P.KU$]9.?LW'6>W0.PJ%[8ZK4X
MW&KQ9S*=*VQOYZN7)KD:>(=SC*I$U2=)+8Q*:;Z@4$B56]*<1Q$UKF@X"94Q
M3)?%7"G:ML.J%.H#2A>0RW\:\X<5ZK@LA6G0[3ZUQ]O47@0*NY7&O9T'JP5&
MXS6@EF(TGMO55_CG/:SRP@F[!JLQ3H,P7H6&$TYL56VX6=':7:Y5C<@'WOYY
M,]\7(5Y7ID^JG!>4XQPEE7:W$H9*CC%**8NBHBBSJ +=$@'A>[])[NX^5LTB
MIA:&.(B?QN:V+RZ!C6J-0/##"I4? ]5#9N^=4:_=A%/SV885[HQD$/2Q36$;
MUNPQ>*V6@5\7?>'-*AGFPX(WGQ?++_R?S].:KZ97@/NMFJ_H_<)YC4C )";!
M?+$,ZA:7]3P4\]LH *>.7U;Y81+TRGG#'X5$(+$(ONSPQT,753CM5A=B #"C
MW9?!2>]?IUF\?6+:Z;J(]5)=$>BS^"M_T/.D5'YEEN4Y+LL45313X?E06B)9
M7J&TC*HJ8XQF):ANS1"N9[VQJ:;>0#\M,?4(&\T,$ _,@>D+&[[8IZZ:4>DZ
MD?4(U/.DM9JQXF"2J^'K=JIBNWA%I[XW;9GGA- J3J-2H"RG%<(1KQ!)RQ#Q
MO,H*0@H<,5"*^F%0GA7"IEZJ49 OVG*2)IBVY:RJV*3]#;#"9(!W9BK!#4=@
M6F"G>.RBK35INMI>=XK@.&V.9'\ T*CB?IS@70DW>,-Y ?MM??5-S9F\F?>?
MF,[I]&G&/ZV;+&!!XYBF":IPE2-<9%3:"*206D#-E MY&D>@\;DG8^0[L6VH
M*EOR/FAQ5([ZUF,=FB<TN3A]K\QTS:@[ %-)HS#?994\C&'^R^8-\7DO=?0P
M]@$*ZX$+GSH+[2.9UK^1V3._;!J^;"[G[-,FYMGE3K+;^1<UBT=B\:"&<S5Z
MJM,FU)!&496$M$1A5&*$,ST!K8P09E0:6*$@E!*[,6@.L/.L=/M3L]HFKE,R
M"V[FS;)^;F5_A69 EH&B)] $J>M)$JP1UT//K,=TNMA$0P?P7%L#T\9;N[+F
M^470XJJ;O_2PW6R1W)2=+1EIA)E#;CJ?7N8"MS,-+G/(UL,SRUP"L53G1.&A
M+?"KQ;R9LNZ:4#4XFKYP=L=K/3=%)=DNYA,JY/^Q*$&B(%)+QQ%3N9(IXFF*
MXX*G(BICD+X&@?>MD$DK]IV;_% O&JA>A7'34'%ZXQ%0,W;LZ1SG+5R"%3*Z
M?T,/'8<:SXH-KE0:#/BX.LN*,6^4DMTJIT;HQ=KRN5LTNJKRLFKT5>$$1TG"
M,QJA(E1.>$5"5*8Y0R4685:DA!(.&]]N -2WAEG?6&W9?"LL@C]6>%B'Z@?X
M"8W3N^$24,><SJ 38O;'*78>L!\ >:9H_7$F' [5&[QKD;IZI7LC:=7T8?HB
M-=.<-=+'K6M.:NGT?N""/,^DOL#RAS3,$8OR$N&$Y5)?1 15(<\K5B0TK<R[
M;IO!]*PNUI!5[(>TL%5 B+70 4F1ABP<5A&>& /3$"W\KO/,AD$W\Z##(;BM
M@P^^& 1(#W7/*+L\T(YAVJ@-V/ 7]1^.<CUAM \F=1HN-5[V)HRVK31-X*L6
MJO*.O.K0T1<^DSJ9W2^N5!NY:J%LN9=-MY!F$D5E1-,H1GD>2>,JX]*XJB*I
M-K,<,Y)&')/$6%F:0O5]T=FA$=0M'JKVAO8Q"<@*%8!F,&:I@?+TP2C@_>>*
M1QT*P?TBV$(BV&#A@TD !>J#678JU G38!H42OR@#C5>;#PM"J5O2X^"7[;T
M4M65]$^DX:P_PWW"\X+AL& HJB*&,(W4".X0HRQC(:VR*&6P!/;]8+Q[HO(0
M0I6"JGJ/KL$"_<[]'#+T-$^F&^A;*GA( PRZ+TC9C.K&3/W<SC,DS;?@^KO"
MQD&#%#-*7?F4^X&,ZT4.$OK&;QQ^VJ70]O;YI]?-(]UGH&>]7?_S67>46%^_
MW2Z_\?K^&YEWTT]^XXU4-C?S.UY/%U+I+,EL';^?D*JL$HICE&0Y1=(3C5&5
M25]4J+;$+$K3I((U-#T+&9Z5CKY/>VGO,$7PY>NO[7W:G?K)A>+QOLNG*+;W
MM'?VBK-/45][!M5KL%?!*KHN@I:RK<MM35NPE,2M!CY=!"U]RC=M*;SH7<'Z
M5L=C[8]7=>^=B'=PG(RU46;'U6C8V!V'6Y6AGQ=+TSIH44:5(*Q +.8J,2>6
M1B[A%*5A&#&"6<%#T"0N2SP\'TAMQ?-,5SSWBOYA9Y$MB\T.DQ$8!SL-=NO*
M5=F5247YPF5%N2/N.-+%MEB,JDQ/9-6N-CQU.=MZC07EG.E&*NV-M?R-A+9\
MO9,?Z?)RKI7MD]*RDZAB252&,:*1M,9QCC-$=',OS/(J2T*>4J,>HQ:P?0<Z
M.TS:GD22JUQWXW_JT-%&-5_A BWJ,&>PF0+SQ#9@V'.+8ZM,EA4B%X%&Y4(S
M[OHHXRR*0< L<%8=8@YYY'(1,$O>UH_ E[#3.C\_$VGD+3F_K6;3AZYA$UD^
MUZN._F5*HP)7&%5EIF8B\ P591RA)!9E6? RC7-02/ 80-]F40M^40<]^/*D
MUQA83G,_RD,S;>*2,S 5<B)3P$K#E%)'FN(HN%'5@RGQNSK!^+U36L/>D^]=
MB/@G/N=BNIQ0GM T$SG*D[Q 6!6-%6G(4$9CDO%(1!EEDSE_T+<5T'ZO;\ 9
M?>-E^XV_ 6K\O=^L6TD&50LW^(&W>  +10]QS4SB3V'"*6T?)<3534#P0P?T
M,.&631P/DN6T)>-;*&=HL'B0U/WM$@\_;ED4NI@O5I7D+81N^75^9,(B+-V%
M%''=XS#B I54R+]BP;($9S$7P#[ 1V%"/F*K_KYMD+7K"KL67]TN]C^!A9I'
M^6<FSDYY A/L/NA@U=RU@_ZCE]128V)=%4D>A3=N$:0I^6^*'(U?M+PD?'YZ
MFNF8+9E=D>;;Q]GBSYNY6-2/9"ME.L_++"VB D5Q(<_U,!:H2+#\J4@+7,;R
MOQFLW,4,KN^[_QX6NKGI;*&G@DB/6-]_"XE5 U0/IAPUO$%SSR?@E5>?10J#
M0*$0]'#PDXH.H]O559(AU''O?F"L>'-9 WS=(M>R*[)NV@H9591W*:0T7LXD
M*")I_+BHKVK.IDL5 >U&4\C?/4Q?I$'3-)>/ZNU)DH>)5"49*BNM8DB$RCP4
M*(NCM.)8.A:%>6=E)RAYUCXK'(-ZC>1%(#9(!$1C 4@^=+,1PYKI/.R%*:TU
M9[_T.$L4AL$:1<7IH$4R4%A>K*;47 0]3(/+\^P!(#MT]+VP2QT=;T]@^:5.
MV3>8?.H&TGB9J4XYLY6VZG9E.\OW^O%IMGCE_"NO7Z:4[\]ID.;WBTY)T.D+
MC4Y(Z/_[U:)9?EXL?^?+;AKFOW1]Z'3!)+J] 9G1)!$AS>(X0HPS*D^W(D1E
M)KWKF$0X$1'.2I)"#.AQT?=\$OZ=3Q^^2301D;X]>>#!DT9"E2W4*\2"Y_GZ
MY^U,7?F79JF[M[VJ\A%@3&[D[\#,['^_NPOT'@PRC5L:5OEQ"FF=2?'*E\$&
M[XLN#TZ?$":39\$>QWE8[LAQ&1GY4?V?\VS,KAMU)BPLO+'/SX\5KV_%;XLE
M;Z[5N)S6_9,@K@G]IC'_&Y^Q294D>9SS"E455?,'6(6*@F.4I83'."^8,)M?
M#X+J^21IT5 !G!>%B%877,)O&WL&WR0& %O>F)4&+I,/!@&COBUO;D6@<0AZ
M2"CS.E!HM*G+P=\\\0G@UOC@EYWGLOM-\1[?]GQ?KDJ'H0P8]#V,%QO/O8#2
MM^5!@%^V<Q)^[=F<]^1[=P'7K,8Y2 >F>9ZIV+Q.O>'+#HM&37>0SZM>S<_+
M;XM:M[&2/@#/,>4%*FDEI ^04*EZRQ11(:I2_A#%&:C-NE/L/"OFFSF;2FR7
M^AJ]#6Q)]YYUJ$HSOT.UR^1;(]N.05EJ; .R01=FY+O=1S,;_FR[ SL5^FCJ
MJ_X5HA?!"M7@R_;N])!MMZ=%-[@TV!ZP7>Z%C8[,;K>XC6I5>V'KKM'L!XB%
M37PK3?!?2/T/OE3YD>NZZ%^X.D4F64A84E*.(B9RA-.P1"6F%1(L#].PP+R*
MC7JO'@?E6<DJV$$+O$WMO;1H\S#,*P-+UQD'8(KL,/'!'RULPT1- RX [%AG
MW+ S7BT^"9B9:D3?H&TZO,)X!JD1)5M6J-D;MKW[E^JZ]JY>J/XX[*?77QM5
M&7>C(PQ;0T F&)<DY1%%F,8$89S&B,1YAO(J#J-2Y(QR"ID&;@X:I,_@X[[5
M+&F=B/'4H:**:W]X;G1EK)J6UR$4D#5&T*;[QDPV,_K\L [HYTNNZ4R-NS[7
M?EUQ;8U+;_R/RV[Y4 8X:XMO#'CD_O=0AKQM= ]>P4[EW&YGFJG+MTF4<B[5
M2HC*7&5ET+!"),FEXYJQD'.IRUF>0'3+'AB>E8@>9*W]%NC$ZB&^F*F#$ZD%
M&T [*9VZWM2=; ]0XTB(]T$855H'2-P5RZ%'[>1/7160NIL%JHJXIHOZ=T[J
M=2_1#V1))IAP+K(T19SS"N&*IXBD>8@H(25F69R5%2B*9 35L^/RZYP\LZFZ
M!KR9R]>GC[V6MPH\3%[-^&@FP<ZY Y/I+?!MI:9$(% 8[+#H(KA;S*;T-?BC
M^]/+M 40.QPI!3.8HZH)$!MV%0?L93M5TIN><#EOYXI]6\SD^TW;@V.2)P63
MASE!215%"/.L1%5," HSEJ=IBC$M,LBY?@R@YT->7[7V1XWK"N:FA\;__E]%
M'.7_5Y>##PS1MN.FF2YQR2.8&OFTPYCK82: U8(I98XTPE%PHRH#4^)W]8#Q
M>[:E'54C/W8^7UZ_J*#J9DQ16.6E2JJ6C%7U741DJ,QXC/*24Y5G765)!"OF
M. #)L]7P]=>?OE[_]Z_7G^^#Z]_D?[]"*S4.,<A,G)V0#9/C#<B@A>EXK+<Q
M:<X*+@[!&;G$X@BY;XLJCKT DUD]%?QYQJ.P2J/+NKZO'^=+]G%&'DSD\/#;
MG@50 0T45!1MM<"[Y_6C-&:6 W-D3<D?%D4WE,-D\#C1P1\* P?B>)R\/7+8
M</H?#XN7_T^^W(D@91O)&UAR%)$[3M)*U@R>A O9Y6QVR?Y']4E^?.KN<@P%
M[.V;GH5+ @PDQ.=FV=ZT+Q=;/2?-)6L/S<>EZC1R81)UA-+CUW<@@3I,F94P
M[5EN-$$Z3$I?B :>LK,LURT9?WI=__BW*:_E0M]>/_$72>_W:3-)!>-10G,4
MTT@@7$4Q(BQCJ,+R%QF7_V\V60$&UK-4]B=AKH'#[$Y#]ID9H>Z9 I/=WC36
M-5CM8GZ^_"WX0\%V:);"B'5DHQH"'=5@A3%BUWH%OGU:?54WFJ#G['8%79.4
M2'>S*"LD2EH@G!.,BDHZI'F>5XG 65%E1@6_QA!]']B4UL^[M4E*%+JN0<!;
MI^,,--,03MD"4PXKT&@UAZ8'?%W;Z;Z$YRBECJMN#L,[2Z',4?(/U;8<?]&Z
M69C.]UOE_=W,[VK^1*;L Q=< F"KGB9SIMOTM#. )X2()"%1A"I:JDXC4E.4
M):>H2%@D.">BRO)5+S$S#6&'B)%\;'<9@RF.#HF@ZTHD16.ANQ71EOL!T6BT
M33G;?VE_ VX^9K,+9DK&(V=M6Y>UJ<L_K##Z43?3[SB]:F>F.-IVAKH<YJA-
M5[,3&.*NZ9D-$F/W1#N!47M:IIVRFKNNJ+^0[]/'YT<)3K<4FE":ITE<YD@D
ME*NV22J%AD:(9WE."XY#G(-N[0U@^HZ^+Z7T5*_!C"^7;7D4U37[IW=#W>6=
MF0IRS!&8OCG0$[6#'ZP0N A^G:L^4ZK\92 XZJ1%Z@':/79)W85X]D:I!UA@
MTBOUT*N6=W'T&V?/JC/S]H"V3?A870&JL5L'_KDW<;RY5PTS)A5+<<:2$N4X
MRQ".8H:*C&0H3%-&1,I%*F##UYRCZ%G_[,P=[$7BU:G>_WMOP,[V2W]H/*$C
MQMWOI9F".^\.P?3A")L#O]3TQC]7MZ'N$1SW&M4;@]_<O_J#9)VZ^3A=K@!?
MZ?D?#WQ.I0_]8=U7<MW[L>(A94D5(T["5.ENZ=1&:G!FC&F6ID7,8 D8(.C>
MU?(:%RWK6]@$&W1,VD8Z8+69:O7&0*C6=,<[F]1.. _<I7@"8(^=Z@EGRYZ4
M3XM%;*-M4FIYL]QJ%]SO(_R9+R>88<XQQDA%X!%6'?M+:3"B.(E)4:05R5/0
ME$X3H)X5SPJ%KLFW;NT-C9 9<,XT'N:6']#H5\>*W=[>NN'6&@>7T2YS<IW%
MM@Q CAS),F?"V[@5X-U3?5#=':7:;5[U18*OIW3)VU14J:=V?O/K?"K55UML
M]JJ-IDW&9)G3+,Z+!"4YB1"NLEQ:-())I1(+P7,F(@JZR_.)K.^X6(>ZGNR[
M1BK06 4:K7;6+Z]U$V;Y:773QP\\O"+"UDOUL-M0?_6\>PC3G4=;%K[9)K6;
M>_?N8KUWG3/KIR9G##X[]W ]H'HF7]<?TP][O1YAPG,J?YVS>O;Z\)73YUJN
M^\L_EG<2)K_Z-G^XDQZ887[E\"J>=;8$SB5T53N[0F#5-$-C$5Q]4PK /.?R
M"$^&%:A;=L#4GR$G=#]6ZB1[PYQ:J_S,(TN/EJMI1F(_;]/P#;C JEYL+U/V
M3-I$0T,!W7[+NS.W F8X?F4/7<>%S)XDJ#^V@N,L)?(P^E92LK/4:%*QGX2^
M%!QXPL$0^/8OG-V*GUY_X62^F4:ONOD<FN3<="GT)(S#HHPIRBDE"!<L1655
M50ACD:CX;<434':S.]0\B^;NV/,5KLK?J>1AH=#MW^HHC(>&HP/3F!QNH9D;
M<YZ-@2D8YWOBL.;"'Q]]#*T_#;'SS;%WPM#!T?9N(-CI[2XS]8[4TF_97-WI
M8UX4.$]3'"+"TQ+ABG!589*@,A8AX:3,*@%2Q .P/&O6#G*@00<]V,>L!C#/
MS#2?(T[ 5)DU$\ *R8 \1QIF"-*H*L. Y%T=8/**G5#W2OXZ(/>+>_)=-7]5
M?1!46]A%O7_0PB1FHB()KY#(<VESQ2E%I,HB%/$RR1DI\SBWF3-] DI&$G'R
M+.JVTDJ>ZKK??-M^636=5S63XGG.@B?R*D',5,=L:#/$4_;#3*'X9J^?@.^Z
M#;9J]J\Z9/?P[:5[NE-,#MCD2'&=@LFHBLT!RW85GXLE+6_J]B[:3V[ZZ77S
M3/?-ZI$SMT_:YI*("3Y=/LNO_F;>#IA9C=BZ;"=L77_G-9TV7$>4)CPI2$'"
M$C'*,H2%U*9%C"/$<$8+C).,%" 3:FP"/-ME'5(!59=U,ZDFU*PQIC++ZD:-
M*FN5,7#NV.B;;'AI]XZWSEZO;[43Z!.CO..]!T [C:RC28^?7%&EZX@T71?!
MBK*@(RU8T=8&RQW>\9UI6US=^XV-_KAW@6?:G#?W@^?"P]:I7UU.JO;&D[@D
M+ ]9CO*L2!#.18&J3&"4Q%68%J2L6%%-)!;5PMR3[P. :)H^&(#GNLX!T$W+
M55[ XV+.7X/']@*-=&-/H7[\%IM,77=;TJ'>^IIF!<BE<[Z/ &?^^-;B([O@
M^PA[ZW7O?>KD9J"W8BNF=S.GLV=ERNZ-W4U8&:99FDF[,(U#A!G&J$@3@2BC
M:8ZQ"'$)*EJT1<2S?=?OCKGJ5"#]:=8/C=OV#K?FO9F<C\'1TZXBUG@<N&JX
MZ#>%\-*1U(HQ[CN5PM X5P=3*V8-=#:U6P^FYYIZ.;FK%^R9+F_K;D!K>S5
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M*_C"7_A\(%O#@ UF:M>:.*![VM'EOE_S7@)<-6#96GO<_BO[R'K3?F7O0_#
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M($)Q3)Z7..89*IAJ;DHI20H1ERQ*;')X].J^PU;K,ML6'+3 >(L1AIZ7+7E
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M[37+WXJ?7C+^89B<,?O?BF7#E0!V2]KD,BQ@KM_Z!=]Y"M>WD'2$A;%C9T4
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M@42>L03'+ N%40/LHY \Z[ 5Z*"%':R  X1WD$\&6LP5]3 5=HCPXU=10 X
M=)<K3M@I+GN.P)26"96#&FMP@?'4E0D=6[K*Z(43!PO?BH%&;&F4EA$-J515
M<85PD@A44<Q1*:B@>99D"0;-R3&"ZM^9:G%0?E0?B_^SZ@)D$ ,_@:=FSI5S
M3L&4G1,FV8\L-B':]>CB09CG&6%LPH:#HXR-7K9)T_YS<?]M\=R0.;O_4\)Y
M_2@_HE6W'U75.WWA=_)C>O/<S9P]4XW:UG.7ZM_7CWZ<BB7G\SWK=:>C]/E(
M',4YXFDF[2A>,432,D:YP%F98?EC5)BG?9^5%L^*3GWJF\9F'?1 @;\(Y+^%
MP8:(G7_7*71Q&*7[7X?D5)_W8S$P)O\ZGP#P2NK/1;#"(F@Q#A1IA[Z(?<\?
M_D N]4.]-SI"]Z]N8R*?^<N!9/?_9;X@RVJ!=_0EN2I*>!=;-ESD<%X41RR:
M>!=[L5V$\3Y0.B4=:6T&_D1F:M[)UV^<+_7H5395TD]FFS23YJ?7K3&NS? <
MU^;R^[29D"+D11''J"B4'<;B!)49J1"-BZ(HDZ+B'-2R9ART/9M<V^.5==J'
M=)0D7* G.=(>FKFB[V]G8):0Q:98IKB-Q2.GV7+>D3Y#XMU8&[$_AV\TZ'8'
MQ&HB;A=/W-_A]_-B_L(;U9!7-?-M=')1_]]5>X3/B^7O?/F%T\7#?/JOKEA&
MK]2^M-OQ=T)R3FG*(\1IF"%,\P@5@N6(17F1$5K%O 0- 3T;)9Z/D>MF.7W4
MTZ>?Y_4:J;9<$%6Z?_G6>&_>9M' SICS?09FQ\Y?8G.!4=5]#>C[*:-K<M9]
MZ;]WVJ"K&[C0O5WD<\O@E2^##5$7P>6CZE#F[D@[._\=G7+GHV/4@^_LV[5[
M%IX?(8O@]A?^+R*>YP_3^673\.7J2E9D:5*Q,D%YE&"$"Y&B*B%JA'5">"F*
M)*^,.M\.P/!\I&R !BU40"CN %,,@JNGDPI3L&^HM(D\'B 7$!$\G6R[2)WY
M)L/"9</T#(:Q#KPZ7GAI&/>ML,^11RW4R5<RX]T]W)743%/6F?%2F?'IBQH>
M=B=5UZ;IV(1S@0M=@A"6!&$6YHA4D>JO47*<Y[G(*O-D1RATSRKH5@A>ZW&Q
M3[4\$  2"6:C@6KRR1R@52@Q65^S*P.OATVP04>WJ.@AY)-_ %WGDX]V6M U
M/V&ZTI8?@UH4O.AX^M66WBW-:[V(3;[YHFENE8:?/LS;/(F/T[D*T^A4T$D8
M1B'.:87*),VEWA41*N(R1'D9YC@A65B)R#S=?!"69WVK@ ?RDR=K\$HJ1(M
M,%,80#*NA]EFH''=,0.F7S4?;K5)M.+#K0@ZV&VNM3L^0!+/G?'#,N_\!+X
ML\Z-*!U..A]>8L2<<R-:ME/.S5YYK]=]GZ9S?B-7;R:""-7/)4590:5N%"E!
M!4T9(F$8XBHJJRHIW]>=WQIWS[JVJS-=DW(1=,0$FAJ=4+6AI]=PH5&#*;=O
MJ!I5.KX*^QUJ<O:'HBS0I+V[N\7-!_->+ABM/@/8*?,^OX!W>)'Y9B_^,K>9
M&\S_S:XTWVS)^/>:;U&P:+FNP\%7$@%^O_AE_C15H.Z5]P">LV*PE.<3I<4@
MT"BH@</WTT<]:?Z7SW<W?>UQ$6BT  W;#;@TK+<], BF:TUY$_RA,7([%A1(
MO5T#>(/UQ^L';T[L5GMXP&MVIF\;I5U/"-[3?HOP2F2L*A$I,HYP$0I4EB5'
M&4[3E(N(9[ FQ4<A^E8*&OY_P@R^XVPR,].<$@\4> WZHC=1W7?/,F-B'5DO
MQ^&-:G,8D[]K*9B_:%FW2+]Q]JRBA4;WRY<SO=7RIUNQN4%N1X[K"2]:(4UX
ME>>X3#@J*:X0)E@ZMDF4(1QE/!:X2N,T!]4Y^L#2LVY9X:R"0"NL5R6];4OL
MH,U<Z6,>;%!7[VV0#UKLVU%$W3D,+:?TLM5FNN[L&PB\0CJ66-3U66+:#;TB
M3],EF?73AH[N$+R6TR<'7=5^>L%QW%I1GVQ^4UOJ%9C=@7"EIR^T5T?M=ZV1
M:;[P1N+&V<=%_?%Y*0\@-1Q;>:V3D&9A3I(4$8K5^ I>H2K/4I1EF<AY'$J=
M#VH*!L; LR)O&P&JIF Z813:%0S.4#.5ZI5-,'79HK*^(&ZQ:<^X)ECA$XA%
M';08!2N4W*E':VXX4GUP^*.J-6OV[*HL^X7>ZW5,:\94<5'F2450):U5A*N(
MH8)S@3#.:1264L%QHXS$D?'VK/ILPN@VINE8N_Q>[D\\FZ\>MNT=7GSXL&#'
MPOK?[,)CT,H=&SS\HN.C"JY<-K?BKJY_KZ_G3!KD_UR^7OY9L^;G>KYD-W/]
M+\W'&?NM6<X?KA9SUGRHY0\O-?N]AHTD<@/-L^:_DTY%'?S.21U<JR8"FT#A
M0JQ:"737!C^K%J92FZ@LZ?EKT'MS^8TLU:LS?9F@;FTOGYYF4ZHO$7[CC6[.
MJ*B;MDKHPW/=_N:%UW)!M8;Y/8RC33Q^53/^_L&T_WO9.L<SI=RRW>H:R1$*
MH]TTN659_S+*\<IVOL$7/E-%G7>D7KY^6#R2Z7R"293E85FB(B(%P@5.I$%/
M*\2S(LYSEB1Y!;J@>@O"L][M  8:8O!'"Q-H3>_ABYGA>QJU,"VU(E0%4#\O
MYG6/[JFZ:3Y&.=@@/4R<(]MQ#X!1S;S#!.Y:9 -/6@8-2?--VG+J#W7 O)"9
M-/3VW5I-<%42'B81"M-2>M=IH0JP<X)"(G*<E%G!*Z-T<#!DSW*K$-#?\N-B
MSE^#1U+_0R6I4:IN PR+ ^'<-(P4^N 1,$*X8H_^H8?%@3MHAX%!*/&N H+&
M<,<-!$+9\28 "%[ (O'LX6%Y7=?J[N/R<6F<8[;UEN_,D8>'FC](+1I(D%+D
M%\_-SD7N</N 8S0?=T/LR07FBIQ(*2P1;"]1=CE?VTN-E]ZUEX2M3*[]3\#D
MA/'IY)/DY>SNF]R4S\_:><6A$)FZ@"M8KHJM2(E(B85*P\!EF;.,5$97<?L6
M]RQ0&ER@X04M0#/9V<N'8>DYE3J8_  (,Q:5(0H&A$6^U@J+_&$C+'L7&T5<
MALA8"<S@,R<=+6T?C ]<S7R:SCF#)S4;K'7N8TAUMI&8!1O4K(ZDP[P"'51.
MV.3X^'K+H> /]PG. !Z<>MH=!G".,_ HN0=.QN/O68ZP7$VJZ5*XFDD6DQPS
M$:,\+T.$LPJCLA $)7F>AS0ILCBM0%,K=R& =(#UH,KUM*.N>QG0Z7S+%S/G
M\B1J8:*\&>AT?8Q$^/C)0V2XFCCY9OUQATP>(N_-7,F##]JFD\U?Y+&F<]9T
MUDB;+M+^>LE9-,F3J.1IQ%#&*Y5OD26HC"A!E/ THV58E2F!I8\=@>@[$K2&
MK^Y;FC8GJLT<"^@*B5/2R8XQU# HY))-P&#0%H>ZK+$N6VP-WV5JF"&ESE+!
MCL$;.?7+D/RWJ5ZF+UJ6'NQ/<MVD6?_TNGFDR\+6]Y9=7[J]F0/K&AQYEN.H
MD+YO5!04X8I25$5IAF(2E5$149%%H-ZH7K'UK)+^SJ</WW073+ESY($'7[@*
M^G=7N!H#-57]TU3H\C]U>0NT'OSNI9E&>S<[!-.&_5J#[;C:!G-5TKZW)J'M
M:MH1<'&H(-[+;*DQN.VJ+L$KKN/6)XS!]C=U"J, M2Q:9?_SW"P5Q.9^L0%T
M1Z;L9MY/47Z#OS[3.@R_\'\^3YOI<E6 T195=$46NO40+<H*8U$B6DKC%(>9
M2A5.!4J2F"4B)7%6@4K:1L+;\\FB<=G30AM843O2'IJ=(^]P9X AK[N;JXO]
MYT6_AFW5 ?MF3FO5.$D7:.AVV#TL'58 C\M65W7$(V$];C7RN%OQIJ9Y9/!6
MHZ=)T]R*OQ,E,,O;^HLRH*^_\YI.&][<S%M@DXHPFI91CBA70ZC+-$<DQCE*
M8U(DK$QXD9CWL3:#Z=M5:*%+6Y*2YMN,-TW 5RC @Q807@XK9T\< @8N%'Q5
ME]UA$-S6@<9!%02OF'0S[VJUW;,(-,G:-:ML9UH[81ETP#6$^".CKHV6&G/H
M-82VG?'7H%>M"_:T-?&!MW_>S-<AY4ZUK]UZFH>LC$..(IPG"&>T0%6IND2$
M%:\JD:0A!B7KFH/V'0+^IJRL1L522-LV7Z6^S::DFLZF*KT5V'$&P%,S$]</
MIV#*=&UV_K#"XD?%L,TESZJ.V$?T LX =P5FIH#'KA$#,F1/F1=T!7CZQAU?
MK&>: %(#=U[S+/YWU[=!>RE[4D;@+JW#HGTBF3#9M:,0E#%Q@!:KY(C=M4;+
M@SA 1#_EX= C)]RI5,<C==5NI.Y.[O0W^<L[-4KB5O3*_*55H$:J3@J>,Y*%
M*<I3'"-<Y=+7H56**L936@J<9SD&7ZAX0=6W>"NXZ[O=8*'=47G0!T\M>'7!
M(O^5KX?."97A_K*JP.NN@N4K3&4ER=\\:,/X![D"6:T!O!3VN.V NY>S;^;H
M%R\K[(/U-['="J6CP?&MBU<^N[QR\8/H^/<M7AF^][+%+T3+S#DU%^ZS9!MI
MOMWH,7/2M+M4\[=5\WWYL^XWO/'N2A*5TKU#123_@QEGJ"PBBHHTR6E1)(2'
M!>2\@('W? 9(/)!"I!O_H=P5-4GEQ<:[ _+53"'[XQ9,R6H\@@Z18(V)=HC7
MN+1=U[TX>G9\<)7T!P,^;D:@%6/>I O:K6(1D>^/^-"!JUOQ:\-U>U0)[],F
MMM+U<8BB)"P%(Z@4!4$XE>9JE44,51469<D9R7-J')H' O>L?+9&RK315'0K
MD,2H'5,82)R"'E* 0#24RP9!>X^\@ZDB*-ML9EU"^0>(Z'ODHUUHW]EG" ON
M6_)A,,H/77.\<+\EM5MQ?]LUK.;]OO#Y,_\HB;A:S.2O%RH"^,)[YNMZ!/?6
MLVT6XM^GRV]7S]*O?NS&T^F+W.Z"MYED+ K5_U EL#0IBRA"5<A3E),JEOH\
MS3-L5-[H'U7/)\ &8-!T$$$#>7UNDL&1\&Y8#SM .E0"A4NPA?AN<^A5M[V=
M-UKT X5_L"+@(NAMYM?WMIF@(<WO9%-M9SV??7.A0Z1'X/>16=0^,1ASI/4(
MG-R9C#T&1"<==S]U+<<OOT^;"28T24@9HX(6.<)95*A2R0@E41RS(L]%&1F-
MTS: Y?D$W1TO%ZQ@G]2X=HM99H$:1RP AK[79"]$T+%B!7DS:.\/A82_EK#[
M2/73QG4+TCE;K^XC^4B[U+VOG*?@2K5]Y$RZ#*HVE,H?[Q?J5[?/RV9)YDI7
MK0J-NCJC56Z1CDA/<$J(P#1!/(DJA%,A4%F%E;+C\X@485J5HU9DG4:.9_W4
M(J?#I+Q#3W7B5!$VG8;)U+%1ZSO']D;1YL;P?-\"X%;Q+['#H]\\KDN^>A_*
M=>]#4;^63VTHO0C>5 &NJ&UO+]]/:9B;;7LGM6,G$O.7*BYSLW&NJ\\<865W
MYG;X-%T)]6HJAA[7,XE$F!=Q'",>,VE.QV&$JBS+4(FK.(U8+E)23.:Z>PV[
M-S\8AV :*;6R56IO()M;UQW(@.IQ9:JPZ*F>OJA\EZ<9H7K78.?5(!_-3I.3
MV6*7*M=!7;<Z6 ^_:6>YN5.[)O0Y4HJ#H$95629$[RH4HW<L@M^?R=/3G=1$
MC_(+?UY.:3>]X-/T<2K%J+OQB2LI\5B:O30OI<R7B72F28117'&:\"S/H]3(
MA3:&Z#L30J(0;./0CAT).BP L4PC!AK$EUVS!2;Q1SEB<[%HQ!I M-8UB^R"
MKO8?#RQ6"J%V,.1IM-!XD4L(75L!2-"+]H,$IVV5I^H7K*>V// YG?)FTP5@
MTT>PJ/*B4MHP4C=Z.",9*BJ2(BI_'S)6\;@$U=?#P'M6DE>WO_QR<__+]>?[
MK\'EYP_!U>WG^YO//U]_OKJY_@H?)PA@JYEIY(]9,-79PZ/M%M['9&M$M=,.
MC:>QP>$$00#PT<<'PAFS;W:@Q2H6EMA77LM%+[M65=-JQG];*&!W<JMX77.F
M#;]UIA@CC!4EPIPS^9\<2P<L#E&<T2A,RBC)0J/"!C!DSTJG126X#'K(!&L\
M6F<$8(& >&I@I/GB%# 4MX])+2*[O+(QVT!, YAOOIAG9\8!F.C(H+.A?]"P
M RTXGH%G0^>6H6>U@(7&W5ZO[12H'&O.UK/[-OT$)V%*Y0[$%.5E)IU@7JD;
MY80BRDA>AJP4O.+&*A<$VK/.W7SMVXT_IQH?RP8:,-X:J%YO' .&QK95P[H'
M:(M*;VCI!AEO7 /H7F_<LU.^+KD(4\)6C!C4PK 5QU/#5I1NZ6&[%>P][Z[R
MJ[,L,DP8ST2"PHI'"*>8HZ+("$HJ0D229 F/@3V6=R#X]I][595P=WF;%^8>
ML36%<*=W19S#F9E'*7'HMVZO?Z[)]OO-H.,/PMM0_,*)\E5UFI=A"XK>*YZ%
MI8-D6(6X2\ZP>)Q "4PH.B#.<M .(&[53J*_SFBM)/8@WV\CL>^?K>HW&B[?
M4!/>/O 7/EL\M;FH>A; )?WG\[3F>K;K@O*FF6"*\S**"D1$@1'.68(J1A-4
M%AFCM&"\3(PZ.%G ]BQ$*WC!=(Z>6HA!W2&H0Y-L@R(H6Q_$7P-;WA_78 *[
MPD-7??4P6<WJN C6+%7MWEIT_'$.5+C@BX.VE0@N.0DM*K#AQ9$J ="28Z;]
MV]"ZD\=OM81E^JXR7;XM9O*-IAWC_GFQY*T_\32;+C?^PQ?UP4434E4DH4S(
M32DYPDF4(=6200TVBEA.\A@36,(M$ '/*EH51LB7NC8\C<( F ,+9:B9Z^"3
M3<#@=@^3_Q.TN*AY9U*%M-Z&QN>B%QD(-$H.4T$M>>$J>1,*?MQT2TOFO$F0
MM%W',J5Q3RCC\GGY;5%/_\79),W#, K3#$649U+KR/\4A#%4EBP+N=RA*#8J
MTC4#=Z9X+EDC8#_)Z0@?S92-.^ZXB=UN8#M,;#2BT55JXS"P<9,;C0A_D]YH
M]A8\ZO%1TK&8<]5B7>J3UP_/_'[1V3JWXGHN%G6;V0MHS E8TK.D=Y@$*U0"
M]LQ5(46'C4K?[>%S >[F"6'>\1B,)[[!=(!CEH%B.18,L(KU0.",%@NR(+X?
M*[)YW5DL:56EW$7C4YP4.2,Y$IDT&7"5J98>88A*+B+.XSS-*_/D&Q.(WIV2
M7HRH[[Q;M78P8*!UB,B>+8X"0RL$;/)JC%AS<@S(GD6.(S_FK'(1[ME/MD60
M9V>A<X=V]M-E$- Y\"),)ZI!]M?SI?3.KA]Y_3"=/_Q<+_Y<?E-%;63^.N%Y
MR7E)*Y0GJK<"+J7+A#.*BJH@"2[C*"EB$TUX!(YG_=="#E:@@Q9VT $WD_!C
MG!I6>0[IARDZ2]*-)=:0L $S1Z[0FCGRAXV9<VS=4<36D+B5L)H^;BNB5UQU
M6IG=S!G__E]<"J<H,TX3%=10T__B0B B[1.4TSS-BK1*4F*4L'80PCABV0$-
M--1 @H4*Y"Y?3$7Q!&JMA-"<4 OQ.T#,"8*WN^+((G> H+?"=NA!NT#BAVGS
MM&BZTJ-U&I0J!="E <^<=1-$%G-=FWDK?EXL6/-U,6.3J,Q22D2"<,XKA.7A
MB(I(.6^LBLN<I *'1NU='>#B/?>IT6UZGNH%>Z;+H&[[0<%BC:>PVBP0.1(#
M8=I@A51;5'C12X;L(Q:L,;MH:[(5NS5V@4+/72#3 8\<13E/P634$*@#ENW&
M1UTL:1$.T:VRO_('Y5!L=W1G.$R3C HDDC)#F(8$%:GJE,]#)O(DQ$EE7A)^
M$(QG-=4V>F]:P,%403;,0#O"'8, AQ.:89JE);>#:=Z_'O19F(<OG## +F:Q
MAQ&.@A-'B1J,2!Q^>[PPQ%$*MF(/QY^&7]E\7LQ_ECJORP[\P!M:3W57G$V%
ML.%-S?&5/"L8-7+CY\O+NV"5&MK#P?P:QH AQV]?W/("IGB&V."X+!I&JM7U
MBL'RH]VJF)/:OTP!O&7M);TU3%0!]98= YT/ US5JXF^QQ!OR_^WS7<_ V(L
M&>'.#@=!']OVMF'-'GO;:AFKT^Z.+S[SQ>7+@YZG2)?/9#9[59/E 4D)1Y89
MX9Q3\S4_R_^M.C5N-XGLT D4/N \A&,\,CK]7+$'?O2YXPST&#2AV?8,'%Q[
MS /0A,B=T\_H%;NC;V!PR82(O,SS.%(%)T(% $/5.Y&B4/ T*@11I>20 .
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M/+B?/NJ)3Q*%X)?/=S>JP+^92B:83F,PX,;Q>P)WC(#IC:,\\'!-;D:KU?7
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MLA ZM=1Q&&.8B10D,>8 )1$"A$G]$2-"HS )I<MNU/QB,DRGO@'O5+E7-X*
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MM6:C#<"96+WL 7L=R'IJ8XA!_1K"(=EFRN LQ</IG4:DLRVM8@IU!^D96'
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MYO?;WS?+.*"0\2 #@H9$&0D9( *I1/X$"4JC$/E:C9Y[8$RMGBJH7@-VX2G
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M.@&O[1SJO #-@%Y'QZL.Q%D/5 ,6'!^A)J_:-V:H;OY72E_74X:7*$ 083\
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MCG4&MNMT++0S91VSTLRXM6-&KZUKN.1\IJ\=K0>6L.42MG->F^!X'2:0T-2
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M??J27';WY:/\Z=__I?U$_H?@@O_[O_P_4$L#!!0    ( .N%J%KD9 5,;9T
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M@>X7!0=)L OMO\=/TRJ$^?IM^$(^C^8J),6 @$H^C[ !/(L&E.?96<5U2M@
M =>?NA4*3.\H.$"272#A-07O2S)A&\%_(/GCB\7)?+W\\6*1<>*DBBZ2]YLP
M4Q M*9P.MA3@44NCBPB*AP; >)"(K7!B>\=).SEW 9N/X?OK3.*;ENGIJ<29
M)4S.Q.!4@JP$64)/WI%#CL"4]"E'&U(Z+%Q^\/%;0<7U#I46LNT")$<YDPI6
M9_^\F<Z13U(2,1L6(/JH">DA@"/D0Q!>.^%#4*S%5G/'H[<"A^\='(?*M%-@
MB$DQT:6D DC#R(-VLH K%&YKEQARD3!*.P@PQ';'5^SY(6,WH?:$C!?T[?'R
MX^+W^404C]E+#V@WI_=:@<^6@S=)\A*T8 ?&JO<\>#M4='RJV4*@/6%BXS0=
M+]\M%]^F\X03)2FNXD&"#0Y!,6?(_@E7+X-*U$8IE1ON)#>>OATZ.C[K;";:
MGB#R;K%:A]G_._VZ<:K)=7;1<@\VR5!CL8IQIB&ZS(I&9J3+[0!R[=G;P:/C
ML\]&8AT9'-7J'2TQ;.B.Q1>1*2IW,85Z(4QT"_H2I9$E"&1%'@:'JT_;#@ =
MGW3N+;J155YOR6?O/B_FYV=S1+LO*1I(LL(U!P,^D#RL]AD%)[!R?Y#:;SYQ
M.]5W?+QYD A'5O\'3"=+@BX7\>-T/<,)(=8E)1*1S>O1+ G!B:*!H3'$EB[!
MF8/4?_.)VZF_XW/-@T0XLOH_+D/-1/KPXTM<S";26I%+,J #RU#E =YZ!Y8I
M;S1BRE8=I/MKC]M.\1T?5.XOO$X6_:OOZ7.8?\+-2;PSS"'/!7021'_6 J*A
M/4NIZ()Q-ADGFBS\JT_=#@,=GT >+,HNPH$7)\LJKM.[V0IITL'):F)8SCX5
M"SI+XB.0+Q.\I0!'*DS>9^_"8:[ 0T_?#AK=GS\V$&T7$'D]IT\C<4R_X<NP
M#F=L302QH6O6*$9&KHYFY.H4$4 SR3(/*(5O$3/>_?3M\J>Z/XAL(-HN(%(O
M^)<OPAH_+98_)E::G'AR$),AT^<=TGY8(G"&2G#+>6ERFG#MH=L!HOLSR/T%
MV04./GP)L]G/)ZOI'%>KB1-:&1XTE$3.$4DE@7.L5)M7#)IH4FIQ3W'MH=OA
MH/O3QOT%V04.7GW!Y2?:\OZR7/R^_OQB\>5KF/^89'IK+MR"<-6L<1LAF$QN
MLP^2XF7-+#LLV?:!AV^'B^Z/&0\7;!?X^/ 99[-SZ@M+Y"?K0FY0L$0]>44A
M\@P2G7;)E\!*B^WBZC.W0T/'9XX'BK$+$!#A7VJ"SR+]]X?/)+?5\<FZUO+4
MR'J2M?(UF1QX8M7D<0[1&@.B%&V=-X$U27YXB(;M0-+QZ61C,8\,FJ,O.,\U
MH_B76?@T(=*<3B6#+:$>MR&AG2L!/&03B\>2[&%[R;7';0>%CD\J]Q=>)XGY
MOTQ7*<S^AF'Y"[VRFC"R9L5HHEEP8B'%<IH&B,&5Q(V(WKN#]'_/@[=#0L='
MERT$VA4F3FM.3IEP$J6QE7XF:WJ7L1 Q2L@R&!/1AJ .<R7N??1VN.CX.+.-
M4/MP+(B-99B]GF?\_N_X8^(Q*ZZ9 *,U<6&C@,@T63_E@L^9):V;^!+7'[L=
M(OH_Q3Q F&/G-)P>IUU:NO/"-$9,2^4B$6TS\1 X^*@9>"6"2X:V0GO8A<=]
M3]ZNSJ_C8\LF(FT&BW_^\RTYOJ$7]BG.)WC/5YCIF]5B1K]=8_XYS&IC 0JR
M<+TZF8>3/*57KS.Q;0G_]A]_<*'_GIP<V [@9 6?0O@ZV>3'U7WDN/PRG=-3
MI[29+$X+ "_01P%IB1$+P4T%4 8-.)L2^9\E>R;1V_Q0D6T)J[A!QME#3Q<A
MSM:K\U<N5^,N=.UK:VX]XV.(,YQ8KD,1VH.1A8'2Y&][%HA5'PQWSC.*KX;B
M<D/!.,T&!D/"N1UJ(.X1-Z9;U+^8A=7JN&P"]*/OT]4DR80JF@(FDA.NE"P0
M?8K /%E57Z(P#UZ?'(2;F\1T J$]-'P?6 X2=P>XN4K_R\67,)U/*)(7A?97
M<*B0. @! HL)!!<J*V^=>K!GP3Z N4U%)T@Y3+V+IK(>$2W5!YE\H" .5T?D
M"9#KMY[2$OKKHB8BO#LG9L/8K[C)7/29Y=H1"KA+JIX$(H2  3)CPC/KO+;^
M,3]GYZ>."YI#U;MX"EGW :+_NL+8G2RI4I0,UH'3F?Q_(U6MZV>TUG0),7.A
M3=D!/H\];YS^.<,!IZE\]X8,41 7K?T;BESP-7V[FG T/K$40!;O03E;SO9O
M48(3F03H'DHR/<BQN:!B7.0,X='L)^ .7)FCU8KBT8M8 &F#-DX$VJD-"</3
M%U?+,'U2VG.3$Y;6\+A.02<NS)[Z7#03;C?0.#MMNHP653"%A;I<9%TN9%\#
M<05"!QZB18^Z#(*0&X2,"Y1#-'LG2 X1<P=8>1%6GX_FN?[SZG].IM_"C)A9
M':U?A.7R![E@?PVS$YQX%7*R$H'%+$%))L%K&2 6*45RY'F9AY+1]@J2MB&L
M!RP=!(";,5-S;70 L?=(DIFF-6[X.D_3+2ZKP*,AS2MB(KL,P3 !)4?)O6>)
MQX>2Y/>!U)V$C.O2M(?0X=+N #)'*=6N1:OWF)!6 7E[;W%]D>"M*<*3SD&*
M)M:-74! IB!GXW,(#/V#/6?WVL@>H&><]I/# :B9[#O $46#7\,TO_K^M5[K
MD&4]7G_&Y3693:03-G''010TH% 9"#I7YIQ)T:/3X:%64OO :0NRQNE@.1RJ
M6FNB W!=)UX+E$)X#2PK3B0C"4<+!3IXJ=":H% /Z5Z/T^QR0#.TMW3WA\9B
M'6:-[,[B*R[7/][- HECGJLS][6&IV1*)S9D8;@.(&(]P/3<44QJR7U3A'8R
ML-GFAYH=[F=P[J>G!P>H23S63.@=V);32U]\@V&%[^N0BN/R&YG-*JR)-=X9
M1YZ_VW3\M!AI516LC5&4MMD4PUM;F@?(Z<']:0*?5B+O #W'M Y"O4"YDYDD
MO?8.&3#M"BBN$E!$*2#*;'E1P@G>.K7B08)Z<'6:(*B=V+NXA+CBH;U=S-/9
M3HPR*!45@MM<"5MEP6OZ@EIK6AR,[.Q#7;SW0L]=A/3@[[1!S<%B[L#BG-(_
M,5;HXG3MWN+H2_$!@MBDQ9,'**,J(;0V+:=/'J?)]V"'RCL)L@-_]\TTQ.EL
MNJZW^//3J]?/BQD)?56=L/6/"]'HQ(W.O( UB#7354+P2H/V.:OH@R!7OC%
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MWQOB97-Q.6&8C5;:@[2) T6:"F(H"M I6V0)L13>&#&WJ>BDM+9A +6?@#N
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MX'VED[UUD7/ (&O%G;$01$S I7"&6T%"NC$ ZY[#^"<G?:NU--ALZ-[7TC.
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MIWDIYP989<F#5Q2&\!) A>1K!I<$';6@?=X9'EO7)SQ,T3@!8DN=W[4+ME'
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MNMSD.QZM5B=?OFX*86KI5LT2>CG]-LTXS^_)79I8'IW1-@#+Q=?! 89\>2'
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M9,Z;0O,+?]7G4 *&#-PH 4KS6KP5+12EL625!!H^**KNHVPK=+GGBJXF^N@
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MGJNM&*%)89T"@DU%0M3+)++Y*HM$KY4B7IFG38C*^KZ'Q+S"UWS%/.#>2FL
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MBX[]>BVSG[Y??BVSB_ ;@\^RRM-PER)5#$7-&.)"!>2TC8AH'H)@RG#:YQO
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M\MC$8)CW_3X1V2V[:"2G[0%<.VFBV %+L>SBPR>(IM]=G/U_[[X>D""L6>7
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M/H3BI@ZI#T-G!156]X#WL2DP ]G,LN'4E^CCX'L.+X#W!_'JI7-4.1(,PLE
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MM-)P8$FS02:!*S%%Q65E"E)*@#<L359J?@=N%\^BM1JP+8PZX2AQ*V>@QX*
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MNJN,X(<Z,S V];^U+H 9 4-V7!<9K3J0WXD$'T8J_/@H$J=F\]7C0[$90LG
MA@5-PPGW0/UO/')X%>@(B>6;&CA(,",2Q<[3VCA/90]X^;W+!I;"9G%:>[2J
M@$6S!<L0L@'@J6!0(1+I-)$=@X9!XD*R>K( &L09P-VRTQ<,<N5UJ=XQ-B/[
MK@[(NI^2:1_,X9 W22(=<+L19W![A:[C\FXJPF<#4X3/^8 \S[.ZW+/_Y.=
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M295^;,=QT=3V1Y@"Z,WUE@I)Q]TU-VGBLI_"07-V$!Q9Q+ JG]FG2XP)HQI
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M=0;Y<0?/SU>6W@W8J3290FJ8FZ+S"GNHP2:KH WAKRE(_&+!Y6$F#,^+UAI
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M&A[B4Y0(2(18@LT;E_:-R80TK4;[)+3T.77WED8S1OAK/N'-X+#0]G"Q([>
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M2J=9DTM\UT1126J@@2%7>0?L4&*OIDJ?EH_8M."GAFF*"4A":1AE/N;XLW\
MPPY>5"!VVPMDIW^W4:'),(9J@*_1I!HUQ JUHY8JW@14=@8J?PHJ,P<=*62D
MY?9"TLC(+41C*SW<NR$VB<VO?,&.*>4-^[Y7NA6 HQ(C2M3(M%&U48Y9R90S
M+;UV4SL'X[*VKR[.>VN1Q6QJ9R$ZR0PLB)4B@CZ6/=T M$V+PYUODA)-#.J6
M:'O=V+7<3QVV7.Z9#KLP#91>175$:Z:TVJ@8&ZJZB:E &QMK&A1!8AM >=V@
M/ *L2F4G.34S".'J=39)JID>S7!78C 30YA2H<-'SS8#E<?CE5-,:+JCJ&L>
MB:"Q@'FM0HV08#YMZN7B-T^!>X$T2@A.,4M(1F%G8Y1(%%P/J*PB*N.J[U0[
MTC0O/K"1@=$*#YJMA?"'<T+620?':$G-I;-H4I2\JY8"B!A%OY.??GX_!B?=
MF[J#TY/@XNCUT8<C:F@1/'MYB%O/*K/62:#DXW8' ?U=WI/$@=C-WNO=!5/#
M/@PMH+VE73[\"GTQSQ]OC;T*GAV'P;,S^+_G?+.G)Z?W]39T,%$3E\Z1A7$/
M#+>50]<_;A]3DZ''UW-^*O,]+#V<!#NZKF*W1TC53-!&U*(:P;BUG49#C+"X
M&%-::WL"@-6)C>JQ'$F*FY T+PHP%8QA"FX@MW:@GGTIGC<5/]5?96JV8CYH
M_42W$5-AT5;H[ *9M]8L=SD<I(F?1Z\PQ2E*\QK+M7''%#G-&S)[M.:-1X9/
M7_&S0_ML^UA']$&.B-<L_FXK288OTJ6Y.:1ZRL\4*^%WXXZ3\FB<(=5@1>YH
M-[=0P<],^'1!S!06I? E'?=Z0EK"4%;BE!5H8TVE[!0O^4F;=N?6$F>A8  +
M7J"K:JJEJ?$KW8+X\:^A7:%E U&K?:7&7\<$HXS]WE'BEIMEB='L1GDSCHC%
M(8:EM"C3PY<-#@\C(YAF]+<BE8/6&)_*]BCMG^E'VGTOHWSVH#/*H_%S?O]]
MS_R<JR@?0_';E_JT+W8')SA(1]-H]/3LZ/EW.!'WV8?3MI/2#3D=4/]NK6:D
MB"C2141E(O:8,/AOK!H*F83*!4UT5(D'AT00*XS ,O\"1D^NRV@YQ[J@45#Z
MO:>:J5&X5L*>$4I-BFU\;=JC2G@QX"&;RZDOQ9<>UY/CE[L[KR?C.:^G1\<D
MN#JI1C#MC$!>BURV !)59>/R#HR%2+"@P^1)/Z(7T*@"W'?<' F^,FCP<RY1
MO>#E'T44XMWK\XM1G!7C8?B32C[-(;M*O^94<OU6+&#+57I1-/DTS?BBRP9+
M@L&!AJO1Y/^/%+G*?P,+W2V,6:G0U5K9$A:U.5S"27=)X:(A\17R .?/WO@*
M)'M*X?=7<I4=+]G;\(H_9L7T$_8+Y:[(P<\IT[)[]S'[Q9H.P>5-1'T#Z?(#
M73$P.DK54=@[#H("*G0O9>GI^&0I9E=J+@8C-E++?T"<YXRYP'Z9-?><J+%0
MG^*NAD6J)8S=]J8+)F41Q11#8GH%.&H10PXD<\2,W-W;*[%\T4RB,'A3(C?/
MVZ*$G_T=SA)\=+4"GS<,/J!S&TE0J(09@W__?2Y5UG \_]]HB?'H^3_G:22
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M.M'BIEV!0YZ@-5 (0EL]0^KYL>"T6A;LA.O(C<F965.6/S9=S5HOG^;.RS#
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ML8172$IA2I^IUBJ8@3$*1;->!&G#%%7C(+@=X5ZW7+</Q-N9C4<"GAT=/]U
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MD\.N<"EI"M@/^Y0D2R5>,&8,5V P%MG4RT3LHX04)ORFQ)'#5\HXH%/)>IO
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MV%>B3#Y[7F#\O'&TIU-9GQOZ_2Y+ 3_\WDH!O8G=MPNW:!KJ26A.850UI/^
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M:S%UGX-'0Q>(C;E1H[+F)]=#)MGE$N]4-]$J'1BY<E$YA<W#X+.AJ:[@I [
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M']OQ&E -_-X%XR#/L[ZPU%SVW&.\\1X3T[X?9.$"_C<II\E?_A]02P,$%
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M/6\TA5UEEDN4VO.AGZ45!>\#BL["B>!!-8Y3@57://"\^P$BAV@7K1 O$-=
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M)UOB?*/&/G&#+J-SHRE[R-0D!7&/V70QT-YSH<"P3&'C085<9HQG4U9D5A>
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MDY XB8VPC*F4Z5I($Z7*%#B/"ERKU$<_URH"@;<-V\-@"\#L^8CV'J.$9_?
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MWF4<6+$ZUF[4@M;1B\-!K?[BV&MJF[5ZJ_U56E\?:S<;;VYK*Z@='1UNI/;
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M)!V9GE75- 1GS%PX!9D2/#5]02RDS!S65YISS]_4>H9V5MG":;DVTZ&GA-1
M&8O125_?K5V1@1Z=F<:)+U4BE;WUFRTP)@%33/B&@B.(6)A93&SN[;]G G=!
MGRNQ;(@V5ANB59!K0[_<1+T*&?(HB DU7;U *F;DD$ 7$]L.=-&&N<';+H)+
M%7T=L[1L=WH!<R;0A&C%>N.<"#7(""IQJX.49HC6W >;VSJ?W4LF,K4-HYZ%
M.$Z\=E.YW#_:IHF[9"$SQ'ZF-[-LNI#:>.U9?.>7L'OV\O=?4$L#!!0    (
M .N%J%K-*\\3S@4  /8=   5    97AH:6)I=#,R,C(P,C4M,#,N:'1M[5EM
M4^,V$/[>7[$-4PYFDF#GE;P<,VD(4Z8]N"-AKOW4D64YUF!+/ED&TE_?E6R3
M<"'<2X_+,27#9&)6N]I]]O%*6@U#'4='PY 1_^BGX<^U&AQ+FL5,:*"*$<U\
MR%(NYO#>9^D5U&K%J+%,%HK/0PT-I]&&]U)=\6N2RS77$3LJ[0P/\N?A@9UD
MZ$E_<33T^35P_W6%>YV>%W2=0R]H^2W:;)*@U6H3I]>AM.L0VOG;K: J#L]U
M4KV(V.M*S$4M9&;^?JM1[[83/;CAO@[[KN/\4K%#CX:!%!KG4ZB?_\S-K!G3
M[%;72,3GHF]#JN2JI9C*2*K^CF,_ R.I!23FT:+_:J0XB5Y54R+26LH4#W)Q
MRO]A_5[=>&6?;W)/NZ@><<%*S]V&\75R&W*/:V@VZHW[CJ[&2]0<0]8R02TT
MN^(R18R9>BJ?6P_Z/)Y<S$Y/3L>CV>GY&;R]O)A>CLYF,#L']Q NZ]/ZN [3
MR=A*W6;;J6X,;,N!C*8P.CY_.YL<KT;QHWI;0MIS.G!^ K/?)C =7?PZ.IM,
M:^=__C'Y"T;CF9$T'.<+N<2%CP'U&]WDR>C_<$RG J@4@E'-I8 ;KD/0(8-W
M&5&(;[2 "Y9(I0&%)U+%X#JU=R #&'.?* *SD"F2L$QSFE;A5- Z[!G]W9W#
M1L,9C&6<$+&P3^Y@'P*IK/D/N7E@&+8/)52K87N$7LV5S(1?*Q ([&?PQ'B\
M(8J&NSMNQQDTW:JMK@^Y]\1> $DAX!%B<Y>1*:.9XIJS%(CP87)+0R+F#%>"
M..9I:K*'?V:DC\L&8%X8ILD,U1)N0DZ-&9X"94KS@%-B$X[_(%H3&N)4Q%@&
M5M3#U33F'"BSB'FNPHDBX@I^)\IC51B'G 5PP@41%(.'\P GP/2B \9*P8)J
M,3?^2#*59@3A1-_,",4^9%PQN^YQ 1=9Q+!PD9K;VO/V2S,K"-Q%/Z+:B-U>
MLU6U <0YI5:]WZ"W#,> -"W> %,N+;]#DAB&=IKF:6:64%-<"U<N!3=+\U0C
MU"G&YS/86Y;>;T@8U_DLOAC"=@?6^?TMT+6*H!!=+;/IL=1F)5[ E9 W2.,Y
MV]UI'PX^IR9VMEX2]]Q]4]?*RA=D$99!BAR.#(7N7L@5SJ8FVH)!>>UPFWL$
MB:O ;>_YGV(P8M,;&!8^$WP:.3Y<8#F/\SJ":X@F.-(WKZ]> 8]PLX@DBJ4&
MIZH1DR@"5&/&%40Q31"XM&JU@KL2@@9];DV;MQ-'95$.LTQPQ3&"]*/R4O\:
M]-JM._0>V*H^G8VV5='$P[)2KGA2^4R9U2XB2<KZY8^!S],D(HL^%S875FE0
MV/*DUC(VY@;7IKA2$A4;).MA+E[NS>M.OC_7Z*7VRYD+<=V*#K2_+FN[]5YW
ML]BINQMECYEMUMUF[ZNL/BYK-[^]KRVG?MCY/(<.++PYQ)C%%-GYNM*LE H)
M\7T\TO4;R2VX]P\3$0O6$IGG\+N]XI8@Q_AZVHH-;\@"#N_O@\KXGV=HOR[N
M+T5;"V;&8UP'SM@-7,B8B/\85K[L;#^J;Y&BW9U6=Y#:[]5]YKW@MON.;3EW
MCHFI\C\D;[%&VK-S@G[*B/M0.O@,F/W"YA<V/ZM2O.%D_T+>%_+^^.3=>ZLX
MTC9!WJ[WILRQ<BD?42HSH<U-2S%@?YWC!_;H]?C![KN?QF?K33U"J3T2FSZ#
M.2 O&[=WK4"N\4P=F>Y5U?0 /68B#S(E>&I:@;BP,G-L7VG3;;^]M87&5MG,
M:3N6+XB4D!I\QF($Z<L;M"LV$%'/M%"H5(E4]J+/6V!. J:8H$:"(XA8F%E,
M;AYMN6<"=T4?.[%LC3976Z-5D&M#/]U.O0D9ZBB(B6_Z>X%4S-@A@2XFMDWG
MHB%SQ[=]))<J.CS\VLI-2',F,(1H)7H#3H0>9 2=N-=+2C-D:X[!Y@;/1U>1
MB4QMZZAO*8X3KUU.+O>3MGWB+%6(A]S/]&:537=0&V\ZB^_\WO7 WO?^"U!+
M 0(4 Q0    ( .N%J%J HIA%D2," *:,$@ 1              "  0    !C
M9'1X+3(P,C4P,S,Q+FAT;5!+ 0(4 Q0    ( .N%J%J)6C1R<!$  ("K   1
M              "  < C @!C9'1X+3(P,C4P,S,Q+GAS9%!+ 0(4 Q0    (
M .N%J%J'4-'J?AH   '_   5              "  5\U @!C9'1X+3(P,C4P
M,S,Q7V-A;"YX;6Q02P$"% ,4    " #KA:A:$ZM>M1ED  "5D@0 %0
M        @ $04 ( 8V1T>"TR,#(U,#,S,5]D968N>&UL4$L! A0#%     @
MZX6H6JG7PRI9> 0 &< & !0              ( !7+0" &-D='@M,C R-3 S
M,S%?9S$N:G!G4$L! A0#%     @ ZX6H6@$+0;O+/PD [# + !0
M     ( !YRP' &-D='@M,C R-3 S,S%?9S(N:G!G4$L! A0#%     @ ZX6H
M6N)8/3N9^   ..X) !4              ( !Y&P0 &-D='@M,C R-3 S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( .N%J%KD9 5,;9T  "* !P 5
M  "  ;!E$0!C9'1X+3(P,C4P,S,Q7W!R92YX;6Q02P$"% ,4    " #KA:A:
MIB?'RS H  #&Z   %0              @ %0 Q( 97AH:6)I=#$P-#(P,C4M
M,#,N:'1M4$L! A0#%     @ ZX6H6O9T)QXLJ   Y5H$ !4
M ( !LRL2 &5X:&EB:70Q,#4R,#(U+3 S+FAT;5!+ 0(4 Q0    ( .N%J%HQ
MDPK1\ <  -HG   5              "  1+4$@!E>&AI8FET,S$Q,C R-2TP
M,RYH=&U02P$"% ,4    " #KA:A:CAY?L/,'  "B)P  %0
M@ $UW!( 97AH:6)I=#,Q,C(P,C4M,#,N:'1M4$L! A0#%     @ ZX6H6IQC
M@V75!0   QX  !4              ( !6^02 &5X:&EB:70S,C$R,#(U+3 S
M+FAT;5!+ 0(4 Q0    ( .N%J%K-*\\3S@4  /8=   5              "
M 6/J$@!E>&AI8FET,S(R,C R-2TP,RYH=&U02P4&      X #@"@ P  9/ 2
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>cdtx-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cdtx="http://cidara.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdtx-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2025-05-05</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdtx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cdtx:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-20</startDate>
            <endDate>2024-11-20</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-20</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-20</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-04-22</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-23</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertibleVotingPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-20</startDate>
            <endDate>2024-11-20</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-26</startDate>
            <endDate>2024-11-26</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-07-19</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-07-17</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-07-18</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyFourEquityIncentivePlanTwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-23</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:FinanceLeaseRightOfUseAssetAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-04-20</startDate>
            <endDate>2023-04-20</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2024-09-09</startDate>
            <endDate>2024-09-09</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-24</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:RezafunginAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-24</startDate>
            <endDate>2024-04-24</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:NappPharmaceuticalGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2024-04-23</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">cdtx:RezafunginMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-08</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>cdtx:vote</measure>
    </unit>
    <unit id="option">
        <measure>cdtx:option</measure>
    </unit>
    <unit id="employee">
        <measure>cdtx:employee</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001610618</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-41"
      decimals="INF"
      id="f-309"
      unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-42" id="f-326">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-103" id="f-459">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36912</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">CIDARA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">6310 Nancy Ridge Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">752-6170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">CDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">12969823</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">168150000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">189825000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">6339000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">6352000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">1694000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">1694000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">12665000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">12866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">188848000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">210737000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">348000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">521000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">703000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">2435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">2739000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">96000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">96000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">191727000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">214796000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">4897000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">3608000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">19833000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">13348000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">20727000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">26045000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">1915000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">4911000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">264000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">1437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">1378000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">48809000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">49554000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">310000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">1236000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">1624000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">50045000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">51488000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-71" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-72" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue contextRef="c-3" id="f-77" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-4" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-79"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-81" unitRef="shares">204725</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-82" unitRef="shares">204725</us-gaap:PreferredStockSharesAuthorized>
    <cdtx:PreferredStockSharesIssuedIncludingConversion contextRef="c-5" decimals="INF" id="f-83" unitRef="shares">240000</cdtx:PreferredStockSharesIssuedIncludingConversion>
    <cdtx:PreferredStockSharesIssuedIncludingConversion contextRef="c-6" decimals="INF" id="f-84" unitRef="shares">240000</cdtx:PreferredStockSharesIssuedIncludingConversion>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-85" unitRef="shares">204725</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-86" unitRef="shares">204725</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-89"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-90"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-91" unitRef="shares">3818495</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-92" unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-93" unitRef="shares">2156713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-94" unitRef="shares">975208</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-95" unitRef="shares">2156713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-96" unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-97" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-8" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-99"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-100"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-101" unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-102" unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-103" unitRef="shares">12209150</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-104" unitRef="shares">12209150</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-105" unitRef="shares">10946635</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-106" unitRef="shares">10946635</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-107" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-109" unitRef="usd">776419000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">774565000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-111" unitRef="usd">-634738000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">-611258000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-113" unitRef="usd">141682000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">163308000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-115" unitRef="usd">191727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">214796000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-9" decimals="-3" id="f-118" unitRef="usd">973000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-3" id="f-120" unitRef="usd">973000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">24600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-122" unitRef="usd">5919000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">6179000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-124" unitRef="usd">3596000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">-5510000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-9" decimals="-3" id="f-126" unitRef="usd">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">25269000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-9" decimals="-3" id="f-128" unitRef="usd">9515000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">-25269000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-130" unitRef="usd">-8542000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">110000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c-9" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:OtherNonoperatingExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">1899000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-9" decimals="-3" id="f-134" unitRef="usd">365000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">1789000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-136" unitRef="usd">365000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">-23480000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-138" unitRef="usd">-8177000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-9" decimals="-3" id="f-140" unitRef="usd">-2149000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">-23480000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">-23480000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-9" decimals="-3" id="f-143" unitRef="usd">-10326000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-144" unitRef="usd">-10326000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-145"
      unitRef="usdPerShare">-1.66</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-146"
      unitRef="usdPerShare">-1.66</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-9"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-1.80</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-9"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-1.80</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-9"
      decimals="2"
      id="f-151"
      unitRef="usdPerShare">-0.48</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-9"
      decimals="2"
      id="f-152"
      unitRef="usdPerShare">-0.48</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">-1.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-2.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">-2.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-157" unitRef="shares">14177743</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-158" unitRef="shares">14177743</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-159" unitRef="shares">4537782</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-160" unitRef="shares">4537782</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">-23480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-162" unitRef="usd">-10326000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">1741000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="-3" id="f-164" unitRef="usd">795000</us-gaap:ShareBasedCompensation>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">305000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-9" decimals="-3" id="f-166" unitRef="usd">188000</cdtx:OperatingLeaseRightOfUseAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">36000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-9" decimals="-3" id="f-168" unitRef="usd">36000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">48000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-9" decimals="-3" id="f-170" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-9" decimals="-3" id="f-172" unitRef="usd">16000</us-gaap:CapitalizedContractCostAmortization>
    <cdtx:LossOnAssignmentOfFinanceLease contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">158000</cdtx:LossOnAssignmentOfFinanceLease>
    <cdtx:LossOnAssignmentOfFinanceLease contextRef="c-9" decimals="-3" id="f-174" unitRef="usd">0</cdtx:LossOnAssignmentOfFinanceLease>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">13000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-9" decimals="-3" id="f-176" unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">7000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-9" decimals="-3" id="f-178" unitRef="usd">16000</us-gaap:PaidInKindInterest>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">-5510000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-9" decimals="-3" id="f-180" unitRef="usd">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-9" decimals="-3" id="f-182" unitRef="usd">-8965000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-9" decimals="-3" id="f-184" unitRef="usd">1172000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-186000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-9" decimals="-3" id="f-186" unitRef="usd">273000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">7775000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-9" decimals="-3" id="f-188" unitRef="usd">-4851000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">192000</cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes>
    <cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes contextRef="c-9" decimals="-3" id="f-190" unitRef="usd">2578000</cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-2996000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-9" decimals="-3" id="f-192" unitRef="usd">689000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-9" decimals="-3" id="f-194" unitRef="usd">-3128000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-329000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-9" decimals="-3" id="f-196" unitRef="usd">-197000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-21950000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-198" unitRef="usd">-6644000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-200" unitRef="usd">23000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">185000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-202" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">185000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-204" unitRef="usd">-23000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">127000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-9" decimals="-3" id="f-206" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-9" decimals="-3" id="f-208" unitRef="usd">4000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">50000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-9" decimals="-3" id="f-210" unitRef="usd">50000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-9" decimals="-3" id="f-212" unitRef="usd">39000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">77000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-214" unitRef="usd">-93000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-21688000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-9" decimals="-3" id="f-216" unitRef="usd">-6760000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-217" unitRef="usd">196177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-3" id="f-218" unitRef="usd">35778000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-219" unitRef="usd">174489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-220" unitRef="usd">29018000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="c-9" decimals="-3" id="f-222" unitRef="usd">105000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-223"
      unitRef="shares">204725</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-224" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-225"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-227"
      unitRef="shares">10946635</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-228" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-229" unitRef="usd">774565000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-230" unitRef="usd">-611258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-231" unitRef="usd">163308000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-17"
      decimals="INF"
      id="f-232"
      unitRef="shares">-1129264</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-18"
      decimals="INF"
      id="f-233"
      unitRef="shares">564632</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cdtx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-18"
      decimals="INF"
      id="f-234"
      unitRef="shares">657052</cdtx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-18"
      decimals="INF"
      id="f-235"
      unitRef="shares">6855</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-19" decimals="-3" id="f-236" unitRef="usd">113000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">113000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-18"
      decimals="INF"
      id="f-238"
      unitRef="shares">33976</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-19" decimals="-3" id="f-239" unitRef="usd">1741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">1741000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-3" id="f-241" unitRef="usd">-23480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">-23480000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-243"
      unitRef="shares">204725</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-244" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-245"
      unitRef="shares">975208</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-246" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-247"
      unitRef="shares">12209150</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-248" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-249" unitRef="usd">776419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-250" unitRef="usd">-634738000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-251" unitRef="usd">141682000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-252"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-254"
      unitRef="shares">4530113</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-255" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-256" unitRef="usd">433220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-257" unitRef="usd">-441431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-258" unitRef="usd">-8210000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-30"
      decimals="INF"
      id="f-259"
      unitRef="shares">31583</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-31" decimals="-3" id="f-260" unitRef="usd">39000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-9" decimals="-3" id="f-261" unitRef="usd">39000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-31" decimals="-3" id="f-262" unitRef="usd">795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-9" decimals="-3" id="f-263" unitRef="usd">795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-32" decimals="-3" id="f-264" unitRef="usd">-10326000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-265" unitRef="usd">-10326000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-33"
      decimals="INF"
      id="f-266"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-267" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-34"
      decimals="INF"
      id="f-268"
      unitRef="shares">4561696</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-269" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-270" unitRef="usd">433976000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-271" unitRef="usd">-451757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-272" unitRef="usd">-17780000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-273">THE COMPANY AND BASIS OF PRESENTATION&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company using its proprietary Cloudbreak&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; platform to develop drug-Fc conjugate, or DFC, therapeutics designed to save lives and improve the standard of care for patients facing serious diseases. The Company&#x2019;s proprietary Cloudbreak platform enables development of novel DFCs that inhibit specific disease targets while simultaneously engaging the immune system.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prophylaxis and treatment of seasonal and pandemic influenza, which has completed Phase 1 and Phase 2a clinical trials under a partnership with J&amp;amp;J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, or Janssen. On April 23, 2024, the Company and Janssen entered into a license and technology transfer agreement, or the Janssen License Agreement, under which the Company reacquired all rights for CD388 from Janssen to develop and commercialize CD388.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company is currently conducting a 5,041 subject, randomized, double-blind, controlled Phase 2b clinical trial, or the NAVIGATE study, evaluating the efficacy and safety of CD388 for pre-exposure prophylaxis of seasonal influenza. Top-line data from the NAVIGATE study is expected in late June 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Rezafungin&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s first commercially approved product in the United States, or U.S., was REZZAYO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 24, 2024, the Company and Napp Pharmaceutical Group Limited, or Napp, an affiliate of Mundipharma Medical Company, or Mundipharma, entered into an asset purchase agreement, or the Napp Purchase Agreement, pursuant to which the Company sold to Napp all of the Company&#x2019;s rezafungin assets and related contracts. The Company completed all conditions of the sale on April 24, 2024. The Company determined that the sale of rezafungin represented a strategic shift that will have a major effect on the Company&#x2019;s operations and financial results. Accordingly, the sale of rezafungin is classified as discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as income from discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all prior year periods presented, including any gain or loss recognized on closing. There were no assets and liabilities related to discontinued operations as of March&#160;31, 2025 and December&#160;31, 2024, as all balances were recognized in income from discontinued operations at the completion of the transaction. See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 23, 2024, the Company effected the approved 1-for-20 reverse stock split of its shares of common stock, or the Reverse Stock Split. All references in this Quarterly Report on Form 10-Q to the number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Stock Split on a retroactive basis. As a result of the Reverse Stock Split, an immaterial amount was reclassified from common stock to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2025, the Company had an accumulated deficit of $634.7 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $174.5 million, which the Company expects will provide sufficient liquidity to support its planned operations for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company&#x2019;s ability to execute on its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company&#x2019;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#x2019;s collaboration, license, and purchase agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, which is the Chief Executive Officer of the Company. The Company views its operations and manages its business as a single reportable segment with a single operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company manages research and development, or R&amp;amp;D, activities on a consolidated basis. The Company expects to generate future revenue from a combination of license fees and other upfront payments, funded R&amp;amp;D agreements, milestone payments, product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing of the successful commercialization of its product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is the measure of segment profit or loss used by CODM in making decisions regarding resource allocation and assessing performance, which is also reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The CODM uses comprehensive loss in making decisions regarding resource allocation and evaluating financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table represents the results of the Company&#x2019;s reportable segment for the three months ended March&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenues generated in the U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development - Cloudbreak platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reversal of indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other segment items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Segment net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(23,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(10,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The settlement of certain indirect tax liabilities resulted in the reversal of $5.5&#160;million in legal liabilities during the three months ended March&#160;31, 2025, which consisted of $3.7&#160;million in indirect tax amounts that were determined not to be due and payable and $1.8&#160;million in indirect tax interest and penalties that were determined not to be due and payable. The Company paid an immaterial amount in penalties for registration and compliance in one jurisdiction during the three months ended March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-37" decimals="INF" id="f-274" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-37" decimals="INF" id="f-275" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-38" decimals="INF" id="f-276" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-38" decimals="INF" id="f-277" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-278">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At March&#160;31, 2025, the Company had an accumulated deficit of $634.7 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, the Company had cash, cash equivalents and restricted cash of $174.5 million, which the Company expects will provide sufficient liquidity to support its planned operations for a period of at least one year following the date that these condensed consolidated financial statements are issued as part of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to execute its current business plan beyond this date depends on its ability to obtain additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. The Company may not be able to raise additional funding on terms acceptable to the Company, or at all, and any failure to raise funds as and when needed will compromise the Company&#x2019;s ability to execute on its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash, cash equivalents and restricted cash on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, the Company may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-279" unitRef="usd">-634700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-280" unitRef="usd">174500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ComparabilityOfPriorYearFinancialData contextRef="c-1" id="f-281">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComparabilityOfPriorYearFinancialData>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-282">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-283">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to estimated collaboration expenses related to the Company&#x2019;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#x2019;s collaboration, license, and purchase agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-284">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or CODM, which is the Chief Executive Officer of the Company. The Company views its operations and manages its business as a single reportable segment with a single operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company manages research and development, or R&amp;amp;D, activities on a consolidated basis. The Company expects to generate future revenue from a combination of license fees and other upfront payments, funded R&amp;amp;D agreements, milestone payments, product sales, government and other third-party funding, and royalties, which depend on the results, regulatory approval, and timing of the successful commercialization of its product candidates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is the measure of segment profit or loss used by CODM in making decisions regarding resource allocation and assessing performance, which is also reported on the condensed consolidated statements of operations and comprehensive loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The CODM uses comprehensive loss in making decisions regarding resource allocation and evaluating financial performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table represents the results of the Company&#x2019;s reportable segment for the three months ended March&#160;31, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenues generated in the U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development - Cloudbreak platform&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Personnel costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reversal of indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other segment items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Segment net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(23,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(10,326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-39" decimals="-3" id="f-286" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-40" decimals="-3" id="f-287" unitRef="usd">973000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-39" decimals="-3" id="f-288" unitRef="usd">21509000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-40" decimals="-3" id="f-289" unitRef="usd">2871000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-39" decimals="-3" id="f-290" unitRef="usd">6077000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-40" decimals="-3" id="f-291" unitRef="usd">4206000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-39" decimals="-3" id="f-292" unitRef="usd">2535000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-40" decimals="-3" id="f-293" unitRef="usd">1768000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-39" decimals="-3" id="f-294" unitRef="usd">658000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-40" decimals="-3" id="f-295" unitRef="usd">670000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-39" decimals="-3" id="f-296" unitRef="usd">-5510000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-40" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-39" decimals="-3" id="f-298" unitRef="usd">1789000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-40" decimals="-3" id="f-299" unitRef="usd">365000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-39" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-40" decimals="-3" id="f-301" unitRef="usd">-2149000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-39" decimals="-3" id="f-302" unitRef="usd">-23480000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-3" id="f-303" unitRef="usd">-23480000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-40" decimals="-3" id="f-304" unitRef="usd">-10326000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-40" decimals="-3" id="f-305" unitRef="usd">-10326000</us-gaap:NetIncomeLoss>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions contextRef="c-1" decimals="-5" id="f-306" unitRef="usd">-5500000</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-5" id="f-307" unitRef="usd">3700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <cdtx:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-5" id="f-308" unitRef="usd">1800000</cdtx:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-310">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Restricted cash consists of cash held as collateral to secure a standby letter of credit as required by certain contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable is stated at the original invoice amount and consists of indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#x2019;s customers is considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of March&#160;31, 2025, or December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:f-326"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Codification&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC, 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#x2019;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842, the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#x2019;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company reports deferred income taxes in accordance with ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indirect Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product were subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense was included in R&amp;amp;D expenses within discontinued operations. Prior to the sale of rezafungin, the related interest and penalties were included in selling, general and administrative, or SG&amp;amp;A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in general and administrative, or G&amp;amp;A, expenses in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#x2019;s supply chain activities or in connection with commercial sales of REZZAYO. When any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses are reversed as part of continuing operations at that time. Indirect tax amounts on the rezafungin asset transfer that can be billed to and recovered from our customers are included in accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 6 and Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist of wages, benefits and stock-based compensation charges for R&amp;amp;D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to R&amp;amp;D expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;G&amp;amp;A expenses relate to finance, human resources, legal and other administrative activities. G&amp;amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other G&amp;amp;A expenses include facility and overhead costs not otherwise included in R&amp;amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, and any accrued interest and penalties on accrued indirect tax liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&amp;amp;D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#x2019;s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company&#x2019;s common stock during the equivalent period of the calculated expected term of the Company&#x2019;s stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Earnings (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance in ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series A Convertible Voting Preferred Stock, or Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and pre-funded warrants, see Note 4 for additional information. Basic net EPS is then calculated by dividing the net income attributable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net EPS by using the more dilutive of the (1) treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method. Dilutive common stock equivalents are comprised of warrants (excluding pre-funded warrants), Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#x2019;s stock option plans and ESPP, on an as converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series A Convertible Preferred Stock or the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#x2019;s losses. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 260, if a company had a discontinued operation, the Company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, as part of its November 2024 Private Placement (as defined below), the Company issued and sold pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). Since the $0.0001 exercise price per pre-funded warrant share represents little consideration and is non-substantive in relation to the purchase price of $14.9119 per pre-funded warrant, and as the pre-funded warrants are exercisable at any time after their original issuance with no further vesting conditions or contingencies associated with them, the shares underlying the pre-funded warrants are therefore included in the calculation of basic net loss per common share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,330,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;487,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,052,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,151,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;828,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,970,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,881,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update, or ASU, 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025, and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#x2019;s condensed consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#x2019;s condensed consolidated financial statements or related disclosures, or do not apply to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-311">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further analysis is required to determine whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="c-1" id="f-312">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company presents discontinued operations when there is a disposal of a component or a group of components that represents a strategic shift that will have a major effect on operations and financial results. The results from discontinued operations of the rezafungin assets prior and subsequent to its sale are presented as net income (loss) from discontinued operations in the unaudited condensed consolidated statements of operations and comprehensive loss for all periods presented, including any gain or loss recognized on closing. The assets and liabilities for the rezafungin operations related activities prior and subsequent to its sale have been classified as discontinued operations and segregated for all periods presented in the unaudited condensed consolidated balance sheets. See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-313">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents. Restricted cash consists of cash held as collateral to secure a standby letter of credit as required by certain contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-315">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-314">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets to the total amount shown at the end of the applicable period in the condensed consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-316" unitRef="usd">168150000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-317" unitRef="usd">189825000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-318" unitRef="usd">6339000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-319" unitRef="usd">6352000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-320" unitRef="usd">174489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-321" unitRef="usd">196177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-322">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable is stated at the original invoice amount and consists of indirect taxes collectible from customers. The Company records accounts receivable net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#x2019;s customers is considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of March&#160;31, 2025, or December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="INF" id="f-323" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-3" decimals="INF" id="f-324" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-325">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:f-326"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-43" id="f-327">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-328">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Codification&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC, 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#x2019;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842, the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#x2019;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-329">&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company reports deferred income taxes in accordance with ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cdtx:TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock contextRef="c-1" id="f-330">&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indirect Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product were subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense was included in R&amp;amp;D expenses within discontinued operations. Prior to the sale of rezafungin, the related interest and penalties were included in selling, general and administrative, or SG&amp;amp;A, expenses within discontinued operations. Subsequent to the sale of rezafungin, the Company retained the liability as part of its continuing operations and continued interest expense is included in general and administrative, or G&amp;amp;A, expenses in continuing operations. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#x2019;s supply chain activities or in connection with commercial sales of REZZAYO. When any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses are reversed as part of continuing operations at that time. Indirect tax amounts on the rezafungin asset transfer that can be billed to and recovered from our customers are included in accounts receivable.&lt;/span&gt;&lt;/div&gt;</cdtx:TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-331">&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 6 and Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-332">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist of wages, benefits and stock-based compensation charges for R&amp;amp;D employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to R&amp;amp;D expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;G&amp;amp;A expenses relate to finance, human resources, legal and other administrative activities. G&amp;amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other G&amp;amp;A expenses include facility and overhead costs not otherwise included in R&amp;amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, and any accrued interest and penalties on accrued indirect tax liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock contextRef="c-1" id="f-334">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to R&amp;amp;D expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;</cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-335">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and 2015 Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#x2019;s stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company&#x2019;s common stock during the equivalent period of the calculated expected term of the Company&#x2019;s stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-336" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Earnings (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance in ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series A Convertible Voting Preferred Stock, or Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and pre-funded warrants, see Note 4 for additional information. Basic net EPS is then calculated by dividing the net income attributable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net EPS by using the more dilutive of the (1) treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method. Dilutive common stock equivalents are comprised of warrants (excluding pre-funded warrants), Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#x2019;s stock option plans and ESPP, on an as converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series A Convertible Preferred Stock or the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#x2019;s losses. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 260, if a company had a discontinued operation, the Company uses income (loss) from continuing operations as its control number to determine whether potential common shares are dilutive or anti-dilutive for purposes of reporting basic and diluted net earnings (loss) per common share from discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, as part of its November 2024 Private Placement (as defined below), the Company issued and sold pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). Since the $0.0001 exercise price per pre-funded warrant share represents little consideration and is non-substantive in relation to the purchase price of $14.9119 per pre-funded warrant, and as the pre-funded warrants are exercisable at any time after their original issuance with no further vesting conditions or contingencies associated with them, the shares underlying the pre-funded warrants are therefore included in the calculation of basic net loss per common share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-44"
      decimals="INF"
      id="f-338"
      unitRef="shares">3149035</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-339"
      unitRef="usdPerShare">14.9119</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-340"
      unitRef="usdPerShare">14.912</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-46"
      decimals="4"
      id="f-341"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-46"
      decimals="4"
      id="f-342"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-343"
      unitRef="usdPerShare">14.9119</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,330,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;487,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,052,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,151,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;828,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,970,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,881,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-47" decimals="0" id="f-345" unitRef="shares">866</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-48" decimals="0" id="f-346" unitRef="shares">866</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-49" decimals="0" id="f-347" unitRef="shares">14330750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-50" decimals="0" id="f-348" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-349" unitRef="shares">487604</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-52" decimals="0" id="f-350" unitRef="shares">1052236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-53" decimals="0" id="f-351" unitRef="shares">3151477</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-54" decimals="0" id="f-352" unitRef="shares">828655</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-353" unitRef="shares">17970697</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-9" decimals="0" id="f-354" unitRef="shares">1881757</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-356">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update, or ASU, 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025, and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#x2019;s condensed consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#x2019;s condensed consolidated financial statements or related disclosures, or do not apply to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-357">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;196,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-359" unitRef="usd">168150000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-360" unitRef="usd">168150000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCash contextRef="c-3" decimals="-3" id="f-363" unitRef="usd">6339000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-55" decimals="-3" id="f-364" unitRef="usd">6339000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-56" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-57" decimals="-3" id="f-366" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-367" unitRef="usd">174489000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-368" unitRef="usd">174489000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">189825000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-372" unitRef="usd">189825000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCash contextRef="c-4" decimals="-3" id="f-375" unitRef="usd">6352000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-58" decimals="-3" id="f-376" unitRef="usd">6352000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-59" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-60" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">196177000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-380" unitRef="usd">196177000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-382" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-383">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 23, 2024, the Company effected the Reverse Stock Split of its shares of common stock and decreased its authorized number of shares of common stock from 200,000,000 shares to 20,000,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;All references in this Quarterly Report on Form 10-Q to the number of common shares, price per share and weighted average number of shares outstanding have been adjusted to reflect the Reverse Stock Split on a retroactive basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Controlled Equity Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Cantor Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald &amp;amp; Co., or Cantor. The Company has not sold any shares of its common stock under the Cantor Sales Agreement since July 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2024 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 23, 2024, the Company entered into a securities purchase agreement with certain institutional and other accredited investors, pursuant to which the Company issued and sold, in a private placement, or the April 2024 Private Placement, 240,000 shares of Series A Convertible Preferred Stock at a purchase price of $1,000 per share. The closing of the April 2024 Private Placement took place on April 24, 2024, and the Company received total gross proceeds of $240.0&#160;million. The Company received total net proceeds of approximately $239.1&#160;million, after deducting issuance costs payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;November 2024 Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On November 20, 2024, the Company entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company issued and sold, in a private placement, or the November 2024 Private Placement, (i) an aggregate of 3,892,274 shares of the Company&#x2019;s common stock at a purchase price of $14.912 per share, and (ii) in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of common stock at a purchase price of $14.9119 per pre-funded warrant (representing the $14.912 per share purchase price less the exercise price of $0.0001 per pre-funded warrant share). The pre-funded warrants are exercisable at any time after their original issuance and will not expire. The closing of the November 2024 Private Placement took place on November 26, 2024, and the Company received total gross proceeds of $105.0&#160;million. The Company received total net proceeds of approximately $98.2&#160;million, after deducting issuance costs payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the Company's amended and restated certificate of incorporation, as amended, the Company&#x2019;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company designated 240,000 shares of preferred stock as Series A Convertible Preferred Stock with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the Company&#x2019;s stockholders approved, for purposes of Nasdaq Listing Rule 5635(b), the issuance of up to 16,800,000 shares of common stock upon conversion of 240,000 shares of Series A Convertible Preferred Stock issued in the April 2024 Private Placement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 19, 2024, the Company issued 2,469,250 shares of common stock upon the automatic conversion of 35,275 shares of Series A Convertible Preferred Stock, subject to the terms and limitations contained in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock, including that shares of Series A Convertible Preferred Stock shall not be convertible if the conversion would result in a holder beneficially owning more than 9.99% of the Company's outstanding shares of common stock as of the applicable conversion date. After conversion, the converted shares of Series A Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series A Convertible Preferred Stock. As of March&#160;31, 2025 and December&#160;31, 2024, shares of preferred stock designated as Series A Convertible Preferred Stock totaled 204,725.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The specific terms of the Series A Convertible Preferred Stock are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Conversion: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into 70 shares of common stock. Holders are not permitted to convert Series A Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#x2019;s for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Holders of Series A Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#x2019;s common stock. If dividends are paid on shares of common stock, holders of Series A Convertible Preferred Stock are entitled to participate in such dividends on an as-if-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Liquidation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Upon the liquidation, dissolution, or winding up of the Company, each holder of Series A Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of Series X Convertible Preferred Stock and common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Voting:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Holders of the Series A Convertible Preferred Stock are entitled to vote together with the holders of common stock on an as-if-converted basis on all matters submitted to a vote of stockholders; provided that holders of Series A Convertible Preferred Stock are not permitted to vote with respect to matters submitted to a vote of stockholders, to the extent that after giving effect to such action, such holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#x2019;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Series A Convertible Preferred Stock for liability or equity classification under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, and determined that equity treatment is appropriate as it does not meet the criteria for liability accounting. Additionally, the Series A Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series A Convertible Preferred Stock is recorded as permanent equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In August 2020, at the request of certain holders, 52,241 shares of the Company&#x2019;s Series X Convertible Preferred Stock were converted to an aggregate of 26,120 shares of the Company&#x2019;s common stock. In March 2025, at the request of certain holders, 1,129,264 shares of the Company&#x2019;s Series X Convertible Preferred Stock were converted to an aggregate of 564,632 shares of the Company&#x2019;s common stock. After conversion, the converted shares of Series X Convertible Preferred Stock resumed the status of authorized but unissued shares of preferred stock and are no longer designated as Series X Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 3,818,495 and 4,947,759, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The specific terms of the Series X Convertible Preferred Stock are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Conversion: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 0.5 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#x2019;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#x2019;s common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Liquidation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Upon the liquidation, dissolution, or winding up of the Company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Voting:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 18, 2024, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 20,000,000 shares to 50,000,000 shares, which amendment was filed by the Company with the Secretary of State of the State of Delaware on July 18, 2024 and was effective as of such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company had 50,000,000 shares of common stock authorized as of March&#160;31, 2025. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#x2019;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#x2019;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, (i) warrants to purchase up to an aggregate of 866 shares of the Company&#x2019;s common stock were outstanding, each with an exercise price of $230.95 per share and (ii) pre-funded warrants to purchase up to an aggregate of 2,491,975 shares of the Company&#x2019;s common stock were outstanding, each with an exercise price of $0.0001 per share. During the three months ended&#160;March&#160;31, 2025, pre-funded warrants to purchase up to 657,060 shares of common stock were cashless exercised resulting in the issuance of 657,052 shares of the Company's common stock and an immaterial cash payment by the Company in lieu of fractional shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, (i) warrants to purchase up to an aggregate of 866 shares of the Company&#x2019;s common stock were outstanding, each with an exercise price of $230.95 per share and (ii) pre-funded warrants to purchase up to an aggregate of 3,149,035 shares of the Company&#x2019;s common stock were outstanding, each with an exercise price of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The warrants had no intrinsic value as of March&#160;31, 2025, and December&#160;31, 2024, and the pre-funded warrants had a total aggregate intrinsic value of $53.7&#160;million and $84.6&#160;million as of March&#160;31, 2025, and December&#160;31, 2024, respectively. The intrinsic value of a warrant and pre-funded warrant exercisable for common stock is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants, including pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,492,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,149,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,330,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,330,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;487,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,052,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options and RSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,151,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,481,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;660,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,021,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;88,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;63,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,211,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,099,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-61"
      decimals="INF"
      id="f-384"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-62"
      decimals="INF"
      id="f-385"
      unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-63"
      decimals="INF"
      id="f-386"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-64"
      decimals="INF"
      id="f-387"
      unitRef="shares">240000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-65"
      decimals="INF"
      id="f-388"
      unitRef="usdPerShare">1000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-66" decimals="-5" id="f-389" unitRef="usd">240000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-66" decimals="-5" id="f-390" unitRef="usd">239100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-67"
      decimals="INF"
      id="f-391"
      unitRef="shares">3892274</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-392"
      unitRef="usdPerShare">14.912</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-44"
      decimals="INF"
      id="f-393"
      unitRef="shares">3149035</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-45"
      decimals="INF"
      id="f-394"
      unitRef="usdPerShare">14.9119</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-46"
      decimals="INF"
      id="f-395"
      unitRef="usdPerShare">14.912</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-46"
      decimals="4"
      id="f-396"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-68" decimals="-5" id="f-397" unitRef="usd">105000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-68" decimals="-5" id="f-398" unitRef="usd">98200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-399" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-400" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-69"
      decimals="INF"
      id="f-401"
      unitRef="shares">240000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-69"
      decimals="INF"
      id="f-402"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-70"
      decimals="INF"
      id="f-403"
      unitRef="shares">16800000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-70"
      decimals="INF"
      id="f-404"
      unitRef="shares">240000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-71"
      decimals="INF"
      id="f-405"
      unitRef="shares">2469250</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-71"
      decimals="INF"
      id="f-406"
      unitRef="shares">35275</us-gaap:ConversionOfStockSharesConverted1>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion contextRef="c-71" decimals="4" id="f-407" unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-408"
      unitRef="shares">204725</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-69"
      decimals="INF"
      id="f-409"
      unitRef="shares">70</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion contextRef="c-73" decimals="4" id="f-410" unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion contextRef="c-73" decimals="4" id="f-411" unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-74"
      decimals="INF"
      id="f-412"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-74"
      decimals="INF"
      id="f-413"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-75"
      decimals="INF"
      id="f-414"
      unitRef="shares">52241</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-76"
      decimals="INF"
      id="f-415"
      unitRef="shares">26120</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-77"
      decimals="INF"
      id="f-416"
      unitRef="shares">1129264</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-78"
      decimals="INF"
      id="f-417"
      unitRef="shares">564632</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-418" unitRef="shares">3818495</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-419" unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-74"
      decimals="INF"
      id="f-420"
      unitRef="shares">0.5</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion contextRef="c-79" decimals="4" id="f-421" unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <cdtx:NumberOfVotesEntitlementForEachShareHeld contextRef="c-80" decimals="INF" id="f-422" unitRef="vote">0</cdtx:NumberOfVotesEntitlementForEachShareHeld>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-81"
      decimals="INF"
      id="f-423"
      unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-82"
      decimals="INF"
      id="f-424"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-425" unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <cdtx:NumberOfVotesEntitlementForEachShareHeld contextRef="c-83" decimals="INF" id="f-426" unitRef="vote">1</cdtx:NumberOfVotesEntitlementForEachShareHeld>
    <cdtx:CommonStockDividendsInArrearsOrDefault contextRef="c-1" decimals="INF" id="f-427" unitRef="usd">0</cdtx:CommonStockDividendsInArrearsOrDefault>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-84"
      decimals="INF"
      id="f-428"
      unitRef="shares">866</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-84"
      decimals="2"
      id="f-429"
      unitRef="usdPerShare">230.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-85"
      decimals="INF"
      id="f-430"
      unitRef="shares">2491975</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-85"
      decimals="4"
      id="f-431"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdtx:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="c-86"
      decimals="INF"
      id="f-432"
      unitRef="shares">657060</cdtx:ClassOfWarrantOrRightExercisesInPeriod>
    <cdtx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-87"
      decimals="INF"
      id="f-433"
      unitRef="shares">657052</cdtx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-88"
      decimals="INF"
      id="f-434"
      unitRef="shares">866</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-88"
      decimals="2"
      id="f-435"
      unitRef="usdPerShare">230.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-89"
      decimals="INF"
      id="f-436"
      unitRef="shares">3149035</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-89"
      decimals="4"
      id="f-437"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding contextRef="c-88" decimals="INF" id="f-438" unitRef="usd">0</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding contextRef="c-84" decimals="INF" id="f-439" unitRef="usd">0</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding contextRef="c-85" decimals="-5" id="f-440" unitRef="usd">53700000</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding contextRef="c-89" decimals="-5" id="f-441" unitRef="usd">84600000</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-442">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.516%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants, including pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,492,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,149,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,330,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,330,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;487,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,052,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options and RSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,151,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,481,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;660,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,021,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;88,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;63,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,211,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,099,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-90"
      decimals="INF"
      id="f-443"
      unitRef="shares">2492841</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-91"
      decimals="INF"
      id="f-444"
      unitRef="shares">3149901</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-92"
      decimals="INF"
      id="f-445"
      unitRef="shares">14330750</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-93"
      decimals="INF"
      id="f-446"
      unitRef="shares">14330750</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-94"
      decimals="INF"
      id="f-447"
      unitRef="shares">487604</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-95"
      decimals="INF"
      id="f-448"
      unitRef="shares">1052236</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-96"
      decimals="INF"
      id="f-449"
      unitRef="shares">3151477</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-97"
      decimals="INF"
      id="f-450"
      unitRef="shares">2481011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-98"
      decimals="INF"
      id="f-451"
      unitRef="shares">660650</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-99"
      decimals="INF"
      id="f-452"
      unitRef="shares">1021947</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-100"
      decimals="INF"
      id="f-453"
      unitRef="shares">88147</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-101"
      decimals="INF"
      id="f-454"
      unitRef="shares">63631</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-455" unitRef="shares">21211469</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-456" unitRef="shares">22099476</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-457">EQUITY INCENTIVE PLANS&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2024 Equity Incentive Plan, 2020 Inducement Incentive Plan and 2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In May 2024, the Company&#x2019;s board of directors approved and adopted the Company&#x2019;s 2024 Equity Incentive Plan, or 2024 EIP. In July 2024, the Company&#x2019;s stockholders approved the adoption of the 2024 EIP. The 2024 EIP is the successor to and continuation of the Company&#x2019;s 2015 Equity Incentive Plan, or 2015 EIP, previously approved and adopted in March 2015 by the Company&#x2019;s board of directors and stockholders. The 2024 EIP became effective on July 18, 2024. Upon the effectiveness of the 2024 EIP, no additional awards were or will be granted under the 2015 EIP, although all outstanding stock awards granted under the 2015 EIP continue to be governed by the terms of the 2015 EIP. Under the 2024 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company&#x2019;s board of directors approved and adopted the 2020 Inducement Incentive Plan, which was most recently amended in February 2025, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Terms of stock award agreements, including vesting requirements, are determined by the board of directors (or the compensation and human capital committee thereof), subject to the provisions of the 2024 EIP, 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a &lt;span style="-sec-ix-hidden:f-459"&gt;three&lt;/span&gt;- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2024 EIP, 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The ESPP allows substantially all employees to purchase the Company&#x2019;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#x2019;s payroll deductions under the ESPP are limited to 15% of the employee&#x2019;s eligible compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March&#160;31, 2025 and 2024, no shares were issued pursuant to the ESPP. As of March&#160;31, 2025, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately 0.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;177,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;206,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;337,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs granted by the Company during the three months ended March&#160;31, 2024 was $13.70 per share. The total fair value of RSUs vested during the three months ended March&#160;31, 2025 and 2024 was approximately $0.6 million and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2025, estimated unrecognized compensation expense related to RSUs granted was approximately $5.9&#160;million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Contractual Life in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,303,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;730,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(213,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,813,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,813,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;661,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted by the Company during the three months ended March&#160;31, 2025, and 2024 was $15.76 and $9.80 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, total unrecognized share-based compensation expense related to unvested stock options was approximately $23.6 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for RSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation expense recorded in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation expense recorded in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-102"
      decimals="INF"
      id="f-458"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-104" id="f-460">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-102" id="f-461">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-102"
      decimals="INF"
      id="f-462"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold
      contextRef="c-102"
      decimals="INF"
      id="f-463"
      unitRef="number">0.10</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-105"
      decimals="INF"
      id="f-464"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-106"
      decimals="INF"
      id="f-465"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-107"
      decimals="INF"
      id="f-466"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-108"
      decimals="INF"
      id="f-467"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-109"
      decimals="INF"
      id="f-468"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-108" id="f-469">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.730%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;177,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;206,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;337,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-110"
      decimals="INF"
      id="f-471"
      unitRef="shares">177273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-110"
      decimals="2"
      id="f-472"
      unitRef="usdPerShare">14.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-111"
      decimals="INF"
      id="f-473"
      unitRef="shares">206410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-111"
      decimals="2"
      id="f-474"
      unitRef="usdPerShare">21.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-111"
      decimals="INF"
      id="f-475"
      unitRef="shares">33976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-111"
      decimals="2"
      id="f-476"
      unitRef="usdPerShare">17.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-111"
      decimals="INF"
      id="f-477"
      unitRef="shares">11953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-111"
      decimals="2"
      id="f-478"
      unitRef="usdPerShare">15.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-112"
      decimals="INF"
      id="f-479"
      unitRef="shares">337754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-112"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">18.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-113"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">13.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-111" decimals="-5" id="f-482" unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-113" decimals="-5" id="f-483" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-112" decimals="-5" id="f-484" unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-111" id="f-485">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-486">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the three months ended March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Contractual Life in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,303,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;730,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(213,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,813,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,813,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;661,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;30.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-487" unitRef="shares">2303738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">18.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-114" id="f-489">P8Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-490" unitRef="usd">29729000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-491" unitRef="shares">730415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">21.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-493" unitRef="shares">7181</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-494"
      unitRef="usdPerShare">16.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-495" unitRef="shares">213249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">22.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-497" unitRef="shares">2813723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-498"
      unitRef="usdPerShare">18.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-499">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-500" unitRef="usd">17215000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-501" unitRef="shares">2813723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-502"
      unitRef="usdPerShare">18.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-503">P8Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-3" decimals="-3" id="f-504" unitRef="usd">17215000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-505" unitRef="shares">661275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-506"
      unitRef="usdPerShare">30.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-507">P6Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-508" unitRef="usd">3490000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">15.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-9"
      decimals="2"
      id="f-510"
      unitRef="usdPerShare">9.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-511" unitRef="usd">23600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-115" id="f-512">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for RSUs, stock options, and the ESPP has been reported in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation expense recorded in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation expense recorded in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-116" decimals="-3" id="f-514" unitRef="usd">450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-3" id="f-515" unitRef="usd">227000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-516" unitRef="usd">1291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-517" unitRef="usd">413000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-518" unitRef="usd">1741000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-121" decimals="-3" id="f-519" unitRef="usd">640000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-122" decimals="-3" id="f-520" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-521" unitRef="usd">155000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-522" unitRef="usd">1741000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-9" decimals="-3" id="f-523" unitRef="usd">795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-524">SIGNIFICANT AGREEMENTS AND CONTRACTS&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 23, 2024, the Company reacquired all rights to develop and commercialize CD388 when the Company and Janssen entered into the Janssen License Agreement, which also effectively terminated the Janssen Collaboration Agreement (as defined below), including the license granted by the Company to Janssen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the Janssen License Agreement, the Company assumed responsibility for further clinical development, manufacture, registration and commercialization of DFCs based on the Company&#x2019;s Cloudbreak platform for the prevention and treatment of influenza, including CD388 and products or compounds containing CD388. Janssen granted the Company an exclusive, worldwide, fee-bearing royalty-free license for certain Janssen-controller technology to develop, manufacture, and commercialize compounds and products, including CD388. Janssen agreed to (i) transfer and disclose to the Company certain Janssen-controlled know-how related to CD388, including manufacturing know-how, data and documentation, (ii) transfer all existing quantities of CD388 clinical materials, and (iii) transfer the cell banks used by or on behalf of Janssen for the production of CD388.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company paid Janssen an upfront payment of $85.0&#160;million on April 24, 2024. The Company is also obligated to pay Janssen up to $150.0&#160;million in development and regulatory milestone payments and up to $455.0&#160;million in commercialization milestone payments, with respect to CD388. The Company has no obligation to pay any royalties to Janssen for future sales of any commercialized CD388 product. The Company&#x2019;s contingent future obligation to pay Janssen with respect to CD388 will be recognized if and when the contingency is resolved and the consideration is paid or becomes payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As the Company had an existing license and collaboration agreement with Janssen, or the Janssen Collaboration Agreement, the Company considered the contract modification and consideration payable to a customer guidance in ASC 606. The Company determined this bundled arrangement would be accounted for as a termination of the existing revenue contract and the creation of a new arrangement. No amounts paid or payable to Janssen were recorded against revenue as the consideration payable to Janssen does not exceed the fair value of the distinct assets acquired in the Janssen License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with authoritative guidance, the Company was determined to be the accounting acquirer and substantially all of the fair value of the gross assets acquired is concentrated in the acquired in-process research and development, or IPR&amp;amp;D, of CD388. The reacquired license to develop, manufacture, and commercialize activities of CD388 is part of the acquired IPR&amp;amp;D. The transaction was accounted for as an asset acquisition. The acquired IPR&amp;amp;D did not have an alternative future use as of the acquisition date. Therefore the initial purchase price of $85.4&#160;million, inclusive of $0.4&#160;million in direct transaction costs, was expensed as of the acquisition date as acquired IPR&amp;amp;D in the condensed consolidated statements of operations and comprehensive loss during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prior to the acquisition, the Company had $0.5&#160;million in contract liabilities related to deferred revenue balances and unearned cancelled performance obligations associated with the Janssen Collaboration Agreement. The settlement of the preexisting contract liabilities was recorded as an offset to the Janssen License Agreement&#x2019;s initial purchase price resulting in $84.9&#160;million expensed as acquired IPR&amp;amp;D in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company&#x2019;s Cloudbreak platform, for the prevention and treatment of influenza, including CD388.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company and Janssen collaborated in the research, preclinical development and early clinical development of CD388, or the Development Candidate, under a mutually-agreed R&amp;amp;D plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, the Company was responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company was the IND holder for the Research Plan clinical trials. Both parties were responsible for conducting certain specified chemistry, manufacturing and controls, or CMC, development activities under the Research Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2023, Janssen delivered its Election to Proceed Notice for CD388, whereby Janssen assumed the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continued to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and was reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement. Following Janssen&#x2019;s Election to Proceed Notice, Janssen was obligated at its sole expense to diligently continue development and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Janssen Collaboration Agreement was terminated upon the effectiveness of the Janssen License Agreement on April 24, 2024, and all potential future milestone payments and royalties were forfeited by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prior to the Janssen Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million, plus the R&amp;amp;D funding of $47.8&#160;million, plus milestones achieved of $10.0&#160;million. The transaction price included the total estimated costs related to R&amp;amp;D and clinical supply services. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&amp;amp;D efforts and costs for manufacturing clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A description of the distinct performance obligations identified under the Janssen Collaboration Agreement was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The R&amp;amp;D services performed represented a distinct performance obligation. The Company recognized revenue based on actual amounts incurred as the underlying services were provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognized revenue based on actual amounts incurred as the underlying services were provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; In March 2022 and September 2023, the Company achieved milestones under the Janssen Collaboration Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was expected to be recognized as revenue over the remaining progress of these performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of the termination date of the Janssen Collaboration Agreement there was no aggregate transaction price allocated to performance obligations that were unsatisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, the Company recorded no accounts receivable or contract liabilities associated with the Janssen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Janssen Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total Revenue from Janssen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-124" decimals="-5" id="f-525" unitRef="usd">85000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory contextRef="c-124" decimals="-5" id="f-526" unitRef="usd">150000000</cdtx:CollaborativeArrangementRightsAndObligationsMilestonePaymentsDevelopmentAndRegulatory>
    <cdtx:CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization contextRef="c-124" decimals="-5" id="f-527" unitRef="usd">455000000</cdtx:CollaborativeArrangementRightsAndObligationsMilestonePaymentsCommercialization>
    <cdtx:ResearchAndDevelopmentExpenseAcquiredInProcess contextRef="c-125" decimals="-5" id="f-528" unitRef="usd">85400000</cdtx:ResearchAndDevelopmentExpenseAcquiredInProcess>
    <cdtx:DirectTransactionCosts contextRef="c-125" decimals="-5" id="f-529" unitRef="usd">400000</cdtx:DirectTransactionCosts>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability contextRef="c-126" decimals="-5" id="f-530" unitRef="usd">500000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability>
    <cdtx:ResearchAndDevelopmentExpenseAcquiredInProcess contextRef="c-127" decimals="-5" id="f-531" unitRef="usd">84900000</cdtx:ResearchAndDevelopmentExpenseAcquiredInProcess>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-128" decimals="-5" id="f-532" unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost contextRef="c-128" decimals="-5" id="f-533" unitRef="usd">47800000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-129" decimals="-5" id="f-534" unitRef="usd">10000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-130" decimals="INF" id="f-535" unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-131" decimals="INF" id="f-536" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-130" decimals="INF" id="f-537" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents collaboration revenue under the Janssen Collaboration Agreement for the three months ended March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.308%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Janssen Collaboration Agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total Revenue from Janssen Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration, License and Commercial Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon milestone achieved&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration, License and Commercial Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-132" decimals="-3" id="f-539" unitRef="usd">971000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-133" decimals="-3" id="f-540" unitRef="usd">2000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-134" decimals="-3" id="f-541" unitRef="usd">973000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-542">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company entered into a finance lease for lab equipment in November 2023. The finance lease had a term of 36 months, monthly lease payments of $25,009, and an option to purchase the lab equipment for $1 at the end of the finance lease term. In March 2025, the Company entered into an assignment and assumption agreement whereby the Company agreed to transfer and assign to a third party all of the Company's present and future rights, interests, duties, obligations and liabilities under the finance lease, resulting in a derecognition of the finance lease right-of-use asset and finance lease liabilities as of March&#160;31, 2025, and the recognition of a $0.2 million loss on disposal in other expense, net in continuing operations during the three months ended March&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Finance lease costs were immaterial for the three months ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company entered into an operating lease for laboratory and office space in San Diego, California in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015. On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional 36 months and increased the base rent to $133,371 per month effective January 1, 2024, subject to 4% increases every January. The operating lease expires on December 31, 2026 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of March&#160;31, 2025, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes. The incremental borrowing rate used in measuring the Company&#x2019;s operating lease liability was 12.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount and timing of cash flows arising from the Company&#x2019;s operating lease as of March&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company&#x2019;s operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025, the weighted average remaining operating lease term was 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities was $0.4 million for each of the three months ended March&#160;31, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $0.4 million for each of the three months ended March&#160;31, 2025 and 2024. These costs are primarily related to the Company&#x2019;s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with vendors for R&amp;amp;D activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reduction in Force&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On September 9, 2024, management of the Company, as authorized by the board of directors of the Company, approved a reduction in the Company&#x2019;s workforce, or the Reduction, of 20 employees, which represented approximately 30% of the Company&#x2019;s workforce. The Reduction reflects the Company&#x2019;s focus on the clinical development of CD388, its influenza product candidate. The Reduction was completed on November 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As a result of the Reduction, the Company incurred charges of $1.2&#160;million for severance payments and employee benefits in 2024. The Company does not expect to incur additional charges related to the Reduction. As of March&#160;31, 2025, all amounts have been paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letter of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On December 11, 2024, the Company established a standby letter of credit with its banking institution, Wells Fargo, for $6.0&#160;million for the benefit of its indirect tax service provider, as it relates to indirect tax compliance services in various tax jurisdictions outside of the U.S. in connection with the rezafungin supply chain activities and commercial sales of REZZAYO. The letter of credit expires on November 30, 2025 and is automatically extended without amendment for an additional one-year period from the current expiration date, unless notified by the Company to terminate prior to 90 days from the expiration date. The cash held as collateral for this standby letter of credit is recorded as restricted cash and is held in an interest-bearing account.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c-135" id="f-543">P36M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <cdtx:LesseeFinanceLeaseMonthlyRate contextRef="c-136" decimals="0" id="f-544" unitRef="usd">25009</cdtx:LesseeFinanceLeaseMonthlyRate>
    <cdtx:LesseeFinanceLeaseOptionPurchaseEquipment contextRef="c-136" decimals="0" id="f-545" unitRef="usd">1</cdtx:LesseeFinanceLeaseOptionPurchaseEquipment>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-137" decimals="-5" id="f-546" unitRef="usd">-200000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-138" id="f-547">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cdtx:LesseeOperatingLeaseMonthlyRate contextRef="c-139" decimals="INF" id="f-548" unitRef="usd">133371</cdtx:LesseeOperatingLeaseMonthlyRate>
    <cdtx:LesseeOperatingLeaseAnnualRateIncrease contextRef="c-139" decimals="2" id="f-549" unitRef="number">0.04</cdtx:LesseeOperatingLeaseAnnualRateIncrease>
    <cdtx:NumberOfOperatingLeaseOptionsForExtension
      contextRef="c-138"
      decimals="INF"
      id="f-550"
      unitRef="option">2</cdtx:NumberOfOperatingLeaseOptionsForExtension>
    <cdtx:LesseeOperatingLeaseOptionRenewalTerm contextRef="c-139" id="f-551">P2Y</cdtx:LesseeOperatingLeaseOptionRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-138" decimals="3" id="f-552" unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount and timing of cash flows arising from the Company&#x2019;s operating lease as of March&#160;31, 2025 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-554" unitRef="usd">1248000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-555" unitRef="usd">1731000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-556" unitRef="usd">2979000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-557" unitRef="usd">306000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-558" unitRef="usd">2673000</us-gaap:OperatingLeaseLiability>
    <cdtx:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-559">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company&#x2019;s operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdtx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-560" unitRef="usd">2435000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-561" unitRef="usd">1437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-562" unitRef="usd">1236000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-563" unitRef="usd">2673000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-564">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-565" unitRef="usd">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-9" decimals="-5" id="f-566" unitRef="usd">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense contextRef="c-9" decimals="-5" id="f-567" unitRef="usd">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-568" unitRef="usd">400000</us-gaap:OperatingLeaseExpense>
    <cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost contextRef="c-1" id="f-569">P30D</cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c-140"
      decimals="INF"
      id="f-570"
      unitRef="employee">20</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <cdtx:RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted contextRef="c-140" decimals="2" id="f-571" unitRef="number">0.30</cdtx:RestructuringAndRelatedCostNumberOfPositionsEliminatedTotalWorkforcePercentImpacted>
    <us-gaap:SeveranceCosts1 contextRef="c-114" decimals="-5" id="f-572" unitRef="usd">1200000</us-gaap:SeveranceCosts1>
    <us-gaap:GuaranteeObligationsMaximumExposure contextRef="c-141" decimals="-5" id="f-573" unitRef="usd">6000000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuarantorObligationTerm1 contextRef="c-142" id="f-574">P1Y</us-gaap:GuarantorObligationTerm1>
    <cdtx:GuarantorObligationsTerminationNoticeTerm contextRef="c-142" id="f-575">P90D</cdtx:GuarantorObligationsTerminationNoticeTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-576">INCOME TAXES&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company estimates an annual effective income tax rate based on projected results for the year and applied the rate to net loss before taxes to calculate income tax expense or (benefit). When applicable, the income tax provision also includes adjustments for discrete tax items. Any refinements made due to subsequent information that affects the estimated annual effective income tax rate are reflected as adjustments in the current period. For the three months ended March&#160;31, 2025, and 2024 the Company recognized no income tax expense or (benefit) from continuing operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-577" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-9" decimals="INF" id="f-578" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-579">DISCONTINUED OPERATIONS&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 24, 2024, the Company and Napp entered into the Napp Purchase Agreement, pursuant to which the Company sold to Napp, effective as of April 24, 2024, the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;all of the Company&#x2019;s rezafungin assets, including all of the Company&#x2019;s right to receive future milestones and royalties under a license agreement between Melinta Therapeutics, LLC, or Melinta, and the Company, or the Melinta License Agreement, and a collaboration and license agreement between Mundipharma and the Company, or the Mundipharma Collaboration Agreement,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;all rezafungin intellectual property rights, including patents and know-how, all product data, regulatory approvals and documentation,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;rezafungin and comparator inventory,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;specified prepaid assets and specified contracts, in exchange for Napp&#x2019;s assumption of certain liabilities of the rezafungin business, including the ongoing costs of the ReSPECT Phase 3 clinical trial and the ReSTORE Phase 3 clinical trial in China and the Company&#x2019;s obligations from and after closing under the Melinta License Agreement,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;the Commercial Supply Agreement between the Company and Melinta, and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;the Commercial Supply Agreement between the Company and Mundipharma, or the Mundipharma Commercial Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;No Company employees were transferred to Napp.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company, Napp and Mundipharma also entered into an Assignment and Novation Agreement to transfer the Mundipharma Collaboration Agreement and Mundipharma Commercial Supply Agreement from the Company to Napp, or the Novation Agreement. In the Novation Agreement, Mundipharma agreed to forgive the Company&#x2019;s obligation to refund a $11.1&#160;million development milestone advance due as of December 31, 2024, net of royalties, to Mundipharma under the Mundipharma Collaboration Agreement, provided that (a) the Company performed its obligation to provide carryover services under a Transition Services Agreement with Napp, or the TSA, for a period of 45 days following the closing, (b) the Company delivered all of the purchased assets, including product know-how and product-data, in accordance with the Napp Purchase Agreement and a know-how transfer plan delivered in connection with the Napp Purchase Agreement and (c) the Company performed its obligation to provide other services in accordance with the TSA for 75 days following the closing. On July 18, 2024, the Company received a notice of satisfaction from Mundipharma that it had completed the required performance obligations under the TSA and, accordingly, the $11.1&#160;million development milestone advance previously made to the Company, and reimbursable to Mundipharma, was forgiven by Mundipharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The action to divest rezafungin was taken because of the Company&#x2019;s strategy to streamline its portfolio and focus on the Cloudbreak platform and other financial considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has determined that the sale of rezafungin represents a strategic shift that had a major effect on its result of operations. Rezafungin met the criteria to be reported as discontinued operations at the time of the sale. The Company has separately reported the financial results of rezafungin as discontinued operations in the condensed consolidated statements of operations and comprehensive loss for all prior year periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;There were no assets and liabilities related to discontinued operations as of March&#160;31, 2025 and December&#160;31, 2024, as all balances were recognized in income from discontinued operations at the completion of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;There were no discontinued operations during the three months ended March&#160;31, 2025. The results of operations from discontinued operations during the three months ended March&#160;31, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Major line items constituting pretax income (loss) of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The cash flows related to discontinued operations have not been segregated and are included in the condensed consolidated statements of cash flows. The total net cash used in operating activities from discontinued operations was $6.9 million for the three months ended March&#160;31, 2024. There were no investing or financing activities from discontinued operations for the three months ended&#160;March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to R&amp;amp;D expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or R&amp;amp;D expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta Therapeutics, LLC, or Melinta, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta were required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represented a distinct performance obligation. The Commercial Supply Agreements were terminated upon the effectiveness of the assignment to Napp on April 24, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The transaction price recognized as revenue for each performance obligation under the Commercial Supply Agreements consisted of variable consideration which was determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue were adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration was included in the transaction price only to the extent that it was considered probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty associated with the variable consideration was subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections were recorded as indirect tax liabilities. The transaction price was fully allocated to the single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that the performance obligation was satisfied and product revenue was recognized when the customer obtained control of the product, which occurred at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#x2019;s product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities that were performed after a customer obtained control of the product were treated as activities to fulfill the promise to a customer and any amounts billed to a customer represented revenues for the product provided. Costs related to such shipping and handling were classified as cost of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Napp Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Napp Purchase Agreement, the Company modified its existing collaboration and license arrangements and Commercial Supply Agreements with Mundipharma and Melinta. As a result of the modified revenue contracts and the termination of these revenue arrangements, the Company concluded the Napp Purchase Agreement and the other aforementioned arrangements represented a bundled arrangement with a single commercial objective that required assessment under the guidance for revenue recognition. As a result, the Company identified the distinct performance obligations within the arrangements (including whether the distinct performance obligations were within the scope of ASC 606), determined the transaction price and the standalone selling prices of the distinct performance obligations, and allocated the transaction price using the relative standalone selling price method to the distinct performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 24, 2024, as of the execution date of the Napp Purchase Agreement (and all other bundled arrangements), the Company determined the transaction price is equal to $21.2&#160;million for the sale of all rezafungin assets, including the Company&#x2019;s right to receive future milestones and royalties from Mundipharma and Melinta, all rezafungin intellectual property rights, including patents and know-how, rezafungin and comparator inventory, specified prepaid assets, the Commercial Supply Agreements with Melinta and Mundipharma, and certain transition services. The transaction price includes the forgiveness of $25.3&#160;million in contract liabilities (inclusive of the $11.1&#160;million development milestone advance) and $0.6&#160;million for the transition services agreement. The Company paid $2.1&#160;million to Napp and forgave $2.6&#160;million in accounts receivable, both of which are included as a reduction to the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The $21.2&#160;million transaction price was allocated to the distinct performance obligations on the basis of their respective relative standalone selling prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;All Rezafungin assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company transferred all rezafungin assets, including all rezafungin intellectual property rights, including patents and know-how, rezafungin and comparator inventory in April 2024 at a point in time. Therefore, the Company recognized the revenue related to this bundled performance obligations in the amount of $20.8&#160;million as revenue in the results from operations from discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Specified Prepaid Assets and Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company transferred specified prepaid and contracts in April 2024 at a point in time. The nature of the assets transferred were determined to be outside the scope of ASC 606 and therefore, the $0.3&#160;million was recorded as part of the loss on disposal of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transition Services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company performed its services under the TSA over the initial 76-day period subsequent to the effective date of the Napp Purchase Agreement. In connection with the carryover services provided after the sale of rezafungin, the Company recognized $0.1&#160;million as revenue in the results of operations from discontinued operations during the second quarter of 2024. The Company's costs to provide the TSA services predominantly related to employee labor costs which were reported within R&amp;amp;D and SG&amp;amp;A expenses within the results of operations from discontinued operations during the second quarter of 2024. The remaining unsatisfied performance obligation as of March&#160;31, 2025 was zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;(ii) Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;.&#160;Under the Mundipharma Collaboration Agreement, the Company was responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that included the Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#x2011;clinical studies and CMC development activities for the Mundipharma Licensed Product. Mundipharma was responsible for performing all development activities, other than Global Development Plan activities, that were necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#x2019;s sole cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;.&#160;The Mundipharma Collaboration Agreement was terminated upon the effectiveness of the assignment to Napp on April 24, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prior to the Mundipharma Collaboration Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front fee of&#160;$30.0&#160;million, plus the R&amp;amp;D funding of $31.2&#160;million, plus milestones achieved of $27.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Mundipharma in September 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company and Mundipharma shared equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represented a distinct performance obligation. The Company recorded these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the R&amp;amp;D services was best measured in an amount proportional to the R&amp;amp;D expenses incurred and the total estimated R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company&#x2019;s initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represented a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services was best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;In November 2020, the Company achieved a milestone under the Mundipharma Collaboration Agreement, and received payment for this milestone in January 2021. Mundipharma was entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma had not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company would have been obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. The full amount was forgiven in July 2024 as part of the rezafungin asset sale and the Company included it in the transaction price of the Napp Purchase Agreement. In December 2021, August 2022, December 2023 and January 2024, the Company achieved milestones under the Mundipharma Collaboration Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in January 2022, September 2022, February 2024 and April 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;(iii) Melinta License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contained or incorporated rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Continued Development and Regulatory Activities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company was responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that included, among other activities, (a) completion of the ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a supplemental new drug application, or sNDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that were required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company remained the holder of the rezafungin IND and new drug application, or NDA, before the Melinta License Agreement was assigned as part of the Napp Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Melinta License Agreement was terminated upon the effectiveness of the assignment to Napp on April 24, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prior to the Melinta License Agreement termination on April 24, 2024, the Company determined the transaction price was equal to the up-front fee of&#160;$30.0&#160;million, plus a milestone achieved of $20.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the R&amp;amp;D efforts and costs for manufacturing clinical supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A description of the distinct performance obligations identified under the Melinta License Agreement was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represented a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company was required to provide R&amp;amp;D services, at its sole expense, as described under the Melinta Development Plan, which represented a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the R&amp;amp;D services was best measured in an amount proportional to the R&amp;amp;D expenses incurred and the total estimated R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company&#x2019;s obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represented a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services was best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;In March 2023, the Company achieved a milestone under the Melinta License Agreement that the Company deemed to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone was allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue was recognized based on the progress of these performance obligations, the unrecognized portion was recorded as contract liabilities at the reporting period end and was recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in April 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license was deemed to be the predominant item to which sales-based royalties related, the Company recognized royalty revenue when the related sales occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of the termination date of both the Mundipharma Collaboration Agreement and the Melinta License Agreement, there was no aggregate transaction price allocated to performance obligations that was unsatisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2025 and December&#160;31, 2024, the Company recorded no accounts receivable or contract liabilities associated with the Mundipharma Collaboration Agreement and Melinta License Agreement. As of March&#160;31, 2025, the Company recorded accounts receivable associated with the Napp Purchase Agreement of $1.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents collaboration and product revenue, included within discontinued operations, disaggregated by collaborator and timing of revenue recognition, for the three months ended March&#160;31, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration, License and Commercial Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon milestone achieved&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration, License and Commercial Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount contextRef="c-143" decimals="-5" id="f-580" unitRef="usd">11100000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount>
    <cdtx:CollaborativeArrangementCarryOverServicesAgreementTerm contextRef="c-143" id="f-581">P45D</cdtx:CollaborativeArrangementCarryOverServicesAgreementTerm>
    <cdtx:CollaborativeArrangementOtherServicesAgreementTerm contextRef="c-143" id="f-582">P75D</cdtx:CollaborativeArrangementOtherServicesAgreementTerm>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount contextRef="c-143" decimals="-5" id="f-583" unitRef="usd">11100000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-37" decimals="INF" id="f-584" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-37" decimals="INF" id="f-585" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-38" decimals="INF" id="f-586" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-38" decimals="INF" id="f-587" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-588">The results of operations from discontinued operations during the three months ended March&#160;31, 2024, have been reflected as loss from discontinued operations, net of income taxes in the condensed consolidated statements of operations and comprehensive loss and consisted of the following:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Major line items constituting pretax income (loss) of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss from discontinued operations, net of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-144" decimals="-3" id="f-589" unitRef="usd">7490000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-144" decimals="-3" id="f-590" unitRef="usd">1563000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <cdtx:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment contextRef="c-144" decimals="-3" id="f-591" unitRef="usd">5674000</cdtx:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-144" decimals="-3" id="f-592" unitRef="usd">2402000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c-144" decimals="-3" id="f-593" unitRef="usd">9639000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-144" decimals="-3" id="f-594" unitRef="usd">-2149000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-144" decimals="-5" id="f-595" unitRef="usd">6900000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-144" decimals="INF" id="f-596" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations contextRef="c-145" decimals="INF" id="f-597" unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-144" decimals="INF" id="f-598" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-145" decimals="INF" id="f-599" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <cdtx:CollaborativeArrangementTransactionValue contextRef="c-146" decimals="-5" id="f-600" unitRef="usd">21200000</cdtx:CollaborativeArrangementTransactionValue>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount contextRef="c-146" decimals="-5" id="f-601" unitRef="usd">25300000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityForgivenessAmount>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount contextRef="c-143" decimals="-5" id="f-602" unitRef="usd">11100000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCostForgivenessAmount>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices contextRef="c-143" decimals="-5" id="f-603" unitRef="usd">600000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerTransitionServices>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-143" decimals="-5" id="f-604" unitRef="usd">2100000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount contextRef="c-146" decimals="-5" id="f-605" unitRef="usd">2600000</cdtx:AccountsReceivableAfterAllowanceForCreditLossCurrentForgivenessAmount>
    <cdtx:CollaborativeArrangementTransactionValue contextRef="c-146" decimals="-5" id="f-606" unitRef="usd">21200000</cdtx:CollaborativeArrangementTransactionValue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-147" decimals="-5" id="f-607" unitRef="usd">20800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <cdtx:DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal contextRef="c-143" decimals="-5" id="f-608" unitRef="usd">300000</cdtx:DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposal>
    <cdtx:CollaborativeArrangementTransitionsServicesTerm contextRef="c-143" id="f-609">P76D</cdtx:CollaborativeArrangementTransitionsServicesTerm>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-148" decimals="-5" id="f-610" unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-149" decimals="INF" id="f-611" unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-150" decimals="-5" id="f-612" unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost contextRef="c-150" decimals="-5" id="f-613" unitRef="usd">31200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-151" decimals="-5" id="f-614" unitRef="usd">27900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-152" decimals="-5" id="f-615" unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-153" decimals="-5" id="f-616" unitRef="usd">20000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-154" decimals="INF" id="f-617" unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-154" decimals="INF" id="f-618" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-155" decimals="INF" id="f-619" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-149" decimals="-5" id="f-620" unitRef="usd">1700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-156" decimals="-3" id="f-621" unitRef="usd">813000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-157" decimals="-3" id="f-622" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-158" decimals="-3" id="f-623" unitRef="usd">2826000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-159" decimals="-3" id="f-624" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-160" decimals="-3" id="f-625" unitRef="usd">26000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-161" decimals="-3" id="f-626" unitRef="usd">76000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-162" decimals="-3" id="f-627" unitRef="usd">3266000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-163" decimals="-3" id="f-628" unitRef="usd">317000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-164" decimals="-3" id="f-629" unitRef="usd">166000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-165" decimals="-3" id="f-630" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-166" decimals="-3" id="f-631" unitRef="usd">7097000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-167" decimals="-3" id="f-632" unitRef="usd">393000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-633">SUBSEQUENT EVENTS&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-funded Warrants Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In April 2025, pre-funded warrants to purchase up to 337,552 shares of common stock were cashless exercised resulting in the issuance of 337,548 shares of the Company's common stock and an immaterial cash payment by the Company in lieu of fractional shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series A Convertible Preferred Stock Conversion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In April 2025, at the request of certain holders, 5,587 shares of the Company&#x2019;s Series A Convertible Preferred Stock were converted to an aggregate of 391,090 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Termination of Controlled Equity Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On May 8, 2025, the Company and Cantor terminated the Cantor Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Entry into Open Market Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On May 8, 2025, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or the Jefferies Sales Agreement, with Jefferies LLC, or Jefferies, under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company's common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company's sales agent. The Company has not sold any shares of its common stock under the Jefferies Sales Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <cdtx:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="c-168"
      decimals="INF"
      id="f-634"
      unitRef="shares">337552</cdtx:ClassOfWarrantOrRightExercisesInPeriod>
    <cdtx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="c-169"
      decimals="INF"
      id="f-635"
      unitRef="shares">337548</cdtx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-170"
      decimals="INF"
      id="f-636"
      unitRef="shares">5587</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-169"
      decimals="INF"
      id="f-637"
      unitRef="shares">391090</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <cdtx:SaleOfStockConsiderationReceivablePerTransaction contextRef="c-171" decimals="-5" id="f-638" unitRef="usd">150000000</cdtx:SaleOfStockConsiderationReceivablePerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-171"
      decimals="INF"
      id="f-639"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-640">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-641">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-642">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-643">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
